U.S. patent application number 10/661156 was filed with the patent office on 2005-05-12 for kdr and vegf/kdr binding peptides and their use in diagnosis and therapy.
This patent application is currently assigned to Dyax Corporation. Invention is credited to Arbogast, Christophe, Bussat, Philippe, Dransfield, Daniel T., Fan, Hong, Khurana, Sudha, Ladner, Robert C., Linder, Karen E., Marinelli, Edmund R., Nanjappan, Palaniappa, Nunn, Adrian D., Pillai, Radhakrishna, Pochon, Sibylle, Ramalingam, Kondareddiar, Sato, Aaron K., Sexton, Daniel J., Shrivastava, Ajay, Song, Bo, Swenson, Rolf E., Von Wronski, Mathew A..
Application Number | 20050100963 10/661156 |
Document ID | / |
Family ID | 32776954 |
Filed Date | 2005-05-12 |
United States Patent
Application |
20050100963 |
Kind Code |
A1 |
Sato, Aaron K. ; et
al. |
May 12, 2005 |
KDR and VEGF/KDR binding peptides and their use in diagnosis and
therapy
Abstract
The present invention provides polypeptides, peptide dimer, and
multimeric complexes comprising at least one binding moiety for KDR
or VEGF/KDR complex, which have a variety of uses wherever
treating, detecting, isolating or localizing angiogenesis is
advantageous. Particularly disclosed are synthetic, isolated
polypeptides capable of binding KDR or VEGF/KDR complex with high
affinity (e.g., having a K.sub.D<1 .mu.M), and dimer and
multimeric constructs comprising these polypeptides.
Inventors: |
Sato, Aaron K.; (Somerville,
MA) ; Sexton, Daniel J.; (Melrose, MA) ;
Dransfield, Daniel T.; (Hanson, MA) ; Ladner, Robert
C.; (Ijamsville, MD) ; Arbogast, Christophe;
(Viuz - En - Sallaz, FR) ; Bussat, Philippe;
(Feigers, FR) ; Fan, Hong; (Plainsboro, NJ)
; Khurana, Sudha; (Plainsboro, NJ) ; Linder, Karen
E.; (Kingston, NJ) ; Marinelli, Edmund R.;
(Lawrenceville, NJ) ; Nanjappan, Palaniappa;
(Dayton, NJ) ; Nunn, Adrian D.; (Lamberville,
NJ) ; Pillai, Radhakrishna; (Cranbury, NJ) ;
Pochon, Sibylle; (Troinex, CH) ; Ramalingam,
Kondareddiar; (Dayton, NJ) ; Shrivastava, Ajay;
(Plainsboro, NJ) ; Song, Bo; (Princeton, NJ)
; Swenson, Rolf E.; (Princeton, NJ) ; Von Wronski,
Mathew A.; (Moorestown, NJ) |
Correspondence
Address: |
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
530 VIRGINIA ROAD
P.O. BOX 9133
CONCORD
MA
01742-9133
US
|
Assignee: |
Dyax Corporation
Cambridge
MA
Bracco International B. V.
|
Family ID: |
32776954 |
Appl. No.: |
10/661156 |
Filed: |
September 11, 2003 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10661156 |
Sep 11, 2003 |
|
|
|
10382082 |
Mar 3, 2003 |
|
|
|
10661156 |
Sep 11, 2003 |
|
|
|
PCT/US03/06731 |
Mar 3, 2003 |
|
|
|
60360851 |
Mar 1, 2002 |
|
|
|
60440411 |
Jan 15, 2003 |
|
|
|
Current U.S.
Class: |
435/7.1 ;
424/1.69; 424/9.34; 424/9.5; 506/18; 514/13.3; 514/19.3; 514/21.1;
514/8.1; 530/317 |
Current CPC
Class: |
C07K 14/001 20130101;
C07K 14/52 20130101; Y02A 50/411 20180101; A61K 38/00 20130101;
A61K 49/221 20130101; A61K 47/62 20170801; Y02A 50/58 20180101;
C07K 2319/00 20130101; A61K 51/088 20130101; C07K 7/08 20130101;
C07K 14/71 20130101; A61K 49/223 20130101; Y02A 50/30 20180101 |
Class at
Publication: |
435/007.1 ;
514/009; 530/317 |
International
Class: |
G01N 033/53; C07K
007/64; A61K 038/12 |
Claims
What is claimed is:
1. An isolated polypeptide having the ability to bind to KDR or
VEGF/KDR complex comprising an amino acid sequence of one of the
following: Loop Consensus Sequence 15:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.- 7-Cys (TN8),
wherein X.sub.2 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys,
Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.4 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro,
Ser, Thr, Trp, Tyr or Val (preferably Asp); X.sub.5 is Ala, Asp,
Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.6 is Arg, Gln,
Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; and X.sub.7 is
Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr;
or Loop Consensus Sequence
16:Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.-
sub.10-X.sub.11-Cys (TN12), wherein X.sub.2 is Arg, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val; X.sub.3 is Ala, Arg,
Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or Tyr; X.sub.4 is Arg,
Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.5 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro, Ser,
Trp, Tyr or Val; X.sub.6 is Asp, Gln, Glu, Gly, His, Ile, Leu, Met,
Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.7 is Ala, Arg, Asn, Asp, Gln,
Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.8 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys, Trp, Tyr or
Val; X.sub.9 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met, Phe, Ser,
Thr, Trp, Tyr or Val; X.sub.10 is Arg, Gln, Glu, His, Leu, Lys,
Met, Phe, Pro, Thr, Trp or Val; and X.sub.11 is Arg, Asn, Asp, Glu,
His, Ile, Leu, Met, Phe, Pro, Thr, Trp, Tyr or Val; or Loop
Consensus Sequence 17: Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6-Cys
(TN7), wherein X.sub.2 is Asn, Asp or Glu; X.sub.3 is Glu, His, Lys
or Phe; X.sub.4 is Asp, Gln, Leu, Lys, Met or Tyr; and X.sub.6 is
Arg, Gln, Leu, Lys or Val; or Loop Consensus Sequence 18:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.- 6-X.sub.7-X.sub.8-Cys
(TN9), wherein X.sub.2 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.3
is Asn, Glu, Gly, His or Leu; X.sub.4 is Gln, Glu, Gly, Met, Lys,
Phe, Tyr or Val; X.sub.5 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser
or Thr; X.sub.6 is His, Pro or Trp; X.sub.7 is Ala, Gly, His, Leu,
Trp or Tyr; and X.sub.8 is Ala, Asp, Gln, Leu, Met, Thr or Trp; or
Loop Consensus Sequence 19:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Ser-Gly-Pro-X.-
sub.9-X.sub.10-X.sub.11-X.sub.12-Cys (MTN13; SEQ ID NO:1), wherein
X.sub.2 is Asp, Glu, His or Thr; X.sub.3 is Arg, His, Lys or Phe;
X.sub.4 is Gln, Ile, Lys, Tyr or Val; X.sub.5 is Gln, Ile, Leu, Met
or Phe; X.sub.9 is Asn, Asp, Gly, His or Tyr; X.sub.10 is Gln, Gly,
Ser or Thr; X.sub.11 is Glu, Lys, Phe or Ser; and X.sub.12 is Glu,
Ile, Ser or Val.
2. The polypeptide of claim 1, wherein the polypeptide comprises an
amino acid sequence of one of the following: Loop Consensus
Sequence 20: Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-Tyr-Cys
(TN8), wherein X.sub.2 is Ala, Arg, Glu, Lys or Ser; X.sub.3 is
Ala, Asp, Gln, Glu, Thr or Val; X.sub.4 is Asp or Glu; X.sub.5 is
Trp or Tyr; and X.sub.6 is Thr or Tyr; or Loop Consensus Sequence
21: Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.- sub.6-X.sub.7-Cys (TN8),
wherein X.sub.2 is Asp, Gln or His; X.sub.3 is His or Tyr; X.sub.4
is His, Ile or Tyr; X.sub.6 is Ile, Met or Val; and X.sub.7 is Gly
or Tyr; or Loop Consensus Sequence 22:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Gly-X.sub.7-Cys (TN8), wherein
X.sub.2 is Ala, Arg, Asn, Asp, His, Phe, Trp or Tyr; X.sub.3 is
Ala, Asp, Gln, His, Lys, Met, Ser, Thr, Trp, Tyr or Val; X.sub.4 is
Ala, Asn, Asp, Gln, Glu, Gly, His, Ile, Leu, Lys, Pro, Ser, Thr or
Val; X.sub.5 is Asp, Phe, Ser, Thr, Trp or Tyr; and X.sub.7 is Ala,
Arg, Gln, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr.
3. The polypeptide of claim 1, wherein the polypeptide comprises an
amino acid sequence of one of the following: Loop Consensus
Sequence 23:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Trp-Gly-Gly-X.sub.9-X.sub.10-Cys
(SEQ ID NO:3; TN11), wherein X.sub.2 is Ala, Phe or Trp; X.sub.3 is
Glu or Lys; X.sub.4 is Asp, Ser, Trp or Tyr; X.sub.5 is Phe, Pro or
Ser; X.sub.9 is Gln or Glu; and X.sub.10 is Ile, Phe or Val; or
Loop Consensus Sequence 24:
Cys-X.sub.2-Glu-X.sub.4-Ser-X.sub.6-Ser-X.sub.8-X.sub.9-X.su-
b.10-Phe-Cys (SEQ ID NO:15; TN12), wherein X.sub.2 is His or Tyr;
X.sub.4 is Leu, His or Thr; X.sub.6 is Asp or Leu; X.sub.8 is Gly
or Val; X.sub.9 is Thr or Val; and X.sub.10 is Arg or Trp; or Loop
Consensus Sequence 25:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-Gly-X.sub.9-Trp-X.sub-
.11-Cys (TN12; SEQ ID NO:16), wherein X.sub.2 is Glu, Met or Thr;
X.sub.3 is Ile, Leu, Met or Phe; X.sub.4 is Arg, Asp, Glu, Met, Trp
or Val; X.sub.5 is Asn, Gln, Gly, Ser or Val; X.sub.6 is Glu or
Asp; X.sub.7 is Lys, Ser, Thr or Val; X.sub.9 is Arg, Gln, Lys or
Trp; and X.sub.11 is Asn, Leu, Phe or Tyr; or Loop Consensus
Sequence 26:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub-
.10-X.sub.11-Cys (TN12), wherein X.sub.2 is Glu or Gly; X.sub.3 is
Trp or Tyr; X.sub.4 is Ser or Thr; X.sub.5 is Asn or Gln; X.sub.6
is Gly or Met; X.sub.7 is Phe or Tyr; X.sub.8 is Asp or Gln;
X.sub.9 is Lys or Tyr; X.sub.10 is Glu or Thr; and X.sub.11 is Glu
or Phe.
4. The polypeptide of claim 1, wherein the polypeptide comprises an
amino acid sequence of the following: Loop Consensus Sequence 27:
Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6-Cys (TN7), wherein X.sub.2
is Asn, Asp or Glu; X.sub.3 is Glu, His, Lys or Phe; X.sub.4 is
Asp, Gln, Leu, Lys, Met or Tyr; and X.sub.6 is Arg, Gln, Leu, Lys
or Val.
5. The polypeptide of claim 1, wherein the polypeptide comprises an
amino acid sequence of the following: Loop Consensus Sequence 28:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-Cys
(TN9), wherein X.sub.2 is Ala, Lys, Ser, Trp or Val; X.sub.3 is
Asn, Glu, Gly, His or Leu; X.sub.4 is Glu, Gly, Lys, Met or Tyr;
X.sub.5 is Ala, Asn, Asp, Leu, Met, Pro or Ser; X.sub.6 is His, Pro
or Trp; X.sub.7 is His, Leu, Trp or Tyr; and X.sub.8 is Ala, Asp,
Gln, Leu, Met, Thr or Trp.
6. The polypeptide of claim 1, wherein the polypeptide comprises an
amino acid sequence of the following: Loop Consensus Sequence 29:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Ser-Gly-Pro-X.sub.9-X.sub.10-X.sub.11-
-X.sub.12-Cys (SEQ ID NO:1; MTN13), wherein X.sub.2 is Asp, Glu,
His or Thr; X.sub.3 is Arg, His, Lys or Phe; X.sub.4 is Gln, Ile,
Lys, Tyr or Val; X.sub.5 is Gln, Ile, Leu, Met or Phe; X.sub.9 is
Asn, Asp, Gly, His or Tyr; X.sub.10 is Gln, Gly, Ser or Thr;
X.sub.11 is Glu, Lys, Phe or Ser; and X.sub.12 is Glu, Ile, Ser or
Val.
7. An isolated polypeptide having the ability to bind to KDR or
VEGF/KDR complex comprising an amino acid sequence of one of the
following: Consensus Sequence 1:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-
-X.sub.8-X.sub.9-X.sub.10-Cys-X.sub.12-X.sub.13-X.sub.14 (TN8),
wherein X.sub.1 is Ala, Arg, Asp, Gly, His, Leu, Lys, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.2 is Asn, Asp, Glu, Gly, Ile, Leu, Lys,
Phe, Ser, Thr, Trp, Tyr or Val; X.sub.3 is Asn, Asp, Gln, Glu, Ile,
Leu, Met, Thr, Trp or Val; X.sub.5 is Ala, Arg, Asn, Asp, Gln, Glu,
His, Ile, Lys, Phe, Pro, Ser, Trp or Tyr; X.sub.6 is Ala, Arg, Asn,
Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp,
Tyr or Val; X.sub.7 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys,
Phe, Pro, Ser, Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asp, Glu, Gly,
Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.9 is Arg, Gln, Glu, Gly,
Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; X.sub.10 is Ala, Arg,
Gin, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr; X.sub.12
is Arg, Asp, Cys, Gin, Glu, His, Ile, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.13 is Arg, Asn, Asp, Gin, Glu, Gly,
His, Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp or Tyr; and X.sub.14 is
Gin, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp or
Tyr; or Consensus Sequence 2:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-
-X.sub.8-X.sub.9-X.sub.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-Cys-X.sub.16-
-X.sub.17-X.sub.18 (TN12), wherein X.sub.1 is Ala, Asn, Asp, Gly,
Leu, Pro, Ser, Trp or Tyr; X.sub.2 is Ala, Arg, Asn, Asp, Gly, His,
Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Asn, Asp, Gin, Glu, Gly,
His, Leu, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.5 is Arg,
Asp, Gin, Glu, Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val;
X.sub.6 is Ala, Arg, Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or
Tyr; X.sub.7 is Arg, Asn, Asp, Gin, Glu, His, Ile, Leu, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asn, Asp, Gin, Glu, Gly, His,
Met, Phe, Pro, Ser, Trp, Tyr or Val; X.sub.9 is Asp, Gin, Glu, Gly,
His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.10 is
Ala, Arg, Asn, Asp, Gin, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.11 is Ala, Arg, Asn, Asp, Gin, Glu,
Gly, His, Lys, Trp, Tyr or Val; X.sub.12 is Ala, Arg, Gin, Gly,
His, Ile, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.13 is
Arg, Gin, Glu, His, Leu, Lys, Met, Phe, Pro, Thr, Trp or Val;
X.sub.14 is Arg, Asn, Asp, Glu, His, Ile, Leu, Met, Phe, Pro, Thr,
Trp, Tyr or Val; X.sub.16 is Ala, Asn, Asp, Gln, Glu, Gly, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.17 is Arg, Asn, Asp,
Cys, Gly, His, Phe, Pro, Ser, Trp or Tyr; and X.sub.18 is Ala, Asn,
Asp, Gly, His, Leu, Phe, Pro, Ser, Trp or Tyr; or Consensus
Sequence 3:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-Gly-X.sub.9-Cys-X.-
sub.11-X.sub.12-X.sub.13 (TN7), wherein X.sub.1 is Gly or Trp;
X.sub.2 is Ile, Tyr or Val; X.sub.3 is Gln, Glu, Thr or Trp;
X.sub.5 is Asn, Asp or Glu; X.sub.6 is Glu, His, Lys or Phe;
X.sub.7 is Asp, Gln, Leu, Lys, Met or Tyr; X.sub.9 is Arg, Gln,
Leu, Lys or Val; X.sub.11 is Arg, Phe, Ser, Trp or Val; X.sub.12 is
Glu, His or Ser; and X.sub.13 is Glu, Gly, Trp or Tyr; or Consensus
Sequence 4: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-
-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys-X.sub.13-X.sub.14-X.sub.15
(TN9), wherein X.sub.1 is Arg, Asp, Gly, Ile, Met, Pro or Tyr;
X.sub.2 is Asp, Gly, His, Pro or Trp; X.sub.3 is Gly, Pro, Phe, Thr
or Trp; X.sub.5 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.6 is Asn,
Glu, Gly, His or Leu; X.sub.7 is Gln, Glu, Gly, Met, Lys, Phe, Tyr
or Val; X.sub.8 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or Thr;
X.sub.9 is His, Pro or Trp; X.sub.10 is Ala, Gly, His, Leu, Trp or
Tyr; X.sub.11 is Ala, Asp, Gln, Leu, Met, Thr or Trp; X.sub.13 is
Ala, Lys, Ser, Trp or Tyr; X.sub.14 is Asp, Gly, Leu, His, Met,
Thr, Trp or Tyr; and X.sub.15 is Asn, Gln, Glu, Leu, Met, Pro or
Trp; or Consensus Sequence 5: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5--
X.sub.6-X.sub.7-X.sub.8-Ser-Gly-Pro-X.sub.12-X.sub.13-X.sub.14-X.sub.15-Cy-
s-X.sub.17-X.sub.18-X.sub.19 (SEQ ID NO:1; MTN13), wherein X.sub.1
is Arg, Glu, His, Ser or Trp; X.sub.2 is Asn, Asp, Leu, Phe, Thr or
Val; X.sub.3 is Arg, Asp, Glu, His, Lys or Thr; X.sub.5 is Asp,
Glu, His or Thr; X.sub.6 is Arg, His, Lys or Phe; X.sub.7 is Gln,
Ile, Lys, Tyr or Val; X.sub.8 is Gln, Ile, Leu, Met or Phe;
X.sub.12 is Asn, Asp, Gly, His or Tyr; X.sub.13 is Gln, Gly, Ser or
Thr; X.sub.14 is Glu, Lys, Phe or Ser; X.sub.15 is Glu, Ile, Ser or
Val; X.sub.17 is Glu, Gly, Lys, Phe, Ser or Val; X.sub.18 is Arg,
Asn, Ser or Tyr; and X.sub.19 is Asp, Gln, Glu, Gly, Met or
Tyr.
8. The polypeptide of claim 7, wherein the polypeptide comprises an
amino acid sequence of one of the following: Consensus Sequence 6:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-Tyr-C-
ys-X.sub.12-X.sub.13-X.sub.14, wherein X.sub.1 is Ala, Arg, Asp,
Leu, Lys, Pro, Ser or Val; X.sub.2 is Asn, Asp, Glu, Lys, Thr or
Ser; X.sub.3 is Ile, Leu, Trp; X.sub.5 is Ala, Arg, Glu, Lys or
Ser; X.sub.6 is Ala, Asp, Gln, Glu, Thr or Val; X.sub.7 is Asp or
Glu; X.sub.8 is Trp or Tyr; X.sub.9 is Thr or Tyr; X.sub.12 is Glu,
Met, Phe, Trp or Tyr; X.sub.13 is Ile, Leu or Met; and X.sub.14 is
Ile, Leu, Met, Phe or Thr; or Consensus Sequence 7:
Trp-Tyr-Trp-Cys-X.sub.5-X.sub.6-X.sub.7-Gly-X.sub.9-X.sub.10--
Cys-X.sub.12-X.sub.13-X.sub.14 (SEQ ID NO:2), wherein X.sub.5 is
Asp, Gln or His; X.sub.6 is His or Tyr; X.sub.7 is Ile, His or Tyr;
X.sub.9 is Ile, Met or Val; X.sub.10 is Gly or Tyr; X.sub.12 is
Asp, Lys or Pro; X.sub.13 is Gln, Gly or Trp; and X.sub.14 is Phe,
Ser or Thr; or Consensus Sequence 8:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-
-X.sub.8-Gly-X.sub.10-Cys-X.sub.12-X.sub.13-X.sub.14, wherein
X.sub.1 is Gly, Leu, His, Thr, Trp, Tyr; X.sub.2 is Ile, Leu, Thr,
Trp or Val; X.sub.3 is Asp, Glu, Gln, Trp or Thr; X.sub.5 is Ala,
Arg, Asn, Asp, His, Phe, Trp or Tyr; X.sub.6 is Ala, Asp, Gln, His,
Lys, Met, Ser, Thr, Trp, Tyr or Val; X.sub.7 is Ala, Asn, Asp, Glu,
Gly, His, Ile, Leu, Lys, Phe, Pro, Ser, Thr or Val; X.sub.8 is Asp,
Phe, Ser, Thr, Trp or Tyr; X.sub.10 is Ala, Arg, Gln, His, Ile,
Leu, Lys, Met, Phe, Trp or Tyr; X.sub.12 is Arg, Gln, His, Ile,
Lys, Met, Phe, Thr, Trp, Tyr or Val; X.sub.13 is Arg, Asn, Asp,
Glu, His, Met, Pro, Ser or Thr; and X.sub.14 is Arg, Gln, Glu, Gly,
Phe, Ser, Trp or Tyr.
9. The polypeptide of claim 7, wherein the polypeptide comprises an
amino acid sequence of one of the following: Consensus Sequence 9:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-X.sub.8-Trp-Gly-Gly-X-
.sub.12-X.sub.13-Cys-X.sub.15-X.sub.16-X.sub.17 (SEQ ID NO:3),
wherein X.sub.1 is Ser, Phe, Trp, Tyr or Gly; X.sub.2 is Arg, Gly,
Ser or Trp; X.sub.3 is Ala, Glu, Ile or Val; X.sub.5 is Ala, Phe or
Trp; X.sub.6 is Glu or Lys; X.sub.7 is Asp, Ser or Trp; X.sub.8 is
Phe, Pro or Ser; X.sub.12 is Gln or Glu; X.sub.13 is Ile, Phe or
Val; X.sub.15 is Gln, Ile, Leu or Phe; X.sub.16 is Arg, Gly or Pro;
and X.sub.17 is Gln, His, Phe, Ser, Tyr or Val; or Consensus
Sequence 10: Tyr-Pro-X.sub.3-Cys-X.sub-
.5-Glu-X.sub.7-Ser-X.sub.9-Ser-X.sub.11-X.sub.12-X.sub.13-Phe-Cys-X.sub.16-
-X.sub.17-X.sub.18 (SEQ ID NO:4; TN12), wherein X.sub.3 is Gly or
Trp; X.sub.5 is His or Tyr; X.sub.7 is His, Leu or Thr; X.sub.9 is
Asp or Leu; X.sub.11 is Gly or Val; X.sub.12 is Thr or Val;
X.sub.13 is Arg or Trp; X.sub.16 is Ala or Val; X.sub.17 is Asp or
Pro; and X.sub.18 is Gly or Trp; or Consensus Sequence 11:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.-
6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-Gly-X.sub.12-Trp-X.sub.14-Cys-X.sub.16--
X.sub.17-X.sub.18 (SEQ ID NO:5; TN12), wherein X.sub.1 is Asp, Gly,
Pro or Ser; X.sub.2 is Arg, Asn, Asp, Gly or Ser; X.sub.3 is Gly,
Thr, Trp or Tyr; X.sub.5 is Glu, Met or Thr; X.sub.6 is Ile, Leu,
Met or Phe; X.sub.7 is Arg, Asp, Glu, Met, Trp or Val; X.sub.8 is
Asn, Gln, Gly, Ser or Val; X.sub.9 is Asp or Glu; X.sub.10 is Lys,
Ser, Thr or Val; X.sub.12 is Arg, Gln, Lys or Trp; X.sub.14 is Asn,
Leu, Phe or Tyr; X.sub.16 is Gly, Phe, Ser or Tyr; X.sub.17 is Gly,
Leu, Pro or Ser; and X.sub.18 is Ala, Asp, Pro, Ser, Trp or Tyr; or
Consensus Sequence 12: Asn-Trp-X.sub.3-Cys-X.sub-
.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-X.sub.12-X.sub.13-X.s-
ub.14-Cys-X.sub.16-X.sub.17-X.sub.18 (SEQ ID NO:6; TN12), wherein
X.sub.3 is Glu or Lys; X.sub.5 is Glu or Gly; X.sub.6 is Trp or
Tyr; X.sub.7 is Ser or Thr; X.sub.8 is Asn or Gln; X.sub.9 is Gly
or Met; X.sub.10 is Phe or Tyr; X.sub.11 is Asp or Gln; X.sub.12 is
Lys or Tyr; X.sub.13 is Glu or Thr; X.sub.14 is Glu or Phe;
X.sub.16 is Ala or Val; X.sub.17 is Arg or Tyr; and X.sub.18 is Leu
or Pro, wherein the polypeptide binds KDR or a VEGF/KDR
complex.
10. An isolated polypeptide having the ability to bind to KDR or
VEGF/KDR complex comprising an amino acid sequence of one of the
following: Consensus Sequence 13:
Z.sub.1-X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Z.- sub.2 (Lin20);
wherein, Z.sub.1 is a polypeptide of at least one amino acid or is
absent; X.sub.1 is Ala, Asp, Gln or Glu; X.sub.2 is Ala, Asp, Gln,
Glu, Pro; X.sub.3 is Ala, Leu, Lys, Phe, Pro, Trp or Tyr; X.sub.4
is Asp, Leu, Ser, Trp, Tyr or Val; X.sub.5 is Ala, Arg, Asp, Glu,
Gly, Leu, Trp or Tyr; and Z.sub.2 is a polypeptide of at least one
amino acid or is absent; or Consensus Sequence 14:
X.sub.1-X.sub.2-X.sub.3-Tyr-Trp-Glu-X.s- ub.7-X.sub.8-X.sub.9-Leu
(Lin20; SEQ ID NO:7), wherein, the sequence can optionally have a
N-terminal polypeptide, C-terminal polypeptide, or a polypeptide at
both termini of at least one amino acid; wherein, X.sub.1 is Asp,
Gly or Ser; X.sub.2 is Ile, Phe or Tyr; X.sub.3 is Ala, Ser or Val;
X.sub.7 is Gln, Glu, Ile or Val; X.sub.8 is Ala, Ile or Val;
X.sub.9 is Ala, Glu, Val or Thr; and
11. The polypeptide of claim 7, wherein the polypeptide comprises
an amino acid sequence selected from the group consisting of: SEQ
ID NOS: 20-86, 87-136, 187-192, 193-203, and 207-259.
12. The polypeptide of claim 10, wherein the polypeptide comprises
an amino acid sequence selected from the group consisting of: SEQ
ID NOS: 137-186.
13. The polypeptide of one of claims 1, 7 or 10, wherein the
polypeptide further comprises N-terminal and/or C-terminal flanking
peptides of one or more amino acids.
14. The polypeptide of one of claims 1, 7 or 10, wherein the
polypeptide comprises a modification selected from the group
consisting of: an amino acid substitution, and amide bond
substitution, a D-amino acid substitution, a glycosylated amino
acid, a disulfide bond, a disulfide mimetic substitution, an amino
acid translocation, a retroinverso peptide, a peptoid, a
retro-inverso peptoid, and a synthetic peptide.
15. The polypeptide of one of claims 1, 7 or 10, wherein the
polypeptide is conjugated to one or more detectable labels or
therapeutic agents, optionally further comprising a linker or
spacer between the polypeptide and the detectable label or the
therapeutic agent.
16. The polypeptide of claim 15, wherein the detectable label or
the therapeutic agent is selected from the group consisting of: an
enzyme, a fluorescent compound, a liposome, an optical dye, one or
more paramagnetic metal ions or a superparamagnetic particle, an
ultrasound contrast agent and one or more radionuclides.
17. The polypeptide of claim 16, wherein the therapeutic agent or
detectable label comprises one or more radionuclides.
18. The polypeptide of claim 17, wherein the radionuclide is
selected from the group consisting of: .sup.18F, .sup.124I,
.sup.125I, .sup.131I, .sup.123I, .sup.77Br, .sup.76Br, .sup.99mTc,
.sup.51Cr, .sup.67Ga, .sup.68Ga, .sup.47Sc, .sup.51Cr, .sup.167Tm,
.sup.141Ce, .sup.111In, .sup.168Yb, .sup.175Yb, .sup.140La,
.sup.90Y, .sup.88Y, .sup.153Sm, .sup.166Ho, .sup.165Dy, .sup.166Dy,
.sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.97Ru, .sup.103Ru, .sup.186Re,
.sup.188Re, .sup.203Pb, .sup.211Bi, .sup.212Bi, .sup.213Bi,
.sup.214Bi, .sup.105Rh, .sup.109Pd, .sup.117mSn, .sup.149Pm,
.sup.161Tb, .sup.177Lu, .sup.198Au and .sup.199Au.
19. The polypeptide of claim 18, wherein the therapeutic agent or
detectable label further comprises a chelator.
20. The polypeptide of claim 19, wherein the chelator comprises a
compound selected from the group consisting of: formula 20, 21, 22,
23a, 23b, 24a, 24b, and 25.
21. The polypeptide of claim 19, wherein the radionuclide is
.sup.99mTc or .sup.111In.
22. The polypeptide of claim 19, wherein the radionuclide is
selected from the group consisting of: .sup.177Lu, .sup.90Y,
.sup.153Sm and .sup.166Ho.
23. The polypeptide of claim 16, wherein the detectable label
comprises an ultrasound contrast agent.
24. The polypeptide of claim 23, wherein the ultrasound contrast
agent is a phospholipid stabilized microbubble or an ultrasound
contrast agent comprising a gas.
25. The polypeptide of claim 24, wherein the ultrasound contrast
agent comprises a fluorinated gas.
26. The polypeptide of claim 16, wherein the detectable label
comprises one or more paramagnetic metal ions and one or more
chelators.
27. The polypeptide of claim 15, wherein the therapeutic agent is
selected from the group consisting of: a bioactive agent, a
cytotoxic agent, a drug, a chemotherapeutic agent and a
radiotherapeutic agent.
28. The polypeptide of claim 1 or 7, wherein the polypeptide has an
apparent K.sub.D for KDR or VEGF/KDR complex of less than 10
.mu.M.
29. The polypeptide of claim 1 or 7, wherein the polypeptide has an
apparent K.sub.D for KDR or VEGF/KDR complex of less than 1.0
.mu.M.
30. The polypeptide of claim 1 or 7, wherein the polypeptide has an
apparent K.sub.D for KDR or VEGF/KDR complex of less than 0.1
.mu.M.
31. The polypeptide of claim 1 or 7, wherein the polypeptide has an
apparent K.sub.D for KDR or VEGF/KDR complex of less than 0.05
.mu.M.
32. A method for isolating phage that bind KDR or a VEGF/KDR
complex, comprising the steps of: (a) immobilizing a KDR or
VEGF/KDR complex target on a solid support; (b) contacting a
library of potential KDR or VEGF/KDR complex binding phage with the
solid support to bind KDR or a VEGF/KDR complex binding phage in
the library; and (c) removing the unbound portion of the phage
library from the solid support, thereby isolating phage that bind
KDR or a VEGF/KDR complex.
33. A method of detecting KDR or VEGF/KDR complex in an animal or
human subject and optionally imaging at least a portion of the
animal or human subject comprising the steps of: (a) detectably
labeling a polypeptide of any one of claims 1, 7 or 10; (b)
administering to the subject the labeled polypeptide; and, (c)
detecting the labeled polypeptide in the subject, and, optionally,
constructing an image.
34. The method of claim 33, wherein the polypeptide is detectably
labeled with a label selected from the group consisting of: an
enzyme, a fluorescent compound, an ultrasound contrast agent, a
liposome and an optical dye, wherein the label optionally further
comprises a linker or a spacer.
35. The method of claim 34, wherein the ultrasound contrast agent
is a phospholipid stabilized microbubble or an ultrasound contrast
agent comprising a gas.
36. The method of claim 35, wherein the ultrasound contrast agent
comprises a fluorinated gas.
37. The method of claim 33, wherein the polypeptide is detectably
labeled with a label that is one or more radioactive labels, one or
more paramagnetic metal atoms or a superparamagnetic particle, and
optionally further comprises a linker or a spacer.
38. The method of claim 37, wherein the radioactive label comprises
one or more radionuclides selected from the group consisting of:
.sup.18F, .sup.124I, .sup.125I, .sup.131I, .sup.123I, .sup.77Br,
.sup.76Br, .sup.99mTc, .sup.51Cr, .sup.67Ga, .sup.68Ga, .sup.47Sc,
.sup.51Cr, .sup.167Tm, .sup.141Ce, .sup.111In, .sup.168Yb,
.sup.175Yb .sup.140La, .sup.90Y, .sup.88Y, .sup.153Sm, .sup.166Ho,
.sup.165Dy, .sup.166Dy, .sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.97Ru,
.sup.103Ru, .sup.186Re, .sup.188Re, .sup.203Pb, .sup.211Bi,
.sup.212Bi, .sup.213Bi, .sup.214Bi, .sup.105Rh, .sup.109Pd,
.sup.117mSn, .sup.149Pm, .sup.161Tb, .sup.177Lu, .sup.198Au and
.sup.199Au.
39. The method of claim 38, wherein the radioactive label further
comprises at least one chelator.
40. The method of claim 39, wherein the chelator is selected from
the group consisting of: formula 20, 21, 22, 23a, 23b, 24a, 24b,
and 25.
41. The method of claim 39, wherein the radionuclide is .sup.99mTc
or .sup.111In.
42. The method of claim 37, wherein the paramagnetic metal atom is
selected from the group consisting of: Mn.sup.2+, Cu.sup.2+,
Fe.sup.2+, Co.sup.2+, Ni.sup.2+, Gd.sup.3+, Eu.sup.3+, Dy.sup.3+,
Pr.sup.3+, Cr.sup.3+, Co.sup.3+, Fe.sup.3+, Ti.sup.3+, Tb.sup.3+,
Nd.sup.3+, Sm.sup.3+, Ho.sup.3+, Er.sup.3+, Pa.sup.4+ and
Eu.sup.2+.
43. The method of claim 42, wherein the paramagnetic label further
comprises a chelator.
44. The method of claim 43, wherein the chelator is selected from
the group consisting of: DTPA, DO3A, DOTA, EDTA, TETA, EHPG, HBED,
NOTA, DOTMA, TETMA, PDTA, TTHA, LICAM, and MECAM.
45. The method of claim 33, wherein detection of the labeled
polypeptide is indicative of the presence of a pathogen selected
from the group consisting of: malaria strains, HIV, SIV, simian
hemorrhagic fever virus and enterohemorrhagic E. coli strains.
46. The method of claim 33, wherein detection of the labeled
polypeptide is indicative of angiogenesis or
neovascularization.
47. The method of claim 36, wherein the ultrasound contrast agent
comprises a fluorinated gas selected from the group of: SF.sub.6
freons, CF.sub.4, C.sub.2F.sub.6, C.sub.3F.sub.8, C.sub.4F.sub.10,
CBrF.sub.3, CCI.sub.2F.sub.2, C.sub.2CIF.sub.5, CBrClF.sub.2 and
perfluorocarbons.
48. The method of claim 47, wherein the ultrasound contrast agent
comprises a perfluorocarbon gas having the formula C.sub.nF.sub.n+2
wherein n is from 1 to 12.
49. A method of treating a condition involving activation of KDR,
comprising administering to an animal or human subject in need of
treatment for such a condition a composition comprising at least
one polypeptide according to one of claims 1, 7 or 10.
50. The method of claim 49, wherein the condition is solid tumor
growth.
51. The method of claim 50, wherein the polypeptide is conjugated
with a tumorcidal agent.
52. A method of treating malaria, HIV infection, SIV infection,
simian hemorrhagic fever virus infection, and enterohemorrhagic E.
coli infection comprising administering to an animal or human
subject in need of treatment for such condition a composition
comprising a polypeptide one of claims 1, 7 or 10.
53. A recombinant bacteriophage displaying a KDR binding or
VEGF/KDR complex binding polypeptide, which polypeptide comprises
an amino acid sequence of one of the following: Consensus Sequence
1:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub-
.10-Cys-X.sub.12-X.sub.13-X.sub.14 (TN8), wherein X.sub.1 is Ala,
Arg, Asp, Gly, His, Leu, Lys, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.2 is Asn, Asp, Glu, Gly, Ile, Leu, Lys, Phe, Ser, Thr, Trp,
Tyr or Val; X.sub.3 is Asn, Asp, Gln, Glu, Ile, Leu, Met, Thr, Trp
or Val; X.sub.5 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys,
Phe, Pro, Ser, Trp or Tyr; X.sub.6 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.7 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro,
Ser, Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asp, Glu, Gly, Leu, Phe,
Pro, Ser, Thr, Trp or Tyr; X.sub.9 is Arg, Gln, Glu, Gly, Ile, Leu,
Met, Pro, Thr, Trp, Tyr or Val; X.sub.10 is Ala, Arg, Gln, Glu,
Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr; X.sub.12 is Arg,
Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr,
Trp, Tyr or Val; X.sub.13 is Arg, Asn, Asp, Gln, Glu, Gly, His,
Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp or Tyr; and X.sub.14 is Gln,
Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp or Tyr;
or Consensus Sequence 2:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub-
.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-Cys-X.sub.16-X.sub.17-X.sub.18
(TN12), wherein X.sub.1 is Ala, Asn, Asp, Gly, Leu, Pro, Ser, Trp
or Tyr; X.sub.2 is Ala, Arg, Asn, Asp, Gly, His, Phe, Pro, Ser, Trp
or Tyr; X.sub.3 is Ala, Asn, Asp, Gln, Glu, Gly, His, Leu, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.5 is Arg, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val; X.sub.6 is Ala, Arg,
Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or Tyr; X.sub.7 is Arg,
Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.8 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro, Ser,
Trp, Tyr or Val; X.sub.9 is Asp, Gln, Glu, Gly, His, Ile, Leu, Met,
Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.10 is Ala, Arg, Asn, Asp,
Gln, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.11 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys, Trp, Tyr
or Val; X.sub.12 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met, Phe,
Ser, Thr, Trp, Tyr or Val; X.sub.13 is Arg, Gln, Glu, His, Leu,
Lys, Met, Phe, Pro, Thr, Trp or Val; X.sub.14 is Arg, Asn, Asp,
Glu, His, Ile, Leu, Met, Phe, Pro, Thr, Trp, Tyr or Val; X.sub.16
is Ala, Asn, Asp, Gln, Glu, Gly, Lys, Met, Phe, Ser, Thr, Trp, Tyr
or Val; X.sub.17 is Arg, Asn, Asp, Cys, Gly, His, Phe, Pro, Ser,
Trp or Tyr; and X.sub.18 is Ala, Asn, Asp, Gly, His, Leu, Phe, Pro,
Ser, Trp or Tyr; or Consensus Sequence 3:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-Gly-X.sub.9-Cys-X.sub-
.11-X.sub.12-X.sub.13 (TN7), wherein X.sub.1 is Gly or Trp; X.sub.2
is Ile, Tyr or Val; X.sub.3 is Gln, Glu, Thr or Trp; X.sub.5 is
Asn, Asp or Glu; X.sub.6 is Glu, His, Lys or Phe; X.sub.7 is Asp,
Gln, Leu, Lys, Met or Tyr; X.sub.9 is Arg, Gln, Leu, Lys or Val;
X.sub.11 is Arg, Phe, Ser, Trp or Val; X.sub.12 is Glu, His or Ser;
and X.sub.13 is Glu, Gly, Trp or Tyr; or Consensus Sequence 4:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-
-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys-X.sub.13-X.sub.14-X.sub.15
(TN9), wherein X.sub.1 is Arg, Asp, Gly, Ile, Met, Pro or Tyr;
X.sub.2 is Asp, Gly, His, Pro or Trp; X.sub.3 is Gly, Pro, Phe, Thr
or Trp; X.sub.5 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.6 is Asn,
Glu, Gly, His or Leu; X.sub.7 is Gln, Glu, Gly, Met, Lys, Phe, Tyr
or Val; X.sub.8 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or Thr;
X.sub.9 is His, Pro or Trp; X.sub.10 is Ala, Gly, His, Leu, Trp or
Tyr; X.sub.11 is Ala, Asp, Gln, Leu, Met, Thr or Trp; X.sub.13 is
Ala, Lys, Ser, Trp or Tyr; X.sub.14 is Asp, Gly, Leu, His, Met,
Thr, Trp or Tyr; and X.sub.15 is Asn, Gln, Glu, Leu, Met, Pro or
Trp; or Consensus Sequence 5: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5--
X.sub.6-X.sub.7-X.sub.8-Ser-Gly-Pro-X.sub.12-X.sub.13-X.sub.14-X.sub.15-Cy-
s-X.sub.17-X.sub.18-X.sub.19 (SEQ ID NO:1; MTN13), wherein X.sub.1
is Arg, Glu, His, Ser or Trp; X.sub.2 is Asn, Asp, Leu, Phe, Thr or
Val; X.sub.3 is Arg, Asp, Glu, His, Lys or Thr; X.sub.5 is Asp,
Glu, His or Thr; X.sub.6 is Arg, His, Lys or Phe; X.sub.7 is Gln,
Ile, Lys, Tyr or Val; X.sub.8 is Gln, Ile, Leu, Met or Phe;
X.sub.12 is Asn, Asp, Gly, His or Tyr; X.sub.13 is Gln, Gly, Ser or
Thr; X.sub.14 is Glu, Lys, Phe or Ser; X.sub.15 is Glu, Ile, Ser or
Val; X.sub.17 is Glu, Gly, Lys, Phe, Ser or Val; X.sub.18 is Arg,
Asn, Ser or Tyr; and X.sub.19 is Asp, Gln, Glu, Gly, Met or Tyr,
and wherein the polypeptide is displayed on the surface of the
recombinant bacteriophage.
54. A magnetic resonance imaging contrast agent comprising a KDR or
VEGF/KDR complex binding polypeptide comprising an amino acid
sequence of one of the following: Consensus Sequence 1:
X.sub.1-X.sub.2-X.sub.3-Cys-X-
.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-Cys-X.sub.12-X.sub.13-X.su-
b.14 (TN8), wherein X.sub.1 is Ala, Arg, Asp, Gly, His, Leu, Lys,
Pro, Ser, Thr, Trp, Tyr or Val; X.sub.2 is Asn, Asp, Glu, Gly, Ile,
Leu, Lys, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.3 is Asn, Asp, Gln,
Glu, Ile, Leu, Met, Thr, Trp or Val; X.sub.5 is Ala, Arg, Asn, Asp,
Gln, Glu, His, Ile, Lys, Phe, Pro, Ser, Trp or Tyr; X.sub.6 is Ala,
Arg, Asn, Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Phe, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.7 is Ala, Asn, Asp, Glu, Gly, His, Ile,
Leu, Lys, Phe, Pro, Ser, Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asp,
Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.9 is Arg, Gln,
Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; X.sub.10 is
Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr;
X.sub.12 is Arg, Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe,
Pro, Ser, Thr, Trp, Tyr or Val; X.sub.13 is Arg, Asn, Asp, Gln,
Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp or Tyr; and
X.sub.14 is Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Trp or Tyr; or Consensus Sequence 2:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.su-
b.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-Cys-X.sub-
.16-X.sub.17-X.sub.18 (TN12), wherein X.sub.1 is Ala, Asn, Asp,
Gly, Leu, Pro, Ser, Trp or Tyr; X.sub.2 is Ala, Arg, Asn, Asp, Gly,
His, Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Asn, Asp, Gln, Glu,
Gly, His, Leu, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.5 is
Arg, Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val;
X.sub.6 is Ala, Arg, Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or
Tyr; X.sub.7 is Arg, Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asn, Asp, Gln, Glu, Gly, His,
Met, Phe, Pro, Ser, Trp, Tyr or Val; X.sub.9 is Asp, Gln, Glu, Gly,
His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.10 is
Ala, Arg, Asn, Asp, Gln, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.11 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Lys, Trp, Tyr or Val; X.sub.12 is Ala, Arg, Gln, Gly,
His, Ile, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.13 is
Arg, Gln, Glu, His, Leu, Lys, Met, Phe, Pro, Thr, Trp or Val;
X.sub.14 is Arg, Asn, Asp, Glu, His, Ile, Leu, Met, Phe, Pro, Thr,
Trp, Tyr or Val; X.sub.16 is Ala, Asn, Asp, Gln, Glu, Gly, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.17 is Arg, Asn, Asp,
Cys, Gly, His, Phe, Pro, Ser, Trp or Tyr; and X.sub.18 is Ala, Asn,
Asp, Gly, His, Leu, Phe, Pro, Ser, Trp or Tyr; or Consensus
Sequence 3:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-Gly-X.sub.9-Cys-X.-
sub.11-X.sub.12-X.sub.13 (TN7), wherein X.sub.1 is Gly or Trp;
X.sub.2 is Ile, Tyr or Val; X.sub.3 is Gln, Glu, Thr or Trp;
X.sub.5 is Asn, Asp or Glu; X.sub.6 is Glu, His, Lys or Phe;
X.sub.7 is Asp, Gln, Leu, Lys, Met or Tyr; X.sub.9 is Arg, Gln,
Leu, Lys or Val; X.sub.11 is Arg, Phe, Ser, Trp or Val; X.sub.12 is
Glu, His or Ser; and X.sub.13 is Glu, Gly, Trp or Tyr; or Consensus
Sequence 4: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-
-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys-X.sub.13-X.sub.14-X.sub.15
(TN9), wherein X.sub.1 is Arg, Asp, Gly, Ile, Met, Pro or Tyr;
X.sub.2 is Asp, Gly, His, Pro or Trp; X.sub.3 is Gly, Pro, Phe, Thr
or Trp; X.sub.5 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.6 is Asn,
Glu, Gly, His or Leu; X.sub.7 is Gin, Glu, Gly, Met, Lys, Phe, Tyr
or Val; X.sub.8 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or Thr;
X.sub.9 is His, Pro or Trp; X.sub.10 is Ala, Gly, His, Leu, Trp or
Tyr; X.sub.11 is Ala, Asp, Gin, Leu, Met, Thr or Trp; X.sub.13 is
Ala, Lys, Ser, Trp or Tyr; X.sub.14 is Asp, Gly, Leu, His, Met,
Thr, Trp or Tyr; and X.sub.15 is Asn, Gin, Glu, Leu, Met, Pro or
Trp; or Consensus Sequence 5: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5--
X.sub.6-X.sub.7-X.sub.8-Ser-Gly-Pro-X.sub.12-X.sub.13-X.sub.14-X.sub.15-Cy-
s-X.sub.17-X.sub.18-X.sub.19 (SEQ ID NO:1; MTN13), wherein X.sub.1
is Arg, Glu, His, Ser or Trp; X.sub.2 is Asn, Asp, Leu, Phe, Thr or
Val; X.sub.3 is Arg, Asp, Glu, His, Lys or Thr; X.sub.5 is Asp,
Glu, His or Thr; X.sub.6 is Arg, His, Lys or Phe; X.sub.7 is Gin,
Ile, Lys, Tyr or Val; X.sub.8 is Gin, Ile, Leu, Met or Phe;
X.sub.12 is Asn, Asp, Gly, His or Tyr; X.sub.13 is Gin, Gly, Ser or
Thr; X.sub.14 is Glu, Lys, Phe or Ser; X.sub.15 is Glu, Ile, Ser or
Val; X.sub.17 is Glu, Gly, Lys, Phe, Ser or Val; X.sub.18 is Arg,
Asn, Ser or Tyr; and X.sub.19 is Asp, Gin, Glu, Gly, Met or Tyr,
wherein the polypeptide is coupled to at least one chelator capable
of complexing a paramagnetic metal or at least one
superparamagnetic particle, and wherein the polypeptide optionally
comprises an N-terminal and/or C-terminal flanking peptide.
55. A magnetic resonance imaging contrast agent comprising at least
one paramagnetic metal atom or superparamagnetic particle and at
least one KDR or VEGF/KDR complex binding moiety comprising a
polypeptide of one of claims 1, 7 or 10.
56. The magnetic resonance imaging contrast agent of claim 55,
wherein the magnetic resonance imaging contrast agent further
comprises at least one chelator selected from the group consisting
of: DTPA, DOTA, EDTA, TETA, EHPG, HBED, NOTA, DOTMA, TETMA, PDTA,
TTHA, LICAM and MECAM.
57. The magnetic resonance imaging contrast agent of claim 56,
wherein the chelator is selected from the group consisting of:
diethylenetriamine, tetraazacyclododecane and a
carboxymethyl-substituted derivative thereof.
58. The magnetic resonance imaging contrast agent of claim 55,
wherein the paramagnetic metal atom is selected from the group
consisting of: Mn.sup.2+, Cu.sup.2+, Fe .sup.2+, Co.sup.2+,
Ni.sup.2+, Gd.sup.3+, Eu.sup.3+, Dy.sup.3+, Pr.sup.3+, Cr.sup.3+,
Co.sup.3+, Fe.sup.3+, Ti.sup.3+, Tb.sup.3+, Nd.sup.3+, Sm.sup.3+,
Ho.sup.3+, Er.sup.3+, Pa.sup.4+ and Eu.sup.2+.
59. The magnetic resonance imaging contrast agent of claim 58,
wherein the multivalent cation is Gd.sup.3+.
60. A method for identifying KDR or VEGF/KDR complex binding
compounds comprising the steps of: (a) utilizing a KDR or VEGF/KDR
complex binding polypeptide of one of claims 1, 7 or 10 to form a
complex with a KDR or VEGF/KDR complex target; (b) contacting the
complex with one or more potential KDR or VEGF/KDR complex binding
compounds; and (c) determining whether the potential KDR or
VEGF/KDR complex binding compound competes with the KDR or VEGF/KDR
complex binding polypeptide to form a complex with the KDR or
VEGF/KDR complex target.
61. A diagnostic imaging contrast agent comprising a polypeptide of
one of claims 1, 7 or 10.
62. A method of medical imaging comprising administering to an
animal or human subject a pharmaceutical preparation of a contrast
agent comprising at least one polypeptide of one of claims 1, 7 or
10, and imaging the contrast agent by a method selected from the
group consisting of: magnetic resonance imaging, ultrasound
imaging, optical imaging, sonoluminescence imaging, photoacoustic
imaging and nuclear imaging.
63. A method of radiotherapy comprising administering to an animal
or human subject in need of such therapy a compound comprising at
least one polypeptide of one of claims 1, 7 or 10 conjugated to one
or more radionuclides useful for radiotherapy.
64. The method of claim 63, wherein the compound further comprises
one or more chelators.
65. The method of claim 64, wherein the compound further comprises
a spacer or linker.
66. The method of claims 64, wherein the chelator is a compound
selected from the group consisting of: formula 20, 21, 22, 23, 24
and 25.
67. The method of claim 63, wherein the radionuclide is .sup.186Re,
.sup.188Re, .sup.177Lu, .sup.90Y, .sup.153Sm or .sup.166Ho.
68. A kit for preparation of a radiopharmaceutical comprising a
polypeptide of one of claims 1, 7 or 10, one or more chelators for
one or more radionuclides, and one or more reducing agents.
69. A method of targeting genetic material to KDR-expressing cells
comprising administering to an animal or a human in need of such
genetic material a polypeptide of one of claims 1, 7 or 10
conjugated to or associated with the genetic material or a delivery
vehicle containing such genetic material.
70. A method of screening binding polypeptides identified by phage
display for their ability to bind to cells expressing the target
comprising the steps of preparing one or more multimeric constructs
comprising one or more binding polypeptides; contacting the
multimeric constructs with cells expressing the target; and
assessing the ability of the multimeric constructs to bind to the
target.
71. The method of claim 70, wherein the cells have been engineered
by recombinant DNA technology to express the target.
72. The method of claim 70, wherein the multimeric constructs are
detectably labeled.
73. The method of claim 70, wherein the ability of the multimeric
constructs to bind to the target is assessed in the presence of
serum.
74. The method of claim 70, wherein the multimeric constructs
comprise biotinylated binding polypeptides complexed with avidin,
streptavidin or neutravidin.
75. The method of claim 70, wherein the target is KDR or the
KDR/VEGF complex.
76. A multimeric polypeptide construct having the ability to bind
to KDR or VEGF/KDR complex comprising at least one amino acid
selected from the group consisting of: Loop Consensus Sequence 15:
Cys-X.sub.2-X.sub.3-X.su- b.4-X.sub.5-X.sub.6-X.sub.7-Cys (TN8),
wherein X2 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys, Phe,
Pro, Ser, Trp or Tyr; X3 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His,
Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; X4 is Ala, Asn,
Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro, Ser, Thr, Trp, Tyr or
Val; X5 is Ala, Asp, Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr;
X6 is Arg, Gln, Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val;
and X7 is Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe,
Trp or Tyr; or Loop Consensus Sequence 16:
Cys-X.sub.2-X.sub.3-X.sub.4-X.-
sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys (TN12),
wherein X2 is Arg, Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Thr,
Trp, Tyr or Val; X3 is Ala, Arg, Asn, Cys, Glu, Ile, Leu, Met, Phe,
Ser, Trp or Tyr; X4 is Arg, Asn, Asp, Gln, Glu, His, Ile, Leu, Pro,
Ser, Thr, Trp, Tyr or Val; X5 is Ala, Asn, Asp, Gln, Glu, Gly, His,
Met, Phe, Pro, Ser, Trp, Tyr or Val; X6 is Asp, Gln, Glu, Gly, His,
Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp or Tyr; X7 is Ala, Arg, Asn,
Asp, Gln, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or
Val; X8 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys, Trp, Tyr or
Val; X9 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met, Phe, Ser, Thr,
Trp, Tyr or Val; X10 is Arg, Gln, Glu, His, Leu, Lys, Met, Phe,
Pro, Thr, Trp or Val; and X11 is Arg, Asn, Asp, Glu, His, Ile, Leu,
Met, Phe, Pro, Thr, Trp, Tyr or Val; or Loop Consensus Sequence 17:
Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6-Cys (TN7), wherein X2 is
Asn, Asp or Glu; X3 is Glu, His, Lys or Phe; X4 is Asp, Gln, Leu,
Lys, Met or Tyr; and X6 is Arg, Gln, Leu, Lys or Val; or Consensus
Sequence IV:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-Cys
(TN9), wherein X2 is Ala, Asp, Lys, Ser, Trp or Val; X3 is Asn,
Glu, Gly, His or Leu; X4 is Gln, Glu, Gly, Met, Lys, Phe, Tyr or
Val; X5 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or Thr; X6 is
His, Pro or Trp; X7 is Ala, Gly, His, Leu, Trp or Tyr; and X8 is
Ala, Asp, Gln, Leu, Met, Thr or Trp; or Loop Consensus Sequence 18:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X- .sub.7-X.sub.8-Cys
(TN9), wherein X.sub.2 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.3
is Asn, Glu, Gly, His or Leu; X.sub.4 is Gln, Glu, Gly, Met, Lys,
Phe, Tyr or Val; X.sub.5 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser
or Thr; X.sub.6 is His, Pro or Trp; X.sub.7 is Ala, Gly, His, Leu,
Trp or Tyr; and X.sub.8 is Ala, Asp, Gln, Leu, Met, Thr or Trp; or
Loop Consensus Sequence 19:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Ser-Gly-Pro-X.-
sub.9-X.sub.10-X.sub.11-X.sub.12-Cys (MTN13; SEQ ID NO:1), wherein
X.sub.2 is Asp, Glu, His or Thr; X.sub.3 is Arg, His, Lys or Phe;
X.sub.4 is Gln, lie, Lys, Tyr or Val; X.sub.5 is Gln, Ile, Leu, Met
or Phe; X.sub.9 is Asn, Asp, Gly, His or Tyr; X.sub.10 is Gln, Gly,
Ser or Thr; X.sub.11 is Glu, Lys, Phe or Ser; and X.sub.12 is Glu,
Ile, Ser or Val.
77. A multimeric polypeptide construct having the ability to bind
to KDR or VEGF/KDR complex comprising at least one amino acid
sequence selected from: Consensus Sequence 1:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X-
.sub.7-X.sub.8-X.sub.9-X.sub.10-Cys-X.sub.12-X.sub.13-X.sub.14
(TN8), wherein X.sub.1 is Ala, Arg, Asp, Gly, His, Leu, Lys, Pro,
Ser, Thr, Trp, Tyr or Val; X.sub.2 is Asn, Asp, Glu, Gly, Ile, Leu,
Lys, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.3 is Asn, Asp, Gln, Glu,
Ile, Leu, Met, Thr, Trp or Val; X.sub.5 is Ala, Arg, Asn, Asp, Gln,
Glu, His, Ile, Lys, Phe, Pro, Ser, Trp or Tyr; X.sub.6 is Ala, Arg,
Asn, Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr,
Trp, Tyr or Val; X.sub.7 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu,
Lys, Phe, Pro, Ser, Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asp, Glu,
Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.9 is Arg, Gln, Glu,
Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; X.sub.10 is Ala,
Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr;
X.sub.12 is Arg, Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe,
Pro, Ser, Thr, Trp, Tyr or Val; X.sub.13 is Arg, Asn, Asp, Gln,
Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp or Tyr; and
X.sub.14 is Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Trp or Tyr; or Consensus Sequence 2:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-
-X.sub.8-X.sub.9-X.sub.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-Cys-X.sub.16-
-X.sub.17-X.sub.18 (TN12), wherein X.sub.1 is Ala, Asn, Asp, Gly,
Leu, Pro, Ser, Trp or Tyr; X.sub.2 is Ala, Arg, Asn, Asp, Gly, His,
Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Asn, Asp, Gln, Glu, Gly,
His, Leu, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.5 is Arg,
Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val;
X.sub.6 is Ala, Arg, Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or
Tyr; X.sub.7 is Arg, Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asn, Asp, Gln, Glu, Gly, His,
Met, Phe, Pro, Ser, Trp, Tyr or Val; X.sub.9 is Asp, Gln, Glu, Gly,
His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.10 is
Ala, Arg, Asn, Asp, Gln, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.11 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Lys, Trp, Tyr or Val; X.sub.12 is Ala, Arg, Gln, Gly,
His, Ile, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.13 is
Arg, Gln, Glu, His, Leu, Lys, Met, Phe, Pro, Thr, Trp or Val;
X.sub.14 is Arg, Asn, Asp, Glu, His, Ile, Leu, Met, Phe, Pro, Thr,
Trp, Tyr or Val; X.sub.16 is Ala, Asn, Asp, Gln, Glu, Gly, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.17 is Arg, Asn, Asp,
Cys, Gly, His, Phe, Pro, Ser, Trp or Tyr; and X.sub.18 is Ala, Asn,
Asp, Gly, His, Leu, Phe, Pro, Ser, Trp or Tyr; or Consensus
Sequence 3:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-Gly-X.sub.9-Cys-X.-
sub.11-X.sub.12-X.sub.13 (TN7), wherein X.sub.1 is Gly or Trp;
X.sub.2 is Ile, Tyr or Val; X.sub.3 is Gln, Glu, Thr or Trp;
X.sub.5 is Asn, Asp or Glu; X.sub.6 is Glu, His, Lys or Phe;
X.sub.7 is Asp, Gln, Leu, Lys, Met or Tyr; X.sub.9 is Arg, Gln,
Leu, Lys or Val; X.sub.11 is Arg, Phe, Ser, Trp or Val; X.sub.12 is
Glu, His or Ser; and X.sub.13 is Glu, Gly, Trp or Tyr; or Consensus
Sequence 4: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-
-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys-X.sub.13-X.sub.14-X.sub.15
(TN9), wherein X.sub.1 is Arg, Asp, Gly, Ile, Met, Pro or Tyr;
X.sub.2 is Asp, Gly, His, Pro or Trp; X.sub.3 is Gly, Pro, Phe, Thr
or Trp; X.sub.5 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.6 is Asn,
Glu, Gly, His or Leu; X.sub.7 is Gln, Glu, Gly, Met, Lys, Phe, Tyr
or Val; X.sub.8 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or Thr;
X.sub.9 is His, Pro or Trp; X.sub.10 is Ala, Gly, His, Leu, Trp or
Tyr; X.sub.11 is Ala, Asp, Gln, Leu, Met, Thr or Trp; X.sub.13 is
Ala, Lys, Ser, Trp or Tyr; X.sub.14 is Asp, Gly, Leu, His, Met,
Thr, Trp or Tyr; and X.sub.15 is Asn, Gln, Glu, Leu, Met, Pro or
Trp; or Consensus Sequence 5: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5--
X.sub.6-X.sub.7-X.sub.8-Ser-Gly-Pro-X.sub.12-X.sub.13-X.sub.14-X.sub.15-Cy-
s-X.sub.17-X.sub.18-X.sub.19 (SEQ ID NO:1; MTN13), wherein X.sub.1
is Arg, Glu, His, Ser or Trp; X.sub.2 is Asn, Asp, Leu, Phe, Thr or
Val; X.sub.3 is Arg, Asp, Glu, His, Lys or Thr; X.sub.5 is Asp,
Glu, His or Thr; X.sub.6 is Arg, His, Lys or Phe; X.sub.7 is Gln,
Ile, Lys, Tyr or Val; X.sub.8 is Gln, Ile, Leu, Met or Phe;
X.sub.12 is Asn, Asp, Gly, His or Tyr; X.sub.13 is Gln, Gly, Ser or
Thr; X.sub.14 is Glu, Lys, Phe or Ser; X.sub.15 is Glu, Ile, Ser or
Val; X.sub.17 is Glu, Gly, Lys, Phe, Ser or Val; X.sub.18 is Arg,
Asn, Ser or Tyr; and X.sub.19 is Asp, Gln, Glu, Gly, Met or
Tyr.
78. A multimeric polypeptide construct having the ability to bind
to KDR or VEGF/KDR complex comprising at least one amino acid
sequence of one of the following: Consensus Sequence 13:
Z.sub.1-X.sub.1-X.sub.2-X.sub.3-X.s- ub.4-X.sub.5-Z.sub.2 (Lin20);
wherein, Z.sub.1 is a polypeptide of at least one amino acid or is
absent; X.sub.1 is Ala, Asp, Gln or Glu; X.sub.2 is Ala, Asp, Gln,
Glu, Pro; X.sub.3 is Ala, Leu, Lys, Phe, Pro, Trp or Tyr; X.sub.4
is Asp, Leu, Ser, Trp, Tyr or Val; X.sub.5 is Ala, Arg, Asp, Glu,
Gly, Leu, Trp or Tyr; and Z.sub.2 is a polypeptide of at least one
amino acid or is absent; or Consensus Sequence 14:
X.sub.1-X.sub.2-X.sub.3-Tyr-Trp-Glu-X.sub.7-X.sub.8-X.sub.9-Leu
(Lin20; SEQ ID NO:7), wherein, the sequence can optionally have a
N-terminal polypeptide, C-terminal polypeptide, or a polypeptide at
both termini of at least one amino acid; wherein, X.sub.2 is Asp,
Gly or Ser; X.sub.2 is Ile, Phe or Tyr; X.sub.3 is Ala, Ser or Val;
X.sub.7 is Gln, Glu, Ile or Val; X.sub.8 is Ala, Ile or Val;
X.sub.9 is Ala, Glu, Val or Thr.
79. The multimeric polypeptide construct of claim 77, comprising at
least one amino acid sequence selected from the group consisting
of: SEQ ID NOS: 20-86, 87-136, 187-192, 193-203 and 207-259.
80. The multimeric polypeptide construct of claim 78, comprising at
least one amino acid sequence selected from the group consisting
of: SEQ ID NOS: 137-186.
81. The multimeric polypeptide construct of any one of claims 76,
77 or 78, wherein at least one amino acid sequence further
comprises N-terminal and/or C-terminal flanking peptides of one or
more amino acids.
82. The multimeric polypeptide construct of any of claims 76, 77 or
78, wherein at least one amino acid sequence comprises a
modification selected from the group consisting of: an amino acid
substitution, and amide bond substitution, a D-amino acid
substitution, a glycosylated amino acid, a disulfide mimetic
substitution, an amino acid translocation, a retroinverso peptide,
a peptoid, a retro-inverso peptoid, and a synthetic peptide.
83. The multimeric polypeptide construct of any one of claims 76,
77 or 78, wherein the multimeric polypeptide construct is
conjugated to one or more detectable labels or therapeutic agents,
optionally further comprising a linker or spacer between the
polypeptide and the detectable label or the therapeutic agent.
84. The multimeric polypeptide construct of claim 83, wherein the
detectable label or the therapeutic agent is selected from the
group consisting of: an enzyme, a fluorescent compound, a liposome,
an optical dye, one or more paramagnetic metal ions or
superparamagnetic particles, an ultrasound contrast agent and one
or more radionuclides.
85. The multimeric polypeptide construct of claim 84, wherein the
therapeutic agent or detectable label comprises one or more
radionuclides.
86. The multimeric polypeptide construct of claim 85, wherein the
radionuclide is selected from the group consisting of: .sup.18F,
.sup.124I, .sup.125I, .sup.131I, .sup.123I, .sup.77Br, .sup.76Br,
.sup.99mTc, .sup.51Cr, .sup.67Ga, .sup.68Ga, .sup.47Sc, .sup.51Cr,
.sup.167Tm, .sup.141Ce, .sup.111In, .sup.168Yb, .sup.175Yb,
.sup.140La, .sup.90Y, .sup.88Y, .sup.153Sm, .sup.166Ho, .sup.165Dy,
.sup.166Dy, .sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.97Ru, .sup.103Ru,
.sup.186Re, .sup.188Re, .sup.203Pb, .sup.211Bi, .sup.212Bi,
.sup.213Bi, .sup.214Bi, .sup.105Rh, .sup.109Pd, .sup.117mSn,
.sup.149Pm, .sup.161Tb, .sup.177Lu, .sup.198Au and .sup.199Au.
87. The multimeric polypeptide construct of claim 86, wherein the
therapeutic agent or detectable label further comprises a
chelator.
88. The multimeric polypeptide construct of claim 87, wherein the
chelator comprises a compound selected from the group consisting
of: formula 20, 21, 22, 23a, 23b, 24a, 24b, and 25.
89. The multimeric polypeptide construct of claim 87, wherein the
radionuclide is .sup.99mTc or .sup.111In.
90. The multimeric polypeptide construct of claim 87, wherein the
radionuclide is selected from the group consisting of: .sup.177Lu,
.sup.90Y, .sup.153Sm and .sup.166Ho.
91. The multimeric polypeptide construct of claim 84, wherein the
detectable label comprises an ultrasound contrast agent.
92. The multimeric polypeptide construct of claim 91, wherein the
ultrasound contrast agent comprises a phospholipid stabilized
microbubble or a microballoon comprising a gas.
93. The multimeric polypeptide construct of claim 91, wherein the
ultrasound contrast agent comprises a fluorinated gas.
94. The multimeric polypeptide construct of claim 84, wherein the
detectable label comprises one or more paramagnetic metal ions and
one or more chelators.
95. The multimeric polypeptide construct of claim 84, wherein the
therapeutic agent is selected from the group consisting of: a
bioactive agent, a cytotoxic agent, a drug, a chemotherapeutic
agent and a radiotherapeutic agent.
96. An ultrasound contrast agent comprising at least one KDR or
VEGF/KDR complex binding polypeptide comprising an amino acid
sequence of one of the following and optionally further comprising
N-terminal and/or C-terminal flanking peptides of one or more amino
acids: Consensus Sequence 1:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X-
.sub.9-X.sub.10-Cys-X.sub.12-X.sub.13-X.sub.14 (TN8), wherein
X.sub.1 is Ala, Arg, Asp, Gly, His, Leu, Lys, Pro, Ser, Thr, Trp,
Tyr or Val; X.sub.2 is Asn, Asp, Glu, Gly, Ile, Leu, Lys, Phe, Ser,
Thr, Trp, Tyr or Val; X.sub.3 is Asn, Asp, Gln, Glu, Ile, Leu, Met,
Thr, Trp or Val; X.sub.5 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile,
Lys, Phe, Pro, Ser, Trp or Tyr; X.sub.6 is Ala, Arg, Asn, Asp, Gln,
Glu, Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.7 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro,
Ser, Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asp, Glu, Gly, Leu, Phe,
Pro, Ser, Thr, Trp or Tyr; X.sub.9 is Arg, Gln, Glu, Gly, Ile, Leu,
Met, Pro, Thr, Trp, Tyr or Val; X.sub.10 is Ala, Arg, Gln, Glu,
Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr; X.sub.12 is Arg,
Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr,
Trp, Tyr or Val; X.sub.13 is Arg, Asn, Asp, Gln, Glu, Gly, His,
Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp or Tyr; and X.sub.14 is Gln,
Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp or Tyr;
or Consensus Sequence 2:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.-
sub.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-Cys-X.sub.16-X.sub.17-X.sub.18
(TN12), wherein X.sub.1 is Ala, Asn, Asp, Gly, Leu, Pro, Ser, Trp
or Tyr; X.sub.2 is Ala, Arg, Asn, Asp, Gly, His, Phe, Pro, Ser, Trp
or Tyr; X.sub.3 is Ala, Asn, Asp, Gln, Glu, Gly, His, Leu, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.5 is Arg, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val; X.sub.6 is Ala, Arg,
Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or Tyr; X.sub.7 is Arg,
Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.8 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro, Ser,
Trp, Tyr or Val; X.sub.9 is Asp, Gln, Glu, Gly, His, Ile, Leu, Met,
Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.10 is Ala, Arg, Asn, Asp,
Gln, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.11 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys, Trp, Tyr
or Val; X.sub.12 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met, Phe,
Ser, Thr, Trp, Tyr or Val; X.sub.13 is Arg, Gln, Glu, His, Leu,
Lys, Met, Phe, Pro, Thr, Trp or Val; X.sub.14 is Arg, Asn, Asp,
Glu, His, Ile, Leu, Met, Phe, Pro, Thr, Trp, Tyr or Val; X.sub.16
is Ala, Asn, Asp, Gln, Glu, Gly, Lys, Met, Phe, Ser, Thr, Trp, Tyr
or Val; X.sub.17 is Arg, Asn, Asp, Cys, Gly, His, Phe, Pro, Ser,
Trp or Tyr; and X.sub.18 is Ala, Asn, Asp, Gly, His, Leu, Phe, Pro,
Ser, Trp or Tyr; or Consensus Sequence 3:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-Gly-X.sub.9-Cys-X.sub-
.11-X.sub.12-X.sub.13 (TN7), wherein X.sub.1 is Gly or Trp; X.sub.2
is Ile, Tyr or Val; X.sub.3 is Gln, Glu, Thr or Trp; X.sub.5 is
Asn, Asp or Glu; X.sub.6 is Glu, His, Lys or Phe; X.sub.7 is Asp,
Gln, Leu, Lys, Met or Tyr; X.sub.9 is Arg, Gln, Leu, Lys or Val;
X.sub.11 is Arg, Phe, Ser, Trp or Val; X.sub.12 is Glu, His or Ser;
and X.sub.13 is Glu, Gly, Trp or Tyr; or Consensus Sequence 4:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-
-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys-X.sub.13-X.sub.14-X.sub.15
(TN9), wherein X.sub.1 is Arg, Asp, Gly, Ile, Met, Pro or Tyr;
X.sub.2 is Asp, Gly, His, Pro or Trp; X.sub.3 is Gly, Pro, Phe, Thr
or Trp; X.sub.5 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.6 is Asn,
Glu, Gly, His or Leu; X.sub.7 is Gln, Glu, Gly, Met, Lys, Phe, Tyr
or Val; X.sub.8 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or Thr;
X.sub.9 is His, Pro or Trp; X.sub.10 is Ala, Gly, His, Leu, Trp or
Tyr; X.sub.11 is Ala, Asp, Gln, Leu, Met, Thr or Trp; X.sub.13 is
Ala, Lys, Ser, Trp or Tyr; X.sub.14 is Asp, Gly, Leu, His, Met,
Thr, Trp or Tyr; and X.sub.15 is Asn, Gln, Glu, Leu, Met, Pro or
Trp; or Consensus Sequence 5: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5--
X.sub.6-X.sub.7-X.sub.8-Ser-Gly-Pro-X.sub.12-X.sub.13-X.sub.14-X.sub.15-Cy-
s-X.sub.17-X.sub.18-X.sub.19 (SEQ ID NO:1; MTN13), wherein X.sub.1
is Arg, Glu, His, Ser or Trp; X.sub.2 is Asn, Asp, Leu, Phe, Thr or
Val; X.sub.3 is Arg, Asp, Glu, His, Lys or Thr; X.sub.5 is Asp,
Glu, His or Thr; X.sub.6 is Arg, His, Lys or Phe; X.sub.7 is Gln,
Ile, Lys, Tyr or Val; X.sub.8 is Gln, Ile, Leu, Met or Phe;
X.sub.12 is Asn, Asp, Gly, His or Tyr; X.sub.13 is Gln, Gly, Ser or
Thr; X.sub.14 is Glu, Lys, Phe or Ser; X.sub.15 is Glu, Ile, Ser or
Val; X.sub.17 is Glu, Gly, Lys, Phe, Ser or Val; X.sub.18 is Arg,
Asn, Ser or Tyr; and X.sub.19 is Asp, Gln, Glu, Gly, Met or Tyr,
wherein at least one polypeptide is conjugated to microvesicles
filled with gas or material useful for preparing microvesicles
filled with gas.
97. The ultrasound contrast agent of claim 96, wherein the gas
filled microvesicles comprise phospholipid stabilized microbubbles
or microballoons.
98. The ultrasound contrast agent of claim 97, wherein the
phospholipid stabilized microbubbles or microballoons further
comprise a fluorinated gas.
99. A scintigraphic imaging agent comprising at least one KDR or
VEGF/KDR complex binding polypeptide comprising an amino acid
sequence of one of the following: Consensus Sequence 1:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5--
X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-Cys-X.sub.12-X.sub.13-X.sub.14
(TN8), wherein X.sub.1 is Ala, Arg, Asp, Gly, His, Leu, Lys, Pro,
Ser, Thr, Trp, Tyr or Val; X.sub.2 is Asn, Asp, Glu, Gly, Ile, Leu,
Lys, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.3 is Asn, Asp, Gln, Glu,
Ile, Leu, Met, Thr, Trp or Val; X.sub.5 is Ala, Arg, Asn, Asp, Gln,
Glu, His, Ile, Lys, Phe, Pro, Ser, Trp or Tyr; X.sub.6 is Ala, Arg,
Asn, Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr,
Tip, Tyr or Val; X.sub.7 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu,
Lys, Phe, Pro, Ser, Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asp, Glu,
Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.9 is Arg, Gln, Glu,
Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; X.sub.10 is Ala,
Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr;
X.sub.12 is Arg, Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe,
Pro, Ser, Thr, Trp, Tyr or Val; X.sub.13 is Arg, Asn, Asp, Gln,
Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp or Tyr; and
X.sub.14 is Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Trp or Tyr; or Consensus Sequence 2:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-
-X.sub.8-X.sub.9-X.sub.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-Cys-X.sub.16-
-X.sub.17-X.sub.18 (TN12), wherein X.sub.1 is Ala, Asn, Asp, Gly,
Leu, Pro, Ser, Trp or Tyr; X.sub.2 is Ala, Arg, Asn, Asp, Gly, His,
Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Asn, Asp, Gln, Glu, Gly,
His, Leu, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.5 is Arg,
Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val;
X.sub.6 is Ala, Arg, Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or
Tyr; X.sub.7 is Arg, Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asn, Asp, Gln, Glu, Gly, His,
Met, Phe, Pro, Ser, Trp, Tyr or Val; X.sub.9 is Asp, Gln, Glu, Gly,
His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.10 is
Ala, Arg, Asn, Asp, Gln, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.11 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Lys, Trp, Tyr or Val; X.sub.12 is Ala, Arg, Gln, Gly,
His, Ile, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.13 is
Arg, Gln, Glu, His, Leu, Lys, Met, Phe, Pro, Thr, Trp or Val;
X.sub.14 is Arg, Asn, Asp, Glu, His, Ile, Leu, Met, Phe, Pro, Thr,
Trp, Tyr or Val; X.sub.16 is Ala, Asn, Asp, Gln, Glu, Gly, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.17 is Arg, Asn, Asp,
Cys, Gly, His, Phe, Pro, Ser, Trp or Tyr; and X.sub.18 is Ala, Asn,
Asp, Gly, His, Leu, Phe, Pro, Ser, Trp or Tyr; or Consensus
Sequence 3:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-Gly-X.sub.9-Cys-X.-
sub.11-X.sub.12-X.sub.13 (TN7), wherein X.sub.1 is Gly or Trp;
X.sub.2 is Ile, Tyr or Val; X.sub.3 is Gln, Glu, Thr or Trp;
X.sub.5 is Asn, Asp or Glu; X.sub.6 is Glu, His, Lys or Phe;
X.sub.7 is Asp, Gln, Leu, Lys, Met or Tyr; X.sub.9 is Arg, Gln,
Leu, Lys or Val; X.sub.11 is Arg, Phe, Ser, Trp or Val; X.sub.12 is
Glu, His or Ser; and X.sub.13 is Glu, Gly, Trp or Tyr; or Consensus
Sequence 4: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-
-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys-X.sub.13-X.sub.14-X.sub.15
(TN9), wherein X.sub.1 is Arg, Asp, Gly, Ile, Met, Pro or Tyr;
X.sub.2 is Asp, Gly, His, Pro or Trp; X.sub.3 is Gly, Pro, Phe, Thr
or Trp; X.sub.5 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.6 is Asn,
Glu, Gly, His or Leu; X.sub.7 is Gln, Glu, Gly, Met, Lys, Phe, Tyr
or Val; X.sub.8 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or Thr;
X.sub.9 is His, Pro or Trp; X.sub.10 is Ala, Gly, His, Leu, Trp or
Tyr; X.sub.11 is Ala, Asp, Gln, Leu, Met, Thr or Trp; X.sub.13 is
Ala, Lys, Ser, Trp or Tyr; X.sub.14 is Asp, Gly, Leu, His, Met,
Thr, Trp or Tyr; and X.sub.15 is Asn, Gln, Glu, Leu, Met, Pro or
Trp; or Consensus Sequence 5: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5--
X.sub.6-X.sub.7-X.sub.8-Ser-Gly-Pro-X.sub.12-X.sub.13-X.sub.14-X.sub.15-Cy-
s-X.sub.17-X.sub.18-X.sub.19 (SEQ ID NO:1; MTN13), wherein X.sub.1
is Arg, Glu, His, Ser or Trp; X.sub.2 is Asn, Asp, Leu, Phe, Thr or
Val; X.sub.3 is Arg, Asp, Glu, His, Lys or Thr; X.sub.5 is Asp,
Glu, His or Thr; X.sub.6 is Arg, His, Lys or Phe; X.sub.7 is Gln,
Ile, Lys, Tyr or Val; X.sub.8 is Gln, Ile, Leu, Met or Phe;
X.sub.12 is Asn, Asp, Gly, His or Tyr; X.sub.13 is Gln, Gly, Ser or
Thr; X.sub.14 is Glu, Lys, Phe or Ser; X.sub.15 is Glu, Ile, Ser or
Val; X.sub.17 is Glu, Gly, Lys, Phe, Ser or Val; X.sub.18 is Arg,
Asn, Ser or Tyr; and X.sub.19 is Asp, Gln, Glu, Gly, Met or Tyr,
wherein at least one polypeptide is coupled to at least one
chelator capable of complexing a radionuclide useful for
scintigraphic imaging, and wherein the polypeptide optionally
further comprises N-terminal and/or C-terminal flanking peptides of
one or more amino acids.
100. A scintigraphic imaging agent comprising at least one
radionuclide useful in scintigraphic imaging and at least one KDR
or VEGF/KDR complex binding moiety comprising a polypeptide of one
of claims 1, 7 or 10.
101. The scintigraphic imaging agent of claim 100, further
comprising at least one chelator selected from the group consisting
of: formula 20, 21, 22, 23a, 23b, 24a, 24b and 25.
102. The scintigraphic imaging agent of claim 101, wherein the
radionuclide is selected from the group consisting of .sup.99mTc
and .sup.111In.
103. An agent useful in radiotherapy comprising at least one KDR or
VEGF/KDR complex binding polypeptide comprising an amino acid
sequence of one of the following: Consensus Sequence 1:
X.sub.1-X.sub.2-X.sub.3-Cys-X-
.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-Cys-X.sub.12-X.sub.13-X.su-
b.14 (TN8), wherein X.sub.1 is Ala, Arg, Asp, Gly, His, Leu, Lys,
Pro, Ser, Thr, Trp, Tyr or Val; X.sub.2 is Asn, Asp, Glu, Gly, Ile,
Leu, Lys, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.3 is Asn, Asp, Gln,
Glu, Ile, Leu, Met, Thr, Trp or Val; X.sub.5 is Ala, Arg, Asn, Asp,
Gln, Glu, His, Ile, Lys, Phe, Pro, Ser, Trp or Tyr; X.sub.6 is Ala,
Arg, Asn, Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Phe, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.7 is Ala, Asn, Asp, Glu, Gly, His, Ile,
Leu, Lys, Phe, Pro, Ser, Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asp,
Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.9 is Arg, Gln,
Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; X.sub.10 is
Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr;
X.sub.12 is Arg, Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe,
Pro, Ser, Thr, Trp, Tyr or Val; X.sub.13 is Arg, Asn, Asp, Gln,
Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp or Tyr; and
X.sub.14 is Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Trp or Tyr; or Consensus Sequence 2:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.su-
b.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-Cys-X.sub-
.16-X.sub.17-X.sub.18 (TN12), wherein X.sub.1 is Ala, Asn, Asp,
Gly, Leu, Pro, Ser, Trp or Tyr; X.sub.2 is Ala, Arg, Asn, Asp, Gly,
His, Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Asn, Asp, Gln, Glu,
Gly, His, Leu, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.5 is
Arg, Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val;
X.sub.6 is Ala, Arg, Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or
Tyr; X.sub.7 is Arg, Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asn, Asp, Gln, Glu, Gly, His,
Met, Phe, Pro, Ser, Trp, Tyr or Val; X.sub.9 is Asp, Gln, Glu, Gly,
His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.10 is
Ala, Arg, Asn, Asp, Gln, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.11 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Lys, Trp, Tyr or Val; X.sub.12 is Ala, Arg, Gln, Gly,
His, Ile, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.13 is
Arg, Gln, Glu, His, Leu, Lys, Met, Phe, Pro, Thr, Trp or Val;
X.sub.14 is Arg, Asn, Asp, Glu, His, Ile, Leu, Met, Phe, Pro, Thr,
Trp, Tyr or Val; X.sub.16 is Ala, Asn, Asp, Gln, Glu, Gly, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.17 is Arg, Asn, Asp,
Cys, Gly, His, Phe, Pro, Ser, Trp or Tyr; and X.sub.18 is Ala, Asn,
Asp, Gly, His, Leu, Phe, Pro, Ser, Trp or Tyr; or Consensus
Sequence 3:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-Gly-X.sub.9-Cys-X.-
sub.11-X.sub.12-X.sub.13 (TN7), wherein X.sub.1 is Gly or Trp;
X.sub.2 is Ile, Tyr or Val; X.sub.3 is Gln, Glu, Thr or Trp;
X.sub.5 is Asn, Asp or Glu; X.sub.6 is Glu, His, Lys or Phe;
X.sub.7 is Asp, Gln, Leu, Lys, Met or Tyr; X.sub.9 is Arg, Gln,
Leu, Lys or Val; X.sub.11 is Arg, Phe, Ser, Trp or Val; X.sub.12 is
Glu, His or Ser; and X.sub.13 is Glu, Gly, Trp or Tyr; or Consensus
Sequence 4: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-
-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys-X.sub.13-X.sub.14-X.sub.15
(TN9), wherein X.sub.1 is Arg, Asp, Gly, Ile, Met, Pro or Tyr;
X.sub.2 is Asp, Gly, His, Pro or Trp; X.sub.3 is Gly, Pro, Phe, Thr
or Trp; X.sub.5 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.6 is Asn,
Glu, Gly, His or Leu; X.sub.7 is Gln, Glu, Gly, Met, Lys, Phe, Tyr
or Val; X.sub.8 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or Thr;
X.sub.9 is His, Pro or Trp; X.sub.10 is Ala, Gly, His, Leu, Trp or
Tyr; X.sub.11 is Ala, Asp, Gln, Leu, Met, Thr or Trp; X.sub.13 is
Ala, Lys, Ser, Trp or Tyr; X.sub.14 is Asp, Gly, Leu, His, Met,
Thr, Trp or Tyr; and X.sub.15 is Asn, Gln, Glu, Leu, Met, Pro or
Trp; Consensus Sequence 5: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.s-
ub.6-X.sub.7-X.sub.8-Ser-Gly-Pro-X.sub.12-X.sub.13-X.sub.14-X.sub.15-Cys-X-
.sub.17-X.sub.18-X.sub.19 (SEQ ID NO:1; MTN13), wherein X.sub.1 is
Arg, Glu, His, Ser or Trp; X.sub.2 is Asn, Asp, Leu, Phe, Thr or
Val; X.sub.3 is Arg, Asp, Glu, His, Lys or Thr; X.sub.5 is Asp,
Glu, His or Thr; X.sub.6 is Arg, His, Lys or Phe; X.sub.7 is Gln,
Ile, Lys, Tyr or Val; X.sub.8 is Gln, Ile, Leu, Met or Phe;
X.sub.12 is Asn, Asp, Gly, His or Tyr; X.sub.13 is Gln, Gly, Ser or
Thr; X.sub.14 is Glu, Lys, Phe or Ser; X.sub.15 is Glu, Ile, Ser or
Val; X.sub.17 is Glu, Gly, Lys, Phe, Ser or Val; X.sub.18 is Arg,
Asn, Ser or Tyr; and X.sub.19 is Asp, Gln, Glu, Gly, Met or Tyr;
Consensus Sequence 13: Z.sub.1-X.sub.1-X.sub.2-X.sub.3-X-
.sub.4-X.sub.5-Z.sub.2 (Lin20); wherein, Z.sub.1 is a polypeptide
of at least one amino acid or is absent; X.sub.1 is Ala, Asp, Gln
or Glu; X.sub.2 is Ala, Asp, Gln, Glu, Pro; X.sub.3 is Ala, Leu,
Lys, Phe, Pro, Trp or Tyr; X.sub.4 is Asp, Leu, Ser, Trp, Tyr or
Val; X.sub.5 is Ala, Arg, Asp, Glu, Gly, Leu, Trp or Tyr; and
Z.sub.2 is a polypeptide of at least one amino acid or is absent;
Consensus Sequence 14:
X.sub.1-X.sub.2-X.sub.3-Tyr-Trp-Glu-X.sub.7-X.sub.8-X.sub.9-Leu
(Lin20; SEQ ID NO:7), wherein, the sequence can optionally have a
N-terminal polypeptide, C-terminal polypeptide, or a polypeptide at
both termini of at least one amino acid; wherein, X.sub.1 is Asp,
Gly or Ser; X.sub.2 is Ile, Phe or Tyr; X.sub.3 is Ala, Ser or Val;
X.sub.7 is Gln, Glu, Ile or Val; X.sub.8 is Ala, Ile or Val;
X.sub.9 is Ala, Glu, Val or Thr; Loop Consensus Sequence 15:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.- 7-Cys (TN8),
wherein X.sub.2 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys,
Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.4 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro,
Ser, Thr, Trp, Tyr or Val (preferably Asp); X.sub.5 is Ala, Asp,
Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.6 is Arg, Gln,
Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; and X.sub.7 is
Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr;
or Loop Consensus Sequence
16:Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.-
sub.10-X.sub.11-Cys (TN12), wherein X.sub.2 is Arg, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val; X.sub.3 is Ala, Arg,
Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or Tyr; X.sub.4 is Arg,
Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.5 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro, Ser,
Trp, Tyr or Val; X.sub.6 is Asp, Gln, Glu, Gly, His, Ile, Leu, Met,
Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.7 is Ala, Arg, Asn, Asp, Gln,
Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.8 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys, Trp, Tyr or
Val; X.sub.9 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met, Phe, Ser,
Thr, Trp, Tyr or Val; X.sub.10 is Arg, Gln, Glu, His, Leu, Lys,
Met, Phe, Pro, Thr, Trp or Val; and X.sub.11 is Arg, Asn, Asp, Glu,
His, Ile, Leu, Met, Phe, Pro, Thr, Trp, Tyr or Val; or Loop
Consensus Sequence 17: Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6-Cys
(TN7), wherein X.sub.2 is Asn, Asp or Glu; X.sub.3 is Glu, His, Lys
or Phe; X.sub.4 is Asp, Gln, Leu, Lys, Met or Tyr; and X.sub.6 is
Arg, Gln, Leu, Lys or Val; or Loop Consensus Sequence 18:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.- 6-X.sub.7-X.sub.8-Cys
(TN9), wherein X.sub.2 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.3
is Asn, Glu, Gly, His or Leu; X.sub.4 is Gln, Glu, Gly, Met, Lys,
Phe, Tyr or Val; X.sub.5 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser
or Thr; X.sub.6 is His, Pro or Trp; X.sub.7 is Ala, Gly, His, Leu,
Trp or Tyr; and X.sub.8 is Ala, Asp, Gln, Leu, Met, Thr or Trp; or
Loop Consensus Sequence 19:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Ser-Gly-Pro-X.-
sub.9-X.sub.10-X.sub.11-X.sub.12-Cys (MTN13; SEQ ID NO: 1), wherein
X.sub.2 is Asp, Glu, His or Thr; X.sub.3 is Arg, His, Lys or Phe;
X.sub.4 is Gln, Ile, Lys, Tyr or Val; X.sub.5 is Gln, Ile, Leu, Met
or Phe; X.sub.9 is Asn, Asp, Gly, His or Tyr; X.sub.10 is Gln, Gly,
Ser or Thr; X.sub.11 is Glu, Lys, Phe or Ser; and X.sub.12 is Glu,
Ile, Ser or Val, wherein at least one polypeptide is coupled to at
least one chelator capable of complexing a radionuclide useful in
radiotherapy and wherein the polypeptide optionally further
comprises N-terminal and/or C-terminal flanking peptides of one or
more amino acids.
104. An agent useful in radiotherapy comprising at least one
radionuclide useful in radiotherapy and at least one KDR or
VEGF/KDR complex binding moiety comprising a polypeptide of one of
claims 1, 7 or 10.
105. The agent useful in radiotherapy of claim 103, further
comprising at least one chelator selected from the group consisting
of: formula 20, 21, 22, 23a, 23b, 24a, 24b and 25.
106. The agent useful in radiotherapy of claim 103, wherein the
radionuclide is selected from the group consisting of: .sup.177Lu,
.sup.90Y, .sup.153Sm and .sup.166Ho.
107. The method of claim 49, wherein the composition further
comprises a therapeutic agent.
108. A method of synthesizing a polypeptide or a multimeric
polypeptide construct having the ability to bind KDR or VEGF/KDR
complex comprising forming a cyclic polypeptide by introducing an
amide bond between two side chains.
109. The method of claim 108, wherein the polypeptide or multimeric
polypeptide comprises a linker comprising at least one glycosylated
amino acid selected from the group consisting of serine, threonine
and homoserine.
110. A method of synthesizing a multimeric polypeptide construct
having the ability to bind KDR or VEGF/KDR complex, comprising: a)
treating a first purified peptide monomer with glutaric acid
bis-N-hydroxysuccinimid- yl ester; and b) contacting the peptide
monomer of (a) with a second purified peptide monomer in the
presence of N,N-(Diisopropyl)aminomethylp- olystyrene, thereby
forming the multimeric polypeptide, wherein one or both of the
purified peptide monomers has the ability to bind KDR or VEGF/KDR
complex.
111. A multimeric polypeptide having the ability to bind to KDR or
VEGF/KDR complex selected from the group consisting of: D1, D2, D3,
D4, D5, D6, D7, D8, D9, D10, D11, D12, D13, D14, D15, D16, D17,
D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28 and D29.
112. A dimeric polypeptide construct having the ability to bind to
KDR or VEGF/KDR, wherein each peptide of the dimer comprises a
sequence selected from the group consisting of: Loop Consensus
Sequence 15:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-Cys (TN8),
wherein X2 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys, Phe,
Pro, Ser, Trp or Tyr; X3 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His,
Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val; X4 is Ala, Asn,
Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro, Ser, Thr, Trp, Tyr or
Val; X5 is Ala, Asp, Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr;
X6 is Arg, Gln, Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val;
and X7 is Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe,
Trp or Tyr; Loop Consensus Sequence 16:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub-
.10-X.sub.11-Cys (TN12), wherein X2 is Arg, Asp, Gln, Glu, Gly,
His, Ile, Lys, Met, Thr, Trp, Tyr or Val; X3 is Ala, Arg, Asn, Cys,
Glu, Ile, Leu, Met, Phe, Ser, Trp or Tyr; X4 is Arg, Asn, Asp, Gln,
Glu, His, Ile, Leu, Pro, Ser, Thr, Trp, Tyr or Val; X5 is Ala, Asn,
Asp, Gln, Glu, Gly, His, Met, Phe, Pro, Ser, Trp, Tyr or Val; X6 is
Asp, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Tip or
Tyr; X7 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, Leu, Lys, Met, Phe,
Pro, Ser, Thr, Trp, Tyr or Val; X8 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Lys, Trp, Tyr or Val; X9 is Ala, Arg, Gln, Gly, His, Ile,
Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X10 is Arg, Gln, Glu,
His, Leu, Lys, Met, Phe, Pro, Thr, Trp or Val; and X11 is Arg, Asn,
Asp, Glu, His, Ile, Leu, Met, Phe, Pro, Thr, Trp, Tyr or Val; Loop
Consensus Sequence 17: Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6-Cys
(TN7), wherein X2 is Asn, Asp or Glu; X3 is Glu, His, Lys or Phe;
X4 is Asp, Gln, Leu, Lys, Met or Tyr; and X6 is Arg, Gln, Leu, Lys
or Val; Loop Consensus Sequence 18:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.- 7-X.sub.8-Cys
(TN9), wherein X.sub.2 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.3
is Asn, Glu, Gly, His or Leu; X.sub.4 is Gln, Glu, Gly, Met, Lys,
Phe, Tyr or Val; X.sub.5 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser
or Thr; X.sub.6 is His, Pro or Trp; X.sub.7 is Ala, Gly, His, Leu,
Trp or Tyr; and X.sub.8 is Ala, Asp, Gln, Leu, Met, Thr or Trp; or
Loop Consensus Sequence 19:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Ser-Gly-Pro-X.-
sub.9-X.sub.10-X.sub.11-X.sub.12-Cys (MTN13; SEQ ID NO:1), wherein
X.sub.2 is Asp, Glu, His or Thr; X.sub.3 is Arg, His, Lys or Phe;
X.sub.4 is Gln, Ile, Lys, Tyr or Val; X.sub.5 is Gln, Ile, Leu, Met
or Phe; X.sub.9 is Asn, Asp, Gly, His or Tyr; X.sub.10 is Gln, Gly,
Ser or Thr; X.sub.11 is Glu, Lys, Phe or Ser; and X.sub.12 is Glu,
Ile, Ser or Val.
113. A dimeric polypeptide construct having the ability to bind to
KDR or VEGF/KDR, wherein each peptide of the dimer comprises a
sequence selected from the group consisting of: Consensus Sequence
1:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub-
.10-Cys-X.sub.12-X.sub.13-X.sub.14 (TN8), wherein X.sub.1 is Ala,
Arg, Asp, Gly, His, Leu, Lys, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.2 is Asn, Asp, Glu, Gly, Ile, Leu, Lys, Phe, Ser, Thr, Trp,
Tyr or Val; X.sub.3 is Asn, Asp, Gln, Glu, Ile, Leu, Met, Thr, Trp
or Val; X.sub.5 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys,
Phe, Pro, Ser, Trp or Tyr; X.sub.6 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.7 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro,
Ser, Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asp, Glu, Gly, Leu, Phe,
Pro, Ser, Thr, Trp or Tyr; X.sub.9 is Arg, Gln, Glu, Gly, Ile, Leu,
Met, Pro, Thr, Trp, Tyr or Val; X.sub.10 is Ala, Arg, Gln, Glu,
Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr; X.sub.12 is Arg,
Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr,
Trp, Tyr or Val; X.sub.13 is Arg, Asn, Asp, Gln, Glu, Gly, His,
Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp or Tyr; and X.sub.14 is Gln,
Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp or Tyr;
Consensus Sequence 2:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub-
.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-Cys-X.sub.16-X.sub.17-X.sub.18
(TN12), wherein X.sub.1 is Ala, Asn, Asp, Gly, Leu, Pro, Ser, Trp
or Tyr; X.sub.2 is Ala, Arg, Asn, Asp, Gly, His, Phe, Pro, Ser, Trp
or Tyr; X.sub.3 is Ala, Asn, Asp, Gln, Glu, Gly, His, Leu, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.5 is Arg, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val; X.sub.6 is Ala, Arg,
Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or Tyr; X.sub.7 is Arg,
Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.8 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro, Ser,
Trp, Tyr or Val; X.sub.9 is Asp, Gln, Glu, Gly, His, Ile, Leu, Met,
Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.10 is Ala, Arg, Asn, Asp,
Gln, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.11 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys, Trp, Tyr
or Val; X.sub.12 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met, Phe,
Ser, Thr, Trp, Tyr or Val; X.sub.13 is Arg, Gln, Glu, His, Leu,
Lys, Met, Phe, Pro, Thr, Trp or Val; X.sub.14 is Arg, Asn, Asp,
Glu, His, Ile, Leu, Met, Phe, Pro, Thr, Trp, Tyr or Val; X.sub.16
is Ala, Asn, Asp, Gln, Glu, Gly, Lys, Met, Phe, Ser, Thr, Trp, Tyr
or Val; X.sub.17 is Arg, Asn, Asp, Cys, Gly, His, Phe, Pro, Ser,
Trp or Tyr; and X.sub.18 is Ala, Asn, Asp, Gly, His, Leu, Phe, Pro,
Ser, Trp or Tyr; Consensus Sequence 3:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-Gly-X.sub.9-Cys-X.sub-
.11-X.sub.12-X.sub.13 (TN7), wherein X.sub.1 is Gly or Trp; X.sub.2
is Ile, Tyr or Val; X.sub.3 is Gln, Glu, Thr or Trp; X.sub.5 is
Asn, Asp or Glu; X.sub.6 is Glu, His, Lys or Phe; X.sub.7 is Asp,
Gln, Leu, Lys, Met or Tyr; X.sub.9 is Arg, Gln, Leu, Lys or Val;
X.sub.11 is Arg, Phe, Ser, Trp or Val; X.sub.12 is Glu, His or Ser;
and X.sub.13 is Glu, Gly, Trp or Tyr; Consensus Sequence 4:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.-
sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys-X.sub.13-X.sub.14-X.sub.15
(TN9), wherein X.sub.1 is Arg, Asp, Gly, Ile, Met, Pro or Tyr;
X.sub.2 is Asp, Gly, His, Pro or Trp; X.sub.3 is Gly, Pro, Phe, Thr
or Trp; X.sub.5 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.6 is Asn,
Glu, Gly, His or Leu; X.sub.7 is Gln, Glu, Gly, Met, Lys, Phe, Tyr
or Val; X.sub.8 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or Thr;
X.sub.9 is His, Pro or Trp; X.sub.10 is Ala, Gly, His, Leu, Trp or
Tyr; X.sub.11 is Ala, Asp, Gln, Leu, Met, Thr or Trp; X.sub.13 is
Ala, Lys, Ser, Trp or Tyr; X.sub.14 is Asp, Gly, Leu, His, Met,
Thr, Trp or Tyr; and X.sub.15 is Asn, Gln, Glu, Leu, Met, Pro or
Trp; or Consensus Sequence 5: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5--
X.sub.6-X.sub.7-X.sub.8-Ser-Gly-Pro-X.sub.12-X.sub.13-X.sub.14-X.sub.15-Cy-
s-X.sub.17-X.sub.18-X.sub.19 (SEQ ID NO:1; MTN13), wherein X.sub.1
is Arg, Glu, His, Ser or Trp; X.sub.2 is Asn, Asp, Leu, Phe, Thr or
Val; X.sub.3 is Arg, Asp, Glu, His, Lys or Thr; X.sub.5 is Asp,
Glu, His or Thr; X.sub.6 is Arg, His, Lys or Phe; X.sub.7 is Gln,
Ile, Lys, Tyr or Val; X.sub.8 is Gln, Ile, Leu, Met or Phe;
X.sub.12 is Asn, Asp, Gly, His or Tyr; X.sub.13 is Gln, Gly, Ser or
Thr; X.sub.14 is Glu, Lys, Phe or Ser; X.sub.15 is Glu, Ile, Ser or
Val; X.sub.17 is Glu, Gly, Lys, Phe, Ser or Val; X.sub.18 is Arg,
Asn, Ser or Tyr; and X.sub.19 is Asp, Gln, Glu, Gly, Met or
Tyr.
114. A dimeric polypeptide construct having the ability to bind to
KDR or VEGF/KDR, wherein each peptide of the dimer comprises a
sequence selected from the group consisting of: Consensus Sequence
13: Z.sub.1-X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Z.sub.2
(Lin20); wherein, Z.sub.1 is a polypeptide of at least one amino
acid or is absent; X.sub.1 is Ala, Asp, Gln or Glu; X.sub.2 is Ala,
Asp, Gln, Glu, Pro; X.sub.3 is Ala, Leu, Lys, Phe, Pro, Trp or Tyr;
X.sub.4 is Asp, Leu, Ser, Trp, Tyr or Val; X.sub.5 is Ala, Arg,
Asp, Glu, Gly, Leu, Trp or Tyr; and Z.sub.2 is a polypeptide of at
least one amino acid or is absent; or Consensus Sequence 14:
X1-X2-X3-Tyr-Trp-Glu-X7-X8-X9-Leu (Lin20; SEQ ID NO:7), wherein,
the sequence can optionally have a N-terminal polypeptide,
C-terminal polypeptide, or a polypeptide at both termini of at
least one amino acid; wherein, X.sub.1 is Asp, Gly or Ser; X.sub.2
is Ile, Phe or Tyr; X.sub.3 is Ala, Ser or Val; X.sub.7 is Gln,
Glu, Ile or Val; X.sub.8 is Ala, Ile or Val; X.sub.9 is Ala, Glu,
Val or Thr.
115. The dimeric polypeptide construct of claim 113, comprising at
least one amino acid sequence selected from the group consisting
of: SEQ ID NOS: 20-86, 87-136, 187-192, 193-203 and 207-259.
116. The dimeric polypeptide construct of claim 114, comprising at
least one amino acid sequence selected from the group consisting
of: SEQ ID NOS: 137-186.
117. The dimeric polypeptide construct of any one of claims 112,
113 or 114, wherein at least one amino acid sequence further
comprises N-terminal and/or C-terminal flanking peptides of one or
more amino acids.
118. The dimeric polypeptide construct of any of claims 112, 113 or
114, wherein at least one amino acid sequence comprises a
modification selected from the group consisting of: an amino acid
substitution, and amide bond substitution, a D-amino acid
substitution, a disulfide bond, a glycosylated amino acid, a
disulfide mimetic substitution, an amino acid translocation, a
retroinverso peptide, a peptoid, a retro-inverso peptoid, and a
synthetic peptide.
119. The dimeric polypeptide construct of any one of claims 112,
113 or 114, conjugated to one or more detectable labels or
therapeutic agents, optionally further comprising a linker or
spacer between the polypeptide and the detectable label or the
therapeutic agent.
120. The dimeric polypeptide construct of claim 119, wherein the
detectable label or the therapeutic agent is selected from the
group consisting of: an enzyme, a fluorescent compound, a liposome,
an optical dye, one or more paramagnetic metal ions or a
superparamagnetic particle, an ultrasound contrast agent and one or
more radionuclides.
121. The dimeric polypeptide construct of claim 120, wherein the
therapeutic agent or detectable label comprises one or more
radionuclides.
122. The dimeric polypeptide construct of claim 121, wherein the
radionuclide is selected from the group consisting of: .sup.18F,
.sup.124I, .sup.125I, .sup.131I, .sup.123I, .sup.77Br, .sup.76Br,
.sup.99mTc, .sup.51Cr, .sup.67Ga, .sup.68Ga, .sup.47Sc, .sup.51Cr
.sup.167Tm, .sup.141Ce, .sup.111In, .sup.168Yb, .sup.175Yb,
.sup.140La, .sup.90Y, .sup.88Y, .sup.153Sm, .sup.166Ho, .sup.165Dy,
.sup.166Dy, .sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.97Ru, .sup.103Ru,
.sup.186Re, .sup.188Re, .sup.203Pb, .sup.211Bi, .sup.212Bi,
.sup.213Bi, .sup.214Bi, .sup.105Rh .sup.109Pd, .sup.117mSn,
.sup.149Pm, .sup.161Tb, .sup.177Lu, .sup.198Au and .sup.199Au.
123. The dimeric polypeptide construct of claim 122, wherein the
therapeutic agent or detectable label further comprises a
chelator.
124. The dimeric polypeptide construct of claim 123, wherein the
chelator comprises a compound selected from the group consisting
of: formula 20, 21, 22, 23a, 23b, 24a, 24b, and 25.
125. The dimeric polypeptide construct of claim 123, wherein the
radionuclide is .sup.99mTc or .sup.111In.
126. The dimeric polypeptide construct of claim 123, wherein the
radionuclide is selected from the group consisting of: .sup.177Lu,
.sup.90Y, .sup.153Sm and .sup.166Ho.
127. The dimeric polypeptide construct of claim 120, wherein the
detectable label comprises an ultrasound contrast agent.
128. The dimeric polypeptide construct of claim 127, wherein the
ultrasound contrast agent comprises a phospholipid stabilized
microbubble or a microballoon comprising a gas.
128. The dimeric polypeptide construct of claim 127, wherein the
ultrasound contrast agent comprises a fluorinated gas.
129. The dimeric polypeptide construct of claim 120, wherein the
detectable label comprises one or more paramagnetic metal ions and
one or more chelators.
130. The dimeric polypeptide construct of claim 120, wherein the
therapeutic agent is selected from the group consisting of: a
bioactive agent, a cytotoxic agent, a drug, a chemotherapeutic
agent and a radiotherapeutic agent.
131. The dimeric polypeptide construct of claims 112, 113 or 114
wherein each peptide of the dimer is selected from an amino acid
sequence selected from the group consisting of the sequences listed
in Tables 1-11 and 27.
132. A multimeric polypeptide having the ability to bind to KDR or
VEGF/KDR complex, wherein the multimeric polypeptide comprises at
least one peptide monomer comprising an amino acid sequence
selected from the group consisting of those sequences listed in
Tables 1-11 and 27.
133. The method of claims 63 or 103, wherein the agent comprises
D13.
134. The method of claims 60 or 62, wherein the polypeptide is
selected from the group consisting of: SEQ ID NOS: 277, 294, 337,
338, 339, 356, 378, 448, 477 and 480.
135. The ultrasound contrast agent of claim 96, wherein the agent
comprises a KDR or KDR/VEGF complex binding moiety selected from
the group consisting of: D23 and SEQ ID NOS:294, 338, 356 and
480.
136. The scintigraphic imaging agent of claim 99, wherein the agent
comprises at least one labeled molecules selected from the group
consisting of: .sup.125I-D5, .sup.111In-labeled SEQ ID NO:338,
.sup.111IN-D4, .sup.177Lu-D11, .sup.177Lu-D13, .sup.99mTc-labeled
SEQ ID NO:339, .sup.99mTc-labeled SEQ ID NO:277, .sup.99mTc-labeled
SEQ ID NO:378, .sup.99mTc-D10, .sup.99mTc-D12 and
.sup.99mTc-D14.
137. A method of inhibiting VEGF-induced vascular permeability
comprising administering an agent comprising a peptide of one of
claims 1, 7 or 10.
138. The method of claim 137, wherein the agent comprises D10.
139. The dimeric polypeptide construct of one of claims 112, 113 or
114 that has an apparent K.sub.D for KDR or VEGF/KDR complex of
less than 10 .mu.M.
140. The dimeric polypeptide construct of claim 139, wherein the
apparent K.sub.D for KDR or VEGF/KDR complex is less than 1
.mu.M.
141. The dimeric polypeptide construct of claim 139, wherein the
apparent K.sub.D for KDR or VEGF/KDR complex is less than 0.1
.mu.M.
142. The dimeric polypeptide construct of claim 139, wherein the
apparent K.sub.D for KDR or VEGF/KDR complex is less than 0.5
.mu.M.
143. The scintigraphic imaging agent of claim 99, wherein the agent
comprises D10.
144. The method of claim 133, wherein the agent comprises
.sup.177Lu-D13.
145. The method of claim 49, wherein the condition is treated by
inhibiting angiogenesis.
146. The method of claim 110, wherein the multimeric polypeptide is
selected from the group consisting of D1, D2, D3, D4, D5, D6, D7,
D8, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21,
D22, D23, D24, D25, D26, D27, D28 and D29.
147. A recombinant bacteriophage displaying a KDR binding or
VEGF/KDR complex binding polypeptide, which polypeptide comprises
an amino acid sequence of one of the following: Consensus Sequence
13: Z.sub.1-X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Z.sub.2
(Lin20); wherein, Z.sub.1 is a polypeptide of at least one amino
acid or is absent; X.sub.1 is Ala, Asp, Gln or Glu; X.sub.2 is Ala,
Asp, Gln, Glu, Pro; X.sub.3 is Ala, Leu, Lys, Phe, Pro, Trp or Tyr;
X.sub.4 is Asp, Leu, Ser, Trp, Tyr or Val; X.sub.5 is Ala, Arg,
Asp, Glu, Gly, Leu, Trp or Tyr; and Z.sub.2 is a polypeptide of at
least one amino acid or is absent; or Consensus Sequence 14:
X.sub.1-X.sub.2-X.sub.3-Tyr-Trp-Glu-X.sub.7-X.sub.8-X.sub.9-- Leu
(Lin20; SEQ ID NO:7), wherein, the sequence can optionally have a
N-terminal polypeptide, C-terminal polypeptide, or a polypeptide at
both termini of at least one amino acid; wherein, X.sub.1 is Asp,
Gly or Ser; X.sub.2 is Ile, Phe or Tyr; X.sub.3 is Ala, Ser or Val;
X.sub.7 is Gln, Glu, Ile or Val; X.sub.8 is Ala, Ile or Val;
X.sub.9 is Ala, Glu, Val or Thr, and wherein the polypeptide is
displayed on the surface of the recombinant bacteriophage.
148. A recombinant bacteriophage displaying a KDR binding or
VEGF/KDR complex binding polypeptide, which polypeptide comprises
an amino acid sequence of one of the following: Loop Consensus
Sequence 15:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-Cys (TN8),
wherein X.sub.2 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys,
Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.4 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro,
Ser, Thr, Trp, Tyr or Val (preferably Asp); X.sub.5 is Ala, Asp,
Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.6 is Arg, Gln,
Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; and X.sub.7 is
Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr;
or Loop Consensus Sequence 16:Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-
-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys (TN12),
wherein X.sub.2 is Arg, Asp, Gln, Glu, Gly, His, Ile, Lys, Met,
Thr, Trp, Tyr or Val; X.sub.3 is Ala, Arg, Asn, Cys, Glu, Ile, Leu,
Met, Phe, Ser, Trp or Tyr; X.sub.4 is Arg, Asn, Asp, Gln, Glu, His,
Ile, Leu, Pro, Ser, Thr, Trp, Tyr or Val; X.sub.5 is Ala, Asn, Asp,
Gln, Glu, Gly, His, Met, Phe, Pro, Ser, Trp, Tyr or Val; X.sub.6 is
Asp, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp or
Tyr; X.sub.7 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, Leu, Lys, Met,
Phe, Pro, Ser, Thr, Trp, Tyr or Val; X.sub.8 is Ala, Arg, Asn, Asp,
Gln, Glu, Gly, His, Lys, Trp, Tyr or Val; X.sub.9 is Ala, Arg, Gln,
Gly, His, Ile, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.10
is Arg, Gln, Glu, His, Leu, Lys, Met, Phe, Pro, Thr, Trp or Val;
and X.sub.11 is Arg, Asn, Asp, Glu, His, Ile, Leu, Met, Phe, Pro,
Thr, Trp, Tyr or Val; or Loop Consensus Sequence 17:
Cys-X.sub.2-X.sub.3-X.sub- .4-Gly-X.sub.6-Cys (TN7), wherein
X.sub.2 is Asn, Asp or Glu; X.sub.3 is Glu, His, Lys or Phe;
X.sub.4 is Asp, Gln, Leu, Lys, Met or Tyr; and X.sub.6 is Arg, Gln,
Leu, Lys or Val; or Loop Consensus Sequence 18:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-Cys
(TN9), wherein X.sub.2 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.3
is Asn, Glu, Gly, His or Leu; X.sub.4 is Gln, Glu, Gly, Met, Lys,
Phe, Tyr or Val; X.sub.5 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser
or Thr; X.sub.6 is His, Pro or Trp; X.sub.7 is Ala, Gly, His, Leu,
Trp or Tyr; and X.sub.8 is Ala, Asp, Gln, Leu, Met, Thr or Trp; or
Loop Consensus Sequence 19:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Ser-Gly-Pro-X.sub.9-X.sub.10-X.sub.11-
-X.sub.12-Cys (MTN13; SEQ ID NO:1), wherein X.sub.2 is Asp, Glu,
His or Thr; X.sub.3 is Arg, His, Lys or Phe; X.sub.4 is Gln, Ile,
Lys, Tyr or Val; X.sub.5 is Gln, Ile, Leu, Met or Phe; X.sub.9 is
Asn, Asp, Gly, His or Tyr; X.sub.10 is Gln, Gly, Ser or Thr;
X.sub.11 is Glu, Lys, Phe or Ser; and X.sub.12 is Glu, Ile, Ser or
Val, and wherein the polypeptide is displayed on the surface of the
recombinant bacteriophage.
149. A magnetic resonance imaging contrast agent comprising a KDR
or VEGF/KDR complex binding polypeptide comprising an amino acid
sequence of one of the following: Consensus Sequence 13:
Z.sub.1-X.sub.1-X.sub.2-X.su- b.3-X.sub.4-X.sub.5-Z.sub.2 (Lin20);
wherein, Z.sub.1 is a polypeptide of at least one amino acid or is
absent; X.sub.1 is Ala, Asp, Gln or Glu; X.sub.2 is Ala, Asp, Gln,
Glu, Pro; X.sub.3 is Ala, Leu, Lys, Phe, Pro, Trp or Tyr; X.sub.4
is Asp, Leu, Ser, Trp, Tyr or Val; X.sub.5 is Ala, Arg, Asp, Glu,
Gly, Leu, Trp or Tyr; and Z.sub.2 is a polypeptide of at least one
amino acid or is absent; or Consensus Sequence 14:
X.sub.1-X.sub.2-X.sub.3-Tyr-Trp-Glu-X.sub.7-X.sub.8-X.sub.9-Leu
(Lin20; SEQ ID NO:7), wherein, the sequence can optionally have a
N-terminal polypeptide, C-terminal polypeptide, or a polypeptide at
both termini of at least one amino acid; wherein, X.sub.1 is Asp,
Gly or Ser; X.sub.2 is Ile, Phe or Tyr; X.sub.3 is Ala, Ser or Val;
X.sub.7 is Gln, Glu, Ile or Val; X.sub.8 is Ala, Ile or Val;
X.sub.9 is Ala, Glu, Val or Thr, and wherein the polypeptide is
coupled to at least one chelator capable of complexing a
paramagnetic metal or at least one paramagnetic particle, and
wherein the polypeptide optionally comprises an N-terminal and/or
C-terminal flanking peptide.
150. A magnetic resonance imaging contrast agent comprising a KDR
or VEGF/KDR complex binding polypeptide comprising an amino acid
sequence of one of the following: Loop Consensus Sequence 15:
Cys-X.sub.2-X.sub.3-X.s- ub.4-X.sub.5-X.sub.6-X.sub.7-Cys (TN8),
wherein X.sub.2 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys,
Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.4 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro,
Ser, Thr, Trp, Tyr or Val (preferably Asp); X.sub.5 is Ala, Asp,
Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.6 is Arg, Gln,
Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; and X.sub.7 is
Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr;
or Loop Consensus Sequence
16:Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-
-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys (TN12), wherein X.sub.2 is
Arg, Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val;
X.sub.3 is Ala, Arg, Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or
Tyr; X.sub.4 is Arg, Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.5 is Ala, Asn, Asp, Gln, Glu, Gly, His,
Met, Phe, Pro, Ser, Trp, Tyr or Val; X.sub.6 is Asp, Gln, Glu, Gly,
His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.7 is Ala,
Arg, Asn, Asp, Gln, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser, Thr,
Trp, Tyr or Val; X.sub.8 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His,
Lys, Trp, Tyr or Val; X.sub.9 is Ala, Arg, Gln, Gly, His, Ile, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.10 is Arg, Gln, Glu,
His, Leu, Lys, Met, Phe, Pro, Thr, Trp or Val; and X.sub.11 is Arg,
Asn, Asp, Glu, His, Ile, Leu, Met, Phe, Pro, Thr, Trp, Tyr or Val;
or Loop Consensus Sequence 17:
Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6-Cy- s (TN7), wherein
X.sub.2 is Asn, Asp or Glu; X.sub.3 is Glu, His, Lys or Phe;
X.sub.4 is Asp, Gln, Leu, Lys, Met or Tyr; and X.sub.6 is Arg, Gln,
Leu, Lys or Val; or Loop Consensus Sequence 18:
Cys-X.sub.2-X.sub.3-X.sub- .4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-Cys
(TN9), wherein X.sub.2 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.3
is Asn, Glu, Gly, His or Leu; X.sub.4 is Gln, Glu, Gly, Met, Lys,
Phe, Tyr or Val; X.sub.5 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser
or Thr; X.sub.6 is His, Pro or Trp; X.sub.7 is Ala, Gly, His, Leu,
Trp or Tyr; and X.sub.8 is Ala, Asp, Gln, Leu, Met, Thr or Trp; or
Loop Consensus Sequence 19: Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-S-
er-Gly-Pro-X.sub.9-X.sub.10-X.sub.11-X.sub.12-Cys (MTN13; SEQ ID
NO:1), wherein X.sub.2 is Asp, Glu, His or Thr; X.sub.3 is Arg,
His, Lys or Phe; X.sub.4 is Gln, Ile, Lys, Tyr or Val; X.sub.5 is
Gln, Ile, Leu, Met or Phe; X.sub.9 is Asn, Asp, Gly, His or Tyr;
X.sub.10 is Gln, Gly, Ser or Thr; X.sub.11 is Glu, Lys, Phe or Ser;
and X.sub.12 is Glu, Ile, Ser or Val, and wherein the polypeptide
is coupled to at least one chelator capable of complexing a
paramagnetic metal or at least one paramagnetic particle, and
wherein the polypeptide optionally comprises an N-terminal and/or
C-terminal flanking peptide.
151. An ultrasound contrast agent comprising at least one KDR or
VEGF/KDR complex binding polypeptide comprising an amino acid
sequence of one of the following and optionally further comprising
N-terminal and/or C-terminal flanking peptides of one or more amino
acids: Consensus Sequence 13:
Z.sub.1-X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Z.sub.2 (Lin20);
wherein, Z.sub.1 is a polypeptide of at least one amino acid or is
absent; X.sub.1 is Ala, Asp, Gln or Glu; X.sub.2 is Ala, Asp, Gln,
Glu, Pro; X.sub.3 is Ala, Leu, Lys, Phe, Pro, Trp or Tyr; X.sub.4
is Asp, Leu, Ser, Trp, Tyr or Val; X.sub.5 is Ala, Arg, Asp, Glu,
Gly, Leu, Trp or Tyr; and Z.sub.2 is a polypeptide of at least one
amino acid or is absent; or Consensus Sequence 14:
X.sub.1-X.sub.2-X.sub.3-Tyr-Trp-Glu-X.s- ub.7-X.sub.8-X.sub.9-Leu
(Lin20; SEQ ID NO:7), wherein, the sequence can optionally have a
N-terminal polypeptide, C-terminal polypeptide, or a polypeptide at
both termini of at least one amino acid; wherein, X.sub.1 is Asp,
Gly or Ser; X.sub.2 is Ile, Phe or Tyr; X.sub.3 is Ala, Ser or Val;
X.sub.7 is Gln, Glu, Ile or Val; X.sub.8 is Ala, Ile or Val;
X.sub.9 is Ala, Glu, Val or Thr, and wherein at least one
polypeptide is conjugated to microvesicles filled with gas or
material useful for preparing microvesicles filled with gas.
152. An ultrasound contrast agent comprising at least one KDR or
VEGF/KDR complex binding polypeptide comprising an amino acid
sequence of one of the following and optionally further comprising
N-terminal and/or C-terminal flanking peptides of one or more amino
acids: Loop Consensus Sequence 15:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-Cys (TN8),
wherein X.sub.2 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys,
Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.4 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro,
Ser, Thr, Trp, Tyr or Val (preferably Asp); X.sub.5 is Ala, Asp,
Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.6 is Arg, Gln,
Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; and X.sub.7 is
Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr;
or Loop Consensus Sequence
16:Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.-
sub.10-X.sub.11-Cys (TN12), wherein X.sub.2 is Arg, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val; X.sub.3 is Ala, Arg,
Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or Tyr; X.sub.4 is Arg,
Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.5 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro, Ser,
Trp, Tyr or Val; X.sub.6 is Asp, Gln, Glu, Gly, His, Ile, Leu, Met,
Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.7 is Ala, Arg, Asn, Asp, Gln,
Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.8 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys, Trp, Tyr or
Val; X.sub.9 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met, Phe, Ser,
Thr, Trp, Tyr or Val; X.sub.10 is Arg, Gln, Glu, His, Leu, Lys,
Met, Phe, Pro, Thr, Trp or Val; and X.sub.11 is Arg, Asn, Asp, Glu,
His, Ile, Leu, Met, Phe, Pro, Thr, Trp, Tyr or Val; or Loop
Consensus Sequence 17: Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6-Cys
(TN7), wherein X.sub.2 is Asn, Asp or Glu; X.sub.3 is Glu, His, Lys
or Phe; X.sub.4 is Asp, Gln, Leu, Lys, Met or Tyr; and X.sub.6 is
Arg, Gln, Leu, Lys or Val; or Loop Consensus Sequence 18:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.- 6-X.sub.7-X.sub.8-Cys
(TN9), wherein X.sub.2 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.3
is Asn, Glu, Gly, His or Leu; X.sub.4 is Gln, Glu, Gly, Met, Lys,
Phe, Tyr or Val; X.sub.5 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser
or Thr; X.sub.6 is His, Pro or Trp; X.sub.7 is Ala, Gly, His, Leu,
Trp or Tyr; and X.sub.8 is Ala, Asp, Gln, Leu, Met, Thr or Trp; or
Loop Consensus Sequence 19:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Ser-Gly-Pro-X.-
sub.9-X.sub.10-X.sub.11-X.sub.12-Cys (MTN13; SEQ ID NO:1), wherein
X.sub.2 is Asp, Glu, His or Thr; X.sub.3 is Arg, His, Lys or Phe;
X.sub.4 is Gln, Ile, Lys, Tyr or Val; X.sub.5 is Gln, Ile, Leu, Met
or Phe; X.sub.9 is Asn, Asp, Gly, His or Tyr; X.sub.10 is Gln, Gly,
Ser or Thr; X.sub.11 is Glu, Lys, Phe or Ser; and X.sub.12 is Glu,
Ile, Ser or Val, and wherein at least one polypeptide is conjugated
to microvesicles filled with gas or material useful for preparing
microvesicles filled with gas.
153. A scintigraphic imaging agent comprising at least one KDR or
VEGF/KDR complex binding polypeptide comprising an amino acid
sequence of one of the following: Consensus Sequence 13:
Z.sub.1-X.sub.1-X.sub.2-X.sub.3-X.s- ub.4-X.sub.5-Z.sub.2 (Lin20);
wherein, Z.sub.1 is a polypeptide of at least one amino acid or is
absent; X.sub.1 is Ala, Asp, Gln or Glu; X.sub.2 is Ala, Asp, Gln,
Glu, Pro; X.sub.3 is Ala, Leu, Lys, Phe, Pro, Trp or Tyr; X.sub.4
is Asp, Leu, Ser, Trp, Tyr or Val; X.sub.5 is Ala, Arg, Asp, Glu,
Gly, Leu, Trp or Tyr; and Z.sub.2 is a polypeptide of at least one
amino acid or is absent; or Consensus Sequence 14:
X.sub.1-X.sub.2-X.sub.3-Tyr-Trp-Glu-X.sub.7-X.sub.8-X.sub.9-Leu
(Lin20; SEQ ID NO:7), wherein, the sequence can optionally have a
N-terminal polypeptide, C-terminal polypeptide, or a polypeptide at
both termini of at least one amino acid; wherein, X.sub.1 is Asp,
Gly or Ser; X.sub.2 is Ile, Phe or Tyr; X.sub.3 is Ala, Ser or Val;
X.sub.7 is Gln, Glu, Ile or Val; X.sub.8 is Ala, Ile or Val;
X.sub.9 is Ala, Glu, Val or Thr, and wherein at least one
polypeptide is coupled to at least one chelator capable of
complexing a radionuclide useful for scintigraphic imaging, and
wherein the polypeptide optionally further comprises N-terminal
and/or C-terminal flanking peptides of one or more amino acids.
154. A scintigraphic imaging agent comprising at least one KDR or
VEGF/KDR complex binding polypeptide comprising an amino acid
sequence of one of the following: Loop Consensus Sequence 15:
Cys-X.sub.2-X.sub.3-X.sub.4-X.- sub.5-X.sub.6-X.sub.7-Cys (TN8),
wherein X.sub.2 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys,
Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.4 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro,
Ser, Thr, Trp, Tyr or Val (preferably Asp); X.sub.5 is Ala, Asp,
Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.6 is Arg, Gln,
Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; and X.sub.7 is
Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr;
or Loop Consensus Sequence
16:Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X-
.sub.9-X.sub.10-X.sub.11-Cys (TN12), wherein X.sub.2 is Arg, Asp,
Gln, Glu, Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val; X.sub.3 is
Ala, Arg, Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or Tyr;
X.sub.4 is Arg, Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser, Thr,
Trp, Tyr or Val; X.sub.5 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met,
Phe, Pro, Ser, Trp, Tyr or Val; X.sub.6 is Asp, Gln, Glu, Gly, His,
Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.7 is Ala, Arg,
Asn, Asp, Gln, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp,
Tyr or Val; X.sub.8 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys,
Trp, Tyr or Val; X.sub.9 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met,
Phe, Ser, Thr, Trp, Tyr or Val; X.sub.10 is Arg, Gln, Glu, His,
Leu, Lys, Met, Phe, Pro, Thr, Trp or Val; and X.sub.11 is Arg, Asn,
Asp, Glu, His, Ile, Leu, Met, Phe, Pro, Thr, Trp, Tyr or Val; or
Loop Consensus Sequence 17:
Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6-Cys (TN7), wherein X.sub.2
is Asn, Asp or Glu; X.sub.3 is Glu, His, Lys or Phe; X.sub.4 is
Asp, Gln, Leu, Lys, Met or Tyr; and X.sub.6 is Arg, Gln, Leu, Lys
or Val; or Loop Consensus Sequence 18:
Cys-X.sub.2-X.sub.3-X.sub.4-X.- sub.5-X.sub.6-X.sub.7-X.sub.8-Cys
(TN9), wherein X.sub.2 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.3
is Asn, Glu, Gly, His or Leu; X.sub.4 is Gln, Glu, Gly, Met, Lys,
Phe, Tyr or Val; X.sub.5 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser
or Thr; X.sub.6 is His, Pro or Trp; X.sub.7 is Ala, Gly, His, Leu,
Trp or Tyr; and X.sub.8 is Ala, Asp, Gln, Leu, Met, Thr or Trp; or
Loop Consensus Sequence 19:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Ser-Gl-
y-Pro-X.sub.9-X.sub.10-X.sub.11-X.sub.12-Cys (MTN13; SEQ ID NO:1),
wherein X.sub.2 is Asp, Glu, His or Thr; X.sub.3 is Arg, His, Lys
or Phe; X.sub.4 is Gln, Ile, Lys, Tyr or Val; X.sub.5 is Gln, Ile,
Leu, Met or Phe; X.sub.9 is Asn, Asp, Gly, His or Tyr; X.sub.10 is
Gln, Gly, Ser or Thr; X.sub.11 is Glu, Lys, Phe or Ser; and
X.sub.12 is Glu, Ile, Ser or Val, and wherein at least one
polypeptide is coupled to at least one chelator capable of
complexing a radionuclide useful for scintigraphic imaging, and
wherein the polypeptide optionally further comprises N-terminal
and/or C-terminal flanking peptides of one or more amino acids.
155. The multimeric polypeptide construct of claim 77, comprising
at least one amino acid sequence selected from the group consisting
of: SEQ ID NOS: 505-516.
156. The dimeric polypeptide construct of claim 113, comprising at
least one amino acid sequence selected from the group consisting
of: SEQ ID NOS:505-516.
157. The polypeptide of claim 7, wherein the polypeptide comprises
an amino acid sequence of one of the following: Consensus Sequence
9A:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.sub-
.10-X.sub.11-X.sub.12-X.sub.13-Cys-X.sub.15-X.sub.16-X.sub.17
(TN11; SEQ ID NO:3), wherein X.sub.1 is Ala, Arg, Asn, Asp, Gln,
Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or
Val; X.sub.2 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Leu, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.3 is Ala, Arg, Asn, Asp,
Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Thr, Trp, Tyr or Val;
X.sub.5 is Ala, Arg, Asp, Gln, Glu, Gly, His, Ile, Leu, Lys, Met,
Phe, Ser, Trp, Tyr or Val; X.sub.6 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp or Tyr;
X.sub.7 is Ala, Arg, Asp, Asn, Gln, Glu, Gly, His, Ile, Leu, Met,
Phe, Ser, Thr, Trp, Tyr or Val; X.sub.8 is Ala, Arg, Asp, Asn, Gln,
Glu, Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.9 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro, Ser,
Trp or Tyr; X.sub.10 is Asp, Gln, Glu, Gly, His, Ile, Leu, Phe,
Ser, Thr, Trp, Tyr or Val; X.sub.11 is Ala, Gln, Glu, Gly, His,
Ile, Leu, Lys, Met, Pro, Ser, Thr, Trp, Tyr or Val; X.sub.12 is
Ala, Asn, Asp, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro,
Ser, Thr, Trp, Tyr or Val; X.sub.13 is Ala, Arg, Asn, Asp, Cys,
Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or
Val; X.sub.15 is Ala, Asp, Asn, Glu, Gly, Ile, His, Leu, Lys, Met,
Phe, Pro, Ser, Thr, Trp, Tyr or Val; X.sub.16 is Ala, Arg, Asn,
Asp, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr,
Trp, Tyr or Val; X.sub.17 is Ala, Arg, Asp, Asn, Gln, Glu, Gly,
His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Tyr or Val, wherein
the polypeptide binds KDR or VEGF/KDR complex.
158. A method of detecting KDR or VEGF/KDR complex in an animal or
human subject and optionally imaging at least a portion of the
animal or human subject comprising the steps of: (a) detectably
labeling a multimeric polypeptide construct of one of claims 76, 77
or 78; (b) administering to the subject the labeled multimeric
polypeptide construct; and, (c) detecting the labeled multimeric
polypeptide construct in the subject, and, optionally, constructing
an image.
159. The method of claim 158, wherein the multimeric polypeptide is
selected from the group consisting of: D1, D2, D3, D4, D5, D6, D7,
D8, D9, D10, D11, D12, D13, D14, D15, D16, D17, D18, D19, D20, D21,
D22, D23, D24, D25, D26, D27, D28, and D29.
160. The method of claim 158, wherein the multimeric polypeptide is
detectably labeled with a label selected from the group consisting
of: an enzyme, a fluorescent compound, an ultrasound contrast
agent, a liposome and an optical dye, wherein the label optionally
further comprises a linker a spacer.
161. The method of claim 160, wherein the ultrasound contrast agent
is a phospholipid stabilized microbubble or an ultrasound contrast
agent comprising a gas.
162. The method of claim 161, wherein the ultrasound contrast agent
comprises a fluorinated gas.
163. The method of claim 158, wherein the multimeric polypeptide
construct is detectably labeled with a label that is one or more
radioactive labels, one or more paramagnetic metal atoms or a
superparamagnetic particle, and optionally further comprises a
linker or a spacer.
164. The method of claim 163, wherein the radioactive label
comprises one or more radionuclides selected from the group
consisting of: .sup.18F, .sup.124I, .sup.125I, .sup.131I,
.sup.123I, .sup.77Br, .sup.76Br, .sup.99mTc, .sup.51Cr, .sup.67Ga,
.sup.68Ga, .sup.47Sc, .sup.51Cr, .sup.167Tm, .sup.141Ce,
.sup.111In, .sup.168Yb, .sup.175Yb, .sup.140La, .sup.90Y, .sup.88Y,
.sup.153Sm, .sup.166Ho, .sup.165Dy, .sup.166Dy, .sup.62Cu,
.sup.64Cu, .sup.67Cu, .sup.97Ru, .sup.103Ru, .sup.186Re,
.sup.188Re, .sup.203Pb, .sup.211Bi, .sup.212Bi, .sup.213Bi,
.sup.214Bi, .sup.109Pd, .sup.117mSn, .sup.149Pm, .sup.161Tb,
.sup.177Lu, .sup.198Au and .sup.199Au.
165. The method of claim 164, wherein the radioactive label further
comprises at least one chelator.
166. The method of claim 165, wherein the chelator is selected from
the group consisting of: formula 20, 21, 22, 23a, 23b, 24a, 24b,
and 25.
167. The method of claim 165, wherein the radionuclide is
.sup.99mTc or .sup.111In.
168. The method of claim 163, wherein the paramagnetic metal atom
is selected from the group consisting of: Mn.sup.2+, Cu.sup.2+,
Fe.sup.2+, Co.sup.2+, Ni.sup.2+, Gd.sup.3+, Eu.sup.3+, Dy.sup.3+,
Pr.sup.3+, Cr.sup.3+, Co.sup.3+, Fe.sup.3+, Ti.sup.3+, Tb.sup.3+,
Nd.sup.3+, Sm.sup.3+, Ho.sup.3+, Er.sup.3+, Pa.sup.4+ and
Eu.sup.2+.
169. The method of claim 168, wherein the paramagnetic label
further comprises a chelator.
170. The method of claim 169, wherein the chelator is selected from
the group consisting of: DTPA, DO3A, DOTA, EDTA, TETA, EHPG, HBED,
NOTA, DOTMA, TETMA, PDTA, TTHA, LICAM, and MECAM.
171. The method of claim 158, wherein detection of the labeled
multimeric polypeptide construct is indicative of the presence of a
pathogen selected from the group consisting of: malaria strains,
HIV, SIV, simian hemorrhagic fever virus and enterohemorrhagic E.
coli strains.
172. The method of claim 158, wherein detection of the labeled
multimeric polypeptide construct is indicative of angiogenesis or
neovascularization.
173. The method of claim 162, wherein the ultrasound contrast agent
comprises a fluorinated gas selected from the group of: SF.sub.6
freons, CF.sub.4, C.sub.2F.sub.6, C.sub.3F.sub.8, C.sub.4F.sub.10,
CBrF.sub.3, CCI.sub.2F.sub.2, C.sub.2CIF.sub.5, CBrCIF.sub.2 and
perfluorocarbons.
174. The method of claim 173, wherein the ultrasound contrast agent
comprises a perfluorocarbon gas having the formula C.sub.nF.sub.n+2
wherein n is from 1 to 12.
175. A multimeric polypeptide having the ability to bind to KDR or
VEGF/KDR complex selected from the group consisting of: D30 and
D31.
176. The scintigraphic imaging agent of claim 99, wherein the agent
comprises .sup.99mTc-D30.
177. The method of claim 110, wherein the multimeric polypeptide
construct is selected from the group consisting of: D30 and
D31.
178. The method of claim 158, wherein the multimeric polypeptide
construct is selected from the group consisting of: D30 and
D31.
179. A method of treating a condition involving activation of KDR,
comprising administering to an animal or human subject in need of
treatment for such a condition a composition comprising at least
one multimeric polypeptide construct according to one of claims 76,
77 or 78.
180. The method of claim 179, wherein the condition is solid tumor
growth.
181. The method of claim 50, wherein the polypeptide construct is
conjugated with a tumorcidal agent.
182. A method of medical imaging comprising administering to an
animal or human subject a pharmaceutical preparation of a contrast
agent comprising at least one multimeric polypeptide construct of
one of claims 76, 77 or 78, and imaging the contrast agent by a
method selected from the group consisting of: magnetic resonance
imaging, ultrasound imaging, optical imaging, sonoluminescence
imaging, photoacoustic imaging and nuclear imaging.
183. A method of radiotherapy comprising administering to an animal
or human subject in need of such therapy a compound comprising at
least one multimeric polypeptide construct of one of claims 76, 77
or 78 conjugated to one or more radionuclides useful for
radiotherapy.
184. The method of claim 183, wherein the compound further
comprises one or more chelators.
185. The method of claim 184, wherein the multimeric polypeptide
further comprises a spacer or linker.
186. The method of claims 184, wherein the chelator is a compound
selected from the group consisting of: formula 20, 21, 22, 23, 24
and 25.
187. The method of claim 183, wherein the radionuclide is
.sup.186Re, .sup.18Re, .sup.177Lu, .sup.90Y, .sup.153Sm or
.sup.166Ho.
188. A method of targeting genetic material to KDR-expressing cells
comprising administering to an animal or a human in need of such
genetic material a multimeric polypeptide construct of one of
claims 76, 77 or 78 conjugated to or associated with the genetic
material or a delivery vehicle containing such genetic
material.
189. The polypeptide of claim 7, wherein the polypeptide comprises
an amino acid sequence selected form the group consisting of SEQ ID
NOS: 505-616.
190. The multimeric polypeptide construct of claim 77, comprising
at least one amino acid sequence selected from the group consisting
of: SEQ ID NOS: 505-616.
191. The dimeric polypeptide construct of claim 113, comprising at
least one amino acid sequence selected from the group consisting
of: SEQ ID NOS: 505-616.
192. A method of inhibiting angiogenesis comprising administering
to an animal or human subject in need of treatment for such
condition a polypeptide having the ability to bind to KDR or
VEGF/KDR complex, or a multimeric polypeptide construct comprising
at least one polypeptide having the ability to bind to KDR or
VEGF/KDR complex, the polypeptide comprising an amino acid sequence
of one of the following: Consensus Sequence 1:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X-
.sub.9-X.sub.10-Cys-X.sub.12-X.sub.13-X.sub.14 (TN8), wherein
X.sub.1 is Ala, Arg, Asp, Gly, His, Leu, Lys, Pro, Ser, Thr, Trp,
Tyr or Val; X.sub.2 is Asn, Asp, Glu, Gly, Ile, Leu, Lys, Phe, Ser,
Thr, Trp, Tyr or Val; X.sub.3 is Asn, Asp, Gln, Glu, Ile, Leu, Met,
Thr, Trp or Val; X.sub.5 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile,
Lys, Phe, Pro, Ser, Trp or Tyr; X.sub.6 is Ala, Arg, Asn, Asp, Gln,
Glu, Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.7 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro,
Ser, Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asp, Glu, Gly, Leu, Phe,
Pro, Ser, Thr, Trp or Tyr; X.sub.9 is Arg, Gln, Glu, Gly, Ile, Leu,
Met, Pro, Thr, Trp, Tyr or Val; X.sub.10 is Ala, Arg, Gln, Glu,
Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr; X.sub.12 is Arg,
Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr,
Trp, Tyr or Val; X.sub.13 is Arg, Asn, Asp, Gln, Glu, Gly, His,
Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp or Tyr; and X.sub.14 is Gln,
Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp or Tyr;
or Consensus Sequence 2:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.-
sub.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-Cys-X.sub.16-X.sub.17-X.sub.18
(TN12), wherein X.sub.1 is Ala, Asn, Asp, Gly, Leu, Pro, Ser, Trp
or Tyr; X.sub.2 is Ala, Arg, Asn, Asp, Gly, His, Phe, Pro, Ser, Trp
or Tyr; X.sub.3 is Ala, Asn, Asp, Gln, Glu, Gly, His, Leu, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.5 is Arg, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val; X.sub.6 is Ala, Arg,
Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or Tyr; X.sub.7 is Arg,
Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.8 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro, Ser,
Trp, Tyr or Val; X.sub.9 is Asp, Gln, Glu, Gly, His, Ile, Leu, Met,
Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.10 is Ala, Arg, Asn, Asp,
Gln, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.11 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys, Trp, Tyr
or Val; X.sub.12 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met, Phe,
Ser, Thr, Trp, Tyr or Val; X.sub.13 is Arg, Gln, Glu, His, Leu,
Lys, Met, Phe, Pro, Thr, Trp or Val; X.sub.14 is Arg, Asn, Asp,
Glu, His, Ile, Leu, Met, Phe, Pro, Thr, Trp, Tyr or Val; X.sub.16
is Ala, Asn, Asp, Gln, Glu, Gly, Lys, Met, Phe, Ser, Thr, Trp, Tyr
or Val; X.sub.17 is Arg, Asn, Asp, Cys, Gly, His, Phe, Pro, Ser,
Trp or Tyr; and X.sub.18 is Ala, Asn, Asp, Gly, His, Leu, Phe, Pro,
Ser, Trp or Tyr; or Consensus Sequence 3:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-Gly-X.sub.9-Cys-X.sub-
.11-X.sub.12-X.sub.13 (TN7), wherein X.sub.1 is Gly or Trp; X.sub.2
is Ile, Tyr or Val; X.sub.3 is Gln, Glu, Thr or Trp; X.sub.5 is
Asn, Asp or Glu; X.sub.6 is Glu, His, Lys or Phe; X.sub.7 is Asp,
Gln, Leu, Lys, Met or Tyr; X.sub.9 is Arg, Gln, Leu, Lys or Val;
X.sub.11 is Arg, Phe, Ser, Trp or Val; X.sub.12 is Glu, His or Ser;
and X.sub.13 is Glu, Gly, Trp or Tyr; or Consensus Sequence 4:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-
-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys-X.sub.13-X.sub.14-X.sub.15
(TN9), wherein X.sub.1 is Arg, Asp, Gly, Ile, Met, Pro or Tyr;
X.sub.2 is Asp, Gly, His, Pro or Trp; X.sub.3 is Gly, Pro, Phe, Thr
or Trp; X.sub.5 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.6 is Asn,
Glu, Gly, His or Leu; X.sub.7 is Gln, Glu, Gly, Met, Lys, Phe, Tyr
or Val; X.sub.8 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or Thr;
X.sub.9 is His, Pro or Trp; X.sub.10 is Ala, Gly, His, Leu, Trp or
Tyr; X.sub.11 is Ala, Asp, Gln, Leu, Met, Thr or Trp; X.sub.13 is
Ala, Lys, Ser, Trp or Tyr; X.sub.14 is Asp, Gly, Leu, His, Met,
Thr, Trp or Tyr; and X.sub.15 is Asn, Gln, Glu, Leu, Met, Pro or
Trp; Consensus Sequence 5: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.s-
ub.6-X.sub.7-X.sub.8-Ser-Gly-Pro-X.sub.12-X.sub.13-X.sub.14-X.sub.15-Cys-X-
.sub.17-X.sub.18-X.sub.19 (SEQ ID NO:1; MTN13), wherein X.sub.1 is
Arg, Glu, His, Ser or Trp; X.sub.2 is Asn, Asp, Leu, Phe, Thr or
Val; X.sub.3 is Arg, Asp, Glu, His, Lys or Thr; X.sub.5 is Asp,
Glu, His or Thr; X.sub.6 is Arg, His, Lys or Phe; X.sub.7 is Gln,
Ile, Lys, Tyr or Val; X.sub.8 is Gln, Ile, Leu, Met or Phe;
X.sub.12 is Asn, Asp, Gly, His or Tyr; X.sub.13 is Gln, Gly, Ser or
Thr; X.sub.14 is Glu, Lys, Phe or Ser; X.sub.15 is Glu, Ile, Ser or
Val; X.sub.17 is Glu, Gly, Lys, Phe, Ser or Val; X.sub.18 is Arg,
Asn, Ser or Tyr; and X.sub.19 is Asp, Gln, Glu, Gly, Met or Tyr;
Consensus Sequence 13: Z.sub.1-X.sub.1-X.sub.2-X.sub.3-X-
.sub.4-X.sub.5-Z.sub.2 (Lin20); wherein, Z.sub.1 is a polypeptide
of at least one amino acid or is absent; X.sub.1 is Ala, Asp, Gln
or Glu; X.sub.2 is Ala, Asp, Gln, Glu, Pro; X.sub.3 is Ala, Leu,
Lys, Phe, Pro, Trp or Tyr; X.sub.4 is Asp, Leu, Ser, Trp, Tyr or
Val; X.sub.5 is Ala, Arg, Asp, Glu, Gly, Leu, Trp or Tyr; and
Z.sub.2 is a polypeptide of at least one amino acid or is absent;
Consensus Sequence 14:
X.sub.1-X.sub.2-X.sub.3-Tyr-Trp-Glu-X.sub.7-X.sub.8-X.sub.9-Leu
(Lin20; SEQ ID NO:7), wherein, the sequence can optionally have a
N-terminal polypeptide, C-terminal polypeptide, or a polypeptide at
both termini of at least one amino acid; wherein, X.sub.1 is Asp,
Gly or Ser; X.sub.2 is Ile, Phe or Tyr; X.sub.3 is Ala, Ser or Val;
X.sub.7 is Gln, Glu, Ile or Val; X.sub.8 is Ala, Ile or Val;
X.sub.9 is Ala, Glu, Val or Thr; Loop Consensus Sequence 15:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.- 7-Cys (TN8),
wherein X.sub.2 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys,
Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.4 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro,
Ser, Thr, Trp, Tyr or Val (preferably Asp); X.sub.5 is Ala, Asp,
Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.6 is Arg, Gln,
Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; and X.sub.7 is
Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr;
or Loop Consensus Sequence
16:Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.-
sub.10-X.sub.11-Cys (TN12), wherein X.sub.2 is Arg, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val; X.sub.3 is Ala, Arg,
Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or Tyr; X.sub.4 is Arg,
Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.5 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro, Ser,
Trp, Tyr or Val; X.sub.6 is Asp, Gln, Glu, Gly, His, Ile, Leu, Met,
Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.7 is Ala, Arg, Asn, Asp, Gln,
Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.8 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys, Trp, Tyr or
Val; X.sub.9 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met, Phe, Ser,
Thr, Trp, Tyr or Val; X.sub.10 is Arg, Gln, Glu, His, Leu, Lys,
Met, Phe, Pro, Thr, Trp or Val; and X.sub.11 is Arg, Asn, Asp, Glu,
His, Ile, Leu, Met, Phe, Pro, Thr, Trp, Tyr or Val; or Loop
Consensus Sequence 17: Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6-Cys
(TN7), wherein X.sub.2 is Asn, Asp or Glu; X.sub.3 is Glu, His, Lys
or Phe; X.sub.4 is Asp, Gln, Leu, Lys, Met or Tyr; and X.sub.6 is
Arg, Gln, Leu, Lys or Val; or Loop Consensus Sequence 18:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.- 6-X.sub.7-X.sub.8-Cys
(TN9), wherein X.sub.2 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.3
is Asn, Glu, Gly, His or Leu; X.sub.4 is Gln, Glu, Gly, Met, Lys,
Phe, Tyr or Val; X.sub.5 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser
or Thr; X.sub.6 is His, Pro or Trp; X.sub.7 is Ala, Gly, His, Leu,
Trp or Tyr; and X.sub.8 is Ala, Asp, Gln, Leu, Met, Thr or Trp; or
Loop Consensus Sequence 19:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Ser-Gly-Pro-X.-
sub.9-X.sub.10-X.sub.11-X.sub.12-Cys (MTN13; SEQ ID NO:1), wherein
X.sub.2 is Asp, Glu, His or Thr; X.sub.3 is Arg, His, Lys or Phe;
X.sub.4 is Gln, Ile, Lys, Tyr or Val; X.sub.5 is Gln, Ile, Leu, Met
or Phe; X.sub.9 is Asn, Asp, Gly, His or Tyr; X.sub.10 is Gln, Gly,
Ser or Thr; X.sub.11 is Glu, Lys, Phe or Ser; and X.sub.12 is Glu,
Ile, Ser or Val.
193. The method according to claim 192, wherein the polypeptide
comprises an amino acid sequence selected from the group consisting
of: SEQ ID NOS: 20-86, 87-136, 137-186, 187-192, 193-203, and
207-259.
194. The method according to claim 192, wherein the polypeptide
comprises an amino acid sequence selected from the group consisting
of: SEQ ID NOS: 505-616.
195. A method of inhibiting VEGF activation of KDR comprising
administering to an animal or human subject in need of treatment
for such condition a polypeptide having the ability to bind to KDR
or VEGF/KDR complex, or a multimeric polypeptide construct
comprising at least one ploypeptide having the ability to bind to
KDR or VEGF/KDR complex, sadi polypeptide comprising an amino acid
sequence of one of the following: Consensus Sequence 1:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-
-X.sub.8-X.sub.9-X.sub.10-Cys-X.sub.12-X.sub.13-X.sub.14 (TN8),
wherein X.sub.1 is Ala, Arg, Asp, Gly, His, Leu, Lys, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.2 is Asn, Asp, Glu, Gly, Ile, Leu, Lys,
Phe, Ser, Thr, Trp, Tyr or Val; X.sub.3 is Asn, Asp, Gln, Glu, Ile,
Leu, Met, Thr, Trp or Val; X.sub.5 is Ala, Arg, Asn, Asp, Gln, Glu,
His, Ile, Lys, Phe, Pro, Ser, Trp or Tyr; X.sub.6 is Ala, Arg, Asn,
Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp,
Tyr or Val; X.sub.7 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys,
Phe, Pro, Ser, Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asp, Glu, Gly,
Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.9 is Arg, Gln, Glu, Gly,
Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; X.sub.10 is Ala, Arg,
Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr; X.sub.12
is Arg, Asp, Cys, Gln, Glu, His, Ile, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.13 is Arg, Asn, Asp, Gln, Glu, Gly,
His, Ile, Leu, Lys, Met, Phe, Ser, Thr, Trp or Tyr; and X.sub.14 is
Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp or
Tyr; or Consensus Sequence 2:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-
-X.sub.8-X.sub.9-X.sub.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-Cys-X.sub.16-
-X.sub.17-X.sub.18 (TN12), wherein X.sub.1 is Ala, Asn, Asp, Gly,
Leu, Pro, Ser, Trp or Tyr; X.sub.2 is Ala, Arg, Asn, Asp, Gly, His,
Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Asn, Asp, Gln, Glu, Gly,
His, Leu, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.5 is Arg,
Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val;
X.sub.6 is Ala, Arg, Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or
Tyr; X.sub.7 is Arg, Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.8 is Ala, Asn, Asp, Gln, Glu, Gly, His,
Met, Phe, Pro, Ser, Trp, Tyr or Val; X.sub.9 is Asp, Gln, Glu, Gly,
His, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.10 is
Ala, Arg, Asn, Asp, Gln, Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser,
Thr, Trp, Tyr or Val; X.sub.11 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Lys, Trp, Tyr or Val; X.sub.12 is Ala, Arg, Gln, Gly,
His, Ile, Lys, Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.13 is
Arg, Gln, Glu, His, Leu, Lys, Met, Phe, Pro, Thr, Trp or Val;
X.sub.14 is Arg, Asn, Asp, Glu, His, Ile, Leu, Met, Phe, Pro, Thr,
Trp, Tyr or Val; X.sub.16 is Ala, Asn, Asp, Gln, Glu, Gly, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val; X.sub.17 is Arg, Asn, Asp,
Cys, Gly, His, Phe, Pro, Ser, Trp or Tyr; and X.sub.18 is Ala, Asn,
Asp, Gly, His, Leu, Phe, Pro, Ser, Trp or Tyr; or Consensus
Sequence 3:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7-Gly-X.sub.9-Cys-X.-
sub.11-X.sub.12-X.sub.13 (TN7), wherein X.sub.1 is Gly or Trp;
X.sub.2 is Ile, Tyr or Val; X.sub.3 is Gln, Glu, Thr or Trp;
X.sub.5 is Asn, Asp or Glu; X.sub.6 is Glu, His, Lys or Phe;
X.sub.7 is Asp, Gln, Leu, Lys, Met or Tyr; X.sub.9 is Arg, Gln,
Leu, Lys or Val; X.sub.11 is Arg, Phe, Ser, Trp or Val; X.sub.12 is
Glu, His or Ser; and X.sub.13 is Glu, Gly, Trp or Tyr; or Consensus
Sequence 4: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-
-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys-X.sub.13-X.sub.14-X.sub.15
(TN9), wherein X.sub.1 is Arg, Asp, Gly, Ile, Met, Pro or Tyr;
X.sub.2 is Asp, Gly, His, Pro or Trp; X.sub.3 is Gly, Pro, Phe, Thr
or Trp; X.sub.5 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.6 is Asn,
Glu, Gly, His or Leu; X.sub.7 is Gln, Glu, Gly, Met, Lys, Phe, Tyr
or Val; X.sub.8 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or Thr;
X.sub.9 is His, Pro or Trp; X.sub.10 is Ala, Gly, His, Leu, Trp or
Tyr; X.sub.11 is Ala, Asp, Gln, Leu, Met, Thr or Trp; X.sub.13 is
Ala, Lys, Ser, Trp or Tyr; X.sub.14 is Asp, Gly, Leu, His, Met,
Thr, Trp or Tyr; and X.sub.15 is Asn, Gln, Glu, Leu, Met, Pro or
Trp; Consensus Sequence 5: X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.s-
ub.6-X.sub.7-X.sub.8-Ser-Gly-Pro-X.sub.12-X.sub.13-X.sub.14-X.sub.15-Cys-X-
.sub.17-X.sub.18-X.sub.19 (SEQ ID NO:1; MTN13), wherein X.sub.1 is
Arg, Glu, His, Ser or Trp; X.sub.2 is Asn, Asp, Leu, Phe, Thr or
Val; X.sub.3 is Arg, Asp, Glu, His, Lys or Thr; X.sub.5 is Asp,
Glu, His or Thr; X.sub.6 is Arg, His, Lys or Phe; X.sub.7 is Gln,
Ile, Lys, Tyr or Val; X.sub.8 is Gln, Ile, Leu, Met or Phe;
X.sub.12 is Asn, Asp, Gly, His or Tyr; X.sub.13 is Gln, Gly, Ser or
Thr; X.sub.14 is Glu, Lys, Phe or Ser; X.sub.15 is Glu, Ile, Ser or
Val; X.sub.17 is Glu, Gly, Lys, Phe, Ser or Val; X.sub.18 is Arg,
Asn, Ser or Tyr; and X.sub.19 is Asp, Gln, Glu, Gly, Met or Tyr;
Consensus Sequence 13: Z.sub.1-X.sub.1-X.sub.2-X.sub.3-X-
.sub.4-X.sub.5-Z.sub.2 (Lin20); wherein, Z.sub.1 is a polypeptide
of at least one amino acid or is absent; X.sub.1 is Ala, Asp, Gln
or Glu; X.sub.2 is Ala, Asp, Gln, Glu, Pro; X.sub.3 is Ala, Leu,
Lys, Phe, Pro, Trp or Tyr; X.sub.4 is Asp, Leu, Ser, Trp, Tyr or
Val; X.sub.5 is Ala, Arg, Asp, Glu, Gly, Leu, Trp or Tyr; and
Z.sub.2 is a polypeptide of at least one amino acid or is absent;
Consensus Sequence 14:
X.sub.1-X.sub.2-X.sub.3-Tyr-Trp-Glu-X.sub.7-X.sub.8-X.sub.9-Leu
(Lin20; SEQ ID NO:7), wherein, the sequence can optionally have a
N-terminal polypeptide, C-terminal polypeptide, or a polypeptide at
both termini of at least one amino acid; wherein, X.sub.1 is Asp,
Gly or Ser; X.sub.2 is Ile, Phe or Tyr; X.sub.3 is Ala, Ser or Val;
X.sub.7 is Gln, Glu, Ile or Val; X.sub.8 is Ala, Ile or Val;
X.sub.9 is Ala, Glu, Val or Thr; Loop Consensus Sequence 15:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.- 7-Cys (TN8),
wherein X.sub.2 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys,
Phe, Pro, Ser, Trp or Tyr; X.sub.3 is Ala, Arg, Asn, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.4 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe, Pro,
Ser, Thr, Trp, Tyr or Val (preferably Asp); X.sub.5 is Ala, Asp,
Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.6 is Arg, Gln,
Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp, Tyr or Val; and X.sub.7 is
Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Trp or Tyr;
or Loop Consensus Sequence
16:Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.6-X.sub.7-X.sub.8-X.sub.9-X.-
sub.10-X.sub.11-Cys (TN12), wherein X.sub.2 is Arg, Asp, Gln, Glu,
Gly, His, Ile, Lys, Met, Thr, Trp, Tyr or Val; X.sub.3 is Ala, Arg,
Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser, Trp or Tyr; X.sub.4 is Arg,
Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.5 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro, Ser,
Trp, Tyr or Val; X.sub.6 is Asp, Gln, Glu, Gly, His, Ile, Leu, Met,
Phe, Pro, Ser, Thr, Trp or Tyr; X.sub.7 is Ala, Arg, Asn, Asp, Gln,
Glu, Gly, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
X.sub.8 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys, Trp, Tyr or
Val; X.sub.9 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met, Phe, Ser,
Thr, Trp, Tyr or Val; X.sub.10 is Arg, Gln, Glu, His, Leu, Lys,
Met, Phe, Pro, Thr, Trp or Val; and X.sub.11 is Arg, Asn, Asp, Glu,
His, Ile, Leu, Met, Phe, Pro, Thr, Trp, Tyr or Val; or Loop
Consensus Sequence 17: Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6-Cys
(TN7), wherein X.sub.2 is Asn, Asp or Glu; X.sub.3 is Glu, His, Lys
or Phe; X.sub.4 is Asp, Gln, Leu, Lys, Met or Tyr; and X.sub.6 is
Arg, Gln, Leu, Lys or Val; or Loop Consensus Sequence 18:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.sub.- 6-X.sub.7-X.sub.8-Cys
(TN9), wherein X.sub.2 is Ala, Asp, Lys, Ser, Trp or Val; X.sub.3
is Asn, Glu, Gly, His or Leu; X.sub.4 is Gln, Glu, Gly, Met, Lys,
Phe, Tyr or Val; X.sub.5 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser
or Thr; X.sub.6 is His, Pro or Trp; X.sub.7 is Ala, Gly, His, Leu,
Trp or Tyr; and X.sub.8 is Ala, Asp, Gln, Leu, Met, Thr or Trp; or
Loop Consensus Sequence 19:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Ser-Gly-Pro-X.-
sub.9-X.sub.10-X.sub.11-X.sub.12-Cys (MTN13; SEQ ID NO:1), wherein
X.sub.2 is Asp, Glu, His or Thr; X.sub.3 is Arg, His, Lys or Phe;
X.sub.4 is Gln, Ile, Lys, Tyr or Val; X.sub.5 is Gln, Ile, Leu, Met
or Phe; X.sub.9 is Asn, Asp, Gly, His or Tyr; X.sub.10 is Gln, Gly,
Ser or Thr; X.sub.11 is Glu, Lys, Phe or Ser; and X.sub.12 is Glu,
Ile, Ser or Val.
196. The method according to claim 195, wherein the polypeptide
comprises an amino acid sequence selected from the group consisting
of: SEQ ID NOS: 20-86, 87-136, 137-186, 187-192, 193-203, and
207-259.
197. The method according to claim 195, wherein the polypeptide
comprises an amino acid sequence selected from the group consisting
of: SEQ ID NOS: 505-616.
198. The method according to claim 195, wherein the polypeptide
comprises an amino acid sequence selected from the group consisting
of: SEQ ID NOS: 140, 267, 269, 294, 301, 305, 306, 307, 366, and
277.
Description
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S.
application Ser. No. 10/382,082, filed Mar. 3, 2003, and a
continuation-in-part of International Application No.
PCT/US03/06731, which designated the United States and was filed on
Mar. 3, 2003. U.S. application Ser. No. 10/382,082 and
International Application No. PCT/US03/06731 claims the benefit of
U.S. Provisional Application No. 60/360,851, filed Mar. 1, 2002,
and U.S. Provisional Application No. 60/440,411, filed Jan. 15,
2003. The entire teachings of the above applications are
incorporated herein by reference.
BACKGROUND OF THE INVENTION
[0002] In the developing embryo, the primary vascular network is
established by in situ differentiation of meso-dermal cells in a
process called vasculogenesis. After embryonic vasculogenesis
however, it is believed that all subsequent generation of new blood
vessels, in the embryo or in adults, is governed by the sprouting
or splitting of new capillaries from the pre-existing vasculature
in a process called angiogenesis (Pepper, M. et al., 1996. Enzyme
Protein, 49:138-162; Risau, W., 1997. Nature, 386:671-674).
Angiogenesis is not only involved in embryonic development and
normal tissue growth and repair, it is also involved in the female
reproductive cycle, establishment and maintenance of pregnancy, and
in repair of wounds and fractures. In addition to angiogenesis that
takes place in the normal individual, angiogenic events are
involved in a number of pathological processes, notably tumor
growth and metastasis, and other conditions in which blood vessel
proliferation is increased, such as diabetic retinopathy, psoriasis
and arthropathies. Angiogenesis is so important in the transition
of a tumor from hyperplastic to neoplastic growth, that inhibition
of angiogenesis has shown promise as a cancer therapy (Kim, K. et
al., 1993. Nature, 362:841-844).
[0003] Tumor-induced angiogenesis is thought to depend on the
production of pro-angiogenic growth factors by the tumor cells,
which overcome other forces that tend to keep existing vessels
quiescent and stable (Hanahan, D. and Folkman, J., 1996. Cell,
86:353-364). The best characterized of these pro-angiogenic agents
is vascular endothelial growth factor (VEGF) (Neufeld, G. et al.,
1999. FASEB J., 13:9-22).
[0004] VEGF is produced naturally by a variety of cell types in
response to hypoxia and some other stimuli. Many tumors also
produce large amounts of VEGF, and/or induce nearby stromal cells
to make VEGF (Fukumura, D. et al., 1998. Cell, 94:715-725). VEGF,
also referred to as VEGF-A, is synthesized as five different splice
isoforms of 121, 145, 165, 189, and 206 amino acids. VEGF.sub.121
and VEGF.sub.165 are the main forms produced, particularly in
tumors (see, Neufeld, G. et al. 1999, supra). VEGF.sub.121 lacks a
basic domain encoded by exons 6 and 7 of the VEGF gene and does not
bind to heparin or extracellular matrix, unlike VEGF.sub.165.
[0005] VEGF family members act primarily by binding to receptor
tyrosine kinases. In general, receptor tyrosine kinases are
glycoproteins having an extracellular domain capable of binding one
or more specific growth factors, a transmembrane domain (usually an
alpha helix), a juxtamembrane domain (where the receptor may be
regulated, e.g., by phosphorylation), a tyrosine kinase domain (the
catalytic component of the receptor), and a carboxy-terminal tail,
which in many receptors is involved in recognition and binding of
the substrates for the tyrosine kinase. There are three endothelial
cell-specific receptor tyrosine kinases known to bind VEGF: VEGFR-1
(Flt-1), VEGFR-2 (KDR or Flk-1), and VEGFR-3 (Flt4). Flt-1 and KDR
have been identified as the primary high affinity VEGF receptors.
While Flt-1 has higher affinity for VEGF, KDR displays more
abundant endothelial cell expression (Bikfalvi, A. et al., 1991. J.
Cell. Physiol., 149:50-59). Moreover, KDR is thought to dominate
the angiogenic response and is therefore of greater therapeutic and
diagnostic interest (see, Neufeld, G. et al. 1999, supra).
Expression of KDR is highly upregulated in angiogenic vessels,
especially in tumors that induce a strong angiogenic response
(Veikkola, T. et al., 2000. Cancer Res., 60:203-212).
[0006] KDR is made up of 1336 amino acids in its mature form.
Because of glycosylation, it migrates on an SDS-PAGE gel with an
apparent molecular weight of about 205 kDa. KDR contains seven
immunoglobulin-like domains in its extracellular domain, of which
the first three are the most important in VEGF binding (Neufeld, G.
et al. 1999, supra). VEGF itself is a homodimer capable of binding
to two KDR molecules simultaneously. The result is that two KDR
molecules become dimerized upon binding and autophosphorylate,
becoming much more active. The increased kinase activity in turn
initiates a signaling pathway that mediates the KDR-specific
biological effects of VEGF.
[0007] From the foregoing, it can be seen that not only is the VEGF
binding activity of KDR in vivo critical to angiogenesis, but the
ability to detect KDR upregulation on endothelial cells or to
detect VEGF/KDR binding complexes would be extremely beneficial in
detecting or monitoring angiogenesis, with particular diagnostic
applications such as detecting malignant tumor growth. It would
also be beneficial in therapeutic applications such as targeting
tumorcidal agents or angiogenesis inhibitors to a tumor site or
targeting agonists of KDR, VEGF/KDR, or angiogenesis to a desired
site.
SUMMARY OF THE INVENTION
[0008] The present invention relates to polypeptides and
compositions useful for detecting and targeting primary receptors
on endothelial cells for vascular endothelial growth factor (VEGF),
i.e., vascular endothelial growth factor receptor-2 (VEGFR-2, also
known as kinase domain region (KDR) and fetal liver kinase-1
(Flk-1)), and for imaging and targeting complexes formed by VEGF
and KDR. The involvement of VEGF and KDR in angiogenesis makes the
VEGF/KDR and KDR binding polypeptides of the present invention
particularly useful for imaging important sites of angiogenesis,
e.g., neoplastic tumors, for targeting substances, e.g.,
therapeutics, including radiotherapeutics, to such sites, and for
treating certain disease states, including those associated with
inappropriate angiogenesis.
[0009] A group of polypeptides has been discovered that bind to KDR
or VEGF/KDR complex (referred to herein as "KDR binding
polypeptides" or "KDR binding moieties" and homologues thereof).
Such KDR and VEGF/KDR binding polypeptides will concentrate at the
sites of angiogenesis, thus providing a means for detecting and
imaging sites of active angiogenesis, which can include sites of
neoplastic tumor growth. Such KDR and VEGF/KDR binding polypeptides
provide novel therapeutics to inhibit or promote, e.g.,
angiogenesis. The preparation, use and screening of such
polypeptides, for example as imaging agents or as fusion partners
for KDR or VEGF/KDR-homing therapeutics, is described in detail
herein.
[0010] In answer to the need for improved materials and methods for
detecting, localizing, measuring and possibly affecting (inhibiting
or enhancing), e.g., angiogenesis, it has been surprisingly
discovered that seven families of non-naturally occurring
polypeptides bind specifically to KDR or VEGF/KDR complex.
Appropriate labeling of such polypeptides provides detectable
imaging agents that can bind, e.g., at high concentration, to
KDR-expressing endothelial cells or cells exhibiting VEGF/KDR
complexes, providing angiogenesis-specific imaging agents. The KDR
and VEGF/KDR binding polypeptides of the instant invention can thus
be used in the detection and diagnosis of such angiogenesis-related
disorders. Conjugation or fusion of such polypeptides with
effective agents such as VEGF inhibitors or tumorcidal agents can
also be used to treat pathogenic tumors, e.g., by causing the
conjugate or fusion to "home" to the site of active angiogenesis,
thereby providing an effective means for treating pathogenic
conditions associated with angiogenesis.
[0011] This invention pertains to KDR and VEGF/KDR binding
polypeptides, and includes use of a single binding polypeptide as a
monomer or in a multimeric or polymeric construct as well as use of
more than one binding polypeptide of the invention in multimeric or
polymeric constructs. Binding polypeptides according to this
invention are useful in any application where binding, detecting or
isolating KDR or VEGF/KDR complex, or fragments thereof retaining
the polypeptide binding site, is advantageous. A particularly
advantageous use of the binding polypeptides disclosed herein is in
a method of imaging angiogenesis in vivo. The method entails the
use of specific binding polypeptides according to the invention for
detecting a site of angiogenesis, where the binding polypeptides
have been detectably labeled for use as imaging agents, including
magnetic resonance imaging (MRI) contrast agents, x-ray imaging
agents, radiopharmaceutical imaging agents, ultrasound imaging
agents, and optical imaging agents.
[0012] Another advantageous use of the KDR and VEGF/KDR complex
binding polypeptides disclosed herein is to target therapeutic
agents (including compounds capable of providing a therapeutic,
radiotherapeutic or cytotoxic effect), or delivery vehicles for
therapeutics (including drugs, genetic material, etc.) to sites of
angiogenesis or other tissue expressing KDR.
[0013] Constructs comprising two or more KDR or KDR/VEGF binding
polypeptides show improved ability to bind the target molecule
compared to the corresponding monomeric binding polypeptides. For
example, as shown in Experiment D of Example 5, tetrameric
constructs of KDR binding polypeptides provided herein showed
improved ability to bind KDR-transfected 293H cells. Combining two
or more binding polypeptides in a single molecular construct
appears to improve the avidity of the construct over the monomeric
binding polypeptides as shown by a decrease in K.sub.D.
[0014] In addition, as demonstrated herein, constructs comprising
two or more binding polypeptides specific for different epitopes of
KDR and/or KDR/VEGF (e.g., "heteromeric" or "heteromultimeric"
constructs, see U.S. Application No. 60/440,201, U.S. application
Ser. No. 10/379,287, filed Mar. 3, 2003, and Attorney Docket No.
057637/01182 by Christophe Arbogast et al., filed Sep. 11, 2003,
the contents of which are incorporated herein) were made.
Constructs comprising two or more binding polypeptides provided
herein are expected to bind to multiple sites on KDR or VEGF/KDR.
The heteromeric constructs show superior binding ability over both
the corresponding monomers and multimeric constructs comprising
multiple copies of the same binding polypeptide. Furthermore,
heteromeric constructs comprising two or more binding peptides
specific for different epitopes, together with a control peptide,
were also able to efficiently bind KDR-transfected 293H cells.
Thus, inclusion of two or more binding polypeptides that recognize
different epitopes further improves the avidity of the construct
for the target molecule, as demonstrated by a decrease in
K.sub.D.
[0015] Heteromeric constructs of the binding polypeptides provided
herein show improved ability to inhibit receptor tyrosine kinase
function. Based on experiments described herein, dimeric and other
multimeric constructs of the present invention comprising at least
two binding polypeptides specific for different epitopes of KDR
and/or KDR/VEGF complex are expected to inhibit the function of
receptor tyrosine kinases. In particular, such constructs are
expected to inhibit the function of VEGFR-2/KDR, VEGFR-1/Flt-1 and
VEGFR-3/Flt-4.
[0016] For the purposes of the present invention, receptor tyrosine
kinase function can include any one of: oligomerization of the
receptor, receptor phosphorylation, kinase activity of the
receptor, recruitment of downstream signaling molecules, induction
of genes, induction of cell proliferation, induction of cell
migration, or combination thereof. For example, heteromeric
constructs of binding polypeptides provided herein inhibit
VEGF-induced KDR receptor activation in human endothelial cells,
demonstrated by the inhibition of VEGF-induced phosphorylation of
the KDR receptor. In addition, heteromeric constructs of binding
peptides provided herein inhibit VEGF-stimulated endothelial cell
migration. As shown herein, targeting two or more distinct epitopes
on KDR with a single binding construct greatly improves the ability
of the construct to inhibit receptor function. Even binding
peptides with weak ability to block receptor activity can be used
to generate heteromeric constructs having improved ability to block
VEGF-induced receptor function.
[0017] Therefore, the present invention also is drawn to constructs
comprising two or more binding polypeptides. In one embodiment, the
multimeric constructs comprise two or more copies of a single
binding polypeptide. In another embodiment, the multimeric
constructs of the present invention comprise two or more binding
polypeptides, such that at least two of the binding polypeptides in
the construct are specific for different epitopes of KDR and/or
KDR/VEGF. These constructs are also referred to herein as
"heteromeric constructs," "heteromultimers," etc. The constructs of
the present invention can also include unrelated, or control
peptide(s). The constructs can include two or more, three or more,
or four or more binding polypeptides. Based on the teachings
provided herein, one of ordinary skill in the art is able to
assemble the binding polypeptides provided herein into multimeric
constructs and to select multimeric constructs having improved
properties, such as improved ability to bind the target molecule,
or improved ability to inhibit receptor tyrosine kinase function.
Such multimeric constructs having improved properties are included
in the present invention.
[0018] Consensus sequences 1-14 have been determined based on the
specific KDR and VEGF/KDR binding polypeptides shown in Tables 1-7.
In specific embodiments, KDR and VEGF/KDR binding polypeptides of
the invention comprise one or more of these sequences. Such
preferred KDR or VEGF/KDR complex binding polypeptides include
polypeptides with the potential to form a cyclic or loop structure
between invariant cysteine residues comprising, or alternatively
consisting of, an amino acid sequence selected from the group
consisting of Consensus Sequences 1-5 below:
[0019] Consensus Sequence 1:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X-
.sub.7-X.sub.8-X.sub.9-X.sub.10-Cys-X.sub.12-X.sub.13-X.sub.14
(TN8), wherein
[0020] X.sub.1 is Ala, Arg, Asp, Gly, His, Leu, Lys, Pro, Ser, Thr,
Trp, Tyr or Val;
[0021] X.sub.2 is Asn, Asp, Glu, Gly, Ile, Leu, Lys, Phe, Ser, Thr,
Trp, Tyr or Val;
[0022] X.sub.3 is Asn, Asp, Gln, Glu, Ile, Leu, Met, Thr, Trp or
Val;
[0023] X.sub.5 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys, Phe,
Pro, Ser, Trp or Tyr;
[0024] X.sub.6 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Ile, Lys,
Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
[0025] X.sub.7 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe,
Pro, Ser, Thr, Trp, Tyr or Val;
[0026] X.sub.8 is Ala, Asp, Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp
or Tyr;
[0027] X.sub.9 is Arg, Gln, Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp,
Tyr or Val;
[0028] X.sub.10 is Ala, Arg, Gin, Glu, Gly, His, Ile, Leu, Lys,
Met, Phe, Trp or Tyr;
[0029] X.sub.12 is Arg, Asp, Cys, Gln, Glu, His, Ile, Leu, Lys,
Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
[0030] X.sub.13 is Arg, Asn, Asp, Gln, Glu, Gly, His, Ile, Leu,
Lys, Met, Phe, Ser, Thr, Trp or Tyr; and
[0031] X.sub.14 is Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe,
Pro, Ser, Thr, Trp or Tyr,
[0032] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0033] Consensus Sequence 2:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X-
.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-Cys-X.-
sub.16-X.sub.17-X.sub.18 (TN12), wherein
[0034] X.sub.1 is Ala, Asn, Asp, Gly, Leu, Pro, Ser, Trp or Tyr
(preferably Asn, Asp, Pro or Tyr);
[0035] X.sub.2 is Ala, Arg, Asn, Asp, Gly, His, Phe, Pro, Ser, Trp
or Tyr (preferably Asp, Gly, Pro, Ser or Trp);
[0036] X.sub.3 is Ala, Asn, Asp, Gin, Glu, Gly, His, Leu, Lys, Met,
Phe, Ser, Thr, Trp, Tyr or Val (preferably Tip);
[0037] X.sub.5 is Arg, Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Thr,
Trp, Tyr or Val (preferably Glu, Ile or Tyr);
[0038] X.sub.6 is Ala, Arg, Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser,
Trp or Tyr (preferably Glu, Phe or Tyr);
[0039] X.sub.7 is Arg, Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser,
Thr, Trp, Tyr or Val (preferably Glu);
[0040] X.sub.8 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro,
Ser, Trp, Tyr or Val (preferably Gln or Ser);
[0041] X.sub.9 is Asp, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Pro,
Ser, Thr, Trp or Tyr (preferably Asp);
[0042] X.sub.10 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, Leu, Lys,
Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val (preferably Lys or
Ser);
[0043] X.sub.11 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys,
Trp, Tyr or Val (preferably Gly or Tyr);
[0044] X.sub.12 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met, Phe,
Ser, Thr, Trp, Tyr or Val (preferably Trp or Thr);
[0045] X.sub.13 is Arg, Gln, Glu, His, Leu, Lys, Met, Phe, Pro,
Thr, Trp or Val (preferably Glu or Trp);
[0046] X.sub.14 is Arg, Asn, Asp, Glu, His, Ile, Leu, Met, Phe,
Pro, Thr, Trp, Tyr or Val (preferably Phe);
[0047] X.sub.16 is Ala, Asn, Asp, Gln, Glu, Gly, Lys, Met, Phe,
Ser, Thr, Trp, Tyr or Val (preferably Asp);
[0048] X.sub.17 is Arg, Asn, Asp, Cys, Gly, His, Phe, Pro, Ser, Trp
or Tyr (preferably Pro or Tyr); and
[0049] X.sub.18 is Ala, Asn, Asp, Gly, His, Leu, Phe, Pro, Ser, Trp
or Tyr (preferably Asn, Pro or Trp),
[0050] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0051] Consensus Sequence 3:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X-
.sub.7-Gly-X.sub.9-Cys-X.sub.11-X.sub.12-X.sub.13 (TN7),
wherein
[0052] X.sub.1 is Gly or Trp;
[0053] X.sub.2 is Ile, Tyr or Val;
[0054] X.sub.3 is Gin, Glu Thr or Trp;
[0055] X.sub.5 is Asn, Asp or Glu;
[0056] X.sub.6 is Glu, His, Lys or Phe;
[0057] X.sub.7 is Asp, Gin, Leu, Lys Met or Tyr;
[0058] X.sub.9 is Arg, Gin, Leu, Lys or Val;
[0059] X.sub.11 is Arg, Phe, Ser, Trp or Val;
[0060] X.sub.12 is Glu, His or Ser; and
[0061] X.sub.13 is Glu, Gly, Trp or Tyr,
[0062] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0063] Consensus Sequence 4:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X-
.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys-X.sub.13-X.sub.14-X.sub.15
(TN9), wherein
[0064] X.sub.1 is Arg, Asp, Gly, Ile, Met, Pro or Tyr (preferably
Tyr);
[0065] X.sub.2 is Asp, Gly, His, Pro or Trp (preferably Gly or
Trp);
[0066] X.sub.3 is Gly, Pro, Phe, Thr or Trp (preferably Pro);
[0067] X.sub.5 is Ala, Asp, Lys, Ser, Trp or Val (preferably
Lys);
[0068] X.sub.6 is Asn, Glu, Gly, His or Leu;
[0069] X.sub.7 is Gin, Glu, Gly, Met, Lys, Phe, Tyr or Val
(preferably Met);
[0070] X.sub.8 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or
Thr;
[0071] X.sub.9 is His, Pro or Trp (preferably Pro);
[0072] X.sub.10 is Ala, Gly, His, Leu, Trp or Tyr (preferably His
or Trp);
[0073] X.sub.11 is Ala, Asp, Gin, Leu, Met, Thr or Trp;
[0074] X.sub.13 is Ala, Lys, Ser, Trp or Tyr (preferably Trp);
[0075] X.sub.14 is Asp, Gly, Leu, His, Met, Thr, Trp or Tyr
(preferably His, Trp, or Tyr); and
[0076] X.sub.15 is Asn, Gin, Glu, Leu, Met, Pro or Trp (preferably
Glu, Met or Trp),
[0077] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0078] Consensus Sequence 5:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X-
.sub.7-X.sub.8-Ser-Gly-Pro-X.sub.12-X.sub.13-X.sub.14-X.sub.15-Cys-X.sub.1-
7-X.sub.18-X.sub.19 (MTN13; SEQ ID NO:1), wherein
[0079] X.sub.1 is Arg, Glu, His, Ser or Trp;
[0080] X.sub.2 is Asn, Asp, Leu, Phe, Thr or Val;
[0081] X.sub.3 is Arg, Asp, Glu, His, Lys or Thr;
[0082] X.sub.5 is Asp, Glu, His or Thr;
[0083] X.sub.6 is Arg, His, Lys or Phe;
[0084] X.sub.7 is Gln, Ile, Lys, Tyr or Val;
[0085] X.sub.8 is Gln, Ile, Leu, Met or Phe;
[0086] X.sub.12 is Asn, Asp, Gly, His or Tyr;
[0087] X.sub.13 is Gln, Gly, Ser or Thr;
[0088] X.sub.14 is Glu, Lys, Phe or Ser;
[0089] X.sub.15 is Glu, Ile, Ser or Val;
[0090] X.sub.17 is Glu, Gly, Lys, Phe, Ser or Val;
[0091] X.sub.18 is Arg, Asn, Ser or Tyr; and
[0092] X.sub.19 is Asp, Gln, Glu, Gly, Met or Tyr,
[0093] and wherein the polypeptide binds KDR or a VEGF/KDR
complex.
[0094] Further analysis of the polypeptides isolated from the TN8
library (see Consensus Sequence 1) revealed sub-families of
preferred binding polypeptides, which are described by the
Consensus Sequences 6, 7 and 8 as follows:
[0095] Consensus Sequence 6:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X-
.sub.7-X.sub.8-X.sub.9-Tyr-Cys-X.sub.12-X.sub.13-X.sub.14,
wherein
[0096] X.sub.1 is Ala, Arg, Asp, Leu, Lys, Pro, Ser or Val;
[0097] X.sub.2 is Asn, Asp, Glu, Lys, Thr or Ser (preferably Asn,
Asp, Glu or Lys);
[0098] X.sub.3 is Ile, Leu or Trp;
[0099] X.sub.5 is Ala, Arg, Glu, Lys or Ser (preferably Glu);
[0100] X.sub.6 is Ala, Asp, Gln, Glu, Thr or Val (preferably Asp or
Glu);
[0101] X.sub.7 is Asp or Glu;
[0102] X.sub.8 is Trp or Tyr;
[0103] X.sub.9 is Thr or Tyr (preferably Tyr);
[0104] X.sub.12 is Glu, Met, Phe, Trp or Tyr (preferably Trp, Phe,
Met, or Tyr);
[0105] X.sub.13 is Ile, Leu or Met; and
[0106] X.sub.14 is Ile, Leu, Met, Phe or Thr (preferably Thr or
Leu),
[0107] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0108] Consensus Sequence 7:
Trp-Tyr-Trp-Cys-X.sub.5-X.sub.6-X.sub.7-Gly-X-
.sub.9-X.sub.10-Cys-X.sub.12-X.sub.13-X.sub.14 (SEQ ID NO:2),
wherein
[0109] X.sub.5 is Asp, Gln or His;
[0110] X.sub.6 is His or Tyr (preferably Tyr);
[0111] X.sub.7 is Ile, His or Tyr;
[0112] X.sub.9 is Ile, Met or Val;
[0113] X.sub.10 is Gly or Tyr;
[0114] X.sub.12 is Asp, Lys or Pro;
[0115] X.sub.13 is Gln, Gly or Trp; and
[0116] X.sub.14 is Phe, Ser or Thr,
[0117] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0118] Consensus Sequence 8:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X-
.sub.7-X.sub.8-Gly-X.sub.10-Cys-X.sub.12-X.sub.13-X.sub.14,
wherein
[0119] X.sub.1 is Gly, Leu, His, Thr, Trp or Tyr (preferably Trp,
Tyr, Leu or His);
[0120] X.sub.2 is Ile, Leu, Thr, Trp or Val (preferably Val, Ile or
Leu);
[0121] X.sub.3 is Asp, Glu, Gin, Trp or Thr, (preferably Glu, Asp
or Gln);
[0122] X.sub.5 is Ala, Arg, Asn, Asp, His, Phe, Trp or Tyr
(preferably Tyr, Trp or Phe);
[0123] X.sub.6 is Ala, Asp, Gln, His, Lys, Met, Ser, Thr, Trp, Tyr
or Val;
[0124] X.sub.7 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe,
Pro, Ser, Thr or Val;
[0125] X.sub.8 is Asp, Phe, Ser, Thr, Trp or Tyr (preferably Thr,
Ser or Asp);
[0126] X.sub.10 is Ala, Arg, Gln, His, Ile, Leu, Lys, Met, Phe, Trp
or Tyr (preferably Arg or Lys);
[0127] X.sub.12 is Arg, Gln, His, Ile, Lys, Met, Phe, Thr, Trp, Tyr
or Val (preferably Tyr, Trp, Phe, Ile or Val);
[0128] X.sub.13 is Arg, Asn, Asp, Glu, His, Met, Pro, Ser or Thr;
and
[0129] X.sub.14 is Arg, Gln, Glu, Gly, Phe, Ser, Trp or Tyr,
[0130] and wherein the polypeptide binds KDR or a VEGF/KDR
complex.
[0131] Further analysis of the polypeptides isolated from the TN12
library (see Consensus Sequence 2) revealed sub-families of
preferred binding polypeptides, which are described by Consensus
Sequences 9-12 and 9A as follows:
[0132] Consensus Sequence 9:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6-X-
.sub.7-X.sub.8-Trp-Gly-Gly-X.sub.12-X.sub.13-Cys-X.sub.15-X.sub.16-X.sub.1-
7 (SEQ ID NO:3)(TN11, i.e., 11-mer binders isolated from the TN12
library), wherein
[0133] X.sub.1 is Ser, Phe, Trp, Tyr or Gly (preferably Ser);
[0134] X.sub.2 is Arg, Gly, Ser or Trp (preferably Arg);
[0135] X.sub.3 is Ala, Glu, Ile or Val (preferably Val or Ile);
[0136] X.sub.5 is Ala, Phe or Trp (preferably Trp or Phe);
[0137] X.sub.6 is Glu or Lys (preferably Glu);
[0138] X.sub.7 is Asp, Ser, Trp or Tyr (preferably Asp, Trp or
Tyr);
[0139] X.sub.8 is Phe, Pro or Ser (preferably Ser);
[0140] X.sub.12 is Gln or Glu (preferably Glu);
[0141] X.sub.13 is Ile, Phe or Val;
[0142] X.sub.15 is Gln, Ile, Leu, Phe or Tyr (preferably Phe, Tyr
or Leu);
[0143] X.sub.16 is Arg, Gly or Pro (preferably Arg); and
[0144] X.sub.17 is Gln, His, Phe, Ser, Tyr or Val (preferably Tyr,
Phe, His or Val),
[0145] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0146] Consensus Sequence 9A:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6--
X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-X.sub.12-X.sub.13-Cys-X.sub.15-X-
.sub.16-X.sub.17 (TN11, i.e., 11-mer binders isolated from the TN12
library; SEQ ID NO:3), wherein
[0147] X.sub.1 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Ile, Leu,
Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
[0148] X.sub.2 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Leu, Lys,
Met, Phe, Ser, Thr, Trp, Tyr or Val;
[0149] X.sub.3 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Ile, Leu,
Lys, Met, Phe, Thr, Trp, Tyr or Val;
[0150] X.sub.5 is Ala, Arg, Asp, Gln, Glu, Gly, His, Ile, Leu, Lys,
Met, Phe, Ser, Trp, Tyr or Val;
[0151] X.sub.6 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Ile, Leu,
Lys, Met, Phe, Pro, Ser, Thr, Trp or Tyr;
[0152] X.sub.7 is Ala, Arg, Asp, Asn, Gln, Glu, Gly, His, Ile, Leu,
Met, Phe, Ser, Thr, Trp, Tyr or Val;
[0153] X.sub.8 is Ala, Arg, Asp, Asn, Gln, Glu, Gly, His, Ile, Lys,
Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
[0154] X.sub.9 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro,
Ser, Trp or Tyr;
[0155] X.sub.10 is Asp, Gln, Glu, Gly, His, Ile, Leu, Phe, Ser,
Thr, Trp, Tyr or Val;
[0156] X.sub.11 is Ala, Gln, Glu, Gly, His, Ile, Leu, Lys, Met,
Pro, Ser, Thr, Trp, Tyr or Val;
[0157] X.sub.12 is Ala, Asn, Asp, Gln, Glu, Gly, His, Ile, Leu,
Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
[0158] X.sub.13 is Ala, Arg, Asn, Asp, Cys, Gln, Glu, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
[0159] X.sub.15 is Ala, Asp, Asn, Glu, Gly, Ile, His, Leu, Lys,
Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
[0160] X.sub.16 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val;
[0161] X.sub.17 is Ala, Arg, Asp, Asn, Gln, Glu, Gly, His, Ile,
Leu, Lys, Met, Phe, Pro, Ser, Thr, Tyr or Val,
[0162] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0163] Consensus Sequence 10:
Tyr-Pro-X.sub.3-Cys-X.sub.5-Glu-X.sub.7-Ser--
X.sub.9-Ser-X.sub.11-X.sub.12-X.sub.13-Phe-Cys-X.sub.16-X.sub.17-X.sub.18
(TN12; SEQ ID NO:4), wherein
[0164] X.sub.3 is Gly or Trp (preferably Trp);
[0165] X.sub.5 is His or Tyr (preferably His, or Tyr);
[0166] X.sub.7 is His, Leu or Thr;
[0167] X.sub.9 is Asp or Leu (preferably Asp);
[0168] X.sub.11 is Gly or Val (preferably Val);
[0169] X.sub.12 is Thr or Val (preferably Thr);
[0170] X.sub.13 is Arg or Trp (preferably Arg);
[0171] X.sub.16 is Ala or Val (preferably Val);
[0172] X.sub.17 is Asp or Pro (preferably Pro); and
[0173] X.sub.18 is Gly or Trp (preferably Trp),
[0174] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0175] Consensus Sequence 11:
X.sub.1-X.sub.2-X.sub.3-Cys-X.sub.5-X.sub.6--
X.sub.7-X.sub.8-X.sub.9-X.sub.10-Gly-X.sub.12-Trp-X.sub.14-Cys-X.sub.16-X.-
sub.17-X.sub.18 (TN12; SEQ ID NO:5), wherein
[0176] X.sub.1 is Asp, Gly, Pro or Ser (preferably Asp);
[0177] X.sub.2 is Arg, Asn, Asp, Gly or Ser (preferably Asp, Asn,
or Ser);
[0178] X.sub.3 is Gly, Thr, Trp or Tyr (preferably Trp or Tyr);
[0179] X.sub.5 is Glu, Met or Thr (preferably Glu);
[0180] X.sub.6 is Ile, Leu, Met or Phe (preferably Met, Leu, or
Phe);
[0181] X.sub.7 is Arg, Asp, Glu, Met, Trp or Val;
[0182] X.sub.8 is Asn, Gln, Gly, Ser or Val;
[0183] X.sub.9 is Asp or Glu;
[0184] X.sub.10 is Lys, Ser, Thr or Val (preferably Lys);
[0185] X.sub.12 is Arg, Gln, Lys or Trp (preferably Trp, Arg, or
Lys);
[0186] X.sub.14 is Asn, Leu, Phe or Tyr (preferably Tyr, Phe, or
Asn);
[0187] X.sub.16 is Gly, Phe, Ser or Tyr (preferably Tyr or
Phe);
[0188] X.sub.17 is Gly, Leu, Pro or Ser (preferably Pro or Ser);
and
[0189] X.sub.18 is Ala, Asp, Pro, Ser, Trp or Tyr,
[0190] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0191] Consensus Sequence 12:
Asn-Trp-X.sub.3-Cys-X.sub.5-X.sub.6-X.sub.7--
X.sub.8-X.sub.9-X.sub.10-X.sub.11-X.sub.12-X.sub.13-X.sub.14-Cys-X.sub.16--
X.sub.17-X.sub.18 (TN12; SEQ ID NO:6), wherein
[0192] X.sub.3 is Glu or Lys;
[0193] X.sub.5 is Glu or Gly;
[0194] X.sub.6 is Trp or Tyr;
[0195] X.sub.7 is Ser or Thr;
[0196] X.sub.8 is Asn or Gln;
[0197] X.sub.9 is Gly or Met;
[0198] X.sub.10 is Phe or Tyr;
[0199] X.sub.11 is Asp or Gin;
[0200] X.sub.12 is Lys or Tyr;
[0201] X.sub.13 is Glu or Thr;
[0202] X.sub.14 is Glu or Phe;
[0203] X.sub.16 is Ala or Val;
[0204] X.sub.17 is Arg or Tyr; and
[0205] X.sub.18 is Leu or Pro,
[0206] and wherein the polypeptide binds KDR or a VEGF/KDR
complex.
[0207] Analysis of the binding polypeptides isolated from a linear
display library (Lin20) defined two families of preferred
embodiments including the amino acid sequences of Consensus
Sequences 13 and 14 as follows:
[0208] Consensus Sequence 13:
Z.sub.1-X.sub.1-X.sub.2-X.sub.3-X.sub.4-X.su- b.5-Z.sub.2 (Lin20),
wherein,
[0209] Z.sub.1 is a polypeptide of at least one amino acid or is
absent;
[0210] X.sub.1 is Ala, Asp, Gln or Glu (preferably Gln or Glu);
[0211] X.sub.2 is Ala, Asp, Gln, Glu Pro (preferably Asp, Glu or
Gln);
[0212] X.sub.3 is Ala, Leu, Lys, Phe, Pro, Trp or Tyr (preferably
Trp, Tyr, Phe or Leu);
[0213] X.sub.4 is Asp, Leu, Ser, Trp, Tyr or Val (preferably Tyr,
Trp, Leu or Val);
[0214] X.sub.5 is Ala, Arg, Asp, Glu, Gly, Leu, Trp or Tyr
(preferably Trp, Tyr or Leu); and
[0215] Z.sub.2 is a polypeptide of at least one amino acid or is
absent,
[0216] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0217] Consensus Sequence 14:
X.sub.1-X.sub.2-X.sub.3-Tyr-Trp-Glu-X.sub.7-- X.sub.8-X.sub.9-Leu
(Lin20; SEQ ID NO:7), wherein, the sequence can optionally have a
N-terminal polypeptide, C-terminal polypeptide, or a polypeptide at
both termini of at least one amino acid; and wherein
[0218] X.sub.1 is Asp, Gly or Ser (preferably Gly);
[0219] X.sub.2 is Ile, Phe or Tyr;
[0220] X.sub.3 is Ala, Ser or Val;
[0221] X.sub.7 is Gln, Glu, Ile or Val;
[0222] X.sub.8 is Ala, Ile or Val (preferably Ile or Val);
[0223] X.sub.9 is Ala, Glu, Val or Thr;
[0224] and wherein the polypeptide binds KDR or a VEGF/KDR
complex.
[0225] Preferred embodiments comprising the Consensus Sequence 1
above, include polypeptides in which X.sub.3 is Trp and the amino
acid sequence of X.sub.7-X.sub.10 is Asp-Trp-Tyr-Tyr (SEQ ID NO:8).
More preferred structures include polypeptides comprising Consensus
Sequence 1, wherein X.sub.3 is Trp and the amino acid sequence of
X.sub.5-X.sub.10 is Glu-Glu-Asp-Trp-Tyr-Tyr (SEQ ID NO:9).
Additional preferred polypeptides comprising Consensus Sequence 1
include polypeptides in which: X.sub.3 is Trp and the amino acid
sequence of X.sub.5-X.sub.10 is Glu-Glu-Asp-Trp-Tyr-Tyr (SEQ ID
NO:9), and the peptide X.sub.13-X.sub.14 is Ile-Thr. Of these
preferred polypeptides, it is additionally preferred that X.sub.1
will be Pro and X.sub.12 will be one of Phe, Trp or Tyr.
[0226] Particular embodiments of the cyclic polypeptide families
described above are disclosed in Tables 1, 2, 4, 5, 6 and 7,
infra.
[0227] Additional cyclic polypeptides found to bind a KDR or
VEGF/KDR target have a cyclic portion (or loop), formed by a
disulfide bond between the two cysteine residues, consisting of ten
amino acids, for example, as follows:
[0228]
Asn-Asn-Ser-Cys-Trp-Leu-Ser-Thr-Thr-Leu-Gly-Ser-Cys-Phe-Phe-Asp
(SEQ ID NO:10),
Asp-His-His-Cys-Tyr-Leu-His-Asn-Gly-Gln-Trp-Ile-Cys-Tyr-P- ro-Phe
(SEQ ID NO:11),
[0229]
Asn-Ser-His-Cys-Tyr-Ile-Trp-Asp-Gly-Met-Trp-Leu-Cys-Phe-Pro-Asp
(SEQ ID NO:12).
[0230] Additional preferred embodiments include linear polypeptides
capable of binding a KDR or VEGF/KDR target comprising, or
alternatively consisting of, a polypeptide having an amino acid
sequence selected from the group of amino acid sequences set forth
in Table 3, infra.
[0231] The polypeptides of the invention can optionally have
additional amino acids attached at either or both of the N- and
C-terminal ends. In preferred embodiments, binding polypeptides
according to the invention can be prepared having N-terminal and/or
C-terminal flanking peptides of one or more, preferably two, amino
acids corresponding to the flanking peptides of the display
construct of the phage selectant from which the binding
polypeptides were isolated. Preferred amino-terminal flanking
peptides include Ala-Gly- (most preferably for TN7, TN8 and TN9
sequences), Gly-Ser- (most preferably for TN10 sequences), Gly-Asp-
(most preferably for TN12 sequences), Ala-Gln- (most preferably for
linear sequences), and Ser-Gly- (most preferably for MTN13
sequences). Preferred carboxy-terminal flanking peptides include
-Gly-Thr (most preferably for TN7, TN8, TN9 sequences), -Ala-Pro
(most preferably for TN10 sequences), -Asp-Pro (most preferably for
TN12 sequences), -Gly-Gly (most preferably for linear sequences),
and -Gly-Ser (most preferably for MTN13 sequences). Single terminal
amino acids can also be added to the binding polypeptides of the
invention, and preferred terminal amino acids will preferably
correspond to the parental phage display construct, e.g., most
preferably, N-terminal amino acids will be selected from Gly- (most
preferably for TN7, TN8, TN9, MTN13 sequences), Ser- (most
preferably for TN10 sequences), Asp- (most preferably for TN12
sequences), and Gln- (most preferably for linear sequences), and
most preferably C-terminal amino acids will be selected from -Gly
(most preferably for TN7, TN8, TN9, MTN13 and linear sequences),
-Ala (most preferably for TN10 sequences), and -Asp (most
preferably for TN12 sequences). Conservative substitutions (i.e.,
substitute amino acids selected within the following groups: {Arg,
His, Lys}, {Glu, Asp}, {Asn, Cys, Glu, Gly, Ser, Thr, Tyr}, {Ala,
Ile, Leu, Met, Phe, Pro, Trp, Val}) for such flanking amino acids
are also contemplated.
[0232] Examination of the sequence information and binding data
from the isolates of libraries containing polypeptides with the
potential to form loop structures (e.g., libraries designated TN7,
TN8, TN9, TN10, TN12 and MTN13) identifies a series of KDR or
VEGF/KDR complex binding polypeptides that may form loop
structures. In specific embodiments, cyclic KDR-- or VEGF/KDR--
binding polypeptides of the invention comprise, or alternatively,
consist of, an amino acid sequence selected from Loop Consensus
Sequences 15-19 as follows:
[0233] Loop Consensus Sequence 15:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.s- ub.6-X.sub.7-Cys (TN8),
wherein
[0234] X.sub.2 is Ala, Arg, Asn, Asp, Gln, Glu, His, Ile, Lys, Phe,
Pro, Ser, Trp or Tyr (preferably Asp, Glu or Tyr);
[0235] X.sub.3 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Ile, Lys,
Met, Phe, Pro, Ser, Thr, Trp, Tyr or Val (preferably Glu, Met or
Tyr);
[0236] X.sub.4 is Ala, Asn, Asp, Glu, Gly, His, Ile, Leu, Lys, Phe,
Pro, Ser, Thr, Trp, Tyr or Val (preferably Asp);
[0237] X.sub.5 is Ala, Asp, Glu, Gly, Leu, Phe, Pro, Ser, Thr, Trp
or Tyr (preferably Trp or Thr);
[0238] X.sub.6 is Arg, Gln, Glu, Gly, Ile, Leu, Met, Pro, Thr, Trp,
Tyr or Val (preferably Gly or Tyr); and
[0239] X.sub.7 is Ala, Arg, Gln, Glu, Gly, His, Ile, Leu, Lys, Met,
Phe, Trp or Tyr (preferably Lys or Tyr),
[0240] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0241] Loop Consensus Sequence 16:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.s-
ub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys (TN12),
wherein
[0242] X.sub.2 is Arg, Asp, Gln, Glu, Gly, His, Ile, Lys, Met, Thr,
Trp, Tyr or Val (preferably Glu, Ile or Tyr);
[0243] X.sub.3 is Ala, Arg, Asn, Cys, Glu, Ile, Leu, Met, Phe, Ser,
Trp or Tyr (preferably Glu, Phe or Tyr);
[0244] X.sub.4 is Arg, Asn, Asp, Gln, Glu, His, Ile, Leu, Pro, Ser,
Thr, Trp, Tyr or Val (preferably Glu);
[0245] X.sub.5 is Ala, Asn, Asp, Gln, Glu, Gly, His, Met, Phe, Pro,
Ser, Trp, Tyr or Val (preferably Gln or Ser);
[0246] X.sub.6 is Asp, Gln, Glu, Gly, His, Ile, Leu, Met, Phe, Pro,
Ser, Thr, Trp or Tyr (preferably Asp);
[0247] X.sub.7 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, Leu, Lys, Met,
Phe, Pro, Ser, Thr, Trp, Tyr or Val (preferably Lys or Ser);
[0248] X.sub.8 is Ala, Arg, Asn, Asp, Gln, Glu, Gly, His, Lys, Trp,
Tyr or Val (preferably Gly or Tyr);
[0249] X.sub.9 is Ala, Arg, Gln, Gly, His, Ile, Lys, Met, Phe, Ser,
Thr, Trp, Tyr or Val (preferably Trp or Thr);
[0250] X.sub.10 is Arg, Gln, Glu, His, Leu, Lys, Met, Phe, Pro,
Thr, Trp or Val (preferably Glu or Trp); and
[0251] X.sub.11 is Arg, Asn, Asp, Glu, His, Ile, Leu, Met, Phe,
Pro, Thr, Trp, Tyr or Val (preferably Phe),
[0252] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0253] Loop Consensus Sequence 17:
Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6- -Cys (TN7), wherein
[0254] X.sub.2 is Asn, Asp or Glu;
[0255] X.sub.3 is Glu, His, Lys or Phe;
[0256] X.sub.4 is Asp, Gln, Leu, Lys, Met or Tyr; and
[0257] X.sub.6 is Arg, Gln, Leu, Lys or Val,
[0258] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0259] Loop Consensus Sequence 18:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.s- ub.6-X.sub.7-X.sub.8-Cys
(TN9), wherein
[0260] X.sub.2 is Ala, Asp, Lys, Ser, Trp or Val (preferably
Lys);
[0261] X.sub.3 is Asn, Glu, Gly, His or Leu;
[0262] X.sub.4 is Gln, Glu, Gly, Met, Lys, Phe, Tyr or Val
(preferably Met);
[0263] X.sub.5 is Ala, Asn, Asp, Gly, Leu, Met, Pro, Ser or
Thr;
[0264] X.sub.6 is His, Pro or Trp (preferably Pro or Trp);
[0265] X.sub.7 is Ala, Gly, His, Leu, Trp or Tyr (preferably Trp);
and
[0266] X.sub.8 is Ala, Asp, Gln, Leu, Met, Thr or Trp,
[0267] and wherein the polypeptide binds KDR or a VEGF/KDR complex;
or
[0268] Loop Consensus Sequence 19:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Ser-
-Gly-Pro-X.sub.9-X.sub.10-X.sub.11-X.sub.12-Cys (MTN13; SEQ ID
NO:13), wherein
[0269] X.sub.2 is Asp, Glu, His or Thr;
[0270] X.sub.3 is Arg, His, Lys or Phe;
[0271] X.sub.4 is Gln, Ile, Lys, Tyr or Val;
[0272] X.sub.5 is Gln, Ile, Leu, Met or Phe;
[0273] X.sub.9 is Asn, Asp, Gly, His or Tyr;
[0274] X.sub.10 is Gln, Gly, Ser or Thr;
[0275] X.sub.11 is Glu, Lys, Phe or Ser; and
[0276] X.sub.12 is Glu, Ile, Ser or Val,
[0277] and wherein the polypeptide binds KDR or a VEGF/KDR
complex.
[0278] Preferred embodiments of the cyclic peptides of Loop
Consensus Sequence 15 include KDR and/or VEGF/KDR complex binding
polypeptides comprising Loop Consensus Sequences 20-22 as
follows:
[0279] Loop Consensus Sequence 20:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.s- ub.6-Tyr-Cys (TN8),
wherein
[0280] X.sub.2 is Ala, Arg, Glu, Lys or Ser (preferably Glu);
[0281] X.sub.3 is Ala, Asp, Gln, Glu, Thr or Val (preferably Asp or
Glu);
[0282] X.sub.4 is Asp or Glu;
[0283] X.sub.5 is Trp or Tyr; and
[0284] X.sub.6 is Thr or Tyr (preferably Tyr); or
[0285] Loop Consensus Sequence 21:
Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6- -X.sub.7-Cys (TN8),
wherein
[0286] X.sub.2 is Asp, Gln or His;
[0287] X.sub.3 is His or Tyr (preferably Tyr);
[0288] X.sub.4 is His, Ile or Tyr;
[0289] X.sub.6 is Ile, Met or Val; and
[0290] X.sub.7 is Gly or Tyr; or
[0291] Loop Consensus Sequence 22:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Gly- -X.sub.7-Cys (TN8),
wherein
[0292] X.sub.2 is Ala, Arg, Asn, Asp, His, Phe, Trp or Tyr
(preferably Tyr, Trp or Phe);
[0293] X.sub.3 is Ala, Asp, Gln, His, Lys, Met, Ser, Thr, Trp, Tyr
or Val;
[0294] X.sub.4 is Ala, Asn, Asp, Gln, Glu, Gly, His, Ile, Leu, Lys,
Pro, Ser, Thr or Val;
[0295] X.sub.5 is Asp, Phe, Ser, Thr, Trp or Tyr (preferably Thr,
Ser or Asp); and
[0296] X.sub.7 is Ala, Arg, Gln, His, Ile, Leu, Lys, Met, Phe, Trp
or Tyr (preferably Arg or Lys).
[0297] Preferred embodiments of the cyclic peptides of Loop
Consensus Sequence 16 include KDR and/or VEGF/KDR complex binding
polypeptides comprising sequences of Loop Consensus Sequences 23-26
as follows:
[0298] Loop Consensus Sequence 23:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Trp-
-Gly-Gly-X.sub.9-X.sub.10-Cys (TN11, i.e., 11-mers based on
isolates of the TN12 library; SEQ ID NO:14), wherein
[0299] X.sub.2 is Ala, Phe or Trp (preferably Trp or Phe);
[0300] X.sub.3 is Glu or Lys (preferably Glu);
[0301] X.sub.4 is Asp, Ser, Trp or Tyr (preferably Asp, Trp or
Tyr);
[0302] X.sub.5 is Phe, Pro or Ser (preferably Ser);
[0303] X.sub.9 is Gln or Glu (preferably Glu); and
[0304] X.sub.10 is Ile, Phe or Val; or
[0305] Loop Consensus Sequence 24:
Cys-X.sub.2-Glu-X.sub.4-Ser-X.sub.6-Ser-
-X.sub.8-X.sub.9-X.sub.10-Phe-Cys (TN12; SEQ ID NO:15), wherein
[0306] X.sub.2 is His or Tyr;
[0307] X.sub.4 is Leu, His or Thr;
[0308] X.sub.6 is Asp or Leu (preferably Asp);
[0309] X.sub.8 is Gly or Val (preferably Val);
[0310] X.sub.9 is Thr or Val (preferably Thr); and
[0311] X.sub.10 is Arg or Trp (preferably Arg); or
[0312] Loop Consensus Sequence 25:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.s-
ub.6-X.sub.7-Gly-X.sub.9-Trp-X.sub.11-Cys (TN12; SEQ ID NO:16),
wherein
[0313] X.sub.2 is Glu, Met or Thr (preferably Glu);
[0314] X.sub.3 is Ile, Leu, Met or Phe (preferably Met, Leu or
Phe);
[0315] X.sub.4 is Arg, Asp, Glu, Met, Trp or Val;
[0316] X.sub.5 is Asn, Gln, Gly, Ser or Val;
[0317] X.sub.6 is Glu or Asp;
[0318] X.sub.7 is Lys, Ser, Thr or Val (preferably Lys);
[0319] X.sub.9 is Arg, Gln, Lys or Trp (preferably Trp, Arg or
Lys); and
[0320] X.sub.11 is Asn, Leu, Phe or Tyr (preferably Tyr, Phe or
Asn); or
[0321] Loop Consensus Sequence 26:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.s-
ub.6-X.sub.7-X.sub.8-X.sub.9-X.sub.10-X.sub.11-Cys (TN12),
wherein
[0322] X.sub.2 is Glu or Gly;
[0323] X.sub.3 is Trp or Tyr;
[0324] X.sub.4 is Ser or Thr;
[0325] X.sub.5 is Asn or Gln;
[0326] X.sub.6 is Gly or Met;
[0327] X.sub.7 is Phe or Tyr;
[0328] X.sub.8 is Asp or Gln;
[0329] X.sub.9 is Lys or Tyr;
[0330] X.sub.10 is Glu or Thr; and
[0331] X.sub.11 is Glu or Phe.
[0332] Preferred embodiments of the cyclic peptides of Loop
Consensus Sequence 17 include KDR and/or VEGF/KDR complex binding
polypeptides comprising sequences of Loop Consensus Sequence 27 as
follows:
[0333] Loop Consensus Sequence 27:
Cys-X.sub.2-X.sub.3-X.sub.4-Gly-X.sub.6- -Cys (TN7), wherein
[0334] X.sub.2 is Asn, Asp or Glu;
[0335] X.sub.3 is Glu, His, Lys or Phe;
[0336] X.sub.4 is Asp, Gln, Leu, Lys, Met or Tyr; and
[0337] X.sub.6 is Arg, Gin, Leu, Lys or Val.
[0338] Preferred embodiments of the cyclic peptides of Loop
Consensus Sequence 18 include KDR and/or VEGF/KDR complex binding
polypeptides comprising sequences of Loop Consensus Sequence 28 as
follows:
[0339] Loop Consensus Sequence 28:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-X.s- ub.6-X.sub.7-X.sub.8-Cys
(TN9), wherein
[0340] X.sub.2 is Ala, Lys, Ser, Trp or Val (preferably Lys);
[0341] X.sub.3 is Asn, Glu, Gly, His or Leu;
[0342] X.sub.4 is Glu, Gly, Lys, Met or Tyr (preferably Met);
[0343] X.sub.5 is Ala, Asn, Asp, Leu, Met, Pro or Ser;
[0344] X.sub.6 is His, Pro or Trp (preferably Pro);
[0345] X.sub.7 is His, Leu, Trp or Tyr (preferably Trp or His);
and
[0346] X.sub.8 is Ala, Asp, Gln, Leu, Met, Thr or Trp.
[0347] Preferred embodiments of the cyclic peptides of Loop
Consensus Sequence 19 include KDR and/or VEGF/KDR complex binding
polypeptides comprising sequences of Loop Consensus Sequence 29 as
follows:
[0348] Loop Consensus Sequence 29:
Cys-X.sub.2-X.sub.3-X.sub.4-X.sub.5-Ser-
-Gly-Pro-X.sub.9-X.sub.10-X.sub.11-X.sub.12-Cys (MTN13; SEQ ID
NO:17), wherein
[0349] X.sub.2 is Asp, Glu, His or Thr;
[0350] X.sub.3 is Arg, His, Lys or Phe;
[0351] X.sub.4 is Gln, Ile, Lys, Tyr or Val;
[0352] X.sub.5 is Gin, Ile, Leu, Met or Phe;
[0353] X.sub.9 is Asn, Asp, Gly, His or Tyr;
[0354] X.sub.10 is Gln, Gly, Ser or Thr;
[0355] X.sub.11 is Glu, Lys, Phe or Ser; and
[0356] X.sub.12 is Glu, Ile, Ser or Val.
[0357] Chemical or physical modifications, as well as any sequence
modifications, described herein are encompassed for use with any of
the specific sequences disclosed herein and/or any specific
sequences that conform to any of the consensus sequences described
herein.
[0358] The KDR and VEGF/KDR binding polypeptides described above
can optionally have additional amino acids attached at either or
both of the N- and C-terminal ends and can be modified, optimized
or employed in multimeric constructs. Further, the invention
includes homologues of the KDR and VEGF/KDR complex binding
peptides as defined herein.
[0359] Another aspect of the present invention relates to
modifications of the foregoing polypeptides to provide specific
angiogenesis imaging agents by detectably labeling a polypeptide
according to the present invention. Such detectable labeling can
involve radiolabeling, enzymatic labeling, or labeling with MRI
paramagnetic chelates or microparticles or superparamagnetic
particles; incorporation into ultrasound bubbles, microparticles,
microspheres, emulsions, or liposomes; or conjugation with optical
dyes.
[0360] In another aspect of the present invention, methods for
isolating KDR or KDR-expressing cells using the present binding
polypeptides are provided.
[0361] Additionally, the KDR and VEGF/KDR complex binding
polypeptides of the invention can be used as therapeutic agents,
either as the sole bioactive agent in a pharmaceutically acceptable
composition or conjugated to (or in combination with) other
therapeutic agents to treat diseases or conditions involving KDR or
VEGF/KDR complex, angiogenesis or diseases associated with a number
of pathogens, including, for example, malaria, HIV, SIV, Simian
hemorrhagic fever, etc.
[0362] When the binding peptides disclosed herein are used as
therapeutic agents, it may be advantageous to enhance the serum
residence time of the peptides. This can be accomplished by: a)
conjugating to the peptide a moiety, such as maleimide, that reacts
with free sulfhydryl groups on serum proteins, such as serum
albumin, b) conjugating to the peptide a moiety, such as a fatty
acid, that binds non-covalently to serum proteins, especially serum
albumin, c) conjugating to the peptide a polymer, such as PEG, that
is known to enhance serum residence time, and/or d) fusing DNA that
encodes the KDR-binding peptide to DNA that encodes a serum protein
such as human serum albumin or an antibody and expressing the
encoded fusion protein.
[0363] In another aspect of the invention, methods of screening
polypeptides identified by phage display for their ability to bind
to cells expressing the target are provided. These methods permit
rapid screening of the binding ability of polypeptides, including
polypeptides with monomeric affinities that are too low for
evaluation in standard cell-binding assays. Additionally, these
methods may be used to rapidly assess the stability of the peptides
in the presence of serum.
[0364] In another embodiment of the invention, a multimeric
polypeptide construct having the ability to bind to KDR or VEGF/KDR
complex comprising at least one amino acid sequence selected from
any of the polypeptides described above is envisioned. In a
particular embodiment, the polypeptide comprises an amino acid
sequence selected from the group consisting of: SEQ ID NOS: 20-86,
87-136, 187-192, 193-203, 207-259 and 505-516. I a particular
embodiment, the amino acid sequence selected from the group
consisting of: SEQ ID NOS: 137-186. In one embodiment, the amino
acid sequence further comprises N-terminal and/or C-terminal
flanking peptides of one or more amino acids. In another
embodiment, the amino acid sequence comprises a modification
selected from the group consisting of: an amino acid substitution,
and amide bond substitution, a D-amino acid substitution, a
glycosylated amino acid, a disulfide mimetic substitution, an amino
acid translocation, a retroinverso peptide, a peptoid, a
retro-inverso peptoid, and a synthetic peptide. In another
embodiment, the polypeptide can be conjugated to a detectable label
or a therapeutic agent, optionally further comprising a linker or
spacer between the polypeptide and the detectable label or the
therapeutic agent. In a particular embodiment, the detectable label
or the therapeutic agent is selected from the group consisting of:
an enzyme, a fluorescent compound, a liposome, an optical dye, a
paramagnetic metal ion, a superparamagnetic particle, an ultrasound
contrast agent and a radionuclide. In one embodiment, the
therapeutic agent or detectable label comprises a radionuclide,
including, for example, .sup.18F, .sup.124I, .sup.125I, .sup.131I,
.sup.123I, .sup.77Br, .sup.76Br, .sup.99mTc, .sup.51Cr, .sup.67Ga,
.sup.68Ga, .sup.47Sc, .sup.51Cr, .sup.167Tm, .sup.141Ce,
.sup.111In, .sup.168Yb, .sup.175Yb, .sup.140La, .sup.90Y, .sup.88Y,
.sup.153Sm, .sup.166Ho, .sup.165Dy, .sup.166Dy, .sup.62Cu,
.sup.64Cu, .sup.67Cu, .sup.97Ru, .sup.103Ru, .sup.186Re,
.sup.188Re, .sup.203Pb, .sup.211Bi, .sup.212Bi, .sup.213Bi,
.sup.214Bi, .sup.105Rh, .sup.109Pd, .sup.117mSn, .sup.149Pm,
.sup.161Tb, .sup.177Lu, .sup.198Au or .sup.199Au. In a particular
embodiment, the therapeutic agent or detectable label further
comprises a chelator, such as, for example, a compound selected
from the group consisting of: formula 20, 21, 22, 23a, 23b, 24a,
24b, and 25. In a particular embodiment, the detectable label
comprises an ultrasound contrast agent that can comprise, for
example, a phospholipid stabilized microbubble or a microballoon
comprising a gas. Alternatively, the detectable label can comprise
one or more paramagnetic metal ions or a superparamagnetic particle
and one or more chelators.
[0365] In another embodiment, the invention is directed to an
ultrasound contrast agent comprising at least one KDR or VEGF/KDR
complex binding polypeptide comprising an amino acid sequence of
one of the following and optionally further comprising N-terminal
and/or C-terminal flanking peptides of one or more amino acids
described herein. In a particular embodiment, the gas filled
microvesicles comprise phospholipid stabilized microbubbles or
microballoons. In one embodiment, the phospholipid stabilized
microbubbles or microballoons further comprise a fluorinated
gas.
[0366] In another embodiment, the invention is directed to a
scintigraphic imaging agent comprising at least one KDR or VEGF/KDR
complex binding polypeptide comprising an amino acid sequence of
one of the following and optionally further comprising N-terminal
and/or C-terminal flanking peptides of one or more amino acids
described herein. In a particular embodiment, the scintigraphic
imaging agent can comprise at least one radionuclide useful in
scintigraphic imaging and at least one KDR or VEGF/KDR complex
binding moiety comprising a polypeptide of the invention. In a
particular embodiment, the scintigraphic imaging agent can comprise
at least one chelator selected from the group consisting of:
formula 20, 21, 22, 23a, 23b, 24a, 24b and 25. In one embodiment,
the radionuclide is selected from the group consisting of
.sup.99mTc and .sup.111In.
[0367] In another embodiment, the invention is directed to an agent
useful in radiotherapy comprising at least one KDR or VEGF/KDR
complex binding polypeptide comprising an amino acid sequence of
one of the following and optionally further comprising N-terminal
and/or C-terminal flanking peptides of one or more amino acids
described herein.
[0368] In another embodiment, the nvention is directed to an agent
useful in radiotherapy comprising at least one radionuclide useful
in radiotherapy and at least one KDR or VEGF/KDR complex binding
moiety comprising a polypeptide of the invention. In a particular
embodiment, the agent can comprise at least one chelator selected
from the group consisting of: formula 20, 21, 22, 23a, 23b, 24a,
24b and 25. In a particular embodiment, the radionuclide is
selected from the group consisting of: .sup.177Lu, .sup.90Y,
.sup.153Sm and .sup.166Ho.
[0369] In another embodiment, the invention is directed to a method
of synthesizing a polypeptide or a multimeric polypeptide construct
having the ability to bind KDR or VEGF/KDR complex comprising a
cyclic polypeptide formed by introducing an amide bond between two
side chains.
[0370] In another embodiment, the invention is directed to a method
of synthesizing a polypeptide or a multimeric polypeptide construct
having the ability to bind KDR or VEGF/KDR complex comprising a
polypeptide and a linker comprising at least one glycosylated amino
acid selected from the group consisting or serine, threonine and
homoserine.
[0371] In another embodiment, the invention is directed to a method
of synthesizing a multimeric polypeptide construct having the
ability to bind KDR or VEGF/KDR complex selected from the group
consisting of D1, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, D12,
D13, D14, D15, D16, D17, D18, D19, D20, D21, D22, D23, D24, D25,
D26, D27, D28, D29, D30 and D31, comprising: a) treating a purified
peptide monomer with glutaric acid bis-N-hydroxysuccinimidyl ester;
and b) contacting the peptide monomer in (a) with a second peptide
monomer in the presence of N,N-(Diisopropyl)aminomethylpolystyrene,
thereby forming the multimeric polypeptide.
[0372] In another embodiment, the invention is directed to a
multimeric polypeptide having the ability to bind to KDR or
VEGF/KDR complex selected from the group consisting of: D1, D2, D3,
D4, D5, D6, D7, D8, D9, D10, D11, D12, D13, D14, D15, D16, D17,
D18, D19, D20, D21, D22, D23, D24, D25, D26, D27, D28, D29, D30 and
D31.
[0373] In another embiment, the invention is directed to a dimeric
polypeptide construct having the ability to bind to KDR or
VEGF/KDR, wherein each peptide of the dimer comprises a sequence of
a polypeptide of the invention. In a particular embodiment, the
amino acid sequence of the polypeptide is selected from the group
consisting of: SEQ ID NOS: 20-86, 87-136, 187-192, 193-203, 207-259
and 505-516. In a particular embodiment, the amino acid sequence of
the polypeptide is selected from the group consisting of: SEQ ID
NOS: 137-186. Any of the dimmers of the invention can comprise
N-terminal and/or C-terminal flanking peptides of one or more amino
acids, as well as a modification such as, for example, an amino
acid substitution, and amide bond substitution, a D-amino acid
substitution, a glycosylated amino acid, a disulfide mimetic
substitution, an amino acid translocation, a retroinverso peptide,
a peptoid, a retro-inverso peptoid or a synthetic peptide. The
dimeric constructs of the invention can be conjugated to a
detectable label or a therapeutic agent, optionally further
comprising a linker or spacer between the polypeptide and the
detectable label or the therapeutic agent. The detectable label or
the therapeutic agent can be, for example, an enzyme, a fluorescent
compound, a liposome, an optical dye, one or more paramagnetic
metal ions or a superparamagnetic particle, an ultrasound contrast
agent or one or more radionuclides. In a particular embodiment, the
therapeutic agent or detectable label comprises one or more
radionuclides. In a particular embodiment, a dimeric construct can
be labeled with one or more radionuclides such as, for example,
.sup.18F, .sup.124I, .sup.125I, .sup.131I, .sup.123I, .sup.77Br,
.sup.76Br, .sup.99mTc, .sup.51Cr, .sup.67Ga, .sup.68Ga, .sup.47Sc,
.sup.51Cr, .sup.167Tm, .sup.141Ce, .sup.111In, .sup.168Yb,
.sup.175Yb, .sup.140La, .sup.90Y, .sup.88Y, .sup.153Sm, .sup.166Ho,
.sup.165Dy, .sup.166Dy, .sup.62Cu, .sup.64Cu, .sup.67Cu, .sup.97Ru,
.sup.103Ru, .sup.186Re, .sup.188Re, .sup.203Pb, .sup.211Bi,
.sup.212Bi, .sup.213Bi, .sup.214Bi, .sup.105Rh, .sup.109Pd,
.sup.117mSn, .sup.149Pm, .sup.161Tb, .sup.177Lu, .sup.198Au or
.sup.199Au. In a particular embodiment, each peptide of the dimer
is selected from an amino acid sequence selected from the group
consisting of the sequences listed in Tables 1-11 and 27.
[0374] In another embodiment, the invention is directed to a
multimeric polypeptide having the ability to bind to KDR or
VEGF/KDR complex, wherein the multimeric polypeptide comprises at
least one peptide monomer comprising an amino acid sequence
selected from the group consisting of those sequences listed in
Tables 1-11 and 27.
[0375] In another embodiment, the invention is directed to a method
of inhibiting VEGF-induced vascular permeability comprising
administering and agent comprising a peptide of the invention. In a
particular embodiment, the agent comprises D10.
[0376] These and other aspects of the present invention will become
apparent with reference to the following detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0377] The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application
publication with color drawings will be provided by the Office upon
request and payment of the necessary fee.
[0378] FIGS. 1A and 1B are graphs illustrating the saturation
binding curves of binding peptide/neutravidin-HRP complexes. FIG.
1A illustrates the saturation binding curve for SEQ ID NO:264 and
SEQ ID NO:294. FIG. 1B illustrates the saturation binding curve for
SEQ ID NO:277 and SEQ ID NO:356. All peptides had a C-terminal
biotin and JJ spacer.
[0379] FIG. 2 is a graph illustrating the binding of
peptide/neutravidin-HRP complexes: control (biotinylated with
spacer, and SEQ ID NOS:264, 294, 277 and 356) to KDR-transfected
and Mock-transfected 293H cells at a single concentration (5.55
nM). All peptides had a C-terminal biotin and JJ spacer.
[0380] FIG. 3 illustrates peptide structures, with and without both
spacer (di(8-amino-3,6-dioxaoctanoic acid) "JJ") and biotin tested
in Example 5((a) biotinylated SEQ ID NO:264 with a JJ spacer; (b)
SEQ ID NO:264 with an N-terminal biotin; (c) biotinylated SEQ ID
NO:294 with the JJ spacer (d) biotinylated SEQ ID NO:294).
[0381] FIG. 4 is a bar graph illustrating binding of
peptide/neutravidin HRP complexes to KDR-transfected and
mock-transfected 293H cells at single a concentration (2.78 nM);
peptides include (a) control (with spacer); (b) control; (c)
biotinylated SEQ ID NO:264 with a JJ spacer; (d) SEQ ID NO:264 with
an N-terminal biotin; and (e) biotinylated SEQ ID NO:294 with the
JJ spacer; and (f) biotinylated SEQ ID NO:294.
[0382] FIG. 5 is a bar graph illustrating specific binding (binding
to KDR transfected cells minus binding to Mock transfected cells)
of peptide/neutravidin-HRP complexes with and without 40% rat
serum. (a) SEQ ID NO:294; (b) SEQ ID NO:264; (c) SEQ ID NO:277; (d)
SEQ ID NO:356. Concentration of peptide/avidin HRP solutions was
6.66 nM for (a) and (b), 3.33 nM for (c), and 2.22 nM for (d). All
peptides had a C-terminal biotin and JJ spacer.
[0383] FIG. 6 is a bar graph illustrating binding of
polypeptide/avidin-HRP solutions (SEQ ID NO:294 and/or SEQ ID
NO:264) to mock- and KDR-transfected cells plotted as absorbance at
450 nm. The proportions of control and KDR binding peptides used to
form each tetrameric complex are indicated in the legend for each
tested multimer.
[0384] FIG. 7 is a bar graph illustrating specific binding of a
peptide comprising SEQ ID NO:294, and a biotinylated SEQ ID NO:264
with a JJ spacer/avidin-HRP complex to KDR transfected cells
(background binding to mock-transfected cells subtracted), plotted
as absorbance at 450 nm. Increasing concentrations (as indicated in
the X axis) of uncomplexed peptides were added to the assay as
indicated. Free SEQ ID NO:264 was able to decrease the binding of
the SEQ ID NO:264 complex to KDR-transfected cells.
[0385] FIG. 8 illustrates structures of binding polypeptide
sequences tested in Example 6: SEQ ID NOS:294, 368, 369, 337, 371
and 372.
[0386] FIG. 9 is a bar graph illustrating the binding of
fluorescent beads to KDR-transfected and mock-transfected cells.
Neutravidin-coated beads with the indicated ligands attached were
tested for binding to KDR-expressing and non-expressing 293H
cells.
[0387] FIG. 10 is a bar graph illustrating percent inhibition of
.sup.125I-labeled VEGF binding by binding polypeptides (a)
acetylated SEQ ID NO:294 (without the modified C-terminus,
GDSRVCWEDSWGGEVCFRYDP; SEQ ID NO:374); (b) SEQ ID NO:263 (without
the modified C-terminus, AGDSWCSTEYTYCEMIGT; SEQ ID NO:375); (c)
biotinylated SEQ ID NO:264 with a JJ spacer; and (d) SEQ ID NO:277
(biotinylated with the JJ spacer), at two concentrations (30 .mu.M
and 0.3 .mu.M), to KDR-expressing 293H transfectants.
[0388] FIG. 11 depicts chemiluminescent detection on film
demonstrating that activated (phosphorylated) KDR was not detected
in immunoprecipitates from unstimulated (-V) HUVECs, but was
abundant in immunoprecipitates from VEGF-stimulated (+V) HUVECs
(upper panel). Reprobing the blot with anti-KDR demonstrated that
comparable amounts of total KDR were present in both
immunoprecipitates (lower panel).
[0389] FIG. 12 depicts chemiluminescent detection on film
demonstrating the ability of an anti-KDR antibody (1 .mu.g/mL;
indicated as ".alpha.-KDR") to partially block VEGF-mediated
phosphorylation.
[0390] FIG. 13 depicts chemiluminescent detection on film
demonstrating the ability of a KDR-binding polypeptide SEQ ID
NO:306 (10 .mu.M) to block VEGF-mediated KDR phosphorylation.
[0391] FIG. 14 is a bar graph showing binding of a Tc-labeled
polypeptide (SEQ ID NO:339) to KDR-transfected 293H cells.
[0392] FIG. 15 is a graph showing the percentage inhibition of
.sup.125I-labeled VEGF binding by SEQ ID NO:277, D2, D1, D3, and
AQDWYYDEILSMADQLRHAFLSGG (SEQ ID NO:376) at three different
concentrations (10 .mu.M, 0.3 .mu.M, and 0.03 .mu.M) to
KDR-transfected 293H cells. The results are from one experiment
carried out in triplicate +/-S.D.
[0393] FIG. 16 is a photograph showing the ability of D1 to
completely block the VEGF-induced phosphorylation of KDR in HUVECs
at 10 nM and the majority of phosphorylation at 1 nM. Reprobing the
blot for total KDR (lower panel) demonstrated that the effects of
the tested compounds was not due to reduced sample loading.
Homodimers (D2 and D3) composed of the two binding sequences
contained in D1 did not interfere with the phosphorylation at up to
100 nM.
[0394] FIG. 17 is a graph showing that D1 potently blocks the
migration/invasion of endothelial cells induced by VEGF. Migrating
cells were quantitated by fluorescence measurement after staining
the migrated cells with a fluorescent dye.
[0395] FIG. 18 is a graph showing the binding of .sup.125I-labeled
D5 to mock and KDR transfected 293H cells in the absence and
presence of 40% mouse serum.
[0396] FIG. 19 is a graph showing the specific binding (KDR-MOCK)
of .sup.125I-labeled D5 to KDR-transfected 293H cells in the
absence and presence of 40% mouse serum.
[0397] FIG. 20 is a graph of plasma clearance as percent injected
dose per mL versus time.
[0398] FIG. 21 shows SE-HPLC profiles of plasma from the Superdex
peptide column. Top panel, sample injected; followed by 0 min, 30
min, and 90 min. The insert within each panel shows time point,
animal number and volume injected for HPLC analysis.
[0399] FIG. 22 is a graph showing the results of testing of KDR
peptides in HUVEC proliferation assay. A: D6; B: SEQ ID NO:277; C:
SEQ ID NO:377 (AEGTGDLHCYFPWVCSLDPGPEGGGK; negative control); F:
SEQ ID NO:377; negative control.
[0400] FIGS. 23A and 23B show the kinetic analysis of D1 (see FIG.
36), binding to murine KDR-Fc. All sensograms are fit to the
bivalent analyte model.
[0401] FIGS. 24A and 24B show the kinetic analysis of D7, a
heterodimer of SEQ ID NO:264 and SEQ ID NO:294. All sensograms are
fit to the bivalent analyte model.
[0402] FIGS. 25A and 25B show the kinetic analysis of fluorescein
labeled SEQ ID NO:277 binding to murine KDR-Fc. All sensograms are
fit to the 1:1 Langmuir model.
[0403] FIG. 26 depicts examples of alpha, beta, gamma or delta
dipeptide or turn mimics (such as .alpha., .beta., .gamma., or
.delta. turn mimics), shown in panels 1, 2 and 3.
[0404] FIG. 27 shows an oxime linker. The amino acids containing an
aminoalcohol function (4), and containing an alkoxyamino function
(5), are incorporated into the peptide chain, not necessarily at
the end of the peptide chain.
[0405] FIG. 28 shows an example of cyclization of cysteine with a
pendant bromoacetamide function.
[0406] FIG. 29 is a schematic showing the formation of cyclic
peptides with a thiazolidine linkage via intramolecular reaction of
peptide aldehydes with cysteine moieties.
[0407] FIG. 30 is a schematic showing lactam surrogate for the
disulfide bond via quasiorthogonal deprotection of Lys and Asp
followed by on-resin cyclization and cleavage from resin.
[0408] FIG. 31 is a schematic showing lactam surrogate for the
disulfide bond via quasiorthogonal deprotection of Lys and Asp
using allyl-based protecting groups followed by on-resin
cyclization and cleavage from resin.
[0409] FIG. 32 is a schematic depicting Grubbs Olefin Metathesis
Cyclization.
[0410] FIG. 33 shows phospholipid structures.
[0411] FIGS. 34A-F depict preferred structures of chelators.
[0412] FIG. 35 shows the structure of a chelating agent.
[0413] FIG. 36 shows dimer 1 (D1; Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ ID
NO:277)
[(Biotin-JJK-(O.dbd.)C(CH.sub.2).sub.3C(.dbd.O)-JJ-NH(CH.sub.2).s-
ub.4--(S)--CH((Ac-VCWEDSWGGEVCFRYDPGGGK(SEQ ID
NO:337))-NH)CONH.sub.2]--NH- .sub.2).
[0414] FIG. 37 shows dimer 2 (D2; Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ ID
NO:277)
[(Biotin-JJK-(O.dbd.)C(CH.sub.2).sub.3C(.dbd.O)-JJ-NH(CH.sub.2).s-
ub.4--(S)--CH((Ac-AGPTWCEDDWYYCWLFGTJK(SEQ ID
NO:493))-NH)CONH.sub.2]--NH.- sub.2).
[0415] FIG. 38 shows dimer 3 (D3; Ac-VCWEDSWGGEVCFRYDPGGGK (SEQ ID
NO:337)[(Biotin-JJK-(O.dbd.)C(CH.sub.2).sub.3C(.dbd.O)-JJ-NH(CH.sub.2).su-
b.4--(S)--CH((Ac-VCWEDSWGGEVCFRYDPGGGK(SEQ ID
NO:337))-NH)CONH.sub.2]--NH.- sub.2).
[0416] FIG. 39 shows dimer 4 (D4; Ac-AGPTWCEDDWYYCWLFGTJK (SEQ ID
NO:338)[DOTA-JJK-(O.dbd.)C(CH.sub.2).sub.3C(.dbd.O)-JJ-NH(CH.sub.2).sub.4-
--(S)--CH((Ac-VCWEDSWGGEVCFRYDPGGGK(SEQ ID
NO:337))-NH)CONH.sub.2]--NH.sub- .2).
[0417] FIG. 40 shows dimer 5 (D5; Ac-VCWEDSWGGEVCFRYDPGGGK (SEQ ID
NO:337)
(JJ-C(.dbd.O)(CH.sub.2).sub.3C(.dbd.O)--K--NH(CH.sub.2).sub.4--(S)--CH((A-
c-AGPTWCEDDWYYCWLFGTGGGK(SEQ ID
NO:277))-NH)CONH.sub.2)--NH.sub.2).
[0418] FIG. 41 shows dimer 8 (D8; Ac-AQDWYYDEILSMADQLRHAFLSGGGGGK
(SEQ ID NO:356) {Ac-AQDWYYDEILSMADQLRHAFLSGGGGGK(SEQ ID
NO:356)(J-Glut-)-NH.sub.2- }K(Biotin-JJ)-NH.sub.2).
[0419] FIG. 42 shows dimer 9 (D9;
Ac-AQDWYYDEILSMADQLRHAFLSGGGGGK(SEQ ID NO:356)
{[Ac-GDSRVCWEDSWGGEVCFRYDPGGGK(SEQ ID NO:294)(JJ-Glut-)]-NH.sub.2-
}K--NH.sub.2).
[0420] FIG. 43 shows dimer 10 (D10Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ ID
NO:277){[Ac-GDSRVCWEDSWGGEVCFRYDPGGGK (SEQ ID NO:294)
(JJ-Glut-NH(CH.sub.2).sub.4--(S)--CH(PnAO6-Glut-NH)(C.dbd.O--)]--NH.sub.2-
}--NH.sub.2).
[0421] FIG. 44 shows dimer 11 (D11; Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ
ID NO:277){Ac-VCWEDSWGGEVCFRYDPGGGK(SEQ ID
NO:337)[JJ-Glut-NH(CH.sub.2).sub.-
4--(S)--CH(DOTA-JJ-NH--)(C.dbd.O)--]--NH.sub.2}--NH.sub.2).
[0422] FIG. 45 shows dimer 12 (D12; Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ
ID NO:277){[PnAO6-Glut-K(Ac-VCWEDSWGGEVCFRYDPGGGK(SEQ ID
NO:337)(--C(.dbd.O)CH.sub.2(OCH.sub.2CH.sub.2).sub.2OCH.sub.2C(.dbd.O)--)-
--NH.sub.2]}--NH.sub.2).
[0423] FIG. 46 shows dimer 13 (D13; Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ
ID NO:277){Ac-VCWEDSWGGEVCFRYDPGGGK (SEQ ID
NO:337)[JJ-Glut-K(BOA)]-NH.sub.2- }--NH.sub.2).
[0424] FIG. 47 shows dimer 14 (D14; Ac-AQDWYYDEILSMADQLRHAFLSGGGGGK
(SEQ ID NO:356){PnAO6-Glut-K[Ac-GDSRVCWEDSWGGEVCFRYDPGGGK (SEQ ID
NO:477) (JJ-Glut)-NH.sub.2]}--NH.sub.2).
[0425] FIG. 48 shows dimer 15 (D15; Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ
ID NO:277) {[Ac-GDSRVCWEDSWGGEVCFRYDPGGGK(SEQ ID
NO:294)[JJ-Glut]-NH.sub.2]-- -K(PnAO6-Glut)}-NH.sub.2).
[0426] FIG. 49 shows dimer 16 (D16; Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ
ID NO:277){PnAO6-Glut-K [Ac-GDSRVCWEDSWGGEVCFRYDPGGGK (SEQ ID
NO:294)[-C(.dbd.O)CH.sub.2O(CH.sub.2CH.sub.2O).sub.2CH.sub.2C(.dbd.O)NH(C-
H.sub.2).sub.3O(CH.sub.2CH.sub.2O).sub.2(CH.sub.2).sub.3NH
C(.dbd.O)CH.sub.2O(CH.sub.2CH.sub.2O).sub.2CH.sub.2C(.dbd.O)--]--NH.sub.2-
]}--NH.sub.2).
[0427] FIG. 50 shows dimer 17 (D17; Ac-AQDWYYDEILJGRGGRGGRGGK (SEQ
ID NO:478){K[Ac-VCWEDSWGGEVCFRYDPGGGK (SEQ ID
NO:337)(JJ-Glut)-NH.sub.2]}--N- H.sub.2).
[0428] FIG. 51 shows dimer 18 (D18; Ac-APGTWCDYDWEYCWLGTFGGGK (SEQ
ID NO:497){PnAO6-Glut-K[Ac-GVDFRCEWSDWGEVGCRSPDYGGGK(SEQ ID
NO:489)(JJ-Glut)-NH.sub.2]}--NH.sub.2).
[0429] FIG. 52 shows dimer 19 (D19; Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ
ID NO:277){Biotin-K[Ac-VCWEDSWGGEVCFRYDPGGGK(SEQ ID
NO:337)(JJ-Glut)-NH.sub.- 2]}--NH.sub.2).
[0430] FIG. 53 shows dimer 20 (D20; (((-JJ)-AGPTWCEDDWYYCWLFGTGGGGK
(SEQ ID NO:480)--NH.sub.2)-Glut-JJ)VCWEDSWGGEVCFRYDPGGG(SEQ ID
NO:370)--NH.sub.2).
[0431] FIG. 54 shows dimer 21 (D21; [(-JJ)-AGPTWCEDDWYYCWLFGTGGGGK
(SEQ ID
NO:480)(PnAO6-Glut)-NH.sub.2]-Glut-(JJ)-VCWEDSWGGEVCFRYDPGGG(SEQ ID
NO:370)--NH.sub.2).
[0432] FIG. 55 shows dimer 22 (D22; Ac-GDSRVCWEDSWGGEVCFRYDPGGGK
(SEQ ID NO:294) {JJ-Glut-JJ-AGPTWCEDDWYYCWLFTGGGK (SEQ ID
NO:481)--NH.sub.2}--NH.- sub.2).
[0433] FIG. 56 shows dimer 23 (D23; Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ
ID NO:277){Ac-VCWEDSWGGEVCFRYDPGGGK (SEQ ID NO:337)
[JJ-Glut-K(SATA)]-NH.sub- .2}--NH.sub.2. D23 is dimer D5
functionalized with the SATA (S-Acetylthioacetyl) group).
[0434] FIG. 57 shows dimer 24 (D24; Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ
ID NO:277){SATA-JJK[Ac-VCWEDSWGGEVCFRYDPGGGK (SEQ ID
NO:337)(JJ-Glut)-NH.sub- .2]}--NH.sub.2).
[0435] FIG. 58 shows dimer 25 (D25; Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ
ID NO:277) {Ac-GDSRVCWEDSWGGEVCFRYDPGGGK (SEQ ID
NO:294)[JJ-Glut-NH(CH.sub.2-
).sub.4--(S)--CH(NH.sub.2)C(.dbd.O)--]--NH.sub.2}--NH.sub.2).
[0436] FIG. 59 shows dimer 26 (D26; AGPTWCEDDWYYCWLFGTGGGK (SEQ ID
NO:277){(-Glut-JJ-VCWEDSWGGEVCFRYDPGGG (SEQ ID
NO:370)--NH.sub.2)--K}--NH- .sub.2).
[0437] FIG. 60 shows dimer 27 (D27; Ac-AGPTWCEDDWYYCWLFGTGGGK (SEQ
ID NO:277){Ac-VCWEDSWGGEVCFRYDPGGGK (SEQ ID
NO:337)[S(GalNAc-alpha-D)-G-S(Ga-
lNAc-alpha-D)-Glut-S(GalNAc-alpha-D)-G-S(GalNAc
-alpha-D)-NH(CH.sub.2).sub-
.4--(S)--CH(Biotin-JJNH-)C(.dbd.O)--]--NH.sub.2}--NH.sub.2).
[0438] FIG. 61 shows dimer 28 (D28; comprising
AQEPEGYAYWEVITLYHEEDGDGGK (SEQ ID NO:305) and
AQAFPRFGGDDYWIQQYLRYTDGGK (SEQ ID NO:306)).
[0439] FIG. 62 shows dimer 29 (D29; comprising
AGPTWCEDDWYYCWLFGTGGGK (SEQ ID NO:277) and VCWEDSWGGEVCFRYDPGGGK
(SEQ ID NO:337)).
[0440] FIG. 63 shows dimer 6 (D6; comprising
GDSRVCWEDSWGGEVCFRYDPGGGK (SEQ ID NO:294) and
AGPTWCEDDWYYCWLFGTGGGK (SEQ ID NO:277)).
[0441] FIG. 64 shows dimer 7 (D7; comprising
GDSRVCWEDSWGGEVCFRYDPGGGK (SEQ ID NO:294) and
AGPKWCEEDWYYCMITGTGGGK (SEQ ID NO:264)).
[0442] FIG. 65 is a graph showing the inhibition of tumor growth by
D6 as a function of D6 concentration.
[0443] FIG. 66 shows that D27 (squares) with its glycosylation and
modified spacer is able to block the effects of VEGF in the
migration assay to block VEGF-stimulated migration even more
potently than D25 (diamonds), which lacks those chemical
modifications.
[0444] FIGS. 67A and 67B show that Adjunct A enhances the potency
of D6 in blocking the biological effects of VEGF in a migration
assay with cultured HUVECs. FIG. 67A: Diamonds: D6 alone at the
indicated concentrations. Squares: D6 at the indicated
concentrations plus 100 nM Adjunct A (constant). FIG. 67B shows the
structure of Adjunct A.
[0445] FIG. 68 is a schematic showing Scheme 1 (synthesis of
Peptide 2).
[0446] FIG. 69 is a schematic showing Scheme 2 (synthesis of
Peptide 4).
[0447] FIG. 70 is a schematic showing Scheme 3 (synthesis of
D27).
[0448] FIG. 71 depicts % inhibition .+-. s.d. of specific
.sup.125I-VEGF binding to KDR-transfected cells by SEQ ID NO:504
(squares) and D1 (diamonds).
[0449] FIG. 72 depicts % maximum VEGF-stimulated migration .+-.
s.d. of HUVEC cells in the presence of the indicated concentrations
of SEQ ID NO:504 (diamonds) or D1 (squares).
[0450] FIG. 73 is a graphical representation showing total binding
of complexes of control peptide and the test peptides (SEQ ID
NOS:321, 320 and 323) with .sup.125 I-streptavidin (in the presence
of VEGF) to mock-transfected and KDR-transfected cells. Only the
complex containing SEQ ID NO:321 showed specific binding
(KDR-mock).
[0451] FIG. 74 is a graphical representation showing specific
binding of complexes of peptide (SEQ ID NO:321) and
.sup.125I-streptavidin (in the absence and presence of VEGF) to
KDR-transfected cells at various concentrations (0-13.33 nM) of
peptide-.sup.125I-streptavidin complex.
[0452] FIG. 75 shows that homodimeric D8 (squares) does not block
the effects of VEGF in the migration assay as carried out in
Example 28 as well the heterodimeric D17 (diamonds).
[0453] FIG. 76 is a schematic showing the synthesis of cyclic
lactam peptides (sample procedure).
[0454] FIG. 77 is a graphical representation showing binding of SEQ
ID NO:482 derivatives with different spacer length and biotin.
Derivatives have none, one J and two J spacers, respectively, in
between the SEQ ID NO:482 targeting sequence and biotin.
[0455] FIG. 78 depicts the binding of Tc-labeled D10 to
KDR-transfected 293H cells as described in Example 32.
Mock=mock-transfected. Trans=KDR-transfected. MS=mouse serum.
[0456] FIGS. 79A-G show derivatives of binding peptides of the
invention.
[0457] FIG. 80 summarizes the results of a radiotherapy study with
D13 conducted in nude mice implanted with PC3 tumors. Each plotted
line represents the growth over time for an individual tumor in a
treated mouse, except for the heavy dashed line, which represents
the average tumor growth in a set of untreated mice, as described
in Example 34.
[0458] FIG. 81 shows uptake and retention of bubble contrast in the
tumor up to 30 minutes post injection for suspensions of
microbubbles conjugated to SEQ ID NO:356. In contrast, the same
bubbles showed only transient (no more than 10 minutes)
visualization/bubble contrast in the AOI situated outside the
matrigel or tumor site (see FIGS. 82 and 83).
[0459] FIG. 82 shows uptake and retention of bubble contrast in the
tumor up to 30 minutes post injection for suspensions of
microbubbles conjugated to a SATA-modified peptide comprising SEQ
ID NO:356. In contrast, the same bubbles showed only transient (no
more than 10 minutes) visualization/bubble contrast in the AOI
situated outside the matrigel.
[0460] FIG. 83 shows uptake and retention of bubble contrast in the
matrigel up to 30 minutes post injection for suspensions of
microbubbles conjugated to a SATA-modified peptide comprising SEQ
ID NO:294. In contrast, the same bubbles showed only transient (no
more than 10 minutes) visualization/bubble contrast in the AOI
situated outside the matrigel.
[0461] FIG. 84 is a graph showing the results of in vitro binding
assays. Microvascular endothelial cells (MVECs, Cascade Biologics,
Portland, Oreg.) were used to assess the in vitro efficacy of D6
and related analogues for their ability to inhibit VEGF-stimulated
proliferation.
[0462] FIG. 85 shows a typical example of peptide-conjugated
ultrasound contrast agents bound to KDR-or mock-transfected cells
in presence of 10% human serum (magnification: 100.times.).
[0463] FIG. 86 is a schematic representaion of the synthesis scheme
used to prepare
4-{2-(2-Hydroxyimino-1,1-dimethylpropylamino)-1-[(2-hydroxyimi-
no-1,1-dimethyl-propylamino)-methyl]-ethylcarbamoyl}-butyric acid,
N-hydroxysuccinimide ester (Compound B) using
4-{2-(2-Hydroxyimino-1,1-di-
methyl-propylamino)-1-[(2-hydroxyimino-1,1-dimethyl-propylamino)-methyl]-e-
thylcarbamoyl}-butyric acid as a starting reagent.
[0464] FIGS. 87A-C are schematic representations depicting
synthesis schemes and structures for Dimer D30. FIG. 87A shows the
synthesis scheme for the preparation of Compound 3. FIG. 87B shows
the synthesis scheme for dimer D30: Preparation of
Ac-VCWEDSWGGEVCFRYDPGGGK (SEQ ID NO:337)
{[PnAO6-Glut-K(-Glut-JJ-NH(CH.sub.2).sub.4--(S)--CH(Ac-AQDWYYDEILJGRGGRGG-
RGG(SEQ ID NO:478)--NH)C(.dbd.O)NH.sub.2]--NH.sub.2}--NH.sub.2: D30
from Compound 3 and Compound 4. FIG. 87C shows the structure of
dimer D30.
[0465] FIGS. 88A-D are schematic representations depicting
synthesis schemes and structures for dimer D31. FIG. 88A shows the
synthesis scheme for the preparation of Compound 2. FIG. 88B shows
the synthesis scheme for the preparation of Compound 4 (a peptide
related to SEQ ID NO:374). FIG. 88C depicts the synthesis scheme
and structure for dimer D31 (i.e., Preparation of
Ac-AGPTWCEDDWYYCWLFGTGGGK(SEQ ID NO:277)[Ac-VCWEDSWGGEVCFR-
YDPGGGK(SEQ ID
NO:337)[SGS-Glut-SGS-(S)--NH(CH.sub.2).sub.4--CH(Biotin-JJ--
NH)--C(.dbd.O)]--NH.sub.2]--NH.sub.2). FIG. 88D shows the structure
of D31.
[0466] FIG. 89 is a graph that shows competition of targeted
bubbles by corresponding free peptide.
[0467] FIG. 90 is a graph that shows competition of targeted
bubbles conjugate to D23 by corresponding free peptide.
[0468] FIG. 91 is a graph that shows competition of targeted
bubbles with free dimer.
[0469] FIG. 92 is a graph showing binding values obtained with the
suspensions of microbubbles conjugated to the D23, SATA-modified
SEQ ID NO:480, SATA-modified SEQ ID NO:294 or SEQ ID NO:294/SEQ ID
NO:480 (50/50) are equivalent (see Example 43).
[0470] FIG. 93 is a graph showing dimer D10 blocks the increased
peritoneal vascular permeability induced by VEGF injected
intraperitoneally. Solutions containing the indicated additions
were injected intraperitoneally, and their effect on peritoneal
permeability was assessed by measuring the O.D. of the injected
fluid at 590 nm after administering Evan's Blue dye i.v. as
described in Example 44.
[0471] FIG. 94 is a graph showing uptake and retention of bubble
contrast in the tumor up to 30 minutes post injection for
suspensions of phospholipid stabilized microbubbles conjugated to a
heteromultimeric construct (D23).
[0472] FIG. 95 is a graph depicting the binding of Lu-D13 to
KDR-transfected 293H cells. Mock=mock-transfected.
Trans=KDR-transfected. MS=mouse serum.
[0473] FIG. 96 is a graph showing the specific binding of a
Tc-labeled polypeptide (SEQ ID NO:339) to KDR-transfected 293H
cells after subtracting the binding to mock-transfected 293H
cells.
[0474] FIG. 97 is a bar graph demonstrating that Tc-labeled SEQ ID
NO:277 with Tc-chelate binding to KDR-transfected 293H cells is
inhibited by about 80% in the presence of 40% rat serum.
DETAILED DESCRIPTION OF THE INVENTION
[0475] A description of preferred embodiments of the invention
follows. While this invention has been particularly shown and
described with references to preferred embodiments thereof, it will
be understood by those skilled in the art that various changes in
form and details may be made therein without departing from the
scope of the invention encompassed by the appended claims.
[0476] Definitions
[0477] In the following sections, the term "recombinant" is used to
describe non-naturally altered or manipulated nucleic acids, host
cells transfected with exogenous nucleic acids, or polypeptides
expressed non-naturally, through manipulation of isolated DNA and
transformation of host cells. Recombinant is a term that
specifically encompasses DNA molecules that have been constructed
in vitro using genetic engineering techniques, and use of the term
"recombinant" as an adjective to describe a molecule, construct,
vector, cell, polypeptide or polynucleotide specifically excludes
naturally occurring such molecules, constructs, vectors, cells,
polypeptides or polynucleotides.
[0478] The term "bacteriophage" is defined as a bacterial virus
containing a DNA core and a protective shell built up by the
aggregation of a number of different protein molecules. The terms
"bacteriophage" and "phage" are used herein interchangeably.
[0479] The term "polypeptide" is used to refer to a compound of two
or more amino acids joined through the main chain (as opposed to
side chain) by a peptide amide bond (--C(:O)NH--). The term
"peptide" is used interchangeably herein with "polypeptide" but is
generally used to refer to polypeptides having fewer than 40, and
preferably fewer than 25 amino acids.
[0480] The term "binding polypeptide" as used herein refers to any
polypeptide capable of forming a binding complex with another
molecule. An equivalent term sometimes used herein is "binding
moiety". "KDR binding polypeptide" is a polypeptide that forms a
complex in vitro or in vivo with vascular endothelial growth factor
receptor-2 (or KDR, Flk-1); "VEGF/KDR complex binding polypeptide"
is a polypeptide that forms a complex in vitro or in vivo with a
binding complex formed between vascular endothelial growth factor
(VEGF) and KDR, in particular the complex of homodimeric VEGF and
one or two KDR molecules that is believed to form at the surface of
endothelial cells during angiogenesis. Specific examples of KDR and
VEGF/KDR binding polypeptides include but are not limited to the
peptides presented in Tables 1-7, infra, and include hybrid and
chimeric polypeptides incorporating such peptides. Also included
within the definition of KDR and VEGF/KDR complex binding
polypeptides are polypeptides that are modified or optimized as
disclosed herein.
[0481] Specific examples of such modifications are discussed in
detail infra, but include substitution of amino acids for those in
the parent polypeptide sequence to optimize properties, obliterate
an enzyme cleavage site, etc.; C- or N-terminal amino acid
substitutions or elongations, e.g., for the purpose of linking the
binding polypeptide to a detectable imaging label or other
substrate, examples of which include, e.g., addition of a
polyhistidine "tail" in order to assist in purification;
truncations; amide bond changes; translocations; retroinverso
peptides; peptoids; retroinversopeptoids; the use of N-terminal or
C-terminal modifications or linkers, such as polyglycine or
polylysine segments; alterations to include functional groups,
notably hydrazide (--NH--NH.sub.2) functionalities or the
C-terminal linker -Gly-Gly-Gly-Lys (SEQ ID NO:18), to assist in
immobilization of binding peptides according to this invention on
solid supports or for attachment of fluorescent dyes;
pharmacokinetic modifications, structural modifications to retain
structural features, formation of salts to increase water
solubility or ease of formulation, and the like.
[0482] In addition to the detectable labels described further
herein, other suitable substrates for the binding polypeptides
include a tumorcidal agent or enzyme, a liposome (e.g., loaded with
a therapeutic agent, an ultrasound appropriate gas, or both), or a
solid support, well, plate, bead, tube, slide, filter or dish.
Moreover, dimers or multimers of one or more KDR or VEGF/KDR
binding polypeptides can be formed. Such constructs may, for
example, exhibit increased ability to bind to KDR. All such
modified binding polypeptides are also considered KDR or VEGF/KDR
complex binding polypeptides so long as they retain the ability to
bind the KDR or VEGF/KDR targets.
[0483] "Homologues" of the binding polypeptides described herein
can be produced using any of the modification or optimization
techniques described herein or known to those skilled in the art.
Such homologous polypeptides will be understood to fall within the
scope of the present invention and the definition of KDR and
VEGF/KDR complex binding polypeptides so long as the substitution,
addition, or deletion of amino acids or other such modification
does not eliminate its ability to bind either KDR or VEGF/KDR
complex. The term "homologous", as used herein, refers to the
degree of sequence similarity between two polymers (i.e.,
polypeptide molecules or nucleic acid molecules). Where the same
nucleotide or amino acid residue or one with substantially similar
properties (i.e., a conservative substitution) occupies a sequence
position in the two polymers under comparison, then the polymers
are homologous at that position. For example, if the amino acid
residues at 60 of 100 amino acid positions in two polypeptide
sequences match or are homologous then the two sequences are 60%
homologous. The homology percentage figures referred to herein
reflect the maximal homology possible between the two polymers,
i.e., the percent homology when the two polymers are so aligned as
to have the greatest number of matched (homologous) positions.
Polypeptide homologues within the scope of the present invention
will be at least 70% and preferably greater than 80% homologous to
at least one of the KDR or VEGF/KDR binding sequences disclosed
herein.
[0484] The term "binding" refers to the determination by standard
assays, including those described herein, that a binding
polypeptide recognizes and binds reversibly to a given target. Such
standard assays include, but are not limited to equilibrium
dialysis, gel filtration, and the monitoring of spectroscopic
changes that result from binding.
[0485] The term "specificity" refers to a binding polypeptide
having a higher binding affinity for one target over another. The
term "KDR specificity" refers to a KDR binding moiety having a
higher affinity for KDR than for an irrelevant target. The term
"VEGF/KDR specificity" refers to a VEGF/KDR complex binding moiety
having a higher affinity for a VEGF/KDR complex than for another
given target. Binding specificity can be characterized by a
dissociation equilibrium constant (K.sub.D) or an association
equilibrium constant (K.sub.a) for the two tested target materials,
or can be any measure of relative binding strength. The binding
polypeptides according to the present invention are specific for
KDR or VEGF/KDR complex and preferably have a K.sub.D for KDR or
VEGF/KDR complex that is lower than 10 .mu.M, more preferably less
than 1.0 .mu.M, most preferably less than 0.5 .mu.M or even
lower.
[0486] The term "patient" as used herein refers to any mammal,
especially humans.
[0487] The term "pharmaceutically acceptable" carrier or excipient
refers to a non-toxic carrier or excipient that can be administered
to a patient, together with a compound of this invention, such that
it does not destroy the biological or pharmacological activity
thereof.
[0488] The following common abbreviations are used throughout this
specification: 9-fluorenylmethyloxycarbonyl (fmoc or Fmoc),
1-hydroxybenzotriazole (HOBt), N,N'-diisopropylcarbodiimide (DIC),
acetic anhydride (Ac.sub.2O),
(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methy- lbutyl (ivDde),
trifluoroacetic acid (TFA), Reagent B
(TFA:H.sub.2O:phenol:triisopropylsilane, 88:5:5:2),
N,N-diisopropylethylamine (DIEA),
0-(1H-benzotriazole-1-yl)-N,N,N',N'-tet- ramethyluronium
hexafluorophosphate (HBTU),O-(7-azabenzotriazol-1-yl)-1,1,-
3,3-tetramethyluronium hexafluorophosphate (HATU),
N-hydroxysuccinimide (NHS), solid phase peptide synthesis (SPPS),
dimethyl sulfoxide (DMSO), dichloromethane (DCM), dimethylformamide
(DMF), and N-methylpyrrolidinone (NMP).
DETAILED DESCRIPTION OF THE INVENTION
[0489] The present invention provides novel binding moieties that
bind KDR or a complex of VEGF and KDR. Such binding moieties make
possible the efficient detection, imaging and localization of
activated endothelial cells exhibiting upregulated KDR expression
and binding to VEGF. Such endothelial cells are characteristic of
active angiogenesis, and therefore the polypeptides described
herein provide a means of detecting, monitoring and localizing
sites of angiogenesis. In particular, the binding polypeptides of
this invention, when appropriately labeled, are useful for
detecting, imaging and localizing tumor-induced angiogenesis. Thus,
the binding polypeptides can be used to form a variety of
diagnostic and therapeutic agents for diagnosing and treating
neoplastic tumor growth or other pathogenic instances of
angiogenesis. In addition, the binding polypeptides can themselves
be used as therapeutic agents.
[0490] Specific KDR and VEGF/KDR complex binding polypeptides
according to the present invention were isolated initially by
screening of phage display libraries, that is, populations of
recombinant bacteriophage transformed to express an exogenous
peptide on their surface. In order to isolate new polypeptide
binding moieties for a particular target, such as KDR or VEGF/KDR,
screening of large peptide libraries, for example using phage
display techniques, is especially advantageous, in that very large
numbers (e.g., 5.times.10.sup.9) of potential binders can be tested
and successful binders isolated in a short period of time.
[0491] In order to prepare a phage library of displaying
polypeptides to screen for binding polypeptides such as KDR or
VEGF/KDR complex binding polypeptides, a candidate binding domain
is selected to serve as a structural template for the peptides to
be displayed in the library. The phage library is made up of a
multiplicity of analogues of the parental domain or template. The
binding domain template may be a naturally occurring or synthetic
protein, or a region or domain of a protein. The binding domain
template may be selected based on knowledge of a known interaction
between the binding domain template and the binding target, but
this is not critical. In fact, it is not essential that the domain
selected to act as a template for the library have any affinity for
the target at all: Its purpose is to provide a structure from which
a multiplicity (library) of similarly structured polypeptides
(analogues) can be generated, which multiplicity of analogues will
hopefully include one or more analogues that exhibit the desired
binding properties (and any other properties screened for).
[0492] In selecting the parental binding domain or template on
which to base the variegated amino acid sequences of the library,
the most important consideration is how the variegated peptide
domains will be presented to the target, i.e., in what conformation
the peptide analogues will come into contact with the target. In
phage display methodologies, for example, the analogues will be
generated by insertion of synthetic DNA encoding the analogues into
phage, resulting in display of the analogue on the surfaces of the
phage. Such libraries of phage, such as M13 phage, displaying a
wide variety of different polypeptides, can be prepared using
techniques as described, e.g., in Kay et al., Phage Display of
Peptides and Proteins: A Laboratory Manual (Academic Press, Inc.,
San Diego, 1996) and U.S. Pat. No. 5,223,409 (Ladner et al.),
incorporated herein by reference.
[0493] In isolating the specific polypeptides according to this
invention, seven cyclic peptide (or "loop") libraries, designated
TN6/VI, TN7/IV, TN8/IX, TN9/IV, TN10/IX, TN12/I, and MTN13/I, and a
linear library, designated Lin20, were used. Each library was
constructed for expression of diversified polypeptides on M13
phage. The seven libraries having a "TN" designation were designed
to display a short, variegated exogenous peptide loop of 6, 7, 8,
9, 10, 12 or 13 amino acids, respectively, on the surface of M13
phage, at the amino terminus of protein III. The libraries are
designated TN6/VI (having a potential 3.3.times.10.sup.12 amino
acid sequence diversity), TN7/IV (having a potential
1.2.times.10.sup.14 amino acid sequence diversity), TN8/IX (having
a potential 2.2.times.10.sup.15 amino acid sequence diversity),
TN9/IV (having a potential 4.2.times.10.sup.16 amino acid sequence
diversity), TN10/IX (having a potential 3.0.times.10.sup.16 amino
acid sequence diversity), TN12/I (having a sequence diversity of
4.6.times.10.sup.19), MTN13/I (having a potential
8.0.times.10.sup.17 amino acid sequence diversity), and Lin20
(having a potential 3.8.times.10.sup.25 amino acid sequence
diversity).
[0494] The TN6/VI library was constructed to display a single
microprotein binding loop contained in a 12-amino acid template.
The TN6/VI library utilized a template sequence of
Xaa.sub.1-Xaa.sub.2-Xaa.sub.3-Cys-Xaa.sub-
.5-Xaa.sub.6-Xaa.sub.7-Xaa.sub.8-Cys-Xaa.sub.10-Xaa.sub.11-Xaa.sub.12.
The amino acids at positions 2, 3, 5, 6, 7, 8, 10, and 11 of the
template were varied to permit any amino acid except cysteine
(Cys). The amino acids at positions 1 and 12 of the template were
varied to permit any amino acid except cysteine (Cys), glutamic
acid (Glu), isoleucine (Ile), lysine (Lys), methionine (Met), and
threonine (Thr).
[0495] The TN7/IV library was constructed to display a single
microprotein binding loop contained in a 13-amino acid template.
The TN7/IV library utilized a template sequence of
Xaa.sub.1-Xaa.sub.2-Xaa.sub.3-Cys-Xaa.sub-
.5-Xaa.sub.6-Xaa.sub.7-Xaa.sub.8-Xaa.sub.9-Cys-Xaa.sub.11-Xaa.sub.12-Xaa.s-
ub.13. The amino acids at amino acid positions 1, 2, 3, 5, 6, 7, 8,
9, 11, 12, and 13 of the template were varied to permit any amino
acid except cysteine (Cys).
[0496] The TN8/IX library was constructed to display a single
microprotein binding loop contained in a 14-amino acid template.
The TN8/IX library utilized a template sequence of
Xaa.sub.1-Xaa.sub.2-Xaa.sub.3-Cys-Xaa.sub-
.5-Xaa.sub.6-Xaa.sub.7-Xaa.sub.8-Xaa.sub.9-Xaa.sub.10-Cys-Xaa.sub.12-Xaa.s-
ub.13-Xaa.sub.14. The amino acids at position 1, 2, 3, 5, 6, 7, 8,
9, 10, 12, 13, and 14 in the template were varied to permit any
amino acid except cysteine (Cys).
[0497] The TN9/IV library was constructed to display a single
microprotein binding loop contained in a 15-amino acid template.
The TN9/IV library utilized a template sequence
Xaa.sub.1-Xaa.sub.2-Xaa.sub.3-Cys-Xaa.sub.5--
Xaa.sub.6-Xaa.sub.7-Xaa.sub.8-Xaa.sub.9-Xaa.sub.10-Xaa.sub.11-Cys-Xaa.sub.-
13-Xaa.sub.14-Xaa.sub.15. The amino acids at position 1, 2, 3, 5,
6, 7, 8, 9, 10, 11, 13, 14 and 15 in the template were varied to
permit any amino acid except cysteine (Cys).
[0498] The TN10/IX library was constructed to display a single
microprotein binding loop contained in a 16-amino acid template.
The TN10/IX library utilized a template sequence
Xaa.sub.1-Xaa.sub.2-Xaa.sub.-
3-Cys-Xaa.sub.5-Xaa.sub.6-Xaa.sub.7-Xaa.sub.8-Xaa.sub.9-Xaa.sub.10-Xaa.sub-
.11-Xaa.sub.12-Cys-Xaa.sub.14-Xaa.sub.15-Xaa.sub.16. The amino
acids at positions 1, 2, 15, and 16 in the template were varied to
permit any amino acid selected from a group of 10 amino acids: D,
F, H, L, N, P, R, S, W, or Y). The amino acids at positions 3 and
14 in the template were varied to permit any amino acid selected
from a group of 14 amino acids: A, D, F, G, H, L, N, P, Q, R, S, V,
W, or Y). The amino acids at positions 5, 6, 7, 8, 9, 10, 11, and
12 in the template were varied to permit any amino acid except
cysteine (Cys).
[0499] The TN12/I library was constructed to display a single
microprotein binding loop contained in an 18-amino acid template.
The TN12/I library utilized a template sequence
Xaa.sub.1-Xaa.sub.2-Xaa.sub.3-Cys-Xaa.sub.5--
Xaa.sub.6-Xaa.sub.7-Xaa.sub.8-Xaa.sub.9-Xaa.sub.10-Xaa.sub.11-Xaa.sub.12-X-
aa.sub.13-Xaa.sub.14-Cys-Xaa.sub.16-Xaa.sub.17-Xaa.sub.18. The
amino acids at position 1, 2, 17, and 18 in the template were
varied to permit any amino acid selected from a group of 12 amino
acids: A, D, F, G, H, L, N, P, R, S, W, or Y). The amino acids at
positions 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 16 were varied
to permit any amino acid except cysteine (Cys).
[0500] The MTN13/I library was constructed to display a single
microprotein binding loop contained in a 19-amino acid template
featuring two variable regions of equal size (i.e., eight amino
acids) separated by a constant region of three amino acids
(Ser-Gly-Pro). The MTN13/I library utilized a template sequence
Xaa.sub.1-Xaa.sub.2-Xaa.sub.3-Cys-Xaa.sub.5--
Xaa.sub.6-Xaa.sub.7-Xaa.sub.8-Ser-Gly-Pro-Xaa.sub.12-Xaa.sub.13-Xaa.sub.14-
-Xaa.sub.15-Cys-Xaa.sub.17-Xaa.sub.18-Xaa.sub.19 (SEQ ID NO:19).
The amino acids at position 1, 2, 3, 5, 6, 7, 8, 12, 13, 14, 15,
17, 18, and 19 in the template were varied to permit any amino acid
except cysteine (Cys).
[0501] The Lin20 library was constructed to display a single linear
peptide in a 20-amino acid template. The amino acids at each
position in the template were varied to permit any amino acid
except cysteine (Cys).
[0502] The binding polypeptides provided herein can include
additions or truncations in the N- and/or C-termini. Such modified
binding polypeptides are expected to bind KDR or VEGF/KDR complex.
For example, the -GGGK linker present at the N-terminus of some of
the binding polypeptides provided herein is an optional linker.
Therefore, polypeptides having the same sequence, except without
the terminal -GGGK sequence, are also encompassed by the present
invention. In addition, binding polypeptides comprising the loop
portion of the templates and sequences provided herein are expected
to bind KDR and/or VEGF/KDR complex and are also encompassed by the
present invention. The loop portion of the templates and sequences
includes the sequences between and including the two cysteine
residues that are expected to form a disulfide bond, thereby
generating a peptide loop structure. Furthermore, the binding
polypeptides of the present invention can include additional amino
acid residues at the N- and/or C-termini.
[0503] The phage display libraries were created by making a
designed series of mutations or variations within a coding sequence
for the polypeptide template, each mutant sequence encoding a
peptide analogue corresponding in overall structure to the template
except having one or more amino acid variations in the sequence of
the template. The novel variegated (mutated) DNA provides sequence
diversity, and each transformant phage displays one variant of the
initial template amino acid sequence encoded by the DNA, leading to
a phage population (library) displaying a vast number of different
but structurally related amino acid sequences. The amino acid
variations are expected to alter the binding properties of the
binding peptide or domain without significantly altering its
structure, at least for most substitutions. It is preferred that
the amino acid positions that are selected for variation (variable
amino acid positions) will be surface amino acid positions, that
is, positions in the amino acid sequence of the domains that, when
the domain is in its most stable conformation, appear on the outer
surface of the domain (i.e., the surface exposed to solution). Most
preferably the amino acid positions to be varied will be adjacent
or close together, so as to maximize the effect of
substitutions.
[0504] As indicated previously, the techniques discussed in Kay et
al., Phage Display of Peptides and Proteins: A Laboratory Manual
(Academic Press, Inc., San Diego, 1996) and U.S. Pat. No. 5,223,409
are particularly useful in preparing a library of potential binders
corresponding to the selected parental template. The seven
libraries discussed above were prepared according to such
techniques, and they were screened for KDR or VEGF/KDR complex
binding polypeptides against an immobilized target, as explained in
the examples to follow.
[0505] In a typical screen, a phage library is contacted with and
allowed to bind the target, or a particular subcomponent thereof.
To facilitate separation of binders and non-binders, it is
convenient to immobilize the target on a solid support. Phage
bearing a target-binding moiety form a complex with the target on
the solid support whereas non-binding phage remain in solution and
may be washed away with excess buffer. Bound phage are then
liberated from the target by changing the buffer to an extreme pH
(pH 2 or pH 10), changing the ionic strength of the buffer, adding
denaturants, or other known means. To isolate the binding phage
exhibiting the polypeptides of the present invention, a protein
elution was performed, i.e., some phage were eluted from target
using VEGF in solution (competitive elution); and also, very high
affinity binding phage that could not be competed off incubating
with VEGF overnight were captured by using the phage still bound to
substrate for infection of E. coli cells.
[0506] The recovered phage may then be amplified through infection
of bacterial cells and the screening process repeated with the new
pool that is now depleted in non-binders and enriched in binders.
The recovery of even a few binding phage is sufficient to carry the
process to completion. After a few rounds of selection, the gene
sequences encoding the binding moieties derived from selected phage
clones in the binding pool are determined by conventional methods,
described below, revealing the peptide sequence that imparts
binding affinity of the phage to the target. When the selection
process works, the sequence diversity of the population falls with
each round of selection until desirable binders remain. The
sequences converge on a small number of related binders, typically
10-50 out of the more than 10 million original candidates from each
library. An increase in the number of phage recovered at each round
of selection, and of course, the recovery of closely related
sequences are good indications that convergence of the library has
occurred in a screen. After a set of binding polypeptides is
identified, the sequence information may be used to design other
secondary phage libraries, biased for members having additional
desired properties.
[0507] Formation of the disulfide binding loop is advantageous
because it leads to increased affinity and specificity for such
peptides. However, in serum, the disulfide bond might be opened by
free cysteines or other thiol-containing molecules. Thus, it may be
useful to modify the cysteine residues to replace the disulfide
cross-link with another less reactive linkage. The
--CH.sub.2--S--S--CH.sub.2-- cross-link has a preferred geometry in
which the dihedral bond between sulfurs is close to 90 degrees, but
the exact geometry is determined by the context of other side
groups and the binding state of the molecule. Preferred
modifications of the closing cross-link of the binding loop will
preserve the overall bond lengths and angles as much as possible.
Suitable such alternative cross-links include thioether linkages
such as --CH.sub.2--S--CH.sub.2--CH.sub.2--,
--CH.sub.2--CH.sub.2--S--CH.sub.2--,
--CH.sub.2--CH.sub.2--S--CH.sub.2--CH.sub.2--; lactam linkages such
as --CH.sub.2--NH--CO--CH.sub.2-- and
--CH.sub.2--CO--NH--CH.sub.2--; ether linkages such as
--CH.sub.2--CH.sub.2--O--CH.sub.2--CH.sub.2--; alkylene bridges
such as --(CH.sub.2).sub.n-- (where n=4,5, or 6); the linkage
--CH.sub.2--NH--CO--NH--CH.sub.2--, and similar groups known in the
art.
[0508] Although polypeptides containing a stable disulfide-linked
binding loop are most preferred, linear polypeptides derived from
the foregoing sequences may be readily prepared, e.g., by
substitution of one or both cysteine residues, which may retain at
least some of the KDR or VEGF/KDR binding activity of the original
polypeptide containing the disulfide linkage. In making such
substitutions for Cys, the amino acids Gly, Ser, and Ala are
preferred, and it is also preferred to substitute both Cys
residues, so as not to leave a single Cys that may cause the
polypeptide to dimerize or react with other free thiol groups in a
solution. All such linearized derivatives that retain KDR or
VEGF/KDR binding properties are within the scope of this
invention.
[0509] Direct synthesis of the polypeptides of the invention may be
accomplished using conventional techniques, including solid-phase
peptide synthesis, solution-phase synthesis, etc. Solid-phase
synthesis is preferred. See Stewart et al., Solid-Phase Peptide
Synthesis (W. H. Freeman Co., San Francisco, 1989); Merrifield, J.
Am. Chem. Soc., 85:2149-2154 (1963); Bodanszky and Bodanszky, The
Practice of Peptide Synthesis (Springer-Verlag, New York, 1984),
incorporated herein by reference.
[0510] Polypeptides according to the invention may also be prepared
commercially by companies providing peptide synthesis as a service
(e.g., BACHEM Bioscience, Inc., King of Prussia, Pa.; Quality
Controlled Biochemicals, Inc., Hopkinton, Mass.). Automated peptide
synthesis machines, such as manufactured by Perkin-Elmer Applied
Biosystems, also are available.
[0511] The polypeptide compound is preferably purified once it has
been isolated or synthesized by either chemical or recombinant
techniques. For purification purposes, there are many standard
methods that may be employed, including reversed-phase
high-pressure liquid chromatography (RP-HPLC) using an alkylated
silica column such as C.sub.4--, C.sub.8-- or C.sub.18-silica. A
gradient mobile phase of increasing organic content is generally
used to achieve purification, for example, acetonitrile in an
aqueous buffer, usually containing a small amount of
trifluoroacetic acid. Ion-exchange chromatography can also be used
to separate peptides based on their charge. The degree of purity of
the polypeptide may be determined by various methods, including
identification of a major large peak on HPLC. A polypeptide that
produces a single peak that is at least 95% of the input material
on an HPLC column is preferred. Even more preferable is a
polypeptide that produces a single peak that is at least 97%, at
least 98%, at least 99% or even 99.5% or more of the input material
on an HPLC column.
[0512] In order to ensure that the peptide obtained using any of
the techniques described above is the desired peptide for use in
compositions of the present invention, analysis of the peptide
composition may be carried out. Such composition analysis may be
conducted using high resolution mass spectrometry to determine the
molecular weight of the peptide. Alternatively, the amino acid
content of the peptide can be confirmed by hydrolyzing the peptide
in aqueous acid, and separating, identifying and quantifying the
components of the mixture using HPLC, or an amino acid analyzer.
Protein sequenators, which sequentially degrade the peptide and
identify the amino acids in order, may also be used to determine
the sequence of the peptide.
[0513] KDR or VEGF/KDR complex binding polypeptides according to
the present invention also may be produced using recombinant DNA
techniques, utilizing nucleic acids (polynucleotides) encoding the
polypeptides according to this invention and then expressing them
recombinantly, i.e., by manipulating host cells by introduction of
exogenous nucleic acid molecules in known ways to cause such host
cells to produce the desired KDR or VEGF/KDR complex binding
polypeptides. Such procedures are within the capability of those
skilled in the art (see Davis et al., Basic Methods in Molecular
Biology, (1986)), incorporated by reference. Recombinant production
of short peptides such as those described herein may not be
practical in comparison to direct synthesis, however recombinant
means of production may be very advantageous where a KDR or
VEGF/KDR complex binding moiety of this invention is incorporated
in a hybrid polypeptide or fusion protein.
[0514] In the practice of the present invention, a determination of
the affinity of the KDR or VEGF/KDR complex binding moiety for KDR
or VEGF/KDR complex relative to another protein or target is a
useful measure, and is referred to as specificity for KDR or
VEGF/KDR complex. Standard assays for quantitating binding and
determining affinity include equilibrium dialysis, equilibrium
binding, gel filtration, or the monitoring of numerous
spectroscopic changes (such as a change in fluorescence
polarization) that may result from the interaction of the binding
moiety and its target. These techniques measure the concentration
of bound and free ligand as a function of ligand (or protein)
concentration. The concentration of bound polypeptide ([Bound]) is
related to the concentration of free polypeptide ([Free]) and the
concentration of binding sites for the polypeptide, i.e., on KDR or
VEGF/KDR complex, (N), as described in the following equation:
[Bound]=N.times.[Free]/((1/K.sub.a)+[Free]).
[0515] A solution of the data to this equation yields the
association constant, K.sub.a, a quantitative measure of the
binding affinity. The association constant, K.sub.a is the
reciprocal of the dissociation constant, K.sub.D. The K.sub.D is
more frequently reported in measurements of affinity. Preferred KDR
or VEGF/KDR complex binding polypeptides have a K.sub.D for KDR or
VEGF/KDR complex in the range of 1 nanomolar (nM) to 100 micromolar
(.mu.M), which includes K.sub.D values of less than 10 nM, less
than 20 nM, less than 40 nM, less than 60 nM, less than 80 nM, less
than 1 .mu.M, less than 5 .mu.M, less than 10 .mu.M, less than 20
.mu.M, less than 40 .mu.M, less than 60 .mu.M, and less than 80
.mu.M.
[0516] Where KDR or VEGF/KDR complex binding moieties are employed
as imaging agents, other aspects of binding specificity may become
more important. Imaging agents operate in a dynamic system in that
binding of the imaging agent to the target (KDR or VEGF/KDR
complex, e.g., on activated endothelium) may not be in a stable
equilibrium state throughout the imaging procedure. For example,
when the imaging agent is initially injected, the concentration of
imaging agent and of agent-target complex rapidly increases.
Shortly after injection, however, the circulating (free) imaging
agent starts to clear through the kidneys or liver, and the plasma
concentration of imaging agent begins to drop. This drop in the
concentration of free imaging agent in the plasma eventually causes
the agent-target complex to dissociate. The usefulness of an
imaging agent depends on the difference in rate of agent-target
dissociation relative to the clearing rate of the agent. Ideally,
the dissociation rate will be slow compared to the clearing rate,
resulting in a long imaging time during which there is a high
concentration of agent-target complex and a low concentration of
free imaging agent (background signal) in the plasma.
[0517] Quantitative measurement of dissociation rates may be easily
performed using several methods known in the art, such as fiber
optic fluorimetry (see, e.g., Anderson & Miller, Clin. Chem.,
34(7):1417-21 (1988)), surface plasmon resonance (see, Malmborg et
al., J. Immunol. Methods, 198(1):51-7 (1996) and Schuck, Current
Opinion in Biotechnology, 8:498-502 (1997)), resonant mirror, and
grating coupled planar waveguiding (see, e.g., Hutchinson, Molec.
Biotechnology, 3:47-54 (1995)). Automated biosensors are
commercially available for measuring binding kinetics: BIAcore
surface plasmon resonance sensor (Biacore AB, Uppsala SE), IAsys
resonant mirror sensor (Fisons Applied Sensor Technology, Cambridge
GB), BIOS-1 grated coupled planar waveguiding sensor (Artificial
Sensor Instruments, Zurich CH).
[0518] Methods of Screening Polypeptides Identified by Phage
Display For Their Ability To Bind To Cells Expressing The
Target:
[0519] In another aspect of the invention, methods of screening
binding polypeptides identified by phage display for their ability
to bind to cells expressing the target (and not to cells that do
not express the target) are provided. These methods address a
significant problem associated with screening peptides identified
by phage display: frequently the peptides so identified do not have
sufficient affinity for the target to be screened against
target-expressing cells in conventional assays. However,
ascertaining that a particular phage-identified peptide binds to
cells that express the target (and does not bind to cells that do
not) is a critical piece of information in identifying binding
peptides that are potential in vivo targeting moieties. The method
takes advantage of the increase in affinity and avidity associated
with multivalent binding and permits screening of polypeptides with
low affinities against target-expressing cells.
[0520] The method generally consists of preparation and screening
of multimeric constructs including one or more binding
polypeptides. For example, polypeptides identified by phage display
as binding to a target are biotinylated and complexed with avidin,
streptavidin or neutravidin to form tetrameric constructs. These
tetrameric constructs are then incubated with cells that express
the desired target and cells that do not, and binding of the
tetrameric construct is detected. Binding may be detected using any
method of detection known in the art. For example, to detect
binding the avidin, streptavidin, or neutravidin may be conjugated
to a detectable marker (e.g., a radioactive label, a fluorescent
label, or an enzymatic label that undergoes a color change, such as
HRP (horse radish peroxidase), TMB (tetramethyl benzidine) or
alkaline phosphatase).
[0521] The biotinylated peptides are preferably complexed with
neutravidin-HRP. Neutravidin exhibits lower non-specific binding to
molecules than the other alternatives due to the absence of lectin
binding carbohydrate moieties and cell adhesion receptor-binding
RYD domain in neutravidin. See, Hiller et al., Biochem. J,
248:167-171 (1987); Alon et al., Biochem. Biophys. Res. Commun.,
170:1236-41 (1990).
[0522] The tetrameric constructs can be screened against cells that
naturally express the target or cells that have been engineered via
recombinant DNA technologies to express the target (e.g.,
transfectants, transformants, etc.). If cells that have been
transfected to express the target are used, mock-transfected cells
(i.e., cells transfected without the genetic material encoding the
target) may be used as a control.
[0523] The tetrameric complexes may optionally be screened in the
presence of serum. Thus, the assay may also be used to rapidly
evaluate the effect of serum on the binding of peptides to the
target.
[0524] The methods disclosed herein are particularly useful in
preparing and evaluating combinations of distinct binding
polypeptides for use in dimeric or multimeric targeting contructs
that contain two or more binding polypeptides. Use of biotin/avidin
complexes allows for relatively easy preparation of tetrameric
constructs containing one to four different binding peptides.
Furthermore, it has now been found that affinity and avidity of a
targeting construct may be increased by inclusion of two or more
targeting moieties that bind to different epitopes on the same
target. The screening methods described herein are useful in
identifying combinations of binding polypeptides that may have
increased affinity when included in such multimeric constructs.
[0525] In a preferred embodiment, the screening methods described
herein may be used to screen KDR and VEGF/KDR complex binding
polypeptides identified by phage display, such as those described
herein. As described in more detail in Example 5 infra, these
methods may be used to assess the specific binding of KDR binding
polypeptides to cells that express KDR or have been engineered to
express KDR. Tetrameric complexes of biotinylated KDR binding
polypeptides of the invention and neutravidin-HRP may be prepared
and screened against cells transfected to express KDR as well as
mock transfected cells (without any KDR).
[0526] As shown in Example 5, the assay can be used to identify KDR
binding polypeptides that bind specifically to KDR-expressing cells
(and do not bind to cells that do not express KDR) even when the
monodentate K.sub.D of the polypeptide is on the order of 200
nM-300 nM. The assay may be used to screen homotetrameric
constructs containing four copies of a single KDR binding
polypeptide of the invention as well as heterotetrameric constructs
(e.g., constructs containing two or more different KDR binding
polypeptides). The methods described herein are particularly useful
for assessing combinations of KDR binding polypeptides for use in
multimeric constructs, particularly constructs containing two or
more KDR binding polypeptides that bind to different epitopes of
KDR.
[0527] The assay may also be used to assess the effect of serum on
the KDR binding polypeptides. Indeed, using the screening methods
disclosed herein, KDR binding polypeptides, such as SEQ ID NOS:264,
294, and 356, were identified whose binding is not significantly
affected by serum.
[0528] Modification or Optimization of KDR and VEGF/KDR Complex
Binding Polypeptides.
[0529] As discussed, modification or optimization of KDR and
VEGF/KDR complex binding polypeptides is within the scope of the
invention and the modified or optimized polypeptides are included
within the definition of "KDR and VEGF/KDR complex binding
polypeptides". Specifically, a polypeptide sequence identified by
phage display can be modified to optimize its potency,
pharmacokinetic behavior, stability and/or other biological,
physical and chemical properties.
Substitution of Amino Acid Residues
[0530] For example, one can make the following isosteric and/or
conservative amino acid changes in the parent polypeptide sequence
with the expectation that the resulting polypeptides would have a
similar or improved profile of the properties described above:
[0531] Substitution of alkyl-substituted hydrophobic amino acids:
Including alanine, leucine, isoleucine, valine, norleucine,
S-2-aminobutyric acid, S-cyclohexylalanine or other simple
alpha-amino acids substituted by an aliphatic side chain from C1-10
carbons including branched, cyclic and straight chain alkyl,
alkenyl or alkynyl substitutions.
[0532] Substitution of aromatic-substituted hydrophobic amino
acids: including phenylalanine, tryptophan, tyrosine,
biphenylalanine, 1-naphthylalanine, 2-naphthylalanine,
2-benzothienylalanine, 3-benzothienylalanine, histidine, amino,
alkylamino, dialkylamino, aza, halogenated (fluoro, chloro, bromo,
or iodo) or alkoxy (from C1-C4)-substituted forms of the previous
listed aromatic amino acids, illustrative examples of which are:
2-,3- or 4-aminophenylalanine, 2-,3- or 4-chlorophenylalanine,
2-,3- or 4-methylphenylalanine, 2-,3- or 4-methoxyphenylalanine,
5-amino-, 5-chloro-, 5-methyl- or 5-methoxytryptophan, 2'-, 3'-, or
4'-amino-, 2'-, 3'-, or 4'-chloro-, 2,3, or 4-biphenylalanine,
2',-3',-or 4'-methyl-2,3 or 4-biphenylalanine, and 2- or
3-pyridylalanine.
[0533] Substitution of amino acids containing basic functions:
Including arginine, lysine, histidine, ornithine,
2,3-diaminopropionic acid, homoarginine, alkyl, alkenyl, or
aryl-substituted (from C1-C10 branched, linear, or cyclic)
derivatives of the previous amino acids, whether the substituent is
on the heteroatoms (such as the alpha nitrogen, or the distal
nitrogen or nitrogens, or on the alpha carbon, in the pro-R
position for example. Compounds that serve as illustrative examples
include: N-epsilon-isopropyl-lysine,
3-(4-tetrahydropyridyl)-glycine, 3-(4-tetrahydropyridyl)-alanine,
N,N-gamma, gamma'-diethyl-homoarginine. Included also are compounds
such as alpha methyl arginine, alpha methyl 2,3-diaminopropionic
acid, alpha methyl histidine, alpha methyl ornithine where alkyl
group occupies the pro-R position of the alpha carbon. Also
included are the amides formed from alkyl, aromatic, heteroaromatic
(where the heteroaromatic group has one or more nitrogens, oxygens
or sulfur atoms singly or in combination) carboxylic acids or any
of the many well-known activated derivatives such as acid
chlorides, active esters, active azolides and related derivatives)
and lysine, ornithine, or 2,3-diaminopropionic acid.
[0534] Substitution of acidic amino acids: Including aspartic acid,
glutamic acid, homoglutamic acid, tyrosine, alkyl, aryl, arylalkyl,
and heteroaryl sulfonamides of 2,4-diaminopriopionic acid,
ornithine or lysine and tetrazole-substituted alkyl amino
acids.
[0535] Substitution of side chain amide residues: Including
asparagine, glutamine, and alkyl or aromatic substituted
derivatives of asparagine or glutamine.
[0536] Substitution of hydroxyl containing amino acids: Including
serine, threonine, homoserine, 2,3-diaminopropionic acid, and alkyl
or aromatic substituted derivatives of serine or threonine. It is
also understood that the amino acids within each of the categories
listed above may be substituted for another of the same group.
Substitution of Amide Bonds
[0537] Another type of modification within the scope of the patent
is to substitute the amide bonds within the backbone of the
polypeptide. For example, to reduce or eliminate undesired
proteolysis, or other degradation pathways that diminish serum
stability, resulting in reduced or abolished bioactivity, or to
restrict or increase conformational flexibility, it is common to
substitute amide bonds within the backbone of the peptides with
functionality that mimics the existing conformation or alters the
conformation in the manner desired. Such modifications may produce
increased binding affinity or improved pharmacokinetic behavior. It
is understood that those knowledgeable in the art of peptide
synthesis can make the following amide bond changes for any amide
bond connecting two amino acids with the expectation that the
resulting peptides could have the same or improved activity:
insertion of alpha-N-methylamides or peptide amide backbone
thioamides, removal of the carbonyl to produce the cognate
secondary amines, replacement of one amino acid with an
aza-aminoacid to produce semicarbazone derivatives, and use of
E-olefins and substituted E-olefins as amide bond surrogates.
Introduction of D-Amino Acids
[0538] Another approach within the scope of the patent is the
introduction of D-alanine, or another D-amino acid, distal or
proximal to the labile peptide bond. In this case it is also
understood to those skilled in the art that such D-amino acid
substitutions can, and at times, must be made, with D-amino acids
whose side chains are not conservative replacements for those of
the L-amino acid being replaced. This is because of the difference
in chirality and hence side-chain orientation, which may result in
the accessing of a previously unexplored region of the binding site
of the target that has moieties of different charge,
hydrophobicity, steric requirements etc. than that serviced by the
side chain of the replaced L-amino acid.
Modifications to Improve Pharmacokinetic or Pharmacodynamic
Properties
[0539] It is also understood that use of the KDR or VEGF/KDR
complex binding polypeptide in a particular application may
necessitate modifications of the peptide or formulations of the
peptide to improve pharmacokinetic and pharmacodynamic behavior. It
is expected that the properties of the peptide may be changed by
attachment of moieties anticipated to bring about the desired
physical or chemical properties. Such moieties may be appended to
the peptide using acids or amines, via amide bonds or urea bonds,
respectively, to the N- or C-terminus of the peptide, or to the
pendant amino group of a suitably located lysine or lysine
derivative, 2,3-diaminopropionic acid, ornithine, or other amino
acid in the peptide that possesses a pendant amine group or a
pendant alkoxyamine or hydrazine group. The moieties introduced may
be groups that are hydrophilic, basic, or nonpolar alkyl or
aromatic groups depending on the peptide of interest and the extant
requirements for modification of its properties.
Glycosylation of Amino Acid Residues
[0540] Yet another modification within the scope of the invention
is to employ glycosylated amino acid residues (e.g., serine,
threonine or asparagine residues), singly or in combination in the
either the binding moiety (or moieties) or the linker moiety or
both. Glycosylation, which may be carried out using standard
conditions, can be used to enhance solubility, alter
pharmacokinetics and pharmacodynamics or to enhance binding via a
specific or non-specific interaction involving the glycosidic
moiety. In another approach glycosylated amino acids such as
O-(2-acetamido-2-deoxy-3,4,6-tri-O-acetyl-.beta.-D-glucopyranosyl)
serine or the analogous threonine derivative (either the D- or
L-amino acids) can be incorporated into the peptide during manual
or automated solid phase peptide synthesis, or in manual or
automated solution phase peptide synthesis. Similarly D- or
L-N.sup..gamma.-(2-acetamido-2-deoxy-3,4,6-tri-
-O-acetyl-.beta.-D-glucopyranosyl)-asparagine can be employed. The
use of amino acids glycosylated on a pendant oxygen, nitrogen or
sulfur function by the agency of suitably functionalized and
activated carbohydrate moieties that can be employed in
glycosylation is anticipated. Such carbohydrate functions could be
monosaccharides, disaccharides or even larger assemblies of
oligosaccharides (Kihlberg, Jan. (2000) Glycopeptide synthesis. In:
Fmoc Solid Phase Peptide Synthesis--A Practical Approach (Chan, W.
C. and White, P. D. Eds) Oxford University Press, New York, N.Y.
Chap. 8, pp 195-213).
[0541] Also anticipated is the appendage of carbohydrate functions
to amino acids by means other than glycosylation via activation of
a leaving group at the anomeric carbon. Linkage of the amino acid
to the glycoside is not limited to the formation of a bond to the
anomeric carbon of the carbohydrate function. Instead, linkage of
the carbohydrate moiety to the amino acid could be through any
suitable, sufficiently reactive oxygen atom, nitrogen atom, carbon
atom or other pendant atom of the carbohydrate function via methods
employed for formation of C-heteroatom, C--C or
heteroatom-heteroatom (examples are S--S, O--N, N--N, P--O, P--N)
bonds known in the art.
Formation of Salts
[0542] It is also within the scope of the invention to form
different salts that may increase the water solubility or the ease
of formulation of these peptides. These may include, but are not
restricted to, N-methylglucamine (meglumine), acetate, oxalates,
ascorbates, etc.
Structural Modifications that Retain Structural Features
[0543] Yet another modification within the scope of the invention
is truncation of cyclic polypeptides. The cyclic nature of many
polypeptides of the invention limits the conformational space
available to the peptide sequence, particularly within the cycle.
Therefore truncation of the peptide by one or more residues distal
or even proximal to the cycle, at either the N-terminal or
C-terminal region may provide truncated peptides with similar or
improved biological activity. A unique sequence of amino acids,
even as small as three amino acids, which is responsible for the
binding activity, may be identified, as noted for RGD peptides
(see, e.g., Plow et al., Blood, 70(1): 110-5 (1987); Oldberg et
al., Journal of Biological Chemistry, 263(36):19433-19436 (1988);
Taub et al., Journal of Biological Chemistry, 264(1):259-65 (1989);
Andrieux et al., Journal of Biological Chemistry, 264(16):9258-65
(1989); and U.S. Pat. No. 5,773,412 and U.S. Pat. No. 5,759,996,
each of which is incorporated herein by reference).
[0544] It has also been shown in the literature that large peptide
cycles can be substantially shortened, eliminating extraneous amino
acids, but substantially including the critical binding residues.
See, U.S. Pat. No. 5,556,939, incorporated by reference herein.
[0545] The shortened cyclic peptides can be formed using disulfide
bonds or amide bonds of suitably located carboxylic acid groups and
amino groups.
[0546] Furthermore, D-amino acids can be added to the peptide
sequence to stabilize turn features (especially in the case of
glycine). In another approach alpha, beta, gamma or delta dipeptide
or turn mimics (such as .alpha., .beta., .gamma., or .delta. turn
mimics), some of which are shown in schematics 1, 2 and 3 as shown
in FIG. 26, can be employed to mimic structural motifs and turn
features in a peptide and simultaneously provide stability from
proteolysis and enhance other properties such as, for example,
conformational stability and solubility (structure 1: Hart et al.,
J. Org. Chem., 64, 2998-2999(1999); structure 2: Hanessian et al.,
"Synthesis of a Versatile Peptidomimetic Scaffold" in Methods in
Molecular Medicine, Vol. 23: Peptidomimetics Protocols, W. M.
Kazmierski, Ed. (Humana Press Inc., Totowa, N.J., 1999), Chapter
10, pp. 161-174; structure 3: WO 01/16135).
Substitution of Disulfide Mimetics
[0547] Also within the scope of the invention is the substitution
of disulfide mimetics for disulfide bonds within the KDR or
VEGF/KDR complex binding peptides of the invention.
[0548] When disulfide-containing peptides are employed in
generating .sup.99mTc-based radiopharmaceuticals, a significant
problem is the presence of the disulfide bond. The integrity of the
disulfide bond is difficult to maintain during procedures designed
to incorporate .sup.99mTc via routes that are reliant upon the
reduction of pertechnetate ion and subsequent incorporation of the
reduced Tc species into substances bearing Tc-specific chelating
groups. This is because the disulfide bond is rather easily reduced
by the reducing agents commonly used in kits devised for one-step
preparation of radiopharmaceuticals. Therefore, the ease with which
the disulfide bond can be reduced during Tc chelation may require
substitution with mimetics of the disulfide bonds. Accordingly,
another modification within the scope of the invention is to
substitute the disulfide moiety with mimetics utilizing the methods
disclosed herein or known to those skilled in the art, while
retaining the activity and other desired properties of the
KDR-binding polypeptides of the invention:
[0549] 1) Oxime Linker
[0550] The oxime moiety has been employed as a linker by
investigators in a number of contexts. Of the most interest is the
work by Mutter et al. (Wahl and Mutter, Tetrahedron Lett.,
37:6861-6864 (1996)). The amino acids 4, containing an aminoalcohol
function, and 5, containing an alkoxyamino function, are
incorporated into the peptide chain, not necessarily at the end of
the peptide chain (FIG. 27). After formation of the peptide the
sidechain protecting groups are removed. The aldehyde group is
unmasked and an oxime linkage is formed.
[0551] 2) Lanthionine Linker
[0552] Lanthionines are cyclic sulfides, wherein the disulfide
linkage (S--S) is replaced by a carbon-sulfur (C--S) linkage. Thus,
the lability to reduction is far lower. Lanthionines have been
prepared by a number of methods since 1971.
Preparation of Lanthionines using Bromoacetylated Peptides
[0553] Lanthionines are readily prepared using known methods. See,
for example, Robey et al., Anal. Biochem., 177:373-377 (1989);
Inman et al., Bioconjugate Chem., 2:458-463 (1991); Ploinsky et
al., Med. Chem., 35:4185-4194 (1992); Mayer et al., "Peptides,
Frontiers of Peptide Science", in Proceedings of the 15.sup.th
American Peptide Symposium, Tam & Kaumaya (Eds.), Jun. 14-19,
1995, Nashville, Term. (Klumer Academic Pub., Boston), pp. 291-292;
Wakao et al., Jpn. Kokai Tokyo Koho, JP 07300452 A2 (1995).
Preparation of peptides using Boc automated peptide synthesis
followed by coupling the peptide terminus with bromoacetic acid
gives bromoacetylated peptides in good yield. Cleavage and
deprotection of the peptides is accomplished using HF/anisole. If
the peptide contains a cysteine group its reactivity can be
controlled with low pH. If the pH of the medium is raised to 6-7
then either polymerization or cyclization of the peptide takes
place. Polymerization is favored at high (100 mg/mL) concentration
whereas cyclization is favored at lower concentrations (1 mg/mL),
e.g., 6 cyclizes to 7 (Scheme 1; FIG. 28).
[0554] Inman et al. demonstrated the use of
N.sup..alpha.-(Boc)-N.sup..eps-
ilon.-[N-(bromoacetyl)-.beta.-alanyl]-L-lysine as a carrier of the
bromoacetyl group that could be employed in Boc peptide synthesis
thus allowing placement of a bromoacetyl bearing moiety anywhere in
a sequence. In preliminary experiments they found that peptides
with 4-6 amino acids separating the bromoacetyl-lysine derivative
from a cysteine tend to cyclize, indicating the potential utility
of this strategy.
Preparation of Lanthionines via Cysteine Thiol Addition to
Acrylamides
[0555] Several variants of this strategy may be implemented.
Resin-bound serine can be employed to prepare the lanthionine ring
on resin either using a bromination-dehydrobromination-thiol
addition sequence or by dehydration with disuccinimidyl carbonate
followed by thiol addition (Ploinsky et al., M. J. Med. Chem.,
35:4185-4194 (1992); Mayer et al., "Peptides, Frontiers of Peptide
Science", in Proceedings of the 15.sup.th American Peptide
Symposium, Tam & Kaumaya (Eds.), Jun. 14-19, 1995, Nashville,
Tenn. (Klumer Academic Pub., Boston), pp. 291-292). Conjugate
addition of thiols to acrylamides has also been amply demonstrated
and a reference to the addition of 2-mercaptoethanol to acrylamide
is provided (Wakao et al., Jpn. Kokai Tokyo Koho, JP 07300452 A2
(1995)).
[0556] 3) Diaryl Ether or Diarylamine Linkage: Diaryl Ether Linkage
From Intramolecular Cyclization of Aryl Boronic Acids and
Tyrosine
[0557] Recently the reaction of arylboronic acids with phenols,
amines and heterocyclic amines in the presence of cupric acetate,
in air, at ambient temperature, in dichloromethane using either
pyridine or triethylamine as a base to provide unsymmetrical diaryl
ethers and the related amines in good yields (as high as 98%) has
been reported. See, Evans et al., Tetrahedron Lett., 39:2937-2940
(1998); Chan et al., Tetrahedron Lett., 39:2933-2936 (1998); Lam et
al., Tetrahedron Lett., 39:2941-2944 (1998). In the case of
N-protected tyrosine derivatives as the phenol component the yields
were also as high as 98%. This demonstrates that amino acid amides
(peptides) are expected to be stable to the transformation and that
yields are high. Precedent for an intramolecular reaction exists in
view of the facile intramolecular cyclizations of peptides to
lactams, intramolecular biaryl ether formation based on the
S.sub.NAr reaction and the generality of intramolecular cyclization
reactions under high dilution conditions or on resin, wherein the
pseudo-dilution effect mimics high dilution conditions.
[0558] 4) Formation of Cyclic Peptides with a Thiazolidine Linkage
via Intramolecular Reaction of Peptide Aldehydes with Cysteine
Moieties
[0559] Another approach that may be employed involves
intramolecular cyclization of suitably located vicinal amino
mercaptan functions (usually derived from placement of a cysteine
at a terminus of the linear sequence or tethered to the sequence
via a side-chain nitrogen of a lysine, for example) and aldehyde
functions to provide thiazolidines that result in the formation of
a bicyclic peptide, one ring of which is that formed by the
residues in the main chain, and the second ring being the
thiazolidine ring. Scheme 2 (FIG. 29) provides an example. The
required aldehyde function can be generated by sodium metaperiodate
cleavage of a suitably located vicinal aminoalcohol function, which
can be present as an unprotected serine tethered to the chain by
appendage to a side chain amino group of a lysine moiety. In some
cases the required aldehyde function is generated by unmasking of a
protected aldehyde derivative at the C-terminus or the N-terminus
of the chain. An example of this strategy is found in: Botti et
al., J. Am. Chem. Soc., 118:10018-10034 (1996).
[0560] 5) Lactams Based on Intramolecular Cyclization of Pendant
Amino Groups with Carboxyl Groups on Resin.
[0561] Macrocyclic peptides have been prepared by lactam formation
by either head to tail or by pendant group cyclization. The basic
strategy is to prepare a fully protected peptide wherein it is
possible to remove selectively an amine protecting group and a
carboxy protecting group. Orthogonal protecting schemes have been
developed. Of those that have been developed the allyl, trityl and
Dde methods have been employed most. See, Mellor et al., "Synthesis
of Modified Peptides", in Fmoc Solid Phase Synthesis: A Practical
Approach, White and Chan (eds) (Oxford University Press, New York,
2000), Chapt. 6, pp. 169-178. The Dde approach is of interest
because it utilizes similar protecting groups for both the
carboxylic acid function (Dmab ester) and the amino group (Dde
group). Both are removed with 2-10% hydrazine in DMF at ambient
temperature. Alternatively, the Dde can be used for the amino group
and the allyl group can be used for the carboxyl.
[0562] A lactam function, available by intramolecular coupling via
standard peptide coupling reagents (such as HATU, PyBOP etc), could
act as a surrogate for the disulfide bond. The Dde/Dmab approach is
shown in FIG. 30.
[0563] Thus, a linear sequence containing, for example, the
Dde-protected lysine and Dmab ester can be prepared on a
Tentagel-based Rink amide resin at low load (.about.0.1-0.2
mmol/g). Deprotection of both functions with hydrazine is then
followed by on-resin cyclization to give the desired products.
[0564] In the allyl approach, shown in FIG. 31, the pendant
carboxyl that is to undergo cyclization is protected as an allyl
ester and the pendant amino group is protected as an alloc group.
On resin, both are selectively unmasked by treatment with palladium
tris-triphenylphosphine in the presence of N-methylmorpholine and
acetic acid in DMF. Residual palladium salts are removed using
sodium diethyldithiocarbamate in the presence of DIEA in DMF,
followed by subsequent washings with DMF. The lactam ring is then
formed employing HATU/HOAt in the presence of N-methylmorpholine.
Other coupling agents can be employed as described above. The
processing of the peptide is then carried out as described above to
provide the desired peptide lactam.
[0565] Subsequently cleavage from resin and purification can also
be carried out. For functionalization of the N-terminus of the
peptide, it is understood that amino acids, such as
trans-4-(iV-Dde)methylaminocycloh- exane carboxylic acid,
trans-4-(iV-Dde)methylaminobenzoic acid, or their alloc congeners
can be employed. Yet another approach is to employ the safety catch
method to intramolecular lactam formation during cleavage from the
resin.
[0566] Thus, a linear sequence containing, for example, the
Dde-protected lysine and Dmab ester may be prepared on a
Tentagel-based Rink amide resin at low load (.about.0.1-0.2
mmol/g). Deprotection of both functions with hydrazine is then
followed by on-resin cyclization to give the desired products.
Subsequently cleavage from resin and purification may also be
carried out. For functionalization of the N-terminus of the peptide
it is understood that diamino acids such as
trans-4-(iv-Dde)methylaminocyclohexane carboxylic acid or
trans-4-(iv-Dde)methylamino benzoic acid would be required. An
alternative scenario is to employ the safety catch method to
intramolecular lactam formation during cleavage from the resin.
[0567] 6) Cyclic Peptides Based on Olefin Metathesis
[0568] The Grubbs reaction (FIG. 32) involves the
metathesis/cyclization of olefin bonds and is illustrated as shown
below. See, Schuster et al., Angewandte. Chem. Int. Edn Engl.,
36:2036-2056 (1997); Miller et al., J. Am. Chem. Soc.,
118:9606-9614 (1996).
[0569] It is readily seen (FIG. 32) that if the starting material
is a diolefin (16) that the resulting product will be cyclic
compound 17. The reaction has in fact been applied to creation of
cycles from olefin-functionalized peptides. See, e.g.,
Pernerstorfer et al., Chem. Commun., 20:1949-50 (1997); see, also,
Covalent capture and stabilization of cylindrical .beta.-sheet
peptide assemblies, Clark et al., Chem. Eur. J., 5(2):782-792
(1999); Highly efficient synthesis of covalently cross-linked
peptide helices by ring-closing metathesis, Blackwell et al.,
Angew. Chem., Int. Ed., 37(23):3281-3284 (1998); Synthesis of novel
cyclic protease inhibitors using Grubbs olefin metathesis, Ripka et
al., Med. Chem. Lett., 8(4):357-360 (1998); Application of
Ring-Closing Metathesis to the Synthesis of Rigidified Amino Acids
and Peptides, Miller et al., J. Am. Chem. Soc., 118(40):9606-9614
(1996); Supramolecular Design by Covalent Capture, Design of a
Peptide Cylinder via Hydrogen-Bond-Promoted Intermolecular Olefin
Metathesis, Clark et al., J. Am. Chem. Soc., 117(49):12364-12365
(1995); Synthesis of Conformationally Restricted Amino Acids and
Peptides Employing Olefin Metathesis, Miller et al., J. Am. Chem.
Soc., 117(21):5855-5856 (1995). One can prepare either C-allylated
amino acids or possibly N-allylated amino acids and employ them in
this reaction in order to prepare carba-bridged cyclic peptides as
surrogates for disulfide bond containing peptides. One may also
prepare novel compounds with olefinic groups. Functionalization of
the tyrosine hydroxyl with an olefin-containing tether is one
option. The lysine .epsilon.-amino group is another option with
appendage of the olefin-containing unit as part of an acylating
moiety, for example. If instead the lysine side chain amino group
is alkylated with an olefin containing tether, it can still
function as a point of attachment for a reporter as well. The use
of 5-pentenoic acid as an acylating agent for the lysine,
ornithine, or diaminopropionic side chain amino groups is another
possibility. The length of the olefin-containing tether can also be
varied in order to explore structure activity relationships.
Manipulation of Peptide Sequences
[0570] Other modifications within the scope of the invention
include common manipulations of peptide sequences, which can be
expected to yield peptides with similar or improved biological
properties. These include amino acid translocations (swapping amino
acids in the sequence), use of retroinverso peptides in place of
the original sequence or a modified original sequence, peptoids and
retro-inverso peptoid sequences. Structures wherein specific
residues are peptoid instead of peptidic, which result in hybrid
molecules, neither completely peptidic nor completely peptoid, are
anticipated as well.
Linkers
[0571] Additional modifications within the scope of the invention
include introduction of linkers or spacers between the targeting
sequence of the KDR or VEGF/KDR complex binding peptide and the
detectable label or therapeutic agent. Use of such linkers/spacers
may improve the relevant properties of the binding peptide (e.g.,
increase serum stability, etc.). These linkers may include, but are
not restricted to, substituted or unsubstituted alkyl chains,
polyethylene glycol derivatives, amino acid spacers, sugars, or
aliphatic or aromatic spacers common in the art. Furthermore,
linkers that are combinations of the moieties described above, can
also be employed to confer special advantage to the properties of
the peptide. Lipid molecules with linkers may be attached to allow
formulation of ultrasound bubbles, liposomes or other aggregation
based constructs. Such constructs could be employed as agents for
targeting and delivery of a diagnostic reporter, a therapeutic
agent (e.g., a chemical "warhead" for therapy) or a combination of
these.
Multimeric Constructs of KDR and VEGF/KDR Complex Binding
Polypeptides
[0572] Constructs employing dimers, multimers or polymers of one or
more VEGF or VEGF/KDR complex binding polypeptides of the invention
are also contemplated. Indeed, there is ample literature evidence
that the binding of low potency peptides or small molecules can be
substantially increased by the formation of dimers and multimers.
Thus, dimeric and multimeric constructs (both homogeneous and
heterogeneous) are within the scope of the instant invention.
Indeed, as discussed in more detail in the Examples, it is within
the scope of the present invention to include multiple KDR or
VEGF/KDR complex binding polypeptide sequences in a dimeric or
multimeric construct. Moreover, as shown in Example 4 infra, these
constructs can exhibit improved binding compared to a monomeric
construct. The polypeptide sequences in the dimeric constructs may
be attached at their N- or C-terminus or the N-epsilon nitrogen of
a suitably placed lysine moiety (or another function bearing a
selectively derivatizable group such as a pendant oxyamino or other
nucleophilic group), or may be joined together via one or more
linkers employing the appropriate attachment chemistry. This
coupling chemistry may include amide, urea, thiourea, oxime, or
aminoacetylamide (from chloro- or bromoacetamide derivatives, but
is not so limited. For example, any of the following methods may be
utilized to prepare dimeric or multimeric constructs of KDR or
VEGF/KDR complex binding polypeptides of the invention. Modified
polypeptides and peptide-derived molecules are shown, for example,
in FIGS. 79A-79G.
Method A
[0573] Fully protected KDR-binding peptides can be built up on
Ellman-type safety catch resin using automated or manual Fmoc
peptide synthesis protocols. Backes et al., J. Am. Chem. Soc.,
118(12):3055-56 (1996). Separately, using standard methods known in
the art of peptide synthesis, a di-lysine derivative can be
constructed on 2-chlorotrityl resin. See, for example, Fields et
al, "Principles and Practice of Solid Phase Synthesis" in Synthetic
Peptides, A Users Guide, Grant, Ed. (W.H. Freeman Co., New York,
1992), Chapt. 3, pp. 77-183; Barlos et al., "Convergent Peptide
Synthesis" in Fmoc Solid Phase Peptide Synthesis, Chan, W. C. and
White, P. D., Eds. (Oxford University Press, New York, 2000),
Chapt. 9, pp. 215-228. Liberation of this from the 2-chlorotrityl
resin without removal of the side-chain protecting groups,
activation of the carboxyl group and coupling to any
amine-functionalized labeling group provides a di-lysine derivative
whose protected pendant nitrogen atoms may be unmasked to give two
free amino groups. The prior-mentioned safety-catch resin is
activated and the desired N-deprotected labeling
group-functionalized di-lysine derivative is added to the activated
safety-catch resin. The pendant amino groups are acylated by the
carboxy-terminus of the safety-catch resin-bound peptide, which is
now detached from the resin and an integral part of the di-lysine
structure. An excess of the safety-catch resin-bound peptide can be
employed to insure complete reaction of the amino groups of the
di-lysine construct. Optimization of the ratio of the reacting
partners in this scheme optimizes the yield. The protecting groups
on the KDR-binding peptides are removed employing trifluoroacetic
acid based cleavage protocols.
[0574] The synthesis of dimeric and multimeric constructs wherein
two or more KDR-binding peptides are present in one construct is
easily accomplished. Orthogonal protection schemes (such as an
allyloxycarbonyl group on one nitrogen and an Fmoc group on the
other, or employing the Fmoc group in conjunction with the iV-Dde
protecting group on the other, for example) can be employed to
distinguish the pendant nitrogen atoms of the di-lysine derivatives
described above. Unmasking of one of the amino groups, followed by
reaction of the resulting product with an activated safety-catch
resin-bound KDR-binding peptide as described above, provides a
di-lysine construct having a single KDR-binding peptide attached.
Removal of the second protecting group unmasks the remaining
nitrogen. See, also, Mellor et al., "Synthesis of Modified
Peptides" in Fmoc Solid Phase Peptide Synthesis, Chan, W. C. and
White, P. D., Eds. (Oxford University Press, New York, 2000),
Chapt. 6, pp. 169-176. The resulting product may be reacted with a
second safety-catch resin bearing another KDR-binding peptide to
provide a fully-protected homodimeric construct, which after
removal of protecting groups with trifluoroacetic acid, provides
the desired material.
Method B
[0575] A KDR-binding peptide is assembled on a Rink-amide resin by
automated or manual peptide coupling methods, usually employing
Fmoc peptide synthesis protocols. The peptide may possess a
C-terminus or N-terminus functionalized with a linker or a
linker-labeling group construct that may possess an additional
nucleophilic group such as the .epsilon.-amino group of a lysine
moiety, for example. Cleavage of the protecting groups is
accomplished employing trifluoroacetic acid with appropriate
modifiers depending on the nature of the peptide. The fully
deprotected peptide is then reacted with a large excess of a
bifunctional electrophile such as the commercially available
glutaric acid bis-N-hydroxysuccinimide ester (Tyger Scientific,
Inc.). The resulting monoamidated, mono-N-hydroxysuccinimidyl ester
of glutaric acid is then treated with an additional equivalent of
the same peptide, or an equivalent of a different KDR-binding
peptide. Purification of the resulting material by HPLC affords the
desired homodimeric construct bearing a suitable labeling
group.
Method C
[0576] A modular scheme can be employed to prepare dimeric or
higher multimeric constructs bearing suitable labeling groups as
defined above. In a simple illustration, fmoc-lysine(iV-Dde) Rink
amide resin is treated with piperidine to remove the fmoc moiety.
Then a labeling function, such as biotin, 5-carboxyfluorescein or
N,N-Dimethyl-Gly-Ser(O-t-Bu)-Cys(Acm)-- Gly-OH is coupled to the
nitrogen atom. The resin is next treated with hydrazine to remove
the iV-Dde group. After thorough washing, the resin is treated with
cyanuric chloride and a hindered base such as diisopropylethylamine
in a suitable solvent such as DMF, NMP or dichloromethane to
provide a monofunctionalized dichlorotriazine bound to the resin.
Subsequent successive displacement of the remaining chlorine atoms
by two equivalents of a KDR-binding peptide provides a resin-bound
homo-dimeric labeling group-functionalized construct. Falorni et
al., Tetrahedron Lett., 39(41):7607-7610 (1998); Johnson et al.,
Tetrahedron Lett., 54(16):4097-4106 (1998); Stankova et al., Mol.
Diversity, 2(1/2):75-80 (1996). The incoming peptides may be
protected or unprotected as the situation warrants. Cleavage of
protecting groups is accomplished employing trifluoroacetic
acid-based deprotection reagents as described above, and the
desired materials are purified by high performance liquid
chromatography.
[0577] It is understood that in each of these methods lysine
derivatives may be serially employed to increase the multiplicity
of the multimers. The use of related, more rigid molecules bearing
the requisite number of masked, or orthogonally protected nitrogen
atoms to act as scaffolds to vary the distance between the
KDR-binding peptides, to increase the rigidity of the construct (by
constraining the motion and relative positions of the KDR-binding
peptides relative to each other and the reporter) is entirely
within the scope of methods A-C and all other methods described
herein. The references cited above are incorporated by reference
herein in their entirety.
[0578] Uses for KDR or VEGF/KDR Complex Binding Polypeptides:
[0579] The KDR or VEGF/KDR complex binding moieties according to
this invention will be extremely useful for detection and/or
imaging of KDR or VEGF/KDR complex in vitro or in vivo, and
particularly for detection and/or imaging of sites of angiogenesis,
in which VEGF and KDR are intimately involved, as explained above.
Any suitable method of assaying or imaging KDR or VEGF/KDR complex
may be employed. The KDR and VEGF/KDR complex binding moieties of
the invention also have utility in the treatment of a variety of
disease states, including those associated with angiogenesis or
those associated with a number of pathogens. The KDR and VEGF/KDR
complex binding moieties of the invention may themselves be used as
therapeutics or may be used to localize one or more therapeutic
agents (e.g., a chemotherapeutic, a radiotherapeutic, genetic
material, etc.) to KDR expressing cells, including sites of
angiogenesis.
[0580] In Vitro:
[0581] For detection of KDR or VEGF/KDR complex in solution, a
binding polypeptide according to the invention can be detectably
labeled, e.g., fluorescently labeled, enzymatically labeled, or
labeled with a radioactive or paramagnetic metal, then contacted
with the solution, and thereafter formation of a complex between
the binding polypeptide and the KDR or VEGF/KDR complex target can
be detected. As an example, a fluorescently labeled KDR or VEGF/KDR
complex binding peptide may be used for in vitro KDR or VEGF/KDR
complex detection assays, wherein the peptide is added to a
solution to be tested for KDR or VEGF/KDR complex under conditions
allowing binding to occur. The complex between the fluorescently
labeled KDR or VEGF/KDR complex binding peptide and KDR or VEGF/KDR
complex target can be detected and quantified by measuring the
increased fluorescence polarization arising from the KDR or
VEGF/KDR complex-bound peptide relative to that of the free
peptide.
[0582] Alternatively, a sandwich-type "ELISA" assay may be used,
wherein a KDR or VEGF/KDR complex binding polypeptide is
immobilized on a solid support such as a plastic tube or well, then
the solution suspected of containing KDR or VEGF/KDR complex target
is contacted with the immobilized binding moiety, non-binding
materials are washed away, and complexed polypeptide is detected
using a suitable detection reagent, such as a monoclonal antibody
recognizing KDR or VEGF/KDR complex. The monoclonal antibody is
detectable by conventional means known in the art, including being
detectably labeled, e.g., radiolabeled, conjugated with an enzyme
such as horseradish peroxidase and the like, or fluorescently
labeled, etc.
[0583] For detection or purification of soluble KDR or VEGF/KDR
complex in or from a solution, binding polypeptides of the
invention can be immobilized on a solid substrate such as a
chromatographic support or other matrix material, then the
immobilized binder can be loaded or contacted with the solution
under conditions suitable for formation of a binding
polypeptide:KDR complex or binding polypeptide:VEGF/KDR complex.
The non-binding portion of the solution can be removed and the
complex may be detected, e.g., using an anti-KDR or anti-VEGF/KDR
complex antibody, or an anti-binding polypeptide antibody, or the
KDR or VEGF/KDR complex target may be released from the binding
moiety at appropriate elution conditions.
[0584] The biology of angiogenesis and the roles of VEGF and KDR in
initiating and maintaining it have been investigated by many
researchers and continues to be an active field for research and
development. In furtherance of such research and development, a
method of purifying bulk amounts of KDR or VEGF/KDR complex in pure
form is desirable, and the binding polypeptides according to this
invention are especially useful for that purpose, using the general
purification methodology described above.
[0585] In Vivo:
Diagnostic Imaging
[0586] A particularly preferred use for the polypeptides according
to the present invention is for creating visually readable images
of KDR expressing tissue, such as, for example, neoplastic tumors,
which require angiogenesis for survival and metastasis, or other
sites of angiogenic activity. The KDR and VEGF/KDR complex binding
polypeptides disclosed herein may be converted to imaging reagents
by conjugating the polypeptides with a label appropriate for
diagnostic detection, optionally via a linker. Preferably, a
peptide exhibiting much greater specificity for KDR or VEGF/KDR
complex than for other serum proteins is conjugated or linked to a
label appropriate for the detection methodology to be employed. For
example, the KDR or VEGF/KDR complex binding polypeptide may be
conjugated with or without a linker to a paramagnetic chelate
suitable for magnetic resonance imaging (MRI), with a radiolabel
suitable for x-ray, PET or scintigrapic imaging (including a
chelator for a radioactive metal), with an ultrasound contrast
agent (e.g., a stabilized microbubble, a ultrasound contrast agent,
a microsphere or what has been referred to as a gas filled
"liposome") suitable for ultrasound detection, or with an optical
imaging dye.
[0587] Suitable linkers can be substituted or unsubstituted alkyl
chains, amino acid chains (e.g., polyglycine), polyethylene
glycols, polyamides, and other simple polymeric linkers known in
the art.
[0588] In general, the technique of using a detectably labeled KDR
or VEGF/KDR complex binding moiety is based on the premise that the
label generates a signal that is detectable outside the patient's
body. For example, when the detectably labeled KDR or VEGF/KDR
complex binding moiety is administered to the patient in which it
is desirable to detect, e.g., angiogenesis, the high affinity of
the KDR or VEGF/KDR complex binding moiety for KDR or VEGF/KDR
complex causes the binding moiety to bind to the site of
angiogenesis and accumulate label at the site of angiogenesis.
Sufficient time is allowed for the labeled binding moiety to
localize at the site of angiogenesis. The signal generated by the
labeled peptide is detected by a scanning device that will vary
according to the type of label used, and the signal is then
converted to an image of the site of angiogenesis.
[0589] In another embodiment, rather than directly labeling a KDR
or VEGF/KDR complex binding polypeptide with a detectable label or
radiotherapeutic construct, the peptide(s) of the invention can be
conjugated with, for example, avidin, biotin, or an antibody or
antibody fragment that will bind the detectable label or
radiotherapeutic. For example, one or more KDR-binding peptides can
be conjugated to streptavidin (potentially generating multivalent
binding) for in vivo binding to KDR-expressing cells. After the
unbound targeting construct has cleared from the body, a
biotinylated detectable label or radiotherapeutic construct (e.g.,
a chelate molecule complexed with a radioactive metal) can be
infused and will rapidly concentrate at the site where the
targeting construct is bound. This approach in some situations can
reduce the time required after administering the detectable label
until imaging can take place. It can also increase signal to noise
ratio in the target site, and decrease the dose of the detectable
label or radiotherapeutic construct required. This is particularly
useful when a radioactive label or radiotherapeutic is used as the
dose of radiation that is delivered to normal but
radiation-sensitive sites in the body, such as bone-marrow,
kidneys, and liver is decreased. This approach, sometimes referred
to as pre-targeting or two-step, or three-step approaches was
reviewed by S. F. Rosebrough in Q. J. Nucl. Med., 40:234-251
(1996), which is incorporated by reference herein.
[0590] A. Magnetic Resonance Imaging (MRI)
[0591] The KDR or VEGF/KDR complex binding moieties of the present
invention can advantageously be conjugated with one or more
paramagnetic metal chelates in order to form a contrast agent for
use in MRI. Preferred paramagnetic metal ions have atomic numbers
21-29, 42, 44, or 57-83. This includes ions of the transition metal
or lanthanide series that have one, and more preferably five or
more, unpaired electrons and a magnetic moment of at least 1.7 Bohr
magneton. Preferred paramagnetic metals include, but are not
limited to, chromium (III), manganese (II), manganese (III), iron
(II), iron (III), cobalt (II), nickel (II), copper (II),
praseodymium (III), neodymium (III), samarium (III), gadolinium
(III), terbium (III), dysprosium (III), holmium (III), erbium
(III), europium (III) and ytterbium (III), chromium (III), iron
(III), and gadolinium (III). The trivalent cation, Gd.sup.3+, is
particularly preferred for MRI contrast agents, due to its high
relaxivity and low toxicity, with the further advantage that it
exists in only one biologically accessible oxidation state, which
minimizes undesired metabolysis of the metal by a patient. Another
useful metal is Cr.sup.3+, which is relatively inexpensive. Gd(III)
chelates have been used for clinical and radiologic MR applications
since 1988, and approximately 30% of MR exams currently employ a
gadolinium-based contrast agent. Additionally, heteromultimers of
the present invention also can be conjugated with one or more
superparamagnetic particles.
[0592] The practitioner will select a metal according to dose
required to detect angiogenesis and considering other factors such
as toxicity of the metal to the subject (Tweedle et al., Magnetic
Resonance Imaging (2nd ed.), vol. 1, Partain et al., Eds. (W. B.
Saunders Co. 1988), pp. 796-797). Generally, the desired dose for
an individual metal will be proportional to its relaxivity,
modified by the biodistribution, pharmacokinetics and metabolism of
the metal.
[0593] The paramagnetic metal chelator(s) is a molecule having one
or more polar groups that act as a ligand for, and complex with, a
paramagnetic metal. Suitable chelators are known in the art and
include acids with methylene phosphonic acid groups, methylene
carbohydroxamine acid groups, carboxyethylidene groups, or
carboxymethylene groups. Examples of chelators include, but are not
limited to, diethylenetriaminepentaacetic acid (DTPA),
1,4,7,10-tetraazacyclo-tetradecane-1,4,7,10-tetraacetic acid
(DOTA), 1-substituted
1,4,7,-tricarboxymethyl-1,4,7,10-teraazacyclododeca- ne (DO3A),
ethylenediaminetetraacetic acid (EDTA), and
1,4,8,11-tetra-azacyclotetradecane-1,4,8,11-tetraacetic acid
(TETA). Additional chelating ligands are ethylene
bis-(2-hydroxy-phenylglycine) (EHPG), and derivatives thereof,
including 5-Cl-EHPG, 5Br-EHPG, 5-Me-EHPG, 5t-Bu-EHPG, and 5
sec-Bu-EHPG; benzodiethylenetriamine pentaacetic acid (benzo-DTPA)
and derivatives thereof, including dibenzo-DTPA, phenyl-DTPA,
diphenyl-DTPA, benzyl-DTPA, and dibenzyl DTPA; bis-2
(hydroxybenzyl)-ethylene-diaminediacetic acid (HBED) and
derivatives thereof; the class of macrocyclic compounds, which
contain at least 3 carbon atoms, more preferably at least 6, and at
least two heteroatoms (O and/or N), which macrocyclic compounds can
consist of one ring, or two or three rings joined together at the
hetero ring elements, e.g., benzo-DOTA, dibenzo-DOTA, and
benzo-NOTA, where NOTA is 1,4,7-triazacyclononane N,N',N"-triacetic
acid, benzo-TETA, benzo-DOTMA, where DOTMA is
1,4,7,10-tetraazacyclotetradecane-1,4,7, 10-tetra(methyl
tetraacetic acid), and benzo-TETMA, where TETMA is
1,4,8,11-tetraazacyclotetradecane-1,4,8,11-(methyl tetraacetic
acid); derivatives of 1,3-propylene-diaminetetraacetic acid (PDTA)
and triethylenetetraaminehexaacetic acid (TTHA); derivatives of
1,5,10-N,N',N"-tris(2,3-dihydroxybenzoyl)-tricatecholate (LICAM);
and 1,3,5-N,N',N"-tris(2,3-dihydroxybenzoyl) aminomethylbenzene
(MECAM). A preferred chelator for use in the present invention is
DTPA, and the use of DO3A is particularly preferred. Examples of
representative chelators and chelating groups contemplated by the
present invention are described in WO 98/18496, WO 86/06605, WO
91/03200, WO 95/28179, WO 96/23526, WO 97/36619, PCT/US98/01473,
PCT/US98/20182, and U.S. Pat. No. 4,899,755, U.S. Pat. No.
5,474,756, U.S. Pat. No. 5,846,519 and U.S. Pat. No. 6,143,274, all
of which are hereby incorporated by reference.
[0594] In accordance with the present invention, the chelator of
the MRI contrast agent is coupled to the KDR or VEGF/KDR complex
binding polypeptide. The positioning of the chelate(s) should be
selected so as not to interfere with the binding affinity or
specificity of the KDR or VEGF/KDR complex binding polypeptide.
Preferably, the chelate(s) will be appended either to the
N-terminus or the C-terminus, however the chelate(s) may also be
attached anywhere within the sequence. In preferred embodiments, a
chelator having a free central carboxylic acid group (e.g.,
DTPA-Asp(.beta.-COOH)-)OtBu) makes it easy to attach at the
N-terminus of the peptide by formation of an amide bond. The
chelate(s) can also be attached at the C-terminus with the aid of a
linker. Alternatively, isothiocyanate conjugation chemistry can be
employed as a way of linking the appropriate isothiocyanate group
bearing DTPA to a free amino group anywhere within the peptide
sequence.
[0595] In general, the KDR or VEGF/KDR complex binding moiety can
be bound directly or covalently to the metal chelator (or other
detectable label), or it may be coupled or conjugated to the metal
chelator using a linker, which may be, without limitation, amide,
urea, acetal, ketal, double ester, carbonyl, carbamate, thiourea,
sulfone, thioester, ester, ether, disulfide, lactone, imine,
phosphoryl, or phosphodiester linkages; substituted or
unsubstituted saturated or unsaturated alkyl chains; linear,
branched, or cyclic amino acid chains of a single amino acid or
different amino acids (e.g., extensions of the N- or C-terminus of
the KDR or VEGF/KDR complex binding moiety); derivatized or
underivatized polyethylene glycol, polyoxyethylene, or
polyvinylpyridine chains; substituted or unsubstituted polyamide
chains; derivatized or underivatized polyamine, polyester,
polyethylenimine, polyacrylate, poly(vinyl alcohol), polyglycerol,
or oligosaccharide (e.g., dextran) chains; alternating block
copolymers; malonic, succinic, glutaric, adipic and pimelic acids;
caproic acid; simple diamines and dialcohols; any of the other
linkers disclosed herein; or any other simple polymeric linkers
known in the art (see, e.g., WO 98/18497, WO 98/18496). Preferably
the molecular weight of the linker can be tightly controlled. The
molecular weights can range in size from less than 100 to greater
than 1000. Preferably the molecular weight of the linker is less
than 100. In addition, it may be desirable to utilize a linker that
is biodegradable in vivo to provide efficient routes of excretion
for the imaging reagents of the present invention. Depending on
their location within the linker, such biodegradable
functionalities can include ester, double ester, amide,
phosphoester, ether, acetal, and ketal functionalities.
[0596] In general, known methods can be used to couple the metal
chelate(s) and the KDR or VEGF/KDR complex binding moiety using
linkers. See, e.g., WO 95/28967, WO 98/18496, WO 98/18497 and
discussion therein. The KDR or VEGF/KDR complex binding moiety can
be linked through its N- or C-terminus via an amide bond, for
example, to a metal coordinating backbone nitrogen of a metal
chelate or to an acetate arm of the metal chelate itself. The
present invention contemplates linking of the chelate on any
position, provided the metal chelate retains the ability to bind
the metal tightly in order to minimize toxicity. Similarly, the KDR
or VEGF/KDR complex binding moiety may be modified or elongated in
order to generate a locus for attachment to a metal chelate,
provided such modification or elongation does not eliminate its
ability to bind KDR or VEGF/KDR complex.
[0597] MRI contrast reagents prepared according to the disclosures
herein may be used in the same manner as conventional MRI contrast
reagents. When imaging a site of angiogenesis, certain MR
techniques and pulse sequences may be preferred to enhance the
contrast of the site to the background blood and tissues. These
techniques include (but are not limited to), for example, black
blood angiography sequences that seek to make blood dark, such as
fast spin echo sequences (see, e.g., Alexander et al., Magnetic
Resonance in Medicine, 40(2): 298-310 (1998)) and flow-spoiled
gradient echo sequences (see, e.g., Edelman et al., Radiology,
177(1): 45-50 (1990)). These methods also include flow independent
techniques that enhance the difference in contrast, such as
inversion-recovery prepared or saturation-recovery prepared
sequences that will increase the contrast between angiogenic tumor
and background tissues. Finally, magnetization transfer
preparations may also improve contrast with these agents (see,
e.g., Goodrich et al., Investigative Radiology, 31(6): 323-32
(1996)).
[0598] The labeled reagent is administered to the patient in the
form of an injectable composition. The method of administering the
MRI contrast agent is preferably parenterally, meaning
intravenously, intraarterially, intrathecally, interstitially, or
intracavitarilly. For imaging active angiogenesis, intravenous or
intraarterial administration is preferred. For MRI, it is
contemplated that the subject will receive a dosage of contrast
agent sufficient to enhance the MR signal at the site of
angiogenesis at least 10%. After injection with the KDR or VEGF/KDR
complex binding moiety-containing MRI reagent, the patient is
scanned in the MRI machine to determine the location of any sites
of angiogenesis. In therapeutic settings, upon angiogenesis (e.g.,
tumor) localization, a tumorcidal agent or anti-angiogenic agent
(e.g., inhibitors of VEGF) can be immediately administered, if
necessary, and the patient can be subsequently scanned to visualize
tumor regression or arrest of angiogenesis.
[0599] B. Ultrasound Imaging
[0600] When ultrasound is transmitted through a substance, the
acoustic properties of the substance will depend upon the velocity
of the transmissions and the density of the substance. Changes in
the acoustic properties will be most prominent at the interface of
different substances (solids, liquids, gases). Ultrasound contrast
agents are intense sound wave reflectors because of the acoustic
differences between the agent and the surrounding tissue. Gas
containing or gas generating ultrasound contrast agents are
particularly useful because of the acoustic difference between
liquid (e.g., blood) and the gas-containing or gas generating
ultrasound contrast agent. Because of their size, ultrasound
contrast agents comprising microbubbles, ultrasound contrast
agents, and the like may remain for a longer time in the blood
stream after injection than other detectable moieties; a targeted
KDR or VEGF/KDR complex-specific ultrasound agent therefore may
demonstrate superior imaging of sites of angiogenesis.
[0601] In this aspect of the invention, the KDR or VEGF/KDR complex
binding moiety may be linked to a material that is useful for
ultrasound imaging. For example, the KDR or VEGF/KDR complex
binding polypeptides may be linked to materials employed to form
vesicles (e.g., microbubbles, ultrasound contrast agents,
microspheres, etc.), or emulsions containing a liquid or gas that
functions as the detectable label (e.g., an echogenic gas or
material capable of generating an echogenic gas). Materials for the
preparation of such vesicles include surfactants, lipids,
sphingolipids, oligolipids, phospholipids, proteins, polypeptides,
carbohydrates, and synthetic or natural polymeric materials. See,
e.g., WO 98/53857, WO 98/18498, WO 98/18495, WO 98/18497, WO
98/18496, and WO 98/18501, incorporated herein by reference in
their entirety.
[0602] For contrast agents comprising suspensions of stabilized
microbubbles (a preferred embodiment), phospholipids, and
particularly saturated phospholipids are preferred. The preferred
gas-filled microbubbles of the invention can be prepared by means
known in the art, such as, for example, by a method described in
any one of the following patents: EP 554213, U.S. Pat. No.
5,413,774, U.S. Pat. No. 5,578,292, EP 744962, EP 682530, U.S. Pat.
No. 5,556,610, U.S. Pat. No. 5,846,518, U.S. Pat. No. 6,183,725, EP
474833, U.S. Pat. No. 5,271,928, U.S. Pat. No. 5,380,519, U.S. Pat.
No. 5,531,980, U.S. Pat. No. 5,567,414, U.S. Pat. No. 5,658,551,
U.S. Pat. No. 5,643,553, U.S. Pat. No. 5,911,972, U.S. Pat. No.
6,110,443, U.S. Pat. No. 6,136,293, EP 619743, U.S. Pat. No.
5,445,813, U.S. Pat. No. 5,597,549, U.S. Pat. No. 5,686,060, U.S.
Pat. No. 6,187,288, and U.S. Pat. No. 5,908,610, which are
incorporated by reference herein in their entirety. In a preferred
embodiment, at least one of the phospholipid moieties has the
structure 18 or 19 (FIG. 33) and described in U.S. Pat. No.
5,686,060, which is herein incorporated by reference. In ultrasound
applications the contrast agents formed by phospholipid stabilized
microbubbles can be administered, for example, in doses such that
the amount of phospholipid injected is in the range 0.1 to 200
.mu.g/kg body weight, preferably from about 0.1 to 30 .mu.g/kg.
[0603] Examples of suitable phospholipids include esters of
glycerol with one or two molecules of fatty acids (the same or
different) and phosphoric acid, wherein the phosphoric acid residue
is in turn bonded to a hydrophilic group, such as choline, serine,
inositol, glycerol, ethanolamine, and the like groups. Fatty acids
present in the phospholipids are in general long chain aliphatic
acids, typically containing from 12 to 24 carbon atoms, preferably
from 14 to 22, that may be saturated or may contain one or more
unsaturations. Examples of suitable fatty acids are lauric acid,
myristic acid, palmitic acid, stearic acid, arachidic acid, behenic
acid, oleic acid, linoleic acid, and linolenic acid. Mono esters of
phospholipid are also known in the art as the "lyso" forms of the
phospholipids.
[0604] Further examples of phospholipids are phosphatidic acids,
i.e., the diesters of glycerol-phosphoric acid with fatty acids,
sphingomyelins, i.e., those phosphatidylcholine analogs where the
residue of glycerol diester with fatty acids is replaced by a
ceramide chain, cardiolipins, i.e. the esters of
1,3-diphosphatidylglycerol with a fatty acid, gangliosides,
cerebrosides, etc. As used herein, the term phospholipids includes
either naturally occurring, semisynthetic or synthetically prepared
products that can be employed either singularly or as mixtures.
Examples of naturally occurring phospholipids are natural lecithins
(phosphatidylcholine (PC) derivatives) such as, typically, soya
bean or egg yolk lecithins.
[0605] Examples of semisynthetic phospholipids are the partially or
fully hydrogenated derivatives of the naturally occurring
lecithins.
[0606] Examples of synthetic phospholipids are e.g.,
dilauryloyl-phosphatidylcholine ("DLPC"),
dimyristoylphosphatidylcholine ("DMPC"),
dipalmitoyl-phosphatidylcholine ("DPPC"),
diarachidoylphosphatidylcholine ("DAPC"),
distearoyl-phosphatidylcholine ("DSPC"),
1-myristoyl-2-palmitoylphosphatidylcholine ("MPPC"),
1-palmitoyl-2-myristoylphosphatidylcholine ("PMPC"),
1-palmitoyl-2-stearoylphosphatid-ylcholine ("PSPC"),
1-stearoyl-2-palmitoyl-phosphatidylcholine ("SPPC"),
dioleoylphosphatidylycholine ("DOPC"), 1,2
Distearoyl-sn-glycero-3-Ethylp- hosphocholine (Ethyl-DSPC),
dilauryloyl-phosphatidylglycerol ("DLPG") and its alkali metal
salts, diarachidoylphosphatidylglycerol ("DAPG") and its alkali
metal salts, dimyristoylphosphatidylglycerol ("DMPG") and its
alkali metal salts, dipalmitoyl-phosphatidylglycerol ("DPPG") and
its alkali metal salts, distearolyphosphatidylglycerol ("DSPG") and
its alkali metal salts, dioleoylphosphatidylglycerol ("DOPG") and
its alkali metal salts, dimyristoyl phosphatidic acid ("DMPA") and
its alkali metal salts, dipalmitoyl phosphatidic acid ("DPPA") and
its alkali metal salts, distearoyl phosphatidic acid ("DSPA"),
diarachidoyl phosphatidic acid ("DAPA") and its alkali metal salts,
dimyristoyl phosphatidyl-ethanolamin- e ("DMPE"), dipalmitoyl
phosphatidylethanolamine ("DPPE"), distearoyl
phosphatidyl-ethanolamine ("DSPE"), dimyristoyl phosphatidylserine
("DMPS"), diarachidoyl phosphatidylserine ("DAPS"), dipalmitoyl
phosphatidylserine ("DPPS"), distearoylphosphatidylserine ("DSPS"),
dioleoylphosphatidylserine ("DOPS"), dipalmitoyl sphingomyelin
("DPSP"), and distearoyl sphingomyelin ("DSSP").
[0607] Other preferred phospholipids include
dipalmitoylphosphatidylcholin- e, dipalmitoylphosphatidic acid and
dipalmitoylphosphatidylserine. The compositions also may contain
PEG-4000 and/or palmitic acid. Any of the gases disclosed herein or
known to the skilled artisan may be employed; however, inert gases,
such as SF.sub.6 or fluorocarbons like CF.sub.4, C.sub.3F.sub.8 and
C.sub.4F.sub.10, are preferred.
[0608] The preferred microbubble suspensions of the present
invention may be prepared from phospholipids using known processes
such as a freeze-drying or spray-drying solutions of the crude
phospholipids in a suitable solvent or using the processes set
forth in EP 554213; U.S. Pat. No. 5,413,774; U.S. Pat. No.
5,578,292; EP 744962; EP 682530; U.S. Pat. No. 5,556,610; U.S. Pat.
No. 5,846,518; U.S. Pat. No. 6,183,725; EP 474833; U.S. Pat. No.
5,271,928; U.S. Pat. No. 5,380,519; U.S. Pat. No. 5,531,980; U.S.
Pat. No. 5,567,414; U.S. Pat. No. 5,658,551; U.S. Pat. No.
5,643,553; U.S. Pat. No. 5,911,972; U.S. Pat. No. 6,110,443; U.S.
Pat. No. 6,136,293; EP 619743; U.S. Pat. No. 5,445,813; U.S. Pat.
No. 5,597,549; U.S. Pat. No. 5,686,060; U.S. Pat. No. 6,187,288;
and U.S. Pat. No. 5,908,610, which are incorporated by reference
herein in their entirety. Most preferably, the phospholipids are
dissolved in an organic solvent and the solution is dried without
going through a liposome formation stage. This can be done by
dissolving the phospholipids in a suitable organic solvent together
with a hydrophilic stabilizer substance or a compound soluble both
in the organic solvent and water and freeze-drying or spray-drying
the solution. In this embodiment the criteria used for selection of
the hydrophilic stabilizer is its solubility in the organic solvent
of choice. Examples of hydrophilic stabilizer compounds soluble in
water and the organic solvent are, e.g., a polymer, like polyvinyl
pyrrolidone (PVP), polyvinyl alcohol (PVA), polyethylene glycol
(PEG), etc., malic acid, glycolic acid, maltol, and the like. Such
hydrophilic compounds also aid in homogenizing the microbubbles
size distribution and enhance stability under storage. Any suitable
organic solvent may be used as long as its boiling point is
sufficiently low and its melting point is sufficiently high to
facilitate subsequent drying. Typical organic solvents include, for
example, dioxane, cyclohexanol, tertiary butanol,
tetrachlorodifluoro ethylene (C.sub.2Cl.sub.4F.sub.2) or
2-methyl-2-butanol. 2-methyl-2-butanol and C.sub.2Cl.sub.4F.sub.2
are preferred.
[0609] Prior to formation of the suspension of microbubbles by
dispersion in an aqueous carrier, the freeze dried or spray dried
phospholipid powders are contacted with air or another gas. When
contacted with the aqueous carrier the powdered phospholipids whose
structure has been disrupted will form lamellarized or laminarized
segments that will stabilize the microbubbles of the gas dispersed
therein. This method permits production of suspensions of
microbubbles that are stable even when stored for prolonged periods
and are obtained by simple dissolution of the dried laminarized
phospholipids (which have been stored under a desired gas) without
shaking or any violent agitation.
[0610] Alternatively, microbubbles can be prepared by suspending a
gas into an aqueous solution at high agitation speed, as disclosed
e.g. in WO 97/29783. A further process for preparing microbubbles
is disclosed in co-pending European patent application no.
03002373, herein incorporated by reference, which comprises
preparing an emulsion of an organic solvent in an aqueous medium in
the presence of a phospholipid and subsequently lyophilizing said
emulsion, after optional washing and/or filtration steps.
[0611] Additives known to those of ordinary skill in the art can be
included in the suspensions of stabilized microbubbles. For
instance, non-film forming surfactants, including polyoxypropylene
glycol and polyoxyethylene glycol and similar compounds, as well as
various copolymers thereof; fatty acids such as myristic acid,
palmitic acid, stearic acid, arachidic acid or their derivatives,
ergosterol, phytosterol, sitosterol, lanosterol, tocopherol, propyl
gallate, ascorbyl palmitate and butylated hydroxytoluene may be
added. The amount of these non-film forming surfactants is usually
up to 50% by weight of the total amount of surfactants but
preferably between 0 and 30%.
[0612] Other gas containing suspensions include those disclosed in,
for example, U.S. Pat. No. 5,798,091, WO 97/29783, also EP 881 915,
incorporated herein by reference in their entirety. These agents
may be prepared as described in U.S. Pat. No. 5,798,091 or
WO97/29783.
[0613] Another preferred ultrasound contrast agent comprises
ultrasound contrast agents. The term "microballoon" refers to gas
filled bodies with a material boundary or envelope. More on
microballoon formulations and methods of preparation may be found
in EP 324 938 (U.S. Pat. No. 4,844,882); U.S. Pat. No. 5,711,933;
U.S. Pat. No. 5,840,275; U.S. Pat. No. 5,863,520; U.S. Pat. No.
6,123,922; U.S. Pat. No. 6,200,548; U.S. Pat. No. 4,900,540; U.S.
Pat. No. 5,123,414; U.S. Pat. No. 5,230,882; U.S. Pat. No.
5,469,854; U.S. Pat. No. 5,585,112; U.S. Pat. No. 4,718,433; U.S.
Pat. No. 4,774,958; WO 95/01187; U.S. Pat. No. 5,529,766; U.S. Pat.
No. 5,536,490; and U.S. Pat. No. 5,990,263, the contents of which
are incorporated herein by reference.
[0614] The preferred microballoons have an envelope including a
biodegradable physiologically compatible polymer or, a
biodegradable solid lipid. The polymers useful for the preparation
of the microballoons of the present invention can be selected from
the biodegradable physiologically compatible polymers, such as any
of those described in any of the following patents: EP 458745, U.S.
Pat. No. 5,711,933, U.S. Pat. No. 5,840,275, EP 554213, U.S. Pat.
No. 5,413,774 and U.S. Pat. No. 5,578,292, the entire contents of
which are incorporated herein by reference. In particular, the
polymer can be selected from biodegradable physiologically
compatible polymers, such as polysaccharides of low water
solubility, polylactides and polyglycolides and their copolymers,
copolymers of lactides and lactones such as .epsilon.-caprolactone,
.gamma.-valerolactone and polypeptides. Other suitable polymers
include poly(ortho)esters (see e.g., U.S. Pat. No. 4,093,709; U.S.
Pat. No. 4,131,648; U.S. Pat. No. 4,138,344; U.S. Pat. No.
4,180,646); polylactic and polyglycolic acid and their copolymers,
for instance DEXON (see J. Heller, Biomaterials 1 (1980), 51;
poly(DL-lactide-co-.epsilon.-caprolact- one),
poly(DL-lactide-co-.gamma.-valerolactone),
poly(DL-lactide-co-.gamma- .-butyrolactone),
polyalkylcyanoacrylates; polyamides, polyhydroxybutyrate;
poly-dioxanone; poly-.beta.-aminoketones (A. S. Angeloni, P.
Ferruti, M. Tramontini and M. Casolaro, The Mannich bases in
polymer synthesis: 3. Reduction of poly(beta-aminoketone)s to
poly(gamma-aminoalcohol)s and their N-alkylation to
poly(gamma-hydroxyquaternary ammonium salt)s, Polymer 23, pp
1693-1697, 1982.); polyphosphazenes (Allcock, Harry R.
Polyphosphazenes: new polymers with inorganic backbone atoms
(Science 193:1214-19 (1976)) and polyanhydrides. The microballoons
of the present invention can also be prepared according to the
methods of WO-A-96/15815, incorporated herein by reference, where
the microballoons are made from a biodegradable membrane comprising
biodegradable lipids, preferably selected from mono- di-,
tri-glycerides, fatty acids, sterols, waxes and mixtures thereof.
Preferred lipids are di- or tri-glycerides, e.g., di- or
tri-myristin, -palmityn or -stearin, in particular tripalmitin or
tristearin. The microballoons may employ any of the gases disclosed
herein of known to the skilled artisan; however, inert gases such
as fluorinated gases are preferred. The microballoons may be
suspended in a pharmaceutically acceptable liquid carrier with
optional additives known to those of ordinary skill in the art and
stabilizers.
[0615] Other gas-containing contrast agent formulations include
microparticles (especially aggregates of microparticles) having gas
contained therein or otherwise associated therewith (for example
being adsorbed on the surface thereof and/or contained within
voids, cavities or pores therein). Methods for the preparation of
these agents are as described in EP 0122624; EP 0123235; EP
0365467; U.S. Pat. No. 5,558,857; U.S. Pat. No. 5,607,661; U.S.
Pat. No. 5,637,289; U.S. Pat. No. 5,558,856; U.S. Pat. No.
5,137,928; WO 95/21631 or WO 93/13809, incorporated herein by
reference in their entirety.
[0616] Any of these ultrasound compositions should also be, as far
as possible, isotonic with blood. Hence, before injection, small
amounts of isotonic agents may be added to any of above ultrasound
contrast agent suspensions. The isotonic agents are physiological
solutions commonly used in medicine and they comprise aqueous
saline solution (0.9% NaCl), 2.6% glycerol solution, 5% dextrose
solution, etc. Additionally, the ultrasound compositions may
include standard pharmaceutically acceptable additives, including,
for example, emulsifying agents, viscosity modifiers,
cryoprotectants, lyoprotectants, bulking agents etc.
[0617] Any biocompatible gas may be used in the ultrasound contrast
agents useful in the invention. The term "gas" as used herein
includes any substances (including mixtures) substantially in
gaseous form at the normal human body temperature. The gas may thus
include, for example, air, nitrogen, oxygen, CO.sub.2, argon, xenon
or krypton, fluorinated gases (including for example,
perfluorocarbons, SF.sub.6, SeF.sub.6) a low molecular weight
hydrocarbon (e.g., containing from 1 to 7 carbon atoms), for
example, an alkane such as methane, ethane, a propane, a butane or
a pentane, a cycloalkane such as cyclopropane, cyclobutane or
cyclopentene, an alkene such as ethylene, propene, propadiene or a
butene, or an alkyne such as acetylene or propyne and/or mixtures
thereof. However, fluorinated gases are preferred. Fluorinated
gases include materials that contain at least one fluorine atom
such as SF.sub.6, freons (organic compounds containing one or more
carbon atoms and fluorine, i.e., CF.sub.4, C.sub.2F.sub.6,
C.sub.3F.sub.8, C.sub.4F.sub.8,C.sub.4F.sub.10,CBrF.sub.3,
CCI.sub.2F.sub.2,C.sub.2CIF.su- b.5, and CBrClF.sub.2) and
perfluorocarbons. The term perfluorocarbon refers to compounds
containing only carbon and fluorine atoms and includes, in
particular, saturated, unsaturated, and cyclic perfluorocarbons.
The saturated perfluorocarbons, which are usually preferred, have
the formula C.sub.nF.sub.n+2, where n is from 1 to 12, preferably
from 2 to 10, most preferably from 3 to 8 and even more preferably
from 3 to 6. Suitable perfluorocarbons include, for example,
CF.sub.4, C.sub.2F.sub.6, C.sub.3F.sub.8C.sub.4F.sub.8,
C.sub.4F.sub.10, C.sub.5F.sub.12, C.sub.6F.sub.12, C.sub.7F.sub.14,
C.sub.8F.sub.18, and C.sub.9F.sub.20. Most preferably the gas or
gas mixture comprises SF.sub.6 or a perfluorocarbon selected from
the group consisting of C.sub.3F.sub.8C.sub.4F.sub.8,
C.sub.4F.sub.10, C.sub.5F.sub.12, C.sub.6F.sub.12, C.sub.7F.sub.14,
C.sub.8F.sub.18, with C.sub.4F.sub.10 being particularly preferred.
See also WO 97/29783, WO 98/53857, WO 98/18498, WO 98/18495, WO
98/18496, WO 98/18497, WO 98/18501, WO 98/05364, WO 98/17324.
[0618] In certain circumstances it may be desirable to include a
precursor to a gaseous substance (e.g., a material that is capable
of being converted to a gas in vivo, often referred to as a "gas
precursor"). Preferably the gas precursor and the gas it produces
are physiologically acceptable. The gas precursor may be
pH-activated, photo-activated, temperature activated, etc. For
example, certain perfluorocarbons may be used as temperature
activated gas precursors. These perfluorocarbons, such as
perfluoropentane, have a liquid/gas phase transition temperature
above room temperature (or the temperature at which the agents are
produced and/or stored) but below body temperature; thus they
undergo a phase shift and are converted to a gas within the human
body.
[0619] As discussed, the gas can comprise a mixture of gases. The
following combinations are particularly preferred gas mixtures: a
mixture of gases (A) and (B) in which, at least one of the gases
(B), present in an amount of between 0.5-41% by vol., has a
molecular weight greater than 80 daltons and is a fluorinated gas
and (A) is selected from the group consisting of air, oxygen,
nitrogen, carbon dioxide and mixtures thereof, the balance of the
mixture being gas A.
[0620] Since ultrasound vesicles may be larger than the other
detectable labels described herein, they may be linked or
conjugated to a plurality of KDR or VEGF/KDR complex binding
polypeptides in order to increase the targeting efficiency of the
agent. Attachment to the ultrasound contrast agents described above
(or known to those skilled in the art) may be via direct covalent
bond between the KDR or VEGF/KDR complex binding polypeptide and
the material used to make the vesicle or via a linker, as described
previously. For example, see WO 98/53857 generally for a
description of the attachment of a peptide to a bifunctional PEG
linker, which is then reacted with a liposome composition. See
also, Lanza et al., Ultrasound in Med. & Bio., 23(6):863-870
(1997).
[0621] A number of methods may be used to prepare suspensions of
microbubbles conjugated to KDR or VEGF/KDR complex binding
polypeptides. For example, one may prepare maleimide-derivatized
microbubbles by incorporating 5% (w/w) of N-MPB-PE
(1,2-dipalmitoyl-sn-glycero-3-phosphoe-
thanolamine-4-(p-maleimido-phenyl butyramide), (Avanti
Polar-Lipids, Inc) in the phospholipid formulation. Then, solutions
of mercaptoacetylated KDR-binding peptides (10 mg/mL in DMF), which
have been incubated in deacetylation solution (50 mM sodium
phosphate, 25 mM EDTA, 0.5 M hydroxylamine.HCl, pH 7.5) are added
to the maleimide-activated microbubble suspension. After incubation
in the dark, under gentle agitation, the peptide conjugated
microbubbles may be purified by centrifugation.
[0622] Compounds that can be used for derivatization of
microbubbles typically include the following components: (a) a
hydrophobic portion, compatible with the material forming the
envelope of the microbubble or of the microballoon, in order to
allow an effective incorporation of the compound in the envelope of
the vesicel; said portion is represented typically by a lipid
moiety (dipalmitin, distearoyl); and (b) a spacer (typically PEGs
of different molecular weights), which may be optional in some
cases (for example, microbubbles may for instance present
difficulties to be freeze dried if the spacer is too long) or
preferred in some others (e.g., peptides may be less active when
conjugated to a microballoon with short spacers); and (c) a
reactive group capable of reacting with a corresponding reacting
moiety on the peptide to be conjugated (e.g., maleimido with the
--SH group of cysteine).
[0623] Alternatively, KDR-binding polypeptide conjugated
microbubbles may be prepared using biotin/avidin. For example,
avidin-conjugated microbubbles may be prepared using a
maleimide-activated phospholipid microbubble suspension, prepared
as described above, which is added to mercaptoacetylated-avidin
(which has been incubated with deacetylation solution).
Biotinylated KDR or VEGF/KDR complex-binding peptides (prepared as
described herein) are then added to the suspension of
avidin-conjugated microbubbles, yielding a suspension of
microbubbles conjugated to KDR or VEGF/KDR complex-binding
peptides.
[0624] Unless it contains a hyperpolarized gas, known to require
special storage conditions, the lyophilized residue may be stored
and transported without need of temperature control of its
environment and in particular it may be supplied to hospitals and
physicians for on site formulation into a ready-to-use
administrable suspension without requiring such users to have
special storage facilities. Preferably in such a case it can be
supplied in the form of a two-component kit, which can include two
separate containers or a dual-chamber container. In the former case
preferably the container is a conventional septum-sealed vial,
wherein the vial containing the lyophilized residue of step b) is
sealed with a septum through which the carrier liquid may be
injected using an optionally prefilled syringe. In such a case the
syringe used as the container of the second component is also used
then for injecting the contrast agent. In the latter case,
preferably the dual-chamber container is a dual-chamber syringe and
once the lyophilizate has been reconstituted and then suitably
mixed or gently shaken, the container can be used directly for
injecting the contrast agent. In both cases means for directing or
permitting application of sufficient bubble forming energy into the
contents of the container are provided. However, as noted above, in
the stabilised contrast agents according to the invention the size
of the gas microbubbles is substantially independent of the amount
of agitation energy applied to the reconstituted dried product.
Accordingly, no more than gentle hand shaking is generally required
to give reproducible products with consistent microbubble size.
[0625] It can be appreciated by one of ordinary skilled in the art
that other two-chamber reconstitution systems capable of combining
the dried powder with the aqueous solution in a sterile manner are
also within the scope of the present invention. In such systems, it
is particularly advantageous if the aqueous phase can be interposed
between the water-insoluble gas and the environment, to increase
shelf life of the product. Where a material necessary for forming
the contrast agent is not already present in the container (e.g. a
targeting ligand to be linked to the phospholipid during
reconstitution), it can be packaged with the other components of
the kit, preferably in a form or container adapted to facilitate
ready combination with the other components of the kit.
[0626] No specific containers, vial or connection systems are
required; the present invention may use conventional containers,
vials and adapters. The only requirement is a good seal between the
stopper and the container. The quality of the seal, therefore,
becomes a matter of primary concern; any degradation of seal
integrity could allow undesirable substances to enter the vial. In
addition to assuring sterility, vacuum retention is essential for
products stoppered at ambient or reduced pressures to assure safe
and proper reconstitution. As to the stopper, it may be a compound
or multicomponent formulation based on an elastomer, such as
poly(isobutylene) or butyl rubber.
[0627] Ultrasound imaging techniques that can be used in accordance
with the present invention include known techniques, such as color
Doppler, power Doppler, Doppler amplitude, stimulated acoustic
imaging, and two- or three-dimensional imaging techniques. Imaging
may be done in harmonic (resonant frequency) or fundamental modes,
with the second harmonic preferred.
[0628] In ultrasound applications the contrast agents formed by
phospholipid stabilized microbubbles may, for example, be
administered in doses such that the amount of phospholipid injected
is in the range 0.1 to 200 .mu.g/kg body weight, preferably from
about 0.1 to 30 .mu.g/kg. Microballoons-containing contrast agents
are typically administered in doses such that the amount of
wall-forming polymer or lipid is from about 10 .mu.g/kg to about 20
mg/kg of body weight.
[0629] As shown in the Examples, ultrasound contrast agents
conjugated to KDR binding moieties of the invention, such as, for
example, those comprising SEQ ID NOS:356, 294 and 480 and the dimer
D23, are able to bind to KDR-expressing tissue and thus are useful
in providing an image of such tissue. Indeed, compounds of the
invention, such as phospholipid stabilized microbubbles conjugated
to the heterodimer D23, can be used to image angiogenic tissue in
vivo.
[0630] C. Optical Imaging, Sonoluminescence or Photoacoustic
Imaging
[0631] In accordance with the present invention, a number of
optical parameters may be employed to determine the location of KDR
or VEGF/KDR complex with in vivo light imaging after injection of
the subject with an optically-labeled KDR or VEGF/KDR complex
binding polypeptide. Optical parameters to be detected in the
preparation of an image may include transmitted radiation,
absorption, fluorescent or phosphorescent emission, light
reflection, changes in absorbance amplitude or maxima, and
elastically scattered radiation. For example, biological tissue is
relatively translucent to light in the near infrared (NIR)
wavelength range of 650-1000 nm. NIR radiation can penetrate tissue
up to several centimeters, permitting the use of the KDR or
VEGF/KDR complex binding polypeptides of the present invention for
optical imaging of KDR or VEGF/KDR complex in vivo.
[0632] The KDR or VEGF/KDR complex binding polypeptides may be
conjugated with photolabels, such as optical dyes, including
organic chromophores or fluorophores, having extensive delocalized
ring systems and having absorption or emission maxima in the range
of 400-1500 nm. The KDR or VEGF/KDR complex binding polypeptide may
alternatively be derivatized with a bioluminescent molecule. The
preferred range of absorption maxima for photolabels is between 600
and 1000 nm to minimize interference with the signal from
hemoglobin. Preferably, photoabsorption labels have large molar
absorptivities, e.g., >10.sup.5 cm.sup.-1M.sup.-1, while
fluorescent optical dyes will have high quantum yields. Examples of
optical dyes include, but are not limited to those described in WO
98/18497, WO 98/18496, WO 98/18495, WO 98/18498, WO 98/53857, WO
96/17628, WO 97/18841, WO 96/23524, WO 98/47538, and references
cited therein. The photolabels may be covalently linked directly to
the KDR or VEGF/KDR complex binding peptide or linked to the KDR or
VEGF/KDR complex binding peptide via a linker, as described
previously.
[0633] After injection of the optically-labeled KDR or VEGF/KDR
complex binding moiety, the patient is scanned with one or more
light sources (e.g., a laser) in the wavelength range appropriate
for the photolabel employed in the agent. The light used may be
monochromatic or polychromatic and continuous or pulsed.
Transmitted, scattered, or reflected light is detected via a
photodetector tuned to one or multiple wavelengths to determine the
location of KDR or VEGF/KDR complex in the subject. Changes in the
optical parameter may be monitored over time to detect accumulation
of the optically-labeled reagent at the site of angiogenesis.
Standard image processing and detecting devices may be used in
conjunction with the optical imaging reagents of the present
invention.
[0634] The optical imaging reagents described above may also be
used for acousto-optical or sonoluminescent imaging performed with
optically-labeled imaging agents (see, U.S. Pat. No. 5,171,298, WO
98/57666, and references cited therein). In acousto-optical
imaging, ultrasound radiation is applied to the subject and affects
the optical parameters of the transmitted, emitted, or reflected
light. In sonoluminescent imaging, the applied ultrasound actually
generates the light detected. Suitable imaging methods using such
techniques are described in WO 98/57666.
[0635] D. Nuclear Imaging (Radionuclide Imaging) and
Radiotherapy
[0636] The KDR or VEGF/KDR complex binding moieties may be
conjugated with a radionuclide reporter appropriate for
scintigraphy, SPECT, or PET imaging and/or with a radionuclide
appropriate for radiotherapy. Constructs in which the KDR or
VEGF/KDR complex binding moieties are conjugated with both a
chelator for a radionuclide useful for diagnostic imaging and a
chelator useful for radiotherapy are within the scope of the
invention.
[0637] For use as a PET agent a peptide is complexed with one of
the various positron emitting metal ions, such as .sup.51Mn,
.sup.52Fe, .sup.60Cu, .sup.68Ga, .sup.72As, .sup.94mTc, or
.sup.110In. The binding moieties of the invention can also be
labeled by halogenation using radionuclides such as .sup.18F,
.sup.124I, .sup.125I, .sup.131I, .sup.123I, .sup.77Br, and
.sup.76Br. Preferred metal radionuclides for scintigraphy or
radiotherapy include .sup.99mTc, .sup.51Cr, .sup.67Ga, .sup.68Ga,
.sup.47Sc, .sup.51Cr, .sup.167Tm, .sup.141Ce, .sup.111In,
.sup.168Yb, .sup.175Yb, .sup.140La, .sup.90Y, .sup.88Y, .sup.153Sm,
.sup.166Ho, .sup.165Dy, .sup.166Dy, .sup.62Cu, .sup.64Cu,
.sup.67Cu, .sup.97Ru, .sup.103Ru, .sup.186Re, .sup.188Re,
.sup.203Pb, .sup.211Bi, .sup.212Bi, .sup.213Bi, .sup.214Bi,
.sup.105Rh, .sup.109Pd, .sup.117mSn, .sup.149Pm, .sup.161Tb,
.sup.177Lu, .sup.198Au and .sup.199Au. The choice of metal will be
determined based on the desired therapeutic or diagnostic
application. For example, for diagnostic purposes the preferred
radionuclides include .sup.64Cu, .sup.67Ga, .sup.68Ga, .sup.99mTc,
and .sup.111In. For therapeutic purposes, the preferred
radionuclides include .sup.64Cu, .sup.90Y, .sup.105Rh, .sup.111In,
.sup.117mSn, .sup.149Pm, .sup.153Sm, .sup.161Tb, .sup.166Dy,
.sup.166Ho, .sup.175Yb, .sup.177Lu, .sup.186/188Re, and .sup.199Au.
.sup.99mTc is particularly preferred for diagnostic applications
because of its low cost, availability, imaging properties, and high
specific activity. The nuclear and radioactive properties of Tc-99m
make this isotope an ideal scintigraphic imaging agent. This
isotope has a single photon energy of 140 keV and a radioactive
half-life of about 6 hours, and is readily available from a
.sup.99Mo--.sup.99mTc generator.
[0638] The metal radionuclides may be chelated by, for example,
linear, macrocyclic, terpyridine, and N.sub.3S, N.sub.2S.sub.2, or
N.sub.4 chelants (see also, U.S. Pat. No. 5,367,080, U.S. Pat. No.
5,364,613, U.S. Pat. No. 5,021,556, U.S. Pat. No. 5,075,099, U.S.
Pat. No. 5,886,142), and other chelators known in the art
including, but not limited to, HYNIC, DTPA, EDTA, DOTA, DO3A, TETA,
and bisamino bisthiol (BAT) chelators (see also U.S. Pat. No.
5,720,934). For example, N.sub.4 chelators are described in U.S.
Pat. No. 6,143,274; U.S. Pat. No. 6,093,382; U.S. Pat. No.
5,608,110; U.S. Pat. No. 5,665,329; U.S. Pat. No. 5,656,254; and
U.S. Pat. No. 5,688,487. Certain N.sub.3S chelators are described
in PCT/CA94/00395, PCT/CA94/00479, PCT/CA95/00249 and in U.S. Pat.
No. 5,662,885; U.S. Pat. No. 5,976,495; and U.S. Pat. No.
5,780,006. The chelator may also include derivatives of the
chelating ligand mercapto-acetyl-acetyl-glycyl-glycine (MAG3),
which contains an N.sub.3S, and N.sub.2S.sub.2 systems such as MAMA
(monoamidemonoaminedith- iols), DADS (N.sub.2S diaminedithiols),
CODADS and the like. These ligand systems and a variety of others
are described in Liu and Edwards, Chem Rev., 99:2235-2268 (1999)
and references therein.
[0639] The chelator may also include complexes containing ligand
atoms that are not donated to the metal in a tetradentate array.
These include the boronic acid adducts of technetium and rhenium
dioximes, such as are described in U.S. Pat. No. 5,183,653; U.S.
Pat. No. 5,387,409; and U.S. Pat. No. 5,118,797, the disclosures of
which are incorporated by reference herein, in their entirety.
[0640] In another embodiment, disulfide bonds of a KDR or VEGF/KDR
complex binding polypeptide of the invention are used as two
ligands for chelation of a radionuclide such as .sup.99mTc. In this
way the peptide loop is expanded by the introduction of Tc
(peptide-S--S-peptide changed to peptide-S--Tc--S-peptide). This
has also been used in other disulfide containing peptides in the
literature (Chen et al., J. Nucl. Med., 42:1847-1855(2001)) while
maintaining biological activity. The other chelating groups for Tc
can be supplied by amide nitrogens of the backbone, another cystine
amino acid or other modifications of amino acids.
[0641] Particularly preferred metal chelators include those of
Formula 20, 21, 22, 23a, 23b, 24a, 24b and 25 (FIGS. 34A-F) and
FIG. 35. Formulas 20-22 (FIGS. 34A-C) are particularly useful for
lanthanides such as paramagnetic Gd.sup.3+ and radioactive
lanthanides such as .sup.177Lu, .sup.90Y, .sup.153Sm, .sup.111In,
or .sup.166Ho. Formulas 23a-24b (FIGS. 34D and F) and FIG. 35 are
particularly useful for radionuclides .sup.99mTc, .sup.186Re, or
.sup.188Re. Formula 25 (FIG. 34F) and the structure shown in FIG.
35 are particularly useful for .sup.99mTc. These and other metal
chelating groups are described in U.S. Pat. No. 6,093,382 and U.S.
Pat. No. 5,608,110, which are incorporated by reference herein in
their entirety. Additionally, the chelating group of formula 22
(FIG. 34C) is described in, for example, U.S. Pat. No. 6,143,274;
the chelating group of formula 24 is described in, for example,
U.S. Pat. No. 5,627,286 and U.S. Pat. No. 6,093,382, and the
chelating groups of formula 25 and FIG. 35 are described in, for
example, U.S. Pat. No. 5,662,885; U.S. Pat. No. 5,780,006; and U.S.
Pat. No. 5,976,495.
[0642] In the above Formulas 24a and 24b (FIG. 34E), X is either
CH.sub.2 or O; Y is C.sub.1-C.sub.10 branched or unbranched alky,
aryl, aryloxy, arylamino, arylaminoacyl, or arylalkyl comprising
C.sub.1-C.sub.10 branched or unbranched alkyl groups, hydroxy or
C.sub.1-C.sub.10 branched or unbranched polyhydroxyalkyl groups,
C.sub.1-C.sub.10 branched or unbranched hydroxy or polyalkoxyalkyl
or polyhydroxy-polyalkoxyalkyl groups; J is C(.dbd.O)--,
OC(.dbd.O)--, SO.sub.2--, NC(.dbd.O)--, NC(.dbd.S)--, N(Y),
NC(.dbd.NCH.sub.3)--, NC(.dbd.NH)--, N.dbd.N--, homopolyamides or
heteropolyamines derived from synthetic or naturally occurring
amino acids; and n is 1-100. Other variants of these structures are
described, for example, in U.S. Pat. No. 6,093,382. The disclosures
of each of the foregoing patents, applications and references are
incorporated by reference herein, in their entirety.
[0643] The chelators may be covalently linked directly to the KDR
or VEGF/KDR complex binding moiety or linked to the KDR or VEGF/KDR
complex binding polypeptide via a linker, as described previously,
and then directly labeled with the radioactive metal of choice
(see, WO 98/52618, U.S. Pat. No. 5,879,658, and U.S. Pat. No.
5,849,261).
[0644] Complexes of radioactive technetium are particularly useful
for diagnostic imaging and complexes of radioactive rhenium are
particularly useful for radiotherapy. In forming a complex of
radioactive technetium with the reagents of this invention, the
technetium complex, preferably a salt of Tc-99m pertechnetate, is
reacted with the reagent in the presence of a reducing agent.
Preferred reducing agents are dithionite, stannous and ferrous
ions; the most preferred reducing agent is stannous chloride. Means
for preparing such complexes are conveniently provided in a kit
form comprising a sealed vial containing a predetermined quantity
of a reagent of the invention to be labeled and a sufficient amount
of reducing agent to label the reagent with Tc-99m. Alternatively,
the complex may be formed by reacting a peptide of this invention
conjugated with an appropriate chelator with a pre-formed labile
complex of technetium and another compound known as a transfer
ligand. This process is known as ligand exchange and is well known
to those skilled in the art. The labile complex may be formed using
such transfer ligands as tartrate, citrate, gluconate or mannitol,
for example. Among the Tc-99m pertechnetate salts useful with the
present invention are included the alkali metal salts such as the
sodium salt, or ammonium salts or lower alkyl ammonium salts.
[0645] Preparation of the complexes of the present invention where
the metal is radioactive rhenium may be accomplished using rhenium
starting materials in the +5 or +7 oxidation state. Examples of
compounds in which rhenium is in the Re(VII) state are
NH.sub.4ReO.sub.4 or KReO.sub.4. Re(V) is available as, for
example, [ReOCl.sub.4](NBu.sub.4), [ReOCl.sub.4](AsPh4),
ReOCl.sub.3(PPh.sub.3).sub.2 and as
ReO.sub.2(pyridine).sub.4.sup.+, where Ph is phenyl and Bu is
n-butyl. Other rhenium reagents capable of forming a rhenium
complex may also be used.
[0646] Radioactively-labeled scintigraphic imaging agents provided
by the present invention are provided having a suitable amount of
radioactivity. In forming Tc-99m radioactive complexes, it is
generally preferred to form radioactive complexes in solutions
containing radioactivity at concentrations of from about 0.01 mCi
to 100 mCi per mL.
[0647] Generally, the unit dose to be administered has a
radioactivity of about 0.01 mCi to about 100 mCi, preferably 1 mCi
to 20 mCi. The solution to be injected at unit dosage is from about
0.01 mL to about 10 mL.
[0648] Typical doses of a radionuclide-labeled KDR or VEGF/KDR
complex binding imaging agents according to the invention provide
10-20 mCi. After injection of the KDR or VEGF/KDR complex-specific
radionuclide imaging agent into the patient, a gamma camera
calibrated for the gamma ray energy of the nuclide incorporated in
the imaging agent is used to image areas of uptake of the agent and
quantify the amount of radioactivity present in the site. Imaging
of the site in vivo can take place in a matter of a few minutes.
However, imaging can take place, if desired, hours or even longer,
after the radiolabeled peptide is injected into a patient. In most
instances, a sufficient amount of the administered dose will
accumulate in the area to be imaged within about 0.1 of an hour to
permit the taking of scintiphotos.
[0649] Proper dose schedules for the radiotherapeutic compounds of
the present invention are known to those skilled in the art. The
compounds can be administered using many methods that include, but
are not limited to, a single or multiple IV or IP injections, using
a quantity of radioactivity that is sufficient to cause damage or
ablation of the targeted KDR-expressing tissue, but not so much
that substantive damage is caused to non-target (normal tissue).
The quantity and dose required is different for different
constructs, depending on the energy and half-life of the isotope
used, the degree of uptake and clearance of the agent from the body
and the mass of the tumor. In general, doses can range from a
single dose of about 30-50 mCi to a cumulative dose of up to about
3 Curies.
[0650] The radiotherapeutic compositions of the invention can
include physiologically acceptable buffers, and can require
radiation stabilizers to prevent radiolytic damage to the compound
prior to injection. Radiation stabilizers are known to those
skilled in the art, and may include, for example, para-aminobenzoic
acid, ascorbic acid, gentistic acid and the like.
[0651] A single, or multi-vial kit that contains all of the
components needed to prepare the complexes of this invention, other
than the radionuclide, is an integral part of this invention.
[0652] A single-vial kit preferably contains a chelating ligand, a
source of stannous salt, or other pharmaceutically acceptable
reducing agent, and is appropriately buffered with pharmaceutically
acceptable acid or base to adjust the pH to a value of about 3 to
about 9. The quantity and type of reducing agent used would depend
highly on the nature of the exchange complex to be formed. The
proper conditions are well known to those that are skilled in the
art. It is preferred that the kit contents be in lyophilized form.
Such a single vial kit may optionally contain labile or exchange
ligands such as glucoheptonate, gluconate, mannitol, malate, citric
or tartaric acid and can also contain reaction modifiers such as
diethylenetriamine-pentaacetic acid (DPTA), ethylenediamine
tetraacetic acid (EDTA), or .alpha.,.beta., or .gamma. cyclodextrin
that serve to improve the radiochemical purity and stability of the
final product. The kit may also contain stabilizers, bulking agents
such as mannitol, that are designed to aid in the freeze-drying
process, and other additives known to those skilled in the art.
[0653] A multi-vial kit preferably contains the same general
components but employs more than one vial in reconstituting the
radiopharmaceutical. For example, one vial may contain all of the
ingredients that are required to form a labile Tc(V) complex on
addition of pertechnetate (e.g., the stannous source or other
reducing agent). Pertechnetate is added to this vial, and after
waiting an appropriate period of time, the contents of this vial
are added to a second vial that contains the ligand, as well as
buffers appropriate to adjust the pH to its optimal value. After a
reaction time of about 5 to 60 minutes, the complexes of the
present invention are formed. It is advantageous that the contents
of both vials of this multi-vial kit be lyophilized. As above,
reaction modifiers, exchange ligands, stabilizers, bulking agents,
etc. may be present in either or both vials.
[0654] As shown in the Examples, compounds of the invention
comprising a radionuclide, particularly heteromultimers such as D10
conjugated to a radionuclide (optionally via a chelator), are
useful in imaging KDR or VEGF/KDR complex expressing tissue (such
as angiogenic tissue).
[0655] Additionally, the Examples establish that compounds of the
invention conjugated to a therapeutic radionuclide, particularly
heteromultimers such as D13 conjugated to a chelator and complexed
with a therapeutic radionuclide, are useful in radiotherapy of
tumors expressing KDR.
Other Therapeutic Applications
[0656] The KDR or VEGF/KDR complex binding polypeptides of the
present invention can be used to improve the activity of
therapeutic agents such as anti-angiogenic or tumorcidal agents
against undesired angiogenesis such as occurs in neoplastic tumors,
by providing or improving their affinity for KDR or VEGF/KDR
complex and their residence time at a KDR or VEGF/KDR complex on
endothelium undergoing angiogenesis. In this aspect of the
invention, hybrid agents are provided by conjugating a KDR or
VEGF/KDR complex binding polypeptide according to the invention
with a therapeutic agent. The therapeutic agent may be a
radiotherapeutic, discussed above, a drug, chemotherapeutic or
tumorcidal agent, genetic material or a gene delivery vehicle, etc.
The KDR or VEGF/KDR complex binding polypeptide portion of the
conjugate causes the therapeutic to "home" to the sites of KDR or
VEGF/KDR complex (i.e., activated endothelium), and to improve the
affinity of the conjugate for the endothelium, so that the
therapeutic activity of the conjugate is more localized and
concentrated at the sites of angiogenesis. Such conjugates will be
useful in treating angiogenesis-associated diseases, especially
neoplastic tumor growth and metastasis, in mammals, including
humans, which method comprises administering to a mammal in need
thereof an effective amount of a KDR or VEGF/KDR complex binding
polypeptide according to the invention conjugated with a
therapeutic agent. The invention also provides the use of such
conjugates in the manufacture of a medicament for the treatment of
angiogenesis associated diseases in mammals, including humans.
[0657] Suitable therapeutic agents for use in this aspect of the
invention include, but are not limited to: antineoplastic agents,
such as platinum compounds (e.g., spiroplatin, cisplatin, and
carboplatin), methotrexate, adriamycin, mitomycin, ansamitocin,
bleomycin, cytosine, arabinoside, arabinosyl adenine,
mercaptopolylysine, vincristine, busulfan, chlorambucil, melphalan
(e.g., PAM, L-PAM, or phenylalanine mustard), mercaptopurine,
mitotane, procarbazine hydrochloride, dactinomycin (actinomycin D),
daunorubcin hydrochloride, doxorubicin hydrochloride, taxol,
mitomycin, plicamycin (mithramycin), aminoglutethimide,
estramustine phosphate sodium, flutamide, leuprolide acetate,
megestrol acetate, tamoxifen citrate, testoiactone, trilostane,
amsacrine (m-AMSA), aparaginase (L-aparaginase), Erwina
aparaginase, etoposide (VP-16), interferon cx-2a, Interferon cx-2b,
teniposide (VM-26, vinblastine sulfate (VLB), vincristine sulfate,
bleomycin sulfate, adriamycin, and arabinosyl; anti-angiogenic
agents such as tyrosine kinase inhibitors with activity toward
signaling molecules important in angiogenesis and/or tumor growth
such as SU5416 and SU6668 (Sugen/Pharmacia & Upjohn),
endostatin (EntreMed), angiostatin (EntreMed), Combrestatin
(Oxigene), cyclosporine, 5-fluorouracil, vinblastine, doxorubicin,
paclitaxel, daunorubcin, immunotoxins; coagulation factors;
antivirals such as acyclovir, amantadine azidothymidine (AZT or
Zidovudine), ribavirin and vidarabine monohydrate (adenine
arahinoside, ara-A); antibiotics, antimalarials, antiprotozoans
such as chloroquine, hydroxychloroquine, metroidazole, quinine and
meglumine antimonate; anti-inflammatories such as diflunisal,
ibuprofen, indomethacin, meclofenamate, mefenamic acid, naproxen,
oxyphenbutazone, phenylbutazone, piroxicam, sulindac, tolmetin,
aspirin and salicylates.
[0658] The KDR or VEGF/KDR complex binding polypeptides of the
present invention may also be used to target genetic material to
KDR-expressing cells. Thus, they may be useful in gene therapy,
particularly for treatment of diseases associated with
angiogenesis. In this embodiment, genetic material or one or more
delivery vehicles containing genetic material useful in treating an
angiogenesis-related disease may be conjugated to one or more KDR
binding moieties of the invention and administered to a patient.
The genetic material may include nucleic acids, such as RNA or DNA,
of either natural or synthetic origin, including recombinant RNA
and DNA and antisense RNA and DNA. Types of genetic material that
may be used include, for example, genes carried on expression
vectors such as plasmids, phagemids, cosmids, yeast artificial
chromosomes (YAC's) and defective or "helper" viruses, antigene
nucleic acids, both single and double stranded RNA and DNA and
analogs thereof, such as phosphorothioate and phosphorodithioate
oligodeoxynucleotides. Additionally, the genetic material may be
combined, for example, with lipids, proteins or other polymers.
Delivery vehicles for genetic material may include, for example, a
virus particle, a retroviral or other gene therapy vector, a
liposome, a complex of lipids (especially cationic lipids) and
genetic material, a complex of dextran derivatives and genetic
material, etc.
[0659] In a preferred embodiment the constructs of the invention
are utilized in gene therapy for treatment of diseases associated
with angiogenesis. In this embodiment, genetic material, or one or
more delivery vehicles containing genetic material, e.g., useful in
treating an angiogenesis-related disease, can be conjugated to one
or more KDR or VEGF/KDR complex binding polypeptides or multimers
(e.g., homomultimers or heteromultimers) of the invention and
administered to a patient.
[0660] Constructs including genetic material and the KDR-binding
polypeptides of the invention may be used, in particular, to
selectively introduce genes into angiogenic endothelial cells,
which may be useful not only to treat cancer, but also after
angioplasty, where inhibition of angiogenesis may inhibit
restenosis.
[0661] Therapeutic agents and the KDR or VEGF/KDR complex binding
moieties of the invention can be linked or fused in known ways,
using the same type of linkers discussed elsewhere in this
application. Preferred linkers will be substituted or unsubstituted
alkyl chains, amino acid chains, polyethylene glycol chains, and
other simple polymeric linkers known in the art. More preferably,
if the therapeutic agent is itself a protein, for which the
encoding DNA sequence is known, the therapeutic protein and KDR or
VEGF/KDR complex binding polypeptide may be coexpressed from the
same synthetic gene, created using recombinant DNA techniques, as
described above. The coding sequence for the KDR or VEGF/KDR
complex binding polypeptide may be fused in frame with that of the
therapeutic protein, such that the peptide is expressed at the
amino- or carboxy-terminus of the therapeutic protein, or at a
place between the termini, if it is determined that such placement
would not destroy the required biological function of either the
therapeutic protein or the KDR or VEGF/KDR complex binding
polypeptide. A particular advantage of this general approach is
that concatamerization of multiple, tandemly arranged KDR or
VEGF/KDR complex binding polypeptides is possible, thereby
increasing the number and concentration of KDR or VEGF/KDR complex
binding sites associated with each therapeutic protein. In this
manner KDR or VEGF/KDR complex binding avidity is increased, which
would be expected to improve the efficacy of the recombinant
therapeutic fusion protein.
[0662] Similar recombinant proteins containing one or more coding
sequences for a KDR and VEGF/KDR complex binding polypeptide may be
useful in imaging or therapeutic applications. For example, in a
variation of the pre-targeting applications discussed infra, the
coding sequence for a KDR or VEGF/KDR complex binding peptide can
be fused in frame to a sequence encoding an antibody (or an
antibody fragment or recombinant DNA construct including an
antibody, etc.) that, for example, binds to a chelator for a
radionuclide (or another detectable label). The antibody expressing
the KDR or VEGF/KDR complex binding polypeptide is then
administered to a patient and allowed to localize and bind to
KDR-expressing tissue. After the non-binding antibodies have been
allowed to clear, the chelator-radionuclide complex (or other
detectable label), which the antibody recognizes is administered,
permitting imaging of or radiotherapy to the KDR-expressing
tissues. Additionally, the coding sequence for a KDR or VEGF/KDR
complex binding peptide may be fused in frame to a sequence
encoding, for example, serum proteins or other proteins that
produce biological effects (such as apoptosis, coagulation,
internalization, differentiation, cellular stasis, immune system
stimulation or suppression, or combinations thereof). The resulting
recombinant proteins are useful in imaging, radiotherapy, and
therapies directed against cancer and other diseases that involve
angiogenesis or diseases associated with the pathogens discussed
herein.
[0663] Additionally, constructs including KDR or KDR/VEGF complex
binding polypeptides of the present invention can themselves be
used as therapeutics to treat a number of diseases. For example,
where binding of a protein or other molecule (e.g., a growth
factor, hormone etc.) is necessary for or contributes to a disease
process and a binding moiety inhibits such binding, constructs
including such binding moieties could be useful as therapeutics.
Similarly, where binding of a binding moiety itself inhibits a
disease process, constructs containing such binding moieties could
also be useful as therapeutics.
[0664] As binding of VEGF and activation of KDR is necessary for
angiogenic activity, in one embodiment constructs including KDR
complex binding polypeptides that inhibit the binding of VEGF to
KDR (or otherwise inhibit activation of KDR) may be used as
anti-angiogenic agents. Some peptides of the invention that inhibit
activation of KDR are discussed in Example 9 infra. Certain
constructs of the invention including multimers and heteromultimers
that inhibit activation of KDR are also discussed in the Examples.
A particularly preferred heteromultimer is the
heterodimer-containing construct D1 (structures provided by the
examples). Other preferred heterodimer constructs include D4, D5,
D6, D10, D13, D17, D23, D27, D30 and D31 (structures provided in
the Examples below). The binding polypeptides and constructs
thereof of the present invention are useful as therapeutic agents
for treating conditions that involve endothelial cells. Because an
important function of endothelial cells is angiogenesis, or the
formation of blood vessels, the polypeptides and constructs thereof
are particularly useful for treating conditions that involve
angiogenesis. Conditions that involve angiogenesis include, for
example, solid tumors, tumor metastases and benign tumors. Such
tumors and related disorders are well known in the art and include,
for example, melanoma, central nervous system tumors,
neuroendocrine tumors, sarcoma, multiple myeloma as wells as cancer
of the breast, lung, prostate, colon, head & neck, and ovaries.
Additional tumors and related disorders are listed in Table I of
U.S. Pat. No. 6,025,331, issued Feb. 15, 2000 to Moses, et al., the
teachings of which are incorporated herein by reference. Benign
tumors include, for example, hemangiomas, acoustic neuromas,
neurofibromas, trachomas, and pyogenic granulomas. As shown in
Example 15, compounds of the invention, including heteromultimers
such as D6, are useful in treating and/or slowing the growth of
certain tumors.
[0665] Other relevant diseases that involve angiogenesis include
for example, rheumatoid arthritis, psoriasis, and ocular diseases,
such as diabetic retinopathy, retinopathy of prematurity, macular
degeneration, corneal graft rejection, neovascular glaucoma,
retrolental fibroplasia, rebeosis, Osler-Webber Syndrome,
myocardial angiogenesis, plaque neovascularization, telangiectasia,
hemophiliac joints, angiofibroma and wound granulation. Other
relevant diseases or conditions that involve blood vessel growth
include intestinal adhesions, atherosclerosis, scleroderma, and
hypertropic scars, and ulcers. Furthermore, the binding
polypeptides and constructs thereof of the present invention can be
used to reduce or prevent uterine neovascularization required for
embryo implantation, for example, as a birth control agent.
Heteromultimers of this invention can also be useful for treating
vascular permeability events that can result when VEGF binds KDR.
In renal failure, for example, it has been shown that anti-VEGF
antibodies can reverse damage. In a similar way, the compounds of
the present invention can reverse renal permeability pathogenesis
in, for example, diabetes.
[0666] Furthermore, the KDR or VEGF/KDR complex binding
polypeptides of the present invention may be useful in treating
diseases associated with certain pathogens, including, for example,
malaria, HIV, SIV, Simian hemorrhagic fever virus, etc. Sequence
homology searches of KDR-binding peptides identified by phage
display using the BLAST program at NCBI has identified a number of
homologous proteins known or expected to be present on the surface
of pathogenic organisms. Homologies were noted between the
polypeptides of the invention and proteins from various malaria
strains, HIV, SIV, simian hemorrhagic fever virus, and an
enterohemorrhagic E. coli strain. Some of the homologous proteins,
such as PfEMP1 and EBL-1, are hypermutable adhesion proteins known
to play roles in virulence. These proteins possess multiple binding
sites that are capable of binding to more than one target molecule
on the host's surface. Their high mutation and recombination rates
allow them to quickly develop new binding sites to promote survival
and/or invasion. Similarly, proteins such as gp120 of HIV (which
also has homology to some of the KDR-binding peptides disclosed
herein) play critical roles in the adhesion of pathogens to their
hosts. Although not reported previously, it is possible that many
of the pathogen proteins with homology to the KDR-binding peptides
disclosed herein also bind to KDR. Comparison of the pathogen
protein sequences with the corresponding peptide sequences may
suggest changes in the peptide sequence or other modifications that
will enhance its binding properties. Additionally, the KDR-binding
peptide sequences disclosed herein may have usefulness in blocking
infection with the pathogen species that possesses the homology.
Indeed, a similar strategy is being employed to block HIV infection
by trying to prevent virus envelope proteins from binding to their
known cellular surface targets such as CD4. See, Howie et al.,
"Synthetic peptides representing discontinuous CD4 binding epitopes
of HIV-1 gp120 that induce T cell apoptosis and block cell death
induced by gp120", FASEB J, 12(11):991-998 (1998). Thus, KDR may
represent a previously unknown target for a number of pathogens,
and the KDR binding peptides of the invention may be useful in
treating the diseases associated with those pathogens.
[0667] The binding polypeptides and constructs thereof can be
administered to an individual over a suitable time course depending
on the nature of the condition and the desired outcome. The binding
polypeptides and constructs thereof can be administered
prophylactically, e.g., before the condition is diagnosed or to an
individual predisposed to a condition. The binding polypeptides and
constructs thereof can be administered while the individual
exhibits symptoms of the condition or after the symptoms have
passed or otherwise been relieved (such as after removal of a
tumor). In addition, the binding polypeptides and constructs
thereof of the present invention can be administered a part of a
maintenance regimen, for example to prevent or lessen the
recurrence or the symptoms or condition. As described below, the
binding polypeptides and constructs thereof of the present
invention can be administered systemically or locally.
[0668] The quantity of material administered will depend on the
seriousness of the condition. For example, for treatment of an
angiogenic condition, e.g., in the case of neoplastic tumor growth,
the position and size of the tumor will affect the quantity of
material to be administered. The precise dose to be employed and
mode of administration must per force in view of the nature of the
complaint be decided according to the circumstances by the
physician supervising treatment. In general, dosages of the agent
conjugate of the present invention will follow the dosages that are
routine for the therapeutic agent alone, although the improved
affinity of a binding polypeptide or heteromultimer of the
invention for its target may allow a decrease in the standard
dosage.
[0669] Such conjugate pharmaceutical compositions are preferably
formulated for parenteral administration, and most preferably for
intravenous or intra-arterial administration. Generally, and
particularly when administration is intravenous or intra-arterial,
pharmaceutical compositions may be given as a bolus, as two or more
doses separated in time, or as a constant or non-linear flow
infusion.
[0670] As used herein the term "therapeutic" includes at least
partial alleviation of symptoms of a given condition. The binding
polypeptides and constructs thereof of the present invention do not
have to produce a complete alleviation of symptoms to be useful.
For example, treatment of an individual can result in a decrease in
the size of a tumor or diseased area, or prevention of an increase
in size of the tumor or diseased area. Treatment can result in
reduction in the number of blood vessels in an area of interest or
can prevent an increase in the number of blood vessels in an area
of interest. Treatment can also prevent or lessen the number or
size of metastatic outgrowths of the main tumor(s).
[0671] Symptoms that can be alleviated include physiological
characteristics such as VEGF receptor activity and migration
ability of endothelial cells. The binding polypeptides and
constructs thereof of the present invention can inhibit activity of
VEGF receptors, including VEGFR-2/KDR, VEGFR-1/Flt-1 and
VEGFR-3/Flt-4. Such inhibition can be detected, for example, by
measuring the phosphorylation state of the receptor in the presence
of or after treatment with the binding polypeptides or constructs
thereof. Such inhibition can also be detected by measuring the
ability of endothelial cells to migrate in the presence of or after
treatment with the binding polypeptides or constructs thereof.
Based on the teachings provided herein, one of ordinary skill in
the art would know how and be able to administer a suitable dose of
binding polypeptide or construct thereof as provided herein, and
measure the effect of treatment on the parameter of interest. For
example, the size of the area of interest (e.g., the tumor or
lesion) can be measured before and after treatment. In another
embodiment, the phosphorylation state of the relevant receptor, or
the migration ability of endothelial in an area of interest can be
measured in samples taken from the individual. The VEGF receptors
or endothelial cells can be isolated from the sample and used in
assays described herein.
[0672] The dosage of the polypeptides and constructs thereof may
depend on the age, sex, health, and weight of the individual, as
well as the nature of the condition and overall treatment regimen.
The biological effects of the polypeptides and constructs thereof
are described herein. Therefore, based on the biological effects of
the binding polypeptides and constructs provided herein, and the
desired outcome of treatment, the preferred dosage is determinable
by one of ordinary skill in the art through routine optimization
procedures. Typically, the daily regimen is in the range of about
0.1 .mu.g/kg to about 1 mg/kg.
[0673] The binding polypeptides and constructs thereof provided
herein can be administered as the sole active ingredient together
with a pharmaceutically acceptable excipient, or can be
administered together with other binding polypeptides and
constructs thereof, other therapeutic agents, or combination
thereof. In addition, the binding polypeptides and constructs
thereof can be conjugated to therapeutic agents, for example, to
improve specificity, residence time in the body, or therapeutic
effect. Such other therapeutic agents include, for example, other
anti-angiogenic compounds, and tumoricidal compounds. The
therapeutic agent can also include antibodies.
[0674] Furthermore, the binding polypeptide or constructs thereof
of the present invention can be used as an endothelial cell homing
device. Therefore, the binding polypeptide or constructs thereof
can be conjugated to nucleic acid encoding, for example, a
therapeutic polypeptide, in order to target the nucleic acid to
endothelial cells. Once exposed to the nucleic acid conjugated
binding polypeptide, the endothelial cell can internalize and
express the conjugated nucleic acid, thereby delivering the
therapeutic peptide to the target cells.
[0675] In another embodiment of the invention, the therapeutic
agent can be associated with an ultrasound contrast agent
composition, said ultrasound contrast agent including the KDR or
VEGF/KDR complex binding peptides of the invention linked to the
material employed to form the vesicles (particularly microbubbles
or microballoons) comprising the contrast agent. For example, the
therapeutic agent can be associated with the contrast agent and
delivered as described in U.S. Pat. No. 6,258,378, herein
incorporated by reference. Thus, after administration of the
ultrasound contrast agent and the optional imaging of the contrast
agent bound to the pathogenic site expressing the KDR or VEGF/KDR
complex, the pathogenic site can be irradiated with an energy beam
(preferably ultrasonic, e.g., with a frequency of from 0.3 to 3
MHz), to rupture or burst of microvesicles. The therapeutic effect
of the therapeutic agent can thus be advantageously enhanced by the
energy released by the rupture of the microvesicles, in particular
causing an effective deliver of the therapeutic agent to the
targeted pathogenic site.
[0676] The binding polypeptides and constructs thereof can be
administered by any suitable route. Suitable routes of
administration include, but are not limited to, topical
application, transdermal, parenteral, gastrointestinal,
intravaginal, and transalveolar. Compositions for the desired route
of administration can be prepared by any of the methods well known
in the pharmaceutical arts, for example, as described in Remington:
The Science and Practice of Pharmacy, 20.sup.th ed., Lippincott,
Williams and Wilkins, 2000.
[0677] For topical application, the binding polypeptides can be
suspended, for example, in a cream, gel or rinse that allows the
polypeptides or constructs to penetrate the skin and enter the
blood stream, for systemic delivery, or contact the area of
interest, for localized delivery. Compositions suitable for topical
application include any pharmaceutically acceptable base in which
the polypeptides are at least minimally soluble.
[0678] For transdermal administration, the polypeptides can be
applied in pharmaceutically acceptable suspension together with a
suitable transdermal device or "patch." Examples of suitable
transdermal devices for administration of the polypeptides of the
present invention are described, for example, in U.S. Pat. No.
6,165,458, issued Dec. 26, 2000 to Foldvari, et al., and U.S. Pat.
No. 6,274,166B1, issued Aug. 4, 2001 to Sintov, et al., the
teachings of which are incorporated herein by reference.
[0679] For parenteral administration, the polypeptides can be
injected intravenously, intramuscularly, intraperitoneally, or
subcutaneously. Typically, compositions for intravenous
administration are solutions in sterile isotonic aqueous buffer.
Other pharmaceutically acceptable carriers include, but are not
limited to, sterile water, saline solution, and buffered saline
(including buffers like phosphate or acetate), alcohol, vegetable
oils, polyethylene glycols, gelatin, lactose, amylose, magnesium
stearate, talc, silicic acid, paraffin, etc. Where necessary, the
composition may also include a solubilizing agent and a local
anaesthetic such as lidocaine to ease pain at the site of the
injection, preservatives, stabilizers, wetting agents, emulsifiers,
salts, lubricants, etc. as long as they do not react deleteriously
with the active compounds. Similarly, the composition may comprise
conventional excipients, i.e. pharmaceutically acceptable organic
or inorganic carrier substances suitable for parenteral, enteral or
intranasal application that do not deleteriously react with the
active compounds. Generally, the ingredients will be supplied
either separately or mixed together in unit dosage form, for
example, as a dry lyophilized powder or water free concentrate in a
hermetically sealed container such as an ampoule or sachette
indicating the quantity of active agent in activity units. Where
the composition is to be administered by infusion, it can be
dispensed with an infusion bottle containing sterile pharmaceutical
grade "water for injection" or saline. Where the composition is to
be administered by injection, an ampoule of sterile water for
injection or saline may be provided so that the ingredients may be
mixed prior to administration.
[0680] For gastrointestinal and intravaginal administration, the
polypeptides can be incorporated into pharmaceutically acceptable
powders, pills or liquids for ingestion, and suppositories for
rectal or vaginal administration.
[0681] For transalveolar, buccal or pulmonary administration, the
polypeptides can be suspended in a pharmaceutically acceptable
excipient suitable for aerosolization and inhalation or as a
mouthwash. Devices suitable for transalveolar administration such
as atomizers and vaporizers are also included within the scope of
the invention. Suitable formulations for aerosol delivery of
polypeptides using buccal or pulmonary routes can be found, for
example in U.S. Pat. No. 6,312,665B1, issued Nov. 6, 2001 to Pankaj
Modi, the teachings of which are incorporated herein by
reference.
[0682] In addition, the polypeptides of the present invention can
be administered nasally or ocularly, where the polypeptide is
suspended in a liquid pharmaceutically acceptable agent suitable
for dropwise dosing.
[0683] The polypeptides of the present invention can be
administered such that the polypeptide is released in the
individual over an extended period of time (sustained or controlled
release). For example, the polypeptide can be formulated into a
composition such that a single administration provides delivery of
the polypeptide for at least one week, or over the period of a year
or more. Controlled release systems include monolithic or
reservoir-type microcapsules, depot implants, osmotic pumps,
vesicles, micelles, liposomes, transdermal patches and
iontophoretic devices. In one embodiment, the polypeptides of the
present invention are encapsulated or admixed in a slowly
degrading, non-toxic polymer. Additional formulations suitable for
controlled release of the polypeptides provided herein are
described in U.S. Pat. No. 4,391,797, issued Jul. 5, 1983, to
Folkman, et al., the teachings of which are incorporated herein by
reference.
[0684] Another suitable method for delivering the polypeptides of
the present to an individual is via in vivo production of the
polypeptide. A gene encoding the polypeptide can be administered to
the individual such that the encoded polypeptide is expressed. The
gene can be transiently expressed. In a particular embodiment, the
gene encoding the polypeptide is transfected into cells that have
been obtained from the patient, a method referred to as ex vivo
gene therapy. Cells expressing the polypeptide are then returned to
the patient's body. Methods of ex vivo gene therapy are well known
in the art and are described, for example, in U.S. Pat. No.
4,391,797, issued Mar. 21, 1998 to Anderson, et al., the teachings
of which are incorporated herein by reference.
[0685] Isolation, formulation and use of KDR or VEGF/KDR complex
binding moieties in accordance with this invention will be further
illustrated in the following examples. The specific parameters
included in the following examples are intended to illustrate the
practice of the invention, and they are not presented to in any way
limit the scope of the invention.
EXAMPLES
Methods for the Examples
[0686] The following methods were employed in Examples 4-10. The
following common abbreviations are used:
9-fluorenylmethyloxycarbonyl (Fmoc), 1-hydroxybenzotriazole (HOBt),
N,N'-diisopropylcarbodiimide (DIC), N-methylpyrrolidinone (NMP),
acetic anhydride (Ac.sub.2O),
(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde),
trifluoroacetic acid (TFA), Reagent B (TFA: H.sub.2O: phenol:
triisopropylsilane 88:5:5:2), diisopropylethylamine (DIEA),
O-(1H-benzotriazole-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate (HBTU),
O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethy- luronium
hexafluorophosphate (HATU), N-hydroxysuccinimide (NHS), solid phase
peptide synthesis (SPPS), dimethyl sulfoxide (DMSO),
dichloromethane (DCM), dimethylformamide (DMF), human serum albumin
(HSA), and radiochemical purity (RCP).
[0687] Method 1 for the ACT 357 MPS and ACT 496 MOS Synthesizers
The peptides were synthesized on NovaSyn TGR (Rink amide) resin
(0.2 mmol/g) using the Advanced ChemTech ACT 357 or ACT 496
Synthesizers employing Fmoc peptide synthesis protocols,
specifically using HOBt/DIC as the coupling reagents and NMP as the
solvent. The Fmoc was removed by treating the Nova-Syn TGR (Rink
amide-available from NovaBiochem, San Diego Calif.) resin-bound
peptide with 25% piperidine in DMF twice (4 min and 10 min). All
amino acids were dissolved in NMP (DMF was added when the amino
acid was not soluble in pure NMP). The concentration of the amino
acid was 0.25M, and the concentrations for HOBt and DIC
respectively were 0.5 M.
[0688] For a 0.04 mmol Scale Synthesis:
[0689] A typical amino acid coupling cycle (not including wash
steps) was to dispense piperidine solution (2.4 mL) to each well
and mix for 4 min, then empty all wells. NMP (320 .mu.L), HOBt
solution (320 .mu.L, 4 eq), amino acid (640 .mu.L, 4 eq) and DIC
(320 .mu.L, 4 eq) solutions were dispensed to each well. The
coupling time was 3 h; then the resin was washed. The cycle was
repeated for each amino acid. After the last amino acid coupling,
the resin-bound peptide was treated with 25% piperidine to remove
the Fmoc protecting group. After washing, the resin bound peptide
was capped with 1.0M Ac.sub.2O (1.2 mL per well) and
diisopropylethylamine in DMF, optionally including varying amounts
of HOBt in the mixture for 30 min. The resin was washed with
methanol and then dichloromethane and dried. Cleavage of the
peptides from the resin and side-chain deprotection was
accomplished using Reagent B for 4.5 h. The cleavage solutions were
collected and the resins were washed with an additional aliquot of
Reagent B. The combined solutions were concentrated to dryness.
Ether was added to the residue with swirling or stirring to
precipitate the peptides. The ether was decanted, and solid was
collected. This procedure was repeated 2-3 times to remove
impurities. The crude linear peptides were dissolved in DMSO and
water mixtures, and purified by HPLC (column: Waters Associates
Xterra C18, 19.times.50 mm; solvents: H.sub.2O with 0.1% TFA and
CH.sub.3CN with 0.1% TFA; UV 220 .mu.m; Flow rate: 50-60 mL/min).
The solutions containing the peptide were lyophilized to give the
desired peptides as white fluffy lyophilizates (>90% purity).
The purified linear di-cysteine containing peptides were dissolved
in water, mixtures of water-acetonitrile, or mixtures of water-DMSO
at concentrations between 0.1 mg/mL and 2.0 mg/mL. The choice of
solvent was a function of the solubility of the crude peptide in
the solvent. The pH of the solution was adjusted to pH 7.5-8.5 with
aqueous ammonia, aqueous ammonium carbonate or aqueous ammonium
bicarbonate. The mixture was stirred vigorously in air for 24-48
hrs. In the case of non-DMSO containing solvent systems, the pH of
the solution was adjusted to pH 2 with aqueous trifluoroacetic
acid. The mixture was lyophilized to provide the crude cyclic
disulfide containing peptide. The cyclic disulfide peptide was then
dissolved to a volume of 1-2 mL in aqueous (0.1% TFA) containing a
minimum of acetonitrile (0.1% TFA). The resulting solution was
loaded onto a reverse phase column and the desired compound
obtained by a gradient elution of acetonitrile into water,
employing a C18, or C8 reverse phase semipreparative or preparative
HPLC column. In the case of the DMSO-containing solutions, the
solution was diluted until the DMSO concentration was minimal
without precipitation of the peptide. The resulting mixture was
quickly acidified to pH 2 with dilute trifluoroacetic acid and
loaded onto the reverse phase HPLC system and purified as
described. Fractions containing the desired materials were pooled
and the peptides isolated by lyophilization.
Method 2 for the ACT 357 MPS and ACT 496 MOS Synthesizers
[0690] The peptides were synthesized as in Method 1 with the
following changes. HBTU/HOBt/DIEA were used as the coupling reagent
and NMP as the solvent. A low load (0.2 mmol/g)
Fmoc-GGGK(Boc)-NovSyn-TGR-resin-prepared from the above-described
Nova-Syn TGR resin was employed for peptide synthesis on 0.01 mmol
scale. For a 0.01 mmol scale synthesis:
[0691] After the Fmoc group was removed, a standard coupling
procedure used a solution of HOBt (720 .mu.l, 6 eq), amino acid
(804 .mu.l, 6.6 eq), HBTU (720 .mu.l, 6 eq) and DIEA (798 .mu.l,
13.3 eq). The mixture was agitated for 15 min., emptied and the
resin washed. After all couplings and after cleavage and
purification as above, the solutions containing desired linear
peptides were lyophilized to give the peptides (>90% purity) as
white fluffy solids. The crude ether-precipitated linear
di-cysteine containing peptides were cyclized by dissolution in
water, mixtures of aqueous acetonitrile (0.1% TFA), or aqueous DMSO
and adjustment of the pH of the solution to pH 7.5-8.5 by addition
of aqueous ammonia, aqueous ammonium carbonate, or aqueous ammonium
bicarbonate solution. The peptide concentration was between 0.1 and
2.0 mg/mL. The mixture was stirred in air for 24-48 hrs., acidified
to a pH 2 with aqueous trifluoroacetic acid, and then purified by
preparative reverse phase HPLC employing a gradient of acetonitrile
into water. Fractions containing the desired material were pooled
and the peptides were isolated by lyophilization.
Method 3 for the ACT 496 MOS Synthesizer
[0692] The peptides were synthesized by using an Advanced ChemTech
ACT 496 MOS Synthesizer as in method 1. The low load (.about.0.2
mmol/g) GGGK(Boc)-NovaSyn-TGR resin was employed for peptide
synthesis. The coupling solvent was NMP/DMSO 8:2. The synthesis was
performed at a 0.02 mmol scale using a coupling time of 3 h. The
crude linear peptides were further processed as described for
Method 1.
Method 4 for the ACT 496 MOS Synthesizer
[0693] The peptides were synthesized using method 3 on the ACT 496
with HBTU/DIEA as the coupling reagents, and NMP as the solvent.
2,4,6-collidine as a 1M solution was used as the base. The low load
Fmoc-GGGK(ivDde)-Novsyn-TGR resin (.about.0.2 mmol/g) was used for
peptide synthesis. The coupling time was 30 minutes. The crude
linear peptides were further processed as described for Method
1.
Method 5 for the ABI 433A Synthesizer
[0694] Synthesis of peptides was carried out on a 0.25 mmol scale
using the FastMoc protocol (Applied Biosystems Inc). In each cycle
of this protocol, 1.0 mmol of a dry protected amino acid in a
cartridge was dissolved in a solution of 0.9 mmol of HBTU, 2 mmol
of DIEA, and 0.9 mmol of HOBt in DMF with additional NMP added. The
peptides were made using 0.1 mmol of NovaSyn TGR (Rink amide) resin
(resin substitution 0.2 mmol/g). The coupling time in this protocol
was 21 min. Fmoc deprotection was carried out with 20% piperidine
in NMP. At the end of the last cycle, the synthesized peptide was
acetylated using acetic anhydride/DIEA/HOBt/NMP. The peptide resin
was washed and dried for further manipulations or cleaved from the
resin (using reagent B). Generally, the cleaved peptides were
cyclized as in Method 1 before purification.
Method 6: Biotinylation of Resin-Bound Peptides
[0695] The peptides were prepared using Method 5. The ivDde
protecting group on the C-terminal lysine was selectively removed
by treatment with 10% hydrazine in DMF. The resin was then treated
with a solution of Biotin-N-hydroxysuccinimidyl ester in DMF in the
presence of DIEA. After washing, the resin was dried and cleavage
was performed using Reagent B. The resin was filtered off and the
filtrate concentrated to dryness. The biotinylated peptide was
dissolved in neat DMSO and treated with DIEA and stirred for 4-6
hours to effect disulfide cyclization. The crude mixture was
purified by preparative HPLC.
[0696] In a typical experiment, 200 mg of the resin-bound peptide
was treated with 10% hydrazine in DMF (2.times.20 mL) and washed
with DMF (2.times.20 mL) and then with dichloromethane (1.times.20
mL). The resin was resuspended in DMF (10 mL) and treated with a
solution of Biotin-NHS ester (0.2 mmol, 5 equivalents) and DIEA
(0.2 mmol), and the resin was mixed with the reagents for 4 h. The
completion of the reaction was checked by the ninhydrin test. The
peptide was then released from the resin by treatment with Reagent
B (10 mL) for 4 h. The resin was filtered off, Reagent B was
removed in vacuo and the peptide was precipitated by addition of
anhydrous ether. The solid formed was collected, washed with ether
and dried. The solid was dissolved in anhydrous DMSO and the
mixture was adjusted to pH 7.5 with DIEA and stirred for 4-6 h to
effect disulfide cyclization. The disulfide cyclization reaction
was monitored by analytical HPLC. After completion of the
cyclization, the mixture solution was diluted with 25% acetonitrile
in water and directly purified by HPLC on a reverse phase C18
column using a gradient of acetonitrile into water (both containing
0.1% TFA). Fractions were analyzed by analytical HPLC and those
containing the pure product were collected and lyophilized to
obtain the required biotinylated peptide.
Method 7: Biotinylation of Purified Peptides
[0697] The purified peptide (10 mg, prepared by methods 1-5)
containing a free amino group was dissolved in anhydrous DMF or
DMSO (1 mL) and Biotin-NHS ester (5 equivalents) and DIEA (5
equivalents) were added. The reaction was monitored by HPLC and
after the completion of the reaction (1-2 h.), the crude reaction
mixture was directly purified by preparative HPLC. Fractions were
analyzed by analytical HPLC, and those containing the pure product
were collected and lyophilized to obtain the required biotinylated
peptide.
Method 8: Biotinylation of Resin-Bound Peptides Containing
Linkers
[0698] In a typical experiment, 400 mg of the resin-containing
peptide (made using the ABI 433A Synthesizer and bearing an
ivDde-protected lysine) was treated with 10% hydrazine in DMF
(2.times.20 mL). The resin was washed with DMF (2.times.20 mL) and
DCM (1.times.20 mL). The resin was resuspended in DMF (10 mL) and
treated with Fmoc-aminodioxaoctanoic acid (0.4 mmol), HOBt (0.4
mmol), DIC (0.4 mmol), DIEA (0.8 mmol) with mixing for 4 h. After
the reaction, the resin was washed with DMF (2.times.10 mL) and
with DCM (1.times.10 mL). The resin was then treated with 20%
piperidine in DMF (2.times.15 mL) for 10 min. each time. The resin
was washed and the coupling with Fmoc-diaminodioxaoctanoic acid and
removal of the Fmoc protecting group were repeated once more. The
resulting resin, containing a peptide with a free amino group, was
treated with a solution of Biotin-NHS ester (0.4 mmol, 5
equivalents) and DIEA (0.4 mmol, 5 equivalents) in DMF for 2 hours.
The peptide-resin was washed and dried as described previously and
then treated with reagent B (20 mL) for 4 h. The mixture was
filtered, and the filtrate concentrated to dryness. The residue was
stirred with ether to produce a solid that was collected, washed
with ether and dried. The solid was dissolved in anhydrous DMSO and
the pH adjusted to 7.5 with DIEA. The mixture was stirred for 4-6
hr to effect the disulfide cyclization reaction, which was
monitored by analytical HPLC. After the completion of the
cyclization, the DMSO solution was diluted with 25% acetonitrile in
water and applied directly to a reverse phase C-18 column.
Purification was effected using a gradient of acetonitrile into
water (both containing 0.1% TFA). Fractions were analyzed by
analytical HPLC, and those containing the pure product were
collected and lyophilized to provide the required biotinylated
peptide.
Method 9: Formation of 5-Carboxyfluorescein-Labeled Peptides
[0699] Peptide-resin obtained via Method 5, containing an ivDde
protecting group on the epsilon nitrogen of lysine, was mixed with
a solution of hydrazine in DMF (10% hydrazine/DMF, 2.times.10 mL,
10 min) to remove the ivDde group. The epsilon nitrogen of the
lysine was labeled with fluorescein-5-isothiocyanate (0.12 mmol)
and diisopropylethylamine (0.12 mmol) in DMF. The mixture was
agitated for 12 h (fluorescein-containing compounds were protected
from light). The resin was then washed with DMF (3.times.10 mL) and
twice with CH.sub.2Cl.sub.2 (10 mL) and dried under nitrogen for 1
h. The peptide was cleaved from the resin using reagent B for 4 h
and the solution collected by filtration. The volatiles were
removed under reduced pressure, and the residue was dried under
vacuum. The peptide was precipitated with ether, collected and the
precipitate was dried under a stream of nitrogen. The precipitate
was added to water (1 mg/mL) and the pH of the mixture was adjusted
to 8 with 10% aqueous meglumine. Cyclization of the peptide was
carried out for 48 h and the solution was freeze-dried. The crude
cyclic peptide was dissolved in water and purified by RP-HPLC on a
C.sub.18 column with a linear gradient of acetonitrile into water
(both phases contained 0.1% TFA). Fractions containing the pure
product were collected and freeze-dried. The peptides were
characterized by ES-MS and the purity was determined by RP-HPLC
(linear gradient of acetonitrile into water/0.1% TFA).
Method 10A: Preparation of Peptidic Chelate for Binding to Tc by
Coupling of Single Amino Acids
[0700] Peptides were synthesized starting with 0.1 mmol of
NovaSyn-TGR resin (0.2 mmol/g substitution). Deprotected (ivDde)
resin was then treated according to the protocol A for the
incorporation of Fmoc-Gly-OH, Fmoc-Cys(Acm)-OH and
Fmoc-Ser(tBu)-OH.
[0701] Protocol A for manual coupling of single amino acid:
[0702] 1. Treat with 4 equivalents of corresponding Fmoc-amino acid
and 4.1 equivalents of HOBt and 4.1 equivalents of DIC for 5 h.
[0703] 2. Wash with DMF (3.times.10 mL)
[0704] 3. Treat with 20% piperidine in DMF (2.times.10 mL, 10
min.)
[0705] 4. Wash with DMF (3.times.10 mL)
[0706] The Fmoc-protected peptide loaded resin was then treated
with 20% piperidine in DMF (2.times.10 mL, 10 min.) and washed with
DMF (3.times.10 mL). A solution of N,N-dimethylglycine (0.11 mmol),
HATU (1 mmol), and DIEA (0.11 mmol) in DMF (10 mL) was then added
to the peptide loaded resin and the manual coupling was continued
for 5 h. After the reaction the resin was washed with DMF
(3.times.10 mL) and CH.sub.2Cl.sub.2 (3.times.10 mL) and dried
under vacuum.
Method 10B: Preparation of Peptidic Chelate for Binding to Tc By
Appendage of the Glutaryl-PnAO6 Chelator to the Peptide
Preparation of
4-{(2-(2-Hydroxyimino-1,1-dimethylpropylamino)-1-[(2-hydrox-
yimino-1,1-dimethyl-propylamino)-methyl]-ethylcarbamoyl}-butyric
Acid, N-hydroxysuccinimide Ester (Compound B, FIG. 86).
[0707]
4-{2-(2-Hydroxyimino-1,1-dimethyl-propylamino)-1-[(2-hydroxyimino-1-
,1-dimethyl-propylamino)-methyl]-ethylcarbamoyl}-butyric acid
(Compound A, FIG. 86) (40 mg) was dissolved in DMF (700 .mu.L).
N-Hydroxysuccinimide (1.5 equiv, 17.2 mg) and
1,3-diisopropylcarbodiimide (1.5 equiv, 24 .mu.L) were added. The
progress of the reaction was monitored by mass spectroscopy. After
17 h, the reaction was complete. The volatiles were removed in
vacuo and the residue was washed with ether (5.times.) to remove
the unreacted NHS. The residue was dried to provide compound B,
which was used directly without further treatment or purification.
See FIG. 86 for reaction scheme.
Functionalization of Peptides with
4-{2-(2-Hydroxyimino-1,1-dimethylpropyl-
amino)-1-[(2-hydroxyimino-1,1-dimethyl-propylamino)-methyl]-ethylcarbamoyl-
}-butyric Acid, N-hydroxysuccinimide Ester--(Compound B)
[0708] The peptide (prepared, for example, by Methods 1-13) is
dissolved in DMF and treated with compound B and DIEA sufficient to
maintain the basicity of the mixture. The progress of the reaction
is monitored by HPLC and mass spectroscopy. At completion of the
reaction the volatiles are removed in vacuo and the residue is
either purified by reverse phase HPLC or processed further by
selective removal of side chain protecting groups or subjected to
cleavage of all remaining protecting groups as required by the next
steps in the synthesis scheme.
Method 11: Formation of Mercaptoacetylated Peptides
Using S-Acetylthioglycolic acid N-Hydoxysuccinimide Ester
[0709] S-acetylthioglycolic acid N-hydroxysuccinimide ester (SATA)
(0.0055 mmol) was added to a solution of a peptide (0.005 mmol,
obtained from Methods 1-5 with a free amine) in DMF (0.25 mL) and
the reaction mixture was stirred at ambient temperature for 6 h.
The volatiles were removed under vacuum and the residue was
purified by preparative HPLC using acetonitrile-water containing
0.1% TFA. Fractions containing the pure product were collected and
freeze-dried to yield the mercaptoacetylated peptide. The
mercaptoacetylated peptide was characterized by ESI-MS and the
purity was determined by reverse phase HPLC analysis employing a
linear gradient of acetonitrile into water (both containing 0.1%
TFA).
[0710] Examples of SATA-modified peptides include, but are not
limited to:
1 SATA-modified SEQ ID NO: 480 Ac-AGPTWCEDDWYYCWLFGTGGGG-
K(SATA-JJ)-NH.sub.2 SATA-modified SEQ ID NO: 356
Ac-AQDWYYDEILSMADQLRHAFLSGGGGGK(SATA)-NH.sub.2 SATA-modified SEQ ID
NO: 356 Ac-AQDWYYDEILSMADQLRHAFLSGGGGGK(SATA- -JJ)-NH.sub.2
[0711] Method 12: Formation of Mercaptoacetylated Peptides using
S-Acetylthioglycolic acid
[0712] Purified peptides from method 5, after disulfide
cyclization, was coupled with S-acetylthioglycolic acid(1.5-10
eq.)/HOBt (1.5-10 eq.)/DIC (1.5-10 eq.) in NMP for 2-16 hours at
room temperature. The mixture was then purified by preparative
HPLC; the fractions containing pure peptide were combined and
lyophilized. In the case of compounds with another lysine protected
by an ivDde group, the deprotection reaction employed 2% hydrazine
in DMSO for 3 h at room temperature. Purification of the reaction
mixture afforded pure peptide.
[0713] In the case when preparing a compound with
S-acetylthioglycolic acid coupled to two aminodioxaoctanoic acid
groups and the peptide, the purified peptide from method 5 (having
a free amino group), was coupled to
AcSCH.sub.2CO--(NH--CH.sub.2--CH.sub.2--O--CH.sub.2--CH.sub.2--O--CH.s-
ub.2--CO).sub.2--OH (30 eq.)/HOBt (30 eq.)/DIC (30 eq.) in NMP for
40 hours at room temperature. The mixture was purified, and the
ivDde group was removed. A second purification gave the final
product as a white lyophilizate.
[0714] Alternatively Fmoc aminodioxaoctanoic acid was coupled twice
successively to the peptide (produced by method 5) followed by Fmoc
removal and coupling to S-acetylthioglycolic acid.
Method 13: Preparation of Homodimers and Heterodimers
[0715] The required purified peptides were prepared by SPPS using
Method 5. To prepare homodimers, half of the peptide needed to
prepare the dimer was dissolved in DMF and treated with 10
equivalents of glutaric acid bis N-hydoxysuccinimidyl ester. The
progress of the reaction was monitored by HPLC analysis and mass
spectroscopy. At completion of the reaction, the volatiles were
removed in vacuo and the residue was washed with ethyl acetate to
remove unreacted bis-NHS ester. The residue was dried, re-dissolved
in anhydrous DMF and treated with another half portion of the
peptide in the presence of 2 equivalents of DIEA. The reaction was
allowed to proceed for 24 h. This mixture was applied directly to a
Waters Associates C-18 XTerra reverse phase HPLC column and
purified by elution with a linear gradient of acetonitrile into
water (both containing 0.1% TFA).
[0716] In the case of heterodimers, one of the monomers was reacted
with the bis NHS ester of glutaric acid and after washing off the
excess of bis NHS ester, the second peptide was added in the
presence of DIEA. After the reaction, the mixture was purified by
preparative HPLC.
Example 1
Library Screening Against KDR and KDR/VEGF Complex Targets
[0717] Chimeric fusions of Ig Fc region with human KDR
(#357-KD-050), murine KDR (#443-KD-050), human VEGFR-1
(#321-FL-050), human VEGFR-3 (#349-F4-050), and human Trail R4
(#633-TR-100) were purchased in carrier-free form (no BSA) from R
& D Systems (Minneapolis, Minn.). Trail R4 Fc is an irrelevant
Fc fusion protein with the same Fc fusion region as the target Fc
fusion (KDR Fc) and is used to deplete the libraries of Fc binders.
VEGF.sub.165 (#100-20) was purchased in carrier-free form from
Peprotech (Rocky Hill, N.J.). Protein A Magnetic Beads (#100.02)
were purchased from Dynal (Oslo, Norway). Heparin (#H-3393) was
purchased from Sigma Chemical Company (St. Louis, Mo.). A
2-component tetramethyl benzidine (TMB) system was purchased from
KPL (Gaithersburg, Md.).
[0718] In the following procedures, microtiter plates were washed
with a Bio-Tek 404 plate washer (Winooski, Vt.). ELISA signals were
read with a Bio-Tek plate reader (Winooski, Vt.). Agitation of
96-well plates was on a LabQuake shaker (Labindustries, Berkeley,
Calif.).
[0719] Eight M13 phage display libraries were prepared for
screening against immobilized KDR and VEGF/KDR targets: Cyclic
peptide display libraries TN6/VI, TN7/IV, TN8/IX, TN9/IV, TN10/IX,
TN12/I, and MTN13/I, and a linear display library, Lin20. The
design of these libraries has been described, supra.
[0720] The DNA encoding the library was synthesized with constant
DNA on either side so that the DNA can be PCR amplified using Taq
DNA polymerase (Perkin-Elmer, Wellesley, Mass.), cleaved with NcoI
and PstI, and ligated to similarly cleaved phage display vector.
XL1-Blue MFR' E. coli cells were transformed with the ligated DNA.
All of the libraries were constructed in same manner.
[0721] KDR Selection Protocol in the Presence of Heparin
[0722] Protein A Magnetic Beads were blocked once with 1.times.PBS
(pH 7.5), 0.01% Tween-20, 0.1% HSA (Blocking Buffer) for 30 minutes
at room temperature and then washed five times with 1.times.PBS (pH
7.5), 0.01% Tween-20, 5 .mu.g/mL heparin (PBSTH Buffer).
[0723] The cyclic peptide, or "constrained loop", libraries were
pooled for the initial screening into two pools: TN6/VI, TN7/IV and
TN8/IX were in one pool; TN9/IV, TN10/IX and TN12/I were in the
second pool. The two pooled libraries and the linear library
(Lin20) were depleted against Trail R4 Fc fusion (an irrelevant Fc
fusion) and then selected against KDR Fc fusion. 10.sup.11 plaque
forming units (pfu) from each library per 100 .mu.L PBSTH were
pooled together, e.g., 3 pooled libraries would result in a total
volume of .about.350 .mu.l in PBSTH.
[0724] To prepare the irrelevant Fc fusion beads, 500 .mu.l of
Trail R4-Fc fusion (0.1 .mu.g/.mu.l stock in PBST (no heparin))
were added to 1000 .mu.l of washed, blocked protein A magnetic
beads. The fusion was allowed to bind to the beads overnight with
agitation at 4.degree. C. The next day, the magnetic beads were
washed 5 times with PBSTH. Each phage pool was incubated with 50
.mu.l of Trail R4 Fc fusion beads on a Labquake shaker for 1 hour
at room temperature (RT). After incubation, the phage supernatant
was removed and incubated with another 50 .mu.L of Trail R4 beads.
This was repeated for a total of 5 rounds of depletion, to remove
non-specific Fc fusion and bead binding phage from the
libraries.
[0725] To prepare the KDR target beads, 500 .mu.l of KDR-Fc fusion
(0.1 .mu.g/.mu.l stock in PBST (no heparin)) were added to 500
.mu.L of washed, blocked beads. The KDR-Fc fusion was allowed to
bind overnight with agitation at 4.degree. C. The next day, the
beads were washed 5 times with PBSTH. Each depleted library pool
was added to 100 .mu.L of KDR-Fc beads and allowed to incubate on a
LabQuake shaker for 1 hour at RT. Beads were then washed as rapidly
as possible with 5.times.1 mL PBSTH using a magnetic stand
(Promega) to separate the beads from the wash buffer. Phage still
bound to beads after the washing were eluted once with 250 .mu.l of
VEGF (50 .mu.g/mL, .about.1 .mu.M) in PBSTH for 1 hour at RT on a
LabQuake shaker. The 1-hour elution was removed and saved. After
the first elution, the beads were incubated again with 250 .mu.l of
VEGF (50 .mu.g/mL, .about.1 .mu.M) overnight at RT on a LabQuake
shaker. The two VEGF elutions were kept separate and a small
aliquot taken from each for titering. Each elution was mixed with
an aliquot of XL1-Blue MRF' (or other F' cell line) E. coli cells
that had been chilled on ice after having been grown to
mid-logarithmic phase. The remaining beads after VEGF elution were
also mixed with cells to amplify the phage still bound to the
beads, i.e., KDR-binding phage that had not been competed off by
the two VEGF incubations (1-hour and overnight (O/N) elutions).
After approximately 15 minutes at room temperature, the phage/cell
mixtures were spread onto Bio-Assay Dishes (243.times.243.times.18
mm, Nalge Nunc) containing 250 mL of NZCYM agar with 50 .mu.g/mL of
ampicillin. The plate was incubated overnight at 37.degree. C. The
next day, each amplified phage culture was harvested from its
respective plate. Over the next day, the input, output and
amplified phage cultures were titered for FOI (i.e., Fraction of
Input=phage output divided by phage input).
[0726] In the first round, each pool yielded three amplified
eluates. These eluates were panned for 2-3 more additional rounds
of selection using .about.10.sup.10 input phage/round according to
the same protocol as described above. For each additional round,
the KDR-Fc beads were prepared the night before the round was
initiated. For the elution step in subsequent rounds, the amplified
elution re-screen on KDR-Fc beads was always eluted in the same
manner, and all other elutions were treated as washes. For example,
for the amplified elution recovered by using th4e still-bound beads
to infect E. coli, the 1-hour and overnight VEGF elutions were
performed and then discarded as washes. Then the beads were used to
again infect E. coli and produce the next round amplified elution.
Using this procedure, each library pool only yielded three final
elutions at the end of the selection. Two pools and one linear
library, therefore, yielded a total of 9 final elutions at the end
of the selection.
[0727] This selection procedure was repeated for all libraries in
the absence of heparin in all binding buffers, i.e., substituting
PBST (PBS (pH 7.5), 0.01% Tween-20) for PBSTH in all steps.
[0728] KDR Selection Protocol in the Absence of Heparin
[0729] A true TN11/1 library was used to screen for KDR binders.
The same selection protocol as above (KDR Selection Protocol in the
Presence of Heparin) was used, except heparin was omitted. The
three elution conditions were VEGF elution (1 uM; 1 hr; same as
original protocol), Dimer D6 elution (0.1 uM; 1 hr), and then bead
elution (same as above). TN11/1 alone was used in the selection and
screening. For selected peptides, see Table 27 and Consensus
Sequence 9A.
[0730] KDR:VEGF Complex Selection Protocol in the Presence of
Heparin
[0731] Protein A magnetic beads were blocked once with Blocking
Buffer for 30 minutes at room temperature and then washed five
times with PBSTH.
[0732] Two pools of constrained loop libraries and a linear library
(Lin20) were prepared as before and then depleted against KDR Fc
fusion alone, instead of Trail-R4 Fc fusion, to remove binders to
the receptor without bound VEGF. Once depleted, the libraries were
selected against the KDR:VEGF.sub.165 complex.
[0733] To prepare KDR-Fc fusion depletion beads, 1 mL of KDR-Fc
fusion (0.1 .mu.g/[L stock in PBST (no heparin)) was added to 1 mL
of washed, blocked beads. The fusion was allowed to bind overnight
with agitation at 4.degree. C. The next day, the beads were washed
5 times with PBSTH. Each phage pool was incubated with 50 .mu.l of
KDR-Fc fusion beads on a LabQuake shaker for 1 hour at RT. After
incubation, the phage supernatant was removed and incubated with
another 50 .mu.L of KDR-Fc beads. This was repeated for a total of
5 rounds of depletion.
[0734] To prepare the KDR:VEGF complex beads, 300 .mu.L of KDR-Fc
fusion beads from above were incubated with 15 .mu.L of VEGF (1
mg/mL). VEGF was allowed to bind for 1 hour at RT. The beads were
washed 5 times with PBSTH. Each depleted library pool was added to
100 .mu.l of KDR:VEGF complex beads and allowed to incubate on a
LabQuake shaker for 1 hour at RT. Beads were then washed as rapidly
as possible with 5.times.1 mL PBSTH using a magnetic stand
(Promega) to separate the beads from the wash buffer. To elute the
phage still bound after washing, the beads were mixed with cells to
amplify the phage still bound to the beads. After approximately 15
minutes at room temperature, the phage/cell mixtures were spread
onto Bio-Assay Dishes (243.times.243.times.18 mm, Nalge Nunc)
containing 250 mL of NZCYM agar with 50 .mu.g/mL of ampicillin. The
plate was incubated overnight at 37.degree. C. The next day, each
amplified phage culture was harvested from its respective plate.
Over the next day, the input, output and amplified phage cultures
were titered for FOI. This selection protocol was repeated for two
additional rounds using 10.sup.10 input phage from each amplified
elution.
[0735] KDR and KDR/VEGF Screening Assay
[0736] 100 .mu.l of KDR-Fc fusion or Trail R4-Fc fusion (1
.mu.g/mL) were added to duplicate Immulon II plates, to every well,
and allowed to incubate at 4.degree. C. overnight. Each plate was
washed twice with PBST (PBS, 0.05% Tween-20). The wells were filled
to the top with 1.times.PBS, 1% BSA and allowed to incubate at RT
for 2 hours. Each plate was washed once with PBST (PBS, 0.05%
Tween-20).
[0737] To assess binding to KDR:VEGF complex, another set of KDR
plates was prepared as above and then 100 .mu.L of VEGF (1
.mu.g/mL) in PBST was added to each KDR well and allowed to
incubate at RT for 30 minutes. Each plate was then washed with PBST
(PBS, 0.05% Tween-20).
[0738] Once the plates were prepared, each overnight phage culture
was diluted 1:1 (or to 10.sup.10 pfu if using purified phage stock)
with PBS, 0.05% Tween-20, 1% BSA. 100 .mu.l of each diluted culture
was added and allowed to incubate at RT for 2-3 hours. Each plate
was washed 5 times with PBST. The binding phage were visualized by
adding 100 .mu.l of a 1:10,000 dilution of HRP-anti-M13 antibody
conjugate (Pharmacia), diluted in PBST, to each well, then
incubating at room temperature for 1 hr. Each plate was washed 7
times with PBST (PBS, 0.05% Tween-20), then the plates were
developed with HRP substrate (.about.10 minutes) and the absorbance
signal (630 nm) detected with plate reader.
[0739] KDR and VEGF/KDR complex binding phage were recovered,
amplified, and the sequences of the display peptides responsible
for the binding were determined by standard DNA sequencing methods.
The binding peptides of the phage isolates are set forth in Tables
1-7, infra.
[0740] After isolation of KDR and VEGF/KDR complex isolates in
initial selection rounds, certain isolates were selected to act as
templates for the construction of secondary libraries, from which
additional high affinity binding polypeptides were isolated. In a
secondary TN8 library, the phage isolate sequence PKWCEEDWYYCMIT
(SEQ ID NO:21) was used as a template to construct a library that
allowed one-, two-, and three-base mutations to the parent sequence
at each variable codon. In a secondary TN12 library, the phage
isolate sequence SRVCWEDSWGGEVCFRY (SEQ ID NO:88) was used as a
template to construct a library that allowed one-, two-, and
three-base mutations to the parent sequence at each variable codon.
In a another TN8 secondary library, a recurrent motif from the
initial TN8 sequences was kept constant (WVEC---TG-C---; SEQ ID
NO:260) and all of the other codon positions (i.e., at "-") were
allowed to vary (all possible 20 amino acids) using NNK codon
substitution, where N stands for any nucleotide and K stands for
any keto nucleotide (G or T).
[0741] Using a method of peptide optimization by soft randomization
as described by Fairbrother et al., Biochemistry,
37(51):17754-17764 (1998), two libraries were prepared based on the
SEQ ID NO:21 and SEQ ID NO:88 sequences. At each residue position,
each nucleotide within a particular codon was allowed to evolve by
adding fixed amounts of the other three nucleotides that did not
correspond to the nucleotide of the parent codon. This nucleotide
mixing is accomplished in the synthesis of the template DNA used to
make the library. For these libraries, the parent nucleotide within
each codon was maintained at 64% for SEQ ID NO:21 and 67% for SEQ
ID NO:88, whereas the other nucleotides were added at the remainder
frequency divided by three. Since the parent nucleotides are in the
majority, the overall consensus sequence for the whole library
should still contain the parental sequence. Inspection of
individual isolates, however, shows that multiple mutations are
possible, thus allowing selection of peptides with improved binding
ability compared to the parent sequence.
[0742] For the third library, the TN8 motif described above was
kept constant and all of the other positions in were allowed to
vary with NNK substitution in the template oligonucleotide. To
extend the substitution, NNK diversity was also permitted in the
two flanking amino acid positions, thus adding variable amino acid
positions N-terminal and C-terminal to the display peptide. The
secondary library template, therefore, encoded a display peptide of
the following sequence:
Xaa-Xaa-Trp-Val-Glu-Cys-Xaa-Xaa-Xaa-Thr-Gly-Xaa-Cys-Xaa-Xaa-Xaa-Xaa-Xaa
(SEQ ID NO:261), where Xaa can be any amino acid. Unlike the
previous two libraries, where the consensus sequence remains the
parental sequence, this library was quite diverse in all allowed
positions and only resembled the parent motif in the residues that
were held constant.
[0743] A total of 2.times.10.sup.11 pfu from each library was used
as before, except the elution strategy was changed. Competition
elution of bound phage was performed using the parental peptide (50
.mu.M) that was used to make the particular secondary library
(i.e., peptides of SEQ ID NOS:21, 88, and 40, respectively).
Binding phage were eluted through three steps: (1) elution for 1
hour at room temperature, the eluted phage being used to infect
cells for amplification, (2) elution overnight, wherein fresh
competition elution peptide was added to the bound phage and
incubated at 4.degree. C. overnight with mixing, the eluted phage
being then used to infect cells for amplification, and (3) the
remaining beads (bearing uneluted binding phage) were used to
infect cells directly. Three rounds of selections were performed.
Plaques were picked from rounds 2 and 3 and analyzed by ELISA and
sequencing. KDR positive isolates were assayed further for
competition with 50 .mu.M free parent peptide. Those peptides that
showed minimal competition with the parent peptide were deemed
higher affinity binders and were synthesized. These sequences are
listed in the following table as SEQ ID NOS:22-33 for the TN8
secondary library and SEQ ID NOS:89-95 for the TN12 secondary
library.
2TABLE 1 TN8/IXLibrary Isolates SEQ Sequence ID NO: Elution Class
DSWCSTEYTYCEMI 20 1 HR NA PKWCEEDWYYCMIT 21 1 HR (III)
SDWCRVDWYYCWLM 22 O/N III ANWCEEDWYYCFIT 23 O/N III ANWCEEDWYYCWIT
24 O/N III PDWCEEDWYYCWIT 25 O/N III SNWCEEDWYYCYIT 26 O/N III
PDWCAADWYYCYIT 27 O/N III PEWCEVDWYYCWLL 28 CELL III PTWCEDDWYYCWLF
29 O/N III SKWCEQDWYYCWLL 30 CELL III RNWCEEDWYYCFIT 31 O/N III
VNWCEEDWYYCWIT 32 O/N III ANWCEEDWYYCYIT 33 O/N III VWECAKTFPFCHWF
34 1 HR I VTVCYEGTRICEWH 35 1 HR NA WVECRYSTGLCINY 36 O/N NA
WYWCDYYGIGCKWT 37 1 HR NA WVECWWKSGQCYEF 38 1 HR, CELL (II)
WIQCDMETGLCTHG 39 1 HR, CELL II WVECFMDTGACYTF 40 CELL, O/N II
WLECYAEFGHCYNF 41 CELL, O/N II WIECDMLTGMCKHG 42 CELL NA
SVECFMDTGACYTF 43 CELL I WIQCNSITGHCTSG 44 CELL II WIECYHPDGICYHF
45 CELL (III) QAWVECYAETGYCWPRSW 46 NA NA VGWVECYQSTGFCYHSRD 47 NA
NA FTWVECHQATGRCVEWTT 48 NA NA DWWVECRVGTGLCYRYDT 49 NA NA
DSWVECDAQTGFCYSFLY 50 NA NA GGWVECYWATGRCIEFAG 51 NA NA
ERWVECRAETGFCYTWVS 52 NA NA GGWVECRAETGHCQEYRL 53 NA NA
VAWVECYQTTGKCYTFRG 54 NA NA EGWVECFANTGACFTYPR 55 NA NA
GVECYKHSGMCRSW 56 O/N II GVWCDMVTGWCYHG 57 CELL II WIECHYKTGHCIHS
58 CELL II DFNCKMIDGFCLLK 59 1 HR II WIQCDRKAGRCSRG 60 CELL II
TITCWMDTGHCMHE 61 CELL II GINCYPATGKCQMG 62 CELL II WTECHYATGKCHSF
63 CELL II LNICKEDWYYCFLL 64 1 HR I/III GITCYSATGKCQMW 65 CELL II
WVQCASDTGKCIMG 66 CELL II TGNCQEDWYYCWYF 67 CELL II KELCEDDWYYCYLM
68 1 HR I/III HWECYSDTGKCWFF 69 O/N II GITCYSDTGKCFSF 70 CELL II
AVTCWALTGHCVEE 71 O/N II YVDCYYDTGRCYHQ 72 CELL II WYWCQYHGVCPQS*
73 1 HR I/III LVMCISPEGYCYEI 74 O/N II LIECYAHTGLCFDF 75 O/N II
HWWCAFQPQECEYW 76 1 HR III HYECWYPEGKCYFY 77 CELL II WYWCHHIGMYCDGF
78 1 HR III WEWCPIDAWECIML 79 1 HR II WLECYTEFGHCYNF 80 1 HR II
WVECWWKYGQCYEF 81 1 HR II PNTCETFDLYCWWI 82 1 HR II WIICDGNLGWCWEG
83 O/N II GEQCSNLAVACCST 84 O/N II WVECYDPWGWCWEW 85 CELL NA
WYWCMHYGLGCPYR 86 CELL NA
[0744]
3TABLE 2 TN12/I Library Isolates* SEQ Sequence ID NO: Elution Class
YPWCHELSDSVTRFCVPW 87 1 HR (III) SRVCWEDSWGGEVCFRY 88 1 HR (III)
SRVCWEYSWGGEVCYRV 89 O/N III FGECWEYFWGGEFCLRV 90 CELL III
WRICWESSWGGEVCIGH 91 CELL III YGVCWEYSWGGEVCLRF 92 CELL III
SSVCFEYSWGGEVCFRY 93 CELL III SRVCWEYSWGGQICLGY 94 CELL III
FSVCWEYSWGGEVCLRQ 95 CELL III DHMCRSPDYQDHVFCMYW 96 CELL (II)
PPLCYFVGTQEWHHCNPF 97 CELL (II) WWECKREEYRNTTWCAWA 98 CELL II
DSYCMMNEKGWWNCYLY 99 CELL NA PAQCWESNYQGIFFCDNP 100 CELL II?
GSWCEMRQDVGKWNCFSD 101 CELL II GWACAKWPWGGEICQPS 102 CELL (II)
ASTCVFHDHPYFPMCQDN 103 CELL I/III PDTCTMWGDSGRWYCFPA 104 CELL (II)
NWKCEYTQGYDYTECVYL 105 O/N II NWECGWSNMFQKEFCARP 106 1 HR (III)
SGYCEFESDTGRWFCSSW 107 O/N II GGWCQLVDHSWWWCGDS 108 O/N II
DNWCEIVVEKGQWFCYGS 109 O/N II YPGCYETSLSGVWFCADG 110 CELL II
GWCQMDAQGIWSCWAD 111 1 HR II DRWCMLDQEKGWWLCGPP 112 CELL II
NSECGCPNMLHKEFCARH 113 1 HR I/III PFWCKFQQSKAMFPCSWF 114 1 HR II
YPWCHEHSDSVTRFCVPW 115 1 HR III SDLCYNQSGWWELCYFD 116 O/N I/II?
LGYCMYDYENRGWTCYPP 117 O/N II YYQCQRYWDGKTWWCEYN 118 1 HR I/III
DSWCELEHQSGIWRCDFW 119 CELL II DWACDEYWSAYSVLCKHP 120 CELL II
LSLCYNDMHGWWEHCQWY 121 CELL II YSHCIETSMENIWFCDFD 122 CELL II
PPFCIYQEPSGQWWCYDH 123 CELL II PGWCDFSPQLGQWMCDWF 124 CELL II
LDNCIWNVWKGVQDCEYS 125 O/N II AGWCEYVAPQGAWRCFHN 126 CELL II
WDDCIWHMWLKKKDCNSG 127 O/N II PGHCEYIWIDEQPWCVRL 128 CELL III
YSDCLFQLWKGSVCPPS 129 CELL II YFFCSFADVAYESCHPL 130 CELL NA
NYMCESEDHTYMFPCWWY 131 CELL NA DAVCYNPWFKYWETCEYN 132 CELL NA
NYMCEYEDHTYMLTCECN 133 CELL NA WDDCIYSMWMVHTVCDR 134 CELL NA
NWKCDAHQEGRIHICWGY 135 CELL NA NGSCWYDFGWETEICFHN 136 CELL II
[0745]
4TABLE 3 Lin20 Library Isolates* SEQ Sequence ID NO: Elution Class
QVQYQFFLGTPRYEQWDLDK 137 CELL II EPEGYAYWEVITLYHEEDGD 138 CELL (II)
WYYDWFHNQRKPPSDWIDNL 139 1 HR III AFPRFGGDDYWIQQYLRYTD 140 1 HR
(III) GDYVYWEIIELTGATDHTPP 141 O/N (III) RGDYQEQYWHQQLVEQLKLL 142 1
HR (III) RSWYLGPPYYEEWDPIPN 143 CELL II PSNSWAAVWEDDMQRLMRQH 144
CELL II PRLGDDFEEAPPLEWWWAHF 145 CELL II MPPGFSYWEQVVLHDDAQVL 146
CELL II KKEDAQQWYWTDYVPSYLYR 147 1 HR III? WVTKQQFIDTYGRKEWTILF 148
CELL II WLYDYWDRQQKSEEFKFWSQ 149 1 HR III PVTDWTPHHPKAPDVWLFYT 150
1 HR III? EWYWTEHVGMKHGFFV 151 1 HR I/III DALEAPKRDWYYDWFLNHSP 152
1 HR III PDNWKEFYESGWKYPSLYKPL 153 1 HR NA EWDAQYWHDLRQQYMLDYIQ 154
1 HR I/III AFEIEYWDSVRNKIWQHFPD 155 1 HR I/III AFPRFGGDDYWIQQYLRYTF
156 1 HR I/III AHMPPWRPVAVDALFDWVE 157 CELL NA AHMPPWWPLAVDAQEDWFE
158 CELL NA AQMPPWWPLAVDALFDWFE 159 CELL II ARMGDDWEEAPPHEWGWADG
160 CELL II DWYWQRERDKLREHYDDAFW 161 1 HR I/III DWYWREWMPMHAQFLADDW
162 1 HR I/III DWYYDEILSMADQLRHAFLS 163 1 HR III
EEQQALYPGCEPAEHWVYAG 164 1 HR III FDVVNWGDGIWYAYPS 165 CELL II
FPSQMWQQKVSHHFFQHKGY 166 CELL II GSDHVRVDNYWWNGMAWEIF 167 1 HR II
ISPWREMSGWGMPWITAVPH 168 1 HR I/III LEEVFEDFQDFWYTEHIIVDR 169 1 HR
II MPPGFSYWEQAALHDDAQDL 170 CELL II PEDSEAWYWLNYRPTMFHQL 171 1 HR
I/III? QIEYVNDKWYWTGGYWNVPF 172 1 HR II QVQYQFILGTPRYEQWDPDK 173
CELL II RDEWGWTGVPYEGEMGYQIS 174 1 HR II STNGDSFVYWEEVELVDHPY 175
O/N II SYEQWLPQYWAQYKSNYFL 176 1 HR I/III? TKWGPNPEHWQYWYSHYASS 177
1 HR I/III? VSKGSIDVGEGISYWEIIEL 178 1 HR III WESDYWDQMRQQLKTAYMKV
179 1 HR I/III WYHDGLHNERKPPSHWIDNV 180 1 HR III
APAWTFGTNWRSIQRVDSLT 181 CELL NA EGWFRNPQEIMGFGDSWDKP 182 CELL NA
GWDLSVNRDKRWFWPWSSRE 183 CELL NA KSGVDAVGWHIPVWLKKYWF 184 CELL NA
GMDLYQYWASDDYWGRHQEL 185 CELL NA GVDIWHYWKSSTRYFHQ 186 CELL NA
[0746]
5TABLE 4 TN7/IV Library Isolates SEQ Sequence ID NO: Eluti n Class
GVECNHMGLCVSW 187 CELL II GITCDELGRCVHW 188 CELL II WIQCNHQGQCFHG
189 CELL II WIECNKDGKCWHY 190 CELL II WVECNHKGLCREY 191 CELL II
WYWCEFYGVCSEE 192 1 HR I/III
[0747]
6TABLE 5 TN9/IV Library Isolates SEQ Sequence ID NO: Elution Class
IDFCKGMAPWLCADM 193 1 HR (III) PWTCWLEDHLACAML 194 CELL II
DWGCSLGNWYWCSTE 195 CELL NA MPWCSEVTWGWCKLN 196 CELL II
RGPCSGQPWHLCYYQ 197 O/N II PWGCDHFGWAWCKGM 198 O/N NA
MPWCVEKDHWDCWWW 199 CELL NA PGPCKGYMPHQCWYM 200 CELL NA
YGPCAEMSPWLCWYP 201 CELL NA YGPCKNMPPWMCWHE 202 CELL NA
GHPCKGMLPHTCWYE 203 CELL NA
[0748]
7TABLE 6 TN10/IX Library Isolates SEQ Sequence ID NO: Elution Class
NNSCWLSTTLGSCFFD 204 O/N NA DHHCYLHNGQWICYPF 205 CELL (III)
NSHCYIWDGMWLCFPD 206 CELL (II)
[0749]
8TABLE 7 MTN13/I Library Isolates SEQ Sequence ID NO: Elution Class
SNKCDHYQSGPHGKICVNY 207 CELL NA SNKCDHYQSGPYGEVCFNY 208 CELL NA
RLDCDKVFSGPYGKVCVSY 209 CELL NA RLDCDKVFSGPDTSCGSQ 210 CELL NA
RLDCDKVFSGPHGKICVRY 211 CELL NA RLDCDKVFSGPHGKICVNY 212 CELL NA
RVDCDKVISGPHGKICVNY 213 CELL NA RTTCHHQISGPHGKICVNY 214 CELL NA
EFHCHHIMSGPHGKICVNY 215 CELL NA HNRCDFKMSGPHGKICVNY 216 CELL NA
WQECTKVLSGPGTFECSYE 217 CELL NA WQECTKVLSGPGQFSCVYG 218 CELL NA
WQECTKVLSGPGQFECEYM 219 CELL NA WQECTKVLSGPNSFECKYD 220 CELL NA
WDRCERQISGPGQFSCVYG 221 CELL NA WQECTKVLSGPGQFLCSYG 222 CELL NA
RLDCDMVFSGPHGKICVNY 223 CELL NA KRCDTTHSGPHGIVCVVY 224 CELL NA
SNKCDHYQSGPYGAVCLHY 225 CELL NA SPHCQYKISGPFGPVCVNY 226 CELL NA
AHQCHHWTSGPYGEVCFNY 227 CELL NA YDKCSSRFSGPFGEICVNY 228 CELL NA
MGGCDFSFSGPFGQICGRY 229 CELL NA RTTCHHQISGPFGDVCVSY 230 CELL NA
WYRCDFNMSGPDFTECLYP 231 CELL NA WMQCNMSASGPKDMYCEYD 232 CELL NA
GISCKWIWSGPDRWKCHHF 233 CELL NA WQVCKPYVSGPAAFSCKYE 234 CELL NA
GWWCYRNDSGPKPFHCRIK 235 CELL NA EGWCWFIDSGPWKTWCEKQ 236 CELL NA
FPKCKFDFSGPPWYQCNTK 237 CELL NA RLDCDKVFSGPYGRVCVKY 238 CELL NA
RLDCDKVFSGPYGNVCVNY 239 CELL NA RLDCDKVFSGPSMGTCKLQ 240 CELL NA
RTTCHHHISGPHGKICVNY 241 CELL NA QFGCEHIMSGPHGKICVNY 242 CELL NA
PVHCSHTISGPHGKICVNY 243 CELL NA SVTCHFQMSGPHGKICVNY 244 CELL NA
PRGCQHMISGPHGKICVNY 245 CELL NA RTTCHHQISGPHGQICVNY 246 CELL NA
WTICHMELSGPHGKICVNY 247 CELL NA FITCALWLSGPHGKICVNY 248 CELL NA
MGGCDFSFSGPHGKICVNY 249 CELL NA KDWCHTTFSGPHGKICVNY 250 CELL NA
AWGCDNMMSGPHGKICVNY 251 CELL NA SNKCDHIMSGPHGKICVNY 252 CELL NA
SNKCDHYQSGPFGDICVMY 253 CELL NA SNKCDHYQSGPFGDVCVSY 254 CELL NA
SNKCDHYQSGPFGDICVSY 255 CELL NA RTTCHHQISGPFGPVCVNY 256 CELL NA
RTTCHHQISGPYGDICVKY 257 CELL NA PHGKICVNYGSESADPSYIE 258 CELL NA
RYKCPRDLSGPPYGPCSPQ 259 CELL NA
[0750]
9TABLE 27 TN11.1 Library Isolates SEQ # of Sequence ID NO: Elution
isolates GSNMVCMDDSYGGTTCYSMAP 505 D6 107 GSYNQCYGDYWGGETCYLIAP 506
Bead 93 GSRVNCGAEDGLSFLCMMDAP 507 Bead 40 GSIWDCQISEYGGEDCYLVAP 508
D6 29 GSYWHCMDDFFGGETCFATAP 509 D6 28 GSGEYCFPSIYGGETCYAHAP 510 D6
24 GSEQLCFEYQYGGVECFGPAP 511 D6 21 GSTGVCSPAPYGGEVCYHFAP 512 D6 20
GSHDECWEDIYGGFTCMLMAP 513 D6 19 GSQHTCFSDPYGGEVCYADAP 514 D6 18
GSWEVCENSNYGGQICYWFAP 515 D6 18 GSHEMCWSDVWGGLTCMTMAP 516 D6 15
GSLSLCKFFGDGSYYCEPPAP 517 D6 14 GSTRFCEPYQWGGEVCYWKAP 518 D6 14
GSFSTCATFPWTTKFCSNMAP 519 VEGF 12 GSHELCFEGTYGGEVCFSMAP 520 D6 12
GSLWHCFNDVYGGENCIPFAP 521 VEGF 12 GSQQYCIPAEYGGMECYPFAP 522 Bead 11
GSIQNCWKYEFGGIVCMDMAP 523 D6 9 GSVSGCKEFWNSSGRCFTHAP 524 D6 9
GSLWECRGDFYGGEVCFNYAP 525 D6 8 GSNLICYDYYYGGQDCYHDAP 526 D6 8
GSEGTCEEYQYGGIVCWWGAP 527 D6 7 PGSGDCDWYYEWLFDCPLNAP 528 VEGF 7
GSDQMCFNESFGGQICFYSAP 529 VEGF 6 GSGMACMSDPYGGQVCYAIAP 530 D6 5
GSELTCWDSAYGGNECFFFAP 531 VEGF 4 GSHFLCVKEMEGGETCYYSAP 532 VEGF 4
GSWEICFAGPYGGSWCIPEAP 533 Bead 4 GSAQYCMESYYGGFTCVTLAP 534 Bead 3
GSFNACGFEEGLEWMCYRQAP 535 D6 3 GSKLLCQYWEHEWWPCMNEAP 536 VEGF 3
GSNMNCGAEQGLESLCGWRAP 537 VEGF 3 GSNWVCLSEGYGGMTCYPSAP 538 VEGF 3
GSPSTCIYSSGLIVDCGLLAP 539 VEGF 3 GSTQHCWPSEYGGMTCVPAAP 540 D6/VEGF
3 GSTWACEEISAHHTKCTYQAP 541 VEGF/Bead 3 GSYTECWEEDYGGVTCFNVAP 542
Bead 3 GSDKFCFKDPWGGVTCYHLAP 543 D6 2 GSDLDCWTDPYGGEVCYWHAP 544 D6
2 GSDYECYNAWFGYFDCPGDAP 545 VEGF/Bead 2 GSLSTCWKQAYGGVWCVDHAP 546
VEGF 2 GSMQLCRQWAYGGQTCYWYAP 547 D6 2 GSNQLCITAQFGGQDCYPIAP 548
VEGF 2 GSPMWCAPWPWGGEHCVGSAP 549 VEGF 2 GSQLLCGSEPELAWMCEQGAP 550
VEGF 2 GSQRQCWDDYFGGIICYVIDA 551 VEGF 2 GSREVCWQDFFGGMVCVRDAP 552
Bead 2 GSSQWCQRDFWGGDICINLAP 553 VEGF 2 GSTDICWPGSYGGEICIPRAP 554
VEGF 2 GSTEYCWPEPHGGQACILLAP 555 VEGF 2 GSTHFCIDYIWGGKHCIADAP 556
VEGF 2 GSTMMCWPAHYGGDECFALAP 557 VEGF 2 GSTQMCFPHQYGGQSCYSFAP 558
VEGF 2 GSVEGCWVEDQTSPFCWIDAP 559 VEGF 2 GSWYTCWDEASGGQVCYQLAP 560
VEGF 2 GSYNLCYPEIYGGQVCYRMAP 561 D6 2 GSYSQCFPDPFGGTTCFVSAP 562 D6
2 GSSMQCFNRVSQLVDCETAAP 563 VEGF 2 GSAKTCRSYWAQSGYCYEYAP 564 D6 1
GSAQTCWDYVYGGFFCLNTAP 565 VEGF 1 GSAWDCFQQDTYSTHCHWRAP 566 VEGF 1
GSAWNCEMLDPWSTQCSWDAP 567 VEGF 1 GSAWVCHPEQEGGTTCYWVAP 568 VEGF 1
GSDELCWPQEFGGWVCIQGAP 569 Bead 1 GSDFQCFNWEGYPTNCYSNAP 570 D6 1
GSDKKCWPSPYGGQICWAVAP 571 VEGF 1 GSDQLCFDQRWGGQVCVFGAP 572 VEGF 1
GSDSGCKEFWNSSDRCYTHAP 573 D6 1 GSEWICWSSFFGGETCTPKAP 574 VEGF 1
GSEWNCLNNTPYQTTCSWRAP 575 Bead 1 GSEWRCWPDVFGGQMCFNMAP 576 VEGF 1
GSEYECYPDWYGGEVCVQKAP 577 VEGF 1 GSFEACWEEAYGGLTCWHDAP 578 D6 1
GSFEECMPYRYGGQTCFMIAP 579 D6 1 GSFWTCVDTNWHTTECFHSAP 580 VEGF 1
GSGQMCWHGQYGGTICVAMAP 581 VEGF 1 GSGWVCKQQGPHKTECLFMAP 582 VEGF 1
GSHDECWEDIYGGFTCMPYGS 583 D6 1 GSHVVCWDDPYGGESCYNTAP 584 VEGF 1
GSIDICTDSYWGGITCYKFAP 585 D6 1 GSKWICVDVKWGGSACYDIAP 586 VEGF 1
GSLWECRIDYYGGEVCFIDAP 587 D6 1 GSLWTCVLSVYGGEDCYNLAP 588 VEGF 1
GSMTMCGAEPDLWYMCYGIAP 589 VEGF 1 GSNQYCMPYDWGGEMCFEVAP 590 D6 1
GSNVFCSEGPFGGEICYGIAP 591 VEGF 1 GSNWACFIEAMGGWTCAPRPT 592 VEGF 1
GSNWTCFIDSFQGETCYPFAP 593 VEGF 1 GSNWWCHSEAFGGHTCYNAAP 594 VEGF 1
GSPCACNNSYGHSDDCDHLAP 595 VEGF 1 GSPGNCKDFWAWSLQCFSFAP 596 VEGF 1
GSPRWCYFSSGIMKDCDILAP 597 VEGF 1 GSPTYCQFHSGVVTLCSMFAP 598 VEGF 1
GSQEICFNSQYGGQVCFDSAP 599 D6 1 GSQMICYPHVFGGQDCFPGAP 600 VEGF 1
GSQWTCTELSDVMTHCSYTAP 601 VEGF 1 GSRVNCGAEDDLSFLCMTEAP 602 VEGF 1
GSSGDCIEMYNDWYYCTILAP 603 Bead 1 GSSWECGEFGDTTIQCNWVAP 604 VEGF 1
GSSWQCFSEAPSGATCVPIAP 605 VEGF 1 GSSWQCVQVDDFHTECSFMAP 606 VEGF 1
GSSWTCVFYPYGGEVCIPDAP 607 D6 1 GSTELCVPYQWGGEVCVAQAP 608 D6 1
GSTVYCHNEYFGGQVCFTIAP 609 VEGF 1 GSTYGCEYYMPFQHKCSVEAP 610 VEGF 1
GSWWGCFPYSWGGEICTSIAP 611 D6 1 GSWWNCVDTSFHTTQCKYAAP 612 VEGF 1
GSYFMCQDGFWGGQDCFYIAP 613 VEGF 1 GSYMWCTESKFGGSTCFNLAP 614 VEGF 1
GSGAYSHLLEYHAVCKNVAP 615 VEGF 1 PGSWTCQNYEPWATTCVYDAP 616 VEGF
1
[0751] * During the course of DNA synthesis, there is always a
small percentage of incomplete couplings at each cycle. Since the
libraries used for these experiments were constructed using TRIM
technology to couple trinucleotides (codons) instead of
nucleotides, the library template DNA often has a small percentage
of deleted codons. In the case of the TN12 library, for instance,
it has been observed that approximately 5.3% of the total library
is phage expressing a cyclic 11-mer, rather than a 12-mer, and
indeed some phage expressing 11-mers were isolated in the
selections described above (see Table 2).
[0752] In the foregoing tables, Class I peptides only bind KDR in
the absence of heparin, and therefore presumably target the heparin
binding domain of KDR; Class II peptides bind in the presence or
absence of heparin or VEGF, and therefore presumably bind at a
non-involved site on KDR; Class III peptides exhibit binding
characteristics that are not affected by heparin but are perturbed
in the presence of VEGF, and therefore presumably these bind either
to VEGF or the VEGF binding domain of KDR. NA signifies data not
available. In the elution column, 1 HR, O/N, and Cell stand for 1
hour VEGF, overnight VEGF, and bead infection elutions,
respectively. In some cases, a particular isolate sequence was
observed in two different elutions. For the isolates identified by
second generation library, VEGF elutions were substituted with
peptide elutions (see below).
Example 2
Peptide Synthesis and Fluorescein Labeling
[0753] Selected KDR or VEGF/KDR complex binding peptides
corresponding to positive phage isolates were synthesized on solid
phase using 9-fluorenylmethoxycarbonyl protocols and purified by
reverse phase chromatography. Peptide masses were confirmed by
electrospray mass spectrometry, and peptides were quantified by
absorbance at 280 nm. For synthesis, two N-terminal and two
C-terminal amino acids from the phage vector sequence from which
the peptide was excised were retained, and a
-Gly-Gly-Gly-Lys-NH.sub.2 linker (SEQ ID NO:262) was added to the
C-terminus of each peptide. Each peptide was N-terminally
acetylated. For peptides with selected lysine residues, these were
protected with
1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl (ivDde),
which allows selective coupling to the C-terminal lysine, is not
removed during peptide cleavage, and can be removed after coupling
with 2% hydrazine in DMF or 0.5 M hydroxylamine, pH 8, in
water.
[0754] Each peptide was labeled with fluorescein on the C-terminal
lysine using fluorescein (N-hydroxysuccinimide ester derivative) or
fluorescein isothiocyanate (FITC) in DMF, 2% diisopropylethylamine
(DIPEA). If the peptide contained an ivDde protected lysine, the
reaction was quenched by the addition of 2% hydrazine, which reacts
with all free NHS-fluorescein and removes the internal protecting
group. For all other peptides, the reaction was quenched by the
addition of an equal volume of 0.5 M hydroxylamine, pH 8. The
quenched reactions were then diluted with water to less than 10%
DMF and then purified using C18 reverse phase chromatography. The
peptides were characterized for purity and correct mass on an LC-MS
system (HP1100 HPLC with in-line SCIEX AP150 single quadrapole mass
spectrometer).
Example 3
Fluorescence Anisotropy Measurements and BiaCore Assays
[0755] Fluorescence anisotropy measurements were performed in
384-well microplates in a volume of 10 .mu.l in binding buffer
(PBS, 0.01% Tween-20, pH 7.5) using a Tecan Polarion fluorescence
polarization plate reader. In some cases, heparin (0.5 .mu.g/mL) or
10% human serum was added to the binding buffer (data not shown).
The concentration of fluorescein labeled peptide was held constant
(20 nM) and the concentration of KDR-Fc (or similar target) was
varied. Binding mixtures were equilibrated for 10 minutes in the
microplate at 30.degree. C. before measurement. The observed change
in anisotropy was fit to the equation below via nonlinear
regression to obtain the apparent K.sub.D. This equation (1)
assumes that the synthetic peptide and KDR form a reversible
complex in solution with 1:1 stoichiometry. 1 r obs = r free + ( r
bound - r free ) ( K D + KDR + P ) - ( K D + KDR + P ) 2 - 4 KDR P
2 P , ( 1 )
[0756] where r.sub.obs is the observed anisotropy, r.sub.free is
the anisotropy of the free peptide, r.sub.bound is the anisotropy
of the bound peptide, K.sub.D is the apparent dissociation
constant, KDR is the total KDR concentration, and P is the total
fluorescein-labeled peptide concentration. K.sub.D was calculated
in a direct binding assay (K.sub.D,B) (see Table 8), and therefore
these values represent KDR binding to the fluorescein labeled
peptide.
[0757] For BiaCore determinations of K.sub.D, KDR-Fc(or other
protein targets) was cross-linked to the dextran surface of a CM5
sensor chip by the standard amine coupling procedure (0.5 mg/mL
solutions diluted 1:20 with 50 mM acetate, pH 6.0, R.sub.L
KDR-Fc=12859). Experiments were performed in HBS-P buffer (0.01 M
HEPES, pH 7.4, 0.15 M NaCl, 0.005% polysorbate 20 (v/v)). Peptide
solutions quantitated by extinction coefficient were diluted to 400
nM in HBS-P. Serial dilutions were performed to produce 200, 100,
50, and 25 nM solutions. For association, peptides were injected at
20 .mu.l/min. for 1 minute using the kinject program. Following a
1-minute dissociation, any remaining peptide was stripped from the
target surface with a quick injection of 1M NaCl for 25 sec. at 50
.mu.l/min. All samples were injected in duplicate. Between each
peptide series a buffer injection and a non-target binding peptide
injection served as additional controls. Sensorgrams were analyzed
using the simultaneous k.sub.a/k.sub.d fitting program in the
BIAevaluation software 3.1. Apparent K.sub.D by this method is set
forth as BiaK.sub.D in Table 8. Unlike the fluorescence anisotropy
experiments above, the unlabeled peptide was used for all testing
using this assay and therefore, these values represent KDR binding
to the unlabeled peptide. Binding affinities determined for the
synthesized polypeptides are set forth in Table 8, below. The
putative disulfide-constrained cyclic peptide moieties of the
polypeptides are in bold.
10TABLE 8 Binding Affinities for Synthesized Peptides K.sub.D,B
BiaK.sub.D SEQ Sequence (.mu.M) (.mu.M) ID NO: TN8
AGDSWCSTEYTYCEMIGTGGGK >2 263 AGPKWCEEDWYYCMITGTGGGK 0.28 0.027
264 AGVWECAKTFPFCHWFGTGGGK 2.60 265 AGWVECWWKSGQCYEFGTGGGK 1.3 266
AGWLECYAEFGHCYNFGTGGGK >10 267 AGWIQCNSITGHCTSGGTGGGK 0.24 268
AGWIECYHPDGICYHFGTGGGK 0.32 0.32 269 AGSDWCRVDWYYCWLMGTGGGK 0.064
270 AGANWCEEDWYYCFITGTGGGK 0.310 271 AGANWCEEDWYYCWITGTGGGK 0.097
272 AGPDWCEEDWYYCWITGTGGGK 0.075 273 AGSNWCEEDWYYCYITGTGGGK 0.046
274 AGPDWCAADWYYCYITGTGGGK 0.057 275 AGPEWCEVDWYYCWLLGTGGGK 0.075
276 AGPTWCEDDWYYCWLFGTGGGK 0.0032 0.079 277 AGSKWCEQDWYYCWLLGTGGGK
0.400 278 AGRNWCEEDWYYCFITGTGGGK 0.190 279 AGVNWCEEDWYYCWITGTGGGK
0.260 280 AGANWCEEDWYYCYITGTGGGK 0.180 281
AGQAWVECYAETGYCWPRSWGTGGGK 0.71 282 AGQAWIECYAEDGYCWPRSWGTGGGK 1.40
283 AGVGWVECYQSTGFCYHSRDGTGGGK 1.30 284 AGFTWVECHqATGRCVEWTTGTGGGK
2.00 285 AGDWWVECRVGTGLCYRYDTGTGGGK 0.93 286
AGDSWVECDAQTGFCYSFLYGTGGGK 2.30 287 AGGGWVECYWATGRCIEFAGGTGGGK NB
288 AGERWVECRAETGFCYTWVSGTGGGK 2.10 289 AGGGWVECRAETGHCQEYRLGTGGGK
1.60 290 AGVAWVECYQTTGKCYTFRGGTGGGK .about.2 291
AGEGWVECFANTGACFTYPRGTGGGK 2.10 292 TN12 GDYPWCHELSDSVTRFCVPWDPGGGK
0.98 0.18 293 GDSRVCWEDSWGGEVCFRYDPGGGK 0.069 0.12 294
GDDHMCRSPDYQDHVFCMYWDPGGGK 0.48 0.14 295 GDPPLCYFVGTQEWHHCNPFDPGGGK
0.60 296 GDDSYCMMNEKGWWNCYLYDPGGGK 1.3 297
GDPAQCWESNYQGIFFCDNPDPGGGK 2.3 298 GDGSWCEMRQDVGKWNCFSDDPGGGK 0.62
0.18 299 GDGWACAKWPWGGEICQPSDPGGGK 1.0 1.5 300
GDPDTCTMWGDSGRWYCFPADPGGGK 0.49 0.26 301 GDNWKCEYTQGYDYTECVYLDPGGGK
0.82 302 GDNWECGWSNMFQKEFCARPDPGGGK 0.21 0.99 303
GDWWECKREEYRNTTWCAWADPGGGK 486 GDSSVCFEYSWGGEVCFRYDPGGG- K 0.058
487 GDSRVCWEYSWGGQICLGYDPGGGK 0.32 488 Lin20
AQQVQYQFFLGTPRYEQWDLDKGGK 1.7 304 AQEPEGYAYWEVITLYHEEDGDGGK 0.27
0.73 305 AQAFPRFGGDDYWIQQYLRYTDGGK 0.53 0.25 306
AQGDYVYWEIIELTGATDHTPPGGK 0.18 307 AQRGDYQEQYWHQQLVEQLKLLGGK 0.31
5.3 308 AQRSWYLGPPYYEEWDPIPNGGK 1.8 309 AQDWYYDEILSMADQLRHAFLSGG-
GK 0.05 310 TN9 AGIDFCKGMAPWLCADMGTGGGK 0.73 0.18 311
AGPWTCWLEDHLACAMLGTGGGK 3.9 312 AGDWGCSLGNWYWCSTEGTGGGK 2.0 313
TN10 GSDHHCYLHNGQWICYPFAPGGGK 0.26 0.15 314
GSNSHCYIWDGMWLCFPDAPGGGK 0.74 315 MTN13 SGRLDCDKVFSGPYGKVCVSYGSGGGK
1.05 316 SGRLDCDKVFSGPHGKICVNYGSGGGK .about.2 317
SGRTTCHHQISGPHGKICVNYGSGGGK 0.65 318 SGAHQCHHWTSGPYGEVCFNYGSGGGK
.about.2 319
[0758] For the analysis of those peptides that bind specifically to
KDR/VEGF complex, each peptide was tested for binding to the
complex in both assays (fluorescence anisotropy/Biacore) as above.
In the anisotropy assay, KDR-VEGF complex was formed by mixing
together a two fold molar excess of VEGF with KDR-Fc. This mixture
was then used in the direct binding titration using a fluorescein
labeled peptide as done previously. As a control, each peptide was
also tested for binding to KDR and VEGF alone to assess their
specificity for complex. Since none of the peptides bound VEGF to
any extent, the presence of excess VEGF in the assay should not
affect the K.sub.D determination. As shown in Table 9, below, all
of the peptides showed a dramatic binding preference, binding for
KDR/VEGF complex over VEGF. Some of them, however, did show some
residual binding to free KDR. To confirm the anisotropy results,
the unlabeled peptides were tested in Biacore as before, except the
chip was saturated with VEGF to form KDR/VEGF complex prior to the
injection of the peptides. In the peptides tested, the BiaK.sub.D
was within at least 2-fold of the anisotropy measurement.
11TABLE 9 KDR/VEGF Complex Specific Peptides SEQ K.sub.D,B
BiaK.sub.D ID K.sub.D, B K.sub.D,B (KDR/) (KDR/) NO: Sequence (KDR)
(VEGF) VEGF) VEGF) 320 AGMPWCVEKDHWDCWWWGTGGGK NB 10 0.14 321
AGPGPCKGYMPHQCWYMGTGGGK 0.4 NB 0.06 0.08 322
AGYGPCAEMSPWLCWYPGTGGGK 3.7 NB 0.13 323 AGYGPCKNMPPWMCWHEGTGGGK 1.8
NB 0.18 0.42 324 AGGHPCKGMLPHTCWYEGTGGGK >10 NB 3.3 325
AQAPAWTFGTNWRSIQRVDSLTGGGGGK NB NB 0.84 326
AQEGWFRNPQEIMGFGDSWDKPGGGGGK NB NB 1.4 The putative
disulfide-constrained cyclic peptide moiety is underscored.
Example 4
Preparation of KDR and VEGF/KDR Complex Binding Polypeptides
[0759] Utilizing the methods set forth above, biotinylated versions
the KDR and VEGF/KDR complex binding polypeptides set forth in
Table 10 were prepared. The letter "J" in the peptide sequences
refers to a spacer or linker group, 8-amino-3,6-dioxaoctanoyl.
[0760] The ability of the biotinylated polypeptides (with the JJ
spacer) to bind to KDR was assessed using the assay set forth in
Example 5, following the procedures disclosed therein. Several
biotinylated peptides bound well to the KDR-expressing cells: SEQ
ID NO:356 (K.sub.D 1.81 nM+/-0.27), SEQ ID NO:264 (K.sub.D
14.87+/-5.0 nM, four experiment average), SEQ ID NO:294+spacer
(K.sub.D 10.00+/-2.36 nM, four experiment average), SEQ ID NO:301
(K.sub.D 4.03+/-0.86 nM, three experiment average), SEQ ID NO:337
(K.sub.D 6.94+/-1.94 nM, one experiment), and SEQ ID NO:338
(K.sub.D 3.02+/-0.75 nM, one experiment).
12TABLE 10 KDR, VEGF/KDR Complex Binding Polypeptides SEQ ID NO:
Structure (or) Sequence Mol. Wt. MS 294
Ac-GDSRVCWEDSWGGEVCFRYDPGGGK-NH.sub.2 2801.98 1399.6 [M-H].sup.-
329 Ac-AGMPWCVEKDHWDCWWGTGGGK-NH.sub.- 2 2730.14 -- 311
Ac-AGIDFCKGMAPWLCADMGTGGGK-NH.sub.2 2324.02 -- 264
Ac-AGPKWCEEDWYYCMITGTGGGK-NH.sub.2 2361 -- 266
Ac-AGWVECWWKSGQCYEFGTGGGK-NH.sub.2 2474.06 -- 330
Ac-AQEGWFRNPQEIMGFGDSWDKPGGGK-NH.sub.2 2934.35 -- 299
Ac-GDGSWCEMRQDVGK(iv-Dde)WNCFSDDPGGGK-NH.sub.2 3075.29 1537.5
[M.sup.2-] 299 Ac-GDGSWCEMRQDVGKWNCFSDDPGGGK-NH.sub.2 2869.16 --
303 Ac-GDNWECGWSNMFQK(iv-Dde)EFCARPDPGGGK-NH.- sub.2 3160.36 1579.6
[M.sup.2-] 303 Ac-GDNWECGWSNMFQKEFCARPDPGGGK-NH.sub.2 2954.23 --
294 Ac-GDSRVCWEDSWGGEVCFRYDPGGGK(Biotin)-NH.sub.2 3030.29 1512.4
[M.sup.2-] 331 Ac-AQRGDYQEQYWHQQLVEQLK(iv-Dde)LLGGGK-NH.sub.2
3318.71 1659.1 [M.sup.2-] 331 Ac-AQRGDYQEQYWHQQLVEQLKLLGG-
GK-NH.sub.2 3112.58 -- 332 Ac-AGWYWCDYYGIGCK(iv-Dde)WTGGG-
K-NH.sub.2 2673.18 333 Ac-AGWYWCDYYGIGCKWTGTGGGK-NH.sub.2 2467.05
334 Ac-AQWYYDWFHNQRKPPSDWIDNLGGGK-NH.sub.2 3218.51 -- 323
Ac-AGYGPCKNMPPWMCWHEGTGGGK-NH.sub.2 2502.05 -- 335
Ac-AGPKWCEEDWYYCMITGTGGGK(N,N-Dimethyl-Gly-
-Ser-Cys(Acm)-Gly)-NH.sub.2 2836.204 2833.4 [M-H].sup.- 264
Ac-AGPK(iv-Dde)WCEEDWYYCMITGTGGGK-NH.sub.2 2698.11 2695.7
[M-H].sup.-; 1347.8 [M-2H].sup.2-/2 336
Ac-WQPCPWESWTFCWDPGGGK(AcSCH.sub.2C(.dbd.O).paren close-st.
NH.sub.2 2422.71 2420.7 [M-H].sup.-, 1209.9 [M-2H].sup.2-/2 264
Ac-AGPKWCEEDWYYCMITGTGGGK(Biotin)-NH.sub.2 2718.13 2833.4
(M-H).sup.- 264 Ac-AGPKWCEEDWYYCMITGTGGGK(Biotin-JJ.paren close-st.
NH.sub.2 3008.44 1502.6.4 (M-2H).sup.2-/2 264
Ac-AGPKWCEEDWYYCMITGTGGGK(AcSCH.sub.2C(.dbd.O).paren close-st.
NH.sub.2 2608.96 1304, [M-2H].sup.2-/2 294 Ac-GDSRVCWEDSWGGEVCFRYD-
PGGGK(Biotin-JJ.paren close-st. NH.sub.2 3316.4 1657.8,
[M-2H].sup.2-/2 294
Ac-GDSRVCWEDSWGGEVCFRYDPGGGK(AcSCH.sub.2C(.dbd.O).paren close-st.
NH.sub.2 2917.15 1457.4, [M-2H].sup.2-/2 294
Biotin-JJGDSRVCWEDSWGGEVCFRYDPGGGK-NH.sub.2 3272.34 1636.7,
[M-2H].sup.2-/2 264 Ac-AGPKWCEEDWYYCMITGTGGGK(AcSCH.sub.2-
C(.dbd.O)-JJ.paren close-st. NH.sub.2 2899.28 1449.2,
[M-2H].sup.2-/2 277 Ac-AGPTWCEDDWYYCWLFGTGGGK(Biotin-JJ.paren
close-st. NH.sub.2 3066.27 1532.8, [M-2H].sup.2-/2 337
Ac-VCWEDSWGGEVCFRYDPGGGK(Biotin-JJ.paren close-st. NH.sub.2 2903.24
1449.3, (M-2H).sup.2-/2; 965.8, (M-3H).sup.3-/3 338
Ac-AGPTWCEDDWYYCWLFGTJK(Biotin-JJ.paren close-st. NH.sub.2 3042.44
1519.7, (M-2H).sup.2-/2-; 294 Ac-GDSRVCWEDSWGGEVCFRYDPGGG-
K(AcSCH.sub.2C(.dbd.O)-JJ.paren close-st. NH.sub.2 3208.48 1602.6,
[M-2H].sup.2-/2 339 Ac-AGPTWCEDDWYYCWLFGTGGGK(N,N-Dimethy-
l-Gly-Ser-Cys(Acm)-Gly-JJ.paren close-st. NH.sub.2 3242.33 1621.5,
[M-2H].sup.2-/2 277 Ac-AGPTWCEDDWYYCWLFGTGGGK(AcSCH.sub.2-
C(.dbd.O)-JJ.paren close-st. NH.sub.2 2907.29 1453.1,
[M-2H].sup.2-/2 340 Ac-AQAHMPPWRPVAVDALFDWVEGGGGGK(Biotin-JJ.paren
close-st. NH.sub.2 3404.64 1701.6, [M-2H].sup.2-/2 341
Ac-AQAHMPPWWPLAVDAQEDWFEGGGGGK(Biotin-JJ.paren close-st. NH.sub.2
3493.59 1746.2, [M-2H].sup.2-/2 342 Ac-AQAQMPPWWPLAVDALFDWFEGGGGG-
K(Biotin-JJ.paren close-st. NH.sub.2 3487.64 1743.2,
[M-2H].sup.2-/2 343 Ac-AQDWYWREWMPMHAQFLADDWGGGGGK(Biotin-JJ.paren
close-st. NH.sub.2 3751.64 1874.3, [M-2H].sup.2-/2 344
AC-AQK(ivDde)K(iv-Dde)EDAQQWYWTDYVPSYLYRGGGGGK(Biotin-JJ.paren
close-st. NH.sub.2 4220.06 2108.9, [M-2H].sup.2-/2 345
Ac-AQPVTDWTPHHPK(iv-Dde)APDVWLFYTGGGGGK(Biotin-JJ.paren close-st.
NH.sub.2 3781.86 1890.4, [M-2H].sup.2-/2 346
Ac-AQDALEAPK(iv-Dde)RDWYYDWFLNHSPGGGGGK(Biotin-JJ.paren close-st.
NH.sub.2 3897.85 1948.0, [M-2H].sup.2-/2 347
Ac-KWCEEDWYYCMITGTGGGK(Biotin-JJ.paren close-st. NH.sub.2 2781.2
1390.0, [M-2H].sup.2-/2 348 Ac-AGPKWCEEDWYYCMIGGGK(Biotin-JJ.pare-
n close-st. NH.sub.2 2747.15 1373.5, [M-2H].sup.2-/2 349
Ac-KWCEEDWYYCMIGGGK(Biotin-JJ.paren close-st. NH.sub.2 2522.04
1260.8, [M-2H].sup.2-/2 350 Ac-AQPDNWK(iv-Dde)EFYESGWK(iv-Dde)YPS-
LYK(iv-Dde)PLGGGGGK 4377.2 2188.4, [M-2H].sup.2-/2 (Biotin-JJ.paren
close-st. NH.sub.2 351
Ac-AQMPPGFSYWEQVVLHDDAQVLGGGGGK(Biotin-JJ.paren close-st. NH.sub.2
3499.7 1749.2, [M-2H].sup.2-/2 352 Ac-AQARMGDDWEEAPPHEWGWADGGGGG-
K(Biotin-JJ.paren close-st. NH.sub.2 3480.5 1740.2, [M-2H].sup.2-/2
353 Ac-AQPEDSEAWYWLNYRPTMFHQLGGGGGK(Biotin-JJ.paren close-st.
NH.sub.2 3751.7 1875.8, [M-2H].sup.2-/2 354
Ac-AQSTNGDSFVYWEEVELVDHPGGGGGK(Biotin-JJ.paren close-st. NH.sub.2
3554.6 1776.4, [M-2H].sup.2-/2 355 Ac-AQWESDYWDQMRQQLK(iv-Dde)TA-
YMK(iv-Dde)VGGGGGK(Biotin-JJ.paren close-st. NH.sub.2 4187.02
2093.0, [M-2H].sup.2-/2 356 Ac-AQDWYYDEILSMADQLRHAFLSGGGGGK(Bioti-
n-JJ.paren close-st. NH.sub.2 3641.69 1820.9, [M-2H].sup.2-/2 The
putative disulfide constrained cyclic peptide is indicated in
bold.
Example 5
Binding of KDR Binding Peptides/Avidin HRP Complex to KDR
Transfected 293H Cells
[0761] To determine the binding of peptides identified by phage
display to KDR expressed in transiently-transfected 293H cells, a
novel assay that measures the binding of biotinylated peptides
complexed with neutravidin HRP to KDR on the surface of the
transfected cells was developed. This assay was used to screen the
biotinylated peptides set forth in Example 4. Neutravidin HRP was
used instead of streptavidin or avidin because it has lower
non-specific binding to molecules other than biotin due to the
absence of lectin binding carbohydrate moieties and also due to the
absence of the cell adhesion receptor-binding RYD domain in
neutravidin.
[0762] In the experiments described herein, tetrameric complexes of
KDR-binding peptides SEQ ID NO:294, SEQ ID NO:264, SEQ ID NO:277
and SEQ ID NO:356 and a control peptide, which does not bind to
KDR, were prepared and tested for their ability to bind 293H cells
that were transiently-transfected with KDR. All four tetrameric
complexes of KDR-binding peptides were biotinylated and contained
the JJ spacer, and bound to the KDR-expressing cells; however, SEQ
ID NO:356 exhibited the best K.sub.D (1.81 nM). The tetrameric
complexes of KDR-binding peptides SEQ ID NO:294, SEQ ID NO:264
exhibited improved binding over monomers of the same peptides.
Moreover, inclusion of a spacer between the KDR-binding peptide and
the biotin was shown to improve binding in Experiment B.
[0763] In Experiment C, it was shown that this assay can be used to
assess the effect of serum on binding of peptides of the invention
to KDR and VEGF/KDR complex. The binding of SEQ ID NO:264, SEQ ID
NO:294, and SEQ ID NO:356 was not significantly affected by the
presence of serum, while the binding of SEQ ID NO:277 was reduced
more than 50% in the presence of serum.
[0764] In Experiment D, it was shown that this assay is useful in
evaluating distinct combinations of KDR and VEGF/KDR complex
binding polypeptides for use in multimeric targeting constructs
that contain more than one KDR and VEGF/KDR complex binding
polypeptide. Moreover, Experiments D and E establish that
tetrameric constructs including two or more KDR binding peptides
that bind to different epitopes exhibited superior binding to
"pure" tetrameric constructs of the targeting peptides alone.
Experiment A
[0765] Preparation of m-RNA & 5' RACE Ready cDNA Library
[0766] HUVEC cells were grown to almost 80% confluence in 175
cm.sup.2 tissue culture flasks (Becton Dickinson, Biocoat, cat #
6478) and then 10 ng/mL of bFGF (Oncogene, cat # PF003) was added
for 24 h to induce expression of KDR. mRNA was isolated using the
micro-fast track 2.0 kit from Invitrogen (cat. # K1520-02). 12
.mu.g of mRNA (measured by absorbance at 260 nM) was obtained from
two flasks (about 30 million cells) following the kit instructions.
Reverse transcription to generate cDNA was performed with 2 .mu.g
of mRNA, oligo dT primer (5'-(T).sub.25GC-3') and/or smart II oligo
(5'AAGCAGTGGTAACAACGCAGAGTACGC- GGG-3') (SEQ ID NO:357) using
Moloney Murine Leukemia Virus (MMLV) reverse transcriptase. The
reaction was performed in a total volume of 20 .mu.l and the
reaction mix contained 2 .mu.l of RNA, 1 .mu.l smart II oligo, 1
.mu.l of oligo dT primer, 4 .mu.l of 5.times. first-strand buffer
(250 mM Tris HCl pH 8.3, 375 mM KCl, 30 mM MgCl.sub.2) 1 .mu.l DTT
(20 mM, also supplied with reverse transcriptase), 1 .mu.l dNTP mix
(10 mM each of dATP, dCTP, dGTP, and dTTP in ddH.sub.2O,
Stratagene, cat. # 200415), 9 .mu.l ddH.sub.2O and 1 .mu.l MMLV
reverse transcriptase (Clonetech, cat #8460-1). The reverse
transcription reaction was performed for 90 minutes at 42.degree.
C., and the reaction was stopped by adding 250 .mu.l of
tricine-EDTA buffer (10 mM tricine, 1.0 mM EDTA). The reverse
transcription product, a 5' RACE ready cDNA library, can be stored
for 3 months at -20.degree. C. Note that all water used for DNA and
RNA application was DNAse and RNAse free from USB (cat. #
70783).
[0767] Cloning of s-KDR into TOPOII Vector
[0768] In order to clone s-KDR, a 5' oligo (G ATG GAG AGC AAG GTG
CTG CTG G) (SEQ ID NO:358) and a 3' oligo (C CAA GTT CGT CTT TTC
CTG GGC A) (SEQ ID NO:359) were used. These were designed to
amplify the complete extracellular domain of KDR (.about.2.2 kbps)
from the 5' RACE ready cDNA library (prepared above) using
polymerase chain reaction (PCR) with pfu polymerase (Stratagene,
cat. # 600135). The PCR reaction was done in total volume of 50
.mu.l and the reaction mix contained 2 .mu.l 5' RACE ready cDNA
library, 1 .mu.l 5' oligo (10 EM), 1 .mu.l 3' oligo (10 .mu.M), 5
.mu.l 10.times.PCR buffer [PCR buffer (200 mM Tris-HCl pH 8.8, 20
mM MgSO.sub.4, 100 mM KCl, 100 mM (NH.sub.4).sub.2SO.sub.4)
supplied with pfu enzyme plus 1% DMSO and 8% glycerol], 1 .mu.l
dNTP mix (10 mM) and 40 .mu.l ddH.sub.2O. The PCR reaction was
performed by using a program set for 40 cycles of 1 minute at 94C,
1 minute at 68C and 4 minutes at 72C. The PCR product was purified
by extraction with 1 volume of phenol, followed by extraction with
1 volume of chloroform and precipitated using 3 volume of ethanol
and {fraction (1/10)} volume of 3M sodium acetate. The PCR product
was resuspended in 17 .mu.l of ddH.sub.2O, the 2 .mu.l of 10.times.
Taq polymerase buffer (100 mM Tris-HCl pH 8.8, 500 mM KCl, 15 mM
MgCl.sub.2, 0.01% gelatin) and 1 .mu.l of Taq polymerase
(Stratagene, cat. # 600131) was added to generate an A overhang to
each end of the product. After incubating for 1 hour at 72C the
modified product was cloned directly into a TOPOII vector
(InVitrogen, Carlsbad, Calif.) following the manufacturer's
protocol to give TOPO-sKDR. The TOPO vector allows easy cloning of
PCR products because of the A-overhang in Taq (PCR enzyme)-treated
PCR products.
[0769] Cloning the Transmembrane and Cytoplasmic Domains of KDR
into TOPO II Vector
[0770] In order to clone the transmembrane and cytoplasmic domains
of KDR, a 5' oligo (TCC CCC GGG ATC ATT ATT CTA GTA GGC ACG GCG
GTG) (SEQ ID NO:360) and a 3' oligo (C AGG AGG AGA GCT CAG TGT GGT
C) (SEQ ID NO:361) were used. These were designed to amplify the
complete transmembrane and cytoplasmic domains of KDR (.about.1.8
kbps) from the 5' RACE ready cDNA library (described above) using
polymerase chain reaction (PCR) with pfu polymerase. PCR reaction
conditions and the program were exactly the same as described above
for s-KDR. Just as with the s-KDR sequence, the PCR product was
purified using phenol chloroform extraction, treated with Taq
polymerase and cloned into TOPOII vector from Invitrogen to give
TOPO-CYTO.
[0771] Cloning of Full-Length KDR into pcDNA6 Vector
[0772] To create the full-length receptor, the extra-cellular
domain and the cytoplasmic domain (with trans-membrane domain) were
amplified by PCR separately from TOPO-sKDR and TOPO-CYTO
respectively and ligated later to create the full-length receptor.
An oligo with a Not1 site at the 5' end of the extracellular domain
(A TAA GAA TGC GGC CGC AGG ATG GAG AGC AAG GTG CTG CTG G) (SEQ ID
NO:362) and an oligo complimentary to the 3' end of the
extracellular domain (TTC CAA GTT CGT CTT TTC CTG GGC ACC) (SEQ ID
NO:363) were used to amplify by PCR the extracellular domain from
TOPO-sKDR. Similarly, the 5' oligo (ATC ATT ATT CTA GTA GGC ACG GCG
GTG) (SEQ ID NO:364) and the 3' oligo, with a Not1 site (A TAA GAA
TGC GGC CGC AAC AGG AGG AGA GCT CAG TGT GGT C) (SEQ ID NO:365),
were used to amplify by PCR the cytoplasmic domain of KDR (with
transmembrane domain) from TOPO-CYTO. Both PCR products were
digested with Not1 and ligated together to create the full-length
receptor. The cDNA encoding the full-length receptor was purified
on an agarose gel and ligated into the Not I site of the
pcDNA6/V5-HisC vector. Purification of DNA and ligation was done as
described earlier for psKDR. The ligation reaction was used to
transform a culture of DH5.alpha. bacteria and a number of
individual clones were analyzed for the presence and orientation of
insert by restriction analysis of purified plasmid from each clone
with EcoRI enzyme.
[0773] Cell Culture
[0774] 293H cells were obtained from Invitrogen (cat. # 11631) and
grown as monolayer culture in their recommended media plus 1 mL/L
pen/strep (Invitrogen, cat. # 15140-148). All the cells were grown
in presence of antibiotic for everyday culture but were split into
antibiotic free media for 16-20 hours prior to transfection.
[0775] Preparation of DNA for Transfection
[0776] E. coli bacteria DH5.alpha. containing pf-KDR was streaked
onto LB with 50 .mu.g/mL ampicillin (LB agar from US biologicals,
cat. # 75851 and ampicillin from Sigma, cat. #A2804) plates from a
glycerol stock and plates were left in a 37.degree. C. incubator to
grow overnight. Next morning, a single colony was picked from the
plate and grown in 3 mL of LB/ampicillin media (LB from US
biologicals, cat. # US75852) at 37.degree. C. After 8 hours, 100
.mu.l of bacterial culture from the 3 mL tube was transferred to
250 mL of LB/ampicillin media for overnight incubation at
37.degree. C. Bacteria were grown up with circular agitation in a
500 mL bottle (Beckman, cat. # 355605) at 220 rpm in a Lab-Line
incubator shaker. The next day, the bacterial culture was processed
using maxi-prep kit (QIAGEN, cat. # 12163). Generally, about 1 mg
of plasmid DNA (as quantitated by absorbance at 260 nm) was
obtained from 250 mL of bacterial culture.
[0777] Transfection of 293H Cells in 96 Well Plate
[0778] Transfection was done as recommended in the lipofectamine
2000 protocol (Invitrogen, cat# 11668-019) using a
poly-D-lysine-coated 96 well plate. 320 ng of KDR DNA
(pc-DNA6-fKDR)/per well in 0.1 mL was used for 96 well
transfection. Transfection was done in serum-containing media, the
transfection reagent mix was removed from cells after 6-8 hours and
replaced with regular serum-containing medium. Transfection was
done in black/clear 96-well plates (Becton Dickinson, cat. #
354640). The left half of the plate (48 wells) were
mock-transfected (with no DNA) and the right half of the plate was
transfected with KDR cDNA. The cells were 80-90% confluent at the
time of transfection and completely confluent next day, at the time
of the assay, otherwise the assay was aborted.
[0779] Preparation of M199 Media
[0780] In order to prepare M199 media for the assay, one M199
medium packet (GIBCO, cat. # 31100-035), 20 mL of 1 mM HEPES
(GIBCO, cat. #15630-080) and 2 gm of DIFCO Gelatin (DIFCO, cat. #
0143-15-1) were added to 950 mL of ddH.sub.2O and the pH of the
solution was adjusted to 7.4 by adding approximately 4 mL of 1N
NaOH. After pH adjustment, the M199 media was warmed to 37.degree.
C. in a water bath for 2 hours to dissolve the gelatin, then filter
sterilized using 0.2 .mu.m filters (Corning, cat. # 43109), and
stored at 4.degree. C. to be used later in the assay.
[0781] Preparation of SoftLink Soft Release Avidin-Sepharose
[0782] SoftLink soft release avidin-sepharose was prepared by
centrifuging the sepharose obtained from Promega (cat. # V2011) at
12,000 rpm for 2 minutes, washing twice with ice cold water
(centrifuging in-between the washes) and resuspending the pellet in
ice cold water to make a 50% slurry in ddH.sub.2O. A fresh 50%
slurry of avidin-sepharose was prepared for each experiment.
[0783] Preparation of Peptide/Neutravidin HRP Solution
[0784] Biotinylated peptides SEQ ID NOS:294, 264, 277, 356, and the
non-binding biotinylated control peptide were used to prepare 250
.mu.M stock solutions in 50% DMSO and a 33 .mu.M stock solution of
neutravidin-HRP was prepared by dissolving 2 mg of neutravidin-HRP
(Pierce, cat. # 31001) in 1 mL of ddH.sub.2O (all polypeptides
contained the JJ spacer). Peptide stock solutions were stored at
-20.degree. C., whereas the Neutravidin HRP stock solution was
stored at -80.degree. C. To prepare peptide/neutravidin-HRP
complexes, 10 .mu.l of 250 .mu.M biotinylated peptide stock
solution and 10 .mu.l of 33 .mu.M neutravidin-HRP were added to 1
mL of M199 medium. This mixture was incubated on a rotator at
4.degree. C. for 60 minutes, followed by addition of 50 .mu.l of
soft release avidin-sepharose (50% slurry in ddH.sub.2O) to remove
excess peptides and another incubation for 30 minutes on a rotator
at 4.degree. C. Finally, the soft release avidin-sepharose was
pelleted by centrifuging at 12,000 rpm for 5 minutes at room
temperature, and the resulting supernatant was used for the assays.
Fresh peptide/neutravidin-HRP complexes were prepared for each
experiment.
[0785] Preparation of Peptide/Neutravidin HRP Dilutions for the
Assay
[0786] For saturation binding experiments, 120 .mu.l, 60 .mu.l, 20
.mu.l, 10 .mu.l, 8 .mu.l, 6 .mu.l, 4 .mu.l, and 1 .mu.l of
peptide/neutravidin HRP complex were added to 1.2 mL aliquots of
M199 medium to create dilutions with final concentrations of 33.33
nM, 16.65 nM, 5.55 nM, 2.78 nM, 1.67 nM, 1.11 nM and 0.28 nM
complex, respectively.
[0787] Preparation of Blocking Solution for Transfected 293H
Cells
[0788] Blocking solution was prepared by adding 20 mL of M199
medium to 10 mg of lyophilized unlabeled neutravidin (Pierce, cat.
# 31000). Fresh blocking solution was used for each experiment.
[0789] Assay to Detect the Binding of Peptide/Neutravidin-HRP
[0790] 24 hours after transfection, each well of the 293H cells was
washed once with 100 .mu.l of M199 medium and incubated with 80
.mu.l of blocking solution at 37.degree. C. After one hour, cells
were washed twice with 100 .mu.l of M199 media and incubated with
70 .mu.l of peptide/neutravidin-HRP dilutions of control peptide,
SEQ ID NO:264, SEQ ID NO:294, SEQ ID NO:277, and SEQ ID NO:356 for
two and half hours at room temperature. Each dilution was added to
three separate wells of mock as well as KDR-transfected 293H cells
(two plates were used for each saturation binding experiment).
After incubation at room temperature, plates were transferred to
4.degree. C. for another half-hour incubation. Subsequently, cells
were washed 5 times with ice-cold M199 media and once with ice-cold
PBS (in that order). After the final wash, 100 .mu.l of ice cold
TMB solution (KPL, cat. # 50-76-00) was added to each well and each
plate was incubated for 30 minutes at 37.degree. C. in an air
incubator. Finally, the HRP enzyme reaction was stopped by adding
50 .mu.l of 1N phosphoric acid to each well, and binding was
quantitated by measuring absorbance at 450 nm using a microplate
reader (BioRad Model 3550).
[0791] Binding of Peptide/Neutravidin HRP to KDR-Transfected
Cells
[0792] In this assay, complexes of control peptide, SEQ ID NO:264,
SEQ ID NO:294, SEQ ID NO:277, and SEQ ID NO:356 peptides, each
biotinylated with the JJ spacer and conjugated with
neutravidin-HRP, were prepared as described above and tested for
their ability to bind 293H cells that were transiently-transfected
with KDR. During the peptide/neutravidin complex preparation, a
7.5-fold excess of biotinylated peptides over neutravidin-HRP was
used to make sure that all four biotin binding sites on neutravidin
were occupied. After complex formation, the excess of free
biotinylated peptides was removed using soft release
avidin-sepharose to avoid any competition between free biotinylated
peptides and neutravidin HRP-complexed biotinylated peptides. The
experiment was performed at several different concentrations of
peptide/neutravidin-HRP, from 0.28 nM to 33.33 nM, to generate
saturation binding curves for SEQ ID NO:264 and SEQ ID NO:294 (FIG.
1A) and 0.28 to 5.55 nM to generate saturation binding curve for
SEQ ID NO:277 and SEQ ID NO:356 (FIG. 1B). In order to draw the
saturation binding curve, the background binding to
mock-transfected cells was subtracted from the binding to
KDR-transfected cells for each distinct peptide/neutravidin HRP
complex at each concentration tested. Therefore, absorbance on the
Y-axis of FIG. 1 is differential absorbance (KDR minus mock) and
not the absolute absorbance. Analysis of the saturation binding
data in FIG. 1 using Graph Pad Prism software (version 3.0) yielded
a K.sub.D of 10.00 nM (+/-2.36) for the tetrameric SEQ ID NO:294,
14.87 nM (+/-5.066) for the tetrameric SEQ ID NO:264, 4.031 nM
(+/-0.86) for the tetrameric SEQ ID NO:277, and 1.814 nM (+/-0.27)
for the tetrameric SEQ ID NO:356 peptide complexes. These binding
constants are, as expected, lower than those measured by FP against
the KDRFc construct for the related monodentate peptides SEQ ID
NO:294 (69 nM), SEQ ID NO:264 (280 nM), SEQ ID NO:310 (51 nM), but
similar to monodentate peptide SEQ ID NO:277 (3 nM). As expected,
no saturation of binding for the control (non-binder)
peptide/neutravidin HRP-complex was observed. The binding of
peptide/neutravidin HRP complexes (FIG. 2) at a single
concentration (5.55 nM) was plotted to demonstrate that a single
concentration experiment can be used to differentiate between a KDR
binding peptide (SEQ ID NOS:264, 294 and 277) from a non-binding
peptide.
Experiment B
[0793] Experiment B was designed to look at the requirement of
spacer (JJ, Table 10) between the KDR binding sequences (SEQ ID
NOS:294 and 264) and biotin. In this experiment, biotinylated
peptides with and without spacer JJ were tested (e.g., biotinylated
SEQ ID NO:264 with the JJ spacer, biotinylated SEQ ID NO:264
without the JJ spacer, SEQ ID NO:294 with a spacer, and
biotinylated SEQ ID NO:294 without the spacer), and a non-KDR
binding, biotinylated control peptide (with and without spacer,
prepared as set forth above) was used as a control. The peptide
structure of all the KDR-binding sequences tested in this
experiment is shown in FIG. 3.
[0794] This experiment was performed as set forth in Experiment A
described above, except that it was only done at a single
concentration of 2.78 nM.
[0795] Results: It is evident from the results shown in the FIG. 4
that the spacer enhances binding of SEQ ID NO:294 and SEQ ID
NO:264. The spacer between the binding sequence and biotin can be
helpful in enhancing binding to target molecule by multiple
mechanisms. First, it could help reduce the steric hindrance
between four biotinylated peptides after their binding to a single
avidin molecule. Second, it could provide extra length necessary to
reach multiple binding sites available on a single cell.
Experiment C
[0796] Experiment C was designed to look at the serum effect on the
binding of SEQ ID NOS: 294, 264, 277 and 356. In this procedure,
biotinylated peptide/avidin HRP complexes of SEQ ID NOS:294, 264,
277 and 356 were tested in M199 media (as described above in
Experiment A) with and without 40% rat serum. This experiment was
performed as described for Experiment A except that it was only
done at single concentration of 6.66 nM for SEQ ID NOS: 294 and
264, 3.33 nM for SEQ ID NO:277 and 2.22 nM for SEQ ID NO:356. Each
of the polypeptides were biotinylated and had the JJ spacer.
[0797] Results: Results in FIG. 5 indicate that binding of SEQ ID
NO:264, SEQ ID NO:294, and SEQ ID NO:356 was not significantly
affected by 40% rat serum, whereas binding of SEQ ID NO:277 (c) was
more than 50% lower in presence of 40% rat serum. More than an 80%
drop in the binding of Tc-labeled SEQ ID NO:277 with Tc-chelate was
observed in the presence of 40% rat serum (FIG. 97). Since the
serum effect on the binding of Tc-labeled SEQ ID NO:277 is mimicked
in the avidin HRP assay disclosed herein, this assay may be used to
rapidly evaluate the serum effect on the binding of peptide(s) to
KDR.
Experiment D
[0798] Experiment D was designed to evaluate the binding of
tetrameric complexes of KDR and VEGF/KDR complex binding
polypeptides SEQ ID NO:294 and SEQ ID NO:264, particularly where
the constructs included at least two KDR binding polypeptides. The
KDR binding peptides and control binding peptide were prepared as
described above. This experiment was performed using the protocol
set forth for Experiment A, except the procedures set forth below
were unique to this experiment.
[0799] Preparation of Peptide/Neutravidin Solutions: 250 .mu.M
stock solutions of biotinylated peptides SEQ ID NOs:264, 294 and
control peptide were prepared in 50% DMSO and a 33 .mu.M stock
solution of Neutravidin HRP was prepared by dissolving 2 mg of
Neutravidin HRP (Pierce, cat. # 31001) in 1 mL of ddH.sub.2O.
Peptide stock solutions were stored at -20C, whereas the
Neutravidin HRP stock solution was stored at -80C. The sequences of
the biotinylated peptides are shown above. To prepare
peptide/neutravidin HRP complexes, a total 5.36 .mu.L of 250 .mu.M
biotinylated peptide stock solution (or a mixture of peptide
solutions, to give peptide molecules four times the number of
avidin HRP molecules) and 10 .mu.L of 33 .mu.M Neutravidin HRP were
added to 1 mL of M199 medium. This mixture was incubated on a
rotator at 4C for 60 minutes, followed by addition of 50 .mu.L of
soft release avidin-sepharose (50% slurry in ddH.sub.2O) to remove
excess peptides and another incubation for 30 minutes on a rotator
at 4C. Finally, the soft release avidin-sepharose was pelleted by
centrifuging at 12,000 rpm for 5 minutes at room temperature, and
the resulting supernatant was used for the assays. Fresh
peptide/neutravidin HRP complexes were prepared for each
experiment.
[0800] Assay to Detect the Binding of Peptide/Neutravidin HRP: 24
hours after transfection, each well of the 293H cells was washed
once with 100 .mu.L of M199 medium and incubated with 80 .mu.L of
blocking solution at 37C. After one hour, cells were washed twice
with 100 .mu.L of M199 media and incubated with 70 .mu.L of 3.33 nM
peptide (or peptide mix)/neutravidin HRP solutions (prepared by
adding 10 .mu.L of stock prepared earlier to 1 mL of M199 media)
for two and half hours at room temperature. Each dilution was added
to three separate wells of mock as well as KDR-transfected 293H
cells. After incubation at room temperature, plates were
transferred to 4C for another half-hour incubation. Subsequently,
cells were washed five times with ice-cold M199 media and once with
ice-cold PBS (in that order). After the final wash, 100 .mu.L of
ice cold TMB solution (KPL, Gaithersburg, Md.) was added to each
well and each plate was incubated for 30 minutes at 37C in an air
incubator. Finally, the HRP enzyme reaction was stopped by adding
50 .mu.L of 1N phosphoric acid to each well, and binding was
quantitated by measuring absorbance at 450 nm using a microplate
reader (BioRad Model 3550).
[0801] Results: This experiment establishes that SEQ ID NO:294 and
SEQ ID NO:264 bind to KDR in multimeric fashion, and cooperate with
each other for binding to KDR in 293H transfected cells. A
biotinylated control peptide that does not bind to KDR was used. As
expected, a tetrameric complex of the control peptide with
avidin-HRP did not show enhanced binding to KDR-transfected cells.
Tetrameric complexes of SEQ ID NO:294 and SEQ ID NO:264 bound to
KDR-transfected cells significantly better than to mock-transfected
cells (see FIG. 6). SEQ ID NO:294 tetramers, however, bound much
better than SEQ ID NO:264 tetramers. If the control peptide was
added to the peptide mixture used to form the tetrameric complexes,
the binding to the KDR-transfected cells decreased. The ratio of
specific binding of tetramer to monomer, dimer and trimer was
calculated by dividing the specific binding (obtained by
subtracting the binding to mock transfected cells from KDR
transfected cells) of tetramer, trimer and dimer with that of
monomer. Results indicate that there is co-operative effect of
multimerization of SEQ ID NOS:264, 294 and 356 on the binding to
KDR-transfected cells.
13 Tetramer Trimer Dimer SEQ ID NO: 264 45.4 5 4.3 SEQ ID NO: 294*
38.6 7.1 2.7 SEQ ID NO: 277 1 1.1 1.1 SEQ ID NO: 356 16 5.7 2.3
*monomeric peptide binding at 2.22 nM was zero, therefore ratios
were calculated using binding at 5.55 nM.
[0802] A mixture of 25% non-binding control peptide with 75% SEQ ID
NO:264 did not bind significantly over background to
KDR-transfected cells, indicating that multivalent binding is
critical for the SEQ ID NO:264/avidn-HRP complex to remain bound to
KDR throughout the assay. This phenomenon also held true for SEQ ID
NO:294, where substituting 50% of the peptide with control peptide
in the tetrameric complex abolished almost all binding to KDR on
the transfected cells.
[0803] Surprisingly, a peptide mixture composed of 50% control
peptide with 25% SEQ ID NO:294 and 25% SEQ ID NO:264 bound quite
well to KDR-transfected cells relative to mock-transfected cells,
indicating that there is a great advantage to targeting two sites
or epitopes on the same target molecule. Furthermore, it was noted
that tetrameric complexes containing different ratios of SEQ ID
NO:294 and SEQ ID NO:264 (3:1, 2:2, and 1:3) all bound much better
to KDR-transfected cells than pure tetramers of either peptide, in
agreement with the idea that targeting two distinct sites on a
single target molecule is superior to multimeric binding to a
single site. This may be because multimeric binding to a single
target requires that the multimeric binding entity span two or more
separate target molecules that are close enough together for it to
bind them simultaneously, whereas a multimeric binder that can bind
two or more distinct sites on a single target molecule does not
depend on finding another target molecule within its reach to
achieve multimeric binding.
Experiment E
[0804] Experiment E was designed to confirm that SEQ ID NO:294 and
SEQ ID NO:264 bind to distinct sites (epitopes) on KDR. If these
peptides bind to the same site on KDR, then they should be able to
compete with each other; however, if they bind to different sites
they should not compete. This experiment was performed using a
single concentration of SEQ ID NO:264/avidin HRP (3.33 nM) solution
in each well and adding a varying concentration (0-2.5 .mu.M) of
biotinylated control peptide with spacer, SEQ ID NO:264 and SEQ ID
NO:294, none of which were complexed with avidin.
[0805] Results: It is evident from FIG. 7 that SEQ ID NO:264 does
compete with SEQ ID NO:264/avidin HRP solution for binding to
recombinant KDR-Fc fusion protein whereas control peptide and SEQ
ID NO:294 do not compete with SEQ ID NO:264/avidin HRP solution for
binding to recombinant KDR-Fc fusion protein. Thus, SEQ ID NO:264
and SEQ ID NO:294 bind to distinct and complementary sites on
KDR.
Example 6
Binding of Analogs of a KDR-Binding Peptide to KDR-Expressing
Cells
[0806] N-terminal and C-terminal truncations of a KDR binding
polypeptide were made and the truncated polypeptides tested for
binding to KDR-expressing cells. The synthesized polypeptides are
shown in FIG. 8. Binding of the polypeptides to KDR-expressing
cells was determined following the procedures of Example 3.
[0807] All of the peptides were N-terminally acetylated and
fluoresceinated for determining apparent K.sub.D according to the
method described above (Example 3). The results indicate that, for
the SEQ ID NO:294 (FIG. 8) polypeptide, the C-terminal residues
outside the disulfide-constrained loop contribute to KDR
binding.
Example 7
Bead-Binding Assay to Confirm Ability of Peptides Identified by
Phage Display to Bind KDR-Expressing Cells
[0808] The following procedures were performed to assess the
ability of KDR-binding peptides to bind to KDR-expressing cells. In
this procedure, KDR-binding peptides containing SEQ ID NOS:264,
337, 363, and 373 were conjugated to fluorescent beads, and their
ability to bind to KDR-expressing 293H cells was assessed. The
experiments show these peptides can be used to bind particles such
as beads to KDR-expressing sites. The results indicate that the
binding of both KDR binding sequences improved with the addition of
a spacer.
Protocol
[0809] Biotinylation of an anti-KDR antibody: Anti-KDR from Sigma
(V-9134), as ascites fluid, was biotinylated using a kit from
Molecular Probes (F-6347) according to the manufacturer's
instructions.
[0810] Preparation of peptide-conjugated fluorescent beads: 0.1 mL
of a 0.2 mM stock solution of each biotinylated peptide (prepared
as set forth above, in 50% DMSO) was incubated with 0.1 mL of
Neutravidin-coated red fluorescent microspheres (2 micron diameter,
custom-ordered from Molecular Probes) and 0.2 mL of 50 mM MES
(Sigma M-8250) buffer, pH 6.0 for 1 hour at room temperature on a
rotator. As a positive control, biotinylated anti-KDR antibody was
incubated with the Neutravidin-coated beads as above, except that
0.03 mg of the biotinylated antibody preparation in PBS (Gibco
#14190-136) was used instead of peptide solution. Beads can be
stored at 4.degree. C. until needed for up to 1 week.
[0811] Binding Assay: From the above bead preparations, 0.12 mL was
spun for 10 minutes at 2000 rpm in a microcentrifuge at room
temperature. The supernatant was removed and 0.06 mL of MES pH 6.0
was added. Each bead solution was then vortexed and sonicated in a
water bath 15 min. To 1.47 mL of DMEM, high glucose (GIBCO
#11965-084) with 1.times. MEM Non-Essential Amino Acids Solution
(NEAA) (GIBCO 11140-050) and 40% FBS (Hyclone SH30070.02) 0.03 mL
of the sonicated bead preparations was added. 96-well plates seeded
with 293H cells that have been mock-transfected in columns 1 to 6,
and KDR-transfected in columns 7 to 12 (as in Example 5), were
drained and washed once with DMEM, high glucose with 1.times. NEAA
and 40% FBS. To each well 0.1 mL of bead solution was added, six
wells per bead preparation. After incubating at room temperature
for 30 minutes, the wells were drained by inverting the plates and
washed four times with 0.1 mL PBS with Ca.sup.++Mg.sup.++ (GIBCO
#14040-117) with shaking at room temperature for 5 minutes each
wash. After draining, 0.1 mL of PBS was added per well. The plates
were then read on a Packard FluoroCount fluorometer at excitation
550 nm/emission 620 nm. Unconjugated neutravidin beads were used as
a negative control while beads conjugated with a biotinylated
anti-KDR antibody were used as the positive control for the
assay.
[0812] To calculate the number of beads bound per well, a standard
curve with increasing numbers of the same fluorescent beads was
included in each assay plate. The standard curve was used to
calculate the number of beads bound per well based on the
fluorescence intensity of each well.
[0813] Results: The positive control beads with anti-KDR attached
clearly bound preferentially to the KDR-expressing cells while
avidin beads with nothing attached did not bind to either cell type
(FIG. 9). Biotinylated SEQ ID NO:264 beads did not bind to the
KDR-transfected cells significantly more than to mock-transfected
cells, but adding a hydrophilic spacer between the peptide moiety
and the biotin group (biotinylated SEQ ID NO:264 with a JJ spacer
beads) enhanced binding to KDR cells without increasing the binding
to mock-transfected cells. Biotinylated SEQ ID NO:294 beads showed
greater binding to KDR-transfected cells, and adding a hydrophilic
spacer between the peptide portion and the biotin of the molecule
(biotinylated SEQ ID NO:294 with the JJ spacer) significantly
improved the specific binding to KDR in the transfected cells.
Thus, the peptide sequences of both SEQ ID NO:264 and SEQ ID NO:294
can be used to bind particles such as beads to KDR-expressing
sites. Addition of a hydrophilic spacer between the peptide and the
group used for attachment to the particle should routinely be
tested with new targeting molecules as it improved the binding for
both of the peptides evaluated here.
Example 8
Competition of KDR Binding Peptides and .sup.125I-Labeled VEGF for
Binding to KDR-Transfected 293H Cells
[0814] KDR-binding polypeptides were next assessed for their
ability to compete with .sup.125I-labeled VEGF for binding to KDR
expressed by transfected 293H cells. The results indicate that
KDR-binding polypeptide SEQ ID NO:263
(Ac-AGDSWCSTEYTYCEMIGTGGGK-NH.sub.2) did not compete significantly
with .sup.125I-labeled VEGF, and SEQ ID NOS:294, 264, and SEQ ID
NO:277 competed very well with .sup.125I-labeled VEGF, inhibiting
96.29.+-.2.97% and 104.48.+-.2.074% of .sup.125I-labeled VEGF
binding.
[0815] Transfection of 293H cells: 293H cells were transfected
using the protocol described in Example 5. Transfection was done in
black/clear 96-well plates (Becton Dickinson, cat. # 354640). The
left half of the plates (48 wells) were mock-transfected (with no
DNA) and the right half of the plates were transfected with KDR
cDNA. The cells were 80-90% confluent at the time of transfection
and completely confluent the next day, at the time of the assay;
otherwise the assay was aborted.
[0816] Preparation of M199 media: M199 medium was prepared as
described in Example 5.
[0817] Preparation of peptide solutions: 3 mM stock solutions of
peptides SEQ ID NO:294, SEQ ID NO:263, SEQ ID NO:264 and SEQ ID
NO:277 were prepared as described above in 50% DMSO.
[0818] Preparation of .sup.125I-labeled VEGF solution for the
assay: 25 .mu.Ci of lyophilized .sup.125I -labeled VEGF (Amersham,
cat. # IM274) was reconstituted with 250 .mu.l of ddH.sub.2O to
create a stock solution, which was stored at -80C for later use.
For each assay, a 300 pM solution of .sup.125I-labeled VEGF was
made fresh by diluting the above stock solution in M199 medium. The
concentration of .sup.125I-labeled VEGF was calculated daily based
on the specific activity of the material on that day.
[0819] Preparation of 30 .mu.M and 0.3 .mu.M peptide solution in
300 pM .sup.125I-labeled VEGF. For each 96 well plate, 10 mL of 300
pM .sup.125I-labeled VEGF in M199 medium was prepared at 4.degree.
C. Each peptide solution (3 mM, prepared as described above) was
diluted 1:100 and 1:10000 in 300 .mu.l of M199 media with 300 pM
.sup.125I-labeled VEGF to prepare 30 .mu.M and 0.3 .mu.M peptide
solutions containing 300 pM of .sup.125I-labeled VEGF. Once
prepared, the solutions were kept on ice until ready to use. The
dilution of peptides in M199 media containing 300 pM
.sup.125I-labeled VEGF was done freshly for each experiment.
[0820] Assay to detect competition with .sup.125I-labeled VEGF in
293H cells: Cells were used 24 hours after transfection, and to
prepare the cells for the assay, they were washed 3 times with room
temperature M199 medium and placed in the refrigerator. After 15
minutes, the M199 medium was removed from the plate and replaced
with 75 .mu.l of 300 pM .sup.125I-labeled VEGF in M199 medium
(prepared as above) with the polypeptides. Each dilution was added
to three separate wells of mock and KDR transfected cells. After
incubating at 4.degree. C. for 2 hours, the plates were washed 5
times with cold binding buffer, gently blotted dry and checked
under a microscope for cell loss. 100 .mu.l of solubilizing
solution (2% Triton X-100, 10% Glycerol, 0.1% BSA) was added to
each well and the plates were incubated at room temperature for 30
minutes. The solubilizing solution in each well was mixed by
pipeting up and down, and transferred to 1.2 mL tubes. Each well
was washed twice with 100 .mu.l of solubilizing solution and the
washes were added to the corresponding 1.2 mL tube. Each 1.2 mL
tube was then transferred to a 15.7.times.100 cm tube to be counted
in an LKB Gamma Counter using program 54 (.sup.125I window for 1
minute).
[0821] Competition of peptides with .sup.125I-labeled VEGF in 293H
cells: The ability of KDR-binding peptides SEQ ID NO:294, SEQ ID
NO:263, SEQ ID NO:264 and SEQ ID NO:277 to specifically block
.sup.125I-labeled VEGF binding to KDR was assessed in
mock-transfected and KDR-transfected cells. SEQ ID NO:263 was used
in the assay as a negative control, as it exhibited poor binding to
KDR in the FP assays described herein and would therefore not be
expected to displace or compete with VEGF. To calculate the
specific binding to KDR, the binding of .sup.125I-labeled VEGF to
mock-transfected cells was subtracted from KDR-transfected cells.
Therefore, the binding of .sup.125I-labeled VEGF to sites other
than KDR (which may or may not be present in 293H cells) is not
included when calculating the inhibition of .sup.125I-labeled VEGF
binding to 293H cells by KDR-binding peptides. Percentage
inhibition was calculated using formula [(Y1-Y2)*100/Y1], where Y1
is specific binding to KDR-transfected 293H cells in the absence
peptides, and Y2 is specific binding to KDR-transfected 293H cells
in the presence of peptides or DMSO. Specific binding to
KDR-transfected 293H cells was calculated by subtracting binding to
mock-transfected 293H cells from binding to KDR-transfected 293H
cells.
[0822] As shown in FIG. 10, in 293 cells, SEQ ID NO:263, which due
to its relatively high K.sub.d (>2 .mu.M) was used as a negative
control, did not compete significantly with .sup.125I-labeled VEGF,
12.69.+-.7.18% at 30 .mu.M and -5.45.+-.9.37% at 0.3 .mu.M (FIG.
10). At the same time, SEQ ID NOS:294 and 277 competed very well
with .sup.125I-labeled VEGF, inhibiting 96.29.+-.2.97% and
104.48.+-.2.074% of .sup.125I-labeled VEGF binding at 30 .mu.M and
52.27.+-.3.78% and 80.96.+-.3.8% at 0.3 .mu.M (FIG. 10)
respectively. The percentage inhibition with SEQ ID NO:264 was
47.95.+-.5.09% of .sup.125I-labeled VEGF binding at 30 .mu.M and
24.41.+-.8.43% at 0.3 .mu.M (FIG. 10). Thus, the three strongly
KDR-binding polypeptides did compete with VEGF, and their potency
increased with their binding affinity. This assay will be useful
for identifying peptides that bind tightly to KDR but do not
compete with VEGF, a feature that may be useful for imaging KDR in
tumors, where there is frequently a high local concentration of
VEGF that would otherwise block the binding of KDR-targeting
molecules.
Example 9
Inhibition of VEGF-Induced KDR Receptor Activation by Peptides
Identified by Phage Display
[0823] The ability of KDR-binding peptides identified by phage
display to inhibit VEGF induced activation (phosphorylation) of KDR
was assessed using the following assay. A number of peptides of the
invention were shown to inhibit activation of KDR in monomeric
and/or tetrameric constructs. As discussed supra, peptides that
inhibit activation of KDR may be useful as anti-angiogenic
agents.
Protocol
[0824] Human umbilical vein endothelial cells (HUVECS)
(Biowhittaker Catalog #CC-2519) were obtained frozen on dry ice and
stored in liquid nitrogen until thawing. These cells were thawed,
passaged, and maintained as described by the manufacturer in EGM-MV
medium (Biowhittaker Catalog #CC-3125). Cells seeded into 100 mm
dishes were allowed to become confluent, then cultured overnight in
basal EBM medium lacking serum (Biowhittaker Catalog #CC-3121). The
next morning, the medium in the dishes was replaced with 10 mL
fresh EBM medium at 37C containing either no additives (negative
control), 5 ng/mL VEGF (Calbiochem Catalog #676472 or Peprotech
Catalog #100-20) (positive control), or 5 ng/mL VEGF plus the
indicated concentration of the KDR-binding peptide (prepared as
described above). In some cases, a neutralizing anti-KDR antibody
(Catalog #AF357, R&D Systems) was used as a positive control
inhibitor of activation. In such cases, the antibody was
pre-incubated with the test cells for 30 min at 37.degree. C. prior
to the addition of fresh medium containing both VEGF and the
antibody. After incubating the dishes 5 min. in a 37.degree. C.
tissue culture incubator they were washed three times with ice-cold
D-PBS containing calcium and magnesium and placed on ice without
removing the last 10 mL of Delbecco's phosphate buffered saline
(D-PBS). The first dish of a set was drained and 0.5 mL of Triton
lysis buffer was added (20 mM Tris base pH 8.0, 137 mM NaCl, 10%
glycerol, 1% Triton X-100, 2 mM EDTA (ethylenediaminetetraacetic
acid), 1 mM PMSF(phenylmethylsulfonylfluoride), 1 mM sodium
orthovanadate, 100 mM NaF, 50 mM sodium pyrophosphate, 10 .mu.g/mL
leupeptin, 10 .mu.g/mL aprotinin). The cells were quickly scraped
into the lysis buffer using a cell scraper (Falcon, Cat No.
#353087), dispersed by pipeting up and down briefly, and the
resulting lysate was transferred to the second drained dish of the
pair. Another 0.5 mL of lysis buffer was used to rinse out the
first dish then transferred to the second dish, which was then also
scraped and dispersed. The pooled lysate from the two dishes was
transferred to a 1.5 mL Eppindorf tube. The above procedure was
repeated for each of the controls and test samples (KDR-binding
peptides), one at a time. The lysates were stored on ice until all
the samples had been processed. At this point samples were either
stored at -70.degree. C. or processed to the end of the assay
without interruption.
[0825] The lysates, freshly prepared or frozen and thawed, were
precleared by adding 20 .mu.l of protein A-sepharose beads (Sigma
3391, preswollen in D-PBS, washed three times with a large excess
of D-PBS, and reconstituted with 6 mL D-PBS to generate a 50%
slurry) and rocking at 4.degree. C. for 30 min. The beads were
pelleted by centrifugation for 2 min. in a Picofuge (Stratgene,
Catalog #400550) at 2000.times.g and the supernatants transferred
to new 1.5 mL tubes. Twenty .mu.g of anti-Flk-1 antibody (Santa
Cruz Biotechnology, Catalog #sc-504) was added to each tube, and
the tubes were incubated overnight (16-18 hr.) at 4C on a rotator
to immunoprecipitate KDR. The next day 40 .mu.l of protein
A-sepharose beads were added to the tubes that were then incubated
4C for 1 hr. on a rotator. The beads in each tube were subsequently
washed three times by centrifuging for 2 min. in a Picofuge,
discarding the supernatant, and dispersing the beads in 1 mL
freshly added TBST buffer (20 mM Tris base pH 7.5, 137 mM NaCl, and
0.1% Tween 20). After centrifuging and removing the liquid from the
last wash, 40 .mu.l of Laemmli SDS-PAGE sample buffer (Bio-Rad,
Catalog #161-0737) was added to each tube and the tubes were capped
and boiled for 5 min. After cooling, the beads in each tube were
pelleted by centrifuging and the supernatants containing the
immunoprecipitated KDR were transferred to new tubes and used
immediately or frozen and stored at -70C for later analysis.
[0826] Detection of phosphorylated KDR as well as total KDR in the
immunoprecipitates was carried out by immunoblot analysis. Half (20
.mu.L) of each immunoprecipitate was resolved on a 7.5% precast
Ready Gel (Bio-Rad, Catalog #161-1154) by SDS-PAGE according to the
method of Laemmli (Nature, 227:680-685 (1970)).
[0827] Using a Bio-Rad mini-Protean 3 apparatus (Catalog
#165-3302), the resolved proteins in each gel were electroblotted
to a PVDF membrane (Bio-Rad, Cat. No. 162-0174) in a Bio-Rad mini
Trans-Blot cell (Catalog #170-3930) in CAPS buffer (10 mM CAPS,
Sigma Catalog #C-6070, 1% ACS grade methanol, pH 11.0) for 2 hr. at
140 mA according to the method of Matsudaira (J. Biol. Chem.,
262:10035-10038 (1987)). Blots were blocked at room temperature in
5% Blotto-TBS (Pierce Catalog #37530) pre-warmed to 37.degree. C.
for 2 hr. The blots were first probed with an anti-phosphotyrosine
antibody (Transduction Labs, Catalog #P11120), diluted 1:200 in 5%
Blotto-TBS with 0.1% Tween 20 added for 2 hr. at room temp. The
unbound antibody was removed by washing the blots four times with
D-PBS containing 0.1% Tween 20 (D-PBST), 5 min. per wash.
Subsequently, blots were probed with an HRP-conjugated sheep
anti-mouse antibody (Amersham Biosciences Catalog #NA931) diluted
1:25,000 in 5% Blotto-TBS with 0.1% Tween 20 added for 1 hr. at
room temp., and washed four times with D-PBST. Finally, the blots
were incubated with 2 mL of a chemiluminescent substrate (ECL Plus,
Amersham Catalog #RPN2132) spread on top for 2 min., drip-drained
well, placed in plastic sheet protector (C-Line Products, Catalog
#62038), and exposed to X-ray film (Kodak BioMax ML, Cat No.
1139435) for varying lengths of time to achieve optimal
contrast.
[0828] To confirm that similar amounts of KDR were compared in the
assay, the blots were stripped by incubating for 30 min. at
37.degree. C. in TBST with its pH adjusted to 2.4 with HCl, blocked
for 1 hr. at room temp. with 5% Blotto-TBS with 0.1% Tween 20
(Blotto-TBST), and reprobed with an anti-Flk-1 polyclonal antibody
(Catalog #sc-315 from Santa Cruz Biotech), 1:200 in 5% Blotto-TBST
with 1% normal goat serum (Life Tech Catalog #16210064) for 2 hr.
at room temp. The unbound antibody was removed by washing the blots
four times with D-PBST, 5 min. per wash. Subsequently, the blots
were probed with an HRP-conjugated donkey anti-rabbit secondary
antibody (Amersham Biosciences Catalog #NA934) diluted 1:10,000 in
5% Blotto-TBST for 1 hr. at room temp., and washed four times with
D-PBST. Finally, the blots were incubated with 2 mL of
chemiluminescent substrate and exposed to X-ray film as described
above.
[0829] Results: Immunoblots of KDR immunoprecipitates prepared from
HUVECs with and without prior VEGF stimulation demonstrated that
activated (phosphorylated) KDR could be detected when the HUVECs
were stimulated with VEGF. An anti-phosphotyrosine antibody (PY-20)
detected no phosphorylated proteins close to the migration position
of KDR from unstimulated HUVECs on the blots, but after five
minutes of VEGF stimulation, an intense band was consistently
observed at the expected location (FIG. 11, upper panel). When the
blots were stripped of bound antibodies by incubation in acidic
solution then reprobed with an anti-KDR antibody (sc-315), the
identity of the phosphorylated protein band was confirmed to be
KDR. Moreover, it was observed that immunoprecipitates from
unstimulated HUVECs contained about as much total KDR as
immunoprecipitates from VEGF-stimulation HUVECs (FIG. 11, lower
panel).
[0830] The foregoing results indicate that the phosphorylated KDR
detected was formed from pre-existing KDR through
autophosphorylation of KDR dimers resulting from VEGF binding, as
five minutes is not enough time to synthesize and process a large
glycosylated cell-surface receptor such as KDR.
[0831] The ability of this assay to detect agents capable of
blocking the VEGF activation of KDR was assessed by adding a series
of compounds to HUVECs in combination with VEGF and measuring KDR
phosphorylation with the immunoblot assay described above. As
negative and positive controls, immunoprecipitates from
unstimulated HUVECs and from HUVECs stimulated with VEGF in the
absence of any test compounds were also tested in every assay. When
a neutralizing anti-KDR antibody (Catalog #AF-357 from R&D
Systems) was combined with the VEGF, the extent of KDR
phosphorylation was greatly reduced (FIG. 12, upper panel),
indicating that the antibody was able to interfere with the ability
of VEGF to bind to and activate KDR. This result was expected since
the ability of the antibody to block VEGF-induced DNA synthesis is
part of the manufacturer's quality control testing of the antibody.
Re-probing the blot with an anti-KDR antibody (FIG. 12, lower
panel) indicated that slightly less total KDR was present in the
VEGF+antibody-treated lane (+V+.alpha.-KDR) relative to the
VEGF-only-treated lane (+V), but the difference was not great
enough to account for the much lower abundance of phosphorylated
KDR in the antibody-treated lane.
[0832] To assess the potency of a linear KDR-binding peptide
(AFPRFGGDDYWIQQYLRYTD, SEQ ID NO:140) identified by phage display,
the assay was repeated with a synthetic peptide containing the
KDR-binding sequence, Ac-AQAFPRFGGDDYWIQQYLRYTDGGK-NH.sub.2 (SEQ ID
NO:306) in the presence of VEGF. SEQ ID NO:306 was able to inhibit
the VEGF-induced phosphorylation of KDR. Re-probing the blot for
total KDR showed that there is even more total KDR in the VEGF+SEQ
ID NO:306-treated cells (+V+SEQ ID NO:306) than in the VEGF
only-treated cells (+V) (FIG. 13, lower panel). Thus, it is clear
that the decreased phosphorylation of KDR in the presence of SEQ ID
NO:306 is not due to differential sample loading, but rather the
ability of the polypeptide to inhibit VEGF-activation of KDR.
[0833] Repeating the foregoing assay, the following polypeptides
demonstrated at least a 50% inhibition of VEGF-induced KDR
phosphorylation at 10 .mu.M:
14 Ac-AGWIECYHPDGICYHFGTGGGK-NH.sub.2 (SEQ ID NO: 269)
Ac-AGWLECYAEFGHCYNFGTGGGK-NH.sub.2 (SEQ ID NO: 267)
Ac-GDSRVCWEDSWGGEVCFRYDPGGGK-NH.sub.2 (SEQ ID NO: 294)
Ac-GDWWECK(ivDde)REEYRNTTWCAWADPG (SEQ ID NO: 366 GGK-NH.sub.2
having a blocked K) Ac-GDPDTCTMWGDSGRWYCFPADPGGGK- -NH.sub.2 (SEQ
ID NO: 301) Ac-AQEPEGYAYWEVITLYHEEDGDGGK-NH- .sub.2 (SEQ ID NO:
305) Ac-AQAFPRFGGDDYWIQQYLRYTDGGK-NH.su- b.2 (SEQ ID NO: 306)
Ac-AQGDYVYWEIIELTGATDHTPPGGK-NH.sub.2- . (SEQ ID NO: 307)
[0834] SEQ ID NOS: 269 and 294 were the most potent compounds in
the assay, producing at least a 50% inhibition of VEGF-induced KDR
phosphorylation at 1 .mu.M.
[0835] The following peptides were tested in the assay and did not
produce significant inhibition of KDR activation at 10 .mu.M:
15 Ac-AGPK(ivDde)WCEEDWYYCMITGTGGGK- (SEQ ID NO: 264) NH.sub.2
Ac-GSDHHCYLHNGQWICYPFAPGGGK-NH.sub.2 (SEQ ID NO: 314)
Ac-GDYPWCHELSDSVTRFCVPWDPGGGK-NH.sub.2 (SEQ ID NO: 293)
Ac-GDDHMCRSPDYQDHVFCMYWDPGGGK-NH.sub.2 (SEQ ID NO: 295)
Ac-GDPPLCYFVGTQEWHHCNPFDPGGGK-NH.sub.2 (SEQ ID NO: 296)
Ac-GDGSWCEMRQDVGK(ivDde)WNCFSDDPGG (SEQ ID NO: 299) GK-NH.sub.2
Ac-AQRGDYQEQYWHQQLVEQLK(ivDde)LLGG (SEQ ID NO: 331) GK-NH.sub.2
Ac-GDNWECGWSNMFQK(ivDde)EFCARPDPGG (SEQ ID NO: 303) GK-NH.sub.2
Ac-AGPGPCK(ivDde)GYMPHQCWYMGTGGGK- (SEQ ID NO: 367) NH.sub.2
Ac-AGYGPCAEMSPWLCWYPGTGGGK-NH.sub.2. (SEQ ID NO: 322)
[0836] In addition, tetrameric complexes of biotinylated
derivatives of SEQ ID NOS:294 and 277 (prepared as described above)
produced at least a 50% inhibition of VEGF-induced KDR
phosphorylation at 10 nM.
Example 10
Binding of Tc-Labeled SEQ ID NO:339 to KDR-Transfected 293H
Cells
[0837] The ability of Tc-labeled SEQ ID NO:339 to bind KDR was
assessed using KDR-transfected 293H cells. Tc-labeled SEQ ID NO:277
(i.e.,
Ac-AGPTWCEDDWYYCWLFGT-GGGK(N,N-dimethyl-Gly-Ser-Cys-Gly-di(aminodioxaocta-
-))-NH.sub.2) bound significantly better to KDR transfected 293H
cells than to mock transfected 293H cells and binding increased
with concentration of Tc-labeled SEQ ID NO:339 in a linear
manner.
[0838] Preparation of Peptidic Chelate for Binding to Tc by SPPS
(FIG. 35)
[0839] To a 250 mL of SPPS reaction vessel was added 6.64 mmol of
H-Gly-2-Cl-trityl resin (0.84 mmol/g, Novabiochem). It was swelled
in 80 mL of DMF for 1 h. For each coupling cycle the resin was
added 26.6 mmol of DIEA, 26.6 mmol of a Fmoc-amino acid in DMF (EM
Science), 26.6 mmol of HOBT (Novabiochem) in DMF, and 26.6 mmol of
DIC. The total volume of DMF was 80 mL. The reaction mixture was
shaken for 4 h. The resin then was filtered and washed with DMF
(3.times.80 mL). A solution of 20% piperidine in DMF (80 mL) was
added to the resin and it was shaken for 10 min. The resin was
filtered and this piperidine treatment was repeated. The resin
finally was washed with DMF (3.times.80 mL) and ready for next
coupling cycle. At the last coupling cycle, N,N-dimethyl glycine
(Aldrich) was coupled using HATU/DIEA activation. Thus, to a
suspension of N,N-dimethyl glycine (26.6 mmol) in DMF was added a
solution of 26.6 mmol of HATU (Perseptive Biosystems) in DMF and
53.1 mmol of DIEA. The clear solution was added to the resin and
shaken for 16 h. Following the synthesis, the resin was filtered
and washed with DMF (3.times.80 mL), CH.sub.2Cl.sub.2 (3.times.80
mL) and dried. The resin was mixed with 80 mL of
AcOH/CF.sub.3CH.sub.2OH/DCM (1/1/8, v/v/v) and shaken for 45 min.
The resin was filtered and the filtrate was evaporated to a paste.
Purification of the crude material by silica gel chromatography
using 25% MeOH/DCM afforded 2.0 g of the final product.
[0840] Coupling of the Peptidic Chelate to the Peptide (Fragment
Coupling)
[0841] Diisopropylcarbodiimide (0.0055 mmol) was added to a mixture
of purified Me.sub.2N-Gly-Cys-(Trt)-Ser(tBu)-Gly-OH and
hydroxybenzotriazole (0.0055 mmol) in DMF (0.25 mL), and the
mixture was stirred at RT for 6 h. The peptide (0.005 mmol) in DMF
(0.25 mL) was then added to the reaction mixture, and stirring was
continued for an additional 6 h. DMF was removed under vacuum and
the residue was treated with reagent B and stirred for 3 h. TFA was
removed under reduced pressure and the residue was purified by
preparative HPLC using acetonitrile-water containing 0.1% TFA.
Fractions containing the pure product were collected and freeze
dried to yield the peptide. The peptide was characterized by ES-MS
and the purity was determined by RP-HPLC (acetonitrile-water/0.1%
TFA) gradient.
[0842] Synthesis of .sup.99mTc-Labeled SEQ ID NO:339
[0843] A stannous gluconate solution was prepared by adding 2 mL of
a 20 .mu.g/mL SnCl.sub.2.2H.sub.2O solution in nitrogen-purged 1N
HCl to 1.0 mL of nitrogen-purged water containing 13 mg of sodium
glucoheptonate. To a 4 mL autosampler vial was added 20-40 .mu.l
(20-40 .mu.g) of SEQ ID NO:339 ligand dissolved in 50/50
ethanol/H.sub.2O, 6-12 mCi of .sup.99mTcO.sub.4.sup.- in saline and
100 .mu.l of stannous glucoheptonate solution. The mixture was
heated at 100.degree. C. for 22 min. The resulting radiochemical
purity (RCP) was 10-47% when analyzed using a Vydac C18 Peptide and
Protein column that was eluted at a flow rate of 1 mL/min. with 66%
H.sub.2O (0.1% TFA)/34% ACN(0.085% TFA). The reaction mixture was
purified by HPLC on a Vydac C18 column (4.6 mm.times.250 mm) at a
flow rate of 1 mL/min., using 0.1% TFA in water as aqueous phase
and 0.085% TFA in acetonitrile as the organic phase. The following
gradient was used: 29.5% org. for 35 min., ramp to 85% over 5 min.,
hold for 10 min. The fraction containing .sup.99mTc SEQ ID NO:339
was collected into 500 .mu.l of a stabilizing buffer containing 5
mg/mL ascorbic acid and 16 mg/mL hydroxypropyl-.alpha.-cyclodextrin
in 50 mM phosphate buffer. The mixture was concentrated using a
speed vacuum apparatus to remove acetonitrile, and 200 .mu.l of
0.1% HSA in 50 mM pH 5 citrate buffer was added. The resulting
product had an RCP of 100%. Prior to injection into animals, the
compound was diluted to the desired radioconcentration with normal
saline.
[0844] Transfection of 293H Cells
[0845] 293H cells were transfected using the protocol described
above. Transfection was done in black/clear 96-well plates (Becton
Dickinson, cat. # 354640). The left half of the plates (48 wells)
were mock-transfected (with no DNA) and the right half of the plate
was transfected with KDR cDNA. The cells were 80-90% confluent at
the time of transfection and completely confluent the next day, at
the time of the assay; otherwise the assay was aborted.
[0846] Preparation of Opti-MEMI Media with 0.1% HSA
[0847] Opti-MEMI was obtained from Invitrogen (cat. # 11058-021)
and human serum albumin (HSA) was obtained from Sigma (cat. #
A-3782). To prepare opti-MEMI media with 0.1% HSA, 0.1% w/v HSA was
added to opti-MEMI, stirred at room temperature for 20 min. and
then filter sterilized using 0.2 .mu.m filter.
[0848] Preparation of Tc-Labeled SEQ ID NO:339 Dilutions for the
Assay
[0849] Stock solution of Tc-labeled SEQ ID NO:339 (117 .mu.Ci/mL)
was diluted 1:100, 1:50, 1:25 and 1:10 in opti-MEMI with 0.1% HSA
to provide solutions with final concentration of 1.17, 2.34, 4.68
and 11.7 [Ci/mL of Tc-labeled SEQ ID NO:339.
[0850] Assay to Detect the Binding of Tc-Labeled SEQ ID NO:339
[0851] Cells were used 24 hours after transfection, and to prepare
the cells for the assay, they were washed once with 100 .mu.l of
room temperature opti-MEMI with 0.1% HSA. After washing, the
opti-MEMI with 0.1% HSA was removed from the plate and replaced
with 70 .mu.l of 1.17, 2.34, 4.68 and 11.7 .mu.Ci/mL of Tc-labeled
SEQ ID NO:339 (prepared as above). Each dilution was added to three
separate wells of mock- and KDR-transfected cells. After incubating
at room temperature for 1 hour, the plates were transferred to
4.degree. C. for 15 minutes and washed 5 times with 100 .mu.l of
cold binding buffer (opti-MEMI with 0.1% HSA), gently blotted dry
and checked under a microscope for cell loss. 100 .mu.l of
solubilizing solution (2% Triton X-100, 10% Glycerol, 0.1% BSA) was
added to each well and the plates were incubated at 37.degree. C.
for 10 minutes. The solubilizing solution in each well was mixed by
pipeting up and down, and transferred to 1.2 mL tubes. Each well
was washed once with 100 .mu.l of solubilizing solution and the
washes were added to the corresponding 1.2 mL tube. Each 1.2 mL
tube was then transferred to a 15.7.times.100 cm tube to be counted
in an LKB Gamma Counter using program 12 (Tc-window for 20
sec).
[0852] Binding of Tc-Labeled SEQ ID NO:339 to KDR Transfected
Cells
[0853] The ability of Tc-labeled SEQ ID NO:339 to specifically bind
to KDR was assessed using transiently transfected 293H cells.
[0854] As shown in FIG. 14, Tc-labeled SEQ ID NO:339 bound
significantly better to KDR transfected 293H cells as compared to
mock transfected 293H cells. To calculate specific binding to KDR,
the binding of Tc-labeled SEQ ID NO:339 polypeptide to
mock-transfected cells was subtracted from the binding to
KDR-transfected cells. A linear increase in the specific binding of
Tc-labeled SEQ ID NO:339 to KDR was observed with increasing
concentration of Tc-labeled SEQ ID NO:339 (FIG. 96). Linear binding
was not surprising because concentration of Tc-labeled SEQ ID
NO:339 was only .about.100 pM (even at the highest concentration,
11.7 .mu.Ci/mL, tested in the assay), which is far below the
K.sub.D value of .about.3-4 nM of SEQ ID NO:277 (as calculated
using avidin HRP assay), so no saturation of binding would be
expected.
Example 11
Preparation of Peptides and Dimeric Peptide Construction
[0855] The following methods were used for the preparation of
individual peptides and dimeric peptide constructs described in the
following Examples (11-15).
[0856] Automated Peptide Synthesis
[0857] Peptide synthesis was carried out on a ABI-433A Synthesizer
(Applied Biosystems Inc., Foster City, Calif.) on a 0.25 mmol scale
using the FastMoc protocol. In each cycle of this protocol
preactivation was accomplished by dissolution of 1.0 mmol of the
requisite dry N.sup..alpha.-Fmoc side-chain protected amino acid in
a cartridge with a solution of 0.9 mmol of HBTU, 2 mmol of DIEA,
and 0.9 mmol of HOBt in a DMF-NMP mixture. The peptides were
assembled on NovaSyn TGR (Rink amide) resin (substitution level 0.2
mmol/g). Coupling was conducted for 21 min. Fmoc deprotection was
carried out with 20% piperidine in NMP. At the end of the last
cycle, the N-terminal Fmoc group was removed and the fully
protected resin-bound peptide was acetylated using acetic
anhydride/DIEA/HOBt/NMP.
[0858] Cleavage, Side-Chain Deprotection and Isolation of Crude
Peptides
[0859] Cleavage of the peptides from the resin and side-chain
deprotection was accomplished using Reagent B for 4.5 h at ambient
temperature. The cleavage solutions were collected and the resins
were washed with an additional aliquot of Reagant B. The combined
solutions were concentrated to dryness. Diethyl ether was added to
the residue with swirling or stirring to precipitate the peptides.
The liquid phase was decanted, and solid was collected. This
procedure was repeated 2-3 times to remove impurities and residual
cleavage cocktail components.
[0860] Cyclization of Di-Cysteine Peptides
[0861] The crude ether-precipitated linear di-cysteine containing
peptides were cyclized by dissolution in water, mixtures of aqueous
acetonitrile (0.1% TFA), aqueous DMSO or 100% DMSO and adjustment
of the pH of the solution to 7.5-8.5 by addition of aqueous
ammonia, aqueous ammonium carbonate, aqueous ammonium bicarbonate
solution or DIEA. The mixture was stirred in air for 16-48 h,
acidified to pH 2 with aqueous trifluoroacetic acid and then
purified by preparative reverse phase HPLC employing a gradient of
acetonitrile into water. Fractions containing the desired material
were pooled and the purified peptides were isolated by
lyophilization.
[0862] Preparation of Peptides Containing Linkers
[0863] In a typical experiment, 400 mg of the resin-bound peptide
bearing an ivDde-protected lysine) was treated with 10% hydrazine
in DMF (2.times.20 mL). The resin was washed with DMF (2.times.20
mL) and DCM (1.times.20 mL). The resin was resuspended in DMF (10
mL) and treated with Fmoc-8-amino-3,6-dioxaoctanoic acid (0.4
mmol), HOBt (0.4 mmol), DIC (0.4 mmol) and DIEA (0.8 mmol) with
mixing for 4 h. After the reaction, the resin was washed with DMF
(2.times.10 mL) and with DCM (1.times.10 mL). The resin was then
treated with 20% piperidine in DMF (2.times.15 mL) for 10 min each
time. The resin was washed and the coupling with
Fmoc-8-amino-3,6-dioxaoctanoic acid and Fmoc protecting group
removal were repeated once more.
[0864] The resulting resin-bound peptide with a free amino group
was washed and dried and then treated with reagent B (20 mL) for 4
h. The mixture was filtered and the filtrate concentrated to
dryness. The residue was stirred with ether to produce a solid,
which was washed with ether and dried. The solid was dissolved in
anhydrous DMSO and the pH adjusted to 7.5 with DIEA. The mixture
was stirred for 16 h to effect the disulfide cyclization and the
reaction was monitored by analytical HPLC. After completion of the
cyclization, the reaction mixture was diluted with 25% acetonitrile
in water and applied directly to a reverse phase C-18 column.
Purification was effected using a gradient of acetonitrile into
water (both containing 0.1% TFA). Fractions were analyzed by HPLC
and those containing the pure product were combined and lyophilized
to provide the required peptide.
[0865] Preparation of Biotinylated Peptides Containing Linkers
[0866] In a typical experiment, 400 mg of the resin-bound peptide
bearing an ivDde-protected lysine, was treated with 10% hydrazine
in DMF (2.times.20 mL). The resin was washed with DMF (2.times.20
mL) and DCM (1.times.20 mL). The resin was resuspended in DMF (10
mL) and treated with Fmoc-8-amino-3,6-dioxaoctanoic acid (0.4
mmol), HOBt (0.4 mmol), DIC (0.4 mmol) and DIEA (0.8 mmol) with
mixing for 4 h. After the reaction, the resin was washed with DMF
(2.times.10 mL) and with DCM (1.times.10 mL). The resin was then
treated with 20% piperidine in DMF (2.times.15 mL) for 10 min each
time. The resin was washed and the coupling with
Fmoc-8-amino-3,6-dioxaoctanoic acid and removal of the Fmoc
protecting group were repeated once more.
[0867] The resulting resin-bound peptide with a free amino group
was treated with a solution of Biotin-NHS ester (0.4 mmol, 5
equiv.) and DIEA (0.4 mmol, 5 equiv.) in DMF for 2 h. The resin was
washed and dried as described previously and then treated with
Reagent B (20 mL) for 4 h. The mixture was filtered and the
filtrate concentrated to dryness. The residue was stirred with
ether to produce a solid that was collected, washed with ether, and
dried. The solid was dissolved in anhydrous DMSO and the pH
adjusted to 7.5 with DIEA. The mixture was stirred for 4-6 h to
effect the disulfide cyclization, which was monitored by HPLC. Upon
completion of the cyclization, the reaction mixture was diluted
with 25% acetonitrile in water and applied directly to a reverse
phase C-18 column. Purification was effected using a gradient of
acetonitrile into water (both containing 0.1% TFA). Fractions were
analyzed by HPLC and those containing the pure product were
collected and lyophilized to provide the required biotinylated
peptide.
[0868] Preparation of DOTA-Conjugated Peptides for Labeling with
Selected Gadolinium or Indium Isotopes
[0869] In a typical experiment, 400 mg of the resin-bound peptide
bearing an N.sup..epsilon.-ivDde-protected lysine moiety was
treated with 10% hydrazine in DMF (2.times.20 mL). The resin was
washed with DMF (2.times.20 mL) and DCM (1.times.20 mL). The resin
was resuspended in DMF (10 mL) and treated with
Fmoc-8-amino-3,6-dioxaoctanoic acid (0.4 mmol), HOBt (0.4 mmol),
DIC (0.4 mmol), DIEA (0.8 mmol) with mixing for 4 h. After the
reaction, the resin was washed with DMF (2.times.10 mL) and with
DCM (1.times.10 mL). The resin was then treated with 20% piperidine
in DMF (2.times.15 mL) for 10 min each time. The resin was washed
and the coupling with Fmoc-8-amino-3,6-dioxaoctanoic acid and
removal of the Fmoc protecting group were repeated once. The
resulting resin-bound peptide with a free amino group was
resuspended in DMF (10 mL) and treated with a solution of
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid,-1,4,7-tris-t-butyl ester (DOTA-tris-t-butyl ester, 0.4 mmol,
5 equiv.), HOBt (0.4 mmol), DIC (0.4 mmol) and DIEA (0.8 mmol) in
DMF (10 mL) with mixing for 4 h. Upon completion of the reaction,
the resin was washed with DMF (2.times.10 mL) and with DCM
(1.times.10 mL) and treated with Reagent B (20 mL) for 4 h. The
mixture was filtered and the filtrate concentrated to dryness. The
residue was stirred in ether to produce a solid that was collected,
washed with ether, and dried. The solid was dissolved in anhydrous
DMSO and the pH adjusted to 7.5 with DIEA. The mixture was stirred
for 16 h to effect the disulfide cyclization, which was monitored
by HPLC. Upon completion of the cyclization, the mixture was
diluted with 25% acetonitrile in water and applied directly to a
reverse phase C-18 HPLC column. Purification was effected using a
gradient of acetonitrile into water (both containing 0.1% TFA).
Fractions were analyzed by HPLC and those containing the pure
product were combined and lyophilized to provide the required
biotinylated peptide.
[0870] The following monomeric peptides of Table 11 were prepared
by the above methods, "PnAO6", as used herein, refers to
3-(2-amino-3-(2-hydroxy-
imino-1,1-dimethyl-propylamino)-propylamino)-3-methyl-butan-2-one
oxime.
16TABLE 11 Sequence or Structure of Monomeric Peptides and Peptide
Derivatives SEQ. ID NO: or Structure or Sequence dimer
Ac-AGPTWCEDDWYYCWLFGTGGGK(BiotinJJ-K)-NH.sub.2 277
(Ac-AGPTWCEDDWYYCWLFGTGGGKK(BiotinJJ.paren close-st. NH.sub.2) 373
Ac-AGPTWCEDDWYYCWLFGTJK(DOTAJJ-K)-NH.sub.2 493
Ac-AGPTWCEDDWYYCWLFGTJK(JJ)-NH.sub.2 493
Ac-AGPTWCEDDWYYCWLFGTGGGK[K(ivDde)]-NH.sub.2 373
Ac-VCWEDSWGGEVCFRYDPGGGK(Biotin-JJK)-NH.sub.2 337
(Ac-VCWEDSWGGEVCFRYDPGGGKK(Biotin-JJ)-NH.sub.2) 494
Ac-VCWEDSWGGEVCFRYDPGGGK(JJ)-NH.sub.2 337
Ac-AQDWYYDEILSMADQLRHAFLSGGGGGK(J)-NH.sub.2 356 Seq 12 derivative
Ac-AQDWYYDEILSMADQLRHAFLSGGGGGKK(ivDde) 495 Application seq 12
derivative Ac-GDSRVCWEDSWGGEVCFRYDPGGG- K(JJ)-NH.sub.2 294 Seq 5
derivative Ac-GDSRVCWEDSWGGEVCFRYDPGGGK(JJ)-NH.sub.2 294/ Seq 5
deriv D10 Ac-AGPTWCEDDWYYCWLFGTGGGK[(PnAO6- 277/
C(.dbd.O)(CH.sub.2).sub.3C(.dbd.O)-K]-NH.sub.2 D10 A Seq 11
derivative Ac-AGPTWCEDDWYYCWLFGTGGGK[K(DOTA- 277/
JJK(iV-Dde)]-NH.sub.2 D11 A Seq 11 derivative
Ac-AGPTWCEDDWYYCWLFGTGGGK[(PnAO6- 476/ C(.dbd.O)(CH.sub.2).sub.3C(-
.dbd.O))K]-NH.sub.2 D12 A Seq 11 derivative
Ac-VCWEDSWGGEVCFRYDPGGGK-NH.sub.2 337/ A Seq 5 derivative
specifically: D12 Seq 5 residues 5-25
Ac-AGPTWCEDDWYYCWLFGTGGGK[K(BOA)]-NH.sub.2 277/ Seq 11 derivative
D13 Ac-AQDWYYDEILSMADQLRHAFLSGGGGGK[PnAO6- 356/
C(.dbd.O)(CH.sub.2).sub.3C(.dbd.O)-K(iV-Dde)]-NH.sub.2 D14
Application seq 12 derivative Ac-GDSRVCWEDSWGGEVCFRYDPGGG-
K(JJ)-NH.sub.2 294/ Seq 5 deriv linker = Glut D15
Ac-AGPTWCEDDWYYCWLFGTGGGK-[PnAO6- 277/ C(.dbd.O)(CH.sub.2).sub.3C(-
.dbd.O)-K]-NH.sub.2 D16 A Seq 11 derivative, new sequence
Ac-AQDWYYEILJGRGGRGGRGGK[K(ivDde)]-NH.sub.2 496/ A Seq 12 (1-9)
derivative D17 Ac-APGTWCDYDWEYCWLGTFGGGK[(6PnAO- 497/
C(.dbd.O)(CH.sub.2).sub.3C(.dbd.O)-K]-NH.sub.2 D18 A scrambled Seq
11 derivative used as a control.
Ac-GVDFRCEWSDWGEVGCRSPDYGGGK(JJ)-NH.sub.2 489/ A scrambled Seq 5
derivative. D18 Ac-AGPTWCEDDWYYCWLFGTGGGK(Biotin-K)-NH.su- b.2,
294/ A Seq 11 derivative D19
JJAGPTWCEDDWYYCWLFGTGGGK(iV-Dde)-NH.sub.2 277/ (SEQ ID NO: 277) D20
JJVCWEDSWGGEVCFRYDPGGG-NH.sub.2 370/ D20
JJAGPTWCEDDWYYCWLFGTGGGK(iV-Dde)-NH.sub.2 277/ D21
Ac-AGPTWCEDDWYYCWLFGTGGGK[K(SATA)]-NH.sub.2 373/ D22
Ac-AGPTWCEDDWYYCWLFGTGGGK[SATA-JJ-K]-NH.sub.2 339/ D23
Ac-GDSRVCWEDSWGGEVCFRYDPGGGK(JJ)-NH.sub.2 294/ D24
H.sub.2N-AGPTWCEDDWYYCWLFGTGGGK[K(iV-Dde)]-NH.sub.2 373/ D25
Ac-AGPTWCEDDWYYCWLFGTGGGK{Biotin-JJK[NH.- sub.2- 337/
Ser(GalNAc(Ac).sub.3-alpha-D)-Gly- D26
Ser(GalNAc(Ac).sub.3-alpha-D]}-NH.sub.2
Ac-VCWEDSWGGEVCFRYDPGGGK(NH.sub.2- 337/ Ser(GalNAc(Ac).sub.3-alpha-
-D)-Gly- D26 Ser(GalNAc(Ac).sub.3-alpha-D)-NH.sub.2
Ac-GSPEMCMMFPFLYPCNHHAPGGGK[(PnAO6)- 482/ C(.dbd.O)(CH.sub.2).sub.-
3C(.dbd.O)-K]}-NH.sub.2 D27 A modified cMet Binding Sequence
Example 12
Preparation of Homodimeric and Heterodimeric Constructs
[0871] The purified peptide monomers mentioned above in Example 8
were used in the preparation of various homodimeric and
heterodimeric constructs.
[0872] Preparation of Homodimer-Containing Constructs
[0873] To prepare homodimeric compounds, half of the peptide needed
to prepare the dimer was dissolved in DMF and treated with 10
equivalents of glutaric acid bis-N-hydoxysuccinimidyl ester. The
progress of the reaction was monitored by HPLC analysis and mass
spectroscopy. At completion of the reaction, the volatiles were
removed in vacuo and the residue was washed with ethyl acetate to
remove the unreacted bis-NHS ester. The residue was dried,
re-dissolved in anhydrous DMF and treated with another half portion
of the peptide in the presence of 2 equivalents of DIEA. The
reaction was allowed to proceed for 24 h. This mixture was applied
directly to a YMC reverse phase HPLC column and purified by elution
with a linear gradient of acetonitrile into water (both containing
0.1% TFA).
[0874] Preparation of Heterodimer-Containing Constructs
[0875] In the case of heterodimers, one of the monomers ("A") was
reacted with the bis-NHS ester of glutaric acid and after washing
off the excess of bis-NHS ester (as described for the homodimeric
compounds), the second monomer ("B") was added in the presence of
DIEA. After the reaction the mixture was purified by preparative
HPLC. Typically, to a solution of glutaric acid bis
N-hydoxysuccinimidyl ester (0.02 mmol, 10 equivalents) in DMF (0.3
mL) was added a solution of peptide "A" and DIEA (2 equiv) in DMF
(0.5 mL) and the mixture was stirred for 2 h. The progress of the
reaction was monitored by HPLC analysis and mass spectroscopy. At
completion of the reaction, the volatiles were removed in vacuo and
the residue was washed with ethyl acetate (3.times.1.0 mL) to
remove the unreacted bis-NHS ester. The residue was dried,
re-dissolved in anhydrous DMF (0.5 mL) and treated with a solution
of peptide "B" and DIEA (2 equiv) in DMF (0.5 mL) for 24 h. The
mixture was diluted with water (1:1,v/v) and applied directly to a
YMC C-18 reverse phase HPLC column and purified by elution with a
linear gradient of acetonitrile into water (both containing 0.1%
TFA). Fractions were analyzed by analytical HPLC and those
containing the pure product were combined and lyophilized to obtain
the required dimer. The dimers depicted in FIGS. 36-63 were
prepared by this method (structure, name, compound reference number
as described in the "Brief Description of the Drawings").
[0876] For the preparation of the dimer D5, after the coupling
reaction of the individual peptides, 50 .mu.L of hydrazine was
added to the reaction mixture (to expose the lysine N'-amino group)
and the solution was stirred for 2 min. The reaction mixture was
diluted with water (1.0 mL) and the pH was adjusted to 2 with TFA.
This was then purified by the method described above.
[0877] The HPLC analysis data and mass spectral data for the
dimeric peptides are given in Table 12 below.
17TABLE 12 Analytical Data for Homodimeric and Heterodimeric
Peptide Constructs HPLC Analysis System Retention Time (System)
Mass Spectral data (API-ES, - ion) D1 8.98 min. (A) 1987.7 (M -
3H)/3, 1490.6 (M - 4H)/4, 1192.3 (M - 5H)/5 D2 16.17 min (B) 2035.3
(M - 3H)/3, 1526.1 (M - 4H)/4, 1220.7 (M - 5H)/5 D3 8.74 min (C)
1933.6 (M - 3H)/3, 1449.9 (M - 4H)/4, 1159.4 (M - 5H)/5 D4 10.96
min (D) 2032.8 (M - 3H)/3 D5 6.57 min (E) 1816.2 (M - 3H)/3, 1361.8
(M - 4H)/4, 1089.4 (M - 5H)/5, 907.7 (M - 6H)/6 D6 D7 D8 4.96 min;
(F) 2379.3 [M - 3H]/3 D9 5.49 min; (G) 2146.4 [M - 3H]/3 D10 5.44
min; (H) 2082.7 [M - 3H]/3, 1561.7 [M - 4H]/4, 1249.1 [M - 5H]/5,
1040.7 [M - 6H]/6 D11 7.23 min; (E) 2041.8 [M - 3H]/3, 1531.1 [M -
4H]/4, 1224.6 [M - 5H]/5 D12 5.84 min; (H) 1877.1 [M - 3H]/3,
1407.6 [M - 4H]/4, 1125.9 [M - 5H]/5, 938.1 [M - 6H]/6. D13 5.367
min; (E) 1965.3 [M - 3H]/3, 1473.8 [M - 4H]/4, 1178.8 [M - 5H]/5,
982.2 [M - 6H]/6 D14 4.78 min; (I) 2275.0 [M - 3H]/3, 1362.8 [M -
5H]/5 D15 5.41 min; (H) 1561.3 [M - 4H]/4, 1249.1 [M - 5H]/5,
1040.8 [M - 6H]/6, 891.8 [M - 7H]/7. D16 5.44 min; (J) 2150.8 [M -
3H]/3, 1613.1 [M - 4H]/4, 1289.9 [M - 5H]/5, 1074.8 [M - 6H]/6,
920.9 [M - 7H]/7. D17 4.78 min; (K) 1789.4 [M - 3H]/3, 1347.7 [M -
4H]/4. D18 4.74 min; (L) 2083.1 [M - 3H]/3, 1562.7 [M - 4H]/4,
1249.5 [M - 5H]/5. D19 7.13 min; (O) 1891.9 [M - 3H]/3, 1418.4 [M -
4H]/4, 1134.8 [M - 5H]/5, 945.5 [M - 6H]/6. D20 9.7 min; (P) 2700.4
[M - 2H]/2, 1799.3[M - 3H]/3 D21 6.1 min; (P) 2891.3 [M - 2H]/2,
1927.2[M - 3H]/3, 1445.1 [M - 4H]/4, 1155.8 [M - 5H]/5. D22 6.23
min; (Q) 1994.4 [M - 3H]/3, 1495.7 [M - 4H]/4, 1196.3 [M - 5H]/5
D23 7.58 min; (J) 1854.4 [M - 3H]/3, 1390.8 [M - 4H]/4, 1112.7 [M -
5H]/5, 927 [M - 6H]/6 D24 8.913 min; (R) 1952.1 [M - 3H]/3, 1463.4
[M - 4H]/4, 1171.1 [M - 5H]/5, 975.3 [M - 6H]/6 D25 5.95 min; (E)
1954.9 [M - 3H]/3, 1466.1 [M - 4H]/4, 1172.4 [M - 5H]/5, 976.8 [M -
6H]/6. D26 6.957 min; (S) 1759.1 [M - 3H]/3, 1319.6 [M - 4H]/4,
1055.1 [M - 5H]/5 D27 5.5 min; (M) 2317.6 [M - 3H]/3, 1737.2[M -
4H]/4, 1389.3[M - 5H]/5, 1157.7 [M - 6H]/6 D30 4.29 min (T) [M +
H]: 5782.3, [M + 4H]/4: 1146.6, [M + 5H]/5: 1157.4, [M + 6H]/6:
964.7 D31 6.6 min (U) [M - 3H]/3: 2045.3. Monomer 6.0 min (U) [M -
2H]/2: 1307.4 Compound 2 Monomer 5.3 min (U) [M - 2H]/2: 1307.4
Compound 4 (SEQ ID NO: 374- related sequence)
[0878]
18TABLE 13 Dimer sequences and linkers Dimer # Sequence D1
Ac-AGPTWCEDDWYYCWLFGTGGGK(SEQ ID NO: 277)[(Biotin-JJK- (FIG. 36)
(O.dbd.)C(CH.sub.2).sub.3C(.dbd.O)-JJ-
-NH(CH.sub.2).sub.4-(S)-CH((Ac- VCWEDSWGGEVCFRYDPGGGK(SEQ ID NO:
337))-NH)CONH.sub.2]-NH.sub.2) D2 Ac-AGPTWCEDDWYYCWLFGTGG- GK(SEQ
ID NO: 277)[(Biotin-JJK- (FIG. 37) (O.dbd.)C(CH.sub.2).sub.3-
C(.dbd.O)-JJ-NH(CH.sub.2).sub.4-(S)-CH((Ac-AGPTWCEDDWYYCWLFGTJK(SEQ
ID NO: 493))-NH)CONH.sub.2]-NH.sub.2 D3
Ac-VCWEDSWGGEVCFRYDPGGGK(SEQ ID NO: 337)[(Biotin-JJK- (FIG. 38)
(O.dbd.)C(CH.sub.2).sub.3C(.dbd.O)-JJ-NH(CH.sub.2).sub.4-(S)-CH((Ac-
VCWEDSWGGEVCFRYDPGGGK(SEQ ID NO: 337))-NH)CONH.sub.2]-NH.sub.2 D4
Ac-AGPTWCEDDWYYCWLFGTJK(SEQ ID NO: 338)[DOTA-JJK- (FIG. 39)
(O.dbd.)C(CH.sub.2).sub.3C(.dbd.O)-JJ-NH(CH.sub.2).sub.4-(S)-CH((Ac-
VGWEDSWGGEVCFRYDPGGGK(SEQ ID NO: 337))-NH)CONH.sub.2]-NH.sub.2 D5
Ac-VCWEDSWGGEVCFRYDPGGGK(SEQ ID NO: 337)
(JJ-C(.dbd.O)(CH.sub.2).sub.3C(.dbd.O)-K- (FIG. 40)
NH(CH.sub.2).sub.4-(S)-CH((Ac-AGPTWCEDDWYYCWLFGTGGGK(SEQ ID NO:
277))- NH)CONH.sub.2)-NH.sub.2 D6 GDSRVCWEDSWGGEVCFRYDPGGGK (SEQ ID
NO: 294)- (FIG. 63) AGPTWCEDDWYYCWLFGTGGGK (SEQ ID NO: 277) (see
FIG. 63 for linkage) D7 GDSRVCWEDSWGGEVCFRYDPGG- GK (SEQ ID NO:
294)- (FIG. 64) AGPKWCEEDWYYCMITGTGGGK (SEQ ID NO: 264) (see FIG.
64 for linkage) D8 Ac-AQDWYYDEILSMADQLRHAF- LSGGGGGK{Ac- (FIG. 41)
AQDWYYDEILSMADQLRHAFLSGGGGGK(J-Glut.paren close-st.
NH.sub.2}K(Biotin-JJ)-NH.sub.2 D9
Ac-AQDWYYDEILSMADQLRHAFLSGGGGGK{[Ac- (FIG. 42)
GDSRVCWEDSWGGEVCFRYDPGGGK(JJ-Glut-)]-NH.sub.2}K-NH.sub.2 D10
Ac-AGPTWCEDDWYYCWLFGTGGGK{[Ac- (FIG. 43)
GDSRVCWEDSWGGEVCFRYDPGGGK(JJ-Glut-NH(CH.sub.2).sub.4-(S)-CH(PnAO6-Glut-
NH)(C.dbd.O-)]-NH.sub.2}-NH.sub.2 D11 Ac-AGPTWCEDDWYYCWLFGTGGGK{Ac-
(FIG. 44) VCWEDSWEDSWGGEVCFRYDPGGGK[-
JJ-Glut-NH(CH.sub.2).sub.4-(S)-CH(DOTA-JJ-NH-
)(C.dbd.O)-]-NH.sub.2}-NH.sub.2 D12
Ac-AGPTWCEDDYCWLFGTGGGK{[PnAO6-Glut-K(Ac- (FIG. 45)
VCWEDSWGGEVCFRYDPGGGK(-C(.dbd.O)CH.sub.2(OCH.sub.2CH.sub.2).sub.2OCH.sub.-
2C(.dbd.O).paren close-st. NH.sub.2]}-NH.sub.2 D13
Ac-AGPTWCEDDWYYCWLFGTGGGK{Ac-VCWEDSWGGEVCFRYDPGGGK[JJ- (FIG. 46)
Glut-K(BOA)]-NH.sub.2}-NH.sub.2: Dimer 13 (D13) D14
Ac-AQDWYYDEILSMADQLRHAFLSGGGGGK{PnAO6-Glut-K[Ac- (FIG. 47)
GSDRVCWEDSWGGEVCFRYDPGGGK(JJ-Glut)-NH.sub.2]}-NH.sub.2 D15
Ac-AGPTWCEDDWYYCWLFGTGGGK{[[Ac- (FIG. 48)
GDSRVCWEDSWGGEVCFRYDPGGGKJJ-Glut]-NH.sub.2]-K(PnAO6-Glut)}NH.sub.2
D16 Ac-AGPTWCEDDWYYCWLFGTGGGGK{PnAO6-Glut-K[Ac- (FIG. 49)
GDSRVCWEDSWGGEVCFRYDPGGGK[- C(.dbd.O)CH.sub.2O(CH.sub.2CH.sub.2O)-
.sub.2CH.sub.2C(.dbd.O)NH(CH.sub.2).sub.3O(CH.sub.2CH.sub.2O).sub.2(CH.sub-
.2).sub.3NH C(.dbd.O)CH.sub.2O(CH.sub.2CH.sub.2O).sub.2CH.sub.2C(.-
dbd.O)-]-NH.sub.2]}-NH.sub.2 D17 Ac-AQDWYYDEILJGRGGRGGRGGK-
{K[Ac-VCWEDSWGGEVCFRYDPGGGK(JJ- (FIG. 50) Glut)-NH.sub.2]}NH.sub.2
D18 Ac-AGPTWCDYDWEYCWLGTFGGGK{PnAO6-Glut-K[Ac- (FIG. 51)
GVDFRCEWSDWGEVGCRSPDYGGGK(JJ-Glut)-NH.sub.2]}-NH.sub.2 D19
Ac-AGPTWCEDDWYYCWLFGTGGGK{Biotin-K[Ac- (FIG. 52)
VCWEDSWGGEVCFRYDPGGGK(JJ-Glut)-NH.sub.2]}-NH.sub.2 D20
(-JJAGPTWCEDDWYYCWLFGTGGGGK-NH.sub.2)-Glut- (FIG. 53)
VCWEDSWGGEVCFRYDPGGG-NH.sub.2 D21 [-JJAGPTWCEDDWYYCWLFGTG-
GGGK(PnAO6-Glut)-NH.sub.2]-Glut- (FIG. 54)
VCWEDSWGGEVCFRYDPGGG-NH.- sub.2 D22
Ac-GDSRVCWEDSWGGEVCFRYDPGGGK{JJ-Glut-JJ- (FIG. 55)
AGPTWCEDDWYYCWLFTGGGK-NH.sub.2}-NH.sub.2 D23
Ac-AGPTWCEDDWYYCWLFGTGGGK{Ac-VCWEDSWGGEVCFRYDPGGGK[JJ- (FIG. 56)
Glut-K(SATA)]-NH.sub.2}-NH.sub.2 D24
Ac-AGPTWCEDDWYYCWLFGTGGGK{SATA-JJK[Ac- (FIG. 57)
VCWEDSWGGEVCFRYDPGGGK(JJ-Glut)-NH.sub.2]}-NH.sub.2 D25
Ac-AGPTWCEDDWYYCWLFGTGGGK{Ac- (FIG. 58) GDSRVCWEDSWGGEVCFRYDPGGGK[-
JJ-Glut-NH(CH.sub.2).sub.4-(S)- CH(NH.sub.2)C(.dbd.O)-]-NH.sub.2}--
NH.sub.2 D26 AGPTWCEDDWYYCWLFGTGGGGK{(-Glut-JJ-VCWEDSWGGEV-
CFRYDPGGG- (FIG. 59) NH.sub.2)-K}-NH.sub.2 D27
Ac-AGPTWCEDDWYYCWLFGTGGGGK{Ac- (FIG. 60) VCWEDSWGGEVCFRYDPGGGK[S(G-
alNAc(Ac).sub.3-alpha-D)-G-S(GalNAc(Ac).sub.3-alpha-
D)-Glut-S(GalNAc(Ac).sub.3-alpha-D)-G-S(GalNAc(Ac).sub.3-alpha-D)-NH(CH.s-
ub.2).sub.4-(S)- CH(Biotin-JJNH-)C(.dbd.O)-]-NH.sub.2}-NH.sub.2 D28
AQEPEGYAYWEVITLYHEEDGDGGK (SEQ ID NO: 305)- (FIG. 61)
AQAFPRFGGDDYWIQQYLRYTDGGK (SEQ ID NO: 306) (see FIG. 61 for
linkage) D29 AGPTWCEDDWYYCWLFGTGGGK (SEQ ID NO: 277)- (FIG. 62)
VCWEDSWGGEVCFRYDPGGGK (SEQ ID NO: 337) (see FIG. 62 for linkage)
D30 Ac-VCWEDSWGGEVCFRYDPGGGK (SEQ ID NO:
337){[PnAO.sub.6-Glut-K(-Glut-JJ- (FIG. 87C)
NH(CH.sub.2).sub.4-(S)-CH(Ac-AQDWYYDEILJGRGGRGGRGG(SEQ ID NO: 478)-
NH)C(.dbd.O)NH.sub.2]-NH.sub.2}-NH.sub.2 (see FIG. 87C) D31
Ac-AGPTWCEDDWYYCWLFGTGGGK(SEQ ID NO: 277)[Ac- (FIG. 88D)
VCWEDSWGGEVCFRYDPGGGK(SEQ ID NO:
337)[SGS-Glut-SGS-(S)-NH(CH.sub.2).sub.4- -
CH(Biotin-JJ-NH)-C(.dbd.O)]-NH.sub.2]-NH.sub.2 (see FIG. 88D)
[0879] HPLC Analysis Systems
[0880] System A: Column: YMC C-4 (4.6.times.250 mm); Eluents: A:
Water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
25% B, linear gradient 25-60% B in 10 min; flow rate: 2.0 mL/min;
detection: UV @ 220 nm.
[0881] System B: Column: YMC C-4 (4.6.times.250 mm); Eluents: A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
25% B, linear gradient 25-60% B in 20 min; flow rate: 2.0 mL/min;
detection: UV @ 220 nm.
[0882] System C: Column: YMC C-4 (4.6.times.250 mm); Eluents: A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
30% B, linear gradient 30-60% B in 10 min; flow rate: 2.0 mL/min;
detection: UV @ 220 nm.
[0883] System D: Column: YMC C-4 (4.6.times.250 mm); Eluents: A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
20% B, linear gradient 20-60% B in 10 min; flow rate: 2.0 mL/min;
Detection: UV @ 220 nm.
[0884] System E: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
10% B, linear gradient 10-60% B in 10 min; flow rate: 3.0 mL/min;
detection: UV @ 220 nm.
[0885] System F: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
water (0.1% TFA), B: Acetonitrile (0.1% TFA); Elution: Initial
condition, 30% B, Linear Gradient 30-70% B in 10 min; Flow rate:
3.0 mL/min; Detection: UV @ 220 nm.
[0886] System G: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
30% B, linear gradient 30-75% B in 10 min; flow rate: 3.0 mL/min;
detection: UV @ 220 nm.
[0887] System H: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
20% B, linear gradient 20-52% B in 10 min; flow rate: 3.0 mL/min;
detection: UV @ 220 nm.
[0888] System I: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
10% B, linear gradient 10-65% B in 10 min; flow rate: 3.0 mL/min;
detection: UV @ 220 nm.
[0889] System J: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
20% B, linear gradient 20-60% B in 10 min; flow rate: 3.0 mL/min;
detection: UV @ 220 nm.
[0890] System K: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition, 5%
B, linear gradient 5-60% B in 10 min; flow rate: 3.0 mL/min;
detection: UV @ 220 nm.
[0891] System L: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition, 5%
B, linear gradient 5-65% B in 10 min; flow rate: 3.0 mL/min;
detection: UV @ 220 nm.
[0892] System M: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
15% B, linear gradient 15-50% B in 10 min; flow rate: 3.0 mL/min;
detection: UV @ 220 nm.
[0893] System N: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
10% B, linear gradient 20-80% B in 10 min; flow rate: 3.0 mL/min;
detection: UV @ 220 nm.
[0894] System O: Column: YMC-C18, 4.6.times.250 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
30% B, linear gradient 30-60% B in 10 min; flow rate: 2.0 mL/min;
detection: UV @ 220 nm.
[0895] System P: Column: YMC-C18, 4.6.times.250 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
20% B, linear gradient 20-80% B in 20 min; flow rate: 2.0 mL/min;
detection: UV @ 220 nm.
[0896] System Q: Column: YMC-C18, 4.6.times.250 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
20% B, linear gradient 20-60% B in 6 min; flow rate: 2.0 mL/min;
detection: UV @ 220 nm.
[0897] System R: Column: YMC-C18, 4.6.times.250 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
25% B, linear gradient 25-60% B in 10 min; flow rate: 2.0 mL/min;
detection: UV @ 220 nm.
[0898] System S: Column: YMC-C18, 4.6.times.100 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
10% B, linear gradient 10-60% B in 10 min; flow rate: 3.0 mL/min;
detection: UV @ 220 nm.
[0899] System T: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition, 5%
B, linear gradient 5-65% B in 8 min; flow rate: 3.0 mL/min;
detection: UV @ 220 nm.
[0900] System U: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
water (0.1% TFA), B: ACN (0.1% TFA); Elution: initial condition,
15% B, linear gradient 15-50% B in 8 min; flow rate: 3.0 mL/min;
detection: UV @ 220 nm.
Example 13
Competition with .sup.125I-VEGF for Binding to KDR on HUVECs and
KDR-Transfected Cells
[0901] The following experiment assessed the ability of KDR-binding
peptides to compete with .sup.125I-labeled VEGF for binding to KDR
expressed by transfected 293H cells.
[0902] Protocol:
[0903] 293H cells were transfected with the KDR cDNA or
mock-transfected by standard techniques. The cells were incubated
with .sup.125I-VEGF in the presence or absence of competing
compounds (at 10 .mu.M, 0.3 .mu.M, and 0.03 .mu.M). After washing
the cells, the bound radioactivity was quantitated on a gamma
counter. The percentage inhibition of VEGF binding was calculated
using the formula [(Y1-Y2).times.100/Y1], where Y1 is specific
binding to KDR-transfected 293H cells in the absence peptides, and
Y2 is specific binding to KDR-transfected 293H cells in the
presence of peptide competitors. Specific binding to
KDR-transfected 293H cells was calculated by subtracting the
binding to mock-transfected 293H cells from the binding to
KDR-transfected 293H cells.
[0904] Results
[0905] As shown in FIG. 15, all of the KDR-binding peptides assayed
were able to compete with .sup.125I-VEGF for binding to
KDR-transfected cells. The heterodimer (D1) was clearly the most
effective at competing with .sup.125I-VEGF, even over the two
homodimers (D2 and D3), confirming the superior binding of D1.
Example 14
Receptor Activation Assay
[0906] The ability of KDR-binding peptides to inhibit VEGF induced
activation (phosphorylation) of KDR was assessed using the
following assay.
[0907] Protocol
[0908] Dishes of nearly confluent HUVECs were placed in basal
medium lacking serum or growth factors overnight. The dishes in
group (c), below were then pretreated for 15 min in basal medium
with a KDR-binding peptide, and then the cells in the dishes in
groups (a), (b), and (c) were placed in fresh basal medium
containing:
[0909] (a) no additives (negative control),
[0910] (b) 5 ng/mL VEGF (positive control), or
[0911] (c) 5 ng/mL VEGF plus the putative competing/inhibiting
peptide.
[0912] After 5 min of treatment, lysates were prepared from each
set of dishes. KDR was immunoprecipitated from the lysates was
analyzed sequentially by immunoblotting for phosphorylation with an
anti-phosphotyrosine antibody, and for total KDR with an anti-KDR
antibody (to control for sample loading).
[0913] Results
[0914] As shown in FIG. 16, D1 was able to completely block the
VEGF-induced phosphorylation of KDR in HUVECs at 10 nM. More than
half of the phosphorylation was inhibited by the compound at 1 nM.
Homodimers D2 and D3, made up of the two individual binding
moieties that are contained in D1, had no effect on phosphorylation
at up to 100 nM, demonstrating the benefit of heterodimer
constructs in blocking a receptor-ligand interaction. In multiple
experiments, the IC.sub.50 for D1 in this assay varied between 0.5
and 1 nM. A different heterodimer containing unrelated binding
sequences, D28, a tail-to-tail heterodimer comprising the
polypeptides of SEQ ID NO:305 and SEQ ID NO:306 (FIG. 61), had no
effect on phosphorylation at 100 nM in spite of it's high binding
affinity (11 nM for KDR by SPR), suggesting that the choice of
KDR-binding moieties is important when constructing a multimer to
compete with VEGF for binding to KDR. One of ordinary skill in the
art would be able to construct suitable heteromultimers using the
binding polypeptides provided herein and routine screening
assays.
[0915] Even though the affinity of D1 for KDR is 10-fold higher
than that of D2 (by SPR analysis), the IC.sub.50 of D1 in the
activation assay is at least 100-fold lower. This suggests that
targeting two distinct epitopes on KDR with a single binding
molecule can generate greater steric hindrance than a molecule with
similar affinity that only binds to a single epitope on KDR and,
therefore, improve the ability to inhibit VEGF induced KDR
activity. Similarly, it should be pointed out that the two
KDR-binding moieties within D1, when tested as monomeric free
peptides (SEQ ID NO:277 and SEQ ID NO:337 in the receptor
activation assay, had IC.sub.50 s of 0.1 and 1 micromolar,
respectively. The IC.sub.50 for the monomeric free peptides were
100 to 1000-fold higher than the IC.sub.50 for D1 in the assay and
14 to 30-fold higher than the K.sub.DS for the fluoresceinated
derivatives of the monomeric peptides. Thus, creating a dimer
containing two peptides with weak VEGF-blocking activity has
resulted in a molecule with very potent VEGF-blocking activity that
goes well beyond the increased binding affinity of D1.
Example 15
Migration Assay
[0916] The following experiment assessed the ability of D1 to block
the VEGF-induced migration of HUVECs in culture.
[0917] Protocol
[0918] Serum-starved HUVECs were placed, 100,000 cells per well,
into the upper chambers of BD Matrigel-coated FluoroBlok 24-well
insert plates (#354141). Basal medium, containing either nothing or
different attractants such as VEGF (10 ng/mL) or serum (5% FBS) in
the presence or absence of potential VEGF-blocking/inhibiting
compounds, was added to the lower chamber of the wells. After 22
hours, quantitation of cell migration/invasion was achieved by
post-labeling cells in the insert plates with a fluorescent dye and
measuring the fluorescence of the invading/migrating cells in a
fluorescent plate reader. The VEGF-induced migration was calculated
by subtracting the migration that occurred when only basal medium
was placed in the lower chamber of the wells.
[0919] Results:
[0920] VEGF induced a large increase in endothelial cell migration
in the assay, which was potently blocked by D1. At 5 nM D1, the
VEGF-stimulated endothelial cell migration was 84% blocked (see
FIG. 17). At 25 nM D1, this migration was almost completely
blocked. In other experiments, a known KDR inhibitor, SU-1498
(Strawn, L. et al., 1996, Cancer Res., 56:3540-3545) was tested in
the assay. SU-1498 at 3 micromolar did not block the VEGF-induced
migration as well as D1 (47% blocked at 3 micromolar). D6
(structure shown below in Example 18), at 50 nM, also produced
essentially complete inhibition of the migration stimulated by
VEGF. Serum was a very powerful attractant in the assay when used
in place of VEGF, but its effect was not significantly diminished
by D1, indicating that D1 specifically inhibits endothelial
migration induced by VEGF.
Example 16
Preparation of Labeled Compounds
[0921] The following experiments describe methods used to prepare
Tc, In, and I-labeled compounds.
[0922] Preparation of .sup.99mTc-378
(Ac-AGPTWC*EDDWYYC*WLFGTGGGK(PnAO.sub-
.6-NH--(O.dbd.)C(CH.sub.2).sub.3C(.dbd.O)-JJ)-NH.sub.2; SEQ ID
NO:378).
[0923] SnCl.sub.2.2H.sub.2O (20 mg) was dissolved in 1 mL of 1 N
HCl, and 10 .mu.L of this solution was added to 1 mL of a DTPA
solution that was prepared by dissolving 10 mg of Ca Na.sub.2
DTPA.2.5H.sub.2O (Fluka) in 1 mL of water. The pH of the stannous
DTPA solution was adjusted to pH 6-8 using 1N NaOH. SEQ ID NO:378
(50 .mu.g in 50 .mu.L of 10% DMF) was mixed with 20 .mu.L of
.sup.99mTcO.sub.4-- (2.4 to 4 mCi, Syncor), followed by 100 .mu.L
of the stannous Sn-DTPA solution. After 30 minutes at RT, the
radiochemical purity (RCP) was 93%. The product was purified on a
Supelco Discovery C16 amide column (4.times.250 mm, 5 um pore size)
eluted at a flow rate of 0.5 mL/min using an aqueous/organic
gradient of 1 g/L ammonium acetate in water (A) and acetonitrile
(B). The following gradient was used: 30.5% B to 35% B in 30
minutes, ramp up to 70% B in 10 min. The compound, which eluted at
a retention time of 21.2 minutes was collected into 500 .mu.L of 50
mM citrate buffer (pH 5.2) containing 1% ascorbic acid and 0.1%
HSA, and acetonitrile was removed using a Speed Vacuum (Savant).
After purification, the compound had an RCP of >98%.
[0924] Preparation of
.sup.111In--Ac-AGPTWCEDDWYYCWLFGTJK(JJ-DOTA)-NH.sub.- 2 (SEQ ID
NO:338).
[0925] SEQ ID NO:338 (50 .mu.g in 50 .mu.L of 10% DMF) was mixed
with .sup.111InCl.sub.3 (50 .mu.L, 400 .mu.Ci, Mallinckrodt) and
100 .mu.L of 0.2M ammonium acetate or citrate buffer at a pH of
5.3. After being heated at 85.degree. C. for 45 minutes, the
radiochemical purity (RCP) ranged from 44% to 52.2% as determined
using HPLC. The .sup.111In-labeled compound was separated from
unlabeled ligand using a Vydac C18 column (4.6.times.25 cm, 5
micron pore size) under following conditions: aqueous phase, 1 g/L
ammonium acetate (pH 6.8); organic phase, acetonitrile. Gradient:
23% org. to 25% org. in 30 minutes, up to 30% org. in 2 minutes,
hold for 10 minutes. The compound, which eluted at a retention time
of 20.8 min, was collected into 200 .mu.L of 50 mM citrate buffer
(pH 5.2) containing 1% ascorbic acid and 0.1% HSA, and the
acetonitrile was removed using a Speed Vacuum (Savant). After
purification the compound had an RCP of >93%.
[0926] Preparation of .sup.111In-D4
[0927] A histidine buffer was prepared by adjusting a 0.1M solution
of histidine (Sigma) to pH 6.25 with concentrated ammonium
hydroxide. Ammonium acetate buffer was prepared by adjusting a 0.2
M solution of ammonium acetate (99.99%, Aldrich) to pH 5.5 using
concentrated HCl (J. T. Baker, Ultra Pure). High purity
.sup.111InCl.sub.3 (100 .mu.L, 1.2 mCi, Malinckrodt, Hazelwood,
Mo.) was added to D4 (200 .mu.g in 200 of 50% DMF, 10% DMSO, 20%
acetonitrile and 20% water), followed by addition of 300 .mu.L of
histidine buffer. The final pH was 5.5. After incubation of the
reaction mixture at 85.degree. C. for 45 minutes, the RCP was
20%.
[0928] Alternatively, .sup.111InCl.sub.3 provided with a
commercially available OctreoScan.TM. Kit (134 .mu.L, 0.6 mCi,
Mallinkrodt) was added to D4 (135 .mu.g) in 162 .mu.L of 0.2M
ammonium acetate buffer. The final pH was 5.5. After incubation of
the reaction mixture at 85.degree. C. for 45 min. the RCP was
20%.
[0929] Preparation of .sup.125I-D5
[0930] D5 (200 .mu.g), in 30 .mu.L of DMF that had been previously
adjusted to pH 8.5-9.0 using diisopropyl amine, was added to 1 mCi
of mono-iodinated .sup.125I Bolton-Hunter Reagent (NEX-120,
Perkin-Elmer) that had been evaporated to dryness. The vial was
shaken and then incubated on ice for 30 minutes with occasional
shaking. After this time, the RCP was 23%. .sup.125I-D5 was
purified by HPLC at a flow rate of 1 mL/min using a Vydac C18
column (4.6.times.250 mm, 5 micron pore size) under the following
conditions. Aqueous phase: 0.1% TFA in water; organic phase: 0.085%
TFA in acetonitrile. Gradient: 30% org. to 36% org. in 30 minutes,
up to 60% org. in 5 minutes, hold for 5 minutes. The compound was
collected into 200 .mu.L of 50 mM citrate buffer (pH 5.2)
containing 1% ascorbic acid and 0.1% HSA. Acetonitrile was removed
using Speed Vacuum (Savant). The resulting compound had an RCP of
97% (see FIG. 65).
[0931] Preparation of .sup.177Lu-D11
[0932] D11 (5 .mu.L of a .about.1 .mu.g/.mu.L solution in 0.05N
NH.sub.4OH/10% EtOH) was added to a glass insert microvial
containing 80 .mu.L of 0.2M NaOAc buffer, pH 5.6. Enough .sup.177Lu
was added to bring the ligand:Lu ratio to .ltoreq.2:1 (1-5 mCi).
The vial was crimp-sealed and heated at 100.degree. C. for 15-20
minutes, cooled for 5 minutes, and treated with 3 .mu.L of 1%
Na.sub.2EDTA.2H.sub.2O in H.sub.2O. The entire reaction mixture was
injected onto a Supelco Discovery RP Amide C16 column (4
mm.times.250 mm.times.5 .mu.m). The following HPLC conditions were
used: Column temperature=50.degree. C., Solvent A=H.sub.2O w/0.1%
TFA, Solvent B=ACN w/0.085% TFA, gradient 0.6/0.25 mL/min A/B at
t=0 minutes to 0.5/0.4 mL/min A/B at t=60 minutes. The retention
time for D11 was .about.40 minutes; that of .sup.177Lu-D11 was
.about.42 minutes. The radioactive peak was collected into 0.7 mL
of 0.05M citrate buffer, pH 5.3 containing 0.1% Human Serum Albumin
Fraction V and 1.0% Ascorbic Acid, and the mixture was spun down in
a Savant Speed Vac to remove organic solvents. Radiochemical
purities of greater than 80% were obtained.
[0933] Preparation of .sup.177Lu-D13
[0934] D13 (306 .mu.g) was added to a 2-mL autosampler vial with a
.about.450 .mu.L conical insert and dissolved in 0.01N NH.sub.4OH
(50 .mu.L). To this was added 300 .mu.L of 0.5M Ammonium Acetate
containing Sodium Ascorbate, Sodium Gentisate, L-Methionine and
L-Tryptophan each at 10 mg/mL, plus Human Serum Albumin Fraction V
at 2 mg/mL, final pH=7.6 adjusted with NaOH. A 6.8 .mu.L aliquot of
.sup.177LuCl.sub.3 in 0.05N HCl (39.3 mCi) was added, the vial was
crimp-sealed, warmed for 15 min at 37C, cooled for 5 minutes, and
10 .mu.L of 1% Na.sub.2EDTA 2H.sub.2O in H.sub.2O was added. A 350
.mu.L aliquot of the reaction mixture was injected onto a Supelco
Discovery RP Amide C16 column (4 mm.times.250 mm.times.5 .mu.m).
The following HPLC conditions were used: column temperature=37C,
Solvent A=H.sub.2O containing 2 g/L NH.sub.4OAc buffer, pH 7.0,
Solvent B=80% ACN/20% H.sub.2O, gradient 0.56/0.24 mL/min A/B at
t=0 minutes to 0.47/0.33 mL/min A/B at t=30 minutes. The retention
time for D13 was .about.28 minutes; the retention time for
.sup.177Lu-BRU 1339 was .about.29 minutes. The radioactive peak was
collected into 1 mL of a buffer containing Sodium Ascorbate, Sodium
Gentisate, L-Methionine and L-Tryptophan each at 10 mg/mL, plus
Human Serum Albumin Fraction V at 2 mg/mL, final pH=7.6 adjusted
with NaOH). It was then spun down .about.40 minutes using a Speed
Vacuum (Savant) to remove ACN. The RCP of the isolated product was
86%.
[0935] Preparation of .sup.99mTc-D10
[0936] SnCl.sub.2 2H.sub.2O (20 mg) was dissolved in 1 mL of 1 N
HCl, and 10 .mu.L of this solution was added to 1 mL of a DTPA
solution that was prepared by dissolving 10 mg of Ca Na.sub.2
DTPA.2.5H.sub.2O (Fluka) in 1 mL of water. D10 (100 .mu.g in 100
.mu.L of 50% DMF) was mixed with 75 .mu.L of 0.1 M, pH 9 phosphate
buffer and 50 .mu.L of .sup.99mTcO.sub.4.sup.- (2.4 to 5 mCi,
Syncor), followed by 100 .mu.L of the stannous Sn-DTPA solution.
After 15 min at RT, the radiochemical purity (RCP) was 72%. The
product was purified on a Supelco Discovery C16 amide column
(4.times.250 mm, 5 um pore size) eluted at a flow rate of 0.7
mL/min using an aqueous/organic gradient of 0.1% TFA in water (A)
and 0.085% TFA in acetonitrile (B; "ACN"). The following gradient
was used: 30% B to 42% B in 36 min, ramp up to 70% B in 10 min. The
compound, which eluted at a retention time of 32 min., was
collected into 500 .mu.L of 50 mM citrate buffer (pH 5.2)
containing 0.2% HSA, and acetonitrile was removed using a Speed
Vacuum (Savant). After purification, the compound had an RCP of
>90%.
[0937] Preparation of .sup.99mTc-D12
[0938] SnCl.sub.2.2H.sub.2O (20 mg) was dissolved in 1 mL of 1 N
HCl, and 10 .mu.L of this solution was added to 1 mL of a DTPA
solution that was prepared by dissolving 10 mg of Ca Na.sub.2
DTPA.2.5H.sub.2O (Fluka) in 1 mL of water. D12 (100 .mu.g in 100
.mu.L of 50% DMF) was mixed with 75 .mu.L of 0.1 M, pH 9 phosphate
buffer and 60 .mu.L of .sup.99mTcO.sub.4.sup.- (2.4 to 4 mCi,
Syncor), followed by 100 .mu.L of the stannous Sn-DTPA solution.
After 10 min at 40.degree. C., the radiochemical purity (RCP) was
16%. The product was purified on a Supelco Discovery C16 amide
column (4.times.250 mm, 5 um pore size) eluted at a flow rate of
0.7 mL/min using an aqueous/organic gradient of 0.1% TFA in water
(A) and 0.085% TFA in acetonitrile (B). The following gradient was
used: 30% B to 42% B in 36 min, ramp up to 70% B in 10 min. The
compound, which eluted at a retention time of 37.1 min. was
collected into 500 .mu.L of 50 mM citrate buffer (pH 5.2)
containing 0.2% HSA, and acetonitrile was removed using a Speed
Vacuum (Savant). After purification, the compound had an RCP of
>90%.
[0939] Preparation of .sup.99mTc-D14
[0940] SnCl.sub.2.2H.sub.2O (20 mg) was dissolved in 1 mL of 1 N
HCl, and 10 .mu.L of this solution was added to 1 mL of a DTPA
solution that was prepared by dissolving 10 mg of Ca Na.sub.2
DTPA.2.5H.sub.2O (Fluka) in 1 mL of water. D14 (100 .mu.g in 100
.mu.L of 50% DMF) was mixed with 50 .mu.L of
.sup.99mTcO.sub.4.sup.- (6 mCi, Syncor) and 125 .mu.L of 0.1M
phosphate buffer, pH 9 followed by 100 .mu.L of the stannous
Sn-DTPA solution. After 15 min at 40.degree. C., the radiochemical
purity (RCP) was 21%. The product was purified on a Vydac peptide
C18 column (4.6.times.250 mm) eluted at a flow rate of 1 mL/min
using an aqueous/organic gradient of 0.1% TFA in water (A) and
0.085% TFA in acetonitrile (B). The following gradient was used:
30% B to 45% B in 40 min. The compound, which eluted at a retention
time of 34.9 min., was collected into 500 .mu.L of 50 mM citrate
buffer (pH 5.3) containing 0.2% HSA, and acetonitrile was removed
using a Speed Vacuum (Savant). After purification, the compound had
an RCP of 92.5%.
[0941] Preparation of .sup.99mTc-D18
[0942] SnCl.sub.2 2H.sub.2O (20 mg) was dissolved in 1 mL of 1 N
HCl, and 10 .mu.L of this solution was added to 1 mL of a DTPA
solution that was prepared by dissolving 10 mg of Ca Na.sub.2 DTPA
2.5H.sub.2O (Fluka) in 1 mL of water. D18 (100 .mu.g in 100 .mu.L
of 50% DMF) was mixed with 50 .mu.L of 0.1 M, pH 9 phosphate buffer
and 90 .mu.L of .sup.99mTcO.sub.4.sup.- (14 mCi, Syncor), followed
by 100 .mu.L of the stannous Sn-DTPA solution. The reaction was
warmed for 20 minutes at 37C. The entire reaction was injected on a
Vydac 218TP54 C18 column (4.6.times.250 mm, 5 um silica) and eluted
at a flow rate of 1.5 mL/min using an aqueous/organic gradient of
0.1% TFA in water (A) and 0.085% TFA in ACN (B). The following
gradient was used: 32% to 39% B in 30 minutes, ramp up to 80% B in
2 min. The free ligand eluted at a retention time of 19 minutes.
The complex, which eluted at 24 minutes, was collected into 500
.mu.L of 50 mM citrate buffer (pH 5.3) containing 0.1% HSA and 1%
Ascorbic Acid. ACN and excess TFA were removed using a Speed Vacuum
(Savant) for 40 minutes. After purification, the compound had an
RCP of 93%.
[0943] Preparation of .sup.99mTc-D30
[0944] SnCl.sub.2.2H.sub.2O (20 mg) was dissolved in 1 mL of 1 N
HCl, and 10 .mu.L of this solution was added to 1 mL of a DTPA
solution that was prepared by dissolving 10 mg of Ca Na.sub.2
DTPA.2.5H.sub.2O (Fluka) in 1 mL of water. D30 (100 .mu.g in 100
.mu.L of DMF) was mixed with 150 .mu.L of 0.1 M pH 8 phosphate
buffer and 50 .mu.L of .sup.99mTcO.sub.4.sup.- (5.2 mCi, Syncor),
followed by 100 .mu.L of the stannous Sn-DTPA solution. After 15
min at 100.degree. C., the radiochemical purity (RCP) was 13%. The
product was purified on a Vydac C18 peptide column (4.6.times.250
mm, 5 um pore size) eluted at a flow rate of 1 mL/min using an
aqueous/organic gradient of 0.1% TFA in water (A) and 0.085% TFA in
acetonitrile (B). The following gradient was used: 10% B to 50% B
in 30 min, hold 50% B for 5 min, back to 70% B in 5 min. The
compound, which eluted at a retention time of 33.2 min., was
collected into 3 mL of 50 mM citrate buffer (pH 5.5) containing
0.2% HSA, and acetonitrile was removed using a Speed Vacuum
(Savant). After purification, the compound had an RCP of 92.4%.
Example 17
Binding to KDR-Transfected Cells
[0945] An experiment was performed to test the ability of
.sup.125]-labeled D5 to bind to KDR-transfected 293H cells. In this
experiment, different amounts of .sup.125I-labeled D5 (1-4
.mu.Ci/mL, labeled with .sup.125I-Bolton-Hunter reagent and
HPLC-purified) were incubated with mock and KDR-transfected 293H
cells in 96-well plates for 1 hr at room temperature. Binding was
performed with and without 40% mouse serum to evaluate the serum
effect on binding to KDR-transfected cells. After washing away the
unbound compound, the cells in each well were lysed with 0.5 N NaOH
and the lysates were counted with a gamma counter.
[0946] The results of this experiment are summarized in FIG. 18 and
FIG. 19. .sup.125I-labeled D5 is able to specifically bind to
KDR-transfected cells, and its binding is not affected by the
presence of 40% mouse serum. Somewhat more binding to
KDR-transfected cells was observed in the absence of serum as
compared to binding in the presence of 40% mouse serum. However,
the binding of .sup.125I-D5 to mock-transfected cells was also
increased by about the same extent when serum was omitted during
the assay, indicating that the increased binding in the absence of
serum was non-specific (FIG. 18). Specific binding to
KDR-transfected cells (after subtracting binding to
mock-transfected cells) looked almost identical with or without
mouse serum (as shown in FIG. 19). In this experiment, 10-14% of
the total CPM added were specifically bound to KDR-transfected
cells (data not shown).
Example 18
Biacore Analysis of Heterodimer Binding to KDR-Fc and Determination
of Affinity Constant
[0947] A peptide heterodimer (FIG. 63) composed of SEQ ID NO:277
and SEQ ID NO:294 was prepared as previously described in Example
12 using glutaric acid bis N-hydoxysuccinimidyl ester. The
heterodimer was tested for binding to KDR-Fc using Biacore, and an
affinity constant was determined as follows.
[0948] Three densities of KDR-Fc were cross-linked to the dextran
surface of a CM5 sensor chip by the standard amine coupling
procedure (0.5 mg/mL solution diluted 1:100 or 1:50 with 50 mM
acetate, pH 6.0). Flow cell 1 was activated and then blocked to
serve as a reference subtraction. Final immobilization levels
achieved:
[0949] R.sub.L Fc 2 KDR-Fc=1607
[0950] R.sub.L Fc 3 KDR-Fc=3001
[0951] R.sub.L Fc 4 KDR-Fc=6319
[0952] Experiments were performed in PBS (5.5 mM phosphate, pH
7.65, 0.15 M NaCl)+0.005% P-20 (v/v)). D6 was diluted to 250 nM in
PBS and serial dilutions were performed to produce 125, 62.5, 31.3
15.6, 7.8, and 3.9 nM solutions. All samples were injected in
duplicate. For association, peptides were injected at 20 .mu.L/min
for 12.5 minutes using the kinject program. Following a 10 minute
dissociation, any remaining peptide was stripped from the KDR
surface with a quickinject of 50 mM NaOH+1 M NaCl for 12 s at 75
.mu.L/min. Sensorgrams were analyzed using BIAevaluation software
3.1 and a hyperbolic double rectangular regression equation in
SigmaPlot 6.0. Heterodimer steady state binding affinities
(K.sub.DAV) were determined at all three KDR immobilization
densities (Table 14).
19TABLE 14 Summary of Parameters K.sub.D1 (nM) R.sub.max1 K.sub.DAV
(nM) R.sub.maxAV R.sup.2* D6 Vs. 46 13.1 1.5 12.6 0.995 1600 RU Vs.
25.5 21.2 0.665 22.7 0.991 3000 RU Vs. 17 61.3 0.662 62.2 0.993
6000 RU
[0953] From these data, it appears that at the higher
immobilization densities, the heterodimer binds KDR with a
sub-nanomolar affinity (.about.0.6 nM).
[0954] To assess the in vivo clearance of this peptide heterodimer,
a small amount of material was iodinated using iodogen and
Na.sup.125I according to standard protocols (Pierce). One tube
coated with the iodogen reagent was pre-wet with 1 mL of 25 mM
Tris, 0.4M NaCl, pH 7.5. This was discarded and 100 .mu.L of the
same buffer added. Using a Hamilton syringe 11 .mu.L of the
.sup.125I--NaI was transferred to the reaction tube. Based on
original estimates of the Na.sup.125I concentration of 143.555
mCi/mL, the 11 .mu.L should contain about 1.5 mCi. After addition,
the sample was swirled and set in a lead pig to incubate for 6 min
with a swirl every 30 sec. After 6 min, the entire sample was
transferred to the protein that was in an Eppendorf tube. The
sample was swirled and set to incubate for 8 min, with a swirl
every 30 sec. After 8 min the reaction was quenched (terminated)
with tyrosine (10 mg/mL, a saturated solution), allowed to sit for
5 min, and then 2 .mu.L was removed for a standard.
[0955] For purification a 10 mL column of the D-salt polyacrylamide
1800 was used to separate the labeled peptide from labeled
tyrosine. The column was first washed with 10 mL saline, then 5 mL
of 25 mM Tris, 0.4M NaCl, pH 7.5 containing 2.5% HSA to block
non-specific sites. After the HSA buffer wash, the column was
eluted with 60 mL of the 25 mM Tris, 0.4 M NaCl buffer, and the
column was stored overnight at 4.degree. C. The labeled sample
contained 1.355 mCi, as determined by the dose calibrator. The 2
.mu.L sample that was removed as a standard contained 8.8 .mu.Ci.
The peptide sample was applied to the D-salt 1800 column and eluted
with the Tris/NaCl buffer, pH 7.5. The flow was controlled by
applying single 0.5 mL aliquots for each fraction, #1-14, and then
1.0 mL for fractions 25-43. FIG. 21 hows the elution profile of
activity versus fraction number. The peak of activity in fractions
# 9, 10, and 11, was assumed to be the peptide. The radioactivity
in 24 through .about.40 is likely the labeled tyrosine. From this
purification, fractions #9-12 were pooled together and used for the
subsequent clearance study (concentration of .sup.125I-D6 in pool
is 7.023 .mu.g/mL; 100 .mu.L=0.702 .mu.g with 8.6 .mu.Ci).
[0956] A total of 15 mice were injected with 100 .mu.L .sup.125I-D6
and mice (in sets of 3) were sacrificed at the following time
points: 0, 7, 15, 30, 90 minutes. After injection more than 2
.mu.Ci was found remaining in the syringe, so actual activity
injected was about 6 .mu.Ci. With 6 .mu.Ci injected, the
corresponding protein administered was .about.0.5 .mu.g per animal.
Once sacrificed, the counts were determined in a 50 .mu.L plasma
sample from each animal. For each set of three animals at each time
point, the counts were averaged, converted to % injected dose/ml
plasma (ID %/mL), and then plotted to assess the rate of clearance
(FIG. 20). This data was fit to either a 4 or 5 parameter equation
to determine the biphasic half life of this molecule. The 4
parameter fit resulted in a T.sub.1/2.alpha. of 2.55 minutes and a
T.sub.1/2.beta. of 64.66 minutes. The 5 parameter fit resulted in a
T.sub.1/2.alpha. of 2.13 minutes and a T.sub.1/2.beta. of 23.26
minutes.
[0957] Larger volumes of plasma were also taken from mice
sacrificed at the 0, 30, and 90 minute time points. These samples
were injected onto a Superdex peptide column (Pharmacia) coupled to
a radioactivity detector to assess the association of the peptide
with serum proteins (FIG. 21). As shown, the labeled peptide does
associate with higher MW proteins, which could explain its biphasic
half life clearance behavior.
[0958] To help assess the potency of the peptide as an
anti-angiogenesis inhibitor, D6 was tested in an endothelial cell
proliferation assay using HUVECs and BrdU detection. Briefly,
freshly isolated HUVECs (between p3-6) were cultured in RPMI+10%
FCS+1% antibiotics+1% L-glutamine+0.4% BBE (bovine brain extract)
and seeded per well, 5000-10000/well in 100 .mu.L. The cells were
allowed to recover for 24 hrs prior to use. Then the cells were
washed with PBS twice and treated for 48 hrs with anti-VEGF
antibody (positive control) or peptides A, B and C (0.1 and 10
ug/mL) in RPMI+0.1% BSA+1% L-glutamine. The following 6 variables
were tested in 2 series (n=4):
[0959] Series I: w/o VEGF
[0960] Series II: w/VEGF (30 ng/mL)
[0961] 1. Standard medium: RPMI+10% FCS+1% antibiotics+1%
L-glutamine+0.4% BBE
[0962] 2. Negative control 1: RPMI (true starvation)
[0963] 3. Negative control 2: RPMI+0.1% BSA+1% L-glutamine
[0964] 4. Positive control: anti-VEGF 10 g/mL in RPMI+0.1% BSA+1%
L-glutamine
[0965] 5. 0.1 .mu.g/mL KDR peptides in RPMI+0.1% BSA+1%
L-glutamine
[0966] 6. 10 .mu.g/mL KDR peptides in RPMI+0.1% BSA+1%
L-glutamine
[0967] Protocol:
[0968] 1) cells are incubated for 48 hours under various
conditions
[0969] 2) 10 .mu.L BrdU dilution (1:100 in EBM) is added to each
well at 24 hours
[0970] 3) incubate for another 24 hours (total 48 hrs)
[0971] 4) aspirate the culture medium
[0972] 5) add 100 .mu.L FixDenat (Roche Applied Science,
Indianapolis, Ind.) to each well, incubate at room temperature for
30 min.
[0973] 6) Discard FixDenat solution
[0974] 7) 100 .mu.L antibody-solution (PBS 1% BSA and anti-BrdU PO)
added to each well.
[0975] 8) incubate at RT for 90 minutes.
[0976] 9) wash 3 times with PBS, 200 .mu.L/well, 5 min.
[0977] 10) add substrate solution (TMB), incubate for 10-30
minutes
[0978] 11) transfer all to a flexible plate
[0979] 12) stop the reaction by adding 2 M H.sub.2SO.sub.4, 25
.mu.L/well
[0980] 13) read absorbance at 450 nm within 5 minutes after
stopping the reaction.
[0981] Background binding was determined by omitting the anti-BrdU
antibody in 4 wells with control cells (cultured in complete
medium; EBM+BulletKit (Clonetics, BioWhittaker, Inc., MD) and by
complete labeling of cells that was not exposed to BrdU.
[0982] Of the two KDR binding peptide tested (D6 and SEQ ID NO:277)
as shown in FIG. 22, D6 (A) completely inhibits HUVEC proliferation
at 10 .mu.g/mL in the presence of VEGF, similar to an anti-VEGF
antibody (positive control). On the other hand, SEQ ID NO:277 (B,
one of the peptides that make up the heterodimer) did not inhibit
proliferation in this assay at the highest concentration tested (10
.mu.g/mL). As a result, the heterodimer shows an enhanced ability
to compete with VEGF in comparison with SEQ ID NO:277 alone.
Example 19
BIAcore Analysis--Murine KDR-Fc Binding of Peptide Dimers D1 and
D7
[0983] Using BIAcore, the binding constants of peptide dimers D1 (a
heterodimer of SEQ ID NO:277 and SEQ ID NO:294 and D7 (a
heterodimer of SEQ ID NO:264 and SEQ ID NO 294; see FIG. 67) for
murine KDR-Fc were determined.
[0984] Procedure
[0985] Three densities of recombinant murine KDR-Fc were
cross-linked to the dextran surface of a CM5 sensor chip by the
standard amine coupling procedure (0.5 mg/mL solution diluted 1:100
or 1:40 with 50 mM acetate, pH 6.0). Flow cell 1 was activated and
then blocked to serve as a reference subtraction. Final
immobilization levels achieved:
[0986] R.sub.L FC 2 KDR-Fc=2770
[0987] R.sub.L FC 3 KDR-Fc=5085
[0988] R.sub.L Fc 4 KDR-Fc=9265
[0989] Experiments were performed in PBS buffer (5.5 mM phosphate,
pH 7.65, 0.15 M NaCl)+0.005% P-20 (v/v)). SEQ ID NO:277, run as a
control, was diluted to 125 nM in PBS. Serial dilutions were
performed to produce 62.5, 31.3, 15.6, 7.8, and 3.9 nM solutions.
D1 and D6 were diluted to 50 nM in PBS and serial dilutions were
performed to produce 25, 12.5, 6.25, 3.13, 1.56, 0.78, and 0.39 nM
solutions. All samples were injected in duplicate. For association,
peptides were injected at 30 .mu.L/min for 3 minutes using the
kinject program. Following a 10 minute dissociation, any remaining
peptide was stripped from the rmKDR-Fc surface with a quickinject
of 50 mM NaOH+1 M NaCl for 12 s at 75 .mu.L/min.
[0990] Sensorgrams were analyzed using the simultaneous
k.sub.a/k.sub.d fitting program in the BIAevaluation software 3.1.
The Results are shown in Table 15 and FIGS. 23-25. The fact that
about the same K.sub.D2 constant was achieved for both heterodimers
even when the density of receptor on the sensor chip was reduced by
half is consistent with multimeric binding of the heterodimers to
individual receptors rather than cross-link-type binding between
receptors.
20TABLE 15 Summary of Kinetic Parameters. ka1 (1/Ms) Kd1 (1/s) ka2
(1/RUs) kd2 (1/s) KD1.sup.# (nM) KD2.sup..dagger-dbl. (nM)
Chi.sup.2* D1 vs. 2700 RU 7.94E+05 0.0139 3.31E-04 5.96E-04 17.5
0.751 0.077 vs. 5000 RU 5.54E+05 8.88E-03 1.17E-04 4.57E-04 16.0
0.825 0.323 D7 vs. 2700 RU 7.59E+05 0.011 3.36E-04 6.44E-04 14.5
0.848 0.082 vs. 5000 RU 5.21E+05 7.39E-03 1.17E-04 4.68E-04 14.2
0.898 0.278 Fluorescein vs. 2700 RU 1.02E+06 0.037 -- -- 36.4 --
0.073 SEQ ID NO: 277 vs. 5000 RU 5.18E+05 0.0174 -- -- 33.6 --
0.167 .sup.#K.sub.D1 is a calculated K.sub.D based on
kd.sub.1/ka.sub.1 .sup..dagger-dbl.K.sub.D2 is a calculated K.sub.D
based on kd.sub.2/ka.sub.1 (i.e., avidity factor) *The chi2 value
is a standard statistical measure of the closeness of the fit. For
good fitting to ideal data, chi2 is of the same order of magnitude
as the instrument noise in RU (typically <2).
Example 20
In Vivo Inhibition of Tumor Growth
[0991] Conditions are described providing methods for determining
efficacy of three (3) concentrations for Test Article (binding
peptide, D6) suspected of having anti-angiogenic activity on SW-480
human colon carcinoma cells using an in vivo xenograft tumor
model.
[0992] Athymic nude mice are acceptable hosts for the growth of
allogenic and heterogenic cells. Nude mice are required in Points
to Consider in the Characterization of Cell Lines used to Produce
Biologicals (Points to Consider in the Characterization of Cell
Lines used to Produce Biologicals, FDA 1993).
[0993] D6 is a synthetic heterodimeric peptide suspected of having
anti-angiogenic activity. This peptide binds to the human VEGF
receptor 2 (KDR) with high affinity and competes with VEGF
binding.
SW-480 Human Carcinoma Cells
[0994] Colon carcinoma, SW-480, cells (ATCC) were cultured in
Dulbecco's Modified Eagles Medium (DMEM) supplemented with 4 mM
L-glutamine, 0.1 mM non-essential amino acids, 50 mg/mL Gentamicin,
250 mg/mL Fungizone and 10% heat inactivated fetal bovine serum at
37.degree. C. in 95% air and 5% CO.sub.2.
[0995] Exponentially growing cells were harvested, washed twice in
phosphate buffered saline (PBS) to remove any traces of trypsin or
serum. Cells were suspended in Hanks Balanced Salt Solution (HBSS)
for injections.
[0996] Sterile phosphate buffered saline (BioWhittaker) was
manufactured in accordance with cGMP regulations and was cell
culture tested to assure compatibility; having a pH of 7.3-7.7 and
an osmolarity of 271-287 mOsm/kg. PBS was the vehicle used to
reconstitute Test Articles and for vehicle control injections.
[0997] Cisplatin (American Pharmaceutical Partners, Inc.; Los
Angeles, Calif.) was prepared according to manufacture's
specifications. Cisplatin was prepared in an aseptic fashion using
a BL2 BioChem guard hood.
Test System
[0998] A. Species/Strain: Mus musculus, Crl:NU/NU-nuBR mice (nude
mice)
[0999] B. Sex: Female
[1000] C. Age: 6-8 weeks at initiation of treatment
[1001] D. Weight Range: No weight requirement
[1002] E. Source: Animals were received from the Gnottobiotic
Department at Charles River Laboratories, Wilmington, Mass.
[1003] F. Number: A total of 115 animals were received and injected
for this study, with 90 mice used on study.
[1004] G. Method of Identification:
[1005] Mice were uniquely numbered using an ear tag system.
Additionally, cages were marked with cage cards minimally
identifying group number, animal number, study number and IACUC
protocol number.
[1006] H. Randomization:
[1007] Animals were randomly assigned to treatment groups using
Microsoft.RTM. Excel 97 SR-1 program.
[1008] I. Humane Care of Animals:
[1009] Treatment and care of the animals were in accordance with
the standard operating procedures of Charles River Laboratories,
which adheres to the regulations outlined in the USDA Animal
Welfare Act (9 CFR, Parts 1, 2, and 3) and the Guide for the Care
and Use of Laboratory Animals.
[1010] This study protocol was covered under the Charles River
Laboratories Institutional Animal Care and Use Committee (IACUC
Protocol Number: P07182001I).
Animal Care
[1011] A. Diet and Drinking Water:
[1012] Mice were fed gamma-irradiated rodent chow ad libitum. Tap
water was sterilized and supplied via bottle and sipper tube ad
libitum.
[1013] B. Animal Environment:
[1014] Animals were housed by groups in semi-rigid isolators. Mice
were housed in flat bottom caging containing five to ten animals.
Cages contained gamma-irradiated contact bedding. The number of
mice in each cage may have been altered due to the behavior of the
mice, changes were noted in the isolator inventory. The housing
conforms to the recommendations set forth in the Guide for the Care
and Use of Laboratory Animals, National Academy Press, Washington,
D.C., 1996 and all subsequent revisions.
[1015] Environmental controls were set to maintain a temperature of
16-26.degree. C. (70.+-.8.degree. F.) with a relative humidity of
30-70. A 12:12 hour light: dark cycle was maintained.
[1016] C. Acclimation:
[1017] Once animals were received, they were allowed to acclimate
to the laboratory environment for 24-hours prior to the study
start. Mice were observed for signs of disease, unusual food and/or
water consumption or other general signs of poor condition. At the
time of animal receipt, animals were clinically observed and
appeared to be healthy.
Experimental Design
[1018] A. General Description:
[1019] Female athymic nude mice (Crl:NU/NU-nuBR) at 6-8 weeks of
age were used in this study. A total of 115 mice were injected
subcutaneously into the right lateral thorax with 5.times.10.sup.6
SW-480, human colon carcinoma cells. When tumors reached a target
window size of approximately 150.+-.75 mg, 90 tumor-bearing mice
were randomly selected and distributed into one of nine groups.
Test Articles and vehicle were administered intraperitoneally (IP),
Cisplatin was administered intravenously (IV). Tumor measurements
were recorded twice weekly using hand-held calipers. Mice were
monitored daily for signs of toxicity and morbidity. At study
termination, animals were euthanized by carbon dioxide overdose and
necropsied for tissue collection.
[1020] B. Group Assignments:
[1021] A total of nine (9) groups were used in this study. Each
group contained ten (10) tumor-bearing mice. Groups 1 and 2
contained untreated and vehicle treated negative control mice,
respectively. Groups 3, 4, and 5 contained mice that received one
of three different concentrations of the D6 anti-angiogenic
peptide. Group 9 contained mice that received cisplatin, a standard
chemotherapeutic compound as a positive control.
[1022] C. Dosing Levels and Regiment:
[1023] Dose levels for each group are provided in Table 16. Dosing
began the same day that animals were randomly sorted into groups
(Study Day 7). Each dose was removed from the dose vial using
aseptic technique for each animal and the injection site was wiped
with an alcohol swab prior to dose administration. Doses were
administered with a 1.0 mL syringe and a 27-gauge.times.1/2" needle
for each mouse.
[1024] The Test Article- and vehicle-treated mice received daily
intraperitoneal (IP) injections for 15 days. Cisplatin was
administered every other workday for a total of five (5) doses via
an intravenous route.
21TABLE 16 Study Treatment Groups Concentration Number of Group
Test Article mg/kg Animals 1 Untreated -- 10 2 Vehicle 0 10 3 D6
0.05 10 4 D6 0.5 10 5 D6 5.0 10 9 Cisplatin 6.0 10
[1025] D. Clinical Observations of Animals:
[1026] Clinical Observations of each animal were performed and
recorded at least once daily for toxicity, morbidity and mortality.
Morbidity included signs of illness such as, but not limited to,
emaciation, dehydration, lethargy, hunched posture, unkempt
appearance, dyspnea and urine or fecal staining.
[1027] E. Tumor Measurements:
[1028] In accordance with the protocol tumor measurements were
taken twice weekly throughout the study by measuring the length and
width of tumors with calibrated calipers. Measurements occurred a
minimum of 3-4 days apart, except when animals were euthanized and
measurements were taken; this sometimes resulted in an interval of
less than 3 days. Tumor weights were calculated using the following
formula: mg=(L.times.W.sup.2)/2. Animals were euthanized either
when mean tumor weight was .gtoreq.1000 mg per group over two (2)
consecutive measurements, or if tumors became ulcerated, impaired
the animal's ability to ambulate or obtain food and water.
[1029] F. Unscheduled Euthanasia and Unexpected Deaths:
[1030] 1. Unscheduled Euthanasia:
[1031] None of the animals required unscheduled euthanasia while on
study.
[1032] 2. Unexpected Deaths:
[1033] None of the animals died while on study.
[1034] G. Necropsy:
[1035] 1. Euthanasia and Necropsy Order:
[1036] All mice in groups 1, 2, 3, 4, and 5 (50 total) were
submitted for necropsy when tumors reached a group mean target size
of .gtoreq.1000 mg over two (2) consecutive measurements within a
group. Animals were submitted for necropsy to the Charles River
Laboratories Health Monitoring Laboratory (HM), Wilmington, Mass.
All animals were euthanized on Study Day 22, short of received the
full 28 day treatment regiment with Test Articles because mean
tumor size was .gtoreq.1000 mg in Test Article Treated Groups
3-8.
[1037] All animals were humanely euthanized by carbon dioxide
(CO.sub.2) inhalation.
[1038] 2. Tissue Collection:
[1039] Tumors were dissected free of surrounding tissue and
overlying skin. Additionally the kidneys were collected. Any
abnormalities noted on the renal surfaces were noted.
[1040] Frozen blocks were made of tumors and kidneys for each
animal. A representative section of the tissue (tumor, kidneys) was
taken. Kidney sections included the cortex and medulla. Tissue
sections were placed in the bottom of a labeled plastic-freezing
mold. Tissue was embedded with OCT medium. Blocks were submerged
into isopentane chilled with dry ice until frozen. Blocks were
briefly examined for quality, and stored on dry ice.
[1041] Blocks were labeled with the animal number and a letter code
corresponding to tissue (A=left kidney; B=right kidney; C=mass).
Blocks from one animal were placed into a labeled bag.
Results
[1042] A. In-Life Measurements and Observations:
[1043] 1. Clinical Observations, Morbidity and Mortality Summary
Statement:
[1044] All animals appeared healthy and were within normal limits
throughout the study. D6 showed no signs of toxicity at the doses
used in this study.
[1045] Animals were euthanized on Study Day 22. All mice, except
Group 9 mice, were euthanized prior to completing Test Article
administration, because mean tumor size was .gtoreq.1000 mg in
Groups 1-8. Group 9, Cisplatin-treated animals were euthanized on
Study Day 22 when mean tumor weight was 995 mg. No animals died
while on study.
[1046] 2. Mass Palpation Summary Statement:
[1047] Throughout the study palpable masses were detected in all
mice, with tumors progressively growing for the duration of the
study. As expected tumors in untreated and vehicle treated negative
control mice (Groups 1 and 2) grew the fastest, reaching a mean
tumor size of 1000 mg on or before Study Day 20. In addition,
animals treated with Cisplatin (Group 9) developed tumors that grew
the slowest reaching a mean tumor size of 995 mg at study
termination (Day 22).
[1048] In general, except for Group 3 mice, all animals treated
with Test Article resulted in slower tumor growth (FIG. 65).
Animals in Group 3, which were treated with the low dose of D6
(0.05 mg/kg) had tumors that grew at approximately the same rate as
the tumors in untreated and vehicle treated animals in Groups 1 and
2. Animals treated with either higher doses of D6 (Groups 4 and 5)
had tumors that grew slower; reaching a mean tumor size of 1000 mg
on Study Day 21. When compared to control Groups 1 and 2 mice, Test
Article treatment resulted in a delay of tumor growth of
approximately 1 day.
[1049] B. Conclusions:
[1050] Data from this study validate the model used because
tumor-bearing mice in negative control Groups 1 and 2 and positive
control Group 9 responded as expected.
[1051] Throughout the study palpable masses were observed in all
groups. In addition, all animals were healthy and within normal
limits throughout the study. Furthermore, D6 did not adversely
affect the animals. Therefore, these data would suggest that
animals treated with D6 Test Article had tumors that grew slowly
(approximately 1 day slower over the 22 day test period than
controls). Also, since the Test Article did not show any
significant toxic effects, higher concentrations of Test Article
could also be used with potentially better tumor regression.
22 TABLE 17 Test Article Untreated Vehicle D6 Cisplatnin Control
Control 0.005 mg/kg 0.05 mg/kg 0.5 mg/kg 6 mg/kg Days 4 48 49 43 51
50 34 Tumor After 7 164 156 157 163 154 160 Weights Cell 8 180 164
156 133 168 173 (mg) Injection 11 340 388 333 298 310 407 14 684
648 726 596 577 675 20 1064 986 973 857 978 635 21 1412 1571 1468
983 1056 839 22 1967 1863 2026 1474 1526 995
Example 21
In Vitro Cell Proliferation Assay
[1052] Microvascular endothelial cells (MVECs, Cascade Biologics,
Portland, Oreg.) were used to assess the in vitro efficacy of D6
and related analogues for their ability to inhibit VEGF-stimulated
proliferation. MVECs (passage 2) were grown to 90% confluency,
trypsinized and plated in gelatin-coated 96-well microtiter plates
at a density of 4-8.times.10.sup.3 cells/well. Sixteen to 24 hours
after plating, the cells were washed one time (200 .mu.L/well) with
media devoid of fetal bovine serum but containing 0.1% bovine serum
albumin (BSA). Fresh BSA-containing media was added to each well
and the cells were incubated for an additional 24 hours. After this
24 hour period of starvation, fresh BSA-containing media
(containing 25 ng/mL VEGF) with or without D6 was added and the
cells were incubated for an additional 48 hours at 37C. To assess
the dose response in this assay, multiple D6 concentrations were
tested in duplicate wells. The media was removed and fresh
BSA-containing media was added with or without BrdU and the cells
were incubated for an additional 24 hours prior to determining the
level of incorporation exactly as described by the manufacturer.
Results are shown in FIG. 84.
Example 22
[1053] The following experiment assessed the ability of D25 and D27
to block the VEGF-induced migration of HUVECs in culture and
demonstrated that the added glycosylation and/or distinct spacer
structure used in D27 enhanced its potency.
[1054] Protocol: Serum-starved HUVECs were placed, 100,000 cells
per well, into the upper chambers of BD fibronectin-coated
FluoroBlok 24-well insert plates. Basal medium, with or without
VEGF (10 ng/mL) in the presence or absence of D25 or D27, was added
to the lower chamber of the wells. After 22 hours, quantitation of
cell migration/invasion was achieved by post-labeling cells in the
insert plates with a fluorescent dye and measuring the fluorescence
of the invading/migrating cells in a fluorescent plate reader. The
VEGF-induced migration was calculated for each experimental
condition by subtracting the amount of migration that occurred when
only basal medium was added to the lower chamber of the wells.
[1055] Results: VEGF induced a large increase in endothelial cell
migration in the assay, which was potently blocked by both D25 and
D27 (FIG. 66). D27 was ten-fold more potent than D25 (IC.sub.50 0.5
nM and 5 nM respectively), indicating that the glycosylation of D27
and/or its distinct spacer properties has enhanced its ability to
bind KDR and block the effects of VEGF.
Example 23
[1056] The following experiment assessed the ability of "Adjunct A"
multimeric construct of TKPPR peptide (SEQ ID NO:503; binds to
NP-1, a VEGF receptor that enhances the effects of VEGF mediated by
KDR), to enhance the inhibition of the VEGF-induced migration of
HUVECs in culture produced by D6. Adjunct
A=5CF-Gly-N{[CH.sub.2CH.sub.2C(.dbd.O)-Gly-N(CH.s-
ub.2CH.sub.2C(.dbd.O)-Adoa-Thr-Lys-Pro-Pro-Arg-OH].sub.2}.sub.2
where Adoa=3,6-dioxa-8-aminooctanoyl, 5CF=5-carboxyfluoresceinyl.
See FIG. 67B.
[1057] Protocol: Serum-starved HUVECs were placed, 100,000 cells
per well, into the upper chambers of BD fibronectin-coated
FluoroBlok 24-well insert plates. Basal medium, containing with or
without VEGF (10 ng/mL) in the presence or absence of varying
concentrations of D6, or varying concentrations of D6 in
combination with a constant 100 nM Adjunct A (synthesized as
described in WO 01/91805 A2), was added to the lower chamber of the
wells. After 22 hours, quantitation of cell migration/invasion was
achieved by post-labeling cells in the insert plates with a
fluorescent dye and measuring the fluorescence of the
invading/migrating cells in a fluorescent plate reader.
VEGF-induced migration was calculated for each experimental
condition by subtracting the amount of migration observed in the
absence of VEGF.
[1058] Results: VEGF induced a large increase in endothelial cell
migration in the assay, which was potently blocked by D6 (IC.sub.50
about 12.5 nM), but not by 100 nM Adjunct A alone (FIG. 67A).
Surprisingly however, Adjunct A was able to enhance the potency of
D6 by about ten-fold when used in the assay simultaneously with D6
(IC.sub.50 about 2.5 nM). This indicates that compounds containing
the TKPPR sequence (or similar) found in Adjunct A can be used to
enhance the potency of certain compounds such as D6, which compete
with VEGF for binding to KDR. In addition, a heteromultimer
containing the peptide sequences found in D6 or similar) as well as
the TKPPR sequence (or similar), in one or more repetitions, would
likely possess enhanced activity in this assay. See U.S. patent
applciation Ser. No. 09/871,974, incorporated by reference in its
entirety, for details regarding the preparation of TKPPR
constructs.
Example 24
Synthesis of D27
[1059] Synthesis of 1 and 3 (See FIGS. 68 and 69)
[1060] Synthesis of the monomers were carried out as described in
Method 5 on a 0.25 mmol scale employing as the starting resin
Fmoc-GGGK(iV-Dde)NH-PAL-PEG-PS resin. The peptide resin was washed
and dried before cleavage or further derivatization by automated or
manual methods.
[1061] Procedure Synthesis of Peptide 2 and Peptide 4 (see FIGS. 68
and 69)
[1062] Appendage of Biotin-JJ, Lysyl, Glycyl and Serinyl
(GalNAc(Ac).sub.3-.alpha.-D moieties onto 1 and 3 was done by
manual SPPS such as described in Method 6 and Method 8. The
coupling of amino acids was carried out in DMF using HOBt/DIC
activation (except for Ser(GalNAc(Ac).sub.3-.alpha.-D). Fmoc
removal was carried out with 20% piperidine in DMF. All couplings
were 5-16 hours duration. After each coupling, the completion was
confirmed by the Kaiser test. In the case of
Ser(GalNAc(Ac).sub.3-.alpha.-D, the coupling was performed in DMF
employing HATU/DIEA as the coupling agent. In cases where the
Kaiser test indicated unreacted amino groups the coupling was
repeated. Removal of the N-terminal Fmoc group and cleavage from
resin was performed. The crude peptide was precipitated in ether
and washed twice by ether and dried under vacuum. The linear crude
peptide was directly cyclized by dissolving the peptide in DMSO (40
mg/mL). The pH of the solyution was adjusted to 8 by addition of
aqueous N-methylglucamine and the solution was was stirred in air
for 48 h at room temperature. The peptides were then purified
employing gradient HPLC as described in Method 1 employing a
Waters-YMC C-18 ODS preparative column (250 mm.times.4.6 mm i.d.).
The pure product-containing fractions were combined and lyophilized
to provide the needed peptides.
[1063] Procedure: Synthesis of D27--Compound 6 (See FIG. 70)
[1064] To a solution of glutaric acid bis-NHS ester (0.122 mmol,
Pierce Scientific Co.) in anhydrous DMF was added dropwise a
solution of 4 in DMF (40 mg, 0.0122 mmol, DIEA was added to
neutralize the trifluoroacetic acid bound to the peptide and
N-hydroxysuccinimide formed during the reaction). This 0.7 mL
solution was stirred for 4 h. The reaction was monitored by HPLC
and mass spectroscopy. DMF was removed under vacuum. The excess
diester was removed by addition of ethyl acetate, which
precipitated the peptide-monoester 5 while dissolving glutaric acid
bis-NHS ester. The mixture was centrifuged and the liquid portion
decanted. This was repeated twice. The residue was kept under
vacuum for 10 min. The residue was dissolved in DMF and mixed with
a solution of 2 (37 mg, 0.009 mmol) in DMF (pH 7). It was stirred
at ambient temperature for 16 h. The volatiles were removed under
high vacuum and the acetate functions were removed by treatment of
the residue with 1 mL of hydrazine/MeOH (15/85, v/v) solution with
stirring for 2.5 h at ambient temperature. Acetone was added to
quench the excess of hydrazine and the volatiles were removed under
vacuum. The resulting residue was dissolved in DMSO and purified by
preparative HPLC as described above to provide 9 mg of the pure
material.
23 Sequence and Analytical Data for Peptides 2, 4 and 6 HPLC
Compound Ret. time Mass Spectrum identifier Sequence (System) (ESI,
neg. ion) Peptide 2: Ac-AGPTWCEDDWYYCWLFGTGGGK{Biotin- 7.4 min
2041.3 [M-2H]/2 New Seq, a
JJK[NH.sub.2-Ser(GalNAc(Ac).sub.3-.alpha.-D)-Gly- (T) Seq 11
Ser(GalNAc(Ac).sub.3-.alpha.-D]}-NH.sub.2 derivative Peptide 4:
Ac-VCWEDSWGGEVCFRYDPGGGK(NH.sub.2 8.0 min 1636.3 [M-2H]/2 New Seq,
a Ser(GalNAc(Ac).sub.3-.alpha.-D)-Gly- (T) Seq 5
Ser(GalNAc(Ac).sub.3-.alpha.-D)-NH.sub.2 derivative D27
Ac-AGPTWCEDDWYYCWLFGTGGGGK{Ac- 5.50 min 1737.2 (M-4H)/4;
VCWEDSWGGEVCFRYDPGGGK[S(GalNAc-.alpha.- (M) 1389.3 (M-5H)/5;
D)-G-S(GalNAc-.alpha.-D)-Glut-S(GalNAc- 1157.7 [M-6H]/6
.alpha.-D)-G-S(GalNAc-.alpha.-D)-NH(CH.sub.2).sub.4-(S)-
CH(Biotin-JJNH-)C(.dbd.O)-]-NH.sub.2}-NH.sub.2
[1065] System T: Column: Waters XTerra, 4.6.times.50 mm; Eluents:A:
Water (0.1% TFA), B: Acetonitrile (0.1% TFA): Elution: Initial
condition, 15% B, Linear Gradient 15-50% B in 8 min; Flow rate: 3.0
mL/min; Detection: UV @ 220 nm.
Example 25
Demonstration of the Distinction Between Binding Affinity and
Biological Potency Through In Vitro Assays
[1066] The following experiments showed that heteromultimeric
peptides can display much greater biological potency than a
monomeric peptide with similar binding affinity to the same
target.
[1067] Protocol experiment 1:293H cells were transfected with the
KDR cDNA or mock-transfected by standard techniques described in
Example 5. The cells were incubated with .sup.125I-VEGF in the
presence or absence of SEQ ID NO:504 or D1 (at 300, 30, 3, and 0.3
nM). After washing the cells, the bound radioactivity was
quantitated on a gamma counter. The percentage inhibition of VEGF
binding was calculated using the formula [(Y1-Y2).times.100/Y1],
where Y1 is specific binding to KDR-transfected 293H cells in the
absence peptides, and Y2 is specific binding to KDR-transfected
293H cells in the presence of peptide competitors. Specific binding
to KDR-transfected 293H cells was calculated by subtracting the
binding to mock-transfected 293H cells from the binding to
KDR-transfected 293H cells.
[1068] Protocol experiment 2: Serum-starved HUVECs were placed,
100,000 cells per well, into the upper chambers of BD
fibronectin-coated FluoroBlok 24-well insert plates. Basal medium,
with or wihout VEGF (10 ng/mL) in the presence or absence of
increasing concentrations of SEQ ID NO:504 or D1, was added to the
lower chamber of the wells. After 22 hours, quantitation of cell
migration/invasion was achieved by post-labeling cells in the
insert plates with a fluorescent dye and measuring the fluorescence
of the invading/migrating cells in a fluorescent plate reader.
VEGF-stimulated migration was derived by subtracting the basal
migration measured in the absence of VEGF.
[1069] Results experiment 1: As shown in FIG. 71, SEQ ID NO:504 AND
D1 competed about equally well with .sup.125I-VEGF for binding to
KDR-transfected cells, indicating that they possess comparable
binding affinities as well as a comparable ability to inhibit VEGF
from binding to KDR.
[1070] Results experiment 2: Despite the fact that both SEQ ID
NO:504 and D1 potently block .sup.125I-VEGF binding to
KDR-expressing cells to the same degree (FIG. 72), the
heterodimeric D1 was much more potent in blocking the biological
effects of VEGF as demonstrated in an endothelial cell migration
assay (FIG. 72) than the monomeric SEQ ID NO:504. At up to 62.5 nM,
a peptide comprising SEQ ID NO:504 had no effect on VEGF-stimulated
migration whereas D1 completely blocked VEGF-stimulated migration
at 50 nM. These data suggest that heteromultimeric binding can more
effectively block the biological activity of a ligand than a
monomer, even when the monomer has a comparable ability to inhibit
ligand binding to its receptor.
Example 26
Identification of Fragments of SEQ ID NO:356 with KDR Binding
Activity
[1071] The following experiment showed that fragments of SEQ ID
NO:356 can maintain significant KDR binding activity.
[1072] Protocol: 293H cells were transfected with the KDR cDNA or
mock-transfected by standard techniques described in Example 6.
Binding of the neutravidin-HRP complexes to the cells was carried
out as in Example 6 with a complex concentration of 5.5 nM in the
presence of 0 to 250 nM or 0 to 1000 nM of the following competing
peptides: SEQ ID NOS:356, 462, 463, and 465. After determining the
specific binding under each experimental condition, the IC.sub.50
for each peptide was determined (where possible).
[1073] Results: As shown in Table 18, SEQ ID NO:462, composed of
just the Asp-Trp-Tyr-Tyr (SEQ ID NO:490) binding motif that is also
shared with SEQ ID NO:286 along with the non-targeted
Gly-Gly-Gly-Lys (SEQ ID NO:262) sequence that was added to most
monomeric peptides synthesized based on phage display data, was the
smallest fragment able to block peptide/neutravidin-HRP complex
binding with an IC.sub.50 below one micromolar. Surprisingly, a
larger fragment comprising SEQ ID NO:356, failed to significantly
inhibit complex binding at one micromolar. However, when a
solubilising motif, (Gly-Arg-Gly).sub.3 was added to the latter
peptide to make SEQ ID NO:465, it was able to compete with the
complex for binding with an IC.sub.50 of 175 nM, confirming that
certain fragments of SEQ ID NO:356 containing the Asp-Trp-Tyr-Tyr
(SEQ ID NO:490) motif retain KDR-binding activity.
24TABLE 18 Fragments of SEQ ID NO: 356 in a displacement assay
competing with a complex composed of binding peptide and
neutravidin-HRP for binding to KDR-expressing cells. Fragment (SEQ
ID NO) IC.sub.50, nM 356 93 462 850 463 >1000 465 175
Example 27
Cell Based Assay for Binding of KDR/VEGF Complex Binders
[1074] The ability of a KDR/VEGF complex-binding peptide to
selectively bind to the KDR/VEGF complex was demonstrated.
[1075] Reagent Preparation
[1076] The reagents for this assay were prepared as described in
Example 5 except where noted.
[1077] Preparation of Peptide-.sup.125I-Neutravidin Solution
[1078] Biotinylated peptides SEQ ID NOS:321, 320 and 323, and a
biotinylated non-binding control peptide were used to prepare 1.25
.mu.M stock solutions in 50% DMSO. A 33.33 nM stock solution of
.sup.125I-neutravidin was purchased from Amersham (Buckinghamshire,
UK). A stock solution of 13.33 nM .sup.125I-neutravidin/100 nM VEGF
was prepared by mixing 850 mL of .sup.125I-neutravidin with 22
.mu.L of 10 .mu.M VEGF and 1275 .mu.L of M199 media. Another stock
solution was prepared in the same manner, but lacking VEGF. To
prepare 13.33 nM peptide-.sup.125I-neutravidin complex solutions
.+-. VEGF, 500 .mu.L of the .sup.125I-neutravidin (with and without
VEGF) stock solutions (prepared in last step) were mixed with 24
.mu.L of 1.25 .mu.M peptide solution of SEQ ID NOS:321, 320 and
323, or control peptide. The mixtures were incubated on a rotator
at 4C for 60 minutes, followed by addition of 50 .mu.L of soft
release avidin-sepharose (50% slurry in ddH.sub.2O) to remove
excess peptides and another incubation for 30 minutes on a rotator
at 4C. Finally, the soft release avidin-sepharose was pelleted by
centrifuging at 12,000 rpm for 5 minutes at room temperature, and
the resulting supernatants were used for the assays.
[1079] Binding of Peptide/Neutravidin HRP to KDR-Transfected
Cells
[1080] Complexes of control peptide and the test peptides (SEQ ID
NOS:321, 320 and 323) with .sup.125I-neutravidin in the presence or
absence of VEGF (prepared as above) were tested for their ability
to bind 293H cells that were transiently-transfected with KDR. The
complex of SEQ ID NO:321 with .sup.125I-neutravidin specifically
bound to KDR-transfected 293H cells as compared to mock transfected
cells in the presence of VEGF (FIG. 73), but not where VEGF was
omitted (FIG. 74). SEQ ID NO:321, was also the best KDR/VEGF
complex binder among the peptides tested using fluorescence
polarization and SPR (BIAcore) assays (Table 9). This example shows
that peptide (SEQ ID NO:321) can specifically bind to the KDR/VEGF
complex present on the cell surface. This establishes a utility for
the assay as useful for targeting the KDR/VEGF complex in vitro and
in vivo for diagnostic or therapeutic purposes. Since the KDR/VEGF
binding peptide only detects the functional and active KDR receptor
and not all the KDR present on cell surface, it will be useful in
detecting and/or treating active angiogenesis in tumors,
metastasis, diabetic retinopathy, psoriasis, and arthropathies.
Example 28
[1081] This example provides more evidence that heterodimeric
peptides targeting two epitopes on KDR are superior to a
homodimeric peptide that binds one of the two epitopes on the
target molecule. The following experiment provides further evidence
that heterodimeric constructs are superior to homodimeric peptides
in their ability to block the biological effects of VEGF.
[1082] Protocol. Serum-starved HUVECs were placed, 100,000 cells
per well, into the upper chambers of BD fibronectin-coated
FluoroBlok 24-well insert plates. Basal medium, containing either
nothing or VEGF in the presence or absence of increasing
concentrations of homodimeric D8 or heterodimeric D17, was added to
the lower chamber of the wells. After 22 hours, quantitation of
cell migration/invasion was achieved by post-labeling cells in the
insert plates with a fluorescent dye and measuring the fluorescence
of the invading/migrating cells in a fluorescent plate reader.
[1083] Results: As shown in FIG. 75, VEGF induced a large increase
in endothelial cell migration in the assay, which was potently
blocked by D17 but not D8. D17 blocked VEGF-induced migration with
an IC.sub.50 of about 250 nM while D8 had no significant effect on
migration even at 800 nM. This is in spite of the fact that D8 used
the full targeting sequence found in SEQ ID NO:356 while D17
contained a truncated version of the SEQ ID NO:356 sequence (as
seen in SEQ ID NO:465) with a lower affinity for KDR (as
demonstrated in Example 26). Thus a heterodimer with the capability
of binding two separate epitopes on KDR is more effective at
blocking ligand binding to KDR than a homodimer containing the same
or even more potent targeting sequences.
Example 29
Preparation of KDR-Binding Peptides in which the Disulfide Bond has
Been Replaced
[1084] Disulfide bond substitution analogs of SEQ ID NO:301, where
the Cys residues at position 6 and 13 are replaced by a pair of
amino acids, one with a carboxy-bearing side-chain (either Glu or
Asp) and the other with an amino-bearing side chain [(Lys or Dpr
(2,3-diaminopropanoic acid)] were prepared. The cycle, encompassing
the same sequence position as those included in SEQ ID NO:301 (made
by formation of the disulfide bond) was made by condensation of the
side-chain amino and side-chain acid moieties, resulting in a
lactam ring that bridges the residues 6-13 as does the disulfide
bond of SEQ ID NO:301.
[1085] Table 19 below displays some examples of the substitutions
made for Cys.sup.6 and Cys.sup.13 of SEQ ID NO:301 in lactam
analogs.
25TABLE 19 Lactam Analogs of SEQ ID NO: 277 Difference in Ring Size
vs SEQ ID Sequence Position 6 Position 13 NO: 277 SEQ ID NO: 277
Cys Cys -- (parent seq) 453 Glu Lys 4 454 Lys Glu 4 455 Dpr Asp 0
456 Asp Dpr 0 457 Asp Lys 3
[1086] Synthesis of Resin Bound SEQ ID NO: 453
[1087] Synthesis of 1 was carried out using Method 5 on a 0.25 mmol
scale. The peptide resin 1 was washed and dried for further
derivatization manually (see FIG. 76).
[1088] Synthesis of 4 (SEQ ID NO:453)
[1089] To 1 (240 mg, 0.06 mmol) was added NMM (N-methyl
morpholine)/HOAc/DMF 1/2/10 (v/v/v) (65 mL). Palladium
tris-triphenylphosphine [Pd(PPh.sub.3).sub.4, 554.4 mg, 0.48 mmol]
was added and the resin was shaken for 20 h shielded from light.
The resin was filtered and washed with a solution of sodium
diethyldithiocarbamate (0.5 g)/DIEA (0.5 mL)/DMF (100 mL), and
finally with DMF (3.times.70 mL). This treatment served to expose
only the carboxy and amino groups of Glu6 and Lys13 that are
required for the lactam forming reaction. The on-resin cyclization
of 2 was carried out using HATU (114 mg, 0.3 mmol), NMM (66 .mu.L,
0.6 mmol) and DMF (10 mL) for 3 h. The completion of the
cyclization was monitored by Kaiser test. The peptide was cleaved
from the peptide resin 3 using reagent B for 4 h. The resin was
filtered and the filtrate was evaporated to a paste. The crude
peptide was precipitated in ether and washed twice with ether. The
cyclic peptide was purified by preparative reverse phase linear
gradient HPLC using a Waters-YMC C-18 column (250 mm.times.30 mm
i.d.) with CH.sub.3CN into H.sub.2O (both with 0.1% TFA) as the
eluent. Lyophilization of the product-containing fractions afforded
8 mg of (SEQ ID NO:453). SEQ ID NOS:454, 455, 456 and 457 were
prepared similarly.
Example 30
Replacement of a Disulfide Bridge While Retaining KDR-Binding
Activity
[1090] The following experiment demonstrated that the lactam SEQ ID
NO:454 replaced a chemically reactive disulfide bridge to maintain
significant KDR binding activity.
[1091] Protocol: 293H cells were transfected with the KDR cDNA or
mock-transfected by standard techniques described in Example 5.
Neutravidin-HRP complexes were prepared as in Example 5. Binding of
the neutravidin-HRP complexes to the cells was carried out as in
Example 5 with a complex concentration of 5.5 nM in the presence of
0 to 250 nM SEQ ID NO:277 or SEQ ID NO:454. After determining the
specific binding under each experimental condition, the IC.sub.50
for each peptide was determined.
[1092] Results: As shown in Table 20, SEQ ID NO:454, containing a
lactam disulfide bridge replacement, was still able to compete with
peptide-neutravidin-HRP complexes for binding to KDR although some
affinity was lost (IC.sub.50 108 nM versus 13 nM).
26TABLE 20 SEQ ID NO:277 and SEQ ID NO:454 (disulfide bridge
replacement analog) in a displacement assay competing with a
neutravidin-HRP/ binding peptide complex for binding to
KDR-expressing cells. Fragment (SEQ ID NO) IC.sub.50, nM 277 13 454
108
Example 31
Use of the Neutravidin/Avidin HRP Assay with Biotinylated Peptides
Identified by Phage Display Allows Identification of Peptides
Capable of Binding to the Target Even where the Affinity of the
Peptides is Too Low for Other Assays
[1093] This example confirms that the neutravidin/HRP screening
assay described herein is an effective technique for screening
peptides whose affinity as monomers is too low for use in
conventional screening assays, such as, for example, an ELISA.
[1094] Three different derivatives of SEQ ID NO:482, which was
identified by phage display as a peptide that binds to cMet, were
prepared as described in U.S. Patent Application No. 60/451,588
(incorporated herein by reference in its entirety), filed on the
same date as U.S. patent application Ser. No. 10/382,082, of which
the present application is a continuation-in-part.
[1095] These three peptides and a control peptide that does not
bind to cMet, were tested as tetrameric complexes with neutravidin
HRP for their ability to bind cMet-expressing MB-231 cells. All
three tetrameric complexes of cMet-binding peptides bound to the
MB231 cells as compared to control peptide.
[1096] Cell Culture: MDA-MB231 cells were obtained from ATCC and
grown as monolayer culture in their recommended media plus 1 mL/L
pen/strep (InVitrogen, Carlsbad, Calif.). Cells were split the day
before the assay, 35000 cells were added to each well of a 96 well
plate. The rest of the experiment was conducted as in Example 6,
except as noted below.
[1097] Binding of Peptide/Neutravidin HRP to MDA-MB-231 Cells
[1098] Complexes of control peptide, and SEQ ID NO:482 derivatives
with 0, 1 or 2 J spacers with neutravidin-HRP were prepared as
described above and tested for their ability to bind MDA-MB-231
cells. During the peptide/neutravidin-HRP complex preparation, a
7.5-fold excess of biotinylated peptides over neutravidin-HRP was
used to make sure that all four biotin binding sites on neutravidin
were occupied. After complex formation, the excess of free
biotinylated peptides was removed using soft release
avidin-sepharose to avoid any competition between free biotinylated
peptides and neutravidin HRP-complexed biotinylated peptides. The
experiment was performed at several different concentrations of
peptide/neutravidin-HRP, from 0.28 nM to 33.33 nM, to generate
saturation binding curves for derivatives with no or one spacer
(FIG. 77) and 0.28 to 16.65 nM to generate a saturation binding
curve for the derivative with two spacers (FIG. 77). In order to
draw the saturation binding curve, the background binding of the
control peptide/neutravidin HRP complex was subtracted from the
binding of the binding derivative peptide/neutravidin-HRP complexes
for each concentration tested. Therefore, absorbance on the Y-axis
of FIG. 77 is differential absorbance (cMet-binding peptide minus
control peptide) and not the absolute absorbance. Analysis of the
saturation binding data in FIG. 77 using Graph Pad Prism software
(version 3.0) yielded a K.sub.D of 12.62 nM (+/-3.16) for the
tetrameric derivative with two spacers, 155.4 nM (+/-86.56) for the
tetrameric derivative with one spacer and 123.8 nM (+/-37.71) for
the tetrameric derivative without a spacer. These binding constants
are, as expected, lower than that measured by FP for the related
monodentate peptide SEQ ID NO:482 (880 nM).
[1099] Results: As was the case where the binding target was KDR,
the neutravidin-HRP assay with biotinylated peptides identified
with phage display was useful for identifying peptides capable of
binding to an immobilized target even when the affinity of the
monomeric binding sequence is too low for an ELISA-type assay (with
washing steps after binding) to work well (see FIG. 77).
Example 32
Binding of Tc-Labeled Heterodimeric Polypeptides to KDR-Transfected
293H Cells
[1100] The ability of Tc-labeled D10 to bind KDR was assessed using
KDR-transfected 293H cells. The results show that Tc-labeled D10
binds significantly better to KDR transfected 293H cells than to
mock transfected 293H cells, and good binding was maintained in the
presence of 40% mouse serum. In addition, a derivative of
Tc-labeled D10 with its amino acid sequence scrambled, D18, was
shown to possess no affinity for KDR-expressing cells, confirming
the specificity of the D10 binding to those cells.
[1101] Transfection of 293H Cells
[1102] 293H cells were transfected using the protocol described in
Example 5. Transfection was done in black/clear 96-well plates
(Becton Dickinson, cat. # 354640). The cells in one half of the
plate (48 wells) were mock-transfected (without DNA) and the cells
in the other half of the plate were transfected with KDR cDNA. The
cells were 80-90% confluent at the time of transfection and
completely confluent the next day, at the time of the assay (the
assay was aborted if these conditions were not satisfied).
[1103] Preparation of Opti-MEMI Media with 0.1% HSA
[1104] Opti-MEMI was obtained from InVitrogen (Carlsbad, Calif.)
and human serum albumin (HSA) was obtained from Sigma (St. Louis,
Mo.). Opti-MEMI media was prepared by adding 0.1% HSA, 0.1% w/v HSA
to opti-MEMI, followed by stirring at room temperature for 20
minutes. The media was filter sterilized using 0.2 .mu.M
filter.
[1105] Preparation of Tc-Labeled Peptide Dilutions for the
Assay
[1106] D10 and D18 were diluted in opti-MEMI with 0.1% HSA to
provide solutions with final concentrations of 1.25, 2.5, 5.0, and
10 .mu.Ci/mL of each Tc-labeled heterodimer. A second set of
dilutions was also prepared using a mixture of 40% mouse serum/60%
opti-MEMI with 0.1% HSA as the diluent.
[1107] Assay to Detect the Binding of the Tc-Labeled
Heterodimers
[1108] Cells were used 24 h after transfection, and to prepare the
cells for the assay, they were washed once with 100 .mu.L of room
temperature opti-MEMI with 0.1% HSA. After washing, the opti-MEMI
with 0.1% HSA was removed from the plate and replaced with 70 .mu.L
of 1.25, 2.5, 5.0, and 10 .mu.Ci/mL of Tc-labeled D10 or D18
(prepared as above with both diluent solutions). Each dilution was
added to three separate wells of mock- and KDR-transfected cells.
After incubating at room temperature for 1 h, the plates were
washed 5 times with 100 .mu.L of cold binding buffer (opti-MEMI
with 0.1% HSA). 100 .mu.L of solubilizing solution (0.5 N NaOH) was
added to each well and the plates were incubated at 37C for 10
minutes. The solubilizing solution in each well was mixed by
pipeting up and down, and transferred to 1.2 mL tubes. Each well
was washed once with 100 .mu.L of solubilizing solution and the
washes were added to the corresponding 1.2 mL tube. Each 1.2 mL
tube was then transferred to a 15.7 mm.times.100 cm tube to be
counted in an LKB Gamma Counter.
[1109] Binding of Tc-Labeled Peptide to KDR Transfected Cells
[1110] The ability of Tc-labeled D10 and D18 to bind specifically
to KDR was demonstrated using transiently transfected 293H cells.
As shown in FIG. 78, Tc-labeled D10 bound better to KDR transfected
293H cells, as compared to mock-transfected (with a scrambled
peptide) 293H cells in both the presence and absence of 40% mouse
serum, although there was some inhibition in the presence of serum.
The total specific binding of this Tc-labeled heterodimer to
KDR-expressing cells was greater than that observed previously with
a Tc-labeled monomeric peptide (Example 10). Tc-labeled D18, the
scrambled peptide, displayed no affinity for either
mock-transfected or KDR-transfected 293H cells (not shown),
confirming the specificity of D10 binding.
Example 33
Binding of a Lu-Labeled Heterodimeric Polypeptide to
KDR-Transfected 293H Cells
[1111] The ability of Lu-labeled D13 to bind KDR was assessed using
KDR-transfected 293H cells. The results show that Lu-labeled D13
binds better to KDR transfected 293H cells than to mock transfected
293H cells, and significant binding was maintained in the presence
of 40% mouse serum.
[1112] Transfection of 293H Cells
[1113] 293H cells were transfected using the protocol described in
Example 5. Transfection was performed in black/clear 96-well plates
(Becton Dickinson, San Jose, Calif.). The cells in one half of the
plate (48 wells) were mock-transfected (without DNA) and the cells
in the other half of the plate were transfected with KDR cDNA. The
cells were 80-90% confluent at the time of transfection and
completely confluent the next day, at the time of assay (the assay
was aborted if these conditions were not satisfied).
[1114] Preparation of Opti-MEMI Media with 0.1% HSA
[1115] Opti-MEMI was prepared as in Example 32.
[1116] Preparation of Lu-Labeled Peptide Dilutions for the
Assay
[1117] A stock solutions of Lu-labeled D13 was diluted in opti-MEMI
with 0.1% HSA to provide solutions with final concentrations of
1.25, 2.5, 5.0, and 10 .mu.Ci/mL of labeled heterodimer. A second
set of dilutions was also prepared using a mixture of 40% mouse
serum/60% opti-MEMI with 0.1% HSA as the diluent.
[1118] Assay to Detect the Binding of the Lu-Labeled
Heterodimers
[1119] Detection of binding was measured as detailed in Example 32
except that Lu-labeled D13 was used in place of the Tc-labeled
heterodimers.
[1120] Binding of Lu-Labeled Peptide to KDR Transfected Cells
[1121] The ability of Lu-labeled D13 to bind specifically to KDR
was demonstrated using transiently-transfected 293H cells. As shown
in FIG. 95, Lu-labeled D13 bound significantly better to KDR
transfected 293H cells, as compared to mock-transfected 293H cells
in both the presence and absence of 40% mouse serum, although there
was some binding inhibition in the presence of serum.
Example 34
Radiotherapy with a Lu-Labeled Heterodimeric Peptide in
Tumor-Bearing Mice
[1122] In this example, the ability of Lu-labeled D13 to inhibit
the growth of PC3 cell tumors implanted in nude mice is
demonstrated.
[1123] Animal Model
[1124] PC3 cells from ATCC, grown as recommended by the supplier,
were injected subcutaneously between the shoulder blades of nude
mice. When their tumors reached 100-400 mm.sup.3, twelve mice were
injected i.v. with 500 microcuries of Lu-labeled D13 and their
growth monitored for an additional 18 days. Mice were sacrificed if
they lost 20% or more of their body weight or their tumors exceeded
2000 mm.sup.3. Tumor growth in the treated mice was compared with
the average tumor growth in 37 untreated nude mice implanted with
PC3 tumors.
[1125] Results
[1126] In 6 of the 12 treated mice in the study, the tumors
experienced a significant or complete growth delay (FIG. 80)
relative to untreated tumor mice, indicating that D13 was effective
in slowing PC3 tumor growth under the conditions employed.
Example 35
Preparation of Ultrasound Contrast Agents Conjugated to KDR-Binding
Peptides
[1127] Ultrasound contrast agents comprising
phospholipid-stabilized microbubbles conjugated to KDR-binding
polypeptides of the invention were prepared as described below.
[1128] 200 mg of DSPC (distearoylphosphatidylcholine), 275 mg of
DPPG.Na (distearoylphosphatidylglycerol sodium salt), 25 mg of
N-MPB-PE were solubilized at 60C in 50 mL of Hexan/isopropanol
(42/8). The solvent was evaporated under vacuum, and then PEG-4000
(35.046 g) was added to the lipids and the mixture was solubilized
in 106.92 g of t-butyl alcohol at 60C, in a water bath. The
solution was filled in vials with 1.5 mL of solution. The samples
were rapidly frozen at -45C and lyophilized. The air in the
headspace was replaced with a mixture of C.sub.4F.sub.10/Air
(50/50) and vials capped and crimped. The lyophilized samples were
reconstituted with 10 mL saline solution (0.9%-NaCl) per vial.
[1129] Peptide Conjugation
[1130] Peptides, e.g., SEQ ID NO:356, SEQ ID NO:294 and SEQ ID
NO:480, were conjugated to a preparation of microbubbles as above
described, according to the following methodology.
[1131] The thioacetylated peptide (200 .mu.g, SEQ ID NO:356) was
dissolved in 20 .mu.L DMSO and then diluted in 1 mL of Phosphate
Buffer Saline (PBS). This solution was mixed to the
N-MPB-functionalized microbubbles dispersed in 18 mL of PBS-EDTA 10
mM, pH 7.5 and 2 mL of deacetylation solution (50 mM sodium
phosphate, 25 mM EDTA, 0.5 M hydroxylamine.HCl, pH 7.5) was added.
The headspace was filled with C.sub.4F.sub.10/Air (35/65) and the
mixture was incubated for 2.5 hours at room temperature under
gentle agitation (rotating wheel), in the dark. Conjugated bubbles
were washed by centrifugation.
Example 36
Preparation of Ultrasound Contrast Agents Conjugated to KDR Binding
Peptides
[1132] Ultrasound contrast agents comprising
phospholipid-stabilized microbubbles conjugated to KDR-binding
polypeptides of the invention were prepared as described below.
[1133] Distilled water (30 mL) containing 6 mg of
dipalmitoylphosphatidyls- erine (DPPS, Genzyme), 24 mg of
distearoylphosphatidylcholine (DSPC, Genzyme) and 3 g of mannitol
was heated to 65C in 15 minutes then cooled to room temperature.
N-MPB-DPPE (1,2-Dipalmitoyl-sn-glycero-3-phosphoetha-
nolamine-N-[4-(p-maleimidophenyl) butyramide] Na salt--Avanti Polar
Lipids) was added (5% molar--1.9 mg). This derivatized phospholipid
was dispersed in the aqueous phase using an ultrasonic bath
(Branson 1210-3 minutes).
[1134] Perfluoroheptane (2.4 mL from Fluka) was emulsified in this
aqueous phase using a high speed homogenizer (Polytron.RTM., 10000
rpm, 1 minute).
[1135] The emulsion was washed once by centrifugation (200 g/10
min) then resuspended in 30 mL of a 10% solution of mannitol in
distilled water. The washed emulsion was frozen (-45C, 5 minutes)
then freeze dried (under 0.2 mBar, for 24 hours).
[1136] Atmospheric pressure was restored by introducing a mixture
of C.sub.4F.sub.10 and air. The lyophilizate was dissolved in
distilled water (30 mL). Microbubbles were washed once by
centrifugation and redispersed in 10 mL of Phosphate Buffer
Saline.
[1137] Peptide Conjugation
[1138] Thioacetylated peptide (200 .mu.g, SEQ ID NO:356) was
dissolved in 20 .mu.L DMSO and then diluted in 1 mL of Phosphate
Buffer Saline (PBS). This solution was mixed to 5 mL of the
N-MPB-functionalized microbubbles. 0.6 mL of deacetylation solution
(50 mM sodium phosphate, 25 mM EDTA, 0.5 M hydroxylamine.HCl, pH
7.5) was added and the suspensions were stirred by inversion for 2
h30.
[1139] Microbubbles were washed twice with a solution of maltose 5%
and Pluronic F68 0.05% in distilled water, by centrifugation (200
g/10 minutes). The final volume was fixed to 5 mL.
Example 37
Preparation of Ultrasound Contrast Agents Conjugated to KDR Binding
Peptides
[1140] Ultrasound contrast agents comprising microballoons
conjugated to KDR-binding polypeptides of the invention were
prepared as described below.
[1141] Distilled water (30 mL) containing 40 mg of
distearoylphosphatidylg- lycerol (DSPG, Genzyme) was heated to 65C
during 15 minutes then cooled to 40C.
[1142] DPPE-PEG2000-Maleimide(3.5 mg--Avanti Polar Lipids) and
tripalmitine (60 mg--Fluka) were dissolved in cyclohexane (0.6 mL)
at 40C in a ultrasound bath for 2 min.
[1143] This organic phase was emulsified in the aqueous phase using
a high speed homogenizer (Polytron.RTM., 10000 rpm, 1 minute).
[1144] Polyvinylalcohol (200 mg) dissolved in distilled water (5
mL) was added to the emulsion. The mixture was cooled to 5C, then
frozen (-45C, 10 minutes) and finally freeze dried (under 0.2 mBar,
for 24 hours).
[1145] The lyophilisate was dispersed in distilled water (15 mL).
The mixture was stirred for 30 min to obtain a homogenous
suspension of microballoons.
[1146] Peptide Conjugation
[1147] The thioacetylated peptide (200 .mu.g) was dissolved in 20
.mu.L DMSO then diluted with PBS (1 mL).
[1148] 7.5 mL of the suspension of microballoons obtained as above
described were centrifuged (500 rpm for 5 min). The infranatant was
discarded and microballoons were redispersed in Phosphate Buffer
Saline (2 mL).
[1149] The microcapsule suspension was mixed with the solution of
peptide. Three hundred microliters of a hydroxylamine solution
(10.4 mg in PBS 50 mM, pH: 7.5) was added to the suspension to
deprotect the thiol. The suspension was stirred by inversion for
two and a half hours.
[1150] The microballoons were washed twice by centrifugation (500
g/5 min) with distilled water containing 5% maltose and 0.05%
Pluronic F68 and finally redispersed in 3 mL of this solution.
Example 38
Ultrasound Contrast Agents Conjugated to KDR Binding Polypeptides
Bind to KDR-Expresing Cells In Vitro and In Vivo
[1151] The ability of ultrasound contrast agents conjugated to
peptides of the invention to bind to KDR-expressing cells in vitro
was assessed using 293H cells transfected to expresss KDR.
Additionally, the ability of ultrasound contrast agents conjugated
to KDR binding polypeptides of the invention to bind to
KDR-expressing tissue in vivo was assessed using two known models
of angiogenesis, the rat matrigel model and the rat MatB III tumor
model.
[1152] Transfection of 293H Cells on Thermanox.RTM. Coverslips
[1153] 293H cells were transfected with KDR DNA as set forth in
Example 5. The transfected cells were incubated with a suspension
of peptide-conjugated ultrasound contrast agents or with a control
peptide (a scrambled version of the conjugated peptide having no
affinity for KDR).
[1154] For the incubation with the transfected cells a small
plastic cap is filled with a suspension containing 1 to
3.times.10.sup.8 peptide-conjugated microbubbles and the cap
covered with an inverted Thermanox.RTM. coverslip as to put the
transfected cells in contact with the conjugated microbubbles.
After about 20 min at RT, the coverslip is lifted with tweezers,
rinsed three times in PBS and examined under a microscope to assess
binding of the conjugated microbubbles.
[1155] FIG. 85 indicates that microballoons conjugated to peptides
of the invention bind specifically to KDR-expressing cells. Indeed,
microballoons conjugated to KDR-binding peptide bound to
KDR-expressing cells while they did not bind appreciably to mock
transfected cells and microballoons bearing a scrambled control
peptide showed no appreciable binding.
[1156] Determination of the % of Surface Covered by
Microvesicles
[1157] Images were acquired with a digital camera DC300F (Leica)
and the percent of surface covered by bound microbubbles or
microballoons in the imaged area was determined using the software
QWin (Leica Microsystem AG, Basel, Switzerland).
[1158] The following table shows the results of the binding
affinity (expressed as coverage % of the imaged surface) of
targeted microvesicles of the invention to KDR transfected cells,
as compared to the binding of the same targeted microvesicles
towards Mock-transfected cells or (only in the case of the peptide)
to the binding of microvesicles targeted with a scrambled peptide
to the same KDR transfected cells.
[1159] As shown in Table 21, targeted microvesicles show increased
binding affinity for KDR.
27 TABLE 21 Coverage % SEQ ID Scrambled NO KDR Mock peptide Example
35 356 14.2% 1.4% 2.1% 277 3.5% 0.9% n.a. 480 16.8% 1.0% n.a.
Example 36 356 18.3% 0.4% 2.2% Example 37 356 6.7% 0.2% 0.1%
[1160] In Vivo Animal Models
[1161] Known models of angiogenic tissue (rat matrigel model and
rat Mat B III model) were used to examine the ability of the
peptide conjugated ultrasound conjugates to localize to and provide
an image of angiogenic tissue.
[1162] Animals: Female Fisher 344 rat (Charles River Laboratories,
France) weighing 120 to 160 g were used for the MATBIII tumor
implantation. Male OFA rats (Charles River Laboratories, France)
weighing 100 to 150 g were used for Matrigel injection.
[1163] Anesthesia: Rats were anesthetized with an intramuscular
injection (1 mL/kg) of Ketaminol/xylazine (Veterinaria AG/Sigma)
(50/10 mg/mL) mixture before implantation of Matrigel or MATBIII
cells. For imaging experiments, animals were anesthetized with the
same mixture, plus subcutaneous injection of 50% urethane (1
g/kg).
[1164] Rat MATBIII tumor model: A rat mammary adenocarcinoma,
designated 13762 Mat B III, was obtained from ATCC(CRL-1666) and
grown in McCoy's 5a medium+10% FCS. 1% glutamine and 1% pen/strep
(Invitrogen cat# 15290-018). Cells in suspension were collected and
washed in growth medium, counted, centrifuged and resuspended in
PBS or growth medium at 1.10.sup.7 cells per mL. For tumor
induction: 1.times.10.sup.6 cells in 0.1 mL were injected into the
mammary fat pad of anesthetized female Fisher 344 rat. Tumors
usually grow to a diameter of 5-8 mm within 8 days.
[1165] Rat matrigel model: Matrigel (400 .mu.L) (ECM, Sigma, St
Louis, Mo.) containing human bFGF (600 ng/mL) (Chemicon: ref:
GF003) was subcutaneously injected in the dorsal flank of each
rat.
[1166] Matrigel solution was kept liquid at 4C until injection.
Immediately after matrigel injection, the injection site was
maintained closed for a few seconds with the hand in order to avoid
leaking of the matrigel. At the body temperature, matrigel becomes
gelatinous. Ten days post-injection, neoangiogenesis was observed
in matrigel plug of rat and imaging experiment were performed.
[1167] In vivo ultrasound imaging: Mat B III tumor or matrigel
imaging was performed using an ultrasound imaging system ATL HDI
5000 apparatus equipped with a L7-4 linear probe. B-mode pulse
inversion at low acoustic power (MI=0.05) was used to follow
accumulation of peptide conjugated-microbubbles on the KDR receptor
expressed on the endothelium of neovessels. For the control
experiments, an intravenous bolus of unconjugated microbubbles or
microbubbles conjugated to non-specific peptide was injected. The
linear probe was fixed on the skin directly on line with the
implanted tumors or matrigel plug and accumulation of targeted
bubbles was followed during thirty minutes.
[1168] In both models, a perfusion of SonoVue.RTM. was
administrated before injecting the test bubble suspension. This
allows for the evaluation of the vascularization status; the video
intensity obtained after SonoVue.RTM. injection is taken as an
internal reference.
[1169] A baseline frame was recorded and then insonation was
stopped during the bubble injection. At various time points after
injection (1, 2, 5, 10, 15, 20, 25, 30 minutes) insonation was
reactivated and 2 frames of one second were recorded on a
videotape.
[1170] Video frames from matrigel or Mat III tumor imaging
experiments were captured and analysed with the video-capture and
Image-Pro Plus 2.0 software respectively. The same rectangular Area
of Interest (AOI) including the whole sectional area of the tumor
or matrigel was selected on images at different time points (1, 2,
5, 10, 15, 20, 25, 30 minutes). At each time point, the sum of the
video pixel inside the AOI was calculated after the substraction of
the AOI baseline. Results are expressed as the percentage of the
signal obtained with SonoVue, which is taken as 100%. Similarly, a
second AOI situated outside from matrigel or tumor, and
representing the freely circulating contrast agent, is also
analysed.
[1171] Results
[1172] The results indicate that ultrasound contrast agents bearing
KDR binding moieties of the invention localize to angiogenic (and
thus KDR expressing) tissue in animal models. Specifically, FIG. 81
shows uptake and retention of bubble contrast in the tumor up to 30
minutes post injection for suspensions of phospholipids stabilized
microbubbles conjugated to KDR peptides of the invention prepared
according to Example 35. In contrast, the same bubbles showed only
transient (no more than 10 minutes) visualization/bubble contrast
in the AOI situated outside the tumor site. Similarly, FIG. 82 and
FIG. 83 show uptake and retention of bubble contrast in the
matrigel at up to 30 minutes post injection for suspensions of
phospholipids stabilized microbubbles conjugated to KDR peptides of
the invention (e.g., SEQ ID NOS:374 and 294, respectively) prepared
according to Example 35. In contrast, the same bubbles showed only
transient (no more than 10 minutes) visualization/bubble contrast
in the AOI situated outside the matrigel site.
Example 39
Enhancing the Serum Residence of KDR-Binding Peptides
[1173] Compounds that contain maleimide and other groups that can
react with thiols react with thiols on serum proteins, especially
serum albumin, when the compounds are injected. The adducts have
serum life times similar to serum albumin, more than 14 days in
humans for example.
[1174] Conjugation to Maleimide
[1175] Methods are available that allow for the direct synthesis of
maleimide-labeled linear peptides encompassed by the present
invention (Holmes, D. et al., 2000. Bioconjug. Chem.,
11:439-444).
[1176] Peptides that include disulfides can be derivatized with
maleimide in one of several ways. For example, a third cysteine can
be added at the carboxy terminus. The added cysteine is protected
with protecting group that is orthogonal to the type of groups used
for the cysteines that are to form the disulfide. The disulfide is
formed by selectively deprotecting the intended cysteines and
oxidizing the peptide. The final cysteine is then deprotected and
the peptide reacted with a large molar excess of a bismaleimide.
The resulting compound has one of the maleimides free to react with
serum albumin or other thiol-containing serum proteins.
[1177] Alternatively, a cyclic peptide of the present invention is
synthesized with a lysine-containing C-terminal extention, such as
-GGGK (SEQ ID NO:262). Lysines of the KDR-binding motif are
protected with ivDde and the C-terminal lysine is deprotected. This
lysine is reacted with a maleimide-contining compound, such as
N-[e-maleimidocaproyloxy]suc- cinimide ester (Pierce Biotechnology,
Rockford, Ill.) or N-(a-Maleimidoacetoxy)succinimide ester (Pierce
Biotechnology).
[1178] Conjugation to a Moiety that Binds Serum Albumin
Non-Covelently
[1179] Polypeptides having a molecular weight less than 50-60 kDa
are rapidly excreted. Many small molecules, such as fatty acids,
bind to serum albumin. Fatty acids containing 10 to 20 carbon atoms
have substantial affinity for serum albumin. Linear and branched
fatty acids can be used. This binding in serum can reduce the rate
of excretion. Using methods known in the art, serum-albumin-binding
moieties can be conjugated to any one of the peptides herein
disclosed. The serum-ablumin-binding moiety can be joined to the
KDR-binding peptide through a linker. The linker can be peptidic or
otherwise, such as PEG. Linkers of zero to about thirty atoms are
preferred. It is preferred that the linker be hydrophilic. The
serum-albumin-binding moiety can be conjugated to the KDR-binding
peptide at either end or though a side group of an appended amino
acid. Suitable side groups include lysine and cysteine. Such
compounds can also comprise chelators for radionuclides, as
discussed herein. A KDR-binding peptide joined to a
serum-ablumin-binding moiety will bind KDR.
[1180] Conjugation to PEG
[1181] Attachment of poly(ethyleneglycol) (PEG) to proteins and
peptides enhances the serum residence of these molecules.
Attachment of PEG (linear or branched) to a KDR-binding peptide is
expected give substantial enhancement of serum residence time. The
molecular weight of the PEG should be at least 10 kDA, more
preferably at least 20 kDa, and most preferably 30 kDa or more. The
PEG could be attached at the N- or C-terminus. Methods of attaching
PEG to peptides are well known in the art (Roberts M. et al., 2002.
Adv. Drug. Deliv. Rev., 54:459-476). PEG can be attached to
reactive side groups such as lysine or cysteine.
[1182] Fusion to Serum Protein
[1183] Proteins comprising serum albumin (SA) and other proteins
have enhanced serum residence times. The amino-acid sequence of
human SA (hSA) is shown in Table 22. Table 23 shows a fusion
protein comprising: AGDWWVECRVGTGLCYRYDTGTGGGK(SEQ ID NO:286)::
PGGSGGEGGSGGEGGRPGGSEGGTGG::m- ature hSA::
GGSGGEGGSGGEGGSGPGEGGEGSGGRP:: GDSRVCWEDSWGGEVCFRYDPGGGK(SEQ ID
NO:294). The KDR-binding peptides are separated from mature hSA by
linkers that are rich in glycine to allow flexible spacing. One
need not use all of hSA to obtain an injectable protein that will
have an enhanced serum residence time. Chemical groups, such as
maleimide and alpha bromo carboxylates, react with the unpaired
cysteine (residue 34) to form stable adducts. Thus, one can attach
a single chelator to hSA fusion proteins so that the adduct will
bind a radionuclide. One can prepare a chelator with a maleimide
group and couple that to hSA or an hSA derivative. Alternatively,
hSA or an hSA derivative can be reacted with a bismaleimide and a
chelator carrying a reactive thiol could be reacted with the
bismaleimide-derivatized hSA.
[1184] Construction of genes that encode a given amino-acid
sequence are known in the art. Expression of HSA fusions in
Saccharomyces cerevisiae is known in the art (Sleep, D et al.,
1991. Biotechnology (NY), 9:183-187).
[1185] Pretargeting Radioactivity or Toxins to KDR Expressing
Tumors
[1186] Conventional radioimmune cancer therapy is plagued by two
problems. The generally attainable targeting ratio (ratio of
administered dose localizing to tumor versus administered dose
circulating in blood or ratio of administered dose localizing to
tumor versus administered dose migrating to bone marrow) is low.
Also, the absolute dose of radiation or therapeutic agent delivered
to the tumor is insufficient in many cases to elicit a significant
tumor response. Improvement in targeting ratio or absolute dose to
tumor would be of great importance for cancer therapy.
[1187] The present invention provides methods of increasing active
agent localization at a target cell site of a mammalian recipient.
The methods include, for example, a) administering to a recipient a
fusion protein comprising a targeting moiety and a member of a
ligand-anti-ligand binding pair; b) thereafter administering to the
recipient a clearing agent capable of directing the clearance of
circulating fusion protein via hepatocyte receptors of the
recipient, wherein the clearing agent incorporates a member of the
ligand-anti-ligand binding pair; and c) subsequently administering
to the recipient an active agent comprising a ligand/anti-ligand
binding pair member.
[1188] Hexoses, particularly the hexoses galactose, glucose,
mannose, mannose-6-phosphate, N-acetylglucosamine, pentamannosyl
phosphate, N-acetylgalactosamine, thioglycosides of galactose, and
mixtures thereof are effective in causing hepatic clearance.
Binding of sugars to hepatic receptors is not, however, the only
means of directing a molecule to the liver.)
[1189] Clearance of carcinoembryonic antigen (CEA) from the
circulation is by binding to Kupffer cells in the liver. We have
shown that CEA binding to Kupffer cells occurs via a peptide
sequence YPELPK representing amino acids 107-112 of the CEA
sequence. This peptide sequence is located in the region between
the N-terminal and the first immunoglobulin like loop domain. Using
native CEA and peptides containing this sequence complexed with a
heterobifunctional crosslinking agent and ligand blotting with
biotinylated CEA and NCA we have shown binding to an 80 kD protein
on the Kupffer cell surface. This binding protein may be important
in the development of hepatic metastases. (Thomas, P. et al., 1992.
Biochem. Biophys. Res. Commun., 188:671-677.
[1190] To use YPELPK (SEQ ID NO:498) as a clearance agent, one
fuses this sequence via a linker to a moiety that binds the fusion
protein (Ab). For example, if the Ab has affinity for DOTA/Re, one
would make a derivative having YPELPK attached to DOTA/Re; for
example, rvYPELPKpsGGG-DOTA. `rvYPELPKps` is a fragment of CEA that
includes the YPELPK sequence identified by Thomas et al. Any
convenient point on DOTA can be use for attachment.
RVYPELPKPSGGG-DOTA/cold Re (SEQ ID NO:499) would then be used as a
clearing agent. The Fab corresponding to the fusion Ab would have
affinity for the clearing agent of Kd<100 nM, preferably
Kd<10 nM, and most preferably Kd<1 nM.
[1191] The therapeutic agent would contain DOTA/.sup.185Re. In a
preferred embodiment, the therapeutic agent would contain two or
more DOTA moieties so that the Ab immobilized on the tumor would
bind the bis-DOTA compound with high avidity. The two DOTA moieties
would preferably be connected with a hydrophilic linker of ten to
thirty units of PEG. PEG is a preferred linker because it is not
degraded, promotes solubility. Ten to thirty units of PEG is not
sufficient to give the bis DOTA compound a very long serum
residence time. A half-life of 30 minutes to 10 hours is
acceptable. The serum half life should be longer than the
radioactive half life of the radionuclide used so that most of the
radiation is delivered to the tumor or to the external
environment.
[1192] In one embodiment, a "fusion protein" of the present
invention comprises at least one KDR-binding peptide fused to the
amino terminus or the carboxy terminus of either the light chain
(LC) or the heavy chain (HC) of a human antibody. Optionally and
preferably, two or more KDR-binding peptides are fused to the
antibody. The antibody is picked to have high affinity for a small
molecule that can be made radioactive or have a toxin attached.
Preferably, the affinity of the Fab corresponding to the Ab has
affinity for the small molecule with Kd less than 100 nM, more
preferably less than 10 nM, and most preferably less than 1 nM. The
small molecule could be a chelator capable of binding a useful
radioactive atom, many of which are listed herein. The small
molecule could be a peptide having one or more tyrosines to which
radioactive iodine can be attached without greatly affecting the
binding property of the peptide.
[1193] Any KDR-binding peptide (KDR-BP) of the present invention
can be fused to either end of either chain of an antibody that is
capable of binding a small radioactive compound. Useful embodiments
include:
[1194] 1) KDR-BP#1::link::LC/HC,
[1195] 2) LC::link::KDR-BP#1/HC,
[1196] 3) LC/KDR-BP#1::link::HC,
[1197] 4) LC/HC::link::KDR-BP#1,
[1198] 5) KDR-BP#1::link1::LC::link2::KDR-BP#2/HC,
[1199] 6) LC/KDR-BP#1::link1::HC::link2::KDR-BP#2,
[1200] 7) KDR-BP#1::link1::LC/KDR-BP#2::link2::HC,
[1201] 8) KDR-BP#1::link1::LC/HC::link2:: KDR-BP#2,
[1202] 9) LC::link1::KDR-BP#1/KDR-BP#2::link2::HC,
[1203] 10) LC::link1::KDR-BP#1/HC::link2:: KDR-BP#2,
[1204] 11)
KDR-BP#1::link1::LC::link2::KDR-BP#2/KDR-BP#3::link3::HC,
[1205] 12)
KDR-BP#1::link1::LC::link2::KDR-BP#2/HC::link3::KDR-BP#3,
[1206] 13)
KDR-BP#3::link3::LC/KDR-BP#1::link1::HC::link2::KDR-BP#2,
[1207] 14)
LC::link3::KDR-BP#3/KDR-BP#1::link1::HC::link2::KDR-BP#2, and
[1208] 15)
KDR-BP#1::link1::LC::link2::KDR-BP#2/KDR-BP#3::link3::HC::link4-
::KDR-BP#4.
[1209] In cases (5)-(15), the linkers (shown as "link1", "link2",
"link3", and "link4") can be the same or different or be absent.
These linkers, if present, are preferably hydrophilic, protease
resistant, non-toxic, non-immunogenic, and flexible. Preferably,
the linkers do not contain glycosylation sites or sequences known
to cause hepatic clearance. A length of zero to fifteen amino acids
is preferred. The KDR-binding peptides (KDR-BP#1, #2, #3, and #4)
could be the same or different. If the encoded amino-acid sequences
are the same, it is preferred that the DNA encoding these sequences
is different.
[1210] Since antibodies are dimeric, each fusion protein will
present two copies of each of the fused peptides. In case (15),
there will be eight KDR-BPs present and binding to KDR-displaying
cells should be highly avid. It is possible that tumor penetration
will be aided by moderate KDR affinity in each of the KDR-BPs
rather than maximal affinity.
[1211] One group of preferred embodiments have SEQ ID NO:294 as one
of the KDR-BPs and SEQ ID NO:286 as the other. For example, in case
(7) (KDR-BP#1::link1::LC/KDR-BP#2::link2::HC), KDR-BP#1 is SEQ ID
NO:294 and KDR-BP#2 is SEQ ID NO:286 and link1 is between 10 and 20
amino acids and link2 is also between ten and twenty amino acids. A
suitable sequence for link1 is GGSGGEGRPGEGGSG (SEQ ID NO:491) and
a suitable sequence for link2 is GSESGGRPEGGSGEGG (SEQ ID NO:492).
Other sequences rich in Gly, Ser, Glu, Asp, Thr, Gln, Arg, and Lys
are suitable. To reduce the risk of proteolysis, it is preferred to
follow Arg or Lys with Pro. To avoid difficulties in production and
poor solubility, it is preferred to avoid long stretches (more than
twelve) of uncharged residues. Since the peptides are displayed at
the amino termini of LC and HC, the combined linker length will
allow them to bind to KDR simultaneously. Additionally, in case
(15)(KDR-BP#1::link1::LC::link2::KDR-BP#2/KDR-BP#3:-
:link3::HC::link4::KDR-BP#4), KDR-BP#1 and KDR-BP#2 are SEQ ID
NO:294 and KDR-BP#3 and KDR-BP#4 are SEQ ID NO:29. Link1 and link3
are 10 to 20 amino acids and link2 and link4 are each 15 to 30
amino acids. Link2 and link4 are longer because they need to allow
a peptide on the carboxy terminus of LC to reach a peptide on the
carboxy terminus of HC.
[1212] The fusion protein is produced in eukaryotic cells so that
the constant parts of the HC will be glycosylated. Preferably, the
cells are mammalian cells, such as CHO cells.
[1213] The fusion proteins are injected into a patient, and time is
allowed for the fusion protein to accumulate at the tumor. A
clearing agent is injected so that fusion protein that has not
become immobilized at the tumor will be cleared. In previous
pretargeting methods, the antibody combining site has been used to
target to the tumor and biotin/avidin or biotin/streptavidin has
been used to attach the radioactive or toxic agent to the
immobilized antibody. The biotin/avidin or streptavidin binding is
essentially irreversible. Here we fuse a target-binding peptide to
the antibody that is picked to bind a radioactive or toxic agent.
Because the fusion protein contains 2, 4, 6, or 8 KDR-BPs, binding
of the fusion protein to the tumor is very avid. A clearing agent
that will cause fusion protein not immobilized at the tumor to
clear can be administered between 2 and 48 hours of the injection
of the fusion protein. Because the clearance agent is monomeric in
the moiety that binds the antibody, complexes of clearance agent
and immobilized fusion protein will not have very long life times.
Within 4 to 48 hours of injecting clearance agent, the immobilized
antibody will have lost any clearance agent that binds there. The
active agent is, preferably, dimeric in the moiety that binds the
fusion protein. The active agent is injected between 2 and
.about.48 hours of injection of clearance agent.
28TABLE 22 Amino-acid sequence of Mature HSA from GenBank entry
AAN17825 DAHKSEVAHR FKDLGEENFK ALVLIAFAQY (SEQ ID NO: 500)
LQQCPFEDHV KLVNEVTEFA KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGEMADC
CAKQEPERNE CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY EIARRHPYFY
APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC ASLQKFGERA
FKAWAVARLS QRFPKAEFAE VSKLVTDLTK VHTECCHGDL LECADDRADL AKYICENQDS
ISSKLKECCE KPLLEKSHCI AEVENDEMPA DLPSLAADFV ESKDVCKNYA EAKDVFLGMF
LYEYARRHPD YSVVLLLRLA KTYKTTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ
NCELFEQLGE YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH PEAKRMPCAE
DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK EFNAETFTFH
ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD FAAFVEKCCK ADDKETCFAE
EGKKLVAASR AALGL
[1214]
29TABLE 23 SEQ ID NO: 286::linker1::HSA::linker2::SEQ ID NO: 294
AGDWWVECRVGTGLCYRYDTGTGGGK (SEQ ID NO: 501)
PGGSGGEGGSGGEGGRPGGSEGGTGG DAHKSEVAHR FKDLGEENFK ALVLIAFAQY
LQQCPFEDHV KLVNEVTEFA KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGEMADC
CAKQEPERNE CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN EETFLKKYLY EIARRHPYFY
APELLFFAKR YKAAFTECCQ AADKAACLLP KLDELRDEGK ASSAKQRLKC ASLQKFGERA
FKAWAVARLS QRFPKAEFAE VSKLVTDLTK VHTECCHGDL LECADDRADL AKYICENQDS
ISSKLKECCE KPLLEKSHCI AEVENDEMPA DLPSLAADFV ESKDVCKNYA EAKDVFLGMF
LYEYARRHPD YSVVLLLRLA KTYKTTLEKC CAAADPHECY AKVFDEFKPL VEEPQNLIKQ
NCELFEQLGE YKFQNALLVR YTKKVPQVST PTLVEVSRNL GKVGSKCCKH PEAKRMPCAE
DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK EFNAETFTFH
ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD FAAFVEKCCK ADDKETCFAE
EGKKLVAASR AALGL GGSGGEGGSGGEGGSGPGEGGEGSGGRP
GDSRVCWEDSWGGEVCFRYDPGGGK
Example 40
Synthesis of Dimers D30 and D31
[1215] Preparation of
Ac-VCWEDSWGGEVCFRYDPGGGK{[PnAO6-Glut-K(-Glut-JJ-NH(C-
H.sub.2).sub.4--(S)--CH(Ac-AQDWYYDEILJGRGGRGGRGG-NH)C(.dbd.O)NH.sub.2]--NH-
.sub.2}--NH.sub.2: Dimer D30
[1216] Preparation of
Ac-VCWEDSWGGEVCFRYDPGGGK[PnAO6-Glut-K]--NH.sub.2 (Compound 3; FIG.
87A)
[1217] Ac-VCWEDSWGGEVCFRYDPGGGK[K(iV-Dde)]-NH.sub.2 [(1),
comprising SEQ ID NO:494, is a SEQ ID NO:374 derivative;
specifically Acetyl-(SEQ ID NO:374, 5-21)-GGGK[K(iV-Dde), 48 mg]
was prepared by the procedures of Method 5. The compound was
dissolved in DMF (0.85 mL) and treated with compound B and DIEA (7
.mu.L) was added to maintain the basicity of the reaction mixture.
The progress of the reaction was monitored by HPLC and mass
spectroscopy. At the completion of the reaction (20 h), the
volatiles were removed in vacuo. The residue, which consists of a
compound 2 (SEQ ID NO:374, 5-21) derivative, specifically
Acetyl-(SEQ ID NO:374,
5-21)-GGGK[(PnAO6-Glut-)K(iV-Dde)]-NH.sub.2), was treated with 10%
hydrazine in DMF (5 .mu.L) for 10 min. HPLC analysis and mass
spectroscopy indicated the completion of the reaction. The mixture
then was applied directly to a Waters Associates XTerra MSC18
preparative HPLC column (50 mm.times.19 mm i.d.) and purified by
elution with a linear gradient of acetonitrile into water (both
containing 0.1% TFA) to provide 11 mg of pure Compound 3.
Preparation of the Dimer D30 from Compound 3 and
Ac-AQDWYYDEIL-Adoa-GRGGRGGRGGGK(Adoa-Adoa)-NH.sub.2 (Compound 4
(comprising SEQ ID NO:617 with modified lysine side chains; based
on the petide binding moiety of SEQ ID NO:376)).
[1218] Disuccinimidyl glutarate (12 mg) was dissolved in DMF (500
.mu.L), and DIEA was added (1 .mu.L). Compound 3 in DMF was added
into the DMF solution of disuccinimidyl glutarate/DIEA. The mixture
was stirred for 2.5 h. HPLC and mass spectroscopy indicated the
completion of the reaction. The volatiles were removed in vacuo and
the residue was washed with ether (3.times.) to remove the
unreacted bis-NHS ester. The residue was dried, re-dissolved in
anhydrous DMF and treated with the Compound 4,
Ac-AQDWYYDEIL-Adoa-GRGGRGGRGGGK(Adoa-Adoa)-NH.sub.2, which was
prepared by Method 5 and Method 8, in the presence of 2 equivalents
of DIEA. The reaction was allowed to proceed for 20 h. The mixture
then was applied directly to a Waters Associates MSC18 reverse
phase preparative (50 mm.times.19 mm i.d.) HPLC column and purified
by elution with a linear gradient of acetonitrile into water (both
containing 0.1% TFA) to provide 2 mg of D30 (For purification and
structure of D30, see below and also FIGS. 87B and C,
respectively).
[1219] Synthesis of
Ac-AGPTWCEDDWYYCWLFGTGGGK[Ac-VCWEDSWGGEVCFRYDPGGGK[SGS-
-Glut-SGS-(S)--NH(CH.sub.2).sub.4--CH(Biotin-JJ-NH)--C(.dbd.O)]--NH.sub.2]-
--NH.sub.2: D31
[1220] Preparation of Monomer Compound 2 and Monomer Compound 4
[1221] See FIG. 88B.
[1222] Synthesis of Monomer Peptide 1 and Monomer Peptide 3
[1223] Monomer Peptide 1 comprises SEQ ID NO:378 with the following
modification: it is an Ne22-iV-Dde-SEQ ID NO:378 peptide.
[1224] Monomer peptide 3 comprises SEQ ID NO:370, and is a
derivative of SEQ ID NO:337. It is an Ne25-iV-Dde-SEQ ID NO:370
peptide.
[1225] Synthesis of the monomers 1 and 3 were carried out using the
procedures of Method 5 for the ABI 433A synthesizer.
[1226] Synthesis of Monomer Peptide 2 and Monomer Peptide 4
[1227] See FIGS. 88A and 88B.
[1228] Appendage of Biotin-JJ, Lys, Gly and Ser onto Compounds 1
and 3 was done by SPPS manually using the appropriate Fmoc amino
acids, Biotin-JJ and Fmoc-J (J=8-amino-3,6-dioxaoctanoic acid)
according to the procedures of Methods 6, 7, 8, 9 and 10. Cleavage
of the peptides from the resin, processing of the crude peptides
was carried out as described in Method 1 for the synthesis of
peptides. Cyclization of the cysteine moieties to form the cyclic
disulfide peptides was performed by the procedures of Method 9.
[1229] Purification of the peptides was carried out using a
Shimadzu LC-10A HPLC system and a YMC C-18 ODS preparative HPLC
column employing a linear gradient elution of acetonitrile (0.1%
TFA) into 0.1% aqueous TFA. Pure fractions were combined and
lyophilized.
[1230] The dimer D31 was prepared using monomer compound 4 to
generate, in situ, the activated monomer compound 5, which was then
reacted with monomer compound 2 using the procedures described in
Method 13, entitled: `Preparation of Heterodimer Containing
Constructs`. The crude compound D31 was purified by preparative
reverse phase HPLC using a Waters-YMC C-18 ODS column to provide 10
mg of the dimer D31.
Example 41
In Vitro Competition Experiments on KDR-Transfected Cells
[1231] The following experiment assessed the specificity of the
binding of peptide-conjugated microbubbles to KDR-expressing
cells.
[1232] Protocol:
[1233] 293H cells were transfected with KDR cDNA. The transfected
cells were incubated with a suspension of peptide-conjugated
microbubbles in presence or absence of the corresponding free
peptide (at 100, 30, 10, 3, 1, 0.3, 0.1 .mu.M). Microbubbles were
conjugated to a SATA-modified peptide comprising SEQ ID NO:480, a
SATA-modified peptide comprising SEQ ID NO:356, or a SATA-modified
peptide comprising SEQ ID NO:356 and a JJ linker. Competition was
also performed using the corresponding non-binding or control free
peptide as competing compound. At the end of the incubation, the
transfected cells were rinsed three times in PBS and examined under
a microscope. Binding of the conjugated bubbles was quantified and
expressed as percent of surface covered by the targeted
microbubbles.
[1234] Results:
[1235] All the KDR-conjugated microbubbles were competed off by the
corresponding free KDR-specific peptide whereas the presence of
control peptide had no effect. Example of curves obtained by
plotting the fraction of residual binding as a function of the
competitor concentration are shown in FIG. 89.
Example 42
In Vitro Competition Experiments on KDR-Transfected Cells
[1236] The following experiment assessed the specificity of the
binding of peptide-conjugated microbubbles to KDR-expressing
cells.
[1237] Protocol:
[1238] 293H cells were transfected with KDR cDNA. The transfected
cells were incubated with a suspension of peptide-conjugated
microbubbles in presence or absence of the corresponding free
peptide (between 100 .mu.M to 3 nM). Competition was also performed
using a non-binding peptide as competing compound. At the end of
the incubation, the transfected cells were rinsed three times in
PBS and examined under a microscope. Binding of the conjugated
bubbles was quantified and expressed as percent of surface covered
by the targeted microbubbles.
[1239] Results:
[1240] Microbubbles conjugated to KDR-specific dimer (D23) or
monomer (SEQ ID NO:338) molecules were competed off by the
corresponding free KDR-specific peptide whereas the presence of
control peptide had no effect. Example of curves obtained by
plotting the fraction of residual binding as a function of the
competitor concentration are shown in FIG. 90.
[1241] In Vitro Competition Experiments on KDR-Transfected
Cells
[1242] The following experiment compares the binding efficiency of
monomers and dimers conjugated to microbubbles on KDR-transfected
cells.
[1243] Protocol:
[1244] 293H cells were transfected with KDR cDNA. The transfected
cells were incubated with a suspension of microbubbles conjugated
to different peptides (monomers or dimers) in presence or absence
of increasing concentrations of free dimer (at 1000, 300, 100, 30,
10, 3, 1 nM). At the end of the incubation, the transfected cells
were rinsed three times in PBS and examined under a microscope.
Binding of the conjugated bubbles was quantified and expressed as
percent of surface covered by the targeted microbubbles.
[1245] Results:
[1246] Microbubbles conjugated to D23 were more resistant to
competition and less easily displaced by the corresponding free
dimeric peptide than KDR-specific monomer-conjugated microbubbles
conjugated to SEQ ID NO:338 or SEQ ID NO:376. Representative curves
obtained by plotting the fraction of residual binding as a function
of the competitor concentration are shown in FIG. 91.
Example 43
In Vitro Binding of Heteromultimers and Dimers Compared to
Multimeric Monomers
[1247] The following experiment aims at comparing the binding
efficiency of mixed monomers, dimers and monomers conjugated to
microbubbles in the KDR-transfected cells assay.
[1248] Protocol:
[1249] Microbubbles were conjugated to either a dimer (D23) or two
different peptides monomers (SEQ ID NO:294 or SEQ ID NO:480). A
fourth conjugation reaction was performed using equal quantities of
each monomer (and the same total peptide load). 293H cells were
transfected with KDR cDNA. The transfected cells were incubated
with the same number of targeted microbubble and in presence of 50%
human serum. At the end of the incubation, the transfected cells
were rinsed three times in PBS and examined under a microscope.
Binding of the conjugated bubbles was quantified and expressed as
percent of surface covered by the targeted microbubbles.
[1250] Results:
[1251] As shown in FIG. 92, microbubbles conjugated with SEQ ID
NO:294 bound poorly compared with microbubbles conjugated with SEQ
ID NO:480 or dimer D23. Surprisingly, microbubbles conjugated to
D23 bound equivalently to those conjugated to SEQ ID NO:480
although D23 has half the load. Moreover, the "mixed monomer"
conjugated microbubbles, which also have half the SEQ ID NO:480
load, bound as well as microbubbles conjugated with SEQ ID NO:480
or D23. These results show the increased binding capacity of
heteromultimers.
Example 44
Blocking VEGF-Enhanced Peritoneal Vascular Permeability with a
Heterodimeric Peptide
[1252] In this example, the ability of heterodimer D10 to inhibit
the enhanced vascular permeability caused by VEGF injected into the
peritoneum of nude mice is demonstrated.
[1253] Protocol
[1254] Male balb/c nu/nu mice were injected intraperitoneally with
2 mL vehicle (1% bovine serum albumin in 95% saline/5% DMSO),
vehicle+1.2 nM VEGF.sub.165, or vehicle+1.2 nM VEGF.sub.165+20
.mu.M D10. Immediately after, the mice were injected with Evan's
Blue Dye (0.5% in saline, 4 mL/kg) i.v. via their tail veins. After
60 min, mice were sacrificed by CO.sub.2 asphyxiation and the
peritoneal fluid was retrieved. After centrifuging the samples
briefly, the absorbance at 590 nm was measured for each.
[1255] Results
[1256] As shown in FIG. 93, VEGF, when added to the fluid injected
intraperitoneally, significantly increased the dye leakage into the
peritoneum, and this increase was substantially blocked by
including D10 with the VEGF.
Example 45
Mouse Xenograft Tumor Model of Human Colon Cancer
[1257] This example assesses the effects of dimer D6 that has been
processed into biodegradable sustained release pellets. Since D6
has a half-life on the order of 1 hour, a way of improving the
residence time in sera was sought. The compound is formulated into
a sustained release format so that greater therapeutic benefit to
animal models is observed.
[1258] The effect of D6 on the tumor model is determined, for
example, by measuring tumor size with and without treatment.
Additionally, the effect of D6, engineered to have a longer
residence time in sera, is compared to the effect of unmodified D6
(see Example 39).
[1259] Briefly, 140 nude mice are injected subcutaneously with the
cell line, SW-480. Tumors are measured, and when tumors reach
100-200 mg, 100 animals are selected and randomized into 10 study
groups of 10 animals each. The overall study is summarized in Table
24 below. The dosing schedule follows the chart shown in Table 25.
Tumor measurements are taken on each animal twice a week during the
normal workweek. Measurements are made by hand-held vernier
caliper. Body weights and tumor measurements are recorded twice a
week. This study is based on a typical four week study from
beginning of dosing and includes removal of 30 tumors.
30TABLE 24 D6 Mouse Tumor Study Cell line SW-480, human colon
carcinoma 5 .times. 10.sup.6, subcutaneous Test Animal nude mouse
(CRL: NU/NU = nuBR) female n = 10/test group Study Initiation >6
weeks age Tumor .about.100 -/+ 50 mg Control 1. untreated 2.
Vehicle 3. Placebo pellet 4. Cisplatin Test Article D6 0.5 mg/kg/d
.times. 21 d 2.0 mg/kg/d .times. 21 d 2.0 mg/kg/d .times. 21 d
pellet Test Article Form 1. solution for injection (PBS, IP) 2.
sustained release pellet (nominal 21 day, subcutaneous) Primary
endpoints 1. tumor growth 2. histopathology (necropsy)
Supplementary measures 1. angiogenesis (CD-31+) (representative
samples) 2. cell proliferation (PCNA) 3. circulating D6 4.
[1260]
31TABLE 25 Treatment Vehicle D6 Dose Cisplatin Dose Group n
Administration Administration Administration 1 10 -- -- -- 2 10 PBS
-- -- 1 IP inj/d, 21 d 3 10 -- 0.5 mg/kg/day -- 1 IP inj/d, 21 d 4
10 -- 2.0 mg/kg/day -- 1 IP inj/d, 21 d 5 10 Vehicle pellet -- --
(1), sc 6 10 -- 2.0 mg/kg/day -- pellet (1), sc 7 10 -- -- [6
mg/kg] 1 IV inj/2 days, to 5 Ttl 8 10 -- 2.0 mg/kg/day [6 mg/kg]
pellet (1), sc 1 IV inj/2 days to 5 Ttl 9 10 -- 2.0 mg/kg/day [3
mg/kg] pellet (1), sc 1 IV/2 days, to 5 Ttl 10 10 -- 2.0 mg/kg/day
[1 mg/kg] pellet (1), sc 1 IV/2 days, to 5 Ttl
Example 46
[1261] The following example describes the preparation of an
ultrasound contrast agent conjugated to a KDR-binding heterodimer
of the invention and the ability of the heterdimer conjugated
contrast agent to localize to KDR-expressing cells in vitro and
angiogenic tissue in vivo.
[1262] Preparation of Derivatized Microbubbles for Peptide
Conjugation.
[1263] 200 mg of DSPC (distearoylphosphatidylcholine), 275 mg of
DPPG.Na (distearoylphosphatidylglycerol sodium salt) and 25 mg of
N-MPB-PE were solubilized at 60.degree. C. in 50 mL of
Hexan/isopropanol (42/8). The solvent was evaporated under vacuum,
and then PEG-4000 (35.046 g) was added to the lipids and the
mixture was solubilized in 106.92 g of t-butyl alcohol at
60.degree. C., in a water bath. The solution was filled in vials
with 1.5 mL of solution. The samples were rapidly frozen at
-45.degree. C. and lyophilized. The air in the headspace was
replaced with a mixture of C.sub.4F.sub.10/Air (50/50) and vials
capped and crimped. The lyophilized samples were reconstituted with
10 mL saline solution (0.9%-NaCl) per vial, yielding a suspension
of phospholipids stabilized microbubbles.
[1264] Peptide Conjugation
[1265] D23 was conjugated with a preparation of microbubbles as
above described, according to the following methodology. The
thioacetylated peptide (200 .mu.g) was dissolved in 20 .mu.L DMSO
and then diluted in 1 ml of Phosphate Buffer Saline (PBS). This
solution was mixed to the N-MPB-functionalized microbubbles
dispersed in 18 mL of PBS-EDTA 10 mM, pH 7.5, and 2 mL of
deacetylation solution (50 mM sodium phosphate, 25 mM EDTA, 0.5 M
hydroxylamine.HCl, pH 7.5) was added. The headspace was filled with
C.sub.4F.sub.10/Air (50/50) and the mixture was incubated for 2.5
hours at room temperature under gentle agitation (rotating wheel),
in the dark. Conjugated bubbles were washed by centrifugation.
Similarly, the monomer peptides making up D23 were separately
conjugated to two different microbubble preparations according to
the methodology described above.
[1266] In Vitro Assay on Transfected Cells
[1267] The ability of phospholipid stabilized microbubbles
conjugated to peptides and heteromultimeric peptide constructs of
the invention to bind to KDR-expressing cells was assessed using
293H cells transfected to expresss KDR.
[1268] Transfection of 293H Cells on Thermanox.RTM. Coverslips
[1269] 293H cells were transfected with KDR DNA as set forth in
Example 5. The transfected cells were incubated with a suspension
of peptide-conjugated microbubbles prepared as described above. For
the incubation with the transfected cells a small plastic cap is
filled with a suspension containing 1 to 3.times.10.sup.8
peptide-conjugated microbubbles and the cap covered with an
inverted Thermanox.RTM. coverslip is placed so that the transfected
cells are in contact with the conjugated microbubbles. After about
20 min at room temperature, the coverslip is lifted with tweezers,
rinsed three times in PBS and examined under a microscope to assess
binding of the conjugated microbubbles.
[1270] Determination of the Percent of Surface Covered by
Microvesicles
[1271] Images were acquired with a digital camera DC300F (Leica)
and the percent of surface covered by bound microbubbles in the
imaged area was determined using the software QWin (Leica
Microsystem AG, Basel, Switzerland). Table 26 shows the results of
the binding affinity (expressed as coverage % of the imaged
surface) of targeted microvesicles of the invention to KDR
transfected cells, as compared to the binding of the same targeted
microvesicles to Mock-transfected cells.
32 TABLE 26 Conjugated microbubbles % of prepared as described
above covered surface Peptide code Batch Id KDR Mock SEQ ID NO:294
BG1979T02 3.5% 0.9% Derivative SEQ ID NO:480 BG1980T02 16.8% 1.0%
Derivative D23 (dimer) BG2002T02 22.9% 3.3% SEQ ID NO. BG1958T02
12.9% 0.8% 294/SEQ ID NO:480 Deriv.
[1272] Where the SEQ ID NO:294-derived sequence and the SEQ ID
NO:480-derived sequence are separately attached to phospholipid
stabilized microbubbles as monomers the resulting preparations
achieve binding of the bubbles to KDR transfected cells in vitro to
a different extent (3.5% and 16.8%). When a preparation of
phospholipid stabilized microbubbles resulting from the addition of
equal quantities of each of these peptide monomers (but the same
total peptide load) is tested in the same system, 12.9% binding is
achieved. Binding is a little more than the average of the two but
as it is achieved with two sequences that bind to different sites
on the target will be more resistant to competition at one or other
of the sites on the target. However, for D23, the dimer, binding is
increased to 22.9% (with the same peptide load). These results
indicate that hetromultimers of the invention permit increased
binding and increased resistance to competition.
[1273] In Vivo Animal Models
[1274] A known model of angiogenic tissue (the rat Mat B III model)
was used to examine the ability of phospholipids-stabilized
microbubbles conjugated to a heteromultimer of the invention to
localize to and provide images of angiogenic tissue.
[1275] Female Fisher 344 rat (Charles River Laboratories, France)
weighing 120 to 160 g were used for the MATBIII tumor implantation.
Male OFA rats (Charles River Laboratories, France) weighing 100 to
150 g were used for Matrigel injection.
[1276] Anesthesia
[1277] Rats were anesthetized with an intramuscular injection (1
mL/kg) of Ketaminol.RTM./xylazine (Veterinaria AG/Sigma) (50/10
mg/mL) mixture before implantation of Matrigel or MatBIII cells.
For imaging experiments, animals were anesthetized with the same
mixture, plus subcutaneous injection of 50% urethane (1 g/kg).
[1278] Rat MATBIII Tumor Model
[1279] A rat mammary adenocarcinoma, designated 13762 Mat B III,
was obtained from ATCC(CRL-1666) and grown in McCoy's 5a medium+10%
FCS. 1% glutamine and 1% pen/strep (In Vitrogen cat# 15290-018).
Cells in suspension were collected and washed in growth medium,
counted, centrifuged and resuspended in PBS or growth medium at
1.times.10.sup.7 cells per mL. For tumor induction:
1.times.10.sup.6 cells in 0.1 mL were injected into the mammary fat
pad of anesthetized female Fisher 344 rat. Tumors usually grow to a
diameter of 5-8 mm within 8 days.
[1280] In Vivo Ultrasound Imaging
[1281] Tumor imaging was performed using an ultrasound imaging
system ATL HDI 5000 apparatus equipped with a L7-4 linear probe.
B-mode pulse inversion at low acoustic power (MI=0.05) was used to
follow accumulation of peptide conjugated-microbubbles on the KDR
receptor expressed on the endothelium of neovessels. For the
control experiments, an intravenous bolus of unconjugated
microbubbles or microbubbles conjugated to non-specific peptide was
injected. The linear probe was fixed on the skin directly on line
with the implanted tumors and accumulation of targeted bubbles was
followed during thirty minutes.
[1282] A perfusion of SonoVue.RTM. was administrated before
injecting the test bubble suspension. This allows for the
evaluation of the vascularization status and the video intensity
obtained after SonoVue.RTM. injection is taken as an internal
reference.
[1283] A baseline frame was recorded and then insonation was
stopped during the injection of the microbubbles. At various time
points after injection (1, 2, 5, 10, 15, 20, 25, 30 minutes)
insonation was reactivated and 2 frames of one second were recorded
on a videotape.
[1284] Video frames from tumor imaging experiments were captured
and analysed with the video-capture and Image-Pro Plus 2.0 software
respectively. The same rectangular Area of Interest (AOI) including
the whole sectional area of the tumor was selected on images at
different time points (1, 2, 5, 10, 15, 20, 25, 30 minutes). At
each time point, the sum of the video pixel inside the AOI was
calculated after the subtraction of the AOI baseline. Results are
expressed as the percentage of the signal obtained with
SonoVue.RTM., which is taken as 100%. Similarly, a second AOI
situated outside the tumor, and representing the freely circulating
contrast agent, is also analyzed.
[1285] FIG. 94 shows uptake and retention of bubble contrast in the
tumor up to 30 minutes post injection for suspensions of
phospholipid stabilized microbubbles conjugated to a
heteromultimeric construct of the invention prepared as described
above (D23). In contrast, the same bubbles showed only transient
(no more than 10 minutes) visualization/bubble contrast in the AOI
situated outside the tumor site.
[1286] While this invention has been particularly shown and
described with references to preferred embodiments thereof, it will
be understood by those skilled in the art that various changes in
form and details may be made therein without departing from the
scope of the invention encompassed by the appended claims. The
publications, patents and other references cited herein are
incorporated by reference herein in their entirety.
Sequence CWU 1
1
617 1 19 PRT Artificial Sequence KDR or VEGF/KDR-Binding Consensus
Sequence 5 1 Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Ser Gly Pro Xaa Xaa
Xaa Xaa Cys 1 5 10 15 Xaa Xaa Xaa 2 14 PRT Artificial Sequence KDR
or VEGF/KDR-Binding Consensus Sequence 7 2 Trp Tyr Trp Cys Xaa Xaa
Xaa Gly Xaa Xaa Cys Xaa Xaa Xaa 1 5 10 3 17 PRT Artificial Sequence
KDR or VEGF/KDR-Binding Consensus Sequence 9 3 Xaa Xaa Xaa Cys Xaa
Xaa Xaa Xaa Trp Gly Gly Xaa Xaa Cys Xaa Xaa 1 5 10 15 Xaa 4 18 PRT
Artificial Sequence KDR or VEGF/KDR-Binding Consensus Sequence 10 4
Tyr Pro Xaa Cys Xaa Glu Xaa Ser Xaa Ser Xaa Xaa Xaa Phe Cys Xaa 1 5
10 15 Xaa Xaa 5 18 PRT Artificial Sequence KDR or VEGF/KDR-Binding
Consensus Sequence 11 5 Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Gly
Xaa Trp Xaa Cys Xaa 1 5 10 15 Xaa Xaa 6 18 PRT Artificial Sequence
KDR or VEGF/KDR-Binding Consensus Sequence 12 6 Asn Trp Xaa Cys Xaa
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa 1 5 10 15 Xaa Xaa 7 10
PRT Artificial Sequence KDR or VEGF/KDR-Binding Consensus Sequence
14 7 Xaa Xaa Xaa Tyr Trp Glu Xaa Xaa Xaa Leu 1 5 10 8 4 PRT
Artificial Sequence KDR or VEGF/KDR Binding Polypeptide 8 Asp Trp
Tyr Tyr 1 9 6 PRT Artificial Sequence KDR or VEGF/KDR Binding
Polypeptide 9 Glu Glu Asp Trp Tyr Tyr 1 5 10 16 PRT Artificial
Sequence KDR or VEGF/KDR Binding Polypeptide 10 Asn Asn Ser Cys Trp
Leu Ser Thr Thr Leu Gly Ser Cys Phe Phe Asp 1 5 10 15 11 16 PRT
Artificial Sequence KDR or VEGF/KDR Binding Polypeptide 11 Asp His
His Cys Tyr Leu His Asn Gly Gln Trp Ile Cys Tyr Pro Phe 1 5 10 15
12 16 PRT Artificial Sequence KDR or VEGF/KDR Binding Polypeptide
12 Asn Ser His Cys Tyr Ile Trp Asp Gly Met Trp Leu Cys Phe Pro Asp
1 5 10 15 13 13 PRT Artificial Sequence KDR-Binding Loop Consensus
Sequence 19 13 Cys Xaa Xaa Xaa Xaa Ser Gly Pro Xaa Xaa Xaa Xaa Cys
1 5 10 14 11 PRT Artificial Sequence KDR-Binding Loop Consensus
Sequence 23 14 Cys Xaa Xaa Xaa Xaa Trp Gly Gly Xaa Xaa Cys 1 5 10
15 12 PRT Artificial Sequence KDR-Binding Loop Consensus Sequence
24 15 Cys Xaa Glu Xaa Ser Xaa Ser Xaa Xaa Xaa Phe Cys 1 5 10 16 12
PRT Artificial Sequence KDR-Binding Loop Consensus Sequence 25 16
Cys Xaa Xaa Xaa Xaa Xaa Xaa Gly Xaa Trp Xaa Cys 1 5 10 17 13 PRT
Artificial Sequence KDR-Binding Loop Consensus Sequence 29 17 Cys
Xaa Xaa Xaa Xaa Ser Gly Pro Xaa Xaa Xaa Xaa Cys 1 5 10 18 4 PRT
Artificial Sequence C-Terminal Linker 18 Gly Gly Gly Lys 1 19 19
PRT Artificial Sequence MTN13/I Template Sequence 19 Xaa Xaa Xaa
Cys Xaa Xaa Xaa Xaa Ser Gly Pro Xaa Xaa Xaa Xaa Cys 1 5 10 15 Xaa
Xaa Xaa 20 14 PRT Artificial Sequence Library Isolate 20 Asp Ser
Trp Cys Ser Thr Glu Tyr Thr Tyr Cys Glu Met Ile 1 5 10 21 14 PRT
Artificial Sequence Library Isolate 21 Pro Lys Trp Cys Glu Glu Asp
Trp Tyr Tyr Cys Met Ile Thr 1 5 10 22 14 PRT Artificial Sequence
Library Isolate 22 Ser Asp Trp Cys Arg Val Asp Trp Tyr Tyr Cys Trp
Leu Met 1 5 10 23 14 PRT Artificial Sequence Library Isolate 23 Ala
Asn Trp Cys Glu Glu Asp Trp Tyr Tyr Cys Phe Ile Thr 1 5 10 24 14
PRT Artificial Sequence Library Isolate 24 Ala Asn Trp Cys Glu Glu
Asp Trp Tyr Tyr Cys Trp Ile Thr 1 5 10 25 14 PRT Artificial
Sequence Library Isolate 25 Pro Asp Trp Cys Glu Glu Asp Trp Tyr Tyr
Cys Trp Ile Thr 1 5 10 26 14 PRT Artificial Sequence Library
Isolate 26 Ser Asn Trp Cys Glu Glu Asp Trp Tyr Tyr Cys Tyr Ile Thr
1 5 10 27 14 PRT Artificial Sequence Library Isolate 27 Pro Asp Trp
Cys Ala Ala Asp Trp Tyr Tyr Cys Tyr Ile Thr 1 5 10 28 14 PRT
Artificial Sequence Library Isolate 28 Pro Glu Trp Cys Glu Val Asp
Trp Tyr Tyr Cys Trp Leu Leu 1 5 10 29 14 PRT Artificial Sequence
Library Isolate 29 Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp
Leu Phe 1 5 10 30 14 PRT Artificial Sequence Library Isolate 30 Ser
Lys Trp Cys Glu Gln Asp Trp Tyr Tyr Cys Trp Leu Leu 1 5 10 31 14
PRT Artificial Sequence Library Isolate 31 Arg Asn Trp Cys Glu Glu
Asp Trp Tyr Tyr Cys Phe Ile Thr 1 5 10 32 14 PRT Artificial
Sequence Library Isolate 32 Val Asn Trp Cys Glu Glu Asp Trp Tyr Tyr
Cys Trp Ile Thr 1 5 10 33 14 PRT Artificial Sequence Library
Isolate 33 Ala Asn Trp Cys Glu Glu Asp Trp Tyr Tyr Cys Tyr Ile Thr
1 5 10 34 14 PRT Artificial Sequence Library Isolate 34 Val Trp Glu
Cys Ala Lys Thr Phe Pro Phe Cys His Trp Phe 1 5 10 35 14 PRT
Artificial Sequence Library Isolate 35 Val Thr Val Cys Tyr Glu Gly
Thr Arg Ile Cys Glu Trp His 1 5 10 36 14 PRT Artificial Sequence
Library Isolate 36 Trp Val Glu Cys Arg Tyr Ser Thr Gly Leu Cys Ile
Asn Tyr 1 5 10 37 14 PRT Artificial Sequence Library Isolate 37 Trp
Tyr Trp Cys Asp Tyr Tyr Gly Ile Gly Cys Lys Trp Thr 1 5 10 38 14
PRT Artificial Sequence Library Isolate 38 Trp Val Glu Cys Trp Trp
Lys Ser Gly Gln Cys Tyr Glu Phe 1 5 10 39 14 PRT Artificial
Sequence Library Isolate 39 Trp Ile Gln Cys Asp Met Glu Thr Gly Leu
Cys Thr His Gly 1 5 10 40 14 PRT Artificial Sequence Library
Isolate 40 Trp Val Glu Cys Phe Met Asp Thr Gly Ala Cys Tyr Thr Phe
1 5 10 41 14 PRT Artificial Sequence Library Isolate 41 Trp Leu Glu
Cys Tyr Ala Glu Phe Gly His Cys Tyr Asn Phe 1 5 10 42 14 PRT
Artificial Sequence Library Isolate 42 Trp Ile Glu Cys Asp Met Leu
Thr Gly Met Cys Lys His Gly 1 5 10 43 14 PRT Artificial Sequence
Library Isolate 43 Ser Val Glu Cys Phe Met Asp Thr Gly Ala Cys Tyr
Thr Phe 1 5 10 44 14 PRT Artificial Sequence Library Isolate 44 Trp
Ile Gln Cys Asn Ser Ile Thr Gly His Cys Thr Ser Gly 1 5 10 45 14
PRT Artificial Sequence Library Isolate 45 Trp Ile Glu Cys Tyr His
Pro Asp Gly Ile Cys Tyr His Phe 1 5 10 46 18 PRT Artificial
Sequence Library Isolate 46 Gln Ala Trp Val Glu Cys Tyr Ala Glu Thr
Gly Tyr Cys Trp Pro Arg 1 5 10 15 Ser Trp 47 18 PRT Artificial
Sequence Library Isolate 47 Val Gly Trp Val Glu Cys Tyr Gln Ser Thr
Gly Phe Cys Tyr His Ser 1 5 10 15 Arg Asp 48 18 PRT Artificial
Sequence Library Isolate 48 Phe Thr Trp Val Glu Cys His Gln Ala Thr
Gly Arg Cys Val Glu Trp 1 5 10 15 Thr Thr 49 18 PRT Artificial
Sequence Library Isolate 49 Asp Trp Trp Val Glu Cys Arg Val Gly Thr
Gly Leu Cys Tyr Arg Tyr 1 5 10 15 Asp Thr 50 18 PRT Artificial
Sequence Library Isolate 50 Asp Ser Trp Val Glu Cys Asp Ala Gln Thr
Gly Phe Cys Tyr Ser Phe 1 5 10 15 Leu Tyr 51 18 PRT Artificial
Sequence Library Isolate 51 Gly Gly Trp Val Glu Cys Tyr Trp Ala Thr
Gly Arg Cys Ile Glu Phe 1 5 10 15 Ala Gly 52 18 PRT Artificial
Sequence Library Isolate 52 Glu Arg Trp Val Glu Cys Arg Ala Glu Thr
Gly Phe Cys Tyr Thr Trp 1 5 10 15 Val Ser 53 18 PRT Artificial
Sequence Library Isolate 53 Gly Gly Trp Val Glu Cys Arg Ala Glu Thr
Gly His Cys Gln Glu Tyr 1 5 10 15 Arg Leu 54 18 PRT Artificial
Sequence Library Isolate 54 Val Ala Trp Val Glu Cys Tyr Gln Thr Thr
Gly Lys Cys Tyr Thr Phe 1 5 10 15 Arg Gly 55 18 PRT Artificial
Sequence Library Isolate 55 Glu Gly Trp Val Glu Cys Phe Ala Asn Thr
Gly Ala Cys Phe Thr Tyr 1 5 10 15 Pro Arg 56 14 PRT Artificial
Sequence Library Isolate 56 Gly Val Glu Cys Tyr Lys His Ser Gly Met
Cys Arg Ser Trp 1 5 10 57 14 PRT Artificial Sequence Library
Isolate 57 Gly Val Trp Cys Asp Met Val Thr Gly Trp Cys Tyr His Gly
1 5 10 58 14 PRT Artificial Sequence Library Isolate 58 Trp Ile Glu
Cys His Tyr Lys Thr Gly His Cys Ile His Ser 1 5 10 59 14 PRT
Artificial Sequence Library Isolate 59 Asp Phe Asn Cys Lys Met Ile
Asp Gly Phe Cys Leu Leu Lys 1 5 10 60 14 PRT Artificial Sequence
Library Isolate 60 Trp Ile Gln Cys Asp Arg Lys Ala Gly Arg Cys Ser
Arg Gly 1 5 10 61 14 PRT Artificial Sequence Library Isolate 61 Thr
Ile Thr Cys Trp Met Asp Thr Gly His Cys Met His Glu 1 5 10 62 14
PRT Artificial Sequence Library Isolate 62 Gly Ile Asn Cys Tyr Pro
Ala Thr Gly Lys Cys Gln Met Gly 1 5 10 63 14 PRT Artificial
Sequence Library Isolate 63 Trp Thr Glu Cys His Tyr Ala Thr Gly Lys
Cys His Ser Phe 1 5 10 64 14 PRT Artificial Sequence Library
Isolate 64 Leu Asn Ile Cys Lys Glu Asp Trp Tyr Tyr Cys Phe Leu Leu
1 5 10 65 14 PRT Artificial Sequence Library Isolate 65 Gly Ile Thr
Cys Tyr Ser Ala Thr Gly Lys Cys Gln Met Trp 1 5 10 66 14 PRT
Artificial Sequence Library Isolate 66 Trp Val Gln Cys Ala Ser Asp
Thr Gly Lys Cys Ile Met Gly 1 5 10 67 14 PRT Artificial Sequence
Library Isolate 67 Thr Gly Asn Cys Gln Glu Asp Trp Tyr Tyr Cys Trp
Tyr Phe 1 5 10 68 14 PRT Artificial Sequence Library Isolate 68 Lys
Glu Leu Cys Glu Asp Asp Trp Tyr Tyr Cys Tyr Leu Met 1 5 10 69 14
PRT Artificial Sequence Library Isolate 69 His Trp Glu Cys Tyr Ser
Asp Thr Gly Lys Cys Trp Phe Phe 1 5 10 70 14 PRT Artificial
Sequence Library Isolate 70 Gly Ile Thr Cys Tyr Ser Asp Thr Gly Lys
Cys Phe Ser Phe 1 5 10 71 14 PRT Artificial Sequence Library
Isolate 71 Ala Val Thr Cys Trp Ala Leu Thr Gly His Cys Val Glu Glu
1 5 10 72 14 PRT Artificial Sequence Library Isolate 72 Tyr Val Asp
Cys Tyr Tyr Asp Thr Gly Arg Cys Tyr His Gln 1 5 10 73 13 PRT
Artificial Sequence Library Isolate 73 Trp Tyr Trp Cys Gln Tyr His
Gly Val Cys Pro Gln Ser 1 5 10 74 14 PRT Artificial Sequence
Library Isolate 74 Leu Val Met Cys Ile Ser Pro Glu Gly Tyr Cys Tyr
Glu Ile 1 5 10 75 14 PRT Artificial Sequence Library Isolate 75 Leu
Ile Glu Cys Tyr Ala His Thr Gly Leu Cys Phe Asp Phe 1 5 10 76 14
PRT Artificial Sequence Library Isolate 76 His Trp Trp Cys Ala Phe
Gln Pro Gln Glu Cys Glu Tyr Trp 1 5 10 77 14 PRT Artificial
Sequence Library Isolate 77 His Tyr Glu Cys Trp Tyr Pro Glu Gly Lys
Cys Tyr Phe Tyr 1 5 10 78 14 PRT Artificial Sequence Library
Isolate 78 Trp Tyr Trp Cys His His Ile Gly Met Tyr Cys Asp Gly Phe
1 5 10 79 14 PRT Artificial Sequence Library Isolate 79 Trp Glu Trp
Cys Pro Ile Asp Ala Trp Glu Cys Ile Met Leu 1 5 10 80 14 PRT
Artificial Sequence Library Isolate 80 Trp Leu Glu Cys Tyr Thr Glu
Phe Gly His Cys Tyr Asn Phe 1 5 10 81 14 PRT Artificial Sequence
Library Isolate 81 Trp Val Glu Cys Trp Trp Lys Tyr Gly Gln Cys Tyr
Glu Phe 1 5 10 82 14 PRT Artificial Sequence Library Isolate 82 Pro
Asn Thr Cys Glu Thr Phe Asp Leu Tyr Cys Trp Trp Ile 1 5 10 83 14
PRT Artificial Sequence Library Isolate 83 Trp Ile Ile Cys Asp Gly
Asn Leu Gly Trp Cys Trp Glu Gly 1 5 10 84 14 PRT Artificial
Sequence Library Isolate 84 Gly Glu Gln Cys Ser Asn Leu Ala Val Ala
Cys Cys Ser Thr 1 5 10 85 14 PRT Artificial Sequence Library
Isolate 85 Trp Val Glu Cys Tyr Asp Pro Trp Gly Trp Cys Trp Glu Trp
1 5 10 86 14 PRT Artificial Sequence Library Isolate 86 Trp Tyr Trp
Cys Met His Tyr Gly Leu Gly Cys Pro Tyr Arg 1 5 10 87 18 PRT
Artificial Sequence Library Isolate 87 Tyr Pro Trp Cys His Glu Leu
Ser Asp Ser Val Thr Arg Phe Cys Val 1 5 10 15 Pro Trp 88 17 PRT
Artificial Sequence Library Isolate 88 Ser Arg Val Cys Trp Glu Asp
Ser Trp Gly Gly Glu Val Cys Phe Arg 1 5 10 15 Tyr 89 17 PRT
Artificial Sequence Library Isolate 89 Ser Arg Val Cys Trp Glu Tyr
Ser Trp Gly Gly Glu Val Cys Tyr Arg 1 5 10 15 Val 90 17 PRT
Artificial Sequence Library Isolate 90 Phe Gly Glu Cys Trp Glu Tyr
Phe Trp Gly Gly Glu Phe Cys Leu Arg 1 5 10 15 Val 91 17 PRT
Artificial Sequence Library Isolate 91 Trp Arg Ile Cys Trp Glu Ser
Ser Trp Gly Gly Glu Val Cys Ile Gly 1 5 10 15 His 92 17 PRT
Artificial Sequence Library Isolate 92 Tyr Gly Val Cys Trp Glu Tyr
Ser Trp Gly Gly Glu Val Cys Leu Arg 1 5 10 15 Phe 93 17 PRT
Artificial Sequence Library Isolate 93 Ser Ser Val Cys Phe Glu Tyr
Ser Trp Gly Gly Glu Val Cys Phe Arg 1 5 10 15 Tyr 94 17 PRT
Artificial Sequence Library Isolate 94 Ser Arg Val Cys Trp Glu Tyr
Ser Trp Gly Gly Gln Ile Cys Leu Gly 1 5 10 15 Tyr 95 17 PRT
Artificial Sequence Library Isolate 95 Phe Ser Val Cys Trp Glu Tyr
Ser Trp Gly Gly Glu Val Cys Leu Arg 1 5 10 15 Gln 96 18 PRT
Artificial Sequence Library Isolate 96 Asp His Met Cys Arg Ser Pro
Asp Tyr Gln Asp His Val Phe Cys Met 1 5 10 15 Tyr Trp 97 18 PRT
Artificial Sequence Library Isolate 97 Pro Pro Leu Cys Tyr Phe Val
Gly Thr Gln Glu Trp His His Cys Asn 1 5 10 15 Pro Phe 98 18 PRT
Artificial Sequence Library Isolate 98 Trp Trp Glu Cys Lys Arg Glu
Glu Tyr Arg Asn Thr Thr Trp Cys Ala 1 5 10 15 Trp Ala 99 17 PRT
Artificial Sequence Library Isolate 99 Asp Ser Tyr Cys Met Met Asn
Glu Lys Gly Trp Trp Asn Cys Tyr Leu 1 5 10 15 Tyr 100 18 PRT
Artificial Sequence Library Isolate 100 Pro Ala Gln Cys Trp Glu Ser
Asn Tyr Gln Gly Ile Phe Phe Cys Asp 1 5 10 15 Asn Pro 101 18 PRT
Artificial Sequence Library Isolate 101 Gly Ser Trp Cys Glu Met Arg
Gln Asp Val Gly Lys Trp Asn Cys Phe 1 5 10 15 Ser Asp 102 17 PRT
Artificial Sequence Library Isolate 102 Gly Trp Ala Cys Ala Lys Trp
Pro Trp Gly Gly Glu Ile Cys Gln Pro 1 5 10 15 Ser 103 18 PRT
Artificial Sequence Library Isolate 103 Ala Ser Thr Cys Val Phe His
Asp His Pro Tyr Phe Pro Met Cys Gln 1 5 10 15 Asp Asn 104 18 PRT
Artificial Sequence Library Isolate 104 Pro Asp Thr Cys Thr Met Trp
Gly Asp Ser Gly Arg Trp Tyr Cys Phe 1 5 10 15 Pro Ala 105 18 PRT
Artificial Sequence Library Isolate 105 Asn Trp Lys Cys Glu Tyr Thr
Gln Gly Tyr Asp Tyr Thr Glu Cys Val 1 5 10 15 Tyr Leu 106 18 PRT
Artificial Sequence Library Isolate 106 Asn Trp Glu Cys Gly Trp Ser
Asn Met Phe Gln Lys Glu Phe Cys Ala 1 5 10 15 Arg Pro 107 18 PRT
Artificial Sequence Library Isolate 107 Ser Gly Tyr Cys Glu Phe Glu
Ser Asp Thr Gly Arg Trp Phe Cys Ser 1 5 10 15 Ser Trp 108 17 PRT
Artificial Sequence Library Isolate 108 Gly Gly Trp Cys Gln Leu Val
Asp His Ser Trp Trp Trp Cys Gly Asp 1 5 10 15 Ser 109 18 PRT
Artificial Sequence Library Isolate 109 Asp Asn Trp Cys Glu Ile Val
Val Glu Lys Gly Gln Trp Phe Cys Tyr 1 5 10 15 Gly Ser 110 18 PRT
Artificial Sequence Library Isolate 110 Tyr Pro Gly Cys Tyr Glu Thr
Ser Leu Ser Gly Val Trp Phe Cys Ala 1 5 10 15 Asp Gly 111 16 PRT
Artificial Sequence Library Isolate 111 Gly Trp Cys Gln Met Asp Ala
Gln Gly Ile Trp Ser Cys Trp Ala Asp 1 5 10 15 112 18 PRT Artificial
Sequence Library Isolate 112 Asp Arg Trp Cys Met Leu Asp Gln Glu
Lys Gly Trp Trp Leu Cys Gly 1 5 10 15 Pro Pro 113 18 PRT Artificial
Sequence Library Isolate 113 Asn Ser Glu Cys Gly Cys Pro Asn Met
Leu His Lys Glu Phe Cys Ala 1 5 10 15
Arg His 114 18 PRT Artificial Sequence Library Isolate 114 Pro Phe
Trp Cys Lys Phe Gln Gln Ser Lys Ala Met Phe Pro Cys Ser 1 5 10 15
Trp Phe 115 18 PRT Artificial Sequence Library Isolate 115 Tyr Pro
Trp Cys His Glu His Ser Asp Ser Val Thr Arg Phe Cys Val 1 5 10 15
Pro Trp 116 17 PRT Artificial Sequence Library Isolate 116 Ser Asp
Leu Cys Tyr Asn Gln Ser Gly Trp Trp Glu Leu Cys Tyr Phe 1 5 10 15
Asp 117 18 PRT Artificial Sequence Library Isolate 117 Leu Gly Tyr
Cys Met Tyr Asp Tyr Glu Asn Arg Gly Trp Thr Cys Tyr 1 5 10 15 Pro
Pro 118 18 PRT Artificial Sequence Library Isolate 118 Tyr Tyr Gln
Cys Gln Arg Tyr Trp Asp Gly Lys Thr Trp Trp Cys Glu 1 5 10 15 Tyr
Asn 119 18 PRT Artificial Sequence Library Isolate 119 Asp Ser Trp
Cys Glu Leu Glu His Gln Ser Gly Ile Trp Arg Cys Asp 1 5 10 15 Phe
Trp 120 18 PRT Artificial Sequence Library Isolate 120 Asp Trp Ala
Cys Asp Glu Tyr Trp Ser Ala Tyr Ser Val Leu Cys Lys 1 5 10 15 His
Pro 121 18 PRT Artificial Sequence Library Isolate 121 Leu Ser Leu
Cys Tyr Asn Asp Met His Gly Trp Trp Glu His Cys Gln 1 5 10 15 Trp
Tyr 122 18 PRT Artificial Sequence Library Isolate 122 Tyr Ser His
Cys Ile Glu Thr Ser Met Glu Asn Ile Trp Phe Cys Asp 1 5 10 15 Phe
Asp 123 18 PRT Artificial Sequence Library Isolate 123 Pro Pro Phe
Cys Ile Tyr Gln Glu Pro Ser Gly Gln Trp Trp Cys Tyr 1 5 10 15 Asp
His 124 18 PRT Artificial Sequence Library Isolate 124 Pro Gly Trp
Cys Asp Phe Ser Pro Gln Leu Gly Gln Trp Met Cys Asp 1 5 10 15 Trp
Phe 125 18 PRT Artificial Sequence Library Isolate 125 Leu Asp Asn
Cys Ile Trp Asn Val Trp Lys Gly Val Gln Asp Cys Glu 1 5 10 15 Tyr
Ser 126 18 PRT Artificial Sequence Library Isolate 126 Ala Gly Trp
Cys Glu Tyr Val Ala Pro Gln Gly Ala Trp Arg Cys Phe 1 5 10 15 His
Asn 127 18 PRT Artificial Sequence Library Isolate 127 Trp Asp Asp
Cys Ile Trp His Met Trp Leu Lys Lys Lys Asp Cys Asn 1 5 10 15 Ser
Gly 128 18 PRT Artificial Sequence Library Isolate 128 Pro Gly His
Cys Glu Tyr Ile Trp Ile Asp Glu Gln Pro Trp Cys Val 1 5 10 15 Arg
Leu 129 17 PRT Artificial Sequence Library Isolate 129 Tyr Ser Asp
Cys Leu Phe Gln Leu Trp Lys Gly Ser Val Cys Pro Pro 1 5 10 15 Ser
130 17 PRT Artificial Sequence Library Isolate 130 Tyr Phe Phe Cys
Ser Phe Ala Asp Val Ala Tyr Glu Ser Cys His Pro 1 5 10 15 Leu 131
18 PRT Artificial Sequence Library Isolate 131 Asn Tyr Met Cys Glu
Ser Glu Asp His Thr Tyr Met Phe Pro Cys Trp 1 5 10 15 Trp Tyr 132
18 PRT Artificial Sequence Library Isolate 132 Asp Ala Val Cys Tyr
Asn Pro Trp Phe Lys Tyr Trp Glu Thr Cys Glu 1 5 10 15 Tyr Asn 133
18 PRT Artificial Sequence Library Isolate 133 Asn Tyr Met Cys Glu
Tyr Glu Asp His Thr Tyr Met Leu Thr Cys Glu 1 5 10 15 Cys Asn 134
17 PRT Artificial Sequence Library Isolate 134 Trp Asp Asp Cys Ile
Tyr Ser Met Trp Met Val His Thr Val Cys Asp 1 5 10 15 Arg 135 18
PRT Artificial Sequence Library Isolate 135 Asn Trp Lys Cys Asp Ala
His Gln Glu Gly Arg Ile His Ile Cys Trp 1 5 10 15 Gly Tyr 136 18
PRT Artificial Sequence Library Isolate 136 Asn Gly Ser Cys Trp Tyr
Asp Phe Gly Trp Glu Thr Glu Ile Cys Phe 1 5 10 15 His Asn 137 20
PRT Artificial Sequence Library Isolate 137 Gln Val Gln Tyr Gln Phe
Phe Leu Gly Thr Pro Arg Tyr Glu Gln Trp 1 5 10 15 Asp Leu Asp Lys
20 138 20 PRT Artificial Sequence Library Isolate 138 Glu Pro Glu
Gly Tyr Ala Tyr Trp Glu Val Ile Thr Leu Tyr His Glu 1 5 10 15 Glu
Asp Gly Asp 20 139 20 PRT Artificial Sequence Library Isolate 139
Trp Tyr Tyr Asp Trp Phe His Asn Gln Arg Lys Pro Pro Ser Asp Trp 1 5
10 15 Ile Asp Asn Leu 20 140 20 PRT Artificial Sequence Library
Isolate 140 Ala Phe Pro Arg Phe Gly Gly Asp Asp Tyr Trp Ile Gln Gln
Tyr Leu 1 5 10 15 Arg Tyr Thr Asp 20 141 20 PRT Artificial Sequence
Library Isolate 141 Gly Asp Tyr Val Tyr Trp Glu Ile Ile Glu Leu Thr
Gly Ala Thr Asp 1 5 10 15 His Thr Pro Pro 20 142 20 PRT Artificial
Sequence Library Isolate 142 Arg Gly Asp Tyr Gln Glu Gln Tyr Trp
His Gln Gln Leu Val Glu Gln 1 5 10 15 Leu Lys Leu Leu 20 143 18 PRT
Artificial Sequence Library Isolate 143 Arg Ser Trp Tyr Leu Gly Pro
Pro Tyr Tyr Glu Glu Trp Asp Pro Ile 1 5 10 15 Pro Asn 144 20 PRT
Artificial Sequence Library Isolate 144 Pro Ser Asn Ser Trp Ala Ala
Val Trp Glu Asp Asp Met Gln Arg Leu 1 5 10 15 Met Arg Gln His 20
145 20 PRT Artificial Sequence Library Isolate 145 Pro Arg Leu Gly
Asp Asp Phe Glu Glu Ala Pro Pro Leu Glu Trp Trp 1 5 10 15 Trp Ala
His Phe 20 146 20 PRT Artificial Sequence Library Isolate 146 Met
Pro Pro Gly Phe Ser Tyr Trp Glu Gln Val Val Leu His Asp Asp 1 5 10
15 Ala Gln Val Leu 20 147 20 PRT Artificial Sequence Library
Isolate 147 Lys Lys Glu Asp Ala Gln Gln Trp Tyr Trp Thr Asp Tyr Val
Pro Ser 1 5 10 15 Tyr Leu Tyr Arg 20 148 20 PRT Artificial Sequence
Library Isolate 148 Trp Val Thr Lys Gln Gln Phe Ile Asp Thr Tyr Gly
Arg Lys Glu Trp 1 5 10 15 Thr Ile Leu Phe 20 149 20 PRT Artificial
Sequence Library Isolate 149 Trp Leu Tyr Asp Tyr Trp Asp Arg Gln
Gln Lys Ser Glu Glu Phe Lys 1 5 10 15 Phe Trp Ser Gln 20 150 20 PRT
Artificial Sequence Library Isolate 150 Pro Val Thr Asp Trp Thr Pro
His His Pro Lys Ala Pro Asp Val Trp 1 5 10 15 Leu Phe Tyr Thr 20
151 16 PRT Artificial Sequence Library Isolate 151 Glu Trp Tyr Trp
Thr Glu His Val Gly Met Lys His Gly Phe Phe Val 1 5 10 15 152 20
PRT Artificial Sequence Library Isolate 152 Asp Ala Leu Glu Ala Pro
Lys Arg Asp Trp Tyr Tyr Asp Trp Phe Leu 1 5 10 15 Asn His Ser Pro
20 153 21 PRT Artificial Sequence Library Isolate 153 Pro Asp Asn
Trp Lys Glu Phe Tyr Glu Ser Gly Trp Lys Tyr Pro Ser 1 5 10 15 Leu
Tyr Lys Pro Leu 20 154 20 PRT Artificial Sequence Library Isolate
154 Glu Trp Asp Ala Gln Tyr Trp His Asp Leu Arg Gln Gln Tyr Met Leu
1 5 10 15 Asp Tyr Ile Gln 20 155 20 PRT Artificial Sequence Library
Isolate 155 Ala Phe Glu Ile Glu Tyr Trp Asp Ser Val Arg Asn Lys Ile
Trp Gln 1 5 10 15 His Phe Pro Asp 20 156 20 PRT Artificial Sequence
Library Isolate 156 Ala Phe Pro Arg Phe Gly Gly Asp Asp Tyr Trp Ile
Gln Gln Tyr Leu 1 5 10 15 Arg Tyr Thr Phe 20 157 19 PRT Artificial
Sequence Library Isolate 157 Ala His Met Pro Pro Trp Arg Pro Val
Ala Val Asp Ala Leu Phe Asp 1 5 10 15 Trp Val Glu 158 19 PRT
Artificial Sequence Library Isolate 158 Ala His Met Pro Pro Trp Trp
Pro Leu Ala Val Asp Ala Gln Glu Asp 1 5 10 15 Trp Phe Glu 159 19
PRT Artificial Sequence Library Isolate 159 Ala Gln Met Pro Pro Trp
Trp Pro Leu Ala Val Asp Ala Leu Phe Asp 1 5 10 15 Trp Phe Glu 160
20 PRT Artificial Sequence Library Isolate 160 Ala Arg Met Gly Asp
Asp Trp Glu Glu Ala Pro Pro His Glu Trp Gly 1 5 10 15 Trp Ala Asp
Gly 20 161 20 PRT Artificial Sequence Library Isolate 161 Asp Trp
Tyr Trp Gln Arg Glu Arg Asp Lys Leu Arg Glu His Tyr Asp 1 5 10 15
Asp Ala Phe Trp 20 162 19 PRT Artificial Sequence Library Isolate
162 Asp Trp Tyr Trp Arg Glu Trp Met Pro Met His Ala Gln Phe Leu Ala
1 5 10 15 Asp Asp Trp 163 20 PRT Artificial Sequence Library
Isolate 163 Asp Trp Tyr Tyr Asp Glu Ile Leu Ser Met Ala Asp Gln Leu
Arg His 1 5 10 15 Ala Phe Leu Ser 20 164 20 PRT Artificial Sequence
Library Isolate 164 Glu Glu Gln Gln Ala Leu Tyr Pro Gly Cys Glu Pro
Ala Glu His Trp 1 5 10 15 Val Tyr Ala Gly 20 165 16 PRT Artificial
Sequence Library Isolate 165 Phe Asp Val Val Asn Trp Gly Asp Gly
Ile Trp Tyr Ala Tyr Pro Ser 1 5 10 15 166 20 PRT Artificial
Sequence Library Isolate 166 Phe Pro Ser Gln Met Trp Gln Gln Lys
Val Ser His His Phe Phe Gln 1 5 10 15 His Lys Gly Tyr 20 167 20 PRT
Artificial Sequence Library Isolate 167 Gly Ser Asp His Val Arg Val
Asp Asn Tyr Trp Trp Asn Gly Met Ala 1 5 10 15 Trp Glu Ile Phe 20
168 20 PRT Artificial Sequence Library Isolate 168 Ile Ser Pro Trp
Arg Glu Met Ser Gly Trp Gly Met Pro Trp Ile Thr 1 5 10 15 Ala Val
Pro His 20 169 21 PRT Artificial Sequence Library Isolate 169 Leu
Glu Glu Val Phe Glu Asp Phe Gln Asp Phe Trp Tyr Thr Glu His 1 5 10
15 Ile Ile Val Asp Arg 20 170 20 PRT Artificial Sequence Library
Isolate 170 Met Pro Pro Gly Phe Ser Tyr Trp Glu Gln Ala Ala Leu His
Asp Asp 1 5 10 15 Ala Gln Asp Leu 20 171 20 PRT Artificial Sequence
Library Isolate 171 Pro Glu Asp Ser Glu Ala Trp Tyr Trp Leu Asn Tyr
Arg Pro Thr Met 1 5 10 15 Phe His Gln Leu 20 172 20 PRT Artificial
Sequence Library Isolate 172 Gln Ile Glu Tyr Val Asn Asp Lys Trp
Tyr Trp Thr Gly Gly Tyr Trp 1 5 10 15 Asn Val Pro Phe 20 173 20 PRT
Artificial Sequence Library Isolate 173 Gln Val Gln Tyr Gln Phe Ile
Leu Gly Thr Pro Arg Tyr Glu Gln Trp 1 5 10 15 Asp Pro Asp Lys 20
174 20 PRT Artificial Sequence Library Isolate 174 Arg Asp Glu Trp
Gly Trp Thr Gly Val Pro Tyr Glu Gly Glu Met Gly 1 5 10 15 Tyr Gln
Ile Ser 20 175 20 PRT Artificial Sequence Library Isolate 175 Ser
Thr Asn Gly Asp Ser Phe Val Tyr Trp Glu Glu Val Glu Leu Val 1 5 10
15 Asp His Pro Tyr 20 176 19 PRT Artificial Sequence Library
Isolate 176 Ser Tyr Glu Gln Trp Leu Pro Gln Tyr Trp Ala Gln Tyr Lys
Ser Asn 1 5 10 15 Tyr Phe Leu 177 20 PRT Artificial Sequence
Library Isolate 177 Thr Lys Trp Gly Pro Asn Pro Glu His Trp Gln Tyr
Trp Tyr Ser His 1 5 10 15 Tyr Ala Ser Ser 20 178 20 PRT Artificial
Sequence Library Isolate 178 Val Ser Lys Gly Ser Ile Asp Val Gly
Glu Gly Ile Ser Tyr Trp Glu 1 5 10 15 Ile Ile Glu Leu 20 179 20 PRT
Artificial Sequence Library Isolate 179 Trp Glu Ser Asp Tyr Trp Asp
Gln Met Arg Gln Gln Leu Lys Thr Ala 1 5 10 15 Tyr Met Lys Val 20
180 20 PRT Artificial Sequence Library Isolate 180 Trp Tyr His Asp
Gly Leu His Asn Glu Arg Lys Pro Pro Ser His Trp 1 5 10 15 Ile Asp
Asn Val 20 181 20 PRT Artificial Sequence Library Isolate 181 Ala
Pro Ala Trp Thr Phe Gly Thr Asn Trp Arg Ser Ile Gln Arg Val 1 5 10
15 Asp Ser Leu Thr 20 182 20 PRT Artificial Sequence Library
Isolate 182 Glu Gly Trp Phe Arg Asn Pro Gln Glu Ile Met Gly Phe Gly
Asp Ser 1 5 10 15 Trp Asp Lys Pro 20 183 20 PRT Artificial Sequence
Library Isolate 183 Gly Trp Asp Leu Ser Val Asn Arg Asp Lys Arg Trp
Phe Trp Pro Trp 1 5 10 15 Ser Ser Arg Glu 20 184 20 PRT Artificial
Sequence Library Isolate 184 Lys Ser Gly Val Asp Ala Val Gly Trp
His Ile Pro Val Trp Leu Lys 1 5 10 15 Lys Tyr Trp Phe 20 185 20 PRT
Artificial Sequence Library Isolate 185 Gly Met Asp Leu Tyr Gln Tyr
Trp Ala Ser Asp Asp Tyr Trp Gly Arg 1 5 10 15 His Gln Glu Leu 20
186 17 PRT Artificial Sequence Library Isolate 186 Gly Val Asp Ile
Trp His Tyr Trp Lys Ser Ser Thr Arg Tyr Phe His 1 5 10 15 Gln 187
13 PRT Artificial Sequence Library Isolate 187 Gly Val Glu Cys Asn
His Met Gly Leu Cys Val Ser Trp 1 5 10 188 13 PRT Artificial
Sequence Library Isolate 188 Gly Ile Thr Cys Asp Glu Leu Gly Arg
Cys Val His Trp 1 5 10 189 13 PRT Artificial Sequence Library
Isolate 189 Trp Ile Gln Cys Asn His Gln Gly Gln Cys Phe His Gly 1 5
10 190 13 PRT Artificial Sequence Library Isolate 190 Trp Ile Glu
Cys Asn Lys Asp Gly Lys Cys Trp His Tyr 1 5 10 191 13 PRT
Artificial Sequence Library Isolate 191 Trp Val Glu Cys Asn His Lys
Gly Leu Cys Arg Glu Tyr 1 5 10 192 13 PRT Artificial Sequence
Library Isolate 192 Trp Tyr Trp Cys Glu Phe Tyr Gly Val Cys Ser Glu
Glu 1 5 10 193 15 PRT Artificial Sequence Library Isolate 193 Ile
Asp Phe Cys Lys Gly Met Ala Pro Trp Leu Cys Ala Asp Met 1 5 10 15
194 15 PRT Artificial Sequence Library Isolate 194 Pro Trp Thr Cys
Trp Leu Glu Asp His Leu Ala Cys Ala Met Leu 1 5 10 15 195 15 PRT
Artificial Sequence Library Isolate 195 Asp Trp Gly Cys Ser Leu Gly
Asn Trp Tyr Trp Cys Ser Thr Glu 1 5 10 15 196 15 PRT Artificial
Sequence Library Isolate 196 Met Pro Trp Cys Ser Glu Val Thr Trp
Gly Trp Cys Lys Leu Asn 1 5 10 15 197 15 PRT Artificial Sequence
Library Isolate 197 Arg Gly Pro Cys Ser Gly Gln Pro Trp His Leu Cys
Tyr Tyr Gln 1 5 10 15 198 15 PRT Artificial Sequence Library
Isolate 198 Pro Trp Gly Cys Asp His Phe Gly Trp Ala Trp Cys Lys Gly
Met 1 5 10 15 199 15 PRT Artificial Sequence Library Isolate 199
Met Pro Trp Cys Val Glu Lys Asp His Trp Asp Cys Trp Trp Trp 1 5 10
15 200 15 PRT Artificial Sequence Library Isolate 200 Pro Gly Pro
Cys Lys Gly Tyr Met Pro His Gln Cys Trp Tyr Met 1 5 10 15 201 15
PRT Artificial Sequence Library Isolate 201 Tyr Gly Pro Cys Ala Glu
Met Ser Pro Trp Leu Cys Trp Tyr Pro 1 5 10 15 202 15 PRT Artificial
Sequence Library Isolate 202 Tyr Gly Pro Cys Lys Asn Met Pro Pro
Trp Met Cys Trp His Glu 1 5 10 15 203 15 PRT Artificial Sequence
Library Isolate 203 Gly His Pro Cys Lys Gly Met Leu Pro His Thr Cys
Trp Tyr Glu 1 5 10 15 204 16 PRT Artificial Sequence Library
Isolate 204 Asn Asn Ser Cys Trp Leu Ser Thr Thr Leu Gly Ser Cys Phe
Phe Asp 1 5 10 15 205 16 PRT Artificial Sequence Library Isolate
205 Asp His His Cys Tyr Leu His Asn Gly Gln Trp Ile Cys Tyr Pro Phe
1 5 10 15 206 16 PRT Artificial Sequence Library Isolate 206 Asn
Ser His Cys Tyr Ile Trp Asp Gly Met Trp Leu Cys Phe Pro Asp 1 5 10
15 207 19 PRT Artificial Sequence Library Isolate 207 Ser Asn Lys
Cys Asp His Tyr Gln Ser Gly Pro His Gly Lys Ile Cys 1 5 10 15 Val
Asn Tyr 208 19 PRT Artificial Sequence Library Isolate 208 Ser Asn
Lys Cys Asp His Tyr Gln Ser Gly Pro Tyr Gly Glu Val Cys 1 5 10 15
Phe Asn Tyr 209 19 PRT Artificial Sequence Library Isolate 209 Arg
Leu Asp Cys Asp Lys Val Phe Ser Gly Pro Tyr Gly Lys Val Cys 1 5 10
15 Val Ser Tyr 210 18 PRT Artificial Sequence Library Isolate 210
Arg
Leu Asp Cys Asp Lys Val Phe Ser Gly Pro Asp Thr Ser Cys Gly 1 5 10
15 Ser Gln 211 19 PRT Artificial Sequence Library Isolate 211 Arg
Leu Asp Cys Asp Lys Val Phe Ser Gly Pro His Gly Lys Ile Cys 1 5 10
15 Val Arg Tyr 212 19 PRT Artificial Sequence Library Isolate 212
Arg Leu Asp Cys Asp Lys Val Phe Ser Gly Pro His Gly Lys Ile Cys 1 5
10 15 Val Asn Tyr 213 19 PRT Artificial Sequence Library Isolate
213 Arg Val Asp Cys Asp Lys Val Ile Ser Gly Pro His Gly Lys Ile Cys
1 5 10 15 Val Asn Tyr 214 19 PRT Artificial Sequence Library
Isolate 214 Arg Thr Thr Cys His His Gln Ile Ser Gly Pro His Gly Lys
Ile Cys 1 5 10 15 Val Asn Tyr 215 19 PRT Artificial Sequence
Library Isolate 215 Glu Phe His Cys His His Ile Met Ser Gly Pro His
Gly Lys Ile Cys 1 5 10 15 Val Asn Tyr 216 19 PRT Artificial
Sequence Library Isolate 216 His Asn Arg Cys Asp Phe Lys Met Ser
Gly Pro His Gly Lys Ile Cys 1 5 10 15 Val Asn Tyr 217 19 PRT
Artificial Sequence Library Isolate 217 Trp Gln Glu Cys Thr Lys Val
Leu Ser Gly Pro Gly Thr Phe Glu Cys 1 5 10 15 Ser Tyr Glu 218 19
PRT Artificial Sequence Library Isolate 218 Trp Gln Glu Cys Thr Lys
Val Leu Ser Gly Pro Gly Gln Phe Ser Cys 1 5 10 15 Val Tyr Gly 219
19 PRT Artificial Sequence Library Isolate 219 Trp Gln Glu Cys Thr
Lys Val Leu Ser Gly Pro Gly Gln Phe Glu Cys 1 5 10 15 Glu Tyr Met
220 19 PRT Artificial Sequence Library Isolate 220 Trp Gln Glu Cys
Thr Lys Val Leu Ser Gly Pro Asn Ser Phe Glu Cys 1 5 10 15 Lys Tyr
Asp 221 19 PRT Artificial Sequence Library Isolate 221 Trp Asp Arg
Cys Glu Arg Gln Ile Ser Gly Pro Gly Gln Phe Ser Cys 1 5 10 15 Val
Tyr Gly 222 19 PRT Artificial Sequence Library Isolate 222 Trp Gln
Glu Cys Thr Lys Val Leu Ser Gly Pro Gly Gln Phe Leu Cys 1 5 10 15
Ser Tyr Gly 223 19 PRT Artificial Sequence Library Isolate 223 Arg
Leu Asp Cys Asp Met Val Phe Ser Gly Pro His Gly Lys Ile Cys 1 5 10
15 Val Asn Tyr 224 18 PRT Artificial Sequence Library Isolate 224
Lys Arg Cys Asp Thr Thr His Ser Gly Pro His Gly Ile Val Cys Val 1 5
10 15 Val Tyr 225 19 PRT Artificial Sequence Library Isolate 225
Ser Asn Lys Cys Asp His Tyr Gln Ser Gly Pro Tyr Gly Ala Val Cys 1 5
10 15 Leu His Tyr 226 19 PRT Artificial Sequence Library Isolate
226 Ser Pro His Cys Gln Tyr Lys Ile Ser Gly Pro Phe Gly Pro Val Cys
1 5 10 15 Val Asn Tyr 227 19 PRT Artificial Sequence Library
Isolate 227 Ala His Gln Cys His His Trp Thr Ser Gly Pro Tyr Gly Glu
Val Cys 1 5 10 15 Phe Asn Tyr 228 19 PRT Artificial Sequence
Library Isolate 228 Tyr Asp Lys Cys Ser Ser Arg Phe Ser Gly Pro Phe
Gly Glu Ile Cys 1 5 10 15 Val Asn Tyr 229 19 PRT Artificial
Sequence Library Isolate 229 Met Gly Gly Cys Asp Phe Ser Phe Ser
Gly Pro Phe Gly Gln Ile Cys 1 5 10 15 Gly Arg Tyr 230 19 PRT
Artificial Sequence Library Isolate 230 Arg Thr Thr Cys His His Gln
Ile Ser Gly Pro Phe Gly Asp Val Cys 1 5 10 15 Val Ser Tyr 231 19
PRT Artificial Sequence Library Isolate 231 Trp Tyr Arg Cys Asp Phe
Asn Met Ser Gly Pro Asp Phe Thr Glu Cys 1 5 10 15 Leu Tyr Pro 232
19 PRT Artificial Sequence Library Isolate 232 Trp Met Gln Cys Asn
Met Ser Ala Ser Gly Pro Lys Asp Met Tyr Cys 1 5 10 15 Glu Tyr Asp
233 19 PRT Artificial Sequence Library Isolate 233 Gly Ile Ser Cys
Lys Trp Ile Trp Ser Gly Pro Asp Arg Trp Lys Cys 1 5 10 15 His His
Phe 234 19 PRT Artificial Sequence Library Isolate 234 Trp Gln Val
Cys Lys Pro Tyr Val Ser Gly Pro Ala Ala Phe Ser Cys 1 5 10 15 Lys
Tyr Glu 235 19 PRT Artificial Sequence Library Isolate 235 Gly Trp
Trp Cys Tyr Arg Asn Asp Ser Gly Pro Lys Pro Phe His Cys 1 5 10 15
Arg Ile Lys 236 19 PRT Artificial Sequence Library Isolate 236 Glu
Gly Trp Cys Trp Phe Ile Asp Ser Gly Pro Trp Lys Thr Trp Cys 1 5 10
15 Glu Lys Gln 237 19 PRT Artificial Sequence Library Isolate 237
Phe Pro Lys Cys Lys Phe Asp Phe Ser Gly Pro Pro Trp Tyr Gln Cys 1 5
10 15 Asn Thr Lys 238 19 PRT Artificial Sequence Library Isolate
238 Arg Leu Asp Cys Asp Lys Val Phe Ser Gly Pro Tyr Gly Arg Val Cys
1 5 10 15 Val Lys Tyr 239 19 PRT Artificial Sequence Library
Isolate 239 Arg Leu Asp Cys Asp Lys Val Phe Ser Gly Pro Tyr Gly Asn
Val Cys 1 5 10 15 Val Asn Tyr 240 19 PRT Artificial Sequence
Library Isolate 240 Arg Leu Asp Cys Asp Lys Val Phe Ser Gly Pro Ser
Met Gly Thr Cys 1 5 10 15 Lys Leu Gln 241 19 PRT Artificial
Sequence Library Isolate 241 Arg Thr Thr Cys His His His Ile Ser
Gly Pro His Gly Lys Ile Cys 1 5 10 15 Val Asn Tyr 242 19 PRT
Artificial Sequence Library Isolate 242 Gln Phe Gly Cys Glu His Ile
Met Ser Gly Pro His Gly Lys Ile Cys 1 5 10 15 Val Asn Tyr 243 19
PRT Artificial Sequence Library Isolate 243 Pro Val His Cys Ser His
Thr Ile Ser Gly Pro His Gly Lys Ile Cys 1 5 10 15 Val Asn Tyr 244
19 PRT Artificial Sequence Library Isolate 244 Ser Val Thr Cys His
Phe Gln Met Ser Gly Pro His Gly Lys Ile Cys 1 5 10 15 Val Asn Tyr
245 19 PRT Artificial Sequence Library Isolate 245 Pro Arg Gly Cys
Gln His Met Ile Ser Gly Pro His Gly Lys Ile Cys 1 5 10 15 Val Asn
Tyr 246 19 PRT Artificial Sequence Library Isolate 246 Arg Thr Thr
Cys His His Gln Ile Ser Gly Pro His Gly Gln Ile Cys 1 5 10 15 Val
Asn Tyr 247 19 PRT Artificial Sequence Library Isolate 247 Trp Thr
Ile Cys His Met Glu Leu Ser Gly Pro His Gly Lys Ile Cys 1 5 10 15
Val Asn Tyr 248 19 PRT Artificial Sequence Library Isolate 248 Phe
Ile Thr Cys Ala Leu Trp Leu Ser Gly Pro His Gly Lys Ile Cys 1 5 10
15 Val Asn Tyr 249 19 PRT Artificial Sequence Library Isolate 249
Met Gly Gly Cys Asp Phe Ser Phe Ser Gly Pro His Gly Lys Ile Cys 1 5
10 15 Val Asn Tyr 250 19 PRT Artificial Sequence Library Isolate
250 Lys Asp Trp Cys His Thr Thr Phe Ser Gly Pro His Gly Lys Ile Cys
1 5 10 15 Val Asn Tyr 251 19 PRT Artificial Sequence Library
Isolate 251 Ala Trp Gly Cys Asp Asn Met Met Ser Gly Pro His Gly Lys
Ile Cys 1 5 10 15 Val Asn Tyr 252 19 PRT Artificial Sequence
Library Isolate 252 Ser Asn Lys Cys Asp His Ile Met Ser Gly Pro His
Gly Lys Ile Cys 1 5 10 15 Val Asn Tyr 253 19 PRT Artificial
Sequence Library Isolate 253 Ser Asn Lys Cys Asp His Tyr Gln Ser
Gly Pro Phe Gly Asp Ile Cys 1 5 10 15 Val Met Tyr 254 19 PRT
Artificial Sequence Library Isolate 254 Ser Asn Lys Cys Asp His Tyr
Gln Ser Gly Pro Phe Gly Asp Val Cys 1 5 10 15 Val Ser Tyr 255 19
PRT Artificial Sequence Library Isolate 255 Ser Asn Lys Cys Asp His
Tyr Gln Ser Gly Pro Phe Gly Asp Ile Cys 1 5 10 15 Val Ser Tyr 256
19 PRT Artificial Sequence Library Isolate 256 Arg Thr Thr Cys His
His Gln Ile Ser Gly Pro Phe Gly Pro Val Cys 1 5 10 15 Val Asn Tyr
257 19 PRT Artificial Sequence Library Isolate 257 Arg Thr Thr Cys
His His Gln Ile Ser Gly Pro Tyr Gly Asp Ile Cys 1 5 10 15 Val Lys
Tyr 258 20 PRT Artificial Sequence Library Isolate 258 Pro His Gly
Lys Ile Cys Val Asn Tyr Gly Ser Glu Ser Ala Asp Pro 1 5 10 15 Ser
Tyr Ile Glu 20 259 19 PRT Artificial Sequence Library Isolate 259
Arg Tyr Lys Cys Pro Arg Asp Leu Ser Gly Pro Pro Tyr Gly Pro Cys 1 5
10 15 Ser Pro Gln 260 14 PRT Artificial Sequence TN8 Secondary
Library Template 260 Trp Val Glu Cys Xaa Xaa Xaa Thr Gly Xaa Cys
Xaa Xaa Xaa 1 5 10 261 18 PRT Artificial Sequence Secondary Library
Template 261 Xaa Xaa Trp Val Glu Cys Xaa Xaa Xaa Thr Gly Xaa Cys
Xaa Xaa Xaa 1 5 10 15 Xaa Xaa 262 4 PRT Artificial Sequence Library
isolate 262 Gly Gly Gly Lys 1 263 22 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 263 Ala Gly Asp Ser Trp Cys Ser
Thr Glu Tyr Thr Tyr Cys Glu Met Ile 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 264 22 PRT Artificial Sequence Synthesized KDR-Binding
Polypeptide 264 Ala Gly Pro Lys Trp Cys Glu Glu Asp Trp Tyr Tyr Cys
Met Ile Thr 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 265 22 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 265 Ala Gly
Val Trp Glu Cys Ala Lys Thr Phe Pro Phe Cys His Trp Phe 1 5 10 15
Gly Thr Gly Gly Gly Lys 20 266 22 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 266 Ala Gly Trp Val Glu Cys Trp
Trp Lys Ser Gly Gln Cys Tyr Glu Phe 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 267 22 PRT Artificial Sequence Synthesized KDR-Binding
Polypeptide 267 Ala Gly Trp Leu Glu Cys Tyr Ala Glu Phe Gly His Cys
Tyr Asn Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 268 22 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 268 Ala Gly
Trp Ile Gln Cys Asn Ser Ile Thr Gly His Cys Thr Ser Gly 1 5 10 15
Gly Thr Gly Gly Gly Lys 20 269 22 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 269 Ala Gly Trp Ile Glu Cys Tyr
His Pro Asp Gly Ile Cys Tyr His Phe 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 270 22 PRT Artificial Sequence Synthesized KDR-Binding
Polypeptide 270 Ala Gly Ser Asp Trp Cys Arg Val Asp Trp Tyr Tyr Cys
Trp Leu Met 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 271 22 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 271 Ala Gly
Ala Asn Trp Cys Glu Glu Asp Trp Tyr Tyr Cys Phe Ile Thr 1 5 10 15
Gly Thr Gly Gly Gly Lys 20 272 22 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 272 Ala Gly Ala Asn Trp Cys Glu
Glu Asp Trp Tyr Tyr Cys Trp Ile Thr 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 273 22 PRT Artificial Sequence Synthesized KDR-Binding
Polypeptide 273 Ala Gly Pro Asp Trp Cys Glu Glu Asp Trp Tyr Tyr Cys
Trp Ile Thr 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 274 22 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 274 Ala Gly
Ser Asn Trp Cys Glu Glu Asp Trp Tyr Tyr Cys Tyr Ile Thr 1 5 10 15
Gly Thr Gly Gly Gly Lys 20 275 22 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 275 Ala Gly Pro Asp Trp Cys Ala
Ala Asp Trp Tyr Tyr Cys Tyr Ile Thr 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 276 22 PRT Artificial Sequence Synthesized KDR-Binding
Polypeptide 276 Ala Gly Pro Glu Trp Cys Glu Val Asp Trp Tyr Tyr Cys
Trp Leu Leu 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 277 22 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 277 Ala Gly
Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15
Gly Thr Gly Gly Gly Lys 20 278 22 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 278 Ala Gly Ser Lys Trp Cys Glu
Gln Asp Trp Tyr Tyr Cys Trp Leu Leu 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 279 22 PRT Artificial Sequence Synthesized KDR-Binding
Polypeptide 279 Ala Gly Arg Asn Trp Cys Glu Glu Asp Trp Tyr Tyr Cys
Phe Ile Thr 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 280 22 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 280 Ala Gly
Val Asn Trp Cys Glu Glu Asp Trp Tyr Tyr Cys Trp Ile Thr 1 5 10 15
Gly Thr Gly Gly Gly Lys 20 281 22 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 281 Ala Gly Ala Asn Trp Cys Glu
Glu Asp Trp Tyr Tyr Cys Tyr Ile Thr 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 282 26 PRT Artificial Sequence Synthesized KDR-Binding
Polypeptide 282 Ala Gly Gln Ala Trp Val Glu Cys Tyr Ala Glu Thr Gly
Tyr Cys Trp 1 5 10 15 Pro Arg Ser Trp Gly Thr Gly Gly Gly Lys 20 25
283 26 PRT Artificial Sequence Synthesized KDR-Binding Polypeptide
283 Ala Gly Gln Ala Trp Ile Glu Cys Tyr Ala Glu Asp Gly Tyr Cys Trp
1 5 10 15 Pro Arg Ser Trp Gly Thr Gly Gly Gly Lys 20 25 284 26 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 284 Ala Gly
Val Gly Trp Val Glu Cys Tyr Gln Ser Thr Gly Phe Cys Tyr 1 5 10 15
His Ser Arg Asp Gly Thr Gly Gly Gly Lys 20 25 285 26 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 285 Ala Gly Phe Thr
Trp Val Glu Cys His Gln Ala Thr Gly Arg Cys Val 1 5 10 15 Glu Trp
Thr Thr Gly Thr Gly Gly Gly Lys 20 25 286 26 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 286 Ala Gly Asp Trp
Trp Val Glu Cys Arg Val Gly Thr Gly Leu Cys Tyr 1 5 10 15 Arg Tyr
Asp Thr Gly Thr Gly Gly Gly Lys 20 25 287 26 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 287 Ala Gly Asp Ser
Trp Val Glu Cys Asp Ala Gln Thr Gly Phe Cys Tyr 1 5 10 15 Ser Phe
Leu Tyr Gly Thr Gly Gly Gly Lys 20 25 288 26 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 288 Ala Gly Gly Gly
Trp Val Glu Cys Tyr Trp Ala Thr Gly Arg Cys Ile 1 5 10 15 Glu Phe
Ala Gly Gly Thr Gly Gly Gly Lys 20 25 289 26 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 289 Ala Gly Glu Arg
Trp Val Glu Cys Arg Ala Glu Thr Gly Phe Cys Tyr 1 5 10 15 Thr Trp
Val Ser Gly Thr Gly Gly Gly Lys 20 25 290 26 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 290 Ala Gly Gly Gly
Trp Val Glu Cys Arg Ala Glu Thr Gly His Cys Gln 1 5 10 15 Glu Tyr
Arg Leu Gly Thr Gly Gly Gly Lys 20 25 291 26 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 291 Ala Gly Val Ala
Trp Val Glu Cys Tyr Gln Thr Thr Gly Lys Cys Tyr 1 5 10 15 Thr Phe
Arg Gly Gly Thr Gly Gly Gly Lys 20 25 292 26 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 292 Ala Gly Glu Gly
Trp Val Glu Cys Phe Ala Asn Thr Gly Ala Cys Phe 1 5 10 15 Thr Tyr
Pro Arg Gly Thr Gly Gly Gly Lys 20 25 293 26 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 293 Gly Asp Tyr Pro
Trp Cys His Glu Leu Ser Asp Ser Val Thr Arg Phe 1 5 10 15 Cys Val
Pro Trp Asp Pro Gly Gly Gly Lys 20 25 294 25 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 294 Gly Asp Ser Arg
Val Cys Trp Glu Asp Ser Trp Gly Gly Glu Val Cys 1 5 10 15 Phe Arg
Tyr Asp Pro Gly Gly Gly Lys 20 25 295 26 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 295 Gly Asp Asp His Met Cys Arg
Ser Pro Asp Tyr Gln Asp His Val Phe 1 5 10 15 Cys Met Tyr Trp Asp
Pro Gly Gly Gly Lys 20 25 296 26 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 296 Gly Asp Pro Pro Leu Cys Tyr
Phe Val Gly Thr Gln Glu Trp
His His 1 5 10 15 Cys Asn Pro Phe Asp Pro Gly Gly Gly Lys 20 25 297
25 PRT Artificial Sequence Synthesized KDR-Binding Polypeptide 297
Gly Asp Asp Ser Tyr Cys Met Met Asn Glu Lys Gly Trp Trp Asn Cys 1 5
10 15 Tyr Leu Tyr Asp Pro Gly Gly Gly Lys 20 25 298 26 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 298 Gly Asp
Pro Ala Gln Cys Trp Glu Ser Asn Tyr Gln Gly Ile Phe Phe 1 5 10 15
Cys Asp Asn Pro Asp Pro Gly Gly Gly Lys 20 25 299 26 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 299 Gly Asp Gly Ser
Trp Cys Glu Met Arg Gln Asp Val Gly Lys Trp Asn 1 5 10 15 Cys Phe
Ser Asp Asp Pro Gly Gly Gly Lys 20 25 300 25 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 300 Gly Asp Gly Trp
Ala Cys Ala Lys Trp Pro Trp Gly Gly Glu Ile Cys 1 5 10 15 Gln Pro
Ser Asp Pro Gly Gly Gly Lys 20 25 301 26 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 301 Gly Asp Pro Asp Thr Cys Thr
Met Trp Gly Asp Ser Gly Arg Trp Tyr 1 5 10 15 Cys Phe Pro Ala Asp
Pro Gly Gly Gly Lys 20 25 302 26 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 302 Gly Asp Asn Trp Lys Cys Glu
Tyr Thr Gln Gly Tyr Asp Tyr Thr Glu 1 5 10 15 Cys Val Tyr Leu Asp
Pro Gly Gly Gly Lys 20 25 303 26 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 303 Gly Asp Asn Trp Glu Cys Gly
Trp Ser Asn Met Phe Gln Lys Glu Phe 1 5 10 15 Cys Ala Arg Pro Asp
Pro Gly Gly Gly Lys 20 25 304 25 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 304 Ala Gln Gln Val Gln Tyr Gln
Phe Phe Leu Gly Thr Pro Arg Tyr Glu 1 5 10 15 Gln Trp Asp Leu Asp
Lys Gly Gly Lys 20 25 305 25 PRT Artificial Sequence Synthesized
KDR-Binding Polypeptide 305 Ala Gln Glu Pro Glu Gly Tyr Ala Tyr Trp
Glu Val Ile Thr Leu Tyr 1 5 10 15 His Glu Glu Asp Gly Asp Gly Gly
Lys 20 25 306 25 PRT Artificial Sequence Synthesized KDR-Binding
Polypeptide 306 Ala Gln Ala Phe Pro Arg Phe Gly Gly Asp Asp Tyr Trp
Ile Gln Gln 1 5 10 15 Tyr Leu Arg Tyr Thr Asp Gly Gly Lys 20 25 307
25 PRT Artificial Sequence Synthesized KDR-Binding Polypeptide 307
Ala Gln Gly Asp Tyr Val Tyr Trp Glu Ile Ile Glu Leu Thr Gly Ala 1 5
10 15 Thr Asp His Thr Pro Pro Gly Gly Lys 20 25 308 25 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 308 Ala Gln
Arg Gly Asp Tyr Gln Glu Gln Tyr Trp His Gln Gln Leu Val 1 5 10 15
Glu Gln Leu Lys Leu Leu Gly Gly Lys 20 25 309 23 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 309 Ala Gln Arg Ser
Trp Tyr Leu Gly Pro Pro Tyr Tyr Glu Glu Trp Asp 1 5 10 15 Pro Ile
Pro Asn Gly Gly Lys 20 310 26 PRT Artificial Sequence Synthesized
KDR-Binding Polypeptide 310 Ala Gln Asp Trp Tyr Tyr Asp Glu Ile Leu
Ser Met Ala Asp Gln Leu 1 5 10 15 Arg His Ala Phe Leu Ser Gly Gly
Gly Lys 20 25 311 23 PRT Artificial Sequence Synthesized
KDR-Binding Polypeptide 311 Ala Gly Ile Asp Phe Cys Lys Gly Met Ala
Pro Trp Leu Cys Ala Asp 1 5 10 15 Met Gly Thr Gly Gly Gly Lys 20
312 23 PRT Artificial Sequence Synthesized KDR-Binding Polypeptide
312 Ala Gly Pro Trp Thr Cys Trp Leu Glu Asp His Leu Ala Cys Ala Met
1 5 10 15 Leu Gly Thr Gly Gly Gly Lys 20 313 23 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 313 Ala Gly Asp Trp
Gly Cys Ser Leu Gly Asn Trp Tyr Trp Cys Ser Thr 1 5 10 15 Glu Gly
Thr Gly Gly Gly Lys 20 314 24 PRT Artificial Sequence Synthesized
KDR-Binding Polypeptide 314 Gly Ser Asp His His Cys Tyr Leu His Asn
Gly Gln Trp Ile Cys Tyr 1 5 10 15 Pro Phe Ala Pro Gly Gly Gly Lys
20 315 24 PRT Artificial Sequence Synthesized KDR-Binding
Polypeptide 315 Gly Ser Asn Ser His Cys Tyr Ile Trp Asp Gly Met Trp
Leu Cys Phe 1 5 10 15 Pro Asp Ala Pro Gly Gly Gly Lys 20 316 27 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 316 Ser Gly
Arg Leu Asp Cys Asp Lys Val Phe Ser Gly Pro Tyr Gly Lys 1 5 10 15
Val Cys Val Ser Tyr Gly Ser Gly Gly Gly Lys 20 25 317 27 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 317 Ser Gly
Arg Leu Asp Cys Asp Lys Val Phe Ser Gly Pro His Gly Lys 1 5 10 15
Ile Cys Val Asn Tyr Gly Ser Gly Gly Gly Lys 20 25 318 27 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 318 Ser Gly
Arg Thr Thr Cys His His Gln Ile Ser Gly Pro His Gly Lys 1 5 10 15
Ile Cys Val Asn Tyr Gly Ser Gly Gly Gly Lys 20 25 319 27 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 319 Ser Gly
Ala His Gln Cys His His Trp Thr Ser Gly Pro Tyr Gly Glu 1 5 10 15
Val Cys Phe Asn Tyr Gly Ser Gly Gly Gly Lys 20 25 320 23 PRT
Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide 320
Ala Gly Met Pro Trp Cys Val Glu Lys Asp His Trp Asp Cys Trp Trp 1 5
10 15 Trp Gly Thr Gly Gly Gly Lys 20 321 23 PRT Artificial Sequence
KDR or KDR/VEGF Complex Binding Polypeptide 321 Ala Gly Pro Gly Pro
Cys Lys Gly Tyr Met Pro His Gln Cys Trp Tyr 1 5 10 15 Met Gly Thr
Gly Gly Gly Lys 20 322 23 PRT Artificial Sequence KDR or KDR/VEGF
Complex Binding Polypeptide 322 Ala Gly Tyr Gly Pro Cys Ala Glu Met
Ser Pro Trp Leu Cys Trp Tyr 1 5 10 15 Pro Gly Thr Gly Gly Gly Lys
20 323 23 PRT Artificial Sequence KDR or KDR/VEGF Complex Binding
Polypeptide 323 Ala Gly Tyr Gly Pro Cys Lys Asn Met Pro Pro Trp Met
Cys Trp His 1 5 10 15 Glu Gly Thr Gly Gly Gly Lys 20 324 23 PRT
Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide 324
Ala Gly Gly His Pro Cys Lys Gly Met Leu Pro His Thr Cys Trp Tyr 1 5
10 15 Glu Gly Thr Gly Gly Gly Lys 20 325 28 PRT Artificial Sequence
KDR or KDR/VEGF Complex Binding Polypeptide 325 Ala Gln Ala Pro Ala
Trp Thr Phe Gly Thr Asn Trp Arg Ser Ile Gln 1 5 10 15 Arg Val Asp
Ser Leu Thr Gly Gly Gly Gly Gly Lys 20 25 326 28 PRT Artificial
Sequence KDR or KDR/VEGF Complex Binding Polypeptide 326 Ala Gln
Glu Gly Trp Phe Arg Asn Pro Gln Glu Ile Met Gly Phe Gly 1 5 10 15
Asp Ser Trp Asp Lys Pro Gly Gly Gly Gly Gly Lys 20 25 327 25 PRT
Artificial Sequence Library isolate 327 Gly Asp Ser Ser Val Cys Phe
Glu Tyr Ser Trp Gly Gly Glu Val Cys 1 5 10 15 Phe Arg Tyr Asp Pro
Gly Gly Gly Lys 20 25 328 25 PRT Artificial Sequence Library
isolate 328 Gly Asp Ser Arg Val Cys Trp Glu Tyr Ser Trp Gly Gly Gln
Ile Cys 1 5 10 15 Leu Gly Tyr Asp Pro Gly Gly Gly Lys 20 25 329 22
PRT Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide
329 Ala Gly Met Pro Trp Cys Val Glu Lys Asp His Trp Asp Cys Trp Trp
1 5 10 15 Gly Thr Gly Gly Gly Lys 20 330 26 PRT Artificial Sequence
KDR or KDR/VEGF Complex Binding Polypeptide 330 Ala Gln Glu Gly Trp
Phe Arg Asn Pro Gln Glu Ile Met Gly Phe Gly 1 5 10 15 Asp Ser Trp
Asp Lys Pro Gly Gly Gly Lys 20 25 331 26 PRT Artificial Sequence
KDR or KDR/VEGF Complex Binding Polypeptide 331 Ala Gln Arg Gly Asp
Tyr Gln Glu Gln Tyr Trp His Gln Gln Leu Val 1 5 10 15 Glu Gln Leu
Lys Leu Leu Gly Gly Gly Lys 20 25 332 20 PRT Artificial Sequence
KDR or KDR/VEGF Complex Binding Polypeptide 332 Ala Gly Trp Tyr Trp
Cys Asp Tyr Tyr Gly Ile Gly Cys Lys Trp Thr 1 5 10 15 Gly Gly Gly
Lys 20 333 22 PRT Artificial Sequence KDR or KDR/VEGF Complex
Binding Polypeptide 333 Ala Gly Trp Tyr Trp Cys Asp Tyr Tyr Gly Ile
Gly Cys Lys Trp Thr 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 334 26 PRT
Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide 334
Ala Gln Trp Tyr Tyr Asp Trp Phe His Asn Gln Arg Lys Pro Pro Ser 1 5
10 15 Asp Trp Ile Asp Asn Leu Gly Gly Gly Lys 20 25 335 22 PRT
Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide 335
Ala Gly Pro Lys Trp Cys Glu Glu Asp Trp Tyr Tyr Cys Met Ile Thr 1 5
10 15 Gly Thr Gly Gly Gly Lys 20 336 19 PRT Artificial Sequence KDR
or KDR/VEGF Complex Binding Polypeptide 336 Trp Gln Pro Cys Pro Trp
Glu Ser Trp Thr Phe Cys Trp Asp Pro Gly 1 5 10 15 Gly Gly Lys 337
21 PRT Artificial Sequence KDR or KDR/VEGF Complex Binding
Polypeptide 337 Val Cys Trp Glu Asp Ser Trp Gly Gly Glu Val Cys Phe
Arg Tyr Asp 1 5 10 15 Pro Gly Gly Gly Lys 20 338 19 PRT Artificial
Sequence KDR or KDR/VEGF Complex Binding Polypeptide 338 Ala Gly
Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15
Gly Thr Lys 339 22 PRT Artificial Sequence KDR or KDR/VEGF Complex
Binding Polypeptide 339 Ala Gly Pro Thr Trp Cys Glu Asp Asp Trp Tyr
Tyr Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 340 27 PRT
Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide 340
Ala Gln Ala His Met Pro Pro Trp Arg Pro Val Ala Val Asp Ala Leu 1 5
10 15 Phe Asp Trp Val Glu Gly Gly Gly Gly Gly Lys 20 25 341 27 PRT
Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide 341
Ala Gln Ala His Met Pro Pro Trp Trp Pro Leu Ala Val Asp Ala Gln 1 5
10 15 Glu Asp Trp Phe Glu Gly Gly Gly Gly Gly Lys 20 25 342 27 PRT
Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide 342
Ala Gln Ala Gln Met Pro Pro Trp Trp Pro Leu Ala Val Asp Ala Leu 1 5
10 15 Phe Asp Trp Phe Glu Gly Gly Gly Gly Gly Lys 20 25 343 27 PRT
Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide 343
Ala Gln Asp Trp Tyr Trp Arg Glu Trp Met Pro Met His Ala Gln Phe 1 5
10 15 Leu Ala Asp Asp Trp Gly Gly Gly Gly Gly Lys 20 25 344 28 PRT
Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide 344
Ala Gln Lys Lys Glu Asp Ala Gln Gln Trp Tyr Trp Thr Asp Tyr Val 1 5
10 15 Pro Ser Tyr Leu Tyr Arg Gly Gly Gly Gly Gly Lys 20 25 345 28
PRT Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide
345 Ala Gln Pro Val Thr Asp Trp Thr Pro His His Pro Lys Ala Pro Asp
1 5 10 15 Val Trp Leu Phe Tyr Thr Gly Gly Gly Gly Gly Lys 20 25 346
28 PRT Artificial Sequence KDR or KDR/VEGF Complex Binding
Polypeptide 346 Ala Gln Asp Ala Leu Glu Ala Pro Lys Arg Asp Trp Tyr
Tyr Asp Trp 1 5 10 15 Phe Leu Asn His Ser Pro Gly Gly Gly Gly Gly
Lys 20 25 347 19 PRT Artificial Sequence KDR or KDR/VEGF Complex
Binding Polypeptide 347 Lys Trp Cys Glu Glu Asp Trp Tyr Tyr Cys Met
Ile Thr Gly Thr Gly 1 5 10 15 Gly Gly Lys 348 19 PRT Artificial
Sequence KDR or KDR/VEGF Complex Binding Polypeptide 348 Ala Gly
Pro Lys Trp Cys Glu Glu Asp Trp Tyr Tyr Cys Met Ile Gly 1 5 10 15
Gly Gly Lys 349 16 PRT Artificial Sequence KDR or KDR/VEGF Complex
Binding Polypeptide 349 Lys Trp Cys Glu Glu Asp Trp Tyr Tyr Cys Met
Ile Gly Gly Gly Lys 1 5 10 15 350 29 PRT Artificial Sequence KDR or
KDR/VEGF Complex Binding Polypeptide 350 Ala Gln Pro Asp Asn Trp
Lys Glu Phe Tyr Glu Ser Gly Trp Lys Tyr 1 5 10 15 Pro Ser Leu Tyr
Lys Pro Leu Gly Gly Gly Gly Gly Lys 20 25 351 28 PRT Artificial
Sequence KDR or KDR/VEGF Complex Binding Polypeptide 351 Ala Gln
Met Pro Pro Gly Phe Ser Tyr Trp Glu Gln Val Val Leu His 1 5 10 15
Asp Asp Ala Gln Val Leu Gly Gly Gly Gly Gly Lys 20 25 352 27 PRT
Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide 352
Ala Gln Ala Arg Met Gly Asp Asp Trp Glu Glu Ala Pro Pro His Glu 1 5
10 15 Trp Gly Trp Ala Asp Gly Gly Gly Gly Gly Lys 20 25 353 28 PRT
Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide 353
Ala Gln Pro Glu Asp Ser Glu Ala Trp Tyr Trp Leu Asn Tyr Arg Pro 1 5
10 15 Thr Met Phe His Gln Leu Gly Gly Gly Gly Gly Lys 20 25 354 27
PRT Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide
354 Ala Gln Ser Thr Asn Gly Asp Ser Phe Val Tyr Trp Glu Glu Val Glu
1 5 10 15 Leu Val Asp His Pro Gly Gly Gly Gly Gly Lys 20 25 355 28
PRT Artificial Sequence KDR or KDR/VEGF Complex Binding Polypeptide
355 Ala Gln Trp Glu Ser Asp Tyr Trp Asp Gln Met Arg Gln Gln Leu Lys
1 5 10 15 Thr Ala Tyr Met Lys Val Gly Gly Gly Gly Gly Lys 20 25 356
28 PRT Artificial Sequence KDR or KDR/VEGF Complex Binding
Polypeptide 356 Ala Gln Asp Trp Tyr Tyr Asp Glu Ile Leu Ser Met Ala
Asp Gln Leu 1 5 10 15 Arg His Ala Phe Leu Ser Gly Gly Gly Gly Gly
Lys 20 25 357 30 DNA Artificial Sequence Smart II Oligonucleotide
357 aagcagtggt aacaacgcag agtacgcggg 30 358 23 DNA Artificial
Sequence Oligonucleotide for Cloning 358 gatggagagc aaggtgctgc tgg
23 359 23 DNA Artificial Sequence Oligonucleotide for Cloning 359
ccaagttcgt cttttcctgg gca 23 360 36 DNA Artificial Sequence
Oligonucleotide for Cloning 360 tcccccggga tcattattct agtaggcacg
gcggtg 36 361 23 DNA Artificial Sequence Oligonucleotide for
Cloning 361 caggaggaga gctcagtgtg gtc 23 362 41 DNA Artificial
Sequence Oligonucleotide for Cloning 362 ataagaatgc ggccgcagga
tggagagcaa ggtgctgctg g 41 363 27 DNA Artificial Sequence
Oligonucleotide for Cloning 363 ttccaagttc gtcttttcct gggcacc 27
364 27 DNA Artificial Sequence Oligonucleotide for Cloning 364
atcattattc tagtaggcac ggcggtg 27 365 41 DNA Artificial Sequence
Oligonucleotide for Cloning 365 ataagaatgc ggccgcaaca ggaggagagc
tcagtgtggt c 41 366 26 PRT Artificial Sequence KDR-Binding
Polypeptide 366 Gly Asp Trp Trp Glu Cys Lys Arg Glu Glu Tyr Arg Asn
Thr Thr Trp 1 5 10 15 Cys Ala Trp Ala Asp Pro Gly Gly Gly Lys 20 25
367 23 PRT Artificial Sequence KDR-Binding Polypeptide 367 Ala Gly
Pro Gly Pro Cys Lys Gly Tyr Met Pro His Gln Cys Trp Tyr 1 5 10 15
Met Gly Thr Gly Gly Gly Lys 20 368 17 PRT Artificial Sequence
KDR-Binding Polypeptide 368 Val Cys Trp Glu Asp Ser Trp Gly Gly Glu
Val Cys Phe Gly Gly Gly 1 5 10 15 Lys 369 21 PRT Artificial
Sequence KDR-Binding Polypeptide 369 Gly Asp Ser Arg Val Cys Trp
Glu Asp Ser Trp Gly Gly Glu Val Cys 1 5 10 15 Phe Gly Gly Gly Lys
20 370 20 PRT Artificial Sequence KDR-Binding Polypeptide 370 Val
Cys Trp Glu Asp Ser Trp Gly Gly Glu Val Cys Phe Arg Tyr Asp 1 5 10
15 Pro Gly Gly Gly
20 371 22 PRT Artificial Sequence KDR-Binding Polypeptide 371 Ser
Arg Val Cys Trp Glu Asp Ser Trp Gly Gly Glu Val Cys Phe Arg 1 5 10
15 Tyr Gly Gly Gly Gly Lys 20 372 23 PRT Artificial Sequence
KDR-Binding Polypeptide 372 Gly Asp Ser Arg Val Cys Trp Glu Asp Ser
Trp Gly Gly Glu Val Cys 1 5 10 15 Phe Arg Tyr Gly Gly Gly Lys 20
373 23 PRT Artificial Sequence KDR-Binding Polypeptide 373 Ala Gly
Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15
Gly Thr Gly Gly Gly Lys Lys 20 374 21 PRT Artificial Sequence
KDR-Binding Polypeptide 374 Gly Asp Ser Arg Val Cys Trp Glu Asp Ser
Trp Gly Gly Glu Val Cys 1 5 10 15 Phe Arg Tyr Asp Pro 20 375 18 PRT
Artificial Sequence KDR-Binding Polypeptide 375 Ala Gly Asp Ser Trp
Cys Ser Thr Glu Tyr Thr Tyr Cys Glu Met Ile 1 5 10 15 Gly Thr 376
24 PRT Artificial Sequence KDR-Binding Polypeptide 376 Ala Gln Asp
Trp Tyr Tyr Asp Glu Ile Leu Ser Met Ala Asp Gln Leu 1 5 10 15 Arg
His Ala Phe Leu Ser Gly Gly 20 377 26 PRT Artificial Sequence
Negative Control Polypeptide 377 Ala Glu Gly Thr Gly Asp Leu His
Cys Tyr Phe Pro Trp Val Cys Ser 1 5 10 15 Leu Asp Pro Gly Pro Glu
Gly Gly Gly Lys 20 25 378 22 PRT Artificial Sequence KDR-Binding
Polypeptide 378 Ala Gly Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr Cys
Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 379 22 PRT
Artificial Sequence KDR-Binding Polypeptide 379 Ala Gly Pro Thr Trp
Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15 Ala Thr Gly
Gly Gly Lys 20 380 26 PRT Artificial Sequence Vector Template 380
Ala Gln Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5
10 15 Xaa Xaa Xaa Xaa Gly Gly Gly Gly Gly Lys 20 25 381 29 PRT
Artificial Sequence Library Isolate 381 Ala Gln Pro Asp Asn Trp Lys
Glu Phe Tyr Glu Ser Gly Trp Lys Tyr 1 5 10 15 Pro Ser Leu Tyr Lys
Pro Leu Gly Gly Gly Gly Gly Lys 20 25 382 28 PRT Artificial
Sequence Library Isolate 382 Ala Gln Gln Ile Glu Tyr Val Asn Asp
Lys Trp Tyr Trp Thr Gly Gly 1 5 10 15 Tyr Trp Asn Val Pro Phe Gly
Gly Gly Gly Gly Lys 20 25 383 28 PRT Artificial Sequence Library
Isolate 383 Ala Gln Asp Ala Leu Glu Ala Pro Lys Arg Asp Trp Tyr Tyr
Asp Trp 1 5 10 15 Phe Leu Asn His Ser Pro Gly Gly Gly Gly Gly Lys
20 25 384 28 PRT Artificial Sequence Library Isolate 384 Ala Gln
Trp Tyr His Asp Gly Leu His Asn Glu Arg Lys Pro Pro Ser 1 5 10 15
His Trp Ile Asp Asn Val Gly Gly Gly Gly Gly Lys 20 25 385 28 PRT
Artificial Sequence Library Isolate 385 Ala Gln Asp Trp Tyr Trp Gln
Arg Glu Arg Asp Lys Leu Arg Glu His 1 5 10 15 Tyr Asp Asp Ala Phe
Trp Gly Gly Gly Gly Gly Lys 20 25 386 22 PRT Artificial Sequence
Library Isolate 386 Ala Ala Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr
Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 387 22 PRT
Artificial Sequence Library Isolate 387 Ala Gly Ala Thr Trp Cys Glu
Asp Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 388 22 PRT Artificial Sequence Library Isolate 388 Ala Gly
Pro Ala Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15
Gly Thr Gly Gly Gly Lys 20 389 22 PRT Artificial Sequence Library
Isolate 389 Ala Gly Pro Thr Ala Cys Glu Asp Asp Trp Tyr Tyr Cys Trp
Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 390 22 PRT Artificial
Sequence Library Isolate 390 Ala Gly Pro Thr Trp Cys Ala Asp Asp
Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20
391 22 PRT Artificial Sequence Library Isolate 391 Ala Gly Pro Thr
Trp Cys Glu Ala Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15 Gly Thr
Gly Gly Gly Lys 20 392 22 PRT Artificial Sequence Library Isolate
392 Ala Gly Pro Thr Trp Cys Glu Asp Ala Trp Tyr Tyr Cys Trp Leu Phe
1 5 10 15 Gly Thr Gly Gly Gly Lys 20 393 22 PRT Artificial Sequence
Library Isolate 393 Ala Gly Pro Thr Trp Cys Glu Asp Asp Ala Tyr Tyr
Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 394 22 PRT
Artificial Sequence Library Isolate 394 Ala Gly Pro Thr Trp Cys Glu
Asp Asp Trp Ala Tyr Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 395 22 PRT Artificial Sequence Library Isolate 395 Ala Gly
Pro Thr Trp Cys Glu Asp Asp Trp Tyr Ala Cys Trp Leu Phe 1 5 10 15
Gly Thr Gly Gly Gly Lys 20 396 22 PRT Artificial Sequence Library
Isolate 396 Ala Gly Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Ala
Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 397 22 PRT Artificial
Sequence Library Isolate 397 Ala Gly Pro Thr Trp Cys Glu Asp Asp
Trp Tyr Tyr Cys Trp Ala Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20
398 22 PRT Artificial Sequence Library Isolate 398 Ala Gly Pro Thr
Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Leu Ala 1 5 10 15 Gly Thr
Gly Gly Gly Lys 20 399 22 PRT Artificial Sequence Library Isolate
399 Ala Gly Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Leu Phe
1 5 10 15 Ala Thr Gly Gly Gly Lys 20 400 22 PRT Artificial Sequence
Library Isolate 400 Ala Gly Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr
Cys Trp Leu Phe 1 5 10 15 Gly Ala Gly Gly Gly Lys 20 401 22 PRT
Artificial Sequence Library Isolate 401 Ala Ala Pro Thr Trp Cys Glu
Asp Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 402 22 PRT Artificial Sequence Library Isolate 402 Ala Gly
Ala Thr Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15
Gly Thr Gly Gly Gly Lys 20 403 22 PRT Artificial Sequence Library
Isolate 403 Ala Gly Pro Ala Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp
Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 404 22 PRT Artificial
Sequence Library Isolate 404 Ala Gly Pro Thr Ala Cys Glu Asp Asp
Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20
405 22 PRT Artificial Sequence Library Isolate 405 Ala Gly Pro Thr
Trp Cys Ala Asp Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15 Gly Thr
Gly Gly Gly Lys 20 406 22 PRT Artificial Sequence Library Isolate
406 Ala Gly Pro Thr Trp Cys Glu Ala Asp Trp Tyr Tyr Cys Trp Leu Phe
1 5 10 15 Gly Thr Gly Gly Gly Lys 20 407 22 PRT Artificial Sequence
Library Isolate 407 Ala Gly Pro Thr Trp Cys Glu Asp Ala Trp Tyr Tyr
Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 408 22 PRT
Artificial Sequence Library Isolate 408 Ala Gly Pro Thr Trp Cys Glu
Asp Asp Ala Tyr Tyr Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 409 22 PRT Artificial Sequence Library Isolate 409 Ala Gly
Pro Thr Trp Cys Glu Asp Asp Trp Ala Tyr Cys Trp Leu Phe 1 5 10 15
Gly Thr Gly Gly Gly Lys 20 410 22 PRT Artificial Sequence Library
Isolate 410 Ala Gly Pro Thr Trp Cys Glu Asp Asp Trp Tyr Ala Cys Trp
Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 411 22 PRT Artificial
Sequence Library Isolate 411 Ala Gly Pro Thr Trp Cys Glu Asp Asp
Trp Tyr Tyr Cys Ala Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20
412 22 PRT Artificial Sequence Library Isolate 412 Ala Gly Pro Thr
Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Ala Phe 1 5 10 15 Gly Thr
Gly Gly Gly Lys 20 413 22 PRT Artificial Sequence Library Isolate
413 Ala Gly Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Leu Ala
1 5 10 15 Gly Thr Gly Gly Gly Lys 20 414 22 PRT Artificial Sequence
Library Isolate 414 Ala Gly Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr
Cys Trp Leu Phe 1 5 10 15 Ala Thr Gly Gly Gly Lys 20 415 22 PRT
Artificial Sequence Library Isolate 415 Ala Gly Pro Thr Trp Cys Glu
Asp Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15 Gly Ala Gly Gly Gly
Lys 20 416 25 PRT Artificial Sequence Library Isolate 416 Gly Asp
Ser Arg Val Cys Trp Glu Asp Ala Trp Gly Gly Glu Val Cys 1 5 10 15
Phe Arg Tyr Asp Pro Gly Gly Gly Lys 20 25 417 25 PRT Artificial
Sequence Library Isolate 417 Gly Asp Ser Arg Val Cys Trp Glu Asp
Ser Trp Ala Gly Glu Val Cys 1 5 10 15 Phe Arg Tyr Asp Pro Gly Gly
Gly Lys 20 25 418 25 PRT Artificial Sequence Library Isolate 418
Gly Asp Ser Arg Val Cys Trp Glu Asp Ser Trp Gly Ala Glu Val Cys 1 5
10 15 Phe Arg Tyr Asp Pro Gly Gly Gly Lys 20 25 419 21 PRT
Artificial Sequence Library Isolate 419 Ala Gly Thr Trp Cys Glu Asp
Asp Trp Tyr Tyr Cys Leu Phe Thr Gly 1 5 10 15 Thr Gly Gly Gly Lys
20 420 4 PRT Artificial Sequence Binding Motif 420 Asp Trp Tyr Tyr
1 421 9 PRT Artificial Sequence Library Isolate 421 Gly Asp Trp Tyr
Tyr Gly Gly Gly Lys 1 5 422 10 PRT Artificial Sequence Library
Isolate 422 Glu Asp Asp Trp Tyr Tyr Gly Gly Gly Lys 1 5 10 423 16
PRT Artificial Sequence Library Isolate 423 Ala Gln Asp Trp Tyr Tyr
Ala Trp Leu Phe Thr Gly Gly Gly Gly Lys 1 5 10 15 424 9 PRT
Artificial Sequence Library Isolate 424 Ala Gln Asp Trp Tyr Tyr Ala
Trp Leu 1 5 425 22 PRT Artificial Sequence Library Isolate 425 Ala
Gly Pro Thr Trp Cys Glu Asp Glu Trp Tyr Tyr Cys Trp Leu Phe 1 5 10
15 Gly Thr Gly Gly Gly Lys 20 426 22 PRT Artificial Sequence
Library Isolate 426 Ala Gly Pro Thr Trp Cys Glu Asp Asp Trp Trp Tyr
Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 427 22 PRT
Artificial Sequence Library Isolate 427 Ala Gly Pro Thr Trp Cys Glu
Asp Asp Trp Phe Tyr Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 428 22 PRT Artificial Sequence Library Isolate 428 Ala Gly
Pro Thr Trp Ala Glu Asp Asp Trp Tyr Tyr Ala Trp Leu Phe 1 5 10 15
Gly Thr Gly Gly Gly Lys 20 429 22 PRT Artificial Sequence Library
Isolate 429 Ala Ala Pro Ala Trp Cys Ala Ala Asp Trp Tyr Tyr Cys Trp
Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 430 22 PRT Artificial
Sequence Library Isolate 430 Ala Gly Pro Thr Trp Cys Ala Asp Asp
Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20
431 17 PRT Artificial Sequence Library Isolate 431 Cys Glu Asp Asp
Trp Tyr Tyr Cys Trp Leu Phe Gly Thr Gly Gly Gly 1 5 10 15 Lys 432
18 PRT Artificial Sequence Library Isolate 432 Trp Cys Glu Asp Asp
Trp Tyr Tyr Cys Trp Leu Phe Gly Thr Gly Gly 1 5 10 15 Gly Lys 433
12 PRT Artificial Sequence Library Isolate 433 Trp Cys Ala Ala Asp
Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 434 12 PRT Artificial Sequence
Library Isolate 434 Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Leu Phe
1 5 10 435 19 PRT Artificial Sequence Library Isolate 435 Val Cys
Trp Glu Asp Ser Trp Gly Gly Glu Val Cys Phe Arg Tyr Gly 1 5 10 15
Gly Gly Lys 436 25 PRT Artificial Sequence Library Isolate 436 Gly
Asp Ser Arg Val Ala Trp Glu Asp Ser Trp Gly Gly Glu Val Ala 1 5 10
15 Phe Arg Tyr Asp Pro Gly Gly Gly Lys 20 25 437 19 PRT Artificial
Sequence Library Isolate 437 Val Cys Trp Glu Asp Ser Trp Gly Gly
Glu Val Cys Phe Arg Tyr Gly 1 5 10 15 Gly Gly Lys 438 25 PRT
Artificial Sequence Library Isolate 438 Gly Asp Ser Arg Val Cys Trp
Glu Asp Ala Trp Gly Gly Glu Val Cys 1 5 10 15 Phe Arg Tyr Asp Pro
Gly Gly Gly Lys 20 25 439 25 PRT Artificial Sequence Library
Isolate 439 Gly Asp Ser Arg Val Cys Trp Glu Asp Phe Trp Gly Gly Glu
Val Cys 1 5 10 15 Phe Arg Tyr Asp Pro Gly Gly Gly Lys 20 25 440 25
PRT Artificial Sequence Library Isolate 440 Gly Asp Ser Arg Val Cys
Trp Glu Asp Lys Trp Gly Gly Glu Val Cys 1 5 10 15 Phe Arg Tyr Asp
Pro Gly Gly Gly Lys 20 25 441 25 PRT Artificial Sequence Library
Isolate 441 Gly Asp Ser Arg Val Cys Trp Glu Asp Ser Trp Gly Phe Glu
Val Cys 1 5 10 15 Phe Arg Tyr Asp Pro Gly Gly Gly Lys 20 25 442 25
PRT Artificial Sequence Library Isolate 442 Gly Asp Ser Arg Val Cys
Trp Glu Asp Ser Trp Gly Lys Glu Val Cys 1 5 10 15 Phe Arg Tyr Asp
Pro Gly Gly Gly Lys 20 25 443 25 PRT Artificial Sequence Library
Isolate 443 Gly Asp Ser Arg Val Cys Trp Glu Asp Ser Trp Gly Glu Glu
Val Cys 1 5 10 15 Phe Arg Tyr Asp Pro Gly Gly Gly Lys 20 25 444 23
PRT Artificial Sequence Library Isolate 444 Ala Gly Met Pro Trp Cys
Val Glu Lys Asp His Trp Asp Cys Trp Trp 1 5 10 15 Trp Gly Thr Gly
Gly Gly Lys 20 445 26 PRT Artificial Sequence Library Isolate 445
Gly Asp Gly Ser Trp Cys Glu Met Arg Gln Asp Val Gly Lys Trp Asn 1 5
10 15 Cys Phe Ser Asp Asp Pro Gly Gly Gly Lys 20 25 446 26 PRT
Artificial Sequence Library Isolate 446 Gly Cys Lys Thr Lys Ile Ser
Lys Val Lys Lys Lys Trp Asn Cys Tyr 1 5 10 15 Ser Asn Asn Lys Val
Thr Gly Gly Gly Lys 20 25 447 26 PRT Artificial Sequence Library
Isolate 447 Lys Gln Phe Cys Glu Glu Asn Trp Glu Arg Gly Arg Asn His
Tyr Tyr 1 5 10 15 Cys Leu Thr Thr Leu Ser Gly Gly Gly Lys 20 25 448
25 PRT Artificial Sequence Library Isolate 448 Gly Asp Ser Arg Val
Cys Trp Glu Asp Trp Gly Gly Val Val Cys Arg 1 5 10 15 Tyr Arg Tyr
Asp Ala Gly Gly Gly Lys 20 25 449 17 PRT Artificial Sequence
Library Isolate 449 Cys Glu Glu Asp Trp Tyr Tyr Cys Met Ile Thr Gly
Thr Gly Gly Gly 1 5 10 15 Lys 450 18 PRT Artificial Sequence
Library Isolate 450 Ala Gly Pro Lys Trp Cys Glu Glu Asp Trp Tyr Tyr
Cys Met Ile Thr 1 5 10 15 Ala Thr 451 21 PRT Artificial Sequence
Library Isolate 451 Ala Ala Pro Lys Trp Cys Glu Glu Asp Tyr Tyr Cys
Met Ile Thr Gly 1 5 10 15 Thr Gly Gly Gly Lys 20 452 17 PRT
Artificial Sequence Library Isolate 452 Ala Gly Pro Asp Trp Cys Ala
Ala Asp Trp Tyr Tyr Cys Tyr Ile Thr 1 5 10 15 Gly 453 22 PRT
Artificial Sequence Library Isolate 453 Ala Gly Pro Thr Trp Glu Glu
Asp Asp Trp Tyr Tyr Lys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 454 22 PRT Artificial Sequence Library Isolate 454 Ala Gly
Pro Thr Trp Lys Glu Asp Asp Trp Tyr Tyr Glu Trp Leu Phe 1 5 10 15
Gly Thr Gly Gly Gly Lys 20 455 22 PRT Artificial Sequence Library
Isolate 455 Ala Gly Pro Thr Trp Xaa Glu Asp Asp Trp Tyr Tyr Cys Trp
Leu Phe 1 5 10
15 Gly Thr Gly Gly Gly Lys 20 456 22 PRT Artificial Sequence
Library Isolate 456 Ala Gly Pro Thr Trp Asp Glu Asp Asp Trp Tyr Tyr
Xaa Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 457 22 PRT
Artificial Sequence Library Isolate 457 Ala Gly Pro Thr Trp Asp Glu
Asp Asp Trp Tyr Tyr Lys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly
Lys 20 458 17 PRT Artificial Sequence Library Isolate 458 Ala Gln
Asp Trp Tyr Tyr Asp Glu Ile Leu Ser Met Ala Asp Gln Leu 1 5 10 15
Arg 459 14 PRT Artificial Sequence Library Isolate 459 Asp Trp Tyr
Tyr Asp Glu Ile Leu Ser Met Ala Asp Gln Leu 1 5 10 460 22 PRT
Artificial Sequence Library Isolate 460 Ala Gln Asp Trp Tyr Tyr Asp
Glu Ile Leu Ser Met Ala Asp Gln Leu 1 5 10 15 Arg His Ala Phe Leu
Ser 20 461 10 PRT Artificial Sequence Library Isolate 461 Ala Gln
Asp Trp Tyr Tyr Gly Gly Gly Lys 1 5 10 462 8 PRT Artificial
Sequence Library Isolate 462 Asp Trp Tyr Tyr Gly Gly Gly Lys 1 5
463 10 PRT Artificial Sequence Library Isolate 463 Ala Gln Asp Trp
Tyr Tyr Asp Glu Ile Leu 1 5 10 464 28 PRT Artificial Sequence
Library Isolate 464 Ala Glu Trp Ser Tyr Gln Asp Met Ile Arg Leu Asp
Tyr Ala Asp Leu 1 5 10 15 Gln Leu Ser His Phe Ala Gly Gly Gly Gly
Gly Lys 20 25 465 19 PRT Artificial Sequence Library Isolate 465
Ala Gln Asp Trp Tyr Tyr Asp Glu Ile Leu Gly Arg Gly Arg Gly Gly 1 5
10 15 Arg Gly Gly 466 16 PRT Artificial Sequence Library Isolate
466 Glu Asp Asp Trp Tyr Tyr Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly
1 5 10 15 467 15 PRT Artificial Sequence Library Isolate 467 Gly
Asp Trp Tyr Tyr Gly Arg Gly Gly Arg Gly Gly Arg Gly Gly 1 5 10 15
468 21 PRT Artificial Sequence Library Isolate 468 Ala Gln Asp Trp
Tyr Tyr Ala Trp Leu Phe Thr Gly Arg Gly Gly Arg 1 5 10 15 Gly Gly
Arg Gly Gly 20 469 19 PRT Artificial Sequence Library Isolate 469
Ala Gln Asp Trp Tyr Tyr Ala Trp Leu Gly Arg Gly Gly Arg Gly Gly 1 5
10 15 Arg Gly Gly 470 22 PRT Artificial Sequence Library Isolate
470 Ala Gln Asp Trp Tyr Tyr Asp Glu Ile Leu Gly Arg Gly Gly Arg Gly
1 5 10 15 Gly Arg Gly Gly Lys Lys 20 471 21 PRT Artificial Sequence
Library Isolate 471 Gly Asp Ser Arg Val Cys Trp Pro Asp Ser Trp Gly
Gly Glu Val Cys 1 5 10 15 Phe Arg Tyr Asp Pro 20 472 21 PRT
Artificial Sequence Library Isolate 472 Gly Asp Ser Arg Val Cys Trp
Glu Asp Ser Trp Gly Gly Val Glu Cys 1 5 10 15 Phe Arg Tyr Asp Pro
20 473 21 PRT Artificial Sequence Library Isolate 473 Ala Gln Asp
Trp Tyr Tyr Asp Glu Ile Leu Gly Arg Gly Gly Arg Gly 1 5 10 15 Gly
Arg Gly Gly Lys 20 474 28 PRT Artificial Sequence Library Isolate
474 Trp Tyr Leu Asp Arg Gln Ala Asp Phe Met Tyr Ser Ala Gln Ala Glu
1 5 10 15 Asp Ser Leu Ile Leu His Gly Gly Gly Gly Gly Lys 20 25 475
25 PRT Artificial Sequence Library isolate 475 Val Cys Trp Glu Asp
Ser Trp Glu Asp Ser Trp Gly Gly Glu Val Cys 1 5 10 15 Phe Arg Tyr
Asp Pro Gly Gly Gly Lys 20 25 476 22 PRT Artificial Sequence
Library Isolate 476 Ala Gly Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr
Cys Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Lys 20 477 25 PRT
Artificial Sequence Library Isolate 477 Gly Asp Ser Arg Val Cys Trp
Glu Asp Ser Trp Gly Gly Glu Val Cys 1 5 10 15 Phe Arg Tyr Asp Pro
Gly Gly Gly Lys 20 25 478 21 PRT Artificial Sequence Synthesized
KDR-Binding Polypeptide 478 Ala Gln Asp Trp Tyr Tyr Asp Glu Ile Leu
Gly Arg Gly Gly Arg Gly 1 5 10 15 Gly Arg Gly Gly Lys 20 479 22 PRT
Artificial Sequence Library isolate 479 Ala Gly Pro Thr Trp Cys Asp
Tyr Asp Trp Glu Tyr Cys Trp Leu Phe 1 5 10 15 Thr Phe Gly Gly Gly
Leu 20 480 23 PRT Artificial Sequence Synthesized KDR-Binding
Polypeptide 480 Ala Gly Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr Cys
Trp Leu Phe 1 5 10 15 Gly Thr Gly Gly Gly Gly Lys 20 481 21 PRT
Artificial Sequence Synthesized KDR-Binding Polypeptide 481 Ala Gly
Pro Thr Trp Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15
Thr Gly Gly Gly Lys 20 482 24 PRT Artificial Sequence Synthesized
KDR-Binding Polypeptide 482 Gly Ser Pro Glu Met Cys Met Met Phe Pro
Phe Leu Tyr Pro Cys Asn 1 5 10 15 His His Ala Pro Gly Gly Gly Lys
20 483 24 PRT Artificial Sequence Library isolate 483 Gly Ser Phe
Phe Pro Cys Trp Arg Ile Asp Arg Phe Gly Tyr Cys His 1 5 10 15 Ala
Asn Ala Pro Gly Gly Gly Lys 20 484 26 PRT Artificial Sequence
Library isolate 484 Ala Gln Glu Trp Glu Arg Glu Tyr Phe Val Asp Gly
Phe Trp Gly Ser 1 5 10 15 Trp Phe Gly Ile Pro His Gly Gly Gly Lys
20 25 485 26 PRT Artificial Sequence Library isolate 485 Gly Asp
Tyr Ser Glu Cys Phe Phe Glu Pro Asp Ser Phe Glu Val Lys 1 5 10 15
Cys Tyr Asp Arg Asp Pro Gly Gly Gly Lys 20 25 486 26 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 486 Gly Asp Trp Trp
Glu Cys Lys Arg Glu Glu Tyr Arg Asn Thr Thr Trp 1 5 10 15 Cys Ala
Trp Ala Asp Pro Gly Gly Gly Lys 20 25 487 25 PRT Artificial
Sequence Synthesized KDR-Binding Polypeptide 487 Gly Asp Ser Ser
Val Cys Phe Glu Tyr Ser Trp Gly Gly Glu Val Cys 1 5 10 15 Phe Arg
Tyr Asp Pro Gly Gly Gly Lys 20 25 488 25 PRT Artificial Sequence
Synthesized KDR-Binding Polypeptide 488 Gly Asp Ser Arg Val Cys Trp
Glu Tyr Ser Trp Gly Gly Gln Ile Cys 1 5 10 15 Leu Gly Tyr Asp Pro
Gly Gly Gly Lys 20 25 489 25 PRT Artificial Sequence Library
Isolate 489 Gly Val Asp Phe Arg Cys Glu Trp Ser Asp Trp Gly Glu Val
Gly Cys 1 5 10 15 Arg Ser Pro Asp Tyr Gly Gly Gly Lys 20 25 490 4
PRT Artificial Sequence Binding Motif 490 Ala Trp Tyr Tyr 1 491 15
PRT Artificial Sequence Polypeptide Linker 491 Gly Gly Ser Gly Gly
Glu Gly Arg Pro Gly Glu Gly Gly Ser Gly 1 5 10 15 492 16 PRT
Artificial Sequence Polypeptide Linker 492 Gly Ser Glu Ser Gly Gly
Arg Pro Glu Gly Gly Ser Gly Glu Gly Gly 1 5 10 15 493 19 PRT
Artificial Sequence KDR-Binding Polypeptide 493 Ala Gly Pro Thr Trp
Cys Glu Asp Asp Trp Tyr Tyr Cys Trp Leu Phe 1 5 10 15 Gly Thr Lys
494 22 PRT Artificial Sequence KDR-Binding Polypeptide 494 Val Cys
Trp Glu Asp Ser Trp Gly Gly Glu Val Cys Phe Arg Tyr Asp 1 5 10 15
Pro Gly Gly Gly Lys Lys 20 495 29 PRT Artificial Sequence
KDR-Binding Polypeptide 495 Ala Gln Asp Trp Tyr Tyr Asp Glu Ile Leu
Ser Met Ala Asp Gln Leu 1 5 10 15 Arg His Ala Phe Leu Ser Gly Gly
Gly Gly Gly Lys Lys 20 25 496 21 PRT Artificial Sequence
KDR-Binding Polypeptide 496 Ala Gln Asp Trp Tyr Tyr Glu Ile Leu Gly
Arg Gly Gly Arg Gly Gly 1 5 10 15 Arg Gly Gly Lys Lys 20 497 22 PRT
Artificial Sequence KDR-Binding Polypeptide 497 Ala Pro Gly Thr Trp
Cys Asp Tyr Asp Trp Glu Tyr Cys Trp Leu Gly 1 5 10 15 Thr Phe Gly
Gly Gly Lys 20 498 6 PRT Artificial Sequence Carcinoembryonic
Antigen-Derived Peptide 498 Tyr Pro Glu Leu Pro Lys 1 5 499 13 PRT
Artificial Sequence Carcinoembryonic Antigen-Derived Peptide 499
Arg Val Tyr Pro Glu Leu Pro Lys Pro Ser Gly Gly Gly 1 5 10 500 585
PRT Artificial Sequence Homo sapiens 500 Asp Ala His Lys Ser Glu
Val Ala His Arg Phe Lys Asp Leu Gly Glu 1 5 10 15 Glu Asn Phe Lys
Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln 20 25 30 Gln Cys
Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu 35 40 45
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys 50
55 60 Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr
Leu 65 70 75 80 Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys
Gln Glu Pro 85 90 95 Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp
Asp Asn Pro Asn Leu 100 105 110 Pro Arg Leu Val Arg Pro Glu Val Asp
Val Met Cys Thr Ala Phe His 115 120 125 Asp Asn Glu Glu Thr Phe Leu
Lys Lys Tyr Leu Tyr Glu Ile Ala Arg 130 135 140 Arg His Pro Tyr Phe
Tyr Ala Pro Glu Leu Leu Phe Phe Ala Lys Arg 145 150 155 160 Tyr Lys
Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala 165 170 175
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser 180
185 190 Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly
Glu 195 200 205 Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln
Arg Phe Pro 210 215 220 Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val
Thr Asp Leu Thr Lys 225 230 235 240 Val His Thr Glu Cys Cys His Gly
Asp Leu Leu Glu Cys Ala Asp Asp 245 250 255 Arg Ala Asp Leu Ala Lys
Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser 260 265 270 Ser Lys Leu Lys
Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His 275 280 285 Cys Ile
Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser 290 295 300
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala 305
310 315 320 Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr
Ala Arg 325 330 335 Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg
Leu Ala Lys Thr 340 345 350 Tyr Lys Thr Thr Leu Glu Lys Cys Cys Ala
Ala Ala Asp Pro His Glu 355 360 365 Cys Tyr Ala Lys Val Phe Asp Glu
Phe Lys Pro Leu Val Glu Glu Pro 370 375 380 Gln Asn Leu Ile Lys Gln
Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu 385 390 395 400 Tyr Lys Phe
Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro 405 410 415 Gln
Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys 420 425
430 Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys
435 440 445 Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val
Leu His 450 455 460 Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys
Cys Thr Glu Ser 465 470 475 480 Leu Val Asn Arg Arg Pro Cys Phe Ser
Ala Leu Glu Val Asp Glu Thr 485 490 495 Tyr Val Pro Lys Glu Phe Asn
Ala Glu Thr Phe Thr Phe His Ala Asp 500 505 510 Ile Cys Thr Leu Ser
Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala 515 520 525 Leu Val Glu
Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu 530 535 540 Lys
Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys 545 550
555 560 Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu
Val 565 570 575 Ala Ala Ser Arg Ala Ala Leu Gly Leu 580 585 501 690
PRT Artificial Sequence HSA-Linked Dimer 501 Ala Gly Asp Trp Trp
Val Glu Cys Arg Val Gly Thr Gly Leu Cys Tyr 1 5 10 15 Arg Tyr Asp
Thr Gly Thr Gly Gly Gly Lys Pro Gly Gly Ser Gly Gly 20 25 30 Glu
Gly Gly Ser Gly Gly Glu Gly Gly Arg Pro Gly Gly Ser Glu Gly 35 40
45 Gly Thr Gly Gly Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys
50 55 60 Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu Ile Ala
Phe Ala 65 70 75 80 Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val
Lys Leu Val Asn 85 90 95 Glu Val Thr Glu Phe Ala Lys Thr Cys Val
Ala Asp Glu Ser Ala Glu 100 105 110 Asn Cys Asp Lys Ser Leu His Thr
Leu Phe Gly Asp Lys Leu Cys Thr 115 120 125 Val Ala Thr Leu Arg Glu
Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala 130 135 140 Lys Gln Glu Pro
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp 145 150 155 160 Asn
Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys 165 170
175 Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr
180 185 190 Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu
Leu Phe 195 200 205 Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys
Cys Gln Ala Ala 210 215 220 Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu
Asp Glu Leu Arg Asp Glu 225 230 235 240 Gly Lys Ala Ser Ser Ala Lys
Gln Arg Leu Lys Cys Ala Ser Leu Gln 245 250 255 Lys Phe Gly Glu Arg
Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser 260 265 270 Gln Arg Phe
Pro Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr 275 280 285 Asp
Leu Thr Lys Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu 290 295
300 Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln
305 310 315 320 Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu Lys
Pro Leu Leu 325 330 335 Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn
Asp Glu Met Pro Ala 340 345 350 Asp Leu Pro Ser Leu Ala Ala Asp Phe
Val Glu Ser Lys Asp Val Cys 355 360 365 Lys Asn Tyr Ala Glu Ala Lys
Asp Val Phe Leu Gly Met Phe Leu Tyr 370 375 380 Glu Tyr Ala Arg Arg
His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg 385 390 395 400 Leu Ala
Lys Thr Tyr Lys Thr Thr Leu Glu Lys Cys Cys Ala Ala Ala 405 410 415
Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu 420
425 430 Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe
Glu 435 440 445 Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val
Arg Tyr Thr 450 455 460 Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu
Val Glu Val Ser Arg 465 470 475 480 Asn Leu Gly Lys Val Gly Ser Lys
Cys Cys Lys His Pro Glu Ala Lys 485 490 495 Arg Met Pro Cys Ala Glu
Asp Tyr Leu Ser Val Val Leu Asn Gln Leu 500 505 510 Cys Val Leu His
Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys 515 520 525 Cys Thr
Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu 530 535 540
Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr 545
550 555 560 Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln
Ile Lys 565 570 575 Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys
Pro Lys Ala Thr 580 585 590 Lys Glu Gln Leu Lys Ala Val Met Asp Asp
Phe Ala Ala Phe Val Glu 595 600 605 Lys Cys Cys Lys Ala Asp Asp Lys
Glu Thr Cys Phe Ala Glu Glu Gly 610
615 620 Lys Lys Leu Val Ala Ala Ser Arg Ala Ala Leu Gly Leu Gly Gly
Ser 625 630 635 640 Gly Gly Glu Gly Gly Ser Gly Gly Glu Gly Gly Ser
Gly Pro Gly Glu 645 650 655 Gly Gly Glu Gly Ser Gly Gly Arg Pro Gly
Asp Ser Arg Val Cys Trp 660 665 670 Glu Asp Ser Trp Gly Gly Glu Val
Cys Phe Arg Tyr Asp Pro Gly Gly 675 680 685 Gly Lys 690 502 19 PRT
Artificial Sequence Mature HSA 502 Trp Gln Pro Cys Pro Trp Glu Ser
Trp Thr Phe Cys Trp Asp Pro Gly 1 5 10 15 Gly Gly Lys 503 5 PRT
Artificial Sequence NP-1 Binding Peptide 503 Thr Lys Pro Pro Arg 1
5 504 21 PRT Artificial Sequence Library Isolate 504 Glu Arg Val
Thr Thr Cys Trp Pro Gly Glu Tyr Gly Gly Val Glu Cys 1 5 10 15 Tyr
Ser Val Ala Tyr 20 505 21 PRT Artificial Sequence Library Isolate
505 Gly Ser Asn Met Val Cys Met Asp Asp Ser Tyr Gly Gly Thr Thr Cys
1 5 10 15 Tyr Ser Met Ala Pro 20 506 21 PRT Artificial Sequence
Library Isolate 506 Gly Ser Tyr Asn Gln Cys Tyr Gly Asp Tyr Trp Gly
Gly Glu Thr Cys 1 5 10 15 Tyr Leu Ile Ala Pro 20 507 21 PRT
Artificial Sequence Library Isolate 507 Gly Ser Arg Val Asn Cys Gly
Ala Glu Asp Gly Leu Ser Phe Leu Cys 1 5 10 15 Met Met Asp Ala Pro
20 508 21 PRT Artificial Sequence Library Isolate 508 Gly Ser Ile
Trp Asp Cys Gln Ile Ser Glu Tyr Gly Gly Glu Asp Cys 1 5 10 15 Tyr
Leu Val Ala Pro 20 509 21 PRT Artificial Sequence Library Isolate
509 Gly Ser Tyr Trp His Cys Met Asp Asp Phe Phe Gly Gly Glu Thr Cys
1 5 10 15 Phe Ala Thr Ala Pro 20 510 21 PRT Artificial Sequence
Library Isolate 510 Gly Ser Gly Glu Tyr Cys Phe Pro Ser Ile Tyr Gly
Gly Glu Thr Cys 1 5 10 15 Tyr Ala His Ala Pro 20 511 21 PRT
Artificial Sequence Library Isolate 511 Gly Ser Glu Gln Leu Cys Phe
Glu Tyr Gln Tyr Gly Gly Val Glu Cys 1 5 10 15 Phe Gly Pro Ala Pro
20 512 21 PRT Artificial Sequence Library Isolate 512 Gly Ser Thr
Gly Val Cys Ser Pro Ala Pro Tyr Gly Gly Glu Val Cys 1 5 10 15 Tyr
His Phe Ala Pro 20 513 21 PRT Artificial Sequence Library Isolate
513 Gly Ser His Asp Glu Cys Trp Glu Asp Ile Tyr Gly Gly Phe Thr Cys
1 5 10 15 Met Leu Met Ala Pro 20 514 21 PRT Artificial Sequence
Library Isolate 514 Gly Ser Gln His Thr Cys Phe Ser Asp Pro Tyr Gly
Gly Glu Val Cys 1 5 10 15 Tyr Ala Asp Ala Pro 20 515 21 PRT
Artificial Sequence Library Isolate 515 Gly Ser Trp Glu Val Cys Glu
Asn Ser Asn Tyr Gly Gly Gln Ile Cys 1 5 10 15 Tyr Trp Phe Ala Pro
20 516 21 PRT Artificial Sequence Library Isolate 516 Gly Ser His
Glu Met Cys Trp Ser Asp Val Trp Gly Gly Leu Thr Cys 1 5 10 15 Met
Thr Met Ala Pro 20 517 21 PRT Artificial Sequence Library Isolate
517 Gly Ser Leu Ser Leu Cys Lys Phe Phe Gly Asp Gly Ser Tyr Tyr Cys
1 5 10 15 Glu Pro Pro Ala Pro 20 518 21 PRT Artificial Sequence
Library Isolate 518 Gly Ser Thr Arg Phe Cys Glu Pro Tyr Gln Trp Gly
Gly Glu Val Cys 1 5 10 15 Tyr Trp Lys Ala Pro 20 519 21 PRT
Artificial Sequence Library Isolate 519 Gly Ser Phe Ser Thr Cys Ala
Thr Phe Pro Trp Thr Thr Lys Phe Cys 1 5 10 15 Ser Asn Met Ala Pro
20 520 21 PRT Artificial Sequence Library Isolate 520 Gly Ser His
Glu Leu Cys Phe Glu Gly Thr Tyr Gly Gly Glu Val Cys 1 5 10 15 Phe
Ser Met Ala Pro 20 521 21 PRT Artificial Sequence Library Isolate
521 Gly Ser Leu Trp His Cys Phe Asn Asp Val Tyr Gly Gly Glu Asn Cys
1 5 10 15 Ile Pro Phe Ala Pro 20 522 21 PRT Artificial Sequence
Library Isolate 522 Gly Ser Gln Gln Tyr Cys Ile Pro Ala Glu Tyr Gly
Gly Met Glu Cys 1 5 10 15 Tyr Pro Phe Ala Pro 20 523 21 PRT
Artificial Sequence Library Isolate 523 Gly Ser Ile Gln Asn Cys Trp
Lys Tyr Glu Phe Gly Gly Ile Val Cys 1 5 10 15 Met Asp Met Ala Pro
20 524 21 PRT Artificial Sequence Library Isolate 524 Gly Ser Val
Ser Gly Cys Lys Glu Phe Trp Asn Ser Ser Gly Arg Cys 1 5 10 15 Phe
Thr His Ala Pro 20 525 21 PRT Artificial Sequence Library Isolate
525 Gly Ser Leu Trp Glu Cys Arg Gly Asp Phe Tyr Gly Gly Glu Val Cys
1 5 10 15 Phe Asn Tyr Ala Pro 20 526 21 PRT Artificial Sequence
Library Isolate 526 Gly Ser Asn Leu Ile Cys Tyr Asp Tyr Tyr Tyr Gly
Gly Gln Asp Cys 1 5 10 15 Tyr His Asp Ala Pro 20 527 21 PRT
Artificial Sequence Library Isolate 527 Gly Ser Glu Gly Thr Cys Glu
Glu Tyr Gln Tyr Gly Gly Ile Val Cys 1 5 10 15 Trp Trp Gly Ala Pro
20 528 21 PRT Artificial Sequence Library Isolate 528 Pro Gly Ser
Gly Asp Cys Asp Trp Tyr Tyr Glu Trp Leu Phe Asp Cys 1 5 10 15 Pro
Leu Asn Ala Pro 20 529 21 PRT Artificial Sequence Library Isolate
529 Gly Ser Asp Gln Met Cys Phe Asn Glu Ser Phe Gly Gly Gln Ile Cys
1 5 10 15 Phe Tyr Ser Ala Pro 20 530 21 PRT Artificial Sequence
Library Isolate 530 Gly Ser Gly Met Ala Cys Met Ser Asp Pro Tyr Gly
Gly Gln Val Cys 1 5 10 15 Tyr Ala Ile Ala Pro 20 531 21 PRT
Artificial Sequence Library Isolate 531 Gly Ser Glu Leu Thr Cys Trp
Asp Ser Ala Tyr Gly Gly Asn Glu Cys 1 5 10 15 Phe Phe Phe Ala Pro
20 532 21 PRT Artificial Sequence Library Isolate 532 Gly Ser His
Phe Leu Cys Val Lys Glu Met Glu Gly Gly Glu Thr Cys 1 5 10 15 Tyr
Tyr Ser Ala Pro 20 533 21 PRT Artificial Sequence Library Isolate
533 Gly Ser Trp Glu Ile Cys Phe Ala Gly Pro Tyr Gly Gly Ser Trp Cys
1 5 10 15 Ile Pro Glu Ala Pro 20 534 21 PRT Artificial Sequence
Library Isolate 534 Gly Ser Ala Gln Tyr Cys Met Glu Ser Tyr Tyr Gly
Gly Phe Thr Cys 1 5 10 15 Val Thr Leu Ala Pro 20 535 21 PRT
Artificial Sequence Library Isolate 535 Gly Ser Phe Asn Ala Cys Gly
Phe Glu Glu Gly Leu Glu Trp Met Cys 1 5 10 15 Tyr Arg Gln Ala Pro
20 536 21 PRT Artificial Sequence Library Isolate 536 Gly Ser Lys
Leu Leu Cys Gln Tyr Trp Glu His Glu Trp Trp Pro Cys 1 5 10 15 Met
Asn Glu Ala Pro 20 537 21 PRT Artificial Sequence Library Isolate
537 Gly Ser Asn Met Asn Cys Gly Ala Glu Gln Gly Leu Glu Ser Leu Cys
1 5 10 15 Gly Trp Arg Ala Pro 20 538 21 PRT Artificial Sequence
Library Isolate 538 Gly Ser Asn Trp Val Cys Leu Ser Glu Gly Tyr Gly
Gly Met Thr Cys 1 5 10 15 Tyr Pro Ser Ala Pro 20 539 21 PRT
Artificial Sequence Library Isolate 539 Gly Ser Pro Ser Thr Cys Ile
Tyr Ser Ser Gly Leu Ile Val Asp Cys 1 5 10 15 Gly Leu Leu Ala Pro
20 540 21 PRT Artificial Sequence Library Isolate 540 Gly Ser Thr
Gln His Cys Trp Pro Ser Glu Tyr Gly Gly Met Thr Cys 1 5 10 15 Val
Pro Ala Ala Pro 20 541 21 PRT Artificial Sequence Library Isolate
541 Gly Ser Thr Trp Ala Cys Glu Glu Ile Ser Ala His His Thr Lys Cys
1 5 10 15 Thr Tyr Gln Ala Pro 20 542 21 PRT Artificial Sequence
Library Isolate 542 Gly Ser Tyr Thr Glu Cys Trp Glu Glu Asp Tyr Gly
Gly Val Thr Cys 1 5 10 15 Phe Asn Val Ala Pro 20 543 21 PRT
Artificial Sequence Library Isolate 543 Gly Ser Asp Lys Phe Cys Phe
Lys Asp Pro Trp Gly Gly Val Thr Cys 1 5 10 15 Tyr His Leu Ala Pro
20 544 21 PRT Artificial Sequence Library Isolate 544 Gly Ser Asp
Leu Asp Cys Trp Thr Asp Pro Tyr Gly Gly Glu Val Cys 1 5 10 15 Tyr
Trp His Ala Pro 20 545 21 PRT Artificial Sequence Library Isolate
545 Gly Ser Asp Tyr Glu Cys Tyr Asn Ala Trp Phe Gly Tyr Phe Asp Cys
1 5 10 15 Pro Gly Asp Ala Pro 20 546 21 PRT Artificial Sequence
Library Isolate 546 Gly Ser Leu Ser Thr Cys Trp Lys Gln Ala Tyr Gly
Gly Val Trp Cys 1 5 10 15 Val Asp His Ala Pro 20 547 21 PRT
Artificial Sequence Library Isolate 547 Gly Ser Met Gln Leu Cys Arg
Gln Trp Ala Tyr Gly Gly Gln Thr Cys 1 5 10 15 Tyr Trp Tyr Ala Pro
20 548 21 PRT Artificial Sequence Library Isolate 548 Gly Ser Asn
Gln Leu Cys Ile Thr Ala Gln Phe Gly Gly Gln Asp Cys 1 5 10 15 Tyr
Pro Ile Ala Pro 20 549 21 PRT Artificial Sequence Library Isolate
549 Gly Ser Pro Met Trp Cys Ala Pro Trp Pro Trp Gly Gly Glu His Cys
1 5 10 15 Val Gly Ser Ala Pro 20 550 21 PRT Artificial Sequence
Library Isolate 550 Gly Ser Gln Leu Leu Cys Gly Ser Glu Pro Glu Leu
Ala Trp Met Cys 1 5 10 15 Glu Gln Gly Ala Pro 20 551 21 PRT
Artificial Sequence Library Isolate 551 Gly Ser Gln Arg Gln Cys Trp
Asp Asp Tyr Phe Gly Gly Ile Ile Cys 1 5 10 15 Tyr Val Ile Asp Ala
20 552 21 PRT Artificial Sequence Library Isolate 552 Gly Ser Arg
Glu Val Cys Trp Gln Asp Phe Phe Gly Gly Met Val Cys 1 5 10 15 Val
Arg Asp Ala Pro 20 553 21 PRT Artificial Sequence Library Isolate
553 Gly Ser Ser Gln Trp Cys Gln Arg Asp Phe Trp Gly Gly Asp Ile Cys
1 5 10 15 Ile Asn Leu Ala Pro 20 554 21 PRT Artificial Sequence
Library Isolate 554 Gly Ser Thr Asp Ile Cys Trp Pro Gly Ser Tyr Gly
Gly Glu Ile Cys 1 5 10 15 Ile Pro Arg Ala Pro 20 555 21 PRT
Artificial Sequence Library Isolate 555 Gly Ser Thr Glu Tyr Cys Trp
Pro Glu Pro His Gly Gly Gln Ala Cys 1 5 10 15 Ile Leu Leu Ala Pro
20 556 21 PRT Artificial Sequence Library Isolate 556 Gly Ser Thr
His Phe Cys Ile Asp Tyr Ile Trp Gly Gly Lys His Cys 1 5 10 15 Ile
Ala Asp Ala Pro 20 557 21 PRT Artificial Sequence Library Isolate
557 Gly Ser Thr Met Met Cys Trp Pro Ala His Tyr Gly Gly Asp Glu Cys
1 5 10 15 Phe Ala Leu Ala Pro 20 558 21 PRT Artificial Sequence
Library Isolate 558 Gly Ser Thr Gln Met Cys Phe Pro His Gln Tyr Gly
Gly Gln Ser Cys 1 5 10 15 Tyr Ser Phe Ala Pro 20 559 21 PRT
Artificial Sequence Library Isolate 559 Gly Ser Val Glu Gly Cys Trp
Val Glu Asp Gln Thr Ser Pro Phe Cys 1 5 10 15 Trp Ile Asp Ala Pro
20 560 21 PRT Artificial Sequence Library Isolate 560 Gly Ser Trp
Tyr Thr Cys Trp Asp Glu Ala Ser Gly Gly Gln Val Cys 1 5 10 15 Tyr
Gln Leu Ala Pro 20 561 21 PRT Artificial Sequence Library Isolate
561 Gly Ser Tyr Asn Leu Cys Tyr Pro Glu Ile Tyr Gly Gly Gln Val Cys
1 5 10 15 Tyr Arg Met Ala Pro 20 562 21 PRT Artificial Sequence
Library Isolate 562 Gly Ser Tyr Ser Gln Cys Phe Pro Asp Pro Phe Gly
Gly Thr Thr Cys 1 5 10 15 Phe Val Ser Ala Pro 20 563 21 PRT
Artificial Sequence Library Isolate 563 Gly Ser Ser Met Gln Cys Phe
Asn Arg Val Ser Gln Leu Val Asp Cys 1 5 10 15 Glu Thr Ala Ala Pro
20 564 21 PRT Artificial Sequence Library Isolate 564 Gly Ser Ala
Lys Thr Cys Arg Ser Tyr Trp Ala Gln Ser Gly Tyr Cys 1 5 10 15 Tyr
Glu Tyr Ala Pro 20 565 21 PRT Artificial Sequence Library Isolate
565 Gly Ser Ala Gln Thr Cys Trp Asp Tyr Val Tyr Gly Gly Phe Phe Cys
1 5 10 15 Leu Asn Thr Ala Pro 20 566 21 PRT Artificial Sequence
Library Isolate 566 Gly Ser Ala Trp Asp Cys Phe Gln Gln Asp Thr Tyr
Ser Thr His Cys 1 5 10 15 His Trp Arg Ala Pro 20 567 21 PRT
Artificial Sequence Library Isolate 567 Gly Ser Ala Trp Asn Cys Glu
Met Leu Asp Pro Trp Ser Thr Gln Cys 1 5 10 15 Ser Trp Asp Ala Pro
20 568 21 PRT Artificial Sequence Library Isolate 568 Gly Ser Ala
Trp Val Cys His Pro Glu Gln Glu Gly Gly Thr Thr Cys 1 5 10 15 Tyr
Trp Val Ala Pro 20 569 21 PRT Artificial Sequence Library Isolate
569 Gly Ser Asp Glu Leu Cys Trp Pro Gln Glu Phe Gly Gly Trp Val Cys
1 5 10 15 Ile Gln Gly Ala Pro 20 570 21 PRT Artificial Sequence
Library Isolate 570 Gly Ser Asp Phe Gln Cys Phe Asn Trp Glu Gly Tyr
Pro Thr Asn Cys 1 5 10 15 Tyr Ser Asn Ala Pro 20 571 21 PRT
Artificial Sequence Library Isolate 571 Gly Ser Asp Lys Lys Cys Trp
Pro Ser Pro Tyr Gly Gly Gln Ile Cys 1 5 10 15 Trp Ala Val Ala Pro
20 572 21 PRT Artificial Sequence Library Isolate 572 Gly Ser Asp
Gln Leu Cys Phe Asp Gln Arg Trp Gly Gly Gln Val Cys 1 5 10 15 Val
Phe Gly Ala Pro 20 573 21 PRT Artificial Sequence Library Isolate
573 Gly Ser Asp Ser Gly Cys Lys Glu Phe Trp Asn Ser Ser Asp Arg Cys
1 5 10 15 Tyr Thr His Ala Pro 20 574 21 PRT Artificial Sequence
Library Isolate 574 Gly Ser Glu Trp Ile Cys Trp Ser Ser Phe Phe Gly
Gly Glu Thr Cys 1 5 10 15 Thr Pro Lys Ala Pro 20 575 21 PRT
Artificial Sequence Library Isolate 575 Gly Ser Glu Trp Asn Cys Leu
Asn Asn Thr Pro Tyr Gln Thr Thr Cys 1 5 10 15 Ser Trp Arg Ala Pro
20 576 21 PRT Artificial Sequence Library Isolate 576 Gly Ser Glu
Trp Arg Cys Trp Pro Asp Val Phe Gly Gly Gln Met Cys 1 5 10 15 Phe
Asn Met Ala Pro 20 577 21 PRT Artificial Sequence Library Isolate
577 Gly Ser Glu Tyr Glu Cys Tyr Pro Asp Trp Tyr Gly Gly Glu Val Cys
1 5 10 15 Val Gln Lys Ala Pro 20 578 21 PRT Artificial Sequence
Library Isolate 578 Gly Ser Phe Glu Ala Cys Trp Glu Glu Ala Tyr Gly
Gly Leu Thr Cys 1 5 10 15 Trp His Asp Ala Pro 20 579 21 PRT
Artificial Sequence Library Isolate 579 Gly Ser Phe Glu Glu Cys Met
Pro Tyr Arg Tyr Gly Gly Gln Thr Cys 1 5 10 15 Phe Met Ile Ala Pro
20 580 21 PRT Artificial Sequence Library Isolate 580 Gly Ser Phe
Trp Thr Cys Val Asp Thr Asn Trp His Thr Thr Glu Cys 1 5 10 15 Phe
His Ser Ala Pro 20 581 21 PRT Artificial Sequence Library Isolate
581 Gly Ser Gly Gln Met Cys Trp His Gly Gln Tyr Gly Gly Thr Ile Cys
1 5 10 15 Val Ala Met Ala Pro 20 582 21 PRT Artificial Sequence
Library Isolate 582 Gly Ser Gly Trp Val Cys Lys Gln Gln Gly Pro His
Lys Thr Glu Cys 1 5 10 15 Leu Phe Met Ala Pro 20 583 21 PRT
Artificial Sequence Library Isolate 583 Gly Ser His Asp Glu Cys Trp
Glu Asp Ile Tyr Gly Gly Phe Thr Cys 1 5 10 15 Met Pro Tyr Gly Ser
20 584 21 PRT Artificial Sequence Library Isolate 584 Gly Ser His
Val Val Cys Trp Asp Asp Pro Tyr Gly Gly Glu Ser Cys 1 5 10 15 Tyr
Asn Thr Ala Pro 20 585 21 PRT Artificial Sequence Library Isolate
585 Gly Ser Ile Asp Ile Cys Thr Asp Ser Tyr Trp Gly Gly Ile Thr Cys
1 5 10 15 Tyr Lys Phe Ala Pro 20 586 21 PRT Artificial Sequence
Library Isolate 586 Gly Ser Lys Trp Ile Cys Val Asp Val Lys Trp Gly
Gly Ser Ala Cys 1 5 10 15 Tyr Asp Ile Ala Pro 20 587 21 PRT
Artificial Sequence Library Isolate 587 Gly Ser Leu Trp Glu Cys Arg
Ile
Asp Tyr Tyr Gly Gly Glu Val Cys 1 5 10 15 Phe Ile Asp Ala Pro 20
588 21 PRT Artificial Sequence Library Isolate 588 Gly Ser Leu Trp
Thr Cys Val Leu Ser Val Tyr Gly Gly Glu Asp Cys 1 5 10 15 Tyr Asn
Leu Ala Pro 20 589 21 PRT Artificial Sequence Library Isolate 589
Gly Ser Met Thr Met Cys Gly Ala Glu Pro Asp Leu Trp Tyr Met Cys 1 5
10 15 Tyr Gly Ile Ala Pro 20 590 21 PRT Artificial Sequence Library
Isolate 590 Gly Ser Asn Gln Tyr Cys Met Pro Tyr Asp Trp Gly Gly Glu
Met Cys 1 5 10 15 Phe Glu Val Ala Pro 20 591 21 PRT Artificial
Sequence Library Isolate 591 Gly Ser Asn Val Phe Cys Ser Glu Gly
Pro Phe Gly Gly Glu Ile Cys 1 5 10 15 Tyr Gly Ile Ala Pro 20 592 21
PRT Artificial Sequence Library Isolate 592 Gly Ser Asn Trp Ala Cys
Phe Ile Glu Ala Met Gly Gly Trp Thr Cys 1 5 10 15 Ala Pro Arg Pro
Thr 20 593 21 PRT Artificial Sequence Library Isolate 593 Gly Ser
Asn Trp Thr Cys Phe Ile Asp Ser Phe Gln Gly Glu Thr Cys 1 5 10 15
Tyr Pro Phe Ala Pro 20 594 21 PRT Artificial Sequence Library
Isolate 594 Gly Ser Asn Trp Trp Cys His Ser Glu Ala Phe Gly Gly His
Thr Cys 1 5 10 15 Tyr Asn Ala Ala Pro 20 595 21 PRT Artificial
Sequence Library Isolate 595 Gly Ser Pro Cys Ala Cys Asn Asn Ser
Tyr Gly His Ser Asp Asp Cys 1 5 10 15 Asp His Leu Ala Pro 20 596 21
PRT Artificial Sequence Library Isolate 596 Gly Ser Pro Gly Asn Cys
Lys Asp Phe Trp Ala Trp Ser Leu Gln Cys 1 5 10 15 Phe Ser Phe Ala
Pro 20 597 21 PRT Artificial Sequence Library Isolate 597 Gly Ser
Pro Arg Trp Cys Tyr Phe Ser Ser Gly Ile Met Lys Asp Cys 1 5 10 15
Asp Ile Leu Ala Pro 20 598 21 PRT Artificial Sequence Library
Isolate 598 Gly Ser Pro Thr Tyr Cys Gln Phe His Ser Gly Val Val Thr
Leu Cys 1 5 10 15 Ser Met Phe Ala Pro 20 599 21 PRT Artificial
Sequence Library Isolate 599 Gly Ser Gln Glu Ile Cys Phe Asn Ser
Gln Tyr Gly Gly Gln Val Cys 1 5 10 15 Phe Asp Ser Ala Pro 20 600 21
PRT Artificial Sequence Library Isolate 600 Gly Ser Gln Met Ile Cys
Tyr Pro His Val Phe Gly Gly Gln Asp Cys 1 5 10 15 Phe Pro Gly Ala
Pro 20 601 21 PRT Artificial Sequence Library Isolate 601 Gly Ser
Gln Trp Thr Cys Thr Glu Leu Ser Asp Val Met Thr His Cys 1 5 10 15
Ser Tyr Thr Ala Pro 20 602 21 PRT Artificial Sequence Library
Isolate 602 Gly Ser Arg Val Asn Cys Gly Ala Glu Asp Asp Leu Ser Phe
Leu Cys 1 5 10 15 Met Thr Glu Ala Pro 20 603 21 PRT Artificial
Sequence Library Isolate 603 Gly Ser Ser Gly Asp Cys Ile Glu Met
Tyr Asn Asp Trp Tyr Tyr Cys 1 5 10 15 Thr Ile Leu Ala Pro 20 604 21
PRT Artificial Sequence Library Isolate 604 Gly Ser Ser Trp Glu Cys
Gly Glu Phe Gly Asp Thr Thr Ile Gln Cys 1 5 10 15 Asn Trp Val Ala
Pro 20 605 21 PRT Artificial Sequence Library Isolate 605 Gly Ser
Ser Trp Gln Cys Phe Ser Glu Ala Pro Ser Gly Ala Thr Cys 1 5 10 15
Val Pro Ile Ala Pro 20 606 21 PRT Artificial Sequence Library
Isolate 606 Gly Ser Ser Trp Gln Cys Val Gln Val Asp Asp Phe His Thr
Glu Cys 1 5 10 15 Ser Phe Met Ala Pro 20 607 21 PRT Artificial
Sequence Library Isolate 607 Gly Ser Ser Trp Thr Cys Val Phe Tyr
Pro Tyr Gly Gly Glu Val Cys 1 5 10 15 Ile Pro Asp Ala Pro 20 608 21
PRT Artificial Sequence Library Isolate 608 Gly Ser Thr Glu Leu Cys
Val Pro Tyr Gln Trp Gly Gly Glu Val Cys 1 5 10 15 Val Ala Gln Ala
Pro 20 609 21 PRT Artificial Sequence Library Isolate 609 Gly Ser
Thr Val Tyr Cys His Asn Glu Tyr Phe Gly Gly Gln Val Cys 1 5 10 15
Phe Thr Ile Ala Pro 20 610 21 PRT Artificial Sequence Library
Isolate 610 Gly Ser Thr Tyr Gly Cys Glu Tyr Tyr Met Pro Phe Gln His
Lys Cys 1 5 10 15 Ser Val Glu Ala Pro 20 611 21 PRT Artificial
Sequence Library Isolate 611 Gly Ser Trp Trp Gly Cys Phe Pro Tyr
Ser Trp Gly Gly Glu Ile Cys 1 5 10 15 Thr Ser Ile Ala Pro 20 612 21
PRT Artificial Sequence Library Isolate 612 Gly Ser Trp Trp Asn Cys
Val Asp Thr Ser Phe His Thr Thr Gln Cys 1 5 10 15 Lys Tyr Ala Ala
Pro 20 613 21 PRT Artificial Sequence Library Isolate 613 Gly Ser
Tyr Phe Met Cys Gln Asp Gly Phe Trp Gly Gly Gln Asp Cys 1 5 10 15
Phe Tyr Ile Ala Pro 20 614 21 PRT Artificial Sequence Library
Isolate 614 Gly Ser Tyr Met Trp Cys Thr Glu Ser Lys Phe Gly Gly Ser
Thr Cys 1 5 10 15 Phe Asn Leu Ala Pro 20 615 20 PRT Artificial
Sequence Library Isolate 615 Gly Ser Gly Ala Tyr Ser His Leu Leu
Glu Tyr His Ala Val Cys Lys 1 5 10 15 Asn Val Ala Pro 20 616 21 PRT
Artificial Sequence Library Isolate 616 Pro Gly Ser Trp Thr Cys Gln
Asn Tyr Glu Pro Trp Ala Thr Thr Cys 1 5 10 15 Val Tyr Asp Ala Pro
20 617 22 PRT Artificial Sequence Library Isolate 617 Ala Gln Asp
Trp Tyr Tyr Asp Glu Ile Leu Gly Arg Gly Gly Arg Gly Gly Arg 1 5 10
15 Gly Gly Gly Lys 20
* * * * *